PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FAN, ST; LO, CM; LAI, ECS; CHU, KM; LIU, CL; WONG, J				FAN, ST; LO, CM; LAI, ECS; CHU, KM; LIU, CL; WONG, J			PERIOPERATIVE NUTRITIONAL SUPPORT IN PATIENTS UNDERGOING HEPATECTOMY FOR HEPATOCELLULAR-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDIUM-CHAIN TRIGLYCERIDES; LIVER-DISEASE; HEPATIC RESECTIONS; RAT-LIVER; CIRRHOSIS; REGENERATION; METABOLISM; EXPERIENCE; CLEARANCE	Background. Resection of hepatocellular carcinoma is associated with high rates of morbidity and mortality. Since intensive nutritional support can reduce the catabolic response and improve protein synthesis and liver regeneration, we performed a prospective study to investigate whether perioperative nutritional support could improve outcome in patients undergoing hepatectomy for hepatocellular carcinoma. Methods. We studied 124 patients undergoing resection of hepatocellular carcinoma. Sixty-four patients (39 with cirrhosis, 18 with chronic active hepatitis, and 7 with no associated liver disease) were randomly assigned to receive perioperative intravenous nutritional support in addition to their oral diet, and 60 patients (33 with cirrhosis, 12 with chronic active hepatitis, and 15 with no associated liver disease) were randomly assigned to a control group. The perioperative nutritional therapy consisted of a solution enriched with 35 percent branched-chain amino acids, dextrose, and lipid emulsion (50 percent medium-chain triglycerides) given intravenously for 14 days perioperatively. Results. There was a reduction in the overall postoperative morbidity rate in the perioperative-nutrition group as compared with the control group (34 percent vs. 55 percent; relative risk, 0.66; 95 percent confidence interval, 0.45 to 0.96), predominantly because of fewer septic complications (17 percent vs. 37 percent; relative risk, 0.57; 95 percent confidence interval, 0.34 to 0.96). There were also a reduction in the requirement for diuretic agents to control ascites (25 percent vs. 50 percent; relative risk, 0.57; 95 percent confidence interval, 0.37 to 0.87), less weight loss after hepatectomy (median loss, 0 kg vs. 1.4 kg; P = 0.01), and less deterioration of liver function as measured by the change in the rate of clearance of indocyanine green (-2.8 percent vs. -4.8 percent at 20 minutes, P = 0.05). These benefits were seen predominantly in the patients with underlying cirrhosis who underwent major hepatectomy. There were five deaths during hospitalization in the perioperative-nutrition group, and nine in the control group (P not significant). Conclusions. Perioperative nutritional support can reduce complications after major hepatectomy for hepatocellular carcinoma associated with cirrhosis.			FAN, ST (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT SURG,HONG KONG,HONG KONG.		Lo, Chung Mau/C-4352-2009; Chu, Kent/C-4251-2009; Fan, Sheung Tat/C-4138-2009					ALMERSJO O, 1969, ANN SURG, V169, P111, DOI 10.1097/00000658-196901000-00011; [Anonymous], 1989, Jpn J Surg, V19, P98; BACH AC, 1982, AM J CLIN NUTR, V36, P950, DOI 10.1093/ajcn/36.5.950; BLACKBURN GL, 1979, SURGERY, V86, P307; BOLZANO K, 1975, HORM METAB RES, V7, P238, DOI 10.1055/s-0028-1093746; BOWER RH, 1986, CLIN NUTR, V2, P602; BUZBY GP, 1984, CLIN NUTR, V1, P127; CAESAR J, 1961, CLIN SCI, V21, P43; CHIBA T, 1983, BIOCHIM BIOPHYS ACTA, V755, P420, DOI 10.1016/0304-4165(83)90245-3; CHOI TK, 1990, HEPATO-GASTROENTEROL, V37, P172; DECKELBAUM R J, 1986, Clinical Nutrition (Edinburgh), V5, P54; DOUGLAS RG, 1989, BRIT J SURG, V76, P115, DOI 10.1002/bjs.1800760205; FAN ST, 1994, J GASTROEN HEPATOL, V9, P391, DOI 10.1111/j.1440-1746.1994.tb01261.x; FAN ST, 1992, JPEN-PARENTER ENTER, V16, P279, DOI 10.1177/0148607192016003279; FEINSTEIN AR, 1977, CLIN BIOSTATISTICS; GOZZETTI G, 1988, SURG GYNECOL OBSTET, V166, P503; GRANT JP, 1981, SURG CLIN N AM, V61, P437; HASEGAWA H, 1985, TUMORI FEGATO, P155; IWATSUKI S, 1988, ANN SURG, V208, P421, DOI 10.1097/00000658-198810000-00004; KANEMATSU T, 1988, SURGERY, V104, P482; LEE CS, 1986, SURGERY, V99, P481; LIM RC, 1984, ARCH SURG-CHICAGO, V119, P637; MARCHESINI G, 1982, HEPATOLOGY, V2, P420; MARCHESINI G, 1981, HEPATOLOGY, V1, P294, DOI 10.1002/hep.1840010403; MATSUMATA T, 1990, BRIT J SURG, V77, P677, DOI 10.1002/bjs.1800770629; MCGOWAN J, 1979, BIOCHEM J, V180, P25, DOI 10.1042/bj1800025; MEZEY E, 1978, GASTROENTEROLOGY, V74, P770; MUSCARITOLI M, 1986, JPEN-PARENTER ENTER, V10, P599, DOI 10.1177/0148607186010006599; NAGAO T, 1987, ANN SURG, V205, P33, DOI 10.1097/00000658-198701000-00006; NAGASUE N, 1993, ANN SURG, V217, P375, DOI 10.1097/00000658-199304000-00009; OKEEFE SJ, 1980, LANCET, V2, P615; OKEEFE SJD, 1987, JPEN-PARENTER ENTER, V11, P447, DOI 10.1177/0148607187011005447; REILLY J, 1990, JPEN-PARENTER ENTER, V14, P386, DOI 10.1177/0148607190014004386; RIGOTTI P, 1986, JPEN-PARENTER ENTER, V10, P17, DOI 10.1177/014860718601000117; SHANBHOGUE RLK, 1987, JPEN-PARENTER ENTER, V11, P305, DOI 10.1177/0148607187011003305; SMITH GW, 1983, SURGERY ALIMENTARY T, P447; TSUZUKI T, 1990, SURGERY, V107, P511; WARD RE, 1983, MANUAL PREOPERATIVE, P757; WOLFRAM G, 1982, FETT PARENTERALEN ER, P28; 1991, NEW ENGL J MED, V325, P525	40	274	291	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1547	1552		10.1056/NEJM199412083312303	http://dx.doi.org/10.1056/NEJM199412083312303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969324	Green Submitted			2022-12-28	WOS:A1994PV29200003
J	ELDERS, JM				ELDERS, JM			REDUCING THE RISK OF SUDDEN-INFANT-DEATH-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ELDERS, JM (corresponding author), US PHS,WASHINGTON,DC 20201, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1646	1646		10.1001/jama.272.21.1646	http://dx.doi.org/10.1001/jama.272.21.1646			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966879				2022-12-28	WOS:A1994PU75900006
J	ELMORE, JG; WELLS, CK; LEE, CH; HOWARD, DH; FEINSTEIN, AR				ELMORE, JG; WELLS, CK; LEE, CH; HOWARD, DH; FEINSTEIN, AR			VARIABILITY IN RADIOLOGISTS INTERPRETATIONS OF MAMMOGRAMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER MORTALITY; OBSERVER VARIATION; AGREEMENT; REDUCTION; EFFICACY; PROGRAM; PROJECT; AUDIT	Background. Despite the proved value of mammography in screening for breast cancer, its efficacy depends on radiologists' interpretations. The variability in such interpretations is not well understood. Methods. Using a technique of stratified random sampling, we selected 150 mammograms obtained in 1987: 27 from women with histopathologically confirmed breast cancer and 123 from women with no evidence of breast cancer after three years of follow-up examinations. Ten radiologists, who were unaware of the diagnoses and research hypothesis, each interpreted the 150 mammograms. Disagreement was analyzed within pairs of the 10 radiologists, as well as for the group of 150 women as a whole. Results. The diagnostic consistency between pairs of radiologists was moderate, with a median weighted percentage of agreement of 78 percent (weighted kappa, 0.47). The frequency of the radiologists' recommendations for an immediate workup ranged from 74 to 96 percent for mammograms from the women with cancer and from 11 to 65 percent for films from the women without cancer. A substantial disagreement in management recommendations - in which one radiologist recommended routine follow-up and another recommended a biopsy for the same patient - occurred in 3 percent of the pairwise comparisons but in 25 percent of the comparisons for the group of women as a whole. When two or more radiologists recommended a biopsy for the same patient, a disagreement in the stated location (right or left breast) occurred in 2 percent of the pairwise comparisons among the radiologists but in 9 percent of comparisons for the group of women as a whole. Because some disagreement was likely, given that 10 radiologists read each film, the pairwise comparison is a more conservative estimate of disagreement. Conclusions. Although mammography is of value in screening women for breast cancer, radiologists can differ, sometimes substantially, in their interpretations of mammograms and in their recommendations for management. Efforts to improve accuracy and reduce variability in interpretation may increase the effectiveness of mammography in detecting early breast cancers.	YALE UNIV,DEPT DIAGNOST RADIOL,NEW HAVEN,CT; YALE UNIV,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT	Yale University; Yale University	ELMORE, JG (corresponding author), YALE UNIV,SCH MED,CTR PRIMARY CARE,DEPT INTERNAL MED,20 YORK ST,NEW HAVEN,CT 06504, USA.		SALAZAR, ANTONIO/A-5806-2013	SALAZAR, ANTONIO/0000-0003-2639-2340				ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; [Anonymous], 1993, BREAST IMAGING REPOR; BAINES CJ, 1990, INVEST RADIOL, V25, P971, DOI 10.1097/00004424-199009000-00002; BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; BOYD NF, 1986, J CHRON DIS, V39, P465, DOI 10.1016/0021-9681(86)90113-X; BOYD NF, 1982, J NATL CANCER I, V68, P357; CICCONE G, 1992, EUR J CANCER, V28A, P1054, DOI 10.1016/0959-8049(92)90455-B; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COLLETTE HJA, 1984, LANCET, V1, P1224; DERSHAW DD, 1992, RADIOLOGY, V184, P415, DOI 10.1148/radiology.184.2.1620839; DORSI CJ, 1993, SEMIN ROENTGENOL, V28, P204, DOI 10.1016/S0037-198X(05)80080-X; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L; Fleiss JL, 1981, STAT METHODS RATES P; KOPANS DB, 1992, RADIOL CLIN N AM, V30, P257; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MCLELLAND R, 1991, AM J ROENTGENOL, V157, P473, DOI 10.2214/ajr.157.3.1872231; PALLI D, 1986, INT J CANCER, V38, P501, DOI 10.1002/ijc.2910380408; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SICKLES EA, 1992, RADIOL CLIN N AM, V30, P265; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; SWETS JA, 1991, MED DECIS MAKING, V11, P9, DOI 10.1177/0272989X9101100102; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; VERBEEK ALM, 1984, LANCET, V1, P1222; VINEIS P, 1988, TUMORI, V74, P275, DOI 10.1177/030089168807400306; 1988, LANCET, V2, P411	27	455	457	1	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1493	1499		10.1056/NEJM199412013312206	http://dx.doi.org/10.1056/NEJM199412013312206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969300				2022-12-28	WOS:A1994PU86600006
J	BORDER, WA; NOBLE, NA				BORDER, WA; NOBLE, NA			TRANSFORMING GROWTH-FACTOR-BETA IN TISSUE FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MESSENGER-RNA; TGF-BETA; EXPERIMENTAL GLOMERULONEPHRITIS; FACTOR-BETA-1 GENE; EXTRACELLULAR-MATRIX; PULMONARY FIBROSIS; ENDOTHELIAL-CELLS; EXPRESSION; DISEASE; RATS				BORDER, WA (corresponding author), UNIV UTAH,SCH MED,DIV NEPHROL,50 N MED DR,SALT LAKE CITY,UT 84132, USA.				NIDDK NIH HHS [DK 43609] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK043609, R01DK043609] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ANSCHER MS, 1993, NEW ENGL J MED, V328, P1592, DOI 10.1056/NEJM199306033282203; APPLETON I, 1993, LAB INVEST, V69, P405; BARCELLOSHOFF MH, 1994, J CLIN INVEST, V93, P892, DOI 10.1172/JCI117045; BARNES JL, 1993, AM J PATHOL, V143, P1366; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BECK LS, 1993, J CLIN INVEST, V92, P2841, DOI 10.1172/JCI116904; Border W., 1993, Journal of the American Society of Nephrology, V4, P675; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BRANDES ME, 1991, J CLIN INVEST, V87, P1108, DOI 10.1172/JCI115073; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; COIMBRA T, 1991, AM J PATHOL, V138, P223; CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; DAVIDSON JM, 1992, INFLAMMATION BASIC P, P809; DEGUCHI Y, 1992, ANN RHEUM DIS, V51, P362, DOI 10.1136/ard.51.3.362; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; FLAUMENHAFT R, 1992, J CELL BIOL, V118, P901, DOI 10.1083/jcb.118.4.901; FLOEGE J, 1993, J CLIN INVEST, V92, P2952, DOI 10.1172/JCI116918; GHAHARY A, 1993, J LAB CLIN MED, V122, P465; GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959; ISAKA Y, 1993, J CLIN INVEST, V92, P2597, DOI 10.1172/JCI116874; JONES CL, 1991, KIDNEY INT, V40, P1020, DOI 10.1038/ki.1991.310; KAGAMI S, 1993, LAB INVEST, V69, P68; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; KANETO H, 1993, KIDNEY INT, V44, P313, DOI 10.1038/ki.1993.246; KHALIL N, 1993, J CLIN INVEST, V92, P1812, DOI 10.1172/JCI116771; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1992, J BIOL CHEM, V267, P13702; KOPP JB, 1992, P NATL ACAD SCI USA, V89, P1577, DOI 10.1073/pnas.89.5.1577; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; KULOZIK M, 1990, J CLIN INVEST, V86, P917, DOI 10.1172/JCI114793; LAFYATIS R, 1989, J IMMUNOL, V143, P1142; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; NAGY P, 1991, HEPATOLOGY, V14, P269, DOI 10.1002/hep.1840140211; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; Ogawa Y, 1991, Growth Factors, V5, P57, DOI 10.3109/08977199109000271; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; OKUDA S, 1991, P NATL ACAD SCI USA, V88, P9765, DOI 10.1073/pnas.88.21.9765; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; OKUDA S, 1990, J CLIN INVEST, V86, P2175; PELTONEN J, 1991, J INVEST DERMATOL, V97, P240, DOI 10.1111/1523-1747.ep12480289; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; POSTLETHWAITE AE, 1987, J EXP MED, V165, P251, DOI 10.1084/jem.165.1.251; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203; ROBERTS AB, 1990, GROWTH FACTORS HLTH, P89; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; SHIHAB F, 1993, J AM SOC NEPHROL, V4, P671; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SPORN MB, 1992, ANN INTERN MED, V117, P408, DOI 10.7326/0003-4819-117-5-408; SPORN MB, 1993, J CLIN INVEST, V92, P2565, DOI 10.1172/JCI116868; TERRELL TG, 1993, INT REV EXP PATHOL, V34, P43; TOMOOKA S, 1992, KIDNEY INT, V42, P1462, DOI 10.1038/ki.1992.442; VARGA J, 1992, ANN INTERN MED, V116, P140, DOI 10.7326/0003-4819-116-2-140; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WAHL SM, 1993, J EXP MED, V177, P225, DOI 10.1084/jem.177.1.225; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WESTERGRENTHORSSON G, 1993, J CLIN INVEST, V92, P632, DOI 10.1172/JCI116631; WILLIAMS RS, 1992, J SURG RES, V52, P65, DOI 10.1016/0022-4804(92)90280-D; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; YAMAMOTO T, 1994, KIDNEY INT, V45, P916, DOI 10.1038/ki.1994.122; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; YOSHIOKA K, 1993, LAB INVEST, V68, P154; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004; ZUGMAIER G, 1991, CANCER RES, V51, P3590	75	2807	2985	3	222	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1286	1292						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP752	7935686				2022-12-28	WOS:A1994PP75200007
J	EIBEN, B; OSTHELDER, B; HAMMANS, W; GOEBEL, R				EIBEN, B; OSTHELDER, B; HAMMANS, W; GOEBEL, R			SAFETY OF EARLY AMNIOCENTESIS VERSUS CVS	LANCET			English	Letter									EVANGEL KRANKENHAUS,FRAUENKLIN,D-46047 OBERHAUSEN,GERMANY		EIBEN, B (corresponding author), EVANGEL KRANKENHAUS,INST KLIN GENET,D-46047 OBERHAUSEN,GERMANY.							EIBEN B, 1994, PRENATAL DIAG, V14, P497, DOI 10.1002/pd.1970140615; EIBEN B, 1993, GEBURTSH FRAUENHEILK, V53, P554, DOI 10.1055/s-2007-1022933; NICOLAIDES, 1994, LANCET, V344, P435; VANDENBUSSCHE, 1994, LANCET, V344, P1032; 1994, LANCET, V344, P825	5	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1303	1304		10.1016/S0140-6736(94)90794-3	http://dx.doi.org/10.1016/S0140-6736(94)90794-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7968015				2022-12-28	WOS:A1994PP70100054
J	VANWEEL, C				VANWEEL, C			TEAMWORK	LANCET			English	Article											VANWEEL, C (corresponding author), UNIV NIJMEGEN,DEPT GEN PRACTICE & SOCIAL MED,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				DRURY M, 1988, J ROY COLL GEN PRACT, V38, P503; GROL T, 1990, HEAL HARM; HASLER JC, 1994, PRIMARY HLTH CARE TE; Lamberts H, 1975, J R Coll Gen Pract, V25, P745; MILTENBURG T, 1992, BALANCING PLURALISM; PALM BTHM, 1993, BRIT J GEN PRACT, V43, P503; PITCHARD P, 1989, J R COLL GEN PRACT, V39, P41; SCHULZ R, 1992, J FAM PRACTICE, V34, P298; van Weel C, 1980, J R Coll Gen Pract, V30, P665; VANWEEL C, 1992, POSTGRAD ED GEN PRAC, V2, P218; White K.L., 1988, TASK MED DIALOGUE WI; WIJKEL D, 1986, THESIS U GRONINGEN G; 1981, 16 ROYAL COLL GEN PR; 1993, VADEMECUM HLTH STATI; 1965, PRESENT STATE FUTURE, V2	15	27	27	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1276	1279		10.1016/S0140-6736(94)90756-0	http://dx.doi.org/10.1016/S0140-6736(94)90756-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967991				2022-12-28	WOS:A1994PP70100014
J	MINSHULL, J; SUN, H; TONKS, NK; MURRAY, AW				MINSHULL, J; SUN, H; TONKS, NK; MURRAY, AW			A MAP KINASE-DEPENDENT SPINDLE ASSEMBLY CHECKPOINT IN XENOPUS EGG EXTRACTS	CELL			English	Article							ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; WILD-TYPE P53; MATURATION-PROMOTING FACTOR; IMMEDIATE-EARLY GENE; M-PHASE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; MICROTUBULE DYNAMICS; CHROMOSOME MOVEMENT	Like early Xenopus embryos, extracts made from Xenopus eggs lack the cell cycle checkpoint that keeps anaphase from occurring before spindle assembly is complete. At very high densities of sperm nuclei, however, microtubule depolymerization arrests the extracts in mitosis. The arrested extracts have high levels of maturation-promoting factor activity, fail to degrade cyclin B, and contain activated ERK2/mitogen-activated protein (MAP) kinase. The addition of the purified MAP kinase-specific phosphatase MKP-1 demonstrates that MAP kinase activity is required for both the establishment and maintenance of the mitotic arrest induced by spindle depolymerization. Increased calcium concentrations, which release unfertilized frog eggs from their natural arrest in metaphase of meiosis II, have no effect on the mitotic arrest.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of California System; University of California San Francisco; Cold Spring Harbor Laboratory	MINSHULL, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, BOX 0444, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA53840] Funding Source: Medline; NIGMS NIH HHS [GM43987] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043987, R01GM043987] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BAGATA N, 1988, NATURE, V335, P519; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; CALLAN H. G., 1957, JOUR GENETICS, V55, P200, DOI 10.1007/BF02981625; CHARLES CH, 1992, ONCOGENE, V7, P187; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1989, MOL CELL BIOL, V9, P3143, DOI 10.1128/MCB.9.7.3143; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; JORDAN MA, 1992, J CELL SCI, V102, P401; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KLINE D, 1988, DEV BIOL, V126, P346, DOI 10.1016/0012-1606(88)90145-5; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KUBIAK JZ, 1993, EMBO J, V12, P3773, DOI 10.1002/j.1460-2075.1993.tb06055.x; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NICKLAS RB, 1993, J CELL SCI, V104, P961; NICKLAS RB, 1992, J CELL SCI, V102, P681; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RIEDER CL, 1992, J CELL SCI, V102, P387; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SLUDER G, 1994, J CELL BIOL, V126, P189, DOI 10.1083/jcb.126.1.189; SLUDER G, 1983, J CELL BIOL, V97, P877, DOI 10.1083/jcb.97.3.877; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	83	358	361	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					475	486		10.1016/0092-8674(94)90256-9	http://dx.doi.org/10.1016/0092-8674(94)90256-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954813				2022-12-28	WOS:A1994PQ48800010
J	NABER, SP				NABER, SP			MOLECULAR MEDICINE - MOLECULAR PATHOLOGY - DIAGNOSIS OF INFECTIOUS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											NABER, SP (corresponding author), BAYSTATE MED CTR,DEPT PATHOL,SPRINGFIELD,MA 01199, USA.							Persing D.H., 1993, DIAGNOSTIC MOL MICRO; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P315, DOI 10.1056/NEJM199408043310508; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P599, DOI 10.1056/NEJM199409013310908; 1994, HUM PATHOL, V25, P555	4	42	42	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1212	1215		10.1056/NEJM199411033311808	http://dx.doi.org/10.1056/NEJM199411033311808			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935661				2022-12-28	WOS:A1994PN80600008
J	ISTRE, O; BJOENNES, J; NAESS, R; HORNBAEK, K; FORMAN, A				ISTRE, O; BJOENNES, J; NAESS, R; HORNBAEK, K; FORMAN, A			POSTOPERATIVE CEREBRAL EDEMA AFTER TRANSCERVICAL ENDOMETRIAL RESECTION AND UTERINE IRRIGATION WITH 1-CENTER-DOT-5-PERCENT GLYCINE	LANCET			English	Article							SYMPTOMATIC HYPONATREMIA; HYPERAMMONEMIA; SERUM	Absorption of irrigating solution during transcervical resection of endometrium can cause dilutional hyponatraemia, nausea, and cerebral oedema. We studied 6 patients who absorbed more than 1500 mL of 1.5% glycine, and 14 patients who absorbed less. Cerebral oedema was diagnosed by blinded, paired comparison of computed tomography (CT) scans 3-6 hours and 3-6 days after operation. The absorbed volume of irrigating glycine solution was correlated with peroperative decrease in serum sodium. 10 patients who absorbed 500 mL of glycine or more had postoperative nausea, with cerebral oedema suspected in 9. None of the 10 patients who absorbed less than 500 mL had nausea; changes on CT scan suggestive of cerebral edema were found in 1. 8 patients who absorbed 1000 mL or more had a decrease in serum sodium of 10 mmol/L or more, nausea, and cerebral oedema on CT scan. Cerebral oedema may contribute to the development of postoperative nausea in patients undergoing transcervical surgery who absorb more than 500 mL of 1.5% glycine irrigating solution.	HEDMARK CENT HOSP,DEPT RADIOL,N-2300 HAMAR,NORWAY; AARHUS UNIV HOSP,DEPT OBSTET & GYNECOL,AARHUS,DENMARK	Aarhus University	ISTRE, O (corresponding author), HEDMARK CENT HOSP,DEPT OBSTET & GYNAECOL,N-2300 HAMAR,NORWAY.			Forman, Axel/0000-0003-1369-1296				ARIEFF AI, 1991, CRIT CARE MED, V19, P748, DOI 10.1097/00003246-199106000-00002; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; BERL T, 1990, ANN INTERN MED, V113, P417, DOI 10.7326/0003-4819-113-6-417; BERNSTEIN GT, 1989, J SURG RES, V46, P135, DOI 10.1016/0022-4804(89)90216-3; HARRISON RH, 1956, J UROLOGY, V75, P91; HENDERSON DJ, 1980, UROLOGY, V15, P267, DOI 10.1016/0090-4295(80)90441-0; HOEKSTRA PT, 1983, J UROLOGY, V130, P704, DOI 10.1016/S0022-5347(17)51414-7; IGLESIAS JJ, 1975, J UROLOGY, V114, P929, DOI 10.1016/S0022-5347(17)67177-5; ISTRE O, 1992, OBSTET GYNECOL, V80, P218; KIRWAN PH, 1993, BRIT J OBSTET GYNAEC, V100, P603, DOI 10.1111/j.1471-0528.1993.tb15321.x; MADSEN PAUL O., 1965, INVEST UROL, V3, P122; MAGOS AL, 1991, LANCET, V337, P1074, DOI 10.1016/0140-6736(91)91718-A; NESBIT RM, 1948, J UROLOGY, V59, P1212, DOI 10.1016/S0022-5347(17)69504-1; PERIER C, 1988, CLIN CHEM, V34, P1471; SHEPARD RL, 1987, BRIT J UROL, V60, P349, DOI 10.1111/j.1464-410X.1987.tb04983.x; WITZ CA, 1993, FERTIL STERIL, V60, P745	16	96	98	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1187	1189		10.1016/S0140-6736(94)90507-X	http://dx.doi.org/10.1016/S0140-6736(94)90507-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934539				2022-12-28	WOS:A1994PN80300008
J	BARNETT, SW; MURTHY, KK; HERNDIER, BG; LEVY, JA				BARNETT, SW; MURTHY, KK; HERNDIER, BG; LEVY, JA			AN AIDS-LIKE CONDITION INDUCED IN BABOONS BY HIV-2	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; RHESUS-MONKEYS; EXPERIMENTAL-INFECTION; CELLULAR-LOCALIZATION; PERSISTENT INFECTION; CYNOMOLGUS MONKEYS; MACACA-NEMESTRINA; LYMPHOID-TISSUES; D RETROVIRUS; MACAQUES	Six baboons (Papio cynocephalus) were intravenously inoculated with the human immunodeficiency virus-type 2 (HIV-2) strain HIV-2(UC2). All seroconverted within 6 week's after inoculation; five animals became persistently infected. Four developed lymphadenopathy, and three of the animals had CD4(+) T cell loss within 18 to 24 months after inoculation. One of these baboons, showing severe clinical symptoms, showed at necropsy widespread dissemination of virus with follicular depletion in the lymph nodes, extensive fibromatosis involving lymphoid and nonlymphoid tissues, and lymphocytic interstitial pneumonitis. Another animal is cachectic and exhibited lymphoid follicular lysis and fibrous skin lesions. Other baboons inoculated with a second strain, HIV-2(UC14), have shown evidence of persistent infection. HIV-2 infection of baboons provides a valuable animal model for studying HIV persistence and pathogenesis and for evaluating approaches to antiviral therapies.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143; SW FDN BIOMED RES,SAN ANTONIO,TX 78228; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,SCH MED,DEPT PATHOL,SAN FRANCISCO,CA 94110	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Texas Biomedical Research Institute; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco					NIAID NIH HHS [U01-AI26471] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI026471] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGY MB, 1992, SCIENCE, V257, P103, DOI 10.1126/science.1621083; ALBINI A, 1988, J CELL BIOCHEM, V36, P369, DOI 10.1002/jcb.240360406; ALTER HJ, 1984, SCIENCE, V226, P549, DOI 10.1126/science.6093251; BABU PG, 1993, INDIAN J MED RES-A, V97, P49; BARNETT SW, 1993, J VIROL, V67, P1006, DOI 10.1128/JVI.67.2.1006-1014.1993; BARNETT SW, UNPUB; BLACKBOURN D, UNPUB; CASTRO BA, 1991, VIROLOGY, V184, P219, DOI 10.1016/0042-6822(91)90838-3; CHALIFOUX LV, 1987, AM J PATHOL, V128, P104; CORTES E, 1989, NEW ENGL J MED, V320, P953, DOI 10.1056/NEJM198904133201501; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DONALDSON YK, 1994, LANCET, V343, P382, DOI 10.1016/S0140-6736(94)91222-X; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EVANS LA, 1988, LANCET, V2, P1389; FRUMKIN LR, 1993, VIROLOGY, V195, P422, DOI 10.1006/viro.1993.1392; FULTZ PN, 1986, J VIROL, V58, P116, DOI 10.1128/JVI.58.1.116-124.1986; GARDNER MB, 1989, FASEB J, V3, P2593, DOI 10.1096/fasebj.3.14.2556312; GREZ M, 1994, J VIROL, V68, P2161, DOI 10.1128/JVI.68.4.2161-2168.1994; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; HIRSCH VM, 1991, J INFECT DIS, V163, P976, DOI 10.1093/infdis/163.5.976; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HSIA K, 1991, J INFECT DIS, V164, P470, DOI 10.1093/infdis/164.3.470; LETVIN NL, 1987, J INFECT DIS, V156, P406, DOI 10.1093/infdis/156.2.406; LI J, 1992, J ACQ IMMUN DEF SYND, V5, P639; LIVARTOWSKI J, 1992, CANCER DETECT PREV, V16, P341; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MARX PA, 1985, J VIROL, V56, P571, DOI 10.1128/JVI.56.2.571-578.1985; MCCLURE J, 1992, 10TH ANN S NONH PRIM; MORROW WJW, 1989, AIDS RES HUM RETROV, V5, P233, DOI 10.1089/aid.1989.5.233; NICOL I, 1989, INTERVIROLOGY, V30, P258, DOI 10.1159/000150101; OBRIEN TR, 1992, JAMA-J AM MED ASSOC, V267, P2775; PAN LZ, 1993, J CLIN MICROBIOL, V31, P283, DOI 10.1128/JCM.31.2.283-288.1993; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PEETERS M, 1991, AIDS, V5, pS29; PUTKONEN P, 1989, J ACQ IMMUN DEF SYND, V2, P366; RACZ P, 1986, PROG ALLERGY, V37, P81; RINGLER DJ, 1989, AM J PATHOL, V134, P373; ROSENBERG YJ, 1993, AIDS RES HUM RETROV, V9, P639, DOI 10.1089/aid.1993.9.639; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHROEDER SA, 1992, CHEST, V101, P1065, DOI 10.1378/chest.101.4.1065; SHIBATA R, 1992, AIDS RES HUM RETROV, V8, P403, DOI 10.1089/aid.1992.8.403; STAHLHENNIG C, 1990, AIDS, V4, P611, DOI 10.1097/00002030-199007000-00001; STROMBERG K, 1984, SCIENCE, V224, P289, DOI 10.1126/science.6200929; TEIRSTEIN AS, 1988, CLIN CHEST MED, V9, P467; WYAND MS, 1989, AM J PATHOL, V134, P385	46	83	84	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					642	646		10.1126/science.7939718	http://dx.doi.org/10.1126/science.7939718			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939718				2022-12-28	WOS:A1994PN80700046
J	KESSLER, DS; MELTON, DA				KESSLER, DS; MELTON, DA			VERTEBRATE EMBRYONIC INDUCTION - MESODERMAL AND NEURAL PATTERNING	SCIENCE			English	Review							FIBROBLAST GROWTH-FACTOR; MATERNAL MESSENGER-RNA; CENTRAL-NERVOUS-SYSTEM; ERYTHROID-DIFFERENTIATION FACTOR; ACTIVIN-BINDING PROTEIN; EARLY AMPHIBIAN EMBRYOS; XENOPUS-LAEVIS EMBRYOS; BONE MORPHOGENETIC PROTEIN-4; TGF-BETA FAMILY; FLOOR PLATE	Within the fertilized egg lies the information necessary to generate a diversity of cell types in the precise pattern of tissues and organs that comprises the vertebrate body. Seminal embryological experiments established the importance of induction, or cell interactions, in the formation of embryonic tissues and provided a foundation for molecular studies. In recent years, secreted gene products capable of inducing or patterning embryonic tissues have been identified. Despite these advances, embryologists remain challenged by fundamental questions: What are the endogenous inducing molecules? How is the action of an inducer spatially and temporally restricted? How does a limited group of inducers give rise to a diversity of tissues? In this review, the focus is on the induction and patterning of mesodermal and neural tissues in the frog Xenopus laevis, with an emphasis on families of secreted molecules that appear to underlie inductive events throughout vertebrate embryogenesis.			KESSLER, DS (corresponding author), HARVARD UNIV, HOWARD HUGHES MED INST, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; KESSLER, DANIEL/0000-0002-3557-2434				ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V116, P67; ALTABA ARI, 1990, DEVELOPMENT, V108, P595; AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANG SL, 1993, DEVELOPMENT, V118, P139; ASASHIMA M, 1990, NATURWISSENSCHAFTEN, V77, P389, DOI 10.1007/BF01135742; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BOLCE ME, 1992, DEVELOPMENT, V115, P681; BOTERENBROOD EC, 1973, ROUX ARCH DEV BIOL, V173, P319, DOI 10.1007/BF00575837; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; BRADLEY LC, 1993, MECH DEVELOP, V40, P73, DOI 10.1016/0925-4773(93)90089-G; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CONLON FL, 1991, DEVELOPMENT, V111, P969; CONLON FL, 1994, DEVELOPMENT, V120, P1919; COOKE J, 1986, NATURE, V319, P60, DOI 10.1038/319060a0; CORNELL RA, 1994, DEVELOPMENT, V120, P453; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1987, DEVELOPMENT, V100, P279; DALE L, 1987, DEVELOPMENT, V99, P527; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V269, P6259; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; DIXON JE, 1989, DEVELOPMENT, V106, P749; DOHRMANN CE, 1993, DEV BIOL, V157, P474, DOI 10.1006/dbio.1993.1150; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; ELINSON RP, 1989, DEV GROWTH DIFFER, V31, P423; ELINSON RP, 1988, DEV BIOL, V128, P185, DOI 10.1016/0012-1606(88)90281-3; Eyal-Giladi H, 1954, ARCH BIOL, V65, P180; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; FUKUI A, 1994, DEV BIOL, V163, P279, DOI 10.1006/dbio.1994.1143; FUKUI A, 1993, DEV BIOL, V159, P131, DOI 10.1006/dbio.1993.1227; GERHART J, 1981, NATURE, V292, P511, DOI 10.1038/292511a0; GERHART J, 1989, DEVELOPMENT, V107, P37; GERHART J, 1991, BOD MAR LAB, P57; GILBERT SF, 1994, DEV BIOL; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1994, DEVELOPMENT, V120, P2271; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; GURDON JB, 1993, CURR BIOL, V3, P1, DOI 10.1016/0960-9822(93)90139-F; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLAND RM, 1994, CURR OPIN GENET DEV, V4, P543, DOI 10.1016/0959-437X(94)90070-J; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLO.A, UNPUB; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1992, DEV DYNAM, V194, P1, DOI 10.1002/aja.1001940102; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; HIRANO S, 1991, SCIENCE, V251, P310, DOI 10.1126/science.1987648; HOLTFRETER J, 1933, ARCH ENTWICKLUNGSMEC, V129, P669; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; IRELAND GW, 1987, J ANAT, V152, P223; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JACOBSON M, 1986, DEV BIOL, V116, P524, DOI 10.1016/0012-1606(86)90153-3; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JESSELL TM, 1992, HARVEY LECT, V86, P87; JONES CM, 1992, DEVELOPMENT, V115, P639; JONES EA, 1989, DEVELOPMENT, V107, P785; JONES EA, 1993, ROUX ARCH DEV BIOL, V202, P233, DOI 10.1007/BF02427884; JONES EA, 1987, DEVELOPMENT, V101, P557; KAGEURA H, 1990, DEV BIOL, V142, P432, DOI 10.1016/0012-1606(90)90365-P; KELL, 1991, GASTRULATION MOVEMEN, P101; KELLER R, 1988, DEVELOPMENT, V103, P193; KELLER R, 1992, DEVELOPMENT, P81; Keller R.E., 1986, P241; KESSLER DA, UNPUB; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KOCHAV S, 1971, SCIENCE, V171, P1027, DOI 10.1126/science.171.3975.1027; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KU M, 1993, DEVELOPMENT, V119, P1161; LABONNE C, 1994, DEVELOPMENT, V120, P463; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MCGREW LL, 1992, DEVELOPMENT, V115, P463; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; MOON RT, 1992, CELL, V71, P709, DOI 10.1016/0092-8674(92)90545-N; MOON RT, 1993, DEVELOPMENT, V119, P97; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NAKAMURA O, 1970, P JPN ACAD, V46, P700, DOI 10.2183/pjab1945.46.700; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V163, P298, DOI 10.1007/BF00577017; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102; NIEUWKOOP PD, 1954, J EMBRYOL EXP MORPH, V2, P175; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; NISHIMATSU SI, 1993, GROWTH FACTORS, V8, P173, DOI 10.3109/08977199309011020; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Oppenheimer JM, 1936, J EXP ZOOL, V72, P409, DOI 10.1002/jez.1400720304; PAPALOPULU N, 1993, DEVELOPMENT, V117, P961; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; RAO Y, 1994, GENE DEV, V8, P939, DOI 10.1101/gad.8.8.939; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REBAGLIATI MR, 1993, DEV BIOL, V159, P574, DOI 10.1006/dbio.1993.1265; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; SAHA MS, 1992, NEURON, V8, P1003, DOI 10.1016/0896-6273(92)90123-U; SAHA MS, 1993, DEVELOPMENT, V118, P193; SATO SM, 1989, DEV BIOL, V134, P263, DOI 10.1016/0012-1606(89)90096-1; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SAXEN L, 1961, DEV BIOL, V3, P140, DOI 10.1016/0012-1606(61)90002-1; SAXEN L, 1989, International Journal of Developmental Biology, V33, P21; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SLACK JMW, 1992, DEVELOPMENT, V114, P285; SLACK JMW, 1988, DEVELOPMENT, V103, P581; SLACK JMW, 1989, DEVELOPMENT, V105, P147; SLACK JMW, 1980, J EMBRYOL EXP MORPH, V56, P283; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SLACK JMW, 1991, DEVELOPMENT, V113, P661; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STERN C, COMMUNICATION; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOREY KG, 1992, DEVELOPMENT, V114, P729; SUDARWAT.S, 1971, ROUX ARCH DEV BIOL, V166, P189, DOI 10.1007/BF00650029; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; SYMES K, 1994, DEVELOPMENT, V120, P2339; SYMES K, 1988, DEVELOPMENT, V104, P609; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; TASHIRO K, 1991, BIOCHEM BIOPH RES CO, V174, P1022, DOI 10.1016/0006-291X(91)91521-D; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; THOMSEN GH, UNPUB; TOLVONEN S, 1975, DIFFERENTIATION, V4, P1; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Ueno N, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046927; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VANSTRAATEN HWM, 1989, DEVELOPMENT, V107, P793; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VANSTRAATEN HWM, 1991, ANAT EMBRYOL, V184, P55; VANSTRAATEN HWM, 1985, ACTA MORPHOL NEER SC, V23, P91; VANSTRAATEN HWM, 1985, DEV BIOL, V110, P247, DOI 10.1016/0012-1606(85)90081-8; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; Waddington CH, 1933, ROUX ARCH DEV BIOL, V128, P522, DOI 10.1007/BF00649863; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WILSON P, 1991, DEVELOPMENT, V112, P289; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WITTBRODT J, 1994, GENE DEV, V8, P1448, DOI 10.1101/gad.8.12.1448; WOLDA SL, 1993, DEV BIOL, V155, P46, DOI 10.1006/dbio.1993.1005; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YAMADA T, 1950, EMBRYOLOGIA, V1, P1; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	218	281	284	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	1994	266	5185					596	604		10.1126/science.7939714	http://dx.doi.org/10.1126/science.7939714			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939714				2022-12-28	WOS:A1994PN80700038
J	PATEL, NH				PATEL, NH			DEVELOPMENTAL EVOLUTION - INSIGHTS FROM STUDIES OF INSECT SEGMENTATION	SCIENCE			English	Article							LOCUST SCHISTOCERCA-GREGARIA; EVEN-SKIPPED PROTEIN; BICOID MESSENGER-RNA; HOMEOBOX GENE XHOX3; PAIR-RULE GENE; DROSOPHILA-MELANOGASTER; PATTERN-FORMATION; LARVAL CUTICLE; ZYGOTIC LOCI; EARLY EMBRYOGENESIS	Rapid advances have been made in the understanding of the genetic basis of development and pattern formation in a variety of model systems. By examining the extent to which these developmental systems are conserved or altered between different organisms, insight can be gained into the evolutionary events that have generated the diversity of organisms around us. The molecular and genetic basis of early pattern formation in Drosophila melanogaster has been particularly well studied, and comparisons to other insects have revealed conservation of some aspects of development, as well as differences that may explain variations in early patterning events.			PATEL, NH (corresponding author), CARNEGIE INST WASHINGTON, DEPT EMBRYOL, 115 W UNIV PKWY, BALTIMORE, MD 21210 USA.			Patel, Nipam/0000-0003-4328-654X				AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM M, IN PRESS DEVELOPME S; ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; [Anonymous], COMMUNICATION; ARIAS AM, 1985, NATURE, V313, P639; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BIER E, 1992, GENE DEV, V6, P2137, DOI 10.1101/gad.6.11.2137; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; BROWN SJ, 1994, DEV GENET, V15, P7, DOI 10.1002/dvg.1020150103; BROWN SJ, IN PRESS P NATL ACAD; Chasan Rebecca, 1993, P387; CHEN LS, 1994, DEVELOPMENT, V120, P1631; DARWIN C, 1993, ORIGIN SPECIWS, P586; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DAWES R, 1994, DEVELOPMENT, V120, P1561; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; DUSH MK, 1992, DEV BIOL, V151, P273, DOI 10.1016/0012-1606(92)90232-6; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FLEIG R, 1990, ROUX ARCH DEV BIOL, V198, P467, DOI 10.1007/BF00399057; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; GOULD SJ, 1977, ONTOGENY PHYLOGENY, P69; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; ISHHOROWICZ D, 1988, DEVELOPMENT, V104, P67; JEFFERY WR, 1992, BIOESSAYS, V14, P219, DOI 10.1002/bies.950140404; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARR TL, 1989, DEVELOPMENT, V105, P605; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; KELSH R, 1993, DEVELOPMENT, V117, P293; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KLINGLER M, 1994, BIOESSAYS, V16, P391, DOI 10.1002/bies.950160605; KRAFT R, 1994, P NATL ACAD SCI USA, V91, P6634, DOI 10.1073/pnas.91.14.6634; KRISTENSEN NP, 1981, ANNU REV ENTOMOL, V26, P135, DOI 10.1146/annurev.en.26.010181.001031; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LABANDEIRA CC, 1993, SCIENCE, V261, P310, DOI 10.1126/science.11536548; LAWRENCE PA, 1988, DEVELOPMENT, V104, P61; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MILES A, 1992, P ROY SOC B-BIOL SCI, V248, P159, DOI 10.1098/rspb.1992.0057; MILLER DJ, 1993, NATURE, V365, P215, DOI 10.1038/365215b0; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; NAGY LM, 1994, NATURE, V367, P460, DOI 10.1038/367460a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Pankratz Michael J., 1993, P467; PATEL NH, 1994, NATURE, V367, P429, DOI 10.1038/367429a0; PATEL NH, 1989, DEVELOPMENT, V107, P201; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; PATEL NH, 1993, EVOLUTIONARY CONSERVATION OF DEVELOPMENTAL MECHANISMS, P85; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PATEL NH, IN PRESS DEVELOPME S; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; PULTZ MA, COMMUNICATION; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; Sander K., 1983, DEV EVOLUTION, P137; SCHRODER R, 1993, ROUX ARCH DEV BIOL, V203, P34, DOI 10.1007/BF00539888; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHWALM FE, 1988, INSECT MORPHOGENESIS, P1; SEEGER MA, 1990, EMBO J, V9, P2977, DOI 10.1002/j.1460-2075.1990.tb07490.x; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SOMMER R, 1991, DEVELOPMENT, V113, P419; SOMMER RJ, 1993, NATURE, V361, P448, DOI 10.1038/361448a0; SOMMER RJ, 1994, SCIENCE, V265, P114, DOI 10.1126/science.8016644; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; SULSTON I, COMMUNICATION; TEAR G, 1990, DEVELOPMENT, V110, P915; WEBSTER PJ, 1994, DEVELOPMENT, V120, P2027; WEDEEN CJ, 1991, DEVELOPMENT, V113, P805; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; WHITING MF, 1994, NATURE, V368, P696, DOI 10.1038/368696a0; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WRAY GA, 1989, DEV BIOL, V132, P458, DOI 10.1016/0012-1606(89)90242-X; WURST W, 1994, DEVELOPMENT, V120, P2065; XU X, 1994, DEVELOPMENT, V120, P277	95	134	137	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	1994	266	5185					581	590		10.1126/science.7939712	http://dx.doi.org/10.1126/science.7939712			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939712				2022-12-28	WOS:A1994PN80700036
J	THOMAS, KB				THOMAS, KB			THE PLACEBO IN GENERAL-PRACTICE	LANCET			English	Article											THOMAS, KB (corresponding author), UNIV SOUTHAMPTON,ALDERMOOR HLTH CTR,DEPT PRIMARY MED CARE,SOUTHAMPTON SO1 6ST,HANTS,ENGLAND.							BALINT M, 1957, DOCTOR PATIENT ILLNE; Cartwright Ann, 1967, PATIENTS THEIR DOCTO; CROMBIE DL, 1963, J COLL GEN PRACTIT, V6, P582; EIMERL TS, 1962, THESIS U LIVERPOOL; Lin T, 1962, SCOPE EPIDEMIOLOGY P; Marinker M, 1970, J R Coll Gen Pract, V19, P79; Marinker M, 1967, J R Coll Gen Pract, V14, P59; SHEPHERD M, 1966, PSYCHIATRIC ILLNESS; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; THOMAS KB, 1974, BRIT MED J, V1, P625, DOI 10.1136/bmj.1.5908.625; THOMAS KB, 1978, BRIT MED J, P1327; THOMAS KB, 1972, THESIS U LIVERPOOL; WILSON RM, 1926, BELOVED PHYSICIAN; 1958, 14 GEN REG OFF SUBJ; 1958, J COLL GEN PRACTIT, V1, P107; 1970, BRIT MED J, V11, P437; 1974, OFFICE POPULATION CE	17	56	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1066	1067		10.1016/S0140-6736(94)91716-7	http://dx.doi.org/10.1016/S0140-6736(94)91716-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934451				2022-12-28	WOS:A1994PL85200016
J	CHALMERS, I; HAYNES, B				CHALMERS, I; HAYNES, B			SYSTEMATIC REVIEWS - REPORTING, UPDATING, AND CORRECTING SYSTEMATIC REVIEWS OF THE EFFECTS OF HEALTH-CARE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIALS; MYOCARDIAL-INFARCTION	The recent growth in the numbers of published systematic reviews reflects growing recognition of their importance for improving knowledge about the effects of health care. In Britain the NHS R&D Programme has established two centres to prepare systematic reviews of existing information, and the Cochrane Collaboration-an international network of individuals and institutions-evolved to produce systematic, periodically updated reviews of randomised controlled trials. The large amount of existing evidence that needs to be considered creates a problem for the reporting of systematic reviews: the need to ensure that methods and results of systematic reviews are adequately described has to be reconciled with the limited space available in printed journals. A possible solution is the use of electronic publications: reviews could be published simultaneously in a short, printed form and in a more detailed electronic form. Electronic publications also have the advantage of the ease with which reviews may be updated as new evidence becomes available or mistakes are identified.	MCMASTER UNIV, MED CTR, CANADIAN COCHRANE CTR, HLTH INFORMAT RES UNIT, HAMILTON L8N 3Z5, ON, CANADA	McMaster University	CHALMERS, I (corresponding author), NHS RES & DEV PROGRAMME, UK COCHRANE CTR, OXFORD OX2 7LG, ENGLAND.							ABE O, 1992, LANCET, V339, P71; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1986, LANCET, V2, P79; [Anonymous], 1994, BMJ, V308, P235; [Anonymous], 1994, BMJ, V308, P159; [Anonymous], 1992, Lancet, V339, P1; [Anonymous], 1986, Lancet, V2, P57; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BAUSELL RB, 1993, EVAL HEALTH PROF, V16, P3, DOI 10.1177/016327879301600101; CHALMERS I, 1986, LANCET, V2, P287; CHALMERS I, 1993, MILBANK Q, V71, P411, DOI 10.2307/3350409; COCHRANE AL, 1979, MED YEAR 2000; DICKERSIN K, 1990, CONTROL CLIN TRIALS, V11, P52, DOI 10.1016/0197-2456(90)90032-W; ENKIN M, IN PRESS GUIDE EFFEC; HAYNES RB, 1990, ANN INTERN MED, V113, P724, DOI 10.7326/0003-4819-113-9-724; HAYNES RB, 1991, BRIT MED J, P116; HUTH EJ, 1987, ANN INTERN MED, V106, P470, DOI 10.7326/0003-4819-106-3-470_2; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; LOCK S, 1992, LANCET, V339, P249, DOI 10.1016/0140-6736(92)90056-9; LOCK S, 1986, QUESTION BALANCE EDI; Lock Stephen P., 1991, FUTURE MED J, P127; LOMAS J, 1993, MILBANK Q, V71, P405, DOI 10.2307/3350408; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PATERSONBROWN S, 1993, BMJ-BRIT MED J, V307, P1464, DOI 10.1136/bmj.307.6917.1464; PENTECOST BL, 1987, OXFORD TXB MED, V2, P13; SAUNDERS MC, 1985, LANCET, V2, P793, DOI 10.1016/S0140-6736(85)90792-5; SMITH R, 1994, BRIT MED J, V308, P69; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; WANG PH, 1993, ONLINE J CURREN 0521; YUSUF S, 1983, DRUGS, V25, P441, DOI 10.2165/00003495-198325050-00001; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; 1992, LANCET, V340, P519; 1993, INTRO BROCHURE; 1993, COCHRANE DATABASE SY	35	110	111	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	1994	309	6958					862	865		10.1136/bmj.309.6958.862	http://dx.doi.org/10.1136/bmj.309.6958.862			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7950620	Green Published			2022-12-28	WOS:A1994PK50100031
J	CHILVERS, C				CHILVERS, C			ORAL-CONTRACEPTIVES AND CANCER	LANCET			English	Editorial Material							BREAST-CANCER; AGE				CHILVERS, C (corresponding author), UNIV NOTTINGHAM,SCH MED,DEPT EPIDEMIOL & PUBL HLTH MED,NOTTINGHAM,ENGLAND.							CHILVERS CED, 1994, BRIT J CANCER, V67, P922; KAY CR, 1988, BRIT J CANCER, V58, P675, DOI 10.1038/bjc.1988.285; LAVECCHIA C, 1992, BREAST, V1, P76; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; PIKE MC, 1983, LANCET, V2, P926; PRENTICE RL, 1987, ADV CANCER RES, V49, P285, DOI 10.1016/S0065-230X(08)60801-5; VESSEY M, 1982, LANCET, V1, P841; VESSEY MP, 1989, BRIT J CANCER, V59, P613, DOI 10.1038/bjc.1989.124; VESSEY MP, 1990, ORAL CONTRACEPTIVES	9	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1378	1379		10.1016/S0140-6736(94)90561-4	http://dx.doi.org/10.1016/S0140-6736(94)90561-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968068				2022-12-28	WOS:A1994PR78600002
J	GRAM, LF				GRAM, LF			DRUG-THERAPY - FLUOXETINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MAJOR DEPRESSIVE DISORDER; SEROTONIN-UPTAKE INHIBITOR; DEBRISOQUINE OXIDATION POLYMORPHISM; OBSESSIVE-COMPULSIVE DISORDER; CONTROLLED CLINICAL-TRIAL; DOUBLE-BLIND PARALLEL; PLASMA-CONCENTRATIONS; NORFLUOXETINE ENANTIOMERS; TRICYCLIC ANTIDEPRESSANTS; DIABETIC NEUROPATHY				GRAM, LF (corresponding author), ODENSE UNIV, MED BIOL INST, DEPT CLIN PHARMACOL, WINSLOWPARKEN 19, DK-5000 ODENSE C, DENMARK.							ALTAMURA AC, 1989, INT J CLIN PHARM RES, V9, P391; Andersen B, 1990, J AFFECT DISORDERS, V18, P289; ANSSEAU M, 1992, BIOL PSYCHIAT, V31, P109; ARONOFF GR, 1984, CLIN PHARMACOL THER, V36, P138, DOI 10.1038/clpt.1984.152; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; BEASLEY CM, 1991, BRIT MED J, V303, P968; BELL IR, 1988, J CLIN PSYCHOPHARM, V8, P447, DOI 10.1097/00004714-198812000-00025; BERGSTROM RF, 1992, CLIN PHARMACOL THER, V51, P239, DOI 10.1038/clpt.1992.18; BERGSTROM RF, 1988, BRIT J PSYCHIAT, V153, P47, DOI 10.1192/S0007125000297286; Borg Stefan, 1992, P30; BORYS DJ, 1992, AM J EMERG MED, V10, P115, DOI 10.1016/0735-6757(92)90041-U; BREMNER JD, 1984, J CLIN PSYCHIAT, V45, P414; BROSEN K, 1991, BRIT J CLIN PHARMACO, V32, P136, DOI 10.1111/j.1365-2125.1991.tb05630.x; BROSEN K, 1989, EUR J CLIN PHARMACOL, V36, P537, DOI 10.1007/BF00637732; BUFF DD, 1991, J CLIN PSYCHIAT, V52, P174; BYERLEY WF, 1988, J CLIN PSYCHOPHARM, V8, P112; CHOUINARD G, 1985, J CLIN PSYCHIAT, V46, P32; COHN JB, 1989, INT CLIN PSYCHOPHARM, V4, P313, DOI 10.1097/00004850-198910000-00006; COHN JB, 1985, J CLIN PSYCHIAT, V46, P26; COOPER GL, 1988, BRIT J PSYCHIAT, V153, P77, DOI 10.1192/S000712500029733X; CORNE SJ, 1989, INT CLIN PSYCHOPHARM, V4, P245, DOI 10.1097/00004850-198907000-00007; DARGA LL, 1991, AM J CLIN NUTR, V54, P321, DOI 10.1093/ajcn/54.2.321; DEJONGHE F, 1991, PHARMACOPSYCHIATRY, V24, P62, DOI 10.1055/s-2007-1014440; DERBY LE, 1992, J CLIN PSYCHOPHARM, V12, P235; DORNSEIF BE, 1989, PSYCHOPHARMACOL BULL, V25, P71; DOWLING B, 1990, IRISH J PSYCHIAT SPR, P3; DUNLOP SR, 1990, PSYCHOPHARMACOL BULL, V26, P173; DURSUN SM, 1993, LANCET, V342, P442, DOI 10.1016/0140-6736(93)92860-V; ELLISON JM, 1990, J CLIN PSYCHIAT, V51, P385; FABRE LF, 1991, J CLIN PSYCHIAT, V52, P62; FAWCETT J, 1989, CURR THER RES CLIN E, V45, P821; FEIGHNER JP, 1985, J CLIN PSYCHIAT, V46, P20; FEIGHNER JP, 1989, INT CLIN PSYCHOPHARM, V4, P127, DOI 10.1097/00004850-198904000-00004; FEIGHNER JP, 1990, J CLIN PSYCHIAT, V51, P222; FEIGHNER JP, 1985, J CLIN PSYCHIAT, V46, P369; FERGUSON JM, 1987, INT J OBESITY, V11, P163; FULLER RW, 1992, NEUROPHARMACOLOGY, V31, P997, DOI 10.1016/0028-3908(92)90100-4; GERRA G, 1992, CURR THER RES CLIN E, V52, P291, DOI 10.1016/S0011-393X(05)80480-1; GOFF DC, 1991, AM J PSYCHIAT, V148, P790; GRAM LF, 1990, CLIN NEUROPHARMACOL, V13, pS35; GRIMSLEY SR, 1991, CLIN PHARMACOL THER, V50, P10, DOI 10.1038/clpt.1991.98; HALMAN M, 1990, BIOL PSYCHIAT, V28, P518, DOI 10.1016/0006-3223(90)90485-K; HALPER JP, 1988, BRIT J PSYCHIAT, V153, P87, DOI 10.1192/S0007125000297341; HERMAN JB, 1990, J CLIN PSYCHIAT, V51, P25; HWANG AS, 1989, AM J PSYCHIAT, V146, P399; HYTTEL J, 1985, ACTA PHARMACOL TOX, V56, P146; ISACSSON G, 1994, BRIT MED J, V308, P506, DOI 10.1136/bmj.308.6927.506; KAYE WH, 1991, J CLIN PSYCHIAT, V52, P464; KEEGAN D, 1991, INT CLIN PSYCHOPHARM, V6, P117, DOI 10.1097/00004850-199100620-00007; Kuha S, 1991, NORD PSYCHIAT TIDSSK, V45, P109; LAAKMANN G, 1988, BRIT J PSYCHIAT, V153, P64, DOI 10.1192/S0007125000297316; LAPIA S, 1992, CURR THER RES CLIN E, V52, P847, DOI 10.1016/S0011-393X(05)80057-8; LAUTERBACH EC, 1991, CLIN NEUROPHARMACOL, V14, P547, DOI 10.1097/00002826-199112000-00007; LEMBERGER L, 1985, J CLIN PSYCHIAT, V46, P14; LEMBERGER L, 1978, CLIN PHARMACOL THER, V23, P421; LEVINE LR, 1987, INT J OBESITY, V11, P185; LEVINE LR, 1989, INT J OBESITY, V13, P635; LEVINE S, 1987, BRIT J PSYCHIAT, V150, P653, DOI 10.1192/bjp.150.5.653; MANN JJ, 1991, ARCH GEN PSYCHIAT, V48, P1027; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; MENKES DB, 1992, BRIT MED J, V305, P346, DOI 10.1136/bmj.305.6849.346; MILLER LG, 1989, AM J PSYCHIAT, V146, P1616; Montgomery S A, 1993, Eur Neuropsychopharmacol, V3, P143, DOI 10.1016/0924-977X(93)90266-O; MUIJEN M, 1988, ACTA PSYCHIAT SCAND, V78, P384, DOI 10.1111/j.1600-0447.1988.tb06353.x; MULY EC, 1993, AM J PSYCHIAT, V150, P1565; NARANJO CA, 1990, CLIN PHARMACOL THER, V47, P490, DOI 10.1038/clpt.1990.62; NIELSEN BM, 1993, ACTA PSYCHIAT SCAND, V87, P269, DOI 10.1111/j.1600-0447.1993.tb03370.x; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; PATO MT, 1991, J CLIN PSYCHOPHARM, V11, P224, DOI 10.1097/00004714-199106000-00024; PIGOTT TA, 1990, ARCH GEN PSYCHIAT, V47, P926; Preskorn S.H., 1991, ANN CLIN PSYCHIATRY, V3, P147, DOI [10.3109/10401239109147984, DOI 10.3109/10401239109147984]; PRESKORN SH, 1990, AM J PSYCHIAT, V147, P532; REMICK RA, 1989, CURR THER RES CLIN E, V46, P842; ROOSE SP, IN PRESS AMJ PSYCHIA; ROTHSCHILD AJ, 1991, J CLIN PSYCHIAT, V52, P491; SCHENKER S, 1988, CLIN PHARMACOL THER, V44, P353, DOI 10.1038/clpt.1988.161; SCHWEIZER E, 1990, J CLIN PSYCHIAT, V51, P8; SHOLOMSKAS AJ, 1990, AM J PSYCHIAT, V147, P1090; SINDRUP SH, 1993, THER DRUG MONIT, V15, P11, DOI 10.1097/00007691-199302000-00002; SINDRUP SH, 1992, CLIN PHARMACOL THER, V52, P547, DOI 10.1038/clpt.1992.183; SPINA E, 1993, THER DRUG MONIT, V15, P247; STARK P, 1985, J CLIN PSYCHIAT, V46, P53; STERNBACH H, 1988, LANCET, V2, P850; STEUR ENHJ, 1993, NEUROLOGY, V43, P211; STONE AB, 1991, J CLIN PSYCHIAT, V52, P290; STRATTA P, 1991, INT CLIN PSYCHOPHARM, V6, P193, DOI 10.1097/00004850-199100630-00007; TAMMINEN TTA, 1989, INT CLIN PSYCHOPHARM, V4, P51; TEICHER MH, 1990, AM J PSYCHIAT, V147, P207; TOROKBOTH GA, 1992, J CHROMATOGR-BIOMED, V579, P99, DOI 10.1016/0378-4347(92)80367-Y; VAUGHAN DA, 1988, AM J PSYCHIAT, V145, P1478; VISHWANATH BM, 1991, AM J PSYCHIAT, V148, P542; WALLEY T, 1993, LANCET, V341, P967, DOI 10.1016/0140-6736(93)91265-N; WALSH BT, 1991, J PSYCHOSOM RES, V35, P33, DOI 10.1016/0022-3999(91)90111-Z; WERNICKE JF, 1988, PSYCHOPHARMACOL BULL, V24, P183; WERNICKE JF, 1987, PSYCHOPHARMACOL BULL, V23, P164; WERNICKE JF, 1985, J CLIN PSYCHIAT, V46, P59; WERNICKE JF, 1989, INT CLIN PSYCHOPHARM, V4, P63; WONG DT, 1975, J PHARMACOL EXP THER, V193, P804; WONG DT, 1985, DRUG DEVELOP RES, V6, P397, DOI 10.1002/ddr.430060412; YOUNG JPR, 1987, BRIT J PSYCHIAT, V151, P337, DOI 10.1192/bjp.151.3.337; 1992, ARCH GEN PSYCHIAT, V49, P139; 1988, INT CLIN PSYCHOPHARM, V3, P75; 1986, PSYCHOPHARMACOLOGY, V90, P131	103	201	204	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1354	1361						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935707				2022-12-28	WOS:A1994PR21600008
J	WEINTRAUB, WS; BOCCUZZI, SJ; KLEIN, JL; KOSINSKI, AS; KING, SB; IVANHOE, R; CEDARHOLM, JC; STILLABOWER, ME; TALLEY, JD; DEMAIO, SJ; ONEILL, WW; FRAZIER, JE; COHENBERNSTEIN, CL; ROBBINS, DC; BROWN, CL; ALEXANDER, RW; OWEN, D; SCHUMACHER, P; MITCHEL, YB; HIRSCH, LJ; MELINO, MR; BEATTIE, OP; GUDEL, D; PLOTKIN, D; TATE, A; ZUPKIS, R; SHAPIRO, D; HALL, WD; KUTNER, M; WATTS, N; SCHLANT, R; SHEN, Y; HICKS, F; CANUP, D; PERLEE, P; LE, A; HOWARD, J; HOWARD, B; BROWN, WV; LI, X; TREASURE, C; GATLIN, S; HURST, JW; SCHROEDER, D; HARRISON, D; DELAFONTAINE, P; RUNGE, M; ALAZRAKI, N; TAYLOR, A; DOUGLAS, JS; KIM, S; THORNTON, A; HAYNES, S; WEBSTER, J; MERLINO, J; MORRIS, DC; LIBERMAN, HA; WEAVER, C; CURRY, C; WILLIS, W; ROSS, D; BERSIN, RM; ELLIOT, CM; HABER, RH; KOWALCHUK, GJ; SIMONTON, CA; WILSON, BH; ZIMMERN, SH; PORTER, B; TUCKER, T; CRENSHAW, M; HALL, D; WALPOLE, H; GLAZER, M; THOMPSON, J; SPITLER, E; CHURCHWELL, A; ROSENTHAL, RL; SCHUMACHER, JR; GRODIN, JM; JOHNSTON, SB; FRANKLIN, JO; LEONARD, BM; ROSENBERG, FR; RAICH, A; GOLDENBERG, EM; DOOREY, A; WEST, J; HOPKINS, JT; BLASETTO, JW; RITTER, JM; ZOLNICK, MR; ALFIERI, A; BOYLE, K; GRUBBS, D; DISABATINO, A; FEEHS, S; PICORA, MJ; DONOHUE, BC; HART, N; GRANATO, J; GRILL, H; STRACCI, P; FLORES, A; SCHULMAN, D; ZAHREN, L; ORIE, JE; ONEILL, C; KENNEDY, K; MCMARTIN, D; YUSSMAN, Z; ETKA, W; CORWIN, J; MOONEY, M; FISHMANMOONEY, J; KUMMER, B; KNOPF, W; LEMBO, N; SHAFTEL, J; CAMP, C; MOYE, R				WEINTRAUB, WS; BOCCUZZI, SJ; KLEIN, JL; KOSINSKI, AS; KING, SB; IVANHOE, R; CEDARHOLM, JC; STILLABOWER, ME; TALLEY, JD; DEMAIO, SJ; ONEILL, WW; FRAZIER, JE; COHENBERNSTEIN, CL; ROBBINS, DC; BROWN, CL; ALEXANDER, RW; OWEN, D; SCHUMACHER, P; MITCHEL, YB; HIRSCH, LJ; MELINO, MR; BEATTIE, OP; GUDEL, D; PLOTKIN, D; TATE, A; ZUPKIS, R; SHAPIRO, D; HALL, WD; KUTNER, M; WATTS, N; SCHLANT, R; SHEN, Y; HICKS, F; CANUP, D; PERLEE, P; LE, A; HOWARD, J; HOWARD, B; BROWN, WV; LI, X; TREASURE, C; GATLIN, S; HURST, JW; SCHROEDER, D; HARRISON, D; DELAFONTAINE, P; RUNGE, M; ALAZRAKI, N; TAYLOR, A; DOUGLAS, JS; KIM, S; THORNTON, A; HAYNES, S; WEBSTER, J; MERLINO, J; MORRIS, DC; LIBERMAN, HA; WEAVER, C; CURRY, C; WILLIS, W; ROSS, D; BERSIN, RM; ELLIOT, CM; HABER, RH; KOWALCHUK, GJ; SIMONTON, CA; WILSON, BH; ZIMMERN, SH; PORTER, B; TUCKER, T; CRENSHAW, M; HALL, D; WALPOLE, H; GLAZER, M; THOMPSON, J; SPITLER, E; CHURCHWELL, A; ROSENTHAL, RL; SCHUMACHER, JR; GRODIN, JM; JOHNSTON, SB; FRANKLIN, JO; LEONARD, BM; ROSENBERG, FR; RAICH, A; GOLDENBERG, EM; DOOREY, A; WEST, J; HOPKINS, JT; BLASETTO, JW; RITTER, JM; ZOLNICK, MR; ALFIERI, A; BOYLE, K; GRUBBS, D; DISABATINO, A; FEEHS, S; PICORA, MJ; DONOHUE, BC; HART, N; GRANATO, J; GRILL, H; STRACCI, P; FLORES, A; SCHULMAN, D; ZAHREN, L; ORIE, JE; ONEILL, C; KENNEDY, K; MCMARTIN, D; YUSSMAN, Z; ETKA, W; CORWIN, J; MOONEY, M; FISHMANMOONEY, J; KUMMER, B; KNOPF, W; LEMBO, N; SHAFTEL, J; CAMP, C; MOYE, R			LACK OF EFFECT OF LOVASTATIN ON RESTENOSIS AFTER CORONARY ANGIOPLASTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FISH OIL SUPPLEMENTS; CONTROLLED TRIAL; ARTERY DISEASE; DOUBLE-BLIND; ATHEROSCLEROSIS-REGRESSION; EICOSAPENTAENOIC ACID; BALLOON ANGIOPLASTY; BYPASS-SURGERY; HEART-DISEASE; PREVENTION	Background. Experimental and clinical observations suggest that lowering serum lipid levels may reduce the risk of restenosis after coronary angioplasty. We report the results of a prospective, randomized, double-blind trial evaluating whether lowering lipid levels with lovastatin can prevent or delay restenosis after angioplasty. Methods. Seven to 10 days before angioplasty, we randomly assigned eligible patients to receive lovastatin (40 mg orally twice daily) or placebo. Patients who underwent successful, complication-free, first-time angioplasty of a native vessel (the index lesion) continued to receive therapy for six months, when a second coronary angiogram was obtained. The primary end point was the-extent of restenosis of the index lesion, as assessed by quantitative coronary arteriography. Of 404 patients randomly assigned to study groups, 384 underwent angioplasty; 354 of the procedures were successful, and 321 patients underwent angiographic restudy at six months. Results. At base line, the patients in the lovastatin group (n = 203) and the placebo group (n = 201) were similar with respect to demographic clinical, angiographic, and laboratory characteristics. At base line the mean (+/-SD) degree of stenosis, expressed as a percentage of the diameter of the vessel, was 64+/-11 percent in the lovastatin group, as compared with 63+/-11 percent in the placebo group (P = 0.22). Despite a 42 percent reduction in the serum level of low-density lipoprotein cholesterol in the lovastatin group, after six months of treatment the amount of stenosis seen in the second angiogram was 46+/-20 percent in the placebo group, as compared with 44+/-21 percent in the lovastatin group (P = 0.50). Similarly, there were no significant differences in minimal luminal diameter or other measures of restenosis. A trend was noted toward more myocardial infarctions in the lovastatin group, as a result of acute vessel closure or restenosis at the site of angioplasty, but there were no other important differences between the two groups in the frequency of fatal or nonfatal events at six months. Conclusions. Treatment with high-dose lovastatin initiated before coronary angioplasty does not prevent or delay the process of restenosis in the first six months after the procedure.	EMORY UNIV,SCH MED,DEPT MED,DIV CARDIOL,ATLANTA,GA; EMORY UNIV,SCH PUBL HLTH,DEPT BIOSTAT,ATLANTA,GA; MERCK & CO INC,RES LABS,RAHWAY,NJ; FLORIDA HOSP MED CTR,ORLANDO,FL; CHARLOTTE MEM HOSP,CHARLOTTE,NC; MED CTR DELAWARE,WILMINGTON,DE; UNIV LOUISVILLE,LOUISVILLE,KY 40292; BAYLOR HOSP,DALLAS,TX; WILLIAM BEAUMONT HOSP,ROYAL OAK,MI; ALLEGHENY MED CTR,PITTSBURGH,PA; WASHINGTON HOSP CTR,WASHINGTON,DC 20010; PIEDMONT HOSP,ATLANTA,GA; EMORY UNIV HOSP,DATA & SAFETY MONITORING BOARD,ATLANTA,GA; EMORY UNIV HOSP,CTR BIOSTAT COORDINATING,ATLANTA,GA; EMORY UNIV HOSP,LIPID CORE LAB,ATLANTA,GA; EMORY UNIV HOSP,ANGIOG CORE LAB,ATLANTA,GA; EMORY UNIV HOSP,ELECTROCARDIOG CORE LAB,ATLANTA,GA; EMORY UNIV HOSP,MORTAL & MORBID COMM,ATLANTA,GA; EMORY UNIV HOSP,THALLIUM ADVISORY BOARD,ATLANTA,GA; ST THOMAS HOSP,NASHVILLE,TN; MINNEAPOLIS HEART INST,MINNEAPOLIS,MN; ST JOSEPHS HOSP,ATLANTA,GA	Emory University; Emory University; Merck & Company; Adventist Health Services; AdventHealth; Carolinas Medical Center; University of Louisville; Beaumont Health; MedStar Washington Hospital Center; Emory University; Emory University; Emory University; Emory University; Emory University; Emory University; Emory University; Saint Thomas Hospital; Minneapolis Heart Institute Foundation			Brown, William/GXN-2777-2022					AUSTIN GE, 1992, CIRCULATION, V85, P1613, DOI 10.1161/01.CIR.85.4.1613; BAIRATI I, 1992, CIRCULATION, V85, P950, DOI 10.1161/01.CIR.85.3.950; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1992, JAMA-J AM MED ASSOC, V268, P1429, DOI 10.1001/jama.268.11.1429; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CARVALHO AC, 1974, NEW ENGL J MED, V290, P434, DOI 10.1056/NEJM197402212900805; DEHMER GJ, 1988, NEW ENGL J MED, V319, P733, DOI 10.1056/NEJM198809223191201; DETRE K, 1989, CIRCULATION, V80, P421, DOI 10.1161/01.CIR.80.3.421; ECKARDT H, 1991, EUR HEART J SUPPL, V12, P9; ELLIS SG, 1989, AM J CARDIOL, V63, P30, DOI 10.1016/0002-9149(89)91071-0; GALAN KM, 1986, HEART LUNG, V15, P585; GELLMAN J, 1991, J AM COLL CARDIOL, V17, P251, DOI 10.1016/0735-1097(91)90735-R; GRIGG LE, 1989, J AM COLL CARDIOL, V13, P665, DOI 10.1016/0735-1097(89)90609-8; HARKER LA, 1987, AM J CARDIOL, V60, pB20; HILLEGASS WB, 1994, TXB INTERVENTIONAL C, V1, P415; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; JACOBS AK, 1994, J AM COLL CARDIOL S, V23, pA59; KENT KM, 1993, CIRCULATION, V88, P506; KLEIN JL, 1992, CIRCULATION, V86, P121; KOPPENSTEINER R, 1990, ATHEROSCLEROSIS, V83, P53, DOI 10.1016/0021-9150(90)90130-B; LAMBERT M, 1988, J AM COLL CARDIOL, V12, P310, DOI 10.1016/0735-1097(88)90399-3; MILNER MR, 1989, AM J CARDIOL, V64, P294, DOI 10.1016/0002-9149(89)90522-5; MYLER RK, 1987, CATHETER CARDIO DIAG, V13, P1, DOI 10.1002/ccd.1810130102; NYE ER, 1990, AUST NZ J MED, V20, P549, DOI 10.1111/j.1445-5994.1990.tb01311.x; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; REIS GJ, 1989, LANCET, V2, P177; SAHNI R, 1991, AM HEART J, V121, P1600, DOI 10.1016/0002-8703(91)90002-Y; SCHNEIDER J E, 1992, Journal of the American College of Cardiology, V19, p163A; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WEINTRAUB WS, 1990, AM J CARDIOL, V65, P183, DOI 10.1016/0002-9149(90)90082-C; WEINTRAUB WS, 1993, J AM COLL CARDIOL, V21, P6, DOI 10.1016/0735-1097(93)90711-9; WEINTRAUB WS, 1992, AM J CARDIOL, V70, P293, DOI 10.1016/0002-9149(92)90607-Z; 1992, CIRCULATION, V86, P100	40	234	243	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1331	1337		10.1056/NEJM199411173312002	http://dx.doi.org/10.1056/NEJM199411173312002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935702	Bronze			2022-12-28	WOS:A1994PR21600002
J	RUBIN, CD; REED, B; SAKHAEE, K; PAK, CYC				RUBIN, CD; REED, B; SAKHAEE, K; PAK, CYC			TREATING A PATIENT WITH THE WERNER SYNDROME AND OSTEOPOROSIS USING RECOMBINANT HUMAN INSULIN-LIKE GROWTH-FACTOR	ANNALS OF INTERNAL MEDICINE			English	Note							FACTOR-I; BONE TURNOVER; SOMATOMEDIN; INHIBITION; WOMEN	Objective: To assess the safety and effect of recombinant human insulin-like growth factor 1 (rhIGF-1) on measures of bone metabolism in a human model of age-related osteoporosis. Design: 6-month prospective case study. Setting: General clinical research center. Patients: 1 patient with the Werner syndrome, a low serum IGF-1 level, and osteoporosis. Intervention: Daily subcutaneous administration of rhIGF-1 for 6 months. Measurements: Serum alkaline phosphatase, osteocalcin, type I procollagen C-peptide and urinary hydroxyproline, calcium, and pyridinoline cross-links as measures of bone metabolism and radial shaft, femoral neck, and lumbar bone masses. Results: Serum osteocalcin and type I procollagen C-peptide increased during rhIGF-1 therapy (P < 0.05). Twenty-four hour urinary calcium, hydroxyproline, and pyridinoline cross-links were also higher after treatment than they were before treatment (P < 0.05). During 6 months of treatment, the bone mineral density of the L2 to L4 vertebrae increased 3%; this value exceeded the coefficient of variation of this measurement. Bone density at the femoral neck and radial shaft changed by less than the coefficient of variation of these measurements. No significant changes in serum glucose values or other adverse effects of treatment were noted. Conclusions: Treatment with rhIGF-1 increased both bone formation and resorption in a patient with the Werner syndrome, a low baseline serum IGF-1 level, and established osteoporosis. Because lumbar bone mass increased without evidence of bone loss in the appendicular skeleton, a net increase in bone formation (formation greater than resorption) may have been responsible.			RUBIN, CD (corresponding author), UNIV TEXAS, SW MED CTR, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG000481] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00633] Funding Source: Medline; NIAMS NIH HHS [R01-AR16061] Funding Source: Medline; NIA NIH HHS [K08-AG00481] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENNETT AE, 1984, J CLIN ENDOCR METAB, V59, P701, DOI 10.1210/jcem-59-4-701; CANALIS E, 1980, J CLIN INVEST, V66, P709, DOI 10.1172/JCI109908; CANALIS E, 1988, ENDOCRINOLOGY, V122, P22, DOI 10.1210/endo-122-1-22; DAUGHADAY WH, 1980, J CLIN ENDOCR METAB, V51, P781, DOI 10.1210/jcem-51-4-781; EBELING PR, 1993, J CLIN ENDOCR METAB, V77, P1384, DOI 10.1210/jc.77.5.1384; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; HASSAGER C, 1992, J BONE MINER RES, V7, P1307; JOHANSSON AG, 1992, LANCET, V339, P1619, DOI 10.1016/0140-6736(92)91889-G; MONNAT RJ, 1992, EXP GERONTOL, V27, P447, DOI 10.1016/0531-5565(92)90080-J; PAK CYC, 1989, J CLIN ENDOCR METAB, V68, P150, DOI 10.1210/jcem-68-1-150; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; RUBIN CD, 1992, J AM GERIATR SOC, V40, P1161, DOI 10.1111/j.1532-5415.1992.tb01808.x; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; ZERWEKH JE, 1981, INVEST UROL, V19, P161	15	24	25	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					665	668		10.7326/0003-4819-121-9-199411010-00007	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944076				2022-12-28	WOS:A1994PN45000007
J	ATKINSON, S; BIHARI, D; SMITHIES, M; DALY, K; MASON, R; MCCOLL, I				ATKINSON, S; BIHARI, D; SMITHIES, M; DALY, K; MASON, R; MCCOLL, I			IDENTIFICATION OF FUTILITY IN INTENSIVE-CARE	LANCET			English	Article							ORGAN-SYSTEM FAILURE; SOCIETY APACHE-II; UNIT PATIENTS; CASE-MIX; MORTALITY; PREDICTION; BRITAIN; IRELAND	Rising costs of intensive care and the ability to prolong the life of critically ill patients creates a need to recognise early those patients who will die despite treatment. We used changes in a modified APACHE II score (organ failure score) to make daily predictions of individual outcome in 3600 patients. 137 patients were predicted to die and of these, 131 (95.6%) died within 90 days of discharge from hospital (sensitivity 23.4%, specificity 99.8%); a false-positive diagnosis rate of 4.4%. 2 of the 6 survivors have subsequently died but 4 are alive with good quality of life. Patients predicted to die stayed 1492 days in intensive care and incurred 16.7% of total intensive care expenditure and 46.4% of the cost of all patients that died. Median survival after a prediction to die was 2 days, accounting for 62% of intensive care patient days in this patient group, giving an effective intensive care cost per survivor of UK pound 129 651. If used prospectively, this algorithm has the potential to indicate the futility of continued intensive care but at the cost of 1 in 20 patients who would survive if intensive care were continued.	GUYS HOSP,DEPT INTENS CARE,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	ATKINSON, S (corresponding author), GUYS HOSP,DEPT SURG,ST THOMAS ST,LONDON SE1 9RT,ENGLAND.							BEDELL SE, 1983, NEW ENGL J MED, V309, P567; CAMPLING EA, 1993, REPORT NATIONAL CONF; CHANG RWS, 1988, CRIT CARE MED, V16, P34, DOI 10.1097/00003246-198801000-00007; CHANG RWS, 1988, INTENS CARE MED, V14, P558, DOI 10.1007/BF00263530; CHANG RWS, 1989, LANCET, V1, P143; Chang RWS, 1993, CLIN INTENSIVE CARE, V4, P208; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; GULATI RS, 1983, LANCET, V2, P267; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; JACOBS S, 1992, ANAESTHESIA, V47, P775, DOI 10.1111/j.1365-2044.1992.tb03255.x; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; RIDLEY S, 1990, BRIT MED J, V301, P1127, DOI 10.1136/bmj.301.6761.1127; ROWAN KM, 1993, BRIT MED J, V307, P977, DOI 10.1136/bmj.307.6910.977; ROWAN KM, 1993, BRIT MED J, V307, P972, DOI 10.1136/bmj.307.6910.972; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SIRIO CA, 1992, CRIT CARE MED, V20, P1207, DOI 10.1097/00003246-199209000-00006; SMITHIES MN, 1994, REANIMATION URGENCES, V3, P495	23	94	94	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1203	1206		10.1016/S0140-6736(94)90514-2	http://dx.doi.org/10.1016/S0140-6736(94)90514-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934546				2022-12-28	WOS:A1994PN80300015
J	PICANO, E; MATHIAS, W; PINGITORE, A; BIGI, R; PREVITALI, M				PICANO, E; MATHIAS, W; PINGITORE, A; BIGI, R; PREVITALI, M			SAFETY AND TOLERABILITY OF DOBUTAMINE-ATROPINE STRESS ECHOCARDIOGRAPHY - A PROSPECTIVE, MULTICENTER STUDY	LANCET			English	Article							CORONARY-ARTERY DISEASE; SURGERY; ALPHA	Diagnostic tests that are hazardous or infeasible, or both, may become accepted before inadequacies are recognised; only multicentre trials can provide the necessary information for an unrestricted acceptance of any new diagnostic procedure. We prospectively studied the results obtained in 24 experienced echocardiography laboratories. 2949 tests were done in 2799 patients. In 341 tests (12% of the overall population, 21% of the negative tests) the test could not be completed because of complex ventricular tachyarrhythmias (134, 38% of all submaximal studies); nausea and/or headache (71, 20%); hypotension and/or bradycardia (62, 17%); supraventricular tachyarrhythmias (44, 12%); hypertension (24, 7%); and others (20, 6%). Dangerous events (life-threatening complications or side-effects requiring specific treatment and lasting more than 3 hours, or new hospital admission) occurred in 14 cases (1 every 210 tests)-9 cardiac (3 ventricular tachycardias; 2 ventricular fibrillations; 2 myocardial infarctions; 1 prolonged antidote-resistant myocardial ischaemia; 1 severe, persistent hypotension) and 5 extracardiac (atropine poisoning with hallucinations lasting several hours in the absence of either myocardial ischaemia or hypotension). Life-threatening and/or longlasting complications may occur during dobutamine/atropine stress echocardiography. The test is generally well tolerated, although may be interrupted by minor, self-limiting, usually symptomless side-effects.			PICANO, E (corresponding author), CNR,INST CLIN PHYSIOL,VIA PAOLO SAVI 8,I-56100 PISA,ITALY.		Picano, E/G-2261-2014; Mathias, Wilson/A-4772-2008	Mathias, Wilson/0000-0003-0201-6754				AFRIDI I, 1994, AM HEART J, V127, P1510, DOI 10.1016/0002-8703(94)90378-6; BROWN BG, 1984, CIRCULATION, V70, P917, DOI 10.1161/01.CIR.70.6.917; BROWN JH, 1992, GOODMAN GILMANS CARD; COHEN JL, 1991, AM J CARDIOL, V67, P1311, DOI 10.1016/0002-9149(91)90457-V; DIAMOND GA, 1986, AM J CARDIOL, V57, P471, DOI 10.1016/0002-9149(86)90775-7; Feinstein AR, 1985, DIAGNOSTIC SPECTRAL, P597; KRAEMER HC, 1992, EVALUATING MED TESTS, P269; LALKA SG, 1992, J VASC SURG, V15, P831, DOI 10.1016/0741-5214(92)90718-N; MANNERING D, 1988, BRIT HEART J, V59, P521; MARCOVITZ PA, 1992, AM J CARDIOL, V69, P1269, DOI 10.1016/0002-9149(92)91219-T; MARCOVITZ PA, 1992, CIRCULATION S1, V86, P1789; MAZEIKA PK, 1992, AM J CARDIOL, V69, P1484, DOI 10.1016/0002-9149(92)90907-G; MAZEIKA PK, 1993, AM J CARDIOL, V71, P33, DOI 10.1016/0002-9149(93)90706-I; MCNEILL AJ, 1992, AM J CARDIOL, V70, P41, DOI 10.1016/0002-9149(92)91387-J; MERTES H, 1993, CIRCULATION, V88, P15, DOI 10.1161/01.CIR.88.1.15; MIYAMOTO MI, 1991, CIRCULATION, V84, P1715, DOI 10.1161/01.CIR.84.4.1715; PICANO E, 1992, CIRCULATION, V85, P1604, DOI 10.1161/01.CIR.85.4.1604; POLDERMANS D, 1994, AM J CARDIOL, V73, P456, DOI 10.1016/0002-9149(94)90675-0; POLDERMANS D, 1993, CIRCULATION, V87, P1506, DOI 10.1161/01.CIR.87.5.1506; PREVITALI M, 1991, CIRCULATION, V83, P27; RUFFOLO RR, 1981, J PHARMACOL EXP THER, V219, P447; RYAN T, 1991, CORONARY ARTERY DIS, V2, P552; SALUSTRI A, 1992, EUR HEART J, V13, P70, DOI 10.1093/oxfordjournals.eurheartj.a060051; SAWADA SG, 1991, CIRCULATION, V83, P1605, DOI 10.1161/01.CIR.83.5.1605; TUTTLE RR, 1975, CIRC RES, V36, P185, DOI 10.1161/01.RES.36.1.185; WILKINSON J A, 1987, Journal of Emergency Medicine, V5, P389, DOI 10.1016/0736-4679(87)90144-2; ZISKIND AA, 1988, POSTGRAD MED, V84, P73	27	288	301	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1190	1192		10.1016/S0140-6736(94)90508-8	http://dx.doi.org/10.1016/S0140-6736(94)90508-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934540				2022-12-28	WOS:A1994PN80300009
J	BLACKWELL, TK; BOWERMAN, B; PRIESS, JR; WEINTRAUB, H				BLACKWELL, TK; BOWERMAN, B; PRIESS, JR; WEINTRAUB, H			FORMATION OF A MONOMERIC DNA-BINDING DOMAIN BY SKN-1 BZIP AND HOMEODOMAIN ELEMENTS	SCIENCE			English	Article							GCN4 ACTIVATOR PROTEIN; LEUCINE ZIPPER MOTIF; C-ELEGANS EMBRYOS; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTOR; BASIC REGION; ANTENNAPEDIA HOMEODOMAIN; NMR-SPECTROSCOPY; HIGH-RESOLUTION; COILED COIL	Maternally expressed Skn-1 protein is required for the correct specification of certain blastomere fates in early Caenorhabditis elegans embryos. Skn-1 contains a basic region similar to those of basic leucine zipper (bZIP) proteins but, paradoxically, it lacks a leucine zipper dimerization segment. Random sequence selection methods were used to show that Skn-1 binds to specific DNA sequences as a monomer. The Skn-1 basic region lies at the carboxyl terminus of an 85-amino acid domain that binds preferentially to a bZIP half-site and also recognizes adjacent 5' AT-rich sequences in the minor groove, apparently with an amino (NH2)-terminal ''arm'' related to those of homeodomain proteins. The intervening residues appear to stabilize interactions of these two subdomains with DNA. The Skn-1 DNA binding domain thus represents an alternative strategy for promoting binding of a basic region segment recognition helix to its cognate half-site. The results point to an underlying modularity in subdomains within established DNA binding domains.	FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center								AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, UNPUB; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, UNPUB; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, IN PRESS DEV BIOL; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MOHLER J, 1990, MECH DEVELOP, V34, P3; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RUBERTI I, 1991, EMBO J, V10, P1787, DOI 10.1002/j.1460-2075.1991.tb07703.x; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHUBERT C, UNPUB; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; SESSA G, 1993, EMBO J, V12, P3507, DOI 10.1002/j.1460-2075.1993.tb06025.x; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	69	135	139	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					621	628		10.1126/science.7939715	http://dx.doi.org/10.1126/science.7939715			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939715				2022-12-28	WOS:A1994PN80700040
J	BAIRD, PA; YEE, IML; SADOVNICK, AD				BAIRD, PA; YEE, IML; SADOVNICK, AD			POPULATION-BASED STUDY OF LONG-TERM OUTCOMES AFTER AMNIOCENTESIS	LANCET			English	Article							MID-TRIMESTER AMNIOCENTESIS; PHYSICAL STATUS; FOLLOW-UP	Amniocentesis is now commonly used in many countries; it is important to know whether there are any long-term adverse effects on children born after this procedure, in particular disabilities that may emerge during childhood or adolescence. We studied consecutive liveborn offspring of women who had had amniocentesis and compared them with matched controls whose mothers had not had amniocentesis. The controls were matched for age of mother, residence by geographic health unit, sex, and when the birth occurred. 1296 cases and 3704 controls were studied. With the exception of one disorder, the offspring of women who had had amniocentesis were no more likely than controls to have a registrable disability (such as hearing disabilities, learning difficulties, visual problems, and limb anomalies) during childhood and adolescence. The follow-up period was 7-18 years. Children of women who had amniocentesis had a significantly higher rate of haemolytic disease due to ABO isoimmunisation than matched controls. The results of this study should therefore be reassuring to women having amniocentesis, and be useful to women making decisions about having this procedure.			BAIRD, PA (corresponding author), UNIV BRITISH COLUMBIA,DEPT MED GENET,222-6174 UNIV BLVD,VANCOUVER V6T 1Z3,BC,CANADA.							AGER RP, 1986, RISKS MIDTRIMESTER A; BAIRD PA, 1988, AM J HUM GENET, V42, P677; Breslow N, 1980, STATISTICAL METHODS, V32; CRANDALL BF, 1980, OBSTET GYNECOL, V56, P625; FINEGAN JAK, 1984, AM J OBSTET GYNECOL, V150, P989, DOI 10.1016/0002-9378(84)90396-X; FINEGAN JAK, 1990, BRIT J OBSTET GYNAEC, V97, P32, DOI 10.1111/j.1471-0528.1990.tb01713.x; FINEGAN JAK, 1985, BRIT J OBSTET GYNAEC, V92, P1015, DOI 10.1111/j.1471-0528.1985.tb02996.x; GILLBERG C, 1982, CLIN GENET, V21, P69; HAMERTON JL, 1993, PRENATAL DIAGNOSIS C, V13, P1; HOWARD JA, 1979, OBSTET GYNECOL, V53, P599; Kellogg B, 1983, Pediatr Nurs, V9, P95; ROBINSON J, 1975, CLIN GENET, V8, P97; SIMPSON NE, 1976, CAN MED ASSOC J, V115, P739; TABOR A, 1986, LANCET, V1, P1287; WALD NJ, 1983, LANCET, V2, P264; 1978, BR J OBSTET GYNEC S2, V85; 1976, JAMA-J AM MED ASSOC, V236, P1471; [No title captured]	18	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1134	1136		10.1016/S0140-6736(94)90635-1	http://dx.doi.org/10.1016/S0140-6736(94)90635-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934498				2022-12-28	WOS:A1994PN06600014
J	RIDDIHOUGH, G				RIDDIHOUGH, G			ONE IN THE EYE	NATURE			English	Article							CRYSTALLINS	A double insight into visual accommodation by the eye lens in birds and into the activity of a superfamily of metabolic enzymes is provided by the structure of turkey lens delta-crystallin.										DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; SIMPSON A, 1994, NAT STRUCT BIOL, V1, P724, DOI 10.1038/nsb1094-724	4	2	2	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					538	538		10.1038/371538a0	http://dx.doi.org/10.1038/371538a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935769	Bronze			2022-12-28	WOS:A1994PK58900063
J	GORDIS, E				GORDIS, E			UNRAVELING THE BRAIN CHEMISTRY BEHIND ALCOHOL-ABUSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GORDIS, E (corresponding author), NIAAA,BETHESDA,MD, USA.							VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P881; IN PRESS NIDA RES MO	3	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1733	1733						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PV815	7966919				2022-12-28	WOS:A1994PV81500020
J	WALSH, DS; BEARD, JS; JAMES, WD				WALSH, DS; BEARD, JS; JAMES, WD			FLUORESCENT SPECTROPHOTOMETRIC ANALYSIS IN THE EVALUATION OF PORPHYRIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PLASMA				WALSH, DS (corresponding author), WALTER REED ARMY MED CTR,DERMATOL SERV,WASHINGTON,DC 20307, USA.							ELDER GH, 1986, SEMIN DERMATOL, V5, P88; POHFITZPATRICK MB, 1980, ARCH DERMATOL, V116, P543, DOI 10.1001/archderm.116.5.543; POHFITZPATRICK MB, 1976, J LAB CLIN MED, V87, P362	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1580	1581						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966866				2022-12-28	WOS:A1994PR40500022
J	XU, M; MORATALLA, R; GOLD, LH; HIROI, N; KOOB, GF; GRAYBIEL, AM; TONEGAWA, S				XU, M; MORATALLA, R; GOLD, LH; HIROI, N; KOOB, GF; GRAYBIEL, AM; TONEGAWA, S			DOPAMINE D1 RECEPTOR MUTANT MICE ARE DEFICIENT IN STRIATAL EXPRESSION OF DYNORPHIN AND IN DOPAMINE-MEDIATED BEHAVIORAL-RESPONSES	CELL			English	Article							C-FOS; RAT STRIATUM; SUBSTANCE-P; MOLECULAR-CLONING; BASAL GANGLIA; AUTORADIOGRAPHIC LOCALIZATION; PHENOTYPICAL CHARACTERIZATION; STRIATONIGRAL DYNORPHIN; MATRIX COMPARTMENTS; PROJECTION NEURONS	The brain dopaminergic system is a critical modulator of basal ganglia function and plasticity. To investigate the contribution of the dopamine D1 receptor to this modulation, we have used gene targeting technology to generate D1 receptor mutant mice. Histological analyses suggested that there are no major changes in general anatomy of the mutant mouse brains, but indicated that the expression of dynorphin is greatly reduced in the striatum and related regions of the basal ganglia. The mutant mice do not respond to the stimulant and suppressive effects of D1 receptor agonists and antagonists, respectively, and they exhibit locomotor hyperactivity. These results suggest that the D1 receptor regulates the neurochemical architecture of the striatum and is critical for the normal expression of motor activity.	MIT, CTR LEARNING & MEMORY, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Scripps Research Institute	XU, M (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Moratalla, Rosario V/H-9280-2015; Hiroi, Noboru/E-2215-2013	Moratalla, Rosario V/0000-0002-7623-8010; Hiroi, Noboru/0000-0002-6846-5969; Graybiel, Ann/0000-0002-4326-7720	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD028341] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028341] Funding Source: NIH RePORTER; NICHD NIH HHS [HD28341] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; AMALRIC M, 1993, NEUROPSYCHOPHARMACOL, V8, P195, DOI 10.1038/npp.1993.21; ANDERSON KD, 1990, J COMP NEUROL, V295, P339, DOI 10.1002/cne.902950302; ANDERSON KD, 1991, BRAIN RES, V568, P235, DOI 10.1016/0006-8993(91)91403-N; ARIANO MA, 1989, P NATL ACAD SCI USA, V86, P8570, DOI 10.1073/pnas.86.21.8570; Bergman J., 1990, Behav Pharmacol, V1, P355; BERNARD V, 1992, J NEUROSCI, V12, P3591; BESSON MJ, 1990, NEUROSCIENCE, V39, P33, DOI 10.1016/0306-4522(90)90220-X; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRONSTEIN DM, 1994, MOL BRAIN RES, V23, P191, DOI 10.1016/0169-328X(94)90226-7; CABIB S, 1991, PSYCHOPHARMACOLOGY, V105, P335, DOI 10.1007/BF02244427; CAINE SB, 1994, J PHARMACOL EXP THER, V270, P209; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; DAUNAIS JB, 1993, NEUROREPORT, V4, P543, DOI 10.1097/00001756-199305000-00020; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DILTS RP, 1993, SYNAPSE, V13, P251, DOI 10.1002/syn.890130308; DREHER JK, 1989, BRAIN RES, V487, P267, DOI 10.1016/0006-8993(89)90831-7; FALLON JH, 1978, J COMP NEUROL, V180, P533, DOI 10.1002/cne.901800309; FENTRESS JC, 1981, ANAT EMBRYOL, V163, P275, DOI 10.1007/BF00315705; FISHELL G, 1991, J COMP NEUROL, V312, P33, DOI 10.1002/cne.903120104; FOSTER GA, 1987, J NEUROSCI, V7, P1994; FUXE K, 1969, NEUROENDOCRINOLOGY, V5, P257, DOI 10.1159/000121887; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GERFEN CR, 1985, P NATL ACAD SCI USA, V82, P8780, DOI 10.1073/pnas.82.24.8780; GERFEN CR, 1991, J NEUROSCI, V11, P1016; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRAYBIEL AM, 1984, NEUROSCIENCE, V13, P1157, DOI 10.1016/0306-4522(84)90293-8; GRAYBIEL AM, 1982, P NATL ACAD SCI-BIOL, V79, P198, DOI 10.1073/pnas.79.1.198; GRAYBIEL AM, 1989, P NATL ACAD SCI USA, V86, P9020, DOI 10.1073/pnas.86.22.9020; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; GRAYBIEL AM, 1990, J NEUROSCI, V10, P720; Graybiel AM, 1984, CORTICAL INTEGRATION, P223; GRAYBIEL AM, 1983, CHEM NEUROANATOMY, P427; HANSON GR, 1987, EUR J PHARMACOL, V144, P245, DOI 10.1016/0014-2999(87)90527-9; HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408; HURD YL, 1992, MOL BRAIN RES, V13, P165, DOI 10.1016/0169-328X(92)90058-J; JIANG HK, 1990, BRAIN RES, V507, P57, DOI 10.1016/0006-8993(90)90522-D; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOOB GF, 1978, J COMP PHYSIOL PSYCH, V92, P917, DOI 10.1037/h0077542; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4; KOOB GF, 1992, SEMIN NEUROSCI, V4, P139; KUBOTA Y, 1993, NEUROREPORT, V5, P205, DOI 10.1097/00001756-199312000-00004; LEMOAL M, 1991, PHYSIOL REV, V71, P155, DOI 10.1152/physrev.1991.71.1.155; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; LI S, 1986, BRAIN RES, V398, P390, DOI 10.1016/0006-8993(86)91502-7; LI SJ, 1988, J PHARMACOL EXP THER, V246, P403; LINDVALL O, 1983, CHEM NEUROANATOMY, P229; LIU FC, 1994, IN PRESS J NEUROSCI; MAILMAN RB, 1984, EUR J PHARMACOL, V101, P159, DOI 10.1016/0014-2999(84)90044-X; MEADORWOODRUFF JH, 1991, NEUROPSYCHOPHARMACOL, V5, P231; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; MOORCROFT WH, 1971, J COMP PHYSIOL PSYCH, V75, P59, DOI 10.1037/h0030670; MORATALLA R, 1993, J NEUROSCI, V13, P423; MORATALLA R, 1992, J NEUROSCI, V12, P2609; MURRIN LC, 1989, BRAIN RES, V480, P170; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; PAUL ML, 1992, J NEUROSCI, V12, P3729, DOI 10.1523/jneurosci.12-10-03729.1992; PENNYPACKER KR, 1992, MOL BRAIN RES, V15, P151, DOI 10.1016/0169-328X(92)90163-6; PERT CB, 1976, P NATL ACAD SCI USA, V73, P3729, DOI 10.1073/pnas.73.10.3729; PERTWEE RG, 1972, BRIT J PHARMACOL, V46, P753, DOI 10.1111/j.1476-5381.1972.tb06900.x; PIOMELLI D, 1991, NATURE, V353, P164, DOI 10.1038/353164a0; SAVASTA M, 1986, BRAIN RES, V375, P291, DOI 10.1016/0006-8993(86)90749-3; SCHAMBRA B, 1994, NEUROSCIENCE, V62, P65, DOI 10.1016/0306-4522(94)90315-8; SHARP T, 1987, BRAIN RES, V401, P322, DOI 10.1016/0006-8993(87)91416-8; SIBLEY DR, 1993, INT REV NEUROBIOL, V35, P391, DOI 10.1016/S0074-7742(08)60573-5; SIVAM SP, 1989, J PHARMACOL EXP THER, V250, P818; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STEINER H, 1993, J NEUROSCI, V13, P5066, DOI 10.1523/JNEUROSCI.13-12-05066.1993; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; VANDERKOOY D, 1987, BRAIN RES, V401, P155, DOI 10.1016/0006-8993(87)91176-0; vanderKooy D, 1987, BASAL GANGLIA, P81; VINCENT SR, 1983, J COMP NEUROL, V217, P252, DOI 10.1002/cne.902170303; VOORN P, 1988, NEUROSCIENCE, V25, P857, DOI 10.1016/0306-4522(88)90041-3; WALAAS SI, 1984, J NEUROSCI, V4, P84; WEINER DM, 1990, P NATL ACAD SCI USA, V87, P7050, DOI 10.1073/pnas.87.18.7050; WEISS B, 1993, NEUROSCIENCE, V55, P607, DOI 10.1016/0306-4522(93)90426-G; WOOLVERTON WL, 1986, PHARMACOL BIOCHEM BE, V24, P531, DOI 10.1016/0091-3057(86)90553-8; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291; ZHANG M, 1993, NEUROSCI LETT, V161, P223, DOI 10.1016/0304-3940(93)90299-Z; ZHANG WQ, 1992, BRAIN RES, V577, P312, DOI 10.1016/0006-8993(92)90289-L; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	91	415	422	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					729	742		10.1016/0092-8674(94)90557-6	http://dx.doi.org/10.1016/0092-8674(94)90557-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954836				2022-12-28	WOS:A1994PT48100019
J	ANNAS, GJ				ANNAS, GJ			DEATH BY PRESCRIPTION - THE OREGON INITIATIVE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1985, AM J PUBLIC HEALTH, V75, P1096, DOI 10.2105/AJPH.75.9.1096; ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; Callahan Daniel, 1993, TROUBLED DREAM LIFE; CAPRON AM, 1992, HASTINGS CENT REP, V22, P30, DOI 10.2307/3562562; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; GIANELLI DM, 1994, AM MED NEWS     0725, P1; GIANELLI DM, 1994, AM MED NEWS     0912, P34; Humphry D., 1992, DYING DIGNITY UNDERS; NULAND SB, 1994, WE DIE, P288; ORENTLICHER D, 1994, MED UNBOUND HUMAN BO, P256; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; SKELLY FJ, 1994, AM MED NEWS     0815, P19; WEILER PC, 1993, MEASURE MALPRACTICE, P55; YANKELOVICH D, 1994, NY TIMES        0917, P23; 1994, DEATH IS SOUGHT ASSI; 1994, AHCPR940592 DEP HLTH, P16; 1992, JAMA-J AM MED ASSOC, V267, P2229; 1994, FINAL REPORT MICHIGA; 1992, HASTINGS CTR REP, V22, P7	19	50	50	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1240	1243		10.1056/NEJM199411033311822	http://dx.doi.org/10.1056/NEJM199411033311822			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935680				2022-12-28	WOS:A1994PN80600038
J	BENATOR, DA; FRENCH, AL; BEAUDET, LM; LEVY, CS; ORENSTEIN, JM				BENATOR, DA; FRENCH, AL; BEAUDET, LM; LEVY, CS; ORENSTEIN, JM			ISOSPORA BELLI INFECTION ASSOCIATED WITH ACALCULOUS CHOLECYSTITIS IN A PATIENT WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS		WASHINGTON HOSP CTR, INFECT DIS SECT, WASHINGTON, DC 20010 USA; WASHINGTON HOSP CTR, DEPT PATHOL, WASHINGTON, DC 20010 USA; GEORGE WASHINGTON UNIV, DEPT PATHOL, WASHINGTON, DC 20037 USA	MedStar Washington Hospital Center; MedStar Washington Hospital Center; George Washington University								CELLO JP, 1992, SEMIN LIVER DIS, V12, P213, DOI 10.1055/s-2007-1007393; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; FRENCH AL, 1993, 33RD INT C ANT AG CH, V1, P222; LIEBMAN WM, 1980, GASTROENTEROLOGY, V78, P579; Ma P, 1984, AIDS RES, V1, P327; POL S, 1993, NEW ENGL J MED, V328, P95, DOI 10.1056/NEJM199301143280204; RESTREPO C, 1987, AM J CLIN PATHOL, V87, P536, DOI 10.1093/ajcp/87.4.536; SHAFFER N, 1989, J INFECT DIS, V159, P596, DOI 10.1093/infdis/159.3.596; SOAVE R, 1988, J INFECT DIS, V157, P225, DOI 10.1093/infdis/157.2.225; STGEORGIEV V, 1993, DRUG DEVELOP RES, V28, P445, DOI 10.1002/ddr.430280402; TRIER JS, 1974, GASTROENTEROLOGY, V66, P923; Wenyon CM, 1915, LANCET, V2, P1173	12	37	41	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					663	664		10.7326/0003-4819-121-9-199411010-00006	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944075				2022-12-28	WOS:A1994PN45000006
J	COOLEY, L; THEURKAUF, WE				COOLEY, L; THEURKAUF, WE			CYTOSKELETAL FUNCTIONS DURING DROSOPHILA OOGENESIS	SCIENCE			English	Article							POLARITY GENE ARMADILLO; CAENORHABDITIS-ELEGANS; INTERCELLULAR BRIDGES; RNA LOCALIZATION; BICOID RNA; PROTEIN; MELANOGASTER; ENCODES; EGG; DIFFERENTIATION	Organismal morphogenesis is driven by a complex series of developmentally coordinated changes in cell shape, size, and number. These changes in cell morphology are in turn dependent on alterations in basic cytoarchitecture. Elucidating the mechanisms of development thus requires an understanding of the cytoskeletal elements that organize the cytoplasm of differentiating cells. Drosophila oogenesis has emerged as a versatile system for the study of cytoskeletal function during development. A series of highly coordinated changes in cytoskeletal organization are required to produce a mature Drosophila oocyte, and these cytoskeletal transformations are amenable to a variety of experimental approaches. Genetic, molecular, and cytological studies have shed light on the specific functions of the cytoskeleton during oogenesis. The results of these studies are reviewed here, and their mechanistic implications are considered.	SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	COOLEY, L (corresponding author), YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA.			Theurkauf, William/0000-0001-7342-1912				BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOHRMANN J, 1994, J CELL SCI, V107, P849; BRYAN J, 1993, P NATL ACAD SCI USA, V90, P9115, DOI 10.1073/pnas.90.19.9115; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; CARPENTER ATC, 1994, CIBA F SYMP, V182, P223; CHOU TB, 1992, GENETICS, V131, P643; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; DEROSIER D, 1977, J MOL BIOL, V113, P679, DOI 10.1016/0022-2836(77)90230-3; DEROSIER DJ, 1981, J MOL BIOL, V146, P77, DOI 10.1016/0022-2836(81)90367-3; DING D, 1993, P NATL ACAD SCI USA, V90, P2512, DOI 10.1073/pnas.90.6.2512; GODT D, 1993, DEVELOPMENT, V119, P799; GONDOS B, 1987, INT J GYNECOL PATHOL, V6, P114, DOI 10.1097/00004347-198706000-00003; GUTZEIT H, 1986, ROUX ARCH DEV BIOL, V195, P173, DOI 10.1007/BF02439435; GUTZEIT HO, 1986, J CELL SCI, V80, P159; GUTZEIT HO, 1982, J EMBRYOL EXP MORPH, V67, P101; HAY B, 1990, DEVELOPMENT, V109, P425; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; KING RC, 1959, SCIENCE, V129, P1674, DOI 10.1126/science.129.3364.1674; KING RC, 1962, GROWTH, V26, P235; KOCH EA, 1983, CELL TISSUE RES, V228, P21; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; LIN HF, 1994, DEVELOPMENT, V120, P947; Louvard D, 1989, CURR OPIN CELL BIOL, V1, P51, DOI 10.1016/S0955-0674(89)80036-5; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MAHAJANMIKLOS S, 1994, CELL, V78, P291, DOI 10.1016/0092-8674(94)90298-4; MAHAJANMIKLOS S, IN PRESS DEV BIOL; MAHOWALD AP, 1970, J CELL BIOL, V45, P306, DOI 10.1083/jcb.45.2.306; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; MATSUDAIRA P, 1983, NATURE, V301, P209, DOI 10.1038/301209a0; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; OWEN C, 1993, J CELL BIOL, V123, P337, DOI 10.1083/jcb.123.2.337; PATERSON J, 1991, GENETICS, V129, P1073; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; POODRY CA, 1970, ROUX ARCH DEV BIOL, V166, P1, DOI 10.1007/BF00576805; Robinson D. A., UNPUB; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SCHUPBACH T, 1991, GENETICS, V129, P1119; Spradling Allan C., 1993, P1; STEWARD R, 1986, GENETICS, V113, P665; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STORTO PD, 1989, DEV GENET, V10, P70, DOI 10.1002/dvg.1020100203; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; Telfer W. H., 1975, Advances Insect Physiol, V11, P223, DOI 10.1016/S0065-2806(08)60164-2; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; THEURKAUF W, IN PRESS DEV BIOL; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; WARN RM, 1985, EXP CELL RES, V157, P355, DOI 10.1016/0014-4827(85)90120-X; WAY M, UNPUB; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YUE L, 1992, GENE DEV, V6, P2443, DOI 10.1101/gad.6.12b.2443	67	168	170	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	1994	266	5185					590	596		10.1126/science.7939713	http://dx.doi.org/10.1126/science.7939713			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939713				2022-12-28	WOS:A1994PN80700037
J	LIN, TA; KONG, XM; HAYSTEAD, TAJ; PAUSE, A; BELSHAM, G; SONENBERG, N; LAWRENCE, JC				LIN, TA; KONG, XM; HAYSTEAD, TAJ; PAUSE, A; BELSHAM, G; SONENBERG, N; LAWRENCE, JC			PHAS-1 AS A LINK BETWEEN MITOGEN-ACTIVATED PROTEIN-KINASE AND TRANSLATION INITIATION	SCIENCE			English	Article							3T3-L1 ADIPOCYTES; INSULIN ACTION; PHOSPHORYLATION; STIMULATION; MECHANISM; INVITRO	PHAS-I is a heat-stable protein (relative molecular mass approximate to 12,400) found in many tissues. It is rapidly phosphorylated in rat adipocytes incubated with insulin or growth factors. Nonphosphorylated PHAS-I bound to initiation factor 4E (eIF-4E) and inhibited protein synthesis. Serine-64 in PHAS-I was rapidly phosphorylated by mitogen-activated (MAP) kinase, the major insulin-stimulated PHAS-I kinase in adipocyte extracts. Results obtained with antibodies, immobilized PHAS-I, and a messenger RNA cap affinity resin indicated that PHAS-I did not bind eIF-4E when serine-64 was phosphorylated. Thus, PHAS-I may be a key mediator of the stimulation of protein synthesis by the diverse group of agents and stimuli that activate MAP kinase.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22903; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,PQ,CANADA	Washington University (WUSTL); University of Virginia; McGill University; McGill University			Belsham, Graham/J-3132-2019; Belsham, Graham J./H-8589-2019	Belsham, Graham/0000-0003-1187-4873; Belsham, Graham J./0000-0003-1187-4873	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11495; AVRUCH J, 1982, FED PROC, V41, P2629; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P1; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DENTON RM, 1981, DIABETOLOGIA, V21, P347; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HU C, 1994, P NATL ACAD SCI USA, V91, P373; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin T.-T., UNPUB; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; PAUSE A, IN PRESS NATURE; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sonenberg Nahum, 1993, Gene Expression, V3, P317	23	595	608	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					653	656		10.1126/science.7939721	http://dx.doi.org/10.1126/science.7939721			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939721				2022-12-28	WOS:A1994PN80700049
J	CECH, TR				CECH, TR			CHROMOSOME END GAMES	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; RNA; TELOMERASE; YEAST; RIBONUCLEOPROTEIN; REPEATS; ENZYME				CECH, TR (corresponding author), UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309, USA.							BLACKBUURN EH, 1994, KEYSTONE S EUKARYOTI; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; MARX J, 1994, SCIENCE, V265, P1656, DOI 10.1126/science.7521969; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955	16	8	9	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					387	388		10.1126/science.7939679	http://dx.doi.org/10.1126/science.7939679			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939679				2022-12-28	WOS:A1994PN27200022
J	FERGUSON, KM; LEMMON, MA; SCHLESSINGER, J; SIGLER, PB				FERGUSON, KM; LEMMON, MA; SCHLESSINGER, J; SIGLER, PB			CRYSTAL-STRUCTURE AT 2.2-ANGSTROM RESOLUTION OF THE PLECKSTRIN HOMOLOGY DOMAIN FROM HUMAN DYNAMIN	CELL			English	Article							X-LINKED AGAMMAGLOBULINEMIA; ADRENERGIC-RECEPTOR KINASE; BETA-GAMMA-SUBUNITS; MOLECULAR-CLONING; SIGNALING PROTEINS; BINDING PROTEINS; MULTIPLE FORMS; PH DOMAIN; EXPRESSION; GTPASE	The X-ray crystal structure of the pleckstrin homology (PH) domain from human dynamin has been refined to 2.2 Angstrom resolution. A seven-stranded beta sandwich of two orthogonal antiparallel beta sheets is closed at one corner by a C-terminal alpha helix. Opposite this helix are the three loops that vary most among PH domains. The basic fold is very similar to that of two other PH domains recently determined by nuclear magnetic resonance, confirming that PH domains are distinct structural modules. Each PH domain with known structure is electrostatically polarized, with the three variable loops forming a positively charged surface. This surface includes the position of the X-linked immunodeficiency mutation in the Btk PH domain and may serve as a ligand-binding surface.	YALE UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Howard Hughes Medical Institute; Yale University; New York University	FERGUSON, KM (corresponding author), YALE UNIV,HOWARD HUGHES MED INST,DEPT CHEM,NEW HAVEN,CT 06510, USA.			Lemmon, Mark/0000-0002-3379-5319	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022324, R01GM015225, R37GM015225] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22324, GM15225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDEN C, 1991, INTRO PROTEIN STRUCT, P59; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; FLOWER DR, 1993, FEBS LETT, V333, P99, DOI 10.1016/0014-5793(93)80382-5; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; MA Y, 1992, BRAIN RES, V594, P75; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PARRUTI G, 1993, BIOCHEM BIOPH RES CO, V190, P475, DOI 10.1006/bbrc.1993.1072; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REED RJ, 1986, ACTA CRYSTALLOGR A, V42, P140; REID TJ, 1981, P NATL ACAD SCI-BIOL, V78, P4767, DOI 10.1073/pnas.78.8.4767; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; VALLEE RB, 1993, CIBA F SYMP, V176, P185; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WAGNER G, 1994, NAT STRUCT BIOL, V1, P497, DOI 10.1038/nsb0894-497; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WOOLFSON DN, 1993, PROTEIN ENG, V6, P461, DOI 10.1093/protein/6.5.461; XU ZH, 1993, J BIOL CHEM, V268, P7874; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZANOTTI G, 1993, J BIOL CHEM, V268, P10727; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41	70	249	252	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					199	209		10.1016/0092-8674(94)90190-2	http://dx.doi.org/10.1016/0092-8674(94)90190-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954789				2022-12-28	WOS:A1994PN63000005
J	CAHILL, L; PRINS, B; WEBER, M; MCGAUGH, JL				CAHILL, L; PRINS, B; WEBER, M; MCGAUGH, JL			BETA-ADRENERGIC ACTIVATION AND MEMORY FOR EMOTIONAL EVENTS	NATURE			English	Article							STORAGE; INVOLVEMENT; BLOCKERS	SUBSTANTIAL evidence from animal studies suggests that enhanced memory associated,vith emotional arousal results from an activation of beta-adrenergic stress hormone systems during and after an emotional experience(1-3). To examine this implication in human subjects, we investigated the effect of the beta-adrenergic receptor antagonist propranolol hydrochloride on long-term memory for an emotionally arousing short story, or a closely matched but more emotionally neutral story. We report here that propranolol significantly impaired memory of the emotionally arousing story but did not affect memory of the emotionally neutral story. The impairing effect of propranolol on memory of the emotional story was not due either to reduced emotional responsiveness or to nonspecific sedative or attentional effects. The results support the hypothesis that enhanced memory associated with emotional experiences involves activation of the beta-adrenergic system.	UNIV CALIF IRVINE,DEPT PSYCHOBIOL,IRVINE,CA 92717; VET AFFAIRS MED CTR,CTR HYPERTENS,LONG BEACH,CA 90822; UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717	University of California System; University of California Irvine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine	CAHILL, L (corresponding author), UNIV CALIF IRVINE,CTR NEUROBIOL LEARNING & MEMORY,IRVINE,CA 92717, USA.							ARNST AFT, 1985, MEMORY DYSFUNCTIONS, P218; DENNIS KE, 1991, HEART LUNG, V20, P459; DIMSDALE JE, 1989, ARCH INTERN MED, V149, P514, DOI 10.1001/archinte.149.3.514; Frankenhaeuser M, 1975, EMOTIONS THEIR PARAM; Gallagher M., 1981, AMYGDALOID COMPLEX, P343; GOLD PE, 1986, BEHAV NEURAL BIOL, V46, P145, DOI 10.1016/S0163-1047(86)90626-6; HEUER F, 1990, MEM COGNITION, V18, P496, DOI 10.3758/BF03198482; MCAINSH J, 1990, PHARMACOL THERAPEUT, V46, P163, DOI 10.1016/0163-7258(90)90092-G; MCCARTY R, 1981, HORM BEHAV, V15, P168, DOI 10.1016/0018-506X(81)90026-X; McGaugh J. L., 1989, PSYCHOENDOCRINOLOGY, P305; MCGAUGH JL, 1989, ANNU REV NEUROSCI, V12, P255, DOI 10.1146/annurev.neuro.12.1.255; MCGAUGH JL, 1990, NEUROSCI BIOBEHAV R, V14, P425, DOI 10.1016/S0149-7634(05)80065-X; MCGAUGH JL, 1983, ANNU REV PSYCHOL, V34, P297, DOI 10.1146/annurev.ps.34.020183.001501; MCGAUGH JL, 1992, HDB EMOTION MEMORY R, P245; MCGAUGH JL, 1908, MEMORY DYSFUNCTIONS, P150; Nies AS, 1990, CARDIOVASCULAR DRUG, P420; SOLOMON S, 1983, ARCH GEN PSYCHIAT, V40, P1109; TURKKAN J, NEUROSCI BIOBEHAV RE, V12, P111	18	956	980	3	85	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					702	704		10.1038/371702a0	http://dx.doi.org/10.1038/371702a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PM773	7935815				2022-12-28	WOS:A1994PM77300056
J	BRENNAN, P; CROFT, P				BRENNAN, P; CROFT, P			INTERPRETING THE RESULTS OF OBSERVATIONAL RESEARCH - CHANCE IS NOT SUCH A FINE THING	BRITISH MEDICAL JOURNAL			English	Article							CONFIDENCE	In a randomised controlled trial, if the design is not flawed, different outcomes in the study groups must be due to the intervention itself or to chance imbalances between the groups. Because of this tests of statistical significance are used to assess the validity of results from randomised studies. Most published papers in medical research, however, describe observational studies which do not include randomised intervention. This paper argues that the continuing application of tests of significance to such non-randomised investigations is inappropriate. It draws a distinction between bias and chance imbalance on the one hand (both randomised and observational studies can be affected) and confounding on the other (a unique problem for observational investigations). It concludes that neither the P value nor the 95% confidence interval should be used as evidence for the validity of an observational result.			BRENNAN, P (corresponding author), UNIV MANCHESTER,SCH MED,ARC EPIDEMIOL RES UNIT,MANCHESTER M13 9PT,ENGLAND.							DAVEYSMITH G, 1992, LANCET, V340, P709; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; Greenland S, 1990, Epidemiology, V1, P421, DOI 10.1097/00001648-199011000-00003; Greenland S., 1987, EVOLUTION EPIDEMIOLO; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; JOLLEY D, 1993, LANCET, V342, P27, DOI 10.1016/0140-6736(93)91886-Q; Lanes S. F., 1988, CAUSAL INFERENCE, P59; Morrison D.E., 1970, SIGNIFICANCE TEST CO; POOLE C, 1987, AM J PUBLIC HEALTH, V77, P195, DOI 10.2105/AJPH.77.2.195; ROSE G, 1983, LANCET, V1, P1165; ROTHMAN KJ, 1978, NEW ENGL J MED, V299, P1362; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SMITHELLS RW, 1983, LANCET, V1, P1027; SMITHELLS RW, 1980, LANCET, V1, P647; STONE DH, 1980, LANCET, V1, P647; 1991, LANCET, V338, P131	16	74	74	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					727	730		10.1136/bmj.309.6956.727	http://dx.doi.org/10.1136/bmj.309.6956.727			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950528	Green Published			2022-12-28	WOS:A1994PH40700029
J	NARAGHI, R; GEIGER, H; CRNAC, J; HUK, W; FAHLBUSCH, R; ENGELS, G; LUFT, FC				NARAGHI, R; GEIGER, H; CRNAC, J; HUK, W; FAHLBUSCH, R; ENGELS, G; LUFT, FC			POSTERIOR-FOSSA NEUROVASCULAR ANOMALIES IN ESSENTIAL-HYPERTENSION	LANCET			English	Article							ROSTRAL VENTROLATERAL MEDULLA; BRAIN-STEM LESIONS; NEUROGENIC HYPERTENSION; HEMIFACIAL SPASM; COMPRESSION; NEURONS; RAT; VASOPRESSIN; ETIOLOGY; RABBIT	Intraoperative observations, necropsy, and angiographic studies support the presumption that neurovascular compression of the left ventrolateral medulla may cause neurogenic hypertension. Pulsatile irritation of the ventrolateral medulla at the root-entry zone of cranial nerves IX and X increases blood pressure in animals. To identify and assess the distribution of neurovascular compression at the ventrolateral medulla in human beings, we did a prospective single-blind study in 24 patients with essential hypertension, in 14 patients with renal hypertension, and in 14 normal subjects. To detect neurovascular compression, we used axial and coronal and magnetic-resonance angiography Blood pressure control and duration of hypertension were not different in the two groups of patients. 20 patients with essential hypertension had magnetic tomographic evidence of left-sided neurovascular compression at the ventrolateral medulla; 2 patients with renal hypertension and 1 of the normal subjects had a positive finding on the left. On the right side, we found signs of neurovascular compression in 4 patients with essential hypertension, in 4 with renal hypertension, and in 2 of the normal subjects. With magnetic resonance tomography, it is possible to evaluate the neurovascular relations in the posterior fossa and detect neurovascular compression at the ventrolateral medulla. These data in living subjects give further evidence of an association between neurovascular compression at the left ventrolateral medulla acid essential hypertension.	UNIV ERLANGEN NURNBERG,DEPT MED NEPHROL,D-91054 ERLANGEN,GERMANY; UNIV ERLANGEN NURNBERG,DEPT MED CARDIOL,D-91054 ERLANGEN,GERMANY	University of Erlangen Nuremberg; University of Erlangen Nuremberg	NARAGHI, R (corresponding author), UNIV ERLANGEN NURNBERG,DEPT NEUROL SURG,D-91054 ERLANGEN,GERMANY.			Naraghi, Ramin/0000-0003-3643-791X; Luft, Friedrich/0000-0002-8635-1199				ADAMS CBT, 1989, J NEUROSURG, V70, P1, DOI 10.3171/jns.1989.70.1.0001; AMENDT K, 1979, J AUTONOM NERV SYST, V1, P103, DOI 10.1016/0165-1838(79)90009-2; [Anonymous], 1873, BERICHT VERHANDL SAC; ARMSTRONG DM, 1982, J COMP NEUROL, V212, P173, DOI 10.1002/cne.902120207; BLESSING WW, 1981, CIRC RES, V49, P949, DOI 10.1161/01.RES.49.4.949; CIRIELLO J, 1986, BRAIN RES, V367, P273, DOI 10.1016/0006-8993(86)91602-1; CIRIELLO J, 1986, BRAIN RES REV, V11, P359, DOI 10.1016/0165-0173(86)90005-6; Cushing H, 1901, B JOHNS HOPKINS HOSP, V12, P290; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; DAMPNEY RAL, 1985, J AUTONOM NERV SYST, V14, P239, DOI 10.1016/0165-1838(85)90113-4; DOBA N, 1973, CIRC RES, V32, P584, DOI 10.1161/01.RES.32.5.584; FEIN JM, 1980, NEUROSURGERY, V6, P615, DOI 10.1227/00006123-198006000-00001; GARDNER WJ, 1962, J NEUROSURG, V19, P947, DOI 10.3171/jns.1962.19.11.0947; IMAIZUMI T, 1985, J HYPERTENS, V3, P491; JANNETTA PJ, 1977, J NEUROSURG, V47, P321, DOI 10.3171/jns.1977.47.3.0321; JANNETTA PJ, 1985, ANN SURG, V201, P391, DOI 10.1097/00000658-198503000-00023; JANNETTA PJ, 1985, ANN SURG, V201, P253; JULIUS S, 1985, J HYPERTENS       S4, V3, P11; KLEINEBERG B, 1992, NEUROSURGERY, V30, P834, DOI 10.1227/00006123-199206000-00003; MARK AL, 1987, J CARDIOVASC PHARM, V10, P56; NAGASEKI Y, 1992, J NEUROSURG, V77, P379, DOI 10.3171/jns.1992.77.3.0379; NARAGHI R, 1992, J NEUROSURG, V77, P103, DOI 10.3171/jns.1992.77.1.0103; ROSS CA, 1984, J COMP NEUROL, V228, P168, DOI 10.1002/cne.902280204; ROSS CA, 1984, J NEUROSCI, V4, P474; TASH R, 1991, AM J NEURORADIOL, V12, P839; VANOUWERKERK WJR, 1989, ADV NEUROSURG, V17, P188	26	108	111	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1466	1470		10.1016/S0140-6736(94)90289-5	http://dx.doi.org/10.1016/S0140-6736(94)90289-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968120				2022-12-28	WOS:A1994PT99500008
J	HICKSON, GB; CLAYTON, EW; ENTMAN, SS; MILLER, CS; GITHENS, PB; WHETTENGOLDSTEIN, K; SLOAN, FA				HICKSON, GB; CLAYTON, EW; ENTMAN, SS; MILLER, CS; GITHENS, PB; WHETTENGOLDSTEIN, K; SLOAN, FA			OBSTETRICIANS PRIOR MALPRACTICE EXPERIENCE AND PATIENTS SATISFACTION WITH CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine the relationship between prior physician malpractice experience and patients' satisfaction with care. Design.-Women were interviewed using a questionnaire that contained structured and open-ended questions. Participants.-Mothers of all stillborn infants, infant deaths, and a random sampling of viable infants drawn from 1987 Florida Vital Statistics were sorted into four groups based on the malpractice claims experience of their obstetricians between 1983 and 1986. Interviews were completed with 963 of 1536 women, most by telephone, 53 by in-person interview. Main Outcome Measures.-Mothers' responses to closed-ended and open-ended questions about their perceptions of the care they received during their pregnancy, labor, and delivery. Results.-Even though none of the women actually filed a claim, a consistent pattern of differences emerged when comparing women's perceptions of care received. Patients seeing physicians with the most frequent numbers of claims but without high payments were significantly more likely to complain that they felt rushed, never received explanations for tests, and were ignored. In response to the open-ended question, ''What part of your care were you least satisfied with?'' women seeing physicians in the High Frequency malpractice risk group offered twice as many complaints as those seeing physicians who had never been sued. Problems with physician-patient communication were the most commonly offered complaints. Conclusion.-Physicians who have been sued frequently are more often the objects of complaints about the interpersonal care they provide even by their patients who do not sue.	VANDERBILT UNIV,SCH MED,DEPT PEDIAT,DIV GEN PEDIAT,NASHVILLE,TN 37212; VANDERBILT UNIV,SCH MED,DEPT OBSTET & GYNECOL,NASHVILLE,TN; VANDERBILT UNIV,SCH LAW,NASHVILLE,TN; VANDERBILT UNIV,INST PUBL POLICY STUDIES,NASHVILLE,TN; DUKE UNIV,CTR HLTH POLICY RES & EDUC,DURHAM,NC	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Duke University			Whetten, Kathryn/C-8572-2009	Whetten, Kathryn/0000-0002-4841-7695; Clayton, Ellen/0000-0002-0308-4110	AHRQ HHS [HSO6499] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1986, COSTS COMPENSATION P; CLAYTON EW, 1993, SUING MED MALPRACTIC, P50; ENTMAN SS, 1994, JAMA-J AM MED ASSOC, V272, P1588, DOI 10.1001/jama.272.20.1588; HICKSON G, 1993, SUING MED MALPRACTIC, P92; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; KORSCH BM, 1968, PEDIATRICS, V42, P855; MAY ML, 1990, LAW SOC REV, V24, P105, DOI 10.2307/3053788; NYE DJ, 1988, GEORGETOWN LAW J, V76, P1495; Pascoe G C, 1983, Eval Program Plann, V6, P185, DOI 10.1016/0149-7189(83)90002-2; SLOAN FA, 1989, JAMA-J AM MED ASSOC, V262, P3291, DOI 10.1001/jama.262.23.3291; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WARE JE, 1976, PB288330, V1; 1989, MED PROFESSIONAL LIA, P35; 1990, PATIENTS DOCTORS LAW	14	299	301	2	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1583	1587		10.1001/jama.272.20.1583	http://dx.doi.org/10.1001/jama.272.20.1583			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PR405	7966867				2022-12-28	WOS:A1994PR40500023
J	STONEHAM, MD; SAVILLE, GM; WILSON, IH				STONEHAM, MD; SAVILLE, GM; WILSON, IH			KNOWLEDGE ABOUT PULSE OXIMETRY AMONG MEDICAL AND NURSING STAFF	LANCET			English	Article							POTENTIAL ERRORS; EVENTS; LIMITATIONS; ANESTHESIA; OXYGEN	Although pulse oximeters are increasingly used to monitor patients on medical and surgical wards, staff seem to receive no specific training in the operation of these devices. We investigated the knowledge of junior doctors and nursing staff about pulse oximetry as used on seriously ill patients in a District General Hospital in Exeter, UK. 30 medical or surgical preregistration house officers or senior house officers and 30 staff nurses answered a structured questionnaire. Questions were asked about the theory behind pulse oximetry, factors affecting readings, ''normal'' values in various patients, values in hypothetical clinical situations, and what training subjects had received. Responses were scored against standard answers from reference texts. 97% of doctors and nurses did not understand how a pulse oximeter worked and were confused about factors influencing readings. Respondents gave a wide range of acceptable saturation values (eg, 90-100% for a fit adult), thus demonstrating poor understanding of physiological principles. There were serious errors made in evaluating saturation readings in hypothetical clinical situations. Only 1 doctor had received formal training in the use of pulse oximetry. Our survey revealed that junior doctors and staff nurses were untrained in pulse oximetry, lacked knowledge of basic principles, and made serious errors in interpretation of readings. Training is needed for staff who use pulse oximeters.	ROYAL DEVON & EXETER HOSP,DEPT ANAESTHET,EXETER EX2 5DW,DEVON,ENGLAND	University of Exeter								BROOME IJ, 1992, ANAESTHESIA, V47, P17, DOI 10.1111/j.1365-2044.1992.tb01945.x; DAVIDSON JAH, 1993, BRIT MED J, V307, P372, DOI 10.1136/bmj.307.6900.372; EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; HUTTON P, 1993, BRIT MED J, V307, P457, DOI 10.1136/bmj.307.6902.457; KING T, 1987, CHEST, V92, P713, DOI 10.1378/chest.92.4.713; MOLLER JT, 1993, ANESTHESIOLOGY, V78, P445, DOI 10.1097/00000542-199303000-00007; NUNN JF, 1993, APPLIED RESPIRATORY; RALSTON AC, 1991, ANAESTHESIA, V46, P202, DOI 10.1111/j.1365-2044.1991.tb09410.x; RALSTON AC, 1991, ANAESTHESIA, V46, P291, DOI 10.1111/j.1365-2044.1991.tb11501.x; RUNCIMAN WB, 1993, ANAESTH INTENS CARE, V21, P543, DOI 10.1177/0310057X9302100509; Severinghaus J W, 1986, J Clin Monit, V2, P270, DOI 10.1007/BF02851177; SEVERINGHAUS JW, 1987, ANESTHESIOLOGY, V67, P551, DOI 10.1097/00000542-198710000-00017; TREMPER KK, 1989, ANESTHESIOLOGY, V70, P98, DOI 10.1097/00000542-198901000-00019; VERHOEFF F, 1990, ANAESTHESIA, V45, P103, DOI 10.1111/j.1365-2044.1990.tb14271.x; WEBB RK, 1991, ANAESTHESIA, V46, P207, DOI 10.1111/j.1365-2044.1991.tb09411.x; 1988, RECOMMENDATIONS STAN; 1990, LANCET, V335, P1130	17	59	59	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1339	1342		10.1016/S0140-6736(94)90697-1	http://dx.doi.org/10.1016/S0140-6736(94)90697-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968031				2022-12-28	WOS:A1994PQ92600013
J	BISSETT, D; DAVIS, JA; GEORGE, WD				BISSETT, D; DAVIS, JA; GEORGE, WD			GYNECOLOGICAL MONITORING DURING TAMOXIFEN THERAPY	LANCET			English	Editorial Material							BREAST-CANCER		STOBHILL GEN HOSP,GLASGOW G21 3UW,LANARK,SCOTLAND		BISSETT, D (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,BEATSON ONCOL CTR,GLASGOW G11 6NT,LANARK,SCOTLAND.							CRAWFORD DJ, 1992, BREAST, V1, P35; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FORNANDER T, 1989, LANCET, V1, P117; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; POWLES TJ, 1992, LANCET, V340, P1145, DOI 10.1016/0140-6736(92)93162-G	5	41	42	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1244	1244		10.1016/S0140-6736(94)90747-1	http://dx.doi.org/10.1016/S0140-6736(94)90747-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967983				2022-12-28	WOS:A1994PP70100005
J	LANG, WH; MORROW, BE; JU, QD; WARNER, JR; REEDER, RH				LANG, WH; MORROW, BE; JU, QD; WARNER, JR; REEDER, RH			A MODEL FOR TRANSCRIPTION TERMINATION BY RNA-POLYMERASE-I	CELL			English	Article							RIBOSOMAL GENE TERMINATOR; SACCHAROMYCES-CEREVISIAE; PROTEIN-BINDING; YEAST; SEQUENCE; ENHANCER; REB1; ELEMENT; EXPRESSION; NUCLEOSOME	The transcription termination site for yeast RNA polymerase I requires not only an 11 bp binding site for Reb1p, but also about 46 bp of 5' flanking sequence. We propose that Reb1p bound to its site is part of a pause element, while the 5' flanking sequence contains a release element. Pausing requires little other than the DNA-binding domain of Reb1p and is not specific for polymerase I. The release element, however, can be polymerase specific. We propose a general model for eukaryotic transcription terminators in which termination occurs when a relatively nonspecific signal induces polymerase to pause in the context of a release element.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	LANG, WH (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Morrow, Bernice/0000-0002-8076-4726	NIGMS NIH HHS [GM41792, GM25532] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025532, R01GM041792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; ELION EA, 1986, MOL CELL BIOL, V6, P2089, DOI 10.1128/MCB.6.6.2089; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; JOHNSON SP, 1989, MOL CELL BIOL, V9, P4986, DOI 10.1128/MCB.9.11.4986; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KUHN A, 1988, EMBO J, V7, P1497, DOI 10.1002/j.1460-2075.1988.tb02968.x; KULKENS T, 1992, EMBO J, V11, P4665, DOI 10.1002/j.1460-2075.1992.tb05568.x; LABHART P, 1987, MOL CELL BIOL, V7, P1900, DOI 10.1128/MCB.7.5.1900; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MORROW BE, 1993, MOL CELL BIOL, V13, P1173, DOI 10.1128/MCB.13.2.1173; MORROW BE, 1990, J BIOL CHEM, V265, P20778; MORROW BE, 1993, MOL CELL BIOL, V13, P1283, DOI 10.1128/MCB.13.2.1283; REEDER RH, 1994, MOL MICROBIOL, V12, P11, DOI 10.1111/j.1365-2958.1994.tb00989.x; REMACLE JE, 1992, MOL CELL BIOL, V12, P5516, DOI 10.1128/MCB.12.12.5516; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SCOTT EW, 1993, MOL CELL BIOL, V13, P543, DOI 10.1128/MCB.13.1.543; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743	28	90	91	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					527	534		10.1016/0092-8674(94)90261-5	http://dx.doi.org/10.1016/0092-8674(94)90261-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954818				2022-12-28	WOS:A1994PQ48800015
J	CASS, RM				CASS, RM			A PILL FOR OLD-PEOPLE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											CASS, RM (corresponding author), UNIV ROCHESTER, ROCHESTER, NY 14620 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					717	717		10.7326/0003-4819-121-9-199411010-00015	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00015			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944084				2022-12-28	WOS:A1994PN45000015
J	ALMARRI, A; BATCHELOR, JR				ALMARRI, A; BATCHELOR, JR			HLA AND HEPATITIS-B INFECTION	LANCET			English	Note							VACCINE	The mechanism underlying the development of chronic infection with hepatitis B virus is not known. We have done two independent studies in Qatar, where such infection is common, to determine whether immunity to this virus is influenced by the HLA phenotype of an individual. The first study generated a hypothesis to test in the second. In both studies, there was a significant deficiency of HLA-DR2 and an excess of HLA-DR7 in patients with chronic persistent infection with hepatitis B virus. We conclude that HLA phenotype is one of the factors influencing the response to infection with this virus.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND; HAMAD HOSP,DEPT CLIN LAB & PATHOL,DOHA,QATAR	Imperial College London; Hamad Medical Corporation; Hamad General Hospital			谷, 雷雷/A-2889-2009					BIDWELL JL, 1988, TRANSPLANTATION, V45, P640, DOI 10.1097/00007890-198803000-00027; CRAVEN DE, 1986, ANN INTERN MED, V105, P356, DOI 10.7326/0003-4819-105-3-356; HATTUM JV, 1987, HEPATOLOGY, V7, P11; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; POZZILLI P, 1987, DIABETOLOGIA, V30, P817; WEISSMAN JY, 1988, JAMA-J AM MED ASSOC, V260, P1734, DOI 10.1001/jama.260.12.1734; YANG PM, 1989, HEPATO-GASTROENTEROL, V36, P363; 1994, LANCET, V343, P927	8	97	106	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1194	1195		10.1016/S0140-6736(94)90510-X	http://dx.doi.org/10.1016/S0140-6736(94)90510-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934542				2022-12-28	WOS:A1994PN80300011
J	GINSBERG, JS; BARRON, WM				GINSBERG, JS; BARRON, WM			PREGNANCY AND PROSTHETIC HEART-VALVES	LANCET			English	Editorial Material							HEPARIN-THERAPY; ANTICOAGULANTS; WARFARIN; FETAL; RISKS; WOMEN		LOYOLA UNIV,MED CTR,DEPT MED,CHICAGO,IL 60611; LOYOLA UNIV,MED CTR,DEPT OBSTET & GYNECOL,CHICAGO,IL	Loyola University Chicago; Loyola University Chicago	GINSBERG, JS (corresponding author), MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON L8N 3Z5,ON,CANADA.		ginsberg, jeffrey s/ABC-1065-2020					BARBOUR LA, 1994, AM J OBSTET GYNECOL, V170, P862, DOI 10.1016/S0002-9378(94)70299-3; BRILLEDWARDS P, 1993, ANN INTERN MED, V119, P104, DOI 10.7326/0003-4819-119-2-199307150-00002; CARUSO A, 1994, EUR J OBSTET GYN R B, V54, P7, DOI 10.1016/0028-2243(94)90074-4; DAHLMAN TC, 1993, AM J OBSTET GYNECOL, V168, P1265, DOI 10.1016/0002-9378(93)90378-V; GINSBERG JS, 1989, CHEST, V95, pS156, DOI 10.1378/chest.95.2.156S; GINSBERG JS, 1990, THROMB HAEMOSTASIS, V64, P286; GINSBERG JS, 1989, ARCH INTERN MED, V149, P2233, DOI 10.1001/archinte.149.10.2233; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; ITURBEALESSIO I, 1986, NEW ENGL J MED, V315, P1390, DOI 10.1056/NEJM198611273152205; SBAROUNI E, 1994, BRIT HEART J, V71, P196; TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802; WONG V, 1993, AM J MED GENET, V45, P17, DOI 10.1002/ajmg.1320450107	14	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1170	1172		10.1016/S0140-6736(94)90501-0	http://dx.doi.org/10.1016/S0140-6736(94)90501-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934533				2022-12-28	WOS:A1994PN80300002
J	AIBA, A; KANO, M; CHEN, C; STANTON, ME; FOX, GD; HERRUP, K; ZWINGMAN, TA; TONEGAWA, S				AIBA, A; KANO, M; CHEN, C; STANTON, ME; FOX, GD; HERRUP, K; ZWINGMAN, TA; TONEGAWA, S			DEFICIENT CEREBELLAR LONG-TERM DEPRESSION AND IMPAIRED MOTOR LEARNING IN MGLUR1 MUTANT MICE	CELL			English	Article							METABOTROPIC GLUTAMATE RECEPTOR; NICTITATING-MEMBRANE RESPONSE; CONDITIONED EYELID RESPONSES; PURKINJE-CELL TRANSMISSION; CENTRAL-NERVOUS-SYSTEM; MEMORY TRACE; INTERPOSITUS NUCLEUS; SYNAPTIC DEPRESSION; CLIMBING FIBER; DEVELOPING RAT	mGluR1 mutant mice are viable but show characteristic cerebellar symptoms such as ataxic gait and intention tremor. The anatomy of the cerebellum is not overtly disturbed. Excitatory synaptic transmission from parallel fibers (PFs) to Purkinje cells and that from climbing fibers (CFs) to Purkinje cells appear to be functional, and voltage-gated Ca2+ channels of Purkinje cells are normal. Both PF and CF synapses display normal short-term synaptic plasticity to paired stimuli. By marked contrast, long-term depression (LTD) is clearly deficient and conditioned eyeblink response is impaired. We conclude that mGluR1 is required for the induction of LTD and that the ataxic behavior and impaired eyeblink conditioning of the mGluR1 mutant mice are primarily due to deficient LTD.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; JICHI MED SCH, DEPT PHYSIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; US EPA, DIV NEUROTOXICOL, RES TRIANGLE PK, NC 27711 USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; CASE WESTERN RESERVE UNIV, SCH MED, ALZHEIMERS RES LABS, CLEVELAND, OH 44106 USA	Massachusetts Institute of Technology (MIT); Jichi Medical University; United States Environmental Protection Agency; University of North Carolina; University of North Carolina Chapel Hill; Case Western Reserve University	AIBA, A (corresponding author), MIT, HOWARD HUGHES MED INST, CTR LEARNING & MEMORY, CAMBRIDGE, MA 02139 USA.		Herrup, Karl/C-5313-2014	Herrup, Karl/0000-0001-7786-5844; Aiba, Atsu/0000-0002-8192-0778; Kano, Masanobu/0000-0002-0725-3292	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925, R01NS020591] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS32925, NS20591] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ALTMAN J, 1973, J COMP NEUROL, V149, P181, DOI 10.1002/cne.901490204; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BLOEDEL JR, 1992, BEHAV BRAIN SCI, V15, P666; BRUNNER RL, 1973, BEHAV BIOL, V9, P169, DOI 10.1016/S0091-6773(73)80154-3; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; CLARK RE, 1992, BEHAV NEUROSCI, V106, P879, DOI 10.1037/0735-7044.106.6.879; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; CREPEL F, 1980, NEUROSCIENCE, V5, P333, DOI 10.1016/0306-4522(80)90109-8; DANIEL H, 1992, EXP BRAIN RES, V90, P327; DISTERHOFT JF, 1977, BRAIN RES, V137, P127, DOI 10.1016/0006-8993(77)91016-2; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EKEROT CF, 1985, BRAIN RES, V342, P357, DOI 10.1016/0006-8993(85)91136-9; FOTUHI M, 1993, J NEUROSCI, V13, P2001; GORMEZANO I, 1962, SCIENCE, V138, P33, DOI 10.1126/science.138.3536.33; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HALL RD, 1973, BEHAV RES METH INSTR, V5, P321, DOI 10.3758/BF03200199; HARTELL NA, 1994, NEUROREPORT, V5, P913, DOI 10.1097/00001756-199404000-00015; HARTKOP TH, 1977, J NEUROPATH EXP NEUR, V36, P519, DOI 10.1097/00005072-197705000-00009; HIRANO T, 1990, NEUROSCI LETT, V119, P145, DOI 10.1016/0304-3940(90)90819-U; ITO M, 1982, J PHYSIOL-LONDON, V324, P113, DOI 10.1113/jphysiol.1982.sp014103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Ito M, 1984, CEREBELLUM NEURAL CO; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; Kano M., 1992, P54; KANO M, 1988, NEUROSCI RES, V5, P544, DOI 10.1016/0168-0102(88)90041-7; KANO M, 1988, NEUROSCI RES, V5, P325, DOI 10.1016/0168-0102(88)90034-X; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; KRUPA DJ, 1993, SCIENCE, V260, P989, DOI 10.1126/science.8493536; LAVOND DG, 1989, BEHAV BRAIN RES, V33, P113, DOI 10.1016/S0166-4328(89)80047-6; LAVOND DG, 1987, EXP BRAIN RES, V67, P569; LIANO I, 1991, NEURON, V7, P577; LIANO I, 1991, J PHYSL, V434, P183; LINCOLN JS, 1982, BRAIN RES, V242, P190, DOI 10.1016/0006-8993(82)90510-8; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LINDEN DJ, 1991, SCIENCE, V254, P1656, DOI 10.1126/science.1721243; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCCORMICK DA, 1982, P NATL ACAD SCI-BIOL, V79, P2731, DOI 10.1073/pnas.79.8.2731; PELLEGRINO LJ, 1979, J COMP PHYSIOL PSYCH, V93, P1, DOI 10.1037/h0077589; PERRETT SP, 1993, J NEUROSCI, V13, P1708; RACINE RJ, 1986, EXP BRAIN RES, V63, P158; RAKIC P, 1975, ADV NEUROL, V12, P117; RAKIC P, 1973, P NATL ACAD SCI USA, V70, P240, DOI 10.1073/pnas.70.1.240; SAKURAI M, 1987, J PHYSIOL-LONDON, V394, P463, DOI 10.1113/jphysiol.1987.sp016881; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SCHMAJUK NA, 1990, PHYSIOL BEHAV, V48, P755, DOI 10.1016/0031-9384(90)90221-O; SCHNEIDERMAN N, 1962, SCIENCE, V136, P650, DOI 10.1126/science.136.3516.650; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SKELTON RW, 1988, BEHAV NEUROSCI, V102, P586, DOI 10.1037/0735-7044.102.4.586; SOTELO C, 1990, J EXP BIOL, V153, P225; STANTON ME, 1992, BEHAV NEUROSCI, V106, P657, DOI 10.1037/0735-7044.106.4.657; STANTON ME, 1994, ENVIRON HEALTH PERSP, V102, P131, DOI 10.2307/3431830; STEINMETZ JE, 1992, J NEUROSCI, V12, P4403; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519; WELSH JP, 1989, J NEUROSCI, V9, P299; WELSH JP, 1991, J PHYSIOL-LONDON, V444, P459, DOI 10.1113/jphysiol.1991.sp018888; WOODWARD DJ, 1975, BRAIN RES, V97, P195, DOI 10.1016/0006-8993(75)90445-X; YEO CH, 1992, EXP BRAIN RES, V88, P623; YEO CH, 1985, EXP BRAIN RES, V60, P87, DOI 10.1007/BF00237022; YEO CH, 1985, EXP BRAIN RES, V60, P99, DOI 10.1007/BF00237023; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	75	729	752	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					377	388						12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954803				2022-12-28	WOS:A1994PN63000020
J	BOYD, JM; MALSTROM, S; SUBRAMANIAN, T; VENKATESH, LK; SCHAEPER, U; ELANGOVAN, B; DSAEIPPER, C; CHINNADURAI, G				BOYD, JM; MALSTROM, S; SUBRAMANIAN, T; VENKATESH, LK; SCHAEPER, U; ELANGOVAN, B; DSAEIPPER, C; CHINNADURAI, G			ADENOVIRUS-E1B 19-KDA AND BCL-2 PROTEINS INTERACT WITH A COMMON SET OF CELLULAR PROTEINS	CELL			English	Article							TUMOR-NECROSIS-FACTOR; CALMODULIN-DEPENDENT PHOSPHODIESTERASE; EARLY REGION E1B; MOLECULAR-CLONING; FOLLICULAR LYMPHOMA; NUCLEAR-ENVELOPE; RNA-POLYMERASE; LP+ LOCUS; APOPTOSIS; DEATH	Adenovirus E1B 19 kDa protein protects against cell death induced by viral infection and certain external stimuli. The Bcl-2 protein can functionally substitute for the E1B 19 kDa protein. To identify cellular targets for the 19 kDa protein, we used the two-hybrid screen in yeast. We have isolated cDNAs for three different proteins, designated Nip1, Nip2, and Nip3, that interact with the 19 kDa protein. Mutational analysis indicates that these proteins do not associate with 19 kDa mutants defective in suppression of cell death, suggesting a correlation between interaction of these proteins and suppression of cell death. These proteins also associate with discrete sequence motifs in the Bcl-2 protein that are homologous to motifs of the 19 kDa protein. our results suggest that two diverse proteins, the E1B 19 kDa and the Bcl-2 proteins, promote cell survival through interaction with a common set of cellular proteins.			BOYD, JM (corresponding author), ST LOUIS UNIV, HLTH SCI CTR, INST MOLEC VIROL, ST LOUIS, MO 63110 USA.				NCI NIH HHS [CA-33616, CA-31719, R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616, R01CA031719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Alberts B., 1989, MOL BIOL CELL; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAKHSHI A, 1985, CELL, V41, P889; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DHALLUIN JC, 1985, J GEN VIROL, V66, P1873, DOI 10.1099/0022-1317-66-9-1873; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EZOE H, 1981, J VIROL, V40, P20, DOI 10.1128/JVI.40.1.20-27.1981; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENGARTNER MO, 1992, NATURE, V356, P495; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUNZIKER W, 1988, MOL ENDOCRINOL, V2, P465, DOI 10.1210/mend-2-5-465; IACOPINO AM, 1990, P NATL ACAD SCI USA, V87, P4078, DOI 10.1073/pnas.87.11.4078; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LASTER SM, 1988, J IMMUNOL, V141, P2629; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; POLLI JW, 1992, P NATL ACAD SCI USA, V89, P11079, DOI 10.1073/pnas.89.22.11079; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REPASKE DR, 1992, J BIOL CHEM, V267, P18683; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rose M. D., 1990, METHODS YEAST GENETI, P198; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SORENSON CM, 1988, CANCER RES, V48, P4484; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUBRAMANIAN T, 1985, MOL CELL BIOL, V5, P3297, DOI 10.1128/MCB.5.11.3297; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; SUMMERHAYES IC, 1982, P NATL ACAD SCI-BIOL, V79, P5292, DOI 10.1073/pnas.79.17.5292; TAKEMORI N, 1984, J VIROL, V52, P793, DOI 10.1128/JVI.52.3.793-805.1984; TAKEMORI N, 1968, VIROLOGY, V36, P575, DOI 10.1016/0042-6822(68)90189-X; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; TARODI B, 1993, INT J ONCOL, V3, P467; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	66	420	444	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					341	351		10.1016/0092-8674(94)90202-X	http://dx.doi.org/10.1016/0092-8674(94)90202-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954800				2022-12-28	WOS:A1994PN63000017
J	DIKSHIT, RK; DIKSHIT, N				DIKSHIT, RK; DIKSHIT, N			COMMERCIAL SOURCE OF DRUG INFORMATION - COMPARISON BETWEEN THE UNITED-KINGDOM AND INDIA	BRITISH MEDICAL JOURNAL			English	Article									BJ MED COLL,DEPT PHYSIOL,AHMEDABAD 380016,GUJARAT,INDIA	B. J. Medical College & Civil Hospital, Ahmedabad	DIKSHIT, RK (corresponding author), BJ MED COLL,DEPT PHARMACOL,AHMEDABAD 380016,GUJARAT,INDIA.							FERNER RE, 1992, BR J CLIN PHARM, V34, P158; HERXHEIMER A, 1990, BRIT MED J, V300, P307, DOI 10.1136/bmj.300.6720.307; STIMSON GV, 1975, BRIT MED J, V4, P508, DOI 10.1136/bmj.4.5995.508; 1989, ABPI DATA SHEET COMP, pR7	4	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					990	991		10.1136/bmj.309.6960.990	http://dx.doi.org/10.1136/bmj.309.6960.990			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950720	Green Published			2022-12-28	WOS:A1994PM41700022
J	GOODALE, MA				GOODALE, MA			ACTIVE MINDS, SLEEPING BODIES	LANCET			English	Editorial Material							REM		UNIV WESTERN ONTARIO,GRAD PROGRAM NEUROSCI,LONDON,ON,CANADA	Western University (University of Western Ontario)	GOODALE, MA (corresponding author), UNIV WESTERN ONTARIO,DEPT PSYCHOL,LONDON,ON,CANADA.		Goodale, Melvyn A/M-5907-2013	Goodale, Melvyn A/0000-0001-6748-0561				ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; BLOCH V, 1977, NEUROBIOLOGY SLEEP M; DEMENT W, 1960, SCIENCE, V131, P1705, DOI 10.1126/science.131.3415.1705; DEMENT W, 1957, J EXP PSYCHOL, V53, P339, DOI 10.1037/h0048189; DUJARDIN K, 1990, PHYSIOL BEHAV, V47, P1271, DOI 10.1016/0031-9384(90)90382-E; KARNI A, 1994, SCIENCE, V265, P679, DOI 10.1126/science.8036518; Kleitman N., 1961, NATURE SLEEP; LAVIE P, 1984, NEUROLOGY, V34, P1118; MCGRATH MJ, 1978, PSYCHOL BULL, V85, P24, DOI 10.1037/0033-2909.85.1.24; SMITH C, 1985, NEUROSCI BIOBEHAV R, V9, P157, DOI 10.1016/0149-7634(85)90042-9; SMITH C, 1991, SLEEP, V14, P325, DOI 10.1093/sleep/14.4.325; VANDERWOLF CH, 1983, HDB BEHAVIORAL NEURO, V6, P67; WYATT RJ, 1971, NEW ENGL J MED, V285, P987, DOI 10.1056/NEJM197110282851802	13	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1036	1037		10.1016/S0140-6736(94)91703-5	http://dx.doi.org/10.1016/S0140-6736(94)91703-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934440				2022-12-28	WOS:A1994PL85200003
J	WEIR, CJ; MURRAY, GD; ADAMS, FG; MUIR, KW; GROSSET, DG; LEES, KR				WEIR, CJ; MURRAY, GD; ADAMS, FG; MUIR, KW; GROSSET, DG; LEES, KR			POOR ACCURACY OF STROKE SCORING SYSTEMS FOR DIFFERENTIAL CLINICAL-DIAGNOSIS OF INTRACRANIAL HEMORRHAGE AND INFARCTION	LANCET			English	Article							HEMORRHAGE; COMMUNITY; PROJECT	The differentiation of cerebral infarction and cerebral haemorrhage is the most important first step in the management of acute stroke, because clinical management of the two disorders differs substantially. The Guy's Hospital and Siriraj stroke diagnostic scores were developed to aid clinicians in this decision. We have tested the performance of the two scores on a group of 1059 patients admitted to the acute stroke unit (ASU) at the Western Infirmary, Glasgow, with suspected stroke between May, 1990, and December, 1993. The diagnosis was confirmed as stroke by computed tomography (CT) scanning or necropsy (n=10) in 991 patients. For each clinical score we subjectively identified the cut-off point that maximised sensitivity to cerebral haemorrhage with the smallest loss of specificity. At its optimum cut-off point the Guy's Hospital score had a sensitivity for the diagnosis of haemorrhage of 70% and specificity of 64%. The corresponding figures for the Siriraj score at its optimum cut-off point were 68% sensitivity and 64% specificity. The overall predictive accuracy of both scores was 64%. The greater complexity of the Guy's Hospital score (thirteen variables included) did not result in substantially superior performance to the Siriraj score (five variables). This validation study suggests that neither score is useful for exclusion of haemorrhage before anticoagulant treatment is initiated or as a diagnostic screening procedure for trials of low-risk treatments such as aspirin. Our findings emphasise the need for routine CT scanning in this setting, since this method remains the most accurate for differentiating between haemorrhage and infarction.	UNIV GLASGOW,WESTERN INFIRM,DEPT MED & THERAPEUT,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,ROBERTSON CTR BIOSTAT,GLASGOW G61 1BD,LANARK,SCOTLAND; WESTERN INFIRM & ASSOCIATED HOSP,DEPT RADIOL,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow			Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X; Murray, Gordon/0000-0001-9866-4734; Grosset, Donald/0000-0002-2757-8203; Weir, Christopher/0000-0002-6494-4903	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen CMC, 1983, Q J MED, V208, P515; ALTMAN DG, 1991, PRACTICAL STAT MED R, P417; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; CELANI MG, 1994, BRIT MED J, V308, P1674, DOI 10.1136/bmj.308.6945.1674; HARRISON MJG, 1980, POSTGRAD MED J, V56, P629, DOI 10.1136/pgmj.56.659.629; MORRIS AD, 1993, J NEUROL NEUROSUR PS, V56, P352, DOI 10.1136/jnnp.56.4.352; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; SANDERCOCK PAG, 1985, BRIT MED J, V291, P1675, DOI 10.1136/bmj.291.6510.1675; SANDERCOCK PAG, 1986, BRIT MED J, V292, P173; VONARBIN M, 1981, STROKE, V12, P288, DOI 10.1161/01.STR.12.3.288	11	88	88	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					999	1002		10.1016/S0140-6736(94)91648-9	http://dx.doi.org/10.1016/S0140-6736(94)91648-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934437				2022-12-28	WOS:A1994PK97800016
J	BONDI, H				BONDI, H			POPPER,KARL (1902-1994) - OBITUARY	NATURE			English	Item About an Individual											BONDI, H (corresponding author), UNIV CAMBRIDGE CHURCHILL COLL,CAMBRIDGE CB3 0DS,ENGLAND.							HESSE H, GLASS BEAD GAME; Magee B., 1973, POPPER; POPPER K, PUBLICATION LIST	3	3	4	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					478	478		10.1038/371478a0	http://dx.doi.org/10.1038/371478a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935759	Bronze			2022-12-28	WOS:A1994PK58900032
J	CAMPBELL, D; COX, D; CRUM, J; FOSTER, K; RILEY, A				CAMPBELL, D; COX, D; CRUM, J; FOSTER, K; RILEY, A			LATER EFFECTS OF GROUNDING OF TANKER BRAER ON HEALTH IN SHETLAND	BRITISH MEDICAL JOURNAL			English	Article									SHETLAND HLTH BOARD,LERWICK ZE1 0RB,ZETLAND,SCOTLAND; GRAMPIAN AREA HLTH BOARD,ABERDEEN AB9 1RE,SCOTLAND; LOTHIAN HLTH BOARD,EDINBURGH EH8 9RS,MIDLOTHIAN,SCOTLAND		CAMPBELL, D (corresponding author), RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW G20 9NB,LANARK,SCOTLAND.							CAMPBELL D, 1993, BRIT MED J, V307, P1251, DOI 10.1136/bmj.307.6914.1251; CAMPBELL DM, 1993, BRIT MED J, V306, P519, DOI 10.1136/bmj.306.6876.519-a; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; LOGUE JN, 1981, EPIDEMIOL REV, V3, P140, DOI 10.1093/oxfordjournals.epirev.a036231	4	31	31	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					773	774		10.1136/bmj.309.6957.773	http://dx.doi.org/10.1136/bmj.309.6957.773			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950562	Green Published			2022-12-28	WOS:A1994PJ28200019
J	FULLER, RW				FULLER, RW			CONTROVERSIES IN MANAGEMENT .4. USE OF BETA(2) AGONISTS IN ASTHMA - MUCH ADO ABOUT NOTHING - ADVERSE-EFFECTS ARE NOT PROVED	BRITISH MEDICAL JOURNAL			English	Article							SALMETEROL; SALBUTAMOL; DEATH				FULLER, RW (corresponding author), GLAXO GRP RES & DEV LTD,RESP MED,STOCKWAY PK W UB11 1BT,MIDDX,ENGLAND.							BRITTON MG, 1992, EUR RESPIR J, V5, P1062; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; DALONZO FE, 1992, AM REV RESPIR DIS S4, V145, P65; FULLER RW, 1992, BETA AGONISTS IN THE TREATMENT OF ASTHMA, P135; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; SPEIZER FE, 1968, BRIT MED J, V3, P245, DOI 10.1136/bmj.3.5612.245; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134	11	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					795	796		10.1136/bmj.309.6957.795	http://dx.doi.org/10.1136/bmj.309.6957.795			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950573	Green Published			2022-12-28	WOS:A1994PJ28200033
J	GEPPERT, M; GODA, Y; HAMMER, RE; LI, C; ROSAHL, TW; STEVENS, CF; SUDHOF, TC				GEPPERT, M; GODA, Y; HAMMER, RE; LI, C; ROSAHL, TW; STEVENS, CF; SUDHOF, TC			SYNAPTOTAGMIN-I - A MAJOR CA2+ SENSOR FOR TRANSMITTER RELEASE AT A CENTRAL SYNAPSE	CELL			English	Article							FROG NEUROMUSCULAR-JUNCTION; NEUROTRANSMITTER RELEASE; DIVALENT-CATIONS; ALPHA-LATROTOXIN; BINDING; PROTEIN; EXOCYTOSIS; DROSOPHILA; P65; CONSERVATION	Mice carrying a mutation in the synaptotagmin I gene were generated by homologous recombination. Mutant mice are phenotypically normal as heterozygotes, but die within 48 hr after birth as homozygotes. Studies of hippocampal neurons cultured from homozygous mutant mice reveal that synaptic transmission is severely impaired. The synchronous, fast component of Ca2+-dependent neurotransmitter release is decreased, whereas asynchronous release processes, including spontaneous synaptic activity (miniature excitatory postsynaptic current frequency) and release triggered by hypertonic solution or alpha-latrotoxin, are unaffected. Our findings demonstrate that synaptotagmin I function is required for Ca2+ triggering of synchronous neurotransmitter release, but is not essential for asynchronous or Ca2+-independent release. We propose that synaptotagmin I is the major low affinity Ca2+ sensor mediating Ca2+ regulation of synchronous neurotransmitter release in hippocampal neurons.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; SALK INST BIOL STUDIES, NEURONAL STRUCT & FUNCT LAB, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, LA JOLLA, CA 92037 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Salk Institute; Howard Hughes Medical Institute; Salk Institute			Goda, Yukiko/A-6576-2016; Goda, Yukiko/AAR-5641-2020	Goda, Yukiko/0000-0003-0352-9498; Goda, Yukiko/0000-0003-0352-9498; Hammer, Robert E./0000-0001-5487-7551	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012961] Funding Source: NIH RePORTER; NINDS NIH HHS [R0 NS 12961-17] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUGUSTINE GJ, 1984, J PHYSIOL-LONDON, V346, P257, DOI 10.1113/jphysiol.1984.sp015020; BARRETT EF, 1972, J PHYSIOL-LONDON, V227, P691, DOI 10.1113/jphysiol.1972.sp010054; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DAVLETOV BA, 1994, IN PRESS J BIOL CHEM, V269; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GODA Y, 1994, IN PRESS P NATL ACAD; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; Sambrook J, 1989, MOL CLONING LABORATO; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P175, DOI 10.1085/jgp.76.2.175; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	41	1194	1214	2	100	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					717	727		10.1016/0092-8674(94)90556-8	http://dx.doi.org/10.1016/0092-8674(94)90556-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954835				2022-12-28	WOS:A1994PT48100018
J	HU, H; WATANABE, H; PAYTON, M; KORRICK, S; ROTNITZKY, A				HU, H; WATANABE, H; PAYTON, M; KORRICK, S; ROTNITZKY, A			THE RELATIONSHIP BETWEEN BONE LEAD AND HEMOGLOBIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY-FLUORESCENCE; OCCUPATIONAL EXPOSURE; BLOOD LEAD; INVIVO; BURDEN	Objective.-To determine whether the concentration of lead in bone constitutes a biological marker that is more sensitive for chronic toxicity than blood lead levels. Design.-Survey. Setting.-A construction trade union with members who engage in carpentry, demolition, and other construction activities. Participants.-Members of the construction trade union. Main Outcome Measures.-We measured blood pressure, serum creatinine, hematocrit, and hemoglobin. We measured blood lead by anodic stripping voltametry and used a cadmium 109 K x-ray fluorescence instrument to make in vivo measurements of lead in the tibia (a heavily cortical bone) and the patella (a heavily trabecular bone). Information was also collected on medical history, smoking, and alcohol ingestion. Results.-Bone lead levels in the patella were found to be significantly correlated with a decrease in hemoglobin and hematocrit, even after adjusting for age, blood lead, body mass index, cigarette smoking, and alcohol ingestion and removing outliers. Blood lead levels were low (mean=0.40 mu mol/L [8.3 mu g/dl]) and were not correlated with either hemoglobin or hematocrit. In the final multivariate regression model that corrected for measurement error, an increase in patella bone lead level from the lowest to highest quintile in this study population (37 mu g/g) was associated with a decrease in hemoglobin and hematocrit of 11 g/L (95% confidence interval [Cl], 2.7 to 19.3 g/L) and 0.03 (95% Cl, 0.01 to 0.05), respectively. Conclusion.-We conclude that patella bone lead levels are associated with decreased hematocrit and hemoglobin levels despite the presence of low blood lead levels. This conclusion may reflect a subclinical effect of bone lead stores on hematopoiesis and is the first epidemiological evidence that bone lead may be an important biological marker of ongoing chronic toxicity.	HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,OCCUPAT HLTH PROGRAM,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; OSAKA MED COLL,OSAKA,JAPAN	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Osaka Medical College	HU, H (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.				NIEHS NIH HHS [P42-ES05947, 2 P30 ES 00002, ES 05257-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005257, P42ES005947, P30ES000002] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMSTRONG R, 1992, BRIT J IND MED, V49, P14; ARO ACA, IN PRESS PHYS MED BI; BARRY PSI, 1970, BRIT J IND MED, V27, P339; Burger D E, 1990, Basic Life Sci, V55, P287; CHRISTOFFERSSON JO, 1986, ARCH ENVIRON HEALTH, V41, P312, DOI 10.1080/00039896.1986.9936703; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Fuller W.A., 2009, MEASUREMENT ERROR MO; GERHARDSSON L, 1992, BRIT J IND MED, V49, P186; GOLDMAN RH, 1994, AM J IND MED, V25, P417, DOI 10.1002/ajim.4700250309; GORDON CL, 1993, BRIT J IND MED, V50, P637; GOYER RA, 1993, ENVIRON HEALTH PERSP, V100, P177, DOI 10.2307/3431524; GRAZIANO JH, 1991, ARCH ENVIRON HEALTH, V46, P347, DOI 10.1080/00039896.1991.9934401; HAJEM S, 1990, ENVIRON RES, V53, P105, DOI 10.1016/S0013-9351(05)80113-6; HERNBERG S, 1967, ARCH ENVIRON HEALTH, V14, P319, DOI 10.1080/00039896.1967.10664739; HU H, 1989, ENVIRON RES, V49, P295, DOI 10.1016/S0013-9351(89)80074-X; Hu H, 1990, Basic Life Sci, V55, P267; HU H, 1990, ARCH ENVIRON HEALTH, V45, P335, DOI 10.1080/00039896.1990.10118752; HU H, 1991, AM J IND MED, V20, P723, DOI 10.1002/ajim.4700200603; HU H, IN PRESS ENV HLTH PE; JONES KW, 1987, IN VIVO BODY COMPOSI, P363; KOSNETT MJ, 1994, JAMA-J AM MED ASSOC, V271, P197, DOI 10.1001/jama.271.3.197; LANDRIGAN PJ, 1994, JAMA-J AM MED ASSOC, V271, P239, DOI 10.1001/jama.271.3.239; LIPPMANN M, 1990, ENVIRON RES, V51, P1, DOI 10.1016/S0013-9351(05)80179-3; MANTON WI, 1985, BRIT J IND MED, V42, P168; MARCUS AH, 1985, ENVIRON RES, V36, P473, DOI 10.1016/0013-9351(85)90039-8; MORGAN WD, 1990, BIOL TRACE ELEM RES, V26-7, P407, DOI 10.1007/BF02992695; NILSSON U, 1991, PHARMACOL TOXICOL, V69, P477; OFLAHERTY EJ, 1991, TOXICOL APPL PHARM, V111, P313, DOI 10.1016/0041-008X(91)90033-B; RABINOWITZ MB, 1991, ENVIRON HEALTH PERSP, V91, P33, DOI 10.2307/3430979; RABINOWITZ MB, 1976, J CLIN INVEST, V58, P260, DOI 10.1172/JCI108467; ROSNER B, 1983, TECHNOMETRICS, V25, P165, DOI 10.2307/1268549; SALTZMAN BE, 1990, ENVIRON RES, V52, P126, DOI 10.1016/S0013-9351(05)80248-8; SCHILTZ A, 1987, ARCH ENVIRON HEALTH, V42, P340; SCHROEDER HA, 1968, ARCH ENVIRON HEALTH, V17, P965, DOI 10.1080/00039896.1968.10665354; SCHWARTZ J, 1990, AM J PUBLIC HEALTH, V80, P165, DOI 10.2105/AJPH.80.2.165; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; SOKAS RK, 1990, ARCH ENVIRON HEALTH, V45, P268, DOI 10.1080/00039896.1990.10118744; SOMERVAILLE LJ, 1985, PHYS MED BIOL, V30, P929, DOI 10.1088/0031-9155/30/9/005; SOMERVAILLE LJ, 1988, BRIT J IND MED, V45, P174; WATANABE H, 1994, AM J IND MED, V26, P255, DOI 10.1002/ajim.4700260211; Wedeen R P, 1988, Contrib Nephrol, V64, P102; WIELOPOLSKI L, 1986, AM J IND MED, V9, P221; WITTMERS LE, 1988, ARCH ENVIRON HEALTH, V43, P381, DOI 10.1080/00039896.1988.9935855	43	72	74	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1512	1517		10.1001/jama.272.19.1512	http://dx.doi.org/10.1001/jama.272.19.1512			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966843				2022-12-28	WOS:A1994PQ90000030
J	SILVER, MT; ROSE, GA; PAUL, SD; ODONNELL, CJ; OGARA, PT; EAGLE, KA				SILVER, MT; ROSE, GA; PAUL, SD; ODONNELL, CJ; OGARA, PT; EAGLE, KA			A CLINICAL RULE TO PREDICT PRESERVED LEFT-VENTRICULAR EJECTION FRACTION IN PATIENTS AFTER MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; VENTRICULAR FUNCTION, LEFT; STROKE VOLUME; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; PREDICTION RULES		Objective: To derive and validate a clinical prediction rule that identifies patients after myocardial infarction who have preserved left ventricular systolic function. Design: Retrospective analysis of a prospective cohort study, with a derivation set to generate a clinical prediction rule and a validation set to test the prediction rule. Setting: Urban tertiary care hospital. Patients: 314 consecutive patients admitted with myocardial infarction who had one or more of the following tests to determine left ventricular ejection fraction: transthoracic echocardiography, contrast left ventriculography, or radionuclide ventriculography. Measurements: Left ventricular ejection fractions were determined by transthoracic echocardiography, contrast left ventriculography, and gated blood pool scan. Results: Multivariate analysis of patients in the derivation set yielded the following rule: The left ventricular ejection fraction is predicted to be 40% or more in patients who have 1) an interpretable electrocardiogram, 2) no previous Q-wave myocardial infraction, 3) no history of congestive heart failure, and 4) an index myocardial infarction that is not a Q-wave anterior infarction. In the derivation and the validation sets, the positive predictive value of the prediction rule was more than 0.98. Conclusions: A simple clinical prediction rule using easily obtained historical and electrocardiographic data reliably identifies a substantial percentage of patients after myocardial infarction (40% in our hospital) who are likely to have preserved left ventricular systolic function. If validated in other patient populations, application of this prediction rule in clinical practice could result in a substantial decrease in the cost of treating uncomplicated myocardial infarction.	MASSACHUSETTS GEN HOSP, CTR AMBULATORY CARE 475, CARDIAC UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Karavite, Dean/0000-0003-0554-5715				DEPACE NL, 1982, AM J CARDIOL, V50, P1262, DOI 10.1016/0002-9149(82)90460-X; EAGLE KA, 1988, ARCH INTERN MED, V148, P882, DOI 10.1001/archinte.148.4.882; ESTES EH, 1974, HEART, P297; FEIGENBAUM H, 1986, ECHOCARDIOGR-J CARD, P153; FIFER MA, 1991, CARDIAC CATHETERIZAT, P303; Gunnar R M, 1990, Circulation, V82, P664; HAMBY RI, 1985, AM HEART J, V109, P338, DOI 10.1016/0002-8703(85)90604-0; MADSEN EB, 1983, AM J CARDIOL, V51, P1579, DOI 10.1016/0002-9149(83)90190-X; MATTLEMAN SJ, 1983, J AM COLL CARDIOL, V1, P417, DOI 10.1016/S0735-1097(83)80068-0; MCNAMARA RF, 1988, AM J CARDIOL, V62, P192, DOI 10.1016/0002-9149(88)90210-X; MONSOUR MJ, 1991, STAT MED, V10, P443, DOI 10.1002/sim.4780100316; PALMERI ST, 1982, NEW ENGL J MED, V306, P4, DOI 10.1056/NEJM198201073060102; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PICARD MH, 1992, AM HEART J, V124, P24, DOI 10.1016/0002-8703(92)90916-J; TAYLOR GJ, 1980, CIRCULATION, V62, P960, DOI 10.1161/01.CIR.62.5.960; 1990, HLTH FACTS	16	35	35	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					750	756		10.7326/0003-4819-121-10-199411150-00004	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944052				2022-12-28	WOS:A1994PQ92800004
J	WILL, RG				WILL, RG			GENE INFLUENCES ON CREUTZFELDT-JAKOB-DISEASE	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; SCRAPIE; POLYMORPHISM; EXPRESSION				WILL, RG (corresponding author), WESTERN GEN HOSP,NATL CREUTZFELDT JAKOB DIS SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BROWN P, 1991, EUR J EPIDEMIOL, V7, P469, DOI 10.1007/BF00143124; BUGIANI O, 1994, NEUROBIOL AGING, V15, pS156, DOI 10.1016/0197-4580(94)93095-3; CARP RI, 1993, ARCH VIROL, V133, P1, DOI 10.1007/BF01309739; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; DESILVA R, 1994, NEUROSCI LETT, V179, P50, DOI 10.1016/0304-3940(94)90932-6; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; HARDY J, 1994, LANCET, V343, P979, DOI 10.1016/S0140-6736(94)90106-6; HUNTER N, 1993, J GEN VIROL, V74, P1025, DOI 10.1099/0022-1317-74-6-1025; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PICKERINGBROWN SM, 1994, LANCET, V343, P1155, DOI 10.1016/S0140-6736(94)90257-7; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q	13	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1310	1311		10.1016/S0140-6736(94)90686-6	http://dx.doi.org/10.1016/S0140-6736(94)90686-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968022				2022-12-28	WOS:A1994PQ92600002
J	KROLL, KL; GERHART, JC				KROLL, KL; GERHART, JC			TRANSGENIC X-LAEVIS EMBRYOS FROM EGGS TRANSPLANTED WITH NUCLEI OF TRANSFECTED CULTURED-CELLS	SCIENCE			English	Article							XENOPUS-LAEVIS; OOCYTES; GENE; RANA	Transgenic Xenopus laevis embryos were produced by transplantation of transfected cultured cell nuclei into unfertilized eggs. A Xenopus cell line, X-C, was stably transfected with plasmids containing a hygromycin-resistance gene and genes for either beta-galactosidase with a heat shock promoter or chloramphenicol acetyltransferase (CAT) with a muscle-specific actin promoter. Nuclei transplanted from these cells into unfertilized eggs directed development of embryos containing stably integrated copies of the plasmids in each cell. Transgenic embryos showed somite-specific expression of CAT and uniform expression of beta-galactosidase. Transgenic embryos produced by nuclear transplantation should be useful for testing the function of cloned genes in amphibian development.			KROLL, KL (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 229 STANLEY HALL, BERKELEY, CA 94720 USA.			Kroll, Kristen/0000-0002-5450-6694	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232, R01GM019363, R37GM019363] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19363, GM07232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIENZ M, 1984, EMBO J, V3, P2477, DOI 10.1002/j.1460-2075.1984.tb02159.x; BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; BRUN RB, 1978, DEV BIOL, V65, P271, DOI 10.1016/0012-1606(78)90027-1; DENT JA, 1989, DEVELOPMENT, V105, P61; DIBERARDINO MA, 1992, DIFFERENTIATION, V50, P1, DOI 10.1111/j.1432-0436.1992.tb00480.x; DIBERARDINO MA, 1983, SCIENCE, V219, P862, DOI 10.1126/science.6600520; DIBERARDINO MA, 1970, DEV BIOL, V23, P185, DOI 10.1016/0012-1606(70)90094-1; DIBERARDINO MA, 1987, AM ZOOL, V27, P623; ETKIN LD, 1987, DEVELOPMENT, V99, P15; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; Gurdon J.B., 1979, International Review of Cytology Supplement, P161; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; GURDON JB, 1986, J CELL SCI, P287; GURDON JB, 1960, Q J MICROSC SCI, V101, P299; GURDON JB, 1970, J EMBRYOL EXP MORPH, V24, P227; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; LASKEY RA, 1970, NATURE, V228, P1332, DOI 10.1038/2281332a0; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SUBTELNY S, 1965, J EXP ZOOL, V159, P59, DOI 10.1002/jez.1401590107; TOMPKINS R, 1978, J EXP ZOOL, V203, P251, DOI 10.1002/jez.1402030207; TYMOWSKA J, 1972, CYTOGENETICS, V11, P270, DOI 10.1159/000130197; VIZE PD, 1991, METHOD CELL BIOL, V36, P367	25	33	35	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	1994	266	5185					650	653		10.1126/science.7939720	http://dx.doi.org/10.1126/science.7939720			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939720				2022-12-28	WOS:A1994PN80700048
J	BICKELL, WH; WALL, MJ; PEPE, PE; MARTIN, RR; GINGER, VF; ALLEN, MK; MATTOX, KL				BICKELL, WH; WALL, MJ; PEPE, PE; MARTIN, RR; GINGER, VF; ALLEN, MK; MATTOX, KL			IMMEDIATE VERSUS DELAYED FLUID RESUSCITATION FOR HYPOTENSIVE PATIENTS WITH PENETRATING TORSO INJURIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANESTHETIZED SWINE; HEMORRHAGE; AORTOTOMY; ANEURYSM; PRESSURE; SHOCK	Background. Fluid resuscitation may be detrimental when given before bleeding is controlled in patients with trauma. The purpose of this study was to determine the effects of delaying fluid resuscitation until the time of operative intervention in hypotensive patients with penetrating injuries to the torso. Methods. We conducted a prospective trial comparing immediate and delayed fluid resuscitation in 598 adults with penetrating torso injuries who presented with a pre; hospital systolic blood pressure less than or equal to 90 mm Hg. The study setting was a city with a single centralized system of prehospital emergency care and a single receiving facility for patients with major trauma. Patients assigned to the immediate-resuscitation group received standard fluid resuscitation before they reached the hospital and in the trauma center, and those assigned to the delayed-resuscitation group received intravenous cannulation but no fluid resuscitation until they reached the operating room. Results. Among the 289 patients who received delayed fluid resuscitation, 203 (70 percent) survived and were discharged from the hospital, as compared with 193 of the 309 patients (62 percent) who received immediate fluid resuscitation (P = 0.04). The mean estimated intraoperative blood loss was similar in the two groups. Among the 238 patients in the delayed-resuscitation group who survived to the postoperative period, 55 (23 percent) had. one or more complications (adult respiratory distress syndrome, sepsis syndrome, acute renal failure, coagulopathy, wound infection, and pneumonia), as compared with 69 of the 227 patients (30 percent) in the immediate-resuscitation group (P = 0.08). The duration of hospitalization was shorter in the delayed-resuscitation group. Conclusions. For hypotensive patients with penetrating torso injuries, delay of aggressive fluid resuscitation until operative intervention improves the outcome.	BAYLOR COLL MED,CORA & WEBB MADING DEPT SURG,HOUSTON,TX 77030; ST FRANCIS HOSP,DEPT EMERGENCY SERV,TULSA,OK; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BEN TAUB GEN HOSP,HOUSTON,TX 77030; HOUSTON EMERGENCY MED SERV,HOUSTON,TX; BROOKE ARMY MED CTR,DEPT SURG,TRAUMA SECT,FT SAM HOUSTON,TX 78234	Baylor College of Medicine; St. Francis Hospital - Oklahoma; Baylor College of Medicine; San Antonio Military Medical Center; United States Department of Defense; United States Army								[Anonymous], 1990, ABBREVIATED INJURY S; BICKELL WH, 1991, SURGERY, V110, P529; BICKELL WH, 1993, ANN EMERG MED, V22, P225, DOI 10.1016/S0196-0644(05)80208-2; BICKELL WH, 1989, J TRAUMA, V29, P409, DOI 10.1097/00005373-198903000-00028; BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1; BICKELL WH, 1989, CIRC SHOCK, V28, P321; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; Cannon WB, 1918, J AMER MED ASSOC, V70, P618; Capono A, 1993, J TRAUMA, V35, P984; CAROLINE NL, 1983, EMERGENCY CARE STREE, P57; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CRAWFORD ES, 1991, J VASC SURG, V13, P348; CRAWFORD ES, 1991, ANN SURG, V213, P417, DOI 10.1097/00000658-199105000-00006; CURKA PA, 1993, ANN EMERG MED, V22, P1688, DOI 10.1016/S0196-0644(05)81307-1; DILLON J, 1966, ARCH SURG-CHICAGO, V93, P537; FOWLER RL, 1988, BASIC TRAUMA LIFE SU, P107; GROSS D, 1988, J TRAUMA, V28, P751, DOI 10.1097/00005373-198806000-00005; HARRIS B H, 1969, Surgical Forum (Chicago), V20, P31; MARTIN RR, 1992, J TRAUMA, V33, P354, DOI 10.1097/00005373-199209000-00004; MATTOX KL, 1989, J TRAUMA, V29, P1104, DOI 10.1097/00005373-198908000-00007; MATTOX KL, 1994, COMPLICATIONS TRAUMA, P305; MILLES G, 1966, SURGERY, V60, P434; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1245, DOI 10.1016/S0025-6196(12)65412-3; PEPE PE, 1984, NEW ENGL J MED, V311, P281, DOI 10.1056/NEJM198408023110502; SHAFTAN GW, 1964, J CARDIOVASC SURG, V5, P251; SHAFTAN GW, 1965, SURGERY, V58, P851; SHIRES T, 1964, ARCH SURG-CHICAGO, V88, P688; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; WANGENST.SL, 1968, SURGERY, V64, P912; WEIGEL CJ, 1991, TRAUMA, P839; WIGGERS CJ, 1950, PHYSL SHOCK, P121; 1993, ADV TRAUMA LIFE SUPP, P75; 1952, SURGERY WORLD WAR 2, P6; 1991, DESCRIPTION EMERGENC; 1989, ADV TRAUMA LIFE SUPP; 1985, ABBREVIATED INJURY S	36	1305	1369	2	41	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1105	1109		10.1056/NEJM199410273311701	http://dx.doi.org/10.1056/NEJM199410273311701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7935634				2022-12-28	WOS:A1994PN06500001
J	TOPILKO, P; SCHNEIDERMAUNOURY, S; LEVI, G; BARONVANEVERCOOREN, A; CHENNOUFI, AB; SEITANIDOU, T; BABINET, C; CHARNAY, P				TOPILKO, P; SCHNEIDERMAUNOURY, S; LEVI, G; BARONVANEVERCOOREN, A; CHENNOUFI, AB; SEITANIDOU, T; BABINET, C; CHARNAY, P			KROX-20 CONTROLS MYELINATION IN THE PERIPHERAL NERVOUS-SYSTEM	NATURE			English	Article							SCHWANN-CELLS; BASIC-PROTEIN; PO PROTEIN; GLYCOPROTEIN; MOUSE; GENE; EXPRESSION; MICE; MOLECULES; ABSENCE	THE molecular mechanisms controlling the process of myelination by Schwann cells remain elusive, despite recent progress in the identification and characterization of genes encoding myelin components (reviewed in ref. 1). We have created a null allele in the mouse Krox-20 gene, which encodes a zinc-finger transcription factor(2,3), by in-frame insertion of the Escherichia coli lacZ gene, and have shown that hindbrain segmentation is affected in Krox-20(-/-) embryos(4). We demonstrate here that Krox-20 is also activated in Schwann cells before the onset of myelination and that its disruption blocks Schwann cells at an early stage in their differentiation, thus preventing myelination in the peripheral nervous system. In Krox-20(-/-) mice, Schwann cells wrap their cytoplasmic processes only one and a half turns around the axon, and although they express the early myelin marker, myelin-associated glycoprotein(5), late myelin gene products are absent, including those for protein zero(6) and myelin basic protein(7). Therefore Krox-20 is likely to control a set of genes required for completion of myelination in the peripheral nervous system.	ADV BIOTECHNOL CTR,I-16132 GENOA,ITALY; HOP LA PITIE SALPETRIERE,INSERM,U134,F-75651 PARIS 13,FRANCE; INST PASTEUR,CNRS,URA 361,F-75724 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	TOPILKO, P (corresponding author), ECOLE NORMALE SUPER,INSERM,U368,46 RUE ULM,F-75230 PARIS 05,FRANCE.		Schneider-Maunoury, Sylvie/K-6795-2017; Evercooren, Anne S Baron-Van/G-3632-2013; Levi, Giovanni/B-4416-2013	Schneider-Maunoury, Sylvie/0000-0002-0797-4735; Levi, Giovanni/0000-0002-7041-6787; Charnay, Patrick/0000-0002-3847-6042	Telethon [94] Funding Source: Medline	Telethon(Fondazione Telethon)		BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; BUNGE MB, 1989, DEV NEUROSCI-BASEL, V11, P348, DOI 10.1159/000111911; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; Gabe M., 1968, TECHNIQUES HISTOLOGI, P468; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; HENRY EW, 1988, SCIENCE, V241, P344, DOI 10.1126/science.3388045; JESSEN KR, 1994, NEURON, V12, P509, DOI 10.1016/0896-6273(94)90209-7; KIES MW, 1961, CHEMICAL PATHOLOGY N, P197; KIMURA M, 1989, P NATL ACAD SCI USA, V86, P5661, DOI 10.1073/pnas.86.14.5661; KIRSCHNER DA, 1980, NATURE, V283, P207, DOI 10.1038/283207a0; LEMKE G, 1993, GLIA, V7, P263, DOI 10.1002/glia.440070402; LEVI G, 1987, J CELL BIOL, V105, P2359, DOI 10.1083/jcb.105.5.2359; LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0; OWENS GC, 1990, GLIA, V3, P118, DOI 10.1002/glia.440030205; SCHNEIDERMAUNOU.S, 1993, CELL, V75, P199; TRAPP BD, 1988, J CELL BIOL, V107, P675, DOI 10.1083/jcb.107.2.675; TRAPP BD, 1982, J CELL BIOL, V92, P877, DOI 10.1083/jcb.92.3.877; TRAPP BD, 1984, J CELL BIOL, V99, P594, DOI 10.1083/jcb.99.2.594; UYEMURA K, 1970, BIOCHIM BIOPHYS ACTA, V214, P190, DOI 10.1016/0005-2795(70)90083-8; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0	24	627	631	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					796	799		10.1038/371796a0	http://dx.doi.org/10.1038/371796a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935840				2022-12-28	WOS:A1994PP01800059
J	HACKETT, M; GUO, L; SHABANOWITZ, J; HUNT, DF; HEWLETT, EL				HACKETT, M; GUO, L; SHABANOWITZ, J; HUNT, DF; HEWLETT, EL			INTERNAL LYSINE PALMITOYLATION IN ADENYLATE-CYCLASE TOXIN FROM BORDETELLA-PERTUSSIS	SCIENCE			English	Article							ESCHERICHIA-COLI PROHAEMOLYSIN; DEPENDENT FATTY ACYLATION; MEMBRANE-TARGETED TOXIN; GRAM-NEGATIVE BACTERIA; ACTIVATION; PROTEINS; RECEPTOR; CYAC; POLYPEPTIDE; HEMOLYSIN	A number of bacterial protein toxins, including adenylate cyclase (AC) toxin from Bordetella pertussis, require the product of an accessory gene in order to express their biological activities. In this study, mass spectrometry was used to demonstrate that activated, wild-type AC toxin was modified by amide-linked palmitoylation on the epsilon-amino group of lysine 983. This modification was absent from a mutant in which the accessory gene had been disrupted. A synthetic palmitoylated peptide corresponding to the tryptic fragment (glutamine 972 to arginine 984) that contained the acylation blocked AC toxin-induced accumulation of adenosine 3',5'-monophosphate, whereas the nonacylated peptide had no effect.	UNIV VIRGINIA,SCH MED,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901; UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22901	University of Virginia; University of Virginia; University of Virginia; University of Virginia			Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIAID NIH HHS [R0-1 AI18000] Funding Source: Medline; NIDDK NIH HHS [DK38942] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT D, 1993, CLIN CHEM, V39, P2005; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; Galazka Artur, 1992, World Health Statistics Quarterly, V45, P238; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; Guo L., UNPUB; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; HEDO JA, 1987, J BIOL CHEM, V262, P954; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; HEWLETT EL, 1993, J BIOL CHEM, V268, P7842; HUGHES C, 1992, FEMS MICROBIOL IMMUN, V105, P37, DOI 10.1111/j.1574-6968.1992.tb05884.x; HUNT DF, 1991, TECHNIQUES PROTEIN C, pCH43; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLSON EN, 1984, J BIOL CHEM, V259, P5364; PEARSON RD, 1987, J IMMUNOL, V139, P2749; PELLETT S, 1990, INFECT IMMUN, V58, P822, DOI 10.1128/IAI.58.3.822-827.1990; PILLAI S, 1987, P NATL ACAD SCI USA, V84, P7654, DOI 10.1073/pnas.84.21.7654; ROGEL A, 1991, J BIOL CHEM, V266, P3154; SCHLESINGER MJ, 1993, LIPID MODIFICATION P, P1; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; STEVENSON FT, 1993, P NATL ACAD SCI USA, V90, P7245, DOI 10.1073/pnas.90.15.7245; STEVENSON FT, 1992, J EXP MED, V176, P1053, DOI 10.1084/jem.176.4.1053; SZABO G, IN PRESS J BIOL CHEM; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; 1992, 40TH P AM SOC MASS S	39	199	205	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					433	435		10.1126/science.7939682	http://dx.doi.org/10.1126/science.7939682			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939682				2022-12-28	WOS:A1994PN27200034
J	ENSOLI, B; GENDELMAN, R; MARKHAM, P; FIORELLI, V; COLOMBINI, S; RAFFELD, M; CAFARO, A; CHANG, HK; BRADY, JN; GALLO, RC				ENSOLI, B; GENDELMAN, R; MARKHAM, P; FIORELLI, V; COLOMBINI, S; RAFFELD, M; CAFARO, A; CHANG, HK; BRADY, JN; GALLO, RC			SYNERGY BETWEEN BASIC FIBROBLAST GROWTH-FACTOR AND HIV-I TAT PROTEIN IN INDUCTION OF KAPOSIS-SARCOMA	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MELANOMA CELL INVASION; LONG-TERM CULTURE; GENE-EXPRESSION; ENDOTHELIAL-CELLS; BASEMENT-MEMBRANE; HTLV-III; AIDS; ANGIOGENESIS; COLLAGENASE	Basic fibroblast growth factor (bFGF) and human immunodeficiency virus type 1 (HIV-1) Tat protein synergize in inducing angiogenic Kaposi's sarcoma-like lesions in mice. Synergy is due to Tat, which enhances endothelial cell growth and type-IV collagenase expression in response to bFGF mimicking extracellular matrix proteins. The bFGF, extracellular Tat and Tat receptors are present in HIV-1-associated KS, which may explain the higher frequency and aggressiveness of this form compared to classical Kaposi's sarcoma where only bFGF is present.	NCI,MOLEC VIROL LAB,BETHESDA,MD 20892; ADV BIOSCI LABS INC,KENSINGTON,MD 20895; HENRY M JACKSON FDN,ROCKVILLE,MD 20850	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	ENSOLI, B (corresponding author), NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892, USA.		Ensoli, Barbara/J-9169-2016; Cafaro, Aurelio/K-5314-2016	Ensoli, Barbara/0000-0002-0545-8737; Cafaro, Aurelio/0000-0001-9675-6344				ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; ALBINI A, IN PRESS P NATN ACAD; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CORDONCARDO C, 1990, LAB INVEST, V63, P832; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ENSOLI B, 1991, HEMATOL ONCOL CLIN N, V5, P281, DOI 10.1016/S0889-8588(18)30441-6; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; ENSOLI B, IN PRESS J CLIN INVE; FAN J, 1993, J IMMUNOL, V151, P5031; FAWELL S, 1994, P NATL ACAD SCI USA, V31, P664; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FUCHS D, 1992, J ACQ IMMUN DEF SYND, V5, P424; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GAY CG, 1991, P NATL ACAD SCI USA, V88, P296, DOI 10.1073/pnas.88.1.296; HOBER D, 1989, CLIN EXP IMMUNOL, V78, P329; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAHONEY SE, 1991, J CLIN INVEST, V88, P174, DOI 10.1172/JCI115275; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; REGEZI JA, 1993, AM J PATHOL, V143, P240; RUSZCZAK Z, 1987, AM J DERMATOPATH, V9, P388, DOI 10.1097/00000372-198710000-00004; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SEFTOR REB, 1993, CANCER RES, V53, P3411; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; XERRI L, 1991, AM J PATHOL, V138, P9; YANG J, 1994, J IMMUNOL, V152, P223; ZHANG YM, 1994, AM J PATHOL, V144, P51; 1982, NEW ENGL J MED, V306, P248	43	514	523	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					674	680		10.1038/371674a0	http://dx.doi.org/10.1038/371674a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935812				2022-12-28	WOS:A1994PM77300047
J	MILLSTONE, E; BRUNNER, E; WHITE, I				MILLSTONE, E; BRUNNER, E; WHITE, I			PLAGIARISM OR PROTECTING PUBLIC-HEALTH	NATURE			English	Editorial Material									UCL, DEPT EPIDEMIOL, LONDON WC1E 6EA, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, MED STAT UNIT, LONDON WC1E 7HT, ENGLAND	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	MILLSTONE, E (corresponding author), UNIV SUSSEX, SCI POLICY RES UNIT, BRIGHTON BN1 9RF, E SUSSEX, ENGLAND.		Brunner, Eric/H-2114-2011	Brunner, Eric/0000-0002-0595-4474; White, Ian/0000-0002-6718-7661				AHMAD SR, 1993, LANCET, V341, P1018, DOI 10.1016/0140-6736(93)91098-7; GERBARG ZB, 1988, J CLIN EPIDEMIOL, V41, P503, DOI 10.1016/0895-4356(88)90053-4; Millstone E. P., 1989, BST MASTITIS PRELIMI; MORSE L, 1994, FINANC TIMES, P22; PEEL CJ, 1989, BIOTECHNOLOGY GROWTH, P110; Phipps R. H., 1989, Use of somatotropin in livestock production., P88; WHITE TC, 1994, J DAIRY SCI, V77, P2249, DOI 10.3168/jds.S0022-0302(94)77168-X; 1993, MILK MARKETING BOARD; 1986, BOVINE SOMATOTROPIN	9	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					647	648		10.1038/371647a0	http://dx.doi.org/10.1038/371647a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935806				2022-12-28	WOS:A1994PM77300022
J	AMBACH, W				AMBACH, W			OCCUPATIONAL LOW-DOSE EXPOSURE TO IONIZING-RADIATION	LANCET			English	Editorial Material											AMBACH, W (corresponding author), UNIV INNSBRUCK, INST MED PHYS, A-6020 INNSBRUCK, AUSTRIA.							Ennemoser O., 1993, Lancet (North American Edition), V341, P828, DOI 10.1016/0140-6736(93)90603-E; PERSHAGEN G, 1994, NEW ENGL J MED, V330, P159, DOI 10.1056/NEJM199401203300302; 1991, IRCP60 INT COMM RAD; 1990, BEIR5 COMM BIOL EFF	4	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1037	1037		10.1016/S0140-6736(94)91704-3	http://dx.doi.org/10.1016/S0140-6736(94)91704-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934441				2022-12-28	WOS:A1994PL85200004
J	CLAGUE, JE; HORAN, MA				CLAGUE, JE; HORAN, MA			URINE CULTURE IN THE ELDERLY - SCIENTIFICALLY DOUBTFUL AND PRACTICALLY USELESS	LANCET			English	Editorial Material							BACTERIURIA; POPULATION				CLAGUE, JE (corresponding author), UNIV MANCHESTER,WITHINGTON HOSP,DEPT GERIATR MED,MANCHESTER M20 8LR,LANCS,ENGLAND.							ABRUTYN E, 1994, ANN INTERN MED, V120, P827, DOI 10.7326/0003-4819-120-10-199405150-00003; BOSCIA JA, 1986, AM J MED, V81, P979, DOI 10.1016/0002-9343(86)90391-8; BOSCIA JA, 1986, AM J MED, V80, P208, DOI 10.1016/0002-9343(86)90011-2; BROCKLEHURST J C, 1977, Age and Ageing, V6, P240; BROCKLEHURST JC, 1968, GERONTOL CLIN, V10, P242, DOI 10.1159/000245189; DONTAS AS, 1977, AGE AGEING, V16, P215; ELLIOTT TSJ, 1985, J INFECTION, V11, P191, DOI 10.1016/S0163-4453(85)92997-4; GUTMAN SI, 1987, AM J CLIN PATHOL, V88, P204, DOI 10.1093/ajcp/88.2.204; KASS EH, 1956, T ASSOC AM PHYSICIAN, V69, P56; NICOLLE LE, 1987, AM J MED, V83, P27, DOI 10.1016/0002-9343(87)90493-1; NORDENSTAM GR, 1986, NEW ENGL J MED, V314, P1152, DOI 10.1056/NEJM198605013141804	11	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1035	1036		10.1016/S0140-6736(94)91702-7	http://dx.doi.org/10.1016/S0140-6736(94)91702-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934439				2022-12-28	WOS:A1994PL85200002
J	SCHMIDT, MI; MATOS, MC; BRANCHTEIN, L; REICHELT, AJ; MENGUE, SS; IOCHIDA, LC; DUNCAN, BB				SCHMIDT, MI; MATOS, MC; BRANCHTEIN, L; REICHELT, AJ; MENGUE, SS; IOCHIDA, LC; DUNCAN, BB			VARIATION IN GLUCOSE-TOLERANCE WITH AMBIENT-TEMPERATURE	LANCET			English	Note							ORAL GLUCOSE; INSULIN	Ambient temperature may affect venous glucose concentration after glucose tolerance tests. We analysed 1030 standardised 75 g tests. Although mean fasting values did not differ, post-load values did: adjusted mean 2 h glucose concentration was 1.03 mmol/L lower at lower (5-14 degrees C) than at higher (25-31 degrees C) temperatures (p<0.001). The occurrence of abnormal glucose tolerance doubled on warmer days. The diagnostic accuracy of the glucose tolerance test showed clinically significant temperature-associated variation. These variations, if confirmed, call for temperature standardisation during glucose tolerance testing and/or alternative strategies for use when standardisation is not feasible.	UNIV FED RIO GRANDE SUL,HOSP CLIN PORTO ALEGRE,PORTO ALEGRE,RS,BRAZIL; ESCOLA PAULISTA MED,DEPT PREVENT MED,SAO PAULO,BRAZIL	Universidade Federal do Rio Grande do Sul; Universidade Federal de Sao Paulo (UNIFESP)	SCHMIDT, MI (corresponding author), UNIV FED RIO GRANDE SUL,FAC MED,DEPT SOCIAL MED,RUA RAMIRO BARCELLOS 2600-414,BR-90035003 PORTO ALEGRE,RS,BRAZIL.		Schmidt, Maria Inês/AGT-5691-2022; de Azevedo Jacob Reichelt areichelt, Angela/AAQ-9556-2020; Duncan, Bruce B/L-4140-2016; Schmidt, Maria Inês/AGP-6441-2022; Schmidt, Maria/V-3196-2019	Duncan, Bruce B/0000-0002-7491-2630; Schmidt, Maria Inês/0000-0002-3837-0731; Mengue, Sotero/0000-0002-3349-8541; de Azevedo Jacob Reichelt, Angela/0000-0002-9393-3445				AKANJI AO, 1987, DIABETOLOGIA, V30, P431, DOI 10.1007/BF00292547; AKANJI AO, 1991, DIABETIC MED, V8, P946, DOI 10.1111/j.1464-5491.1991.tb01534.x; BURRIN JM, 1990, DIABETIC MED, V7, P199, DOI 10.1111/j.1464-5491.1990.tb01370.x; Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; FRAYN KN, 1989, CLIN SCI, V76, P323, DOI 10.1042/cs0760323; KATZ LD, 1983, DIABETES, V32, P675, DOI 10.2337/diabetes.32.7.675; Trinder P., 1969, ANN CLIN BIOCHEM, V6, P24, DOI [10.1177/000456326900600108, DOI 10.1177/000456326900600108]; VALLERAND AL, 1987, AM J PHYSIOL, V253, pE179, DOI 10.1152/ajpendo.1987.253.2.E179; VALLERAND AL, 1988, J APPL PHYSIOL, V65, P2395, DOI 10.1152/jappl.1988.65.6.2395; [No title captured]; 1979, DIABETES, V28, P1039	11	35	35	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1054	1055		10.1016/S0140-6736(94)91711-6	http://dx.doi.org/10.1016/S0140-6736(94)91711-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934447				2022-12-28	WOS:A1994PL85200011
J	BROWN, DJ				BROWN, DJ			OPINIONS OF GENERAL-PRACTITIONERS IN NOTTINGHAMSHIRE ABOUT PROVISION OF INTRAPARTUM CARE	BRITISH MEDICAL JOURNAL			English	Article							OBSTETRICS	Objective-To examine the beliefs of general practitioners concerning intrapartum care. Design-Postal questionnaire survey. Subjects-Ah general practitioners with patients in Nottinghamshire Family Health Services Authority in September 1993. Main outcome measures-General practitioners' current involvement in maternity care, and beliefs on intrapartum care. Results-Of 694 general practitioners sent questionnaires, 550 (79.2%) replied. 529 of these were on the obstetric list; 437 had not attended a delivery in the past 12 months; 36 had attended two or more; 358 general practitioners did not wish to provide more intrapartum care; 349 did not feel competent to do so. Reasons for not wanting to provide intrapartum care included current workload (453), disruption to personal life (407), and the fear of litigation (377). General practitioners who already booked women for home delivery were more Likely to wish to do more deliveries (62/42 v 61/316, chi(2) = 85.3; P < 0.0001) and to have more positive attitudes towards increasing women's choice in maternity care (90/22 v 195/151, chi(2) = 227; P < 0.0001). Conclusions-The involvement of general practitioners in intrapartum care in Nottinghamshire is low, and most general practitioners are unwilling to increase their role. However, general practitioners who already book for home delivery are keen to do more.	UNIV NOTTINGHAM,SCH MED,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham				Hamblin-Brown, DJ/0000-0002-7353-8691				Bull M J, 1981, J R Coll Gen Pract, V31, P357; CAMPBELL R, 1987, WHERE BE BORN DEBATE; Campbell R., 1990, POLITICS MATERNITY C; CHAMBERS R, 1993, BRIT J GEN PRACT, V43, P410; KADRI AZ, 1992, BRIT MED J, V304, P112; KIETLY P, 1992, PREGNANCY CARE 1990S; KLEIN M, 1989, EFFECTIVE CARE PREGN, V1; LOUDON I, 1990, BRIT MED J, V301, P703, DOI 10.1136/bmj.301.6754.703; MACKENZIE GM, 1993, BRIT MED J, V307, P452; MARSH GN, 1985, BRIT MED J, V290, P901, DOI 10.1136/bmj.290.6472.901; MARTINBATES C, 1993, BRIT J GEN PRACT, V43, P413; NESBITT TS, 1992, WESTERN J MED, V157, P44; PHAFF J, 1986, PERINATAL HLTH SERVI; SMITH LFP, 1991, BRIT MED J, V303, P1443, DOI 10.1136/bmj.303.6815.1443; SMITH LFP, 1991, BRIT MED J, V303, P1447, DOI 10.1136/bmj.303.6815.1447; Tew M., 1990, SAFER CHILDBIRTH CRI; WALL EM, 1991, J AM BOARD FAM PRACT, V4, P440; YOUNG G, 1987, BRIT MED J, V294, P744, DOI 10.1136/bmj.294.6574.744; YOUNG G, 1993, PRACTITIONER, V237, P736; 1993, CHANGING CHILDBIRTH; 1992, 2ND HOUS COMM SEL CO, V1; 1959, REPORT MATERNITY SER; 1980, PERINATAL NEONATAL M; 1970, DOMICILIARY MIDWIFER; 1981, BRIT MED J, V282, P1171; 1992, YOUR CHOICES FUTURE	26	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					777	779		10.1136/bmj.309.6957.777	http://dx.doi.org/10.1136/bmj.309.6957.777			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950566	Green Published			2022-12-28	WOS:A1994PJ28200023
J	CARTER, J				CARTER, J			PRESIDENTIAL DISABILITY AND THE 25TH-AMENDMENT - A PRESIDENTS PERSPECTIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CARTER, J (corresponding author), CARTER CTR,1 COPENHILL,ATLANTA,GA 30307, USA.								0	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1698	1698		10.1001/jama.272.21.1698	http://dx.doi.org/10.1001/jama.272.21.1698			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PU759	7966899				2022-12-28	WOS:A1994PU75900031
J	VANDENBROUCKE, JP; KOSTER, T; BRIET, E; REITSMA, PH; BERTINA, RM; ROSENDAAL, FR				VANDENBROUCKE, JP; KOSTER, T; BRIET, E; REITSMA, PH; BERTINA, RM; ROSENDAAL, FR			INCREASED RISK OF VENOUS THROMBOSIS IN ORAL-CONTRACEPTIVE USERS WHO ARE CARRIERS OF FACTOR-V LEIDEN MUTATION	LANCET			English	Article							POOR ANTICOAGULANT RESPONSE; NONFATAL VASCULAR-DISEASE; ACTIVATED PROTEIN-C; THROMBOEMBOLISM; THROMBOPHILIA; WOMEN	We investigated whether the occurrence of venous thrombosis in young women who use oral contraceptives might be explained by the factor V Leiden mutation, which leads to resistance to activated protein C and enhances susceptibility to thrombosis. We compared 155 consecutive premenopausal women, aged 15 to 49, who had developed deep venous thrombosis in the absence of other underlying diseases, with 169 population controls. The risk of thrombosis among users of oral contraceptives was increased 4-fold (relative risk 3.8 [95% CI 2.4-6.0]). The risk of thrombosis among carriers of the mutation compared with non-carriers was increased 8-fold (7.9 [3.2-19.4]). Compared with women who did not use oral contraceptives and were not, carriers of the mutation, the risk of thrombosis among those with both risk factors was increased more than 30-fold (34.7 [7.8-154]). Recalculation of population incidences from these relative risks shows that the absolute risk of venous thrombosis in young women who use oral contraceptives is much larger when they carry the factor V Leiden mutation. When a young woman develops thrombosis, her factor V Leiden status should be considered in counselling about her future method of contraception.	LEIDEN UNIV HOSP, HAEMOSTASIS & THROMBOSIS RES CTR, 2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	VANDENBROUCKE, JP (corresponding author), LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, BLDG 1-CO-P, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Rosendaal, Frits/Q-3842-2017; Bertina, Rogier/AGQ-5246-2022; Vandenbroucke, Jan/AAM-3928-2020	Rosendaal, Frits/0000-0003-2558-7496; Vandenbroucke, Jan/0000-0001-5668-6716				[Anonymous], 1985, THEORETICAL EPIDEMIO; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BRIET E, 1994, BRIT J HAEMATOL, V87, P348, DOI 10.1111/j.1365-2141.1994.tb04920.x; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; GIROLAMI A, 1993, BLOOD COAGUL FIBRIN, V4, P841, DOI 10.1097/00001721-199304050-00029; HELMRICH SP, 1987, OBSTET GYNECOL, V69, P91; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; JORDAN WM, 1961, LANCET, V2, P1146, DOI DOI 10.1016/S0140-6736(61)91061-3; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOELMAN JH, 1992, J NEUROL, V230, P105; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; PABINGER I, 1994, THROMB HAEMOSTASIS, V5, P548; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; PORTER JB, 1982, OBSTET GYNECOL, V59, P299; ROSENDAAL FR, 1994, LANCET, V343, P1289; ROSENDAAL FR, IN PRESS BLOOD; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P311; SARTWELL PE, 1982, EPIDEMIOL REV, V4, P95, DOI 10.1093/oxfordjournals.epirev.a036253; SCHLESSELMAN JJ, 1987, CASE CONTROL STUDIES; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; TRAUCHSTVANHORN JJ, 1992, AM J OBSTET GYNECOL, V167, P9968; TUDDENHAM EGD, 1994, LANCET, V343, P1515, DOI 10.1016/S0140-6736(94)92932-7; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; 1993, STATISTISCH JB 1993	29	939	963	2	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1453	1457		10.1016/S0140-6736(94)90286-0	http://dx.doi.org/10.1016/S0140-6736(94)90286-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968118				2022-12-28	WOS:A1994PT99500005
J	BAKER, DW; JONES, R; HEDGES, J; MASSIE, BM; KONSTAM, MA; ROSE, EA				BAKER, DW; JONES, R; HEDGES, J; MASSIE, BM; KONSTAM, MA; ROSE, EA			MANAGEMENT OF HEART-FAILURE .3. THE ROLE OF REVASCULARIZATION IN THE TREATMENT OF PATIENTS WITH MODERATE OR SEVERE LEFT-VENTRICULAR SYSTOLIC DYSFUNCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-ARTERY SURGERY; LONG-TERM SURVIVAL; BYPASS-SURGERY; MYOCARDIAL REVASCULARIZATION; ISCHEMIC CARDIOMYOPATHY; CARDIAC TRANSPLANTATION; ANGIOGRAPHIC PREDICTORS; OPERATIVE MORTALITY; EJECTION FRACTION; RISK-FACTORS	Objective.-This article reviews the benefits and risks of coronary artery bypass grafting and angioplasty for patients with moderate or severe left ventricular systolic dysfunction and summarizes the recommendations of the expert panel for the Agency for Health Care Policy and Research Heart Failure Guideline. Data Sources.-Data were obtained from studies published in English and referenced in MEDLINE or EMBASE between 1966 and 1993. We used the search terms heart failure, congestive, congestive heart failure; heart failure; cardiac failure; and dilated cardiomyopathy in conjunction with the terms coronary artery bypass grafting and angioplasty. Study Selection.-All cohort studies and case series that provided separate outcomes data on a subgroup of patients with a left ventricular ejection fraction less than 0.40 were reviewed. Data Extraction and Synthesis.-Studies were reviewed for inclusion and exclusion criteria, survival, and functional status measures using a standardized form. Cohort studies were assessed on eight aspects of study quality using a defined list of study flaws. Conclusion.-Coronary artery bypass grafting improves 3-year survival by approximately 30% to 50% and physical functioning by approximately one New York Heart Association class in patients with moderate to severe left ventricular dysfunction and limiting angina. However, the operative mortality ranges from 5% to 30% depending on patients' ejection fractions and comorbidity. It is not clear whether patients whose predominant symptom is heart failure rather than angina benefit from bypass surgery or how much ischemia is required to justify surgical intervention. Clinical outcomes after angioplasty have not been adequately studied to determine the relative risks and benefits compared with bypass grafting.	UNIV CALIF LOS ANGELES, HARBOR MED CTR, TORRANCE, CA 90509 USA; DUKE UNIV, SCH MED, DEPT SURG, DURHAM, NC USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, MINNEAPOLIS, MN 55455 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA USA; TUFTS UNIV, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, DEPT RADIOL, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Duke University; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Francisco; Tufts University; Tufts University; Tufts Medical Center; Columbia University; NewYork-Presbyterian Hospital	BAKER, DW (corresponding author), RAND CORP, HLTH SCI PROGRAM, 1700 MAIN ST, POB 2138, SANTA MONICA, CA 90407 USA.		Rose, Eric/AAJ-2281-2020; Hedges, Jerris/AAC-1847-2021		PHS HHS [282-91-0064] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADLER DS, 1986, AM J CARDIOL, V58, P195, DOI 10.1016/0002-9149(86)90046-9; AKINS CW, 1980, AM J CARDIOL, V46, P695, DOI 10.1016/0002-9149(80)90522-6; ALDERMAN EL, 1983, CIRCULATION, V68, P785, DOI 10.1161/01.CIR.68.4.785; BECKMAN CB, 1980, CONN MED, V44, P618; BEDARD P, 1975, CAN J SURG, V18, P237; BEN DY, 1983, THORAC CARDIOVASC SU, V31, P377; BJORK VO, 1981, SCAND J THORAC CARD, V15, P31, DOI 10.3109/14017438109101022; BLAKEMAN BM, 1990, J HEART TRANSPLANT, V9, P468; BOUNOUS EP, 1988, CIRCULATION, V78, P151; Brockman S K, 1987, Cardiovasc Clin, V17, P65; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CHRISTAKIS GT, 1989, CIRCULATION, V80, P151; COHEN M, 1988, J AM COLL CARDIOL, V12, P1193, DOI 10.1016/0735-1097(88)92599-5; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN PF, 1975, CIRCULATION, V51, P414, DOI 10.1161/01.CIR.51.3.414; COLES JG, 1981, J THORAC CARDIOV SUR, V81, P846; CUKINGNAN RA, 1982, J THORAC CARDIOV SUR, V83, P711; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; FAULKNER SL, 1977, J THORAC CARDIOV SUR, V74, P77; FOX HE, 1975, J THORAC CARDIOV SUR, V70, P1064; HAMMERMEISTER KE, 1983, PROG CARDIOVASC DIS, V25, P297, DOI 10.1016/0033-0620(83)90012-9; HAMMERMEISTER KE, 1982, CIRCULATION, V65, P53, DOI 10.1161/01.CIR.65.7.53; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HARTZLER GO, 1988, AM J CARDIOL, V87, P475; HIGGINS TL, 1992, JAMA-J AM MED ASSOC, V267, P2344, DOI 10.1001/jama.267.17.2344; HUNG J, 1980, J THORAC CARDIOV SUR, V79, P718; JONES EL, 1982, INT J CARDIOL, V2, P109, DOI 10.1016/0167-5273(82)90016-X; KENNEDY JW, 1980, J THORAC CARDIOV SUR, V80, P876; KENNEDY JW, 1981, CIRCULATION, V63, P793, DOI 10.1161/01.CIR.63.4.793; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KILLIP T, 1985, CIRCULATION, V72, P102; KLEIN HH, 1990, EUR HEART J, V11, P280, DOI 10.1093/oxfordjournals.eurheartj.a059698; KRON IL, 1989, ANN SURG, V210, P348, DOI 10.1097/00000658-198909000-00011; LAWRIE GM, 1991, ANN SURG, V213, P377, DOI 10.1097/00000658-199105000-00001; LEA RE, 1972, CIRCULATION, V46, P49; LUU M, 1990, AM HEART J, V119, P668, DOI 10.1016/S0002-8703(05)80292-3; MANLEY JC, 1976, J THORAC CARDIOV SUR, V72, P841; MITCHEL BF, 1975, J THORAC CARDIOV SUR, V69, P52; MOCHTAR B, 1985, THORAC CARDIOV SURG, V33, P30; MYERS WO, 1985, ANN THORAC SURG, V40, P245, DOI 10.1016/S0003-4975(10)60037-9; PELLETIER C, 1980, CAN J SURG, V23, P199; PIGOTT JD, 1985, J AM COLL CARDIOL, V5, P1036, DOI 10.1016/S0735-1097(85)80003-6; QUYYUMI AA, 1985, BRIT HEART J, V54, P22; REINFELD HB, 1985, CATHETER CARDIO DIAG, V11, P273, DOI 10.1002/ccd.1810110307; SEROTA H, 1991, AM J CARDIOL, V67, P367, DOI 10.1016/0002-9149(91)90043-K; SHEARN DL, 1986, AM J MED, V80, P405, DOI 10.1016/0002-9343(86)90714-X; SOLIGNAC A, 1974, CAN J SURG, V17, P76; SOLIGNAC A, 1973, ARCH MAL COEUR VAISS, V66, P1117; SPENCER FC, 1971, J THORAC CARDIOV SUR, V62, P529, DOI 10.1016/S0022-5223(19)42022-9; STAHLE E, 1989, THORAC CARDIOV SURG, V37, P355, DOI 10.1055/s-2007-1020352; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TAYLOR GJ, 1986, AM HEART J, V111, P840, DOI 10.1016/0002-8703(86)90631-9; TILLISCH J, 1986, NEW ENGL J MED, V314, P884, DOI 10.1056/NEJM198604033141405; Uretzky G, 1986, Adv Cardiol, V34, P195; VLIETSTRA RE, 1977, MAYO CLIN PROC, V52, P85; WECHSLER AS, 1989, CIRCULATION, V79, P92; WILLIAMS SV, 1991, JAMA-J AM MED ASSOC, V266, P810, DOI 10.1001/jama.266.6.810; YATTEAU RF, 1974, AM J CARDIOL, V34, P520, DOI 10.1016/0002-9149(74)90121-0; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZUBIATE P, 1977, J THORAC CARDIOV SUR, V73, P84; 1993, CORONARY ARTERY BYPA; 1993, CARDIAC SURGERY NEW	62	142	151	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1528	1534		10.1001/jama.272.19.1528	http://dx.doi.org/10.1001/jama.272.19.1528			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966846				2022-12-28	WOS:A1994PQ90000033
J	FUJISE, K; SHERMAN, W				FUJISE, K; SHERMAN, W			CORONARY ARTERIOVENOUS-FISTULA ON CORONARY ANGIOGRAPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									BETH ISRAEL MED CTR,NEW YORK,NY 10003	Harvard University; Beth Israel Deaconess Medical Center	FUJISE, K (corresponding author), UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77030, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1265	1265						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP752	7935684				2022-12-28	WOS:A1994PP75200004
J	LEWIS, P; GRIFFIN, S; MARSDEN, P; GEE, T; NUNAN, T; MALSEY, M; DUSSEK, J				LEWIS, P; GRIFFIN, S; MARSDEN, P; GEE, T; NUNAN, T; MALSEY, M; DUSSEK, J			WHOLE-BODY F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN PREOPERATIVE EVALUATION OF LUNG-CANCER	LANCET			English	Note							BRONCHOGENIC-CARCINOMA; PET; FLUORODEOXYGLUCOSE	Despite use of computed tomography, some lung cancer patients are found to have unresectable disease at surgery, or they present early with metastases. We studied whether whole-body -positron emission tomography (PET) with F-18-fluorodeoxyglucose ((18)FDG) would improve the preoperative detection of metastases. We retrospectively analysed 34 patients with ''operable'' non-small-cell lung cancer who underwent (18)FDG PET after routine assessment. Management changes produced by the PET scan and confirmatory tests were reviewed. PET unsuspected malignant lesions in 10 (29%) Management changes occurred in 14 (41%), including 6 (18%) patients who were changed to non-surgical therapy. These data suggest that whole-body (18)FDG PET improves preoperative assessment of lung cancer patients.	GUYS & ST THOMAS HOSP TRUST,CTR CLIN POSITRON ELECTRON TOMAG,LONDON,ENGLAND; GUYS & ST THOMAS HOSP TRUST,DEPT CARDIOTHORAC SURG,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								GUPTA NC, 1992, RADIOLOGY, V184, P441, DOI 10.1148/radiology.184.2.1620844; IZBICKI JR, 1992, J THORAC CARDIOV SUR, V104, P413; KADVI MA, 1991, EUR J CARDIO-THORAC, V5, P132; KNOPP MV, 1993, J NUCL MED, V34, pP21; KUBOTA K, 1990, J NUCL MED, V31, P1927; PATZ EF, 1993, RADIOLOGY, V188, P487, DOI 10.1148/radiology.188.2.8327702; REGE SD, 1993, CANCER-AM CANCER SOC, V72, P82, DOI 10.1002/1097-0142(19930701)72:1<82::AID-CNCR2820720117>3.0.CO;2-3; TAHARA T, 1989, J COMPUT ASSIST TOMO, V13, P829, DOI 10.1097/00004728-198909000-00014; WEBB WR, 1991, RADIOLOGY, V178, P705, DOI 10.1148/radiology.178.3.1847239	9	180	182	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1265	1266		10.1016/S0140-6736(94)90753-6	http://dx.doi.org/10.1016/S0140-6736(94)90753-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967988				2022-12-28	WOS:A1994PP70100011
J	CHRISTAKIS, NA; JACOBS, JA; MESSIKOMER, CM				CHRISTAKIS, NA; JACOBS, JA; MESSIKOMER, CM			CHANGE IN SELF-DEFINITION FROM SPECIALIST TO GENERALIST IN A NATIONAL SAMPLE OF PHYSICIANS	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY-CARE; INTERNAL-MEDICINE; HEALTH-CARE; REFORM	Objective: Current proposals to reform the health care system call for a physician work force composed of at least 50% generalists. Achieving this objective will likely require that some physicians who are currently specialists become generalists. We sought to determine the extent of such change before any concerted reform efforts and the types of physicians most amenable to such change. Design: Retrospective cohort study. Participants: 335 438 physicians in active practice. Measurements: Rates of change between 1982 and 1986 in self-defined specialties, analyzed with demographic methods and logistic regression. Results: In 1982, our participants comprised 134 647 (40.1%) generalists and 200 791 (59.9%) specialists. Over the 4-year period of the study, 8319 (6.2%) of the generalists became specialists and 4322 (2.2%) of the specialists became generalists. Although physicians younger than 40 years of age were more likely than those older than 40 years of age to switch into generalist disciplines, specialist physicians between the ages of 40 and 69 years (who accounted for 62.0% of the physician work force) made most of the moves into generalist fields (58.4%). After adjustment for other factors, the physicians most likely to switch into generalist disciplines were women, subspecialty internists, emergency medicine physicians, subspecialty pediatricians, and pathologists. In 1986, the 130 650 physicians (38.9%) in this cohort who considered themselves generalists were supplemented by another 49 226 (14.7%) who considered themselves to have a secondary interest in generalist practice. Physicians with such a secondary interest in 1982 constituted 65% of the new generalists in 1986. Conclusions: Our findings support three principal conclusions. First, change from specialist to generalist disciplines is not uncommon, even for physicians older than 40 years of age. Second, many physicians already consider a generalist discipline to be a secondary emphasis of their practices. And third, efforts to retrain specialists to be generalists might effectively target those physicians predisposed to become generalists.	UNIV PENN, DEPT SOCIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Christakis, Nicholas A/B-6690-2008; Christakis, Nicholas A/C-3205-2009					AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; COHEN JJ, 1993, NEW ENGL J MED, V329, P1810, DOI 10.1056/NEJM199312093292412; ERDMANN JB, 1979, AAMC LONGITUDINAL ST; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GELLER G, 1990, SOC SCI MED, V31, P619, DOI 10.1016/0277-9536(90)90098-D; GESENSWAY D, 1993, ACP OBSERVER, V13, P1; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; Hobcraft J., 1985, COHORT ANAL SOCIAL R, P89; HOLDEN WD, 1978, JAMA-J AM MED ASSOC, V239, P205, DOI 10.1001/jama.239.3.205; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; KINDIG DA, 1994, JAMA-J AM MED ASSOC, V271, P1505, DOI 10.1001/jama.271.19.1505; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; LUNDERG GD, 1993, JAMA-J AM MED ASSOC, V270, P380, DOI 10.1001/jama.270.3.380; MONK MA, 1956, NEW ENGL J MED, V255, P1135, DOI 10.1056/NEJM195612132552405; NOBLE J, 1992, ANN INTERN MED, V116, P482, DOI 10.7326/0003-4819-116-6-482; RABINOWITZ HK, 1988, NEW ENGL J MED, V319, P480, DOI 10.1056/NEJM198808253190805; RIVO ML, 1993, ANN INTERN MED, V119, P146, DOI 10.7326/0003-4819-119-2-199307150-00009; RIVO ML, 1994, JAMA-J AM MED ASSOC, V271, P1499, DOI 10.1001/jama.271.19.1499; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; ROLAND M, 1988, BRIT MED J, V297, P599, DOI 10.1136/bmj.297.6648.599; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V267, P1665, DOI 10.1001/jama.267.12.1665; ROSENBLATT RA, 1993, AM J PUBLIC HEALTH, V83, P322, DOI 10.2105/AJPH.83.3.322; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P373, DOI 10.1001/jama.252.3.373; STEVENS RA, 1984, COMING PHYSICIAN SUR, P83; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WEISKOTTEN HG, 1961, J MED EDUC, V36, P1565; WEISS JE, 1971, HSMHA HEALTH REP, V86, P46, DOI 10.2307/4594088; WRIGHT RA, 1993, JAMA-J AM MED ASSOC, V269, P2544, DOI 10.1001/jama.269.19.2544; 1993, HLTH PROFESSIONS ED; 1992, IMPROVING ACCESS HLT; 1993, PROPOSAL REFORM AM H; 1993, ANN REPORT C; 1984, PHYSICIAN CHARACTERI; 1979, PHYSICIAN DISTRIBUTI; 1992, ANN REPORT J MACY JR; 1993, PRIMARY CARE WORK FO; 1981, REPORT GRADUATE MED	39	12	12	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					669	675		10.7326/0003-4819-121-9-199411010-00008	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944077				2022-12-28	WOS:A1994PN45000008
J	GOLDSTEIN, RA; PAUL, WE; METCALFE, DD; BUSSE, WW; REECE, ER				GOLDSTEIN, RA; PAUL, WE; METCALFE, DD; BUSSE, WW; REECE, ER			ASTHMA	ANNALS OF INTERNAL MEDICINE			English	Article							COLONY-STIMULATING FACTOR; HUMAN MAST-CELLS; CD4+ T-CELLS; HUMAN EOSINOPHILS; MUCOSAL INFLAMMATION; MONOCLONAL-ANTIBODY; AIRWAY INFLAMMATION; CHANGING PATTERNS; INTERFERON-GAMMA; PROGENITOR CELLS	Asthma is characterized by inflammation, reversible airway obstruction, and increased airway responsiveness to various stimuli. It has received wide public attention in recent years because of increasing morbidity and deaths,(-1) particularly among black persons. The important role of inflammation in the immunopathogenesis of asthma has led to a newer therapeutic approach directed at interrupting this inflammatory process. Among immune regulatory pathways involved in asthma pathogenesis, two lymphokines appear to be particularly important in controlling IgE production. Interleukin-4 is required for IgE production; without it, IgE production is inhibited. interferon-gamma can diminish cell priming for interleukin-4 production. Thus, the interplay of these two cytokines will determine whether cells that can make interleukin-4 will be produced and, therefore, whether IgE will be produced in response to allergic stimuli. Further, in response to appropriate stimuli, mast cells and eosinophils are attracted to airways and release cytokines, lipid mediators, and preformed substances that cause inflammation. Modern asthma treatment is directed at interrupting this inflammatory process and places a much greater emphasis on use of anti-inflammatory agents, such as aerosolized or parenteral corticosteroids, and on nonsteroidal anti-inflammatory agents, such as cromolyn sodium and nedocromil sodium. Research advances without therapeutic application, however, limit success. Projects such as the National Institute of Allergy and Infectious Diseases' National Cooperative Inner-City Asthma Study, which is directed toward underserved populations, are intended to identify more clearly the factors responsible for increasing morbidity and to develop appropriate therapeutic interventions.	NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA; NIAID, CLIN INVEST LAB, ALLERG DIS SECT, BETHESDA, MD 20892 USA; UNIV WISCONSIN, MADISON, WI USA; HOWARD UNIV, COLL MED, MED CTR, ALLERGY & IMMUNOL SECT, WASHINGTON, DC 20059 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Wisconsin System; University of Wisconsin Madison; Howard University	GOLDSTEIN, RA (corresponding author), NIAID, DIV ALLERGY IMMUNOL & TRANSPLANTAT, SOLAR BLDG, ROOM 4A18, BETHESDA, MD 20892 USA.							ALTER SC, 1987, BIOCHEM J, V248, P821, DOI 10.1042/bj2480821; ALTMAN LK, 1993, NY TIMES        0420, pC3; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BERNSTEIN IL, 1985, CHEST, V87, pS68, DOI 10.1378/chest.87.1_Supplement.68S; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BUSSE WW, 1992, ALLERGY PRINCIPLES P, P1173; CHUNG KF, 1991, ASTHMA ITS PATHOLOGY, P93; CLUTTERBUCK EJ, 1990, BLOOD, V75, P1774; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; COSTA JJ, 1993, J CLIN INVEST, V91, P2673, DOI 10.1172/JCI116506; CRAIG SS, 1993, LAB INVEST, V69, P552; CRAIG SS, 1988, LAB INVEST, V58, P682; CRAIG SS, 1986, AM J PATHOL, V124, P427; CRIMI E, 1989, J ALLERGY CLIN IMMUN, V83, P985, DOI 10.1016/0091-6749(89)90116-4; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Dvorak A. M., 1992, MAST CELL HLTH DIS, P1; EVANS R, 1992, CHEST, V101, pS368; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HAMID Q, 1992, BLOOD, V80, P1496; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; KIRSHENBAUM AS, 1991, J IMMUNOL, V146, P1410; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEE TC, 1984, J BIOL CHEM, V259, P5526; Lemanske RF, 1993, ALLERGY PRINCIPLES P, P320; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MCFADDEN ER, 1989, J ALLERGY CLIN IMMUN, V84, P151, DOI 10.1016/0091-6749(89)90318-7; METCALFE DD, 1992, INFLAMMATION BASIC P, P709; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NIJKAMP FP, 1990, AM REV RESPIR DIS, V141, pS145, DOI 10.1164/ajrccm/141.3_Pt_2.S145; PAUWELS RA, 1989, J ALLERGY CLIN IMMUN, V83, P548, DOI 10.1016/0091-6749(89)90036-5; PETTY TL, 1989, AM REV RESPIR DIS, V139, P694, DOI 10.1164/ajrccm/139.3.694; RAPHAEL GD, 1986, EUR J RESPIR DIS, V69, P44; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; SHAW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; SOMMERHOFF CP, 1990, FASEB J, V4, pA1940; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SUR S, 1993, ALLERGY PRINCIPLES P, P169; SWAIN SL, 1988, J IMMUNOL, V141, P3445; THOMPSON HL, 1992, MAST CELL HLTH DISEA, P763; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WEINBERGER M, 1992, ALLERGY PRINCIPLES P, P816; Weiss J W, 1982, Trans Assoc Am Physicians, V95, P30; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673; 1991, J ALLERGY CLIN IMMUN, V88, P425; 1990, MMWR-MORBID MORTAL W, V39, P493; 1991, PEDIATRIC ASTHMA ALL, V5, P57	76	54	55	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					698	708		10.7326/0003-4819-121-9-199411010-00011	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00011			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944080				2022-12-28	WOS:A1994PN45000011
J	SCHNEIDER, HC; BERTHOLD, J; BAUER, MF; DIETMEIER, K; GUIARD, B; BRUNNER, M; NEUPERT, W				SCHNEIDER, HC; BERTHOLD, J; BAUER, MF; DIETMEIER, K; GUIARD, B; BRUNNER, M; NEUPERT, W			MITOCHONDRIAL HSP70/MIM44 COMPLEX FACILITATES PROTEIN IMPORT	NATURE			English	Article							TRANSLOCATION CONTACT SITES; YEAST MITOCHONDRIA; INNER MEMBRANE; PRECURSOR PROTEINS; INTERMEMBRANE SPACE; MOLECULAR CHAPERONES; MATRIX; HSP70; PATHWAY; BINDING	Protein translocation into mitochondria requires the mitochondrial protein Hsp70. This molecular chaperone of the mitochondrial matrix is recruited to the protein import machinery by MIM44, a component associated with the inner membrane of the mitochondria. Formation of the mt-Hsp70/MIM44 complex is regulated by ATP. MIM44 and mt-Hsp70 interact in a sequential manner with incoming segments of unfolded preproteins and thereby facilitate stepwise vectorial translocation of proteins across the mitochondrial membranes. The complex appears to act as a molecular ratchet which is energetically driven by the hydrolysis of ATP.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY	University of Munich				Brunner, Michael/0000-0001-9798-3047				ARRETZ M, 1993, J BIOL CHEM, V269, P4959; BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BROACH JR, 1983, EXPT MANIPULATION GE, P85; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1994, BIOL HEAT SHOCK PROT, P85; CYR DM, 1993, J BIOL CHEM, V268, P23751; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HORST M, 1993, EMBO J, V12, P3035, DOI 10.1002/j.1460-2075.1993.tb05972.x; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; JUNGNICKEL B, 1994, FEBS LETT, V346, P73, DOI 10.1016/0014-5793(94)00367-X; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OHBA M, 1987, EMBO J, V6, P2109, DOI 10.1002/j.1460-2075.1987.tb02477.x; OSTERMANN J, 1990, FEBS LETT, V277, P281, DOI 10.1016/0014-5793(90)80865-G; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; UNGERMANN C, IN PRESS SCIENCE; [No title captured]	51	333	336	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					768	774		10.1038/371768a0	http://dx.doi.org/10.1038/371768a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935837				2022-12-28	WOS:A1994PP01800050
J	BRAIG, K; OTWINOWSKI, Z; HEGDE, R; BOISVERT, DC; JOACHIMIAK, A; HORWICH, AL; SIGLER, PB				BRAIG, K; OTWINOWSKI, Z; HEGDE, R; BOISVERT, DC; JOACHIMIAK, A; HORWICH, AL; SIGLER, PB			THE CRYSTAL-STRUCTURE OF THE BACTERIAL CHAPERONIN GROEL AT 2.8-ANGSTROM	NATURE			English	Article							ESCHERICHIA-COLI GROEL; MOLECULAR CHAPERONE; HEAT-SHOCK; PROTEIN MODELS; CENTRAL CAVITY; HYDROLYSIS; INTERFACES; SURFACE; ERRORS; CYCLE	The crystal structure of Escherichia coli GroEL shows a porous cylinder of 14 subunits made of two nearly 7-fold rotationally symmetrical rings stacked back-to-back with dyad symmetry. The subunits consist of three domains: a targe equatorial domain that forms the foundation of the assembly at its waist and holds the rings together; a large loosely structured apical domain that forms the ends of the cylinder; and a small slender intermediate domain that connects the two, creating side windows. The three-dimensional structure places most of the mutationally defined functional sites on the channel walls and its outward invaginations, and at the ends of the cylinder.	YALE UNIV,SCH MED,BOYER CTR,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University; Yale University			Bremner, James D/B-1632-2013; Otwinowski, Zbyszek/F-3665-2011	Otwinowski, Zbyszek/0000-0003-3640-8545				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BURNETT B, IN PRESS J BACT; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; ELLIS RJ, 1993, NATURE, V366, P213, DOI 10.1038/366213a0; ELLIS RJ, 1991, REV BIOCH, V60, P321; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; IKAZAKI A, 1994, NATURE STRUCT BIOL, V1, P439; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, P CCP4 STUD WEEK MOL, P91; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MCLENNAN NF, 1993, MOL MICROBIOL, V7, P49, DOI 10.1111/j.1365-2958.1993.tb01096.x; MCMULLIN TW, 1987, MOL CELL BIOL, V7, P4414, DOI 10.1128/MCB.7.12.4414; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER S, 1989, PROTEIN ENG, V3, P77, DOI 10.1093/protein/3.2.77; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SVENSSON LA, 1994, J MOL BIOL, V235, P47; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	52	1189	1201	2	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					578	586		10.1038/371578a0	http://dx.doi.org/10.1038/371578a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935790				2022-12-28	WOS:A1994PL55900043
J	FU, H; XIA, K; PALLAS, DC; CUI, C; CONROY, K; NARSIMHAN, RP; MAMON, H; COLLIER, RJ; ROBERTS, TM				FU, H; XIA, K; PALLAS, DC; CUI, C; CONROY, K; NARSIMHAN, RP; MAMON, H; COLLIER, RJ; ROBERTS, TM			INTERACTION OF THE PROTEIN-KINASE RAF-1 WITH 14-3-3-PROTEINS	SCIENCE			English	Article							P21(RAS); REGION; FAMILY; MIDDLE; RAS	Members of a family of highly conserved proteins, termed 14-3-3 proteins, were found by several experimental approaches to associate with Raf-1, a central component of a key signal transduction pathway. Optimal complex formation required the amino-terminal regulatory domain of Raf-1. The association of 14-3-3 proteins and Raf-1 was not substantially affected by the activation state of Raf.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,SHIPLEY INST MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Mamon, Harvey J/B-2335-2009	Mamon, Harvey J/0000-0002-6060-9059; Collier, R John/0000-0002-2427-4239	NCI NIH HHS [R01 CA057327, CA57327] Funding Source: Medline; NIAID NIH HHS [AI22021] Funding Source: Medline; NICHD NIH HHS [HD24926] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022021, R01AI022021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, UNPUB; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PALLAS D, UNPUB; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; XIA K, UNPUB; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	26	258	261	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					126	129		10.1126/science.7939632	http://dx.doi.org/10.1126/science.7939632			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939632				2022-12-28	WOS:A1994PK58200040
J	FUTREAL, PA; LIU, QY; SHATTUCKEIDENS, D; COCHRAN, C; HARSHMAN, K; TAVTIGIAN, S; BENNETT, LM; HAUGENSTRANO, A; SWENSEN, J; MIKI, Y; EDDINGTON, K; MCCLURE, M; FRYE, C; WEAVERFELDHAUS, J; DING, W; GHOLAMI, Z; SODERKVIST, P; TERRY, L; JHANWAR, S; BERCHUCK, A; IGLEHART, JD; MARKS, J; BALLINGER, DG; BARRETT, JC; SKOLNICK, MH; KAMB, A; WISEMAN, R				FUTREAL, PA; LIU, QY; SHATTUCKEIDENS, D; COCHRAN, C; HARSHMAN, K; TAVTIGIAN, S; BENNETT, LM; HAUGENSTRANO, A; SWENSEN, J; MIKI, Y; EDDINGTON, K; MCCLURE, M; FRYE, C; WEAVERFELDHAUS, J; DING, W; GHOLAMI, Z; SODERKVIST, P; TERRY, L; JHANWAR, S; BERCHUCK, A; IGLEHART, JD; MARKS, J; BALLINGER, DG; BARRETT, JC; SKOLNICK, MH; KAMB, A; WISEMAN, R			BRCA1 MUTATIONS IN PRIMARY BREAST AND OVARIAN CARCINOMAS	SCIENCE			English	Article							FAMILIAL BREAST; ALLELE LOSSES; CANCER; REGION; CHROMOSOME-17Q; TUMORS; PROGRESSION; LINKAGE	Loss of heterozygosity data from familial tumors suggest that BRCA1, a gene that confers susceptibility to ovarian and early-onset breast cancer, encodes a tumor suppressor. The BRCA1 region is also subject to allelic loss in sporadic breast and ovarian cancers, an indication that BRCA1 mutations may occur somatically in these tumors. The BRCA1 coding region was examined for mutations in primary breast and ovarian tumors that show allele loss at the BRCA1 locus. Mutations were detected in 3 of 32 breast and 1 of 12 ovarian carcinomas; all four mutations were germline alterations and occurred in early-onset cancers. These results suggest that mutation of BRCA1 may not be critical in the development of the majority of breast and ovarian cancers that arise in the absence of a mutant germline allele.	MYRIAD GENET,SALT LAKE CITY,UT 84108; UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84123; FAC HLTH SCI LINKOPING,DEPT OCCUPAT MED,S-58185 LINKOPING,SWEDEN; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY 10021; DUKE UNIV,MED CTR,DEPT GYNECOL ONCOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Myriad Genetics, Inc; Utah System of Higher Education; University of Utah; Linkoping University; Memorial Sloan Kettering Cancer Center; Duke University; Duke University	FUTREAL, PA (corresponding author), NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709, USA.				NCI NIH HHS [CA56749, CA48711, CA55914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055914, P01CA048711, R01CA056749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CROPP CS, 1993, CANCER RES, V53, P5617; CROPP CS, 1994, CANCER RES, V54, P2548; EASTON DF, 1993, AM J HUM GENET, V52, P678; ECCLES DM, 1990, ONCOGENE, V5, P1599; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; FUTREAL PA, 1992, CANCER RES, V52, P2624; FUTREAL PA, UNPUB; GLEBOV OK, 1994, CANCER RES, V54, P3703; GOLDGAR DE, UNPUB; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JACOBS IJ, 1993, CANCER RES, V53, P1218; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; KNUDSON AG, 1978, SEMIN ONCOL, V5, P57; LYNCH HT, 1990, GYNECOL ONCOL, V36, P48, DOI 10.1016/0090-8258(90)90107-V; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NEUHAUSEN SL, UNPUB; PARKIN DM, 1992, CANCER INCIDENCE 5 C, V6; SAITO H, 1993, CANCER RES, V53, P3382; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1990, CANCER RES, V50, P7184; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128	23	1093	1141	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					120	122		10.1126/science.7939630	http://dx.doi.org/10.1126/science.7939630			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939630				2022-12-28	WOS:A1994PK58200038
J	WANG, MH; RONSIN, C; GESNEL, MC; COUPEY, L; SKEEL, A; LEONARD, EJ; BREATHNACH, R				WANG, MH; RONSIN, C; GESNEL, MC; COUPEY, L; SKEEL, A; LEONARD, EJ; BREATHNACH, R			IDENTIFICATION OF THE RON GENE-PRODUCT AS THE RECEPTOR FOR THE HUMAN MACROPHAGE STIMULATING PROTEIN	SCIENCE			English	Article							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; SCATTER FACTOR; MET PROTOONCOGENE; CELL CARCINOMA; SHORT ARM; C-MET; CHROMOSOME-3; EXPRESSION; HOMOLOGY	Macrophage-stimulating protein (MSP) is a member of the hepatocyte growth factor-scatter factor (HGF-SF) family. Labeled MSP bound to Madin-Darby canine kidney (MDCK) cells transfected with complementary DNA encoding Ron, a cell membrane protein tyrosine kinase. Cross-lin king of I-125-labeled MSP to transfected cells (MDCK-RE7 cells) and immunoprecipitation by antibodies to Ron revealed a 220-kilodalton complex, a size consistent with that of MSP (80 kilodaltons) cross-linked to the beta chain of Ron (150 kilodaltons). The binding of I-125-labeled MSP to MDCK-RE7 cells was inhibited by unlabeled MSP, but not by HGF-SF. MSP caused phosphorylation of the beta chain of Ron and induced migration of MDCK-RE7 cells. These results establish the ron gene product as a specific cell-surface receptor tor MSP.	CHR NANTES,INST BIOL,INSERM,U211,F-44035 NANTES 01,FRANCE; FAC MED LIMOGES,HEMATOL EXPTL LAB,F-87025 LIMOGES,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes	WANG, MH (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,FREDERICK,MD 21702, USA.		Breathnach, Richard/K-7599-2015					BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; LANE K, UNPUB; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; RONSIN C, UNPUB; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKEEL A, 1994, J IMMUNOL, V152, P4618; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1994, J BIOL CHEM, V269, P13806; WANG MH, 1994, J BIOL CHEM, V269, P3436; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	25	245	256	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					117	119		10.1126/science.7939629	http://dx.doi.org/10.1126/science.7939629			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939629				2022-12-28	WOS:A1994PK58200037
J	GURDON, JB; HARGER, P; MITCHELL, A; LEMAIRE, P				GURDON, JB; HARGER, P; MITCHELL, A; LEMAIRE, P			ACTIVIN SIGNALING AND RESPONSE TO A MORPHOGEN GRADIENT	NATURE			English	Article							DROSOPHILA EMBRYO; XENOPUS-LAEVIS; MESODERM INDUCTION; AXIAL MESODERM; RETINOIC ACID; PROTEIN; HOMOLOG; PATTERN; CELLS; THRESHOLDS	Using combinations of amphibian embryo tissues, it is shown that the selection of genes expressed by a cell is determined by its distance from a source of activin, a peptide growth factor contained in vegetal cells and able to induce other cells to form mesoderm. This long-range signal spreads over at least 10 cell diameters In a few hours. It does so by passive diffusion, because It can by-pass cells that do not themselves respond to the signal nor synthesize protein. These results provide direct support for the operation of a morphogen concentration gradient In vertebrate development.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge	GURDON, JB (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Lemaire, Patrick/D-4237-2009; Lemaire, Patrick/P-8228-2019; Lemaire, Patrick/B-5560-2012	Lemaire, Patrick/0000-0003-4925-2009; Lemaire, Patrick/0000-0003-4925-2009; GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BURRUS LW, 1994, BIOESSAYS, V16, P155, DOI 10.1002/bies.950160303; CASCIO S, 1987, DEVELOPMENT, V100, P297; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CORNELL RA, 1994, DEVELOPMENT, V120, P453; COUSO JP, 1994, DEVELOPMENT, V120, P621; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1987, DEVELOPMENT, V99, P527; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1994, DEVELOPMENT, V120, P2271; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GURDON JB, 1985, P NATL ACAD SCI USA, V82, P139, DOI 10.1073/pnas.82.1.139; GURDON JB, 1989, DEVELOPMENT, V105, P27; GURDON JB, 1992, DEVELOPMENT, P137; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HOPWOOD ND, 1992, DEVELOPMENT, V114, P31; JONES EA, 1987, DEVELOPMENT, V101, P557; LAWRENCE PA, 1988, CELL, V54, P1, DOI 10.1016/0092-8674(88)90172-9; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MOODY SA, 1987, DEV BIOL, V122, P300, DOI 10.1016/0012-1606(87)90296-X; NAKAMURA O, 1971, P JPN ACAD, V47, P313, DOI 10.2183/pjab1945.47.313; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; PLACZEK M, 1990, DEVELOPMENT, V110, P19; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WOLPERT L, 1989, DEVELOPMENT S, P3	47	306	309	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					487	492		10.1038/371487a0	http://dx.doi.org/10.1038/371487a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935761				2022-12-28	WOS:A1994PK58900046
J	ALARY, M; JOLY, JR; MOUTQUIN, JM; MONDOR, M; BOUCHER, M; FORTIER, A; PINAULT, JJ; PARIS, G; CARRIER, S; CHAMBERLAND, H; BERNATCHEZ, H; PARADIS, JF				ALARY, M; JOLY, JR; MOUTQUIN, JM; MONDOR, M; BOUCHER, M; FORTIER, A; PINAULT, JJ; PARIS, G; CARRIER, S; CHAMBERLAND, H; BERNATCHEZ, H; PARADIS, JF			RANDOMIZED COMPARISON OF AMOXICILLIN ACID ERYTHROMYCIN IN TREATMENT OF GENITAL CHLAMYDIAL INFECTION IN PREGNANCY	LANCET			English	Article							GONOCOCCAL URETHRITIS; TRACHOMATIS INFECTION; AMOXICILLIN THERAPY; CERVICAL INFECTION; MEN; OXYTETRACYCLINE; MOTHERS; INFANTS	Erythromycin, the standard treatment for chlamydial infection in pregnant women, commonly causes side-effects, which limits its efficacy. In a randomised, double-blind study, we compared amoxycillin with erythromycin in this setting. 210 pregnant women with Chlamydia trachomatis infection were randomly assigned 7 days' treatment with amoxycillin (500 mg three times daily) or erythromycin (500 mg four times daily). Control cultures were obtained 21 days after treatment, during late pregnancy, and from the infant within a week of birth. Treatment was judged a failure if any post-treatment culture was positive or if the patient had to stop therapy because of severe side-effects. 11 women (5.2%) were lost to follow-up. 1 (of 100) amoxycillin-treated women had to stop treatment because of severe side-effects compared with 12 (of 99) erythromycin-treated women (p=0.002). 1 woman in the amoxycillin group had a positive culture at the third-trimester examination. No positive post-treatment culture was found in the erythromycin group. Severe gastrointestinal side-effects were more common in women who received erythromycin (31 vs 6%, p<0.001). The overall failure rate was therefore 2% in the amoxycillin group and 12% in the erythromycin group (p=0.005). These results suggest that amoxycillin is an acceptable alternative to erythromycin for C trachomatis infection in, pregnant women.	UNIV LAVAL, FAC MED, RECH EPIDEMIOL GRP, QUEBEC CITY G1K 7P4, PQ, CANADA; HOP ST FRANCOIS ASSISE, SERV OBSTET, QUEBEC CITY, PQ, CANADA; HOP ST JUSTINE, SERV OBSTET, MONTREAL H3T 1C5, PQ, CANADA; HOP JEFFERY HALE, SERV OBSTET, QUEBEC CITY, PQ, CANADA; HOTEL DIEU HOSP, SERV OBSTET, LEVIS, PQ, CANADA; HOP REG, SERV OBSTET, RIMOUSKI, PQ, CANADA; HOP CHICOUTIMI, SERV OBSTET, QUEBEC CITY, PQ, CANADA	Laval University; Laval University; Universite de Montreal; Laval University								ALARY M, 1993, OBSTET GYNECOL, V82, P399; ALEXANDER ER, 1982, CHLAMYDIAL INFECTION, P225; ALEXANDER ER, 1977, NONGONOCOCCAL URETHR, P148; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; ARAL SO, 1990, SEXUALLY TRANSMITTED, P19; Auger P, 1990, Can Dis Wkly Rep, V16, P45; BELL TA, 1982, CHLAMYDIAL INFECTION, P221; BOWIE WR, 1986, ANTIMICROB AGENTS CH, V29, P713, DOI 10.1128/AAC.29.4.713; BOWIE WR, 1981, SEX TRANSM DIS, V8, P79, DOI 10.1097/00007435-198104000-00010; CROMBLEHOLME WR, 1990, OBSTET GYNECOL, V75, P752; CSANGO PA, 1984, BRIT J VENER DIS, V60, P95; CSANGO PA, 1985, SEX TRANSM DIS, V12, P93, DOI 10.1097/00007435-198504000-00009; FROMMELL GT, 1979, J PEDIATR-US, V95, P28, DOI 10.1016/S0022-3476(79)80077-3; HEGGIE AD, 1981, AM J DIS CHILD, V135, P507, DOI 10.1001/archpedi.1981.02130300007005; KRAMER MJ, 1979, J INFECT DIS, V139, P717, DOI 10.1093/infdis/139.6.717; KUO CC, 1977, ANTIMICROB AGENTS CH, V12, P80, DOI 10.1128/AAC.12.1.80; LYCKE E, 1980, SEX TRANSM DIS, V7, P6, DOI 10.1097/00007435-198001000-00002; MAGAT AH, 1993, OBSTET GYNECOL, V81, P745; NORTON HJ, 1990, OBSTET GYNECOL, V76, P896; ORIEL JD, 1980, J INFECTION, V2, P259, DOI 10.1016/S0163-4453(80)90722-7; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; ROBSON HG, 1983, SEX TRANSM DIS, V10, P130, DOI 10.1097/00007435-198307000-00006; SCHACHTER J, 1989, NEW ENGL J MED, V320, P802, DOI 10.1056/NEJM198903233201210; SCHACHTER J, 1986, NEW ENGL J MED, V314, P276, DOI 10.1056/NEJM198601303140503; SILVERMAN NS, 1994, AM J OBSTET GYNECOL, V170, P829, DOI 10.1016/S0002-9378(94)70292-6; Steigbigel N., 1990, PRINCIPLES PRACTICE, P308; WORM AM, 1987, GENITOURIN MED, V63, P19; 1992, CAN COMUN DIS REP S1, V8, P1; 1992, LANCET, V339, P711; 1991, WHO TECH REP SER, V810	30	22	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 26	1994	344	8935					1461	1465		10.1016/S0140-6736(94)90288-7	http://dx.doi.org/10.1016/S0140-6736(94)90288-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968119				2022-12-28	WOS:A1994PT99500007
J	ATKINSON, MA; MACLAREN, NK				ATKINSON, MA; MACLAREN, NK			MECHANISMS OF DISEASE - THE PATHOGENESIS OF INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ISLET-CELL ANTIBODIES; GLUTAMIC-ACID DECARBOXYLASE; MAJOR HISTOCOMPATIBILITY COMPLEX; RECENT-ONSET; BETA-CELLS; HIGH-RISK; 1ST-DEGREE RELATIVES; AUTOIMMUNE-DISEASE; INTERFERON-GAMMA; IDENTICAL-TWINS				ATKINSON, MA (corresponding author), UNIV FLORIDA,COLL MED,DEPT PATHOL & LAB MED,JHMHC BOX 100275,GAINESVILLE,FL 32610, USA.				NICHD NIH HHS [R01 HD19469] Funding Source: Medline; NIDDK NIH HHS [R29DK45342] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045342] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMIEL SA, 1991, J CLIN ENDOCR METAB, V72, P277, DOI 10.1210/jcem-72-2-277; ASAYAMA K, 1986, J LAB CLIN MED, V107, P459; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; ATKINSON MA, 1993, J CLIN INVEST, V91, P350, DOI 10.1172/JCI116192; ATKINSON MA, 1990, DIABETES, V39, P933, DOI 10.2337/diabetes.39.8.933; ATKINSON MA, 1993, NEW ENGL J MED, V329, P1853, DOI 10.1056/NEJM199312163292505; ATKINSON MA, 1986, DIABETES, V35, P894, DOI 10.2337/diabetes.35.8.894; BAEKKESKOV S, 1990, NATURE, V347, P782, DOI 10.1038/347782a0; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BINGLEY PJ, 1993, DIABETES, V42, P213, DOI 10.2337/diabetes.42.2.213; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BOTTAZZO GF, 1985, NEW ENGL J MED, V313, P353, DOI 10.1056/NEJM198508083130604; BOTTAZZO GF, 1974, LANCET, V2, P1279, DOI 10.1016/S0140-6736(74)90140-8; BOUGNERES PF, 1988, NEW ENGL J MED, V318, P663, DOI 10.1056/NEJM198803173181103; BOUGNERES PF, 1990, DIABETES, V39, P1264, DOI 10.2337/diabetes.39.10.1264; BRUINING GJ, 1989, LANCET, V1, P1100; BUSCHARD K, 1991, AUTOIMMUNITY, V10, P65, DOI 10.3109/08916939108997149; BUSCHARD K, 1993, LANCET, V342, P840, DOI 10.1016/0140-6736(93)92697-R; CAILLATZUCMAN S, 1993, EUR J IMMUNOL, V23, P1784, DOI 10.1002/eji.1830230808; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; CASTANO L, 1991, J CLIN ENDOCR METAB, V73, P1197, DOI 10.1210/jcem-73-6-1197; CHASE HP, 1990, DIABETOLOGIA, V33, P444, DOI 10.1007/BF00404097; CHRISTIE MR, 1993, J CLIN INVEST, V92, P240, DOI 10.1172/JCI116556; CHRISTIE MR, 1992, DIABETES, V41, P782, DOI 10.2337/diabetes.41.7.782; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; DALTON TA, 1992, AM J MED, V92, P183, DOI 10.1016/0002-9343(92)90110-W; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DESCHAMPS I, 1992, DIABETOLOGIA, V35, P951, DOI 10.1007/BF00401424; DRYKONINGEN CEM, 1992, DIABETOLOGIA, V35, P139, DOI 10.1007/BF00402545; EISENBARTH GS, 1992, J AUTOIMMUN, V5, P241, DOI 10.1016/0896-8411(92)90039-S; ELLIOTT RB, 1991, DIABETOLOGIA, V34, P362, DOI 10.1007/BF00405010; FATHMAN CG, 1992, NEW ENGL J MED, V326, P1693, DOI 10.1056/NEJM199206183262509; FAUSTMAN D, 1991, SCIENCE, V254, P1756, DOI 10.1126/science.1763324; FOULIS AK, 1987, LANCET, V2, P1423; FOULIS AK, 1986, DIABETOLOGIA, V29, P267, DOI 10.1007/BF00452061; FOULIS AK, 1991, J PATHOL, V165, P97, DOI 10.1002/path.1711650203; GANDA OP, 1984, DIABETES, V33, P516, DOI 10.2337/diabetes.33.6.516; GENOVESE S, 1992, DIABETOLOGIA, V35, P385, DOI 10.1007/BF00401207; GEPTS W, 1965, DIABETES, V14, P619, DOI 10.2337/diab.14.10.619; GEPTS W, 1985, DIABETIC PANCREAS, P337; GIANANI R, 1992, DIABETES, V41, P347, DOI 10.2337/diabetes.41.3.347; GOTFREDSEN CF, 1985, DIABETOLOGIA, V28, P933, DOI 10.1007/BF00703140; GREEN A, 1992, LANCET, V339, P905, DOI 10.1016/0140-6736(92)90938-Y; HANNINEN A, 1992, J CLIN INVEST, V90, P1901, DOI 10.1172/JCI116067; HARRISON LC, 1992, J CLIN INVEST, V89, P1161, DOI 10.1172/JCI115698; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; INMAN LR, 1993, P NATL ACAD SCI USA, V90, P1281, DOI 10.1073/pnas.90.4.1281; JOHNSON JH, 1990, NEW ENGL J MED, V322, P653, DOI 10.1056/NEJM199003083221003; JOHNSON JH, 1990, NEW ENGL J MED, V322, P1019; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P1252; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; KAROUNOS DG, 1993, J IMMUNOL, V150, P3080; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KELLER RJ, 1990, J AUTOIMMUN, V3, P321, DOI 10.1016/0896-8411(90)90150-Q; KELLER RJ, 1993, LANCET, V341, P927, DOI 10.1016/0140-6736(93)91215-8; KOSTRABA JN, 1994, DIABETES CARE, V17, P87, DOI 10.2337/diacare.17.1.87; KRISCHER JP, 1993, J CLIN ENDOCR METAB, V77, P743, DOI 10.1210/jc.77.3.743; KROLEWSKI AS, 1987, NEW ENGL J MED, V317, P1390; LAPORTE RE, 1985, NIH951468 DEP HLTH H; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; Maclaren N, 1988, Autoimmunity, V1, P197, DOI 10.3109/08916938808997164; MACLAREN N, 1992, NEW ENGL J MED, V327, P348, DOI 10.1056/NEJM199207303270509; Major cross-country differences in risk of dying for people with IDDM, 1991, DIABETES CARE, V14, P49; MANDRUPPOULSEN T, 1986, DIABETOLOGIA, V29, P63, DOI 10.1007/BF02427283; MASIELLO P, 1985, DIABETOLOGIA, V28, P683, DOI 10.1007/BF00291976; NAYAK RC, 1985, DIABETES, V34, P617, DOI 10.2337/diabetes.34.6.617; NEPOM GT, 1990, DIABETES, V39, P1153, DOI 10.2337/diabetes.39.10.1153; NOMIKOS IN, 1989, IMMUNOL CELL BIOL, V67, P85, DOI 10.1038/icb.1989.12; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; PALMER JP, 1991, DIABETES, V40, P943, DOI 10.2337/diabetes.40.8.943; PICKUP G, 1991, TXB DIABETES; PIETROPAOLO M, 1993, J CLIN INVEST, V92, P359, DOI 10.1172/JCI116574; RAFFEL LJ, 1991, METABOLISM, V40, P1244, DOI 10.1016/0026-0495(91)90023-P; Reddy S, 1990, Diabetes Res, V15, P95; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; ROEP BO, 1991, LANCET, V337, P1439, DOI 10.1016/0140-6736(91)93127-U; SHAH SC, 1989, NEW ENGL J MED, V320, P550, DOI 10.1056/NEJM198903023200902; SHEEHY MJ, 1992, DIABETES, V41, P123, DOI 10.2337/diabetes.41.2.123; SHEHADEH N, 1994, LANCET, V343, P706, DOI 10.1016/S0140-6736(94)91583-0; SHIZURU JA, 1988, SCIENCE, V240, P659, DOI 10.1126/science.2966437; SILVERSTEIN J, 1988, NEW ENGL J MED, V319, P599, DOI 10.1056/NEJM198809083191002; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; STEWART TA, 1993, SCIENCE, V260, P1942, DOI 10.1126/science.8100367; STILLER CR, 1984, SCIENCE, V223, P1362, DOI 10.1126/science.6367043; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TODD JA, 1990, IMMUNOL TODAY, V11, P122, DOI 10.1016/0167-5699(90)90049-F; TODD JA, 1992, DIABETES, V41, P1029, DOI 10.2337/diabetes.41.9.1029; TUOMILEHTO J, 1991, DIABETOLOGIA, V34, P282, DOI 10.1007/BF00405089; VADHEIM CM, 1986, NEW ENGL J MED, V315, P1314, DOI 10.1056/NEJM198611203152103; VARDI P, 1988, DIABETES CARE, V11, P736, DOI 10.2337/diacare.11.9.736; VARDI P, 1987, DIABETES, V36, P1286, DOI 10.2337/diabetes.36.11.1286; VARDI P, 1991, DIABETOLOGIA, V34, P93, DOI 10.1007/BF00500379; Wang Y, 1987, DIABETES, V36, P535, DOI 10.2337/diabetes.36.4.535; WARRAM JH, 1984, NEW ENGL J MED, V311, P149, DOI 10.1056/NEJM198407193110304; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252; ZIEGLER AG, 1990, J AUTOIMMUN, V3, P619, DOI 10.1016/S0896-8411(05)80029-0; ZIEGLER R, 1991, DIABETES, V40, P709, DOI 10.2337/diabetes.40.6.709	102	826	862	0	57	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1428	1436						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7969282				2022-12-28	WOS:A1994PU53300007
J	ROGERS, MC; SNYDERMAN, R; ROGERS, EL				ROGERS, MC; SNYDERMAN, R; ROGERS, EL			CULTURAL AND ORGANIZATIONAL IMPLICATIONS OF ACADEMIC MANAGED-CARE NETWORKS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							REFORM; CENTERS		DUKE UNIV,MED CTR,DURHAM,NC 27710	Duke University								BLUMENTHAL D, 1993, NEW ENGL J MED, V329, P1812, DOI 10.1056/NEJM199312093292413; BULGER RJ, 1992, HEALTH AFFAIR, V11, P261, DOI 10.1377/hlthaff.11.4.261-a; Burns L R, 1993, Health Care Manage Rev, V18, P7; COHEN JJ, 1993, NEW ENGL J MED, V329, P1810, DOI 10.1056/NEJM199312093292412; DEBAKEY ME, 1993, SCIENCE, V262, P523, DOI 10.1126/science.8211176; Fogel B J, 1993, J Fla Med Assoc, V80, P595; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; IGLEHART JK, 1993, NEW ENGL J MED, V329, P1052, DOI 10.1056/NEJM199309303291428; IGLEHART JK, 1994, NEW ENGL J MED, V330, P1167, DOI 10.1056/NEJM199404213301628; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KNAPP RM, 1992, ACAD MED, V67, P452, DOI 10.1097/00001888-199207000-00006; ROGERS MC, 1994, ANN SURG, V220, P1; ROGERS MC, IN PRESS 1994 P DUK; Straley P F, 1993, Top Health Care Financ, V19, P24; THIER SO, 1994, ACAD MED, V69, P185, DOI 10.1097/00001888-199403000-00003; Vanselow N A, 1990, Acad Med, V65, P560, DOI 10.1097/00001888-199009000-00004	16	53	53	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1374	1377		10.1056/NEJM199411173312013	http://dx.doi.org/10.1056/NEJM199411173312013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935712				2022-12-28	WOS:A1994PR21600013
J	CRAVEN, DE; STEGER, KA; LACHAPELLE, R; ALLEN, DM				CRAVEN, DE; STEGER, KA; LACHAPELLE, R; ALLEN, DM			FACTITIOUS HIV-INFECTION - THE IMPORTANCE OF DOCUMENTING INFECTION	ANNALS OF INTERNAL MEDICINE			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; AIDS	Objective: To examine possible causes for factitious human immunodeficiency virus (HIV) infection among patients in an HIV clinic. Design: Retrospective chart review, a case-control study, and a survey of local hospital practices for documenting HIV infection. Setting: Clinical acquired immunodeficiency syndrome (AIDS) program at a municipal hospital. Results: Seven patients with self-reported, undocumented HIV infection were identified as HIV seronegative after a mean of 9.2 months of care in our clinical AIDS program. The median CD4 count for these patients was 740 cells/mm(3); 6 patients had a history of illicit narcotic use and clinical symptoms consistent with HIV disease. Compared with 70 randomly selected controls from HIV clinics, patients with factitious HIV infection had higher CD4 counts (difference, 519 cells/mm(3); P < 0.001) and were more likely to have an HIV-infected sexual partner (odds ratio, 15.0; P = 0.005) and a history of a suicide attempt (odds ratio, 9.8; P = 0.02). Known cases of alleged HIV infection have occurred at 8 of the 10 other local hospitals surveyed. However, only 1 of the 10 hospitals routinely documented HIV infection in patients before initiating care. Conclusions: Limitations of the current serologic tests for HIV, the use of anonymous HIV testing, and recent reports of factitious HIV disease or immune deficiency syndromes that may mimic AIDS underscore the need for clear documentation of HIV infection before medical care is started.	BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA	Boston University								[Anonymous], 1993, MMWR Recomm Rep, V42, P1; ARNOW PM, 1988, AM J KIDNEY DIS, V11, P383, DOI 10.1016/S0272-6386(88)80050-7; BLENDON RJ, 1988, NEW ENGL J MED, V319, P1022, DOI 10.1056/NEJM198810133191522; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; BYLUND DJ, 1992, CLIN LAB MED, V12, P305, DOI 10.1016/S0272-2712(18)30517-1; DICKENS BM, 1988, SCIENCE, V239, P580, DOI 10.1126/science.3340844; DUNCAN RA, 1993, NEW ENGL J MED, V328, P393, DOI 10.1056/NEJM199302113280604; GOSTIN LO, 1989, JAMA-J AM MED ASSOC, V261, P1621; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; LEVINE SS, 1988, WESTERN J MED, V148, P337; LEWIS CE, 1990, JAMA-J AM MED ASSOC, V264, P2764, DOI 10.1001/jama.264.21.2764; LO B, 1989, ANN INTERN MED, V110, P727; LOURIA DB, 1992, CLIN INFECT DIS, V15, P707, DOI 10.1093/clind/15.4.707; MACKENZIE WR, 1992, JAMA-J AM MED ASSOC, V268, P1015, DOI 10.1001/jama.268.8.1015; MAHORNEY SL, 1988, AM J PSYCHIAT, V145, P1130; MILLER D, 1985, BRIT J PSYCHIAT, V146, P550, DOI 10.1192/bjp.146.5.550; Rothman K, 1986, MODERN EPIDEMIOLOGY; SNO HN, 1991, INT J PSYCHIAT MED, V21, P93, DOI 10.2190/4BJM-U288-Q8KR-JQ3C; TYSON E, 1987, JAMA-J AM MED ASSOC, V258, P1889; ZUGER A, 1992, CLIN INFECT DIS, V14, P211, DOI 10.1093/clinids/14.1.211; 1987, MMWR-MORBID MORTAL W, V36, P509	21	17	17	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					763	766		10.7326/0003-4819-121-10-199411150-00006	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944054				2022-12-28	WOS:A1994PQ92800006
J	LANTING, CI; FIDLER, V; HUISMAN, M; TOUWEN, BCL; BOERSMA, ER				LANTING, CI; FIDLER, V; HUISMAN, M; TOUWEN, BCL; BOERSMA, ER			NEUROLOGICAL DIFFERENCES BETWEEN 9-YEAR-OLD CHILDREN FED BREAST-MILK OR FORMULA-MILK AS BABIES	LANCET			English	Article							FATTY-ACID COMPOSITION; COGNITIVE-DEVELOPMENT; PRETERM INFANTS; BRAIN; BIRTH; GROWTH	The presence of minor neurological dysfunction is associated with behavioural and cognitive development at school age. We have previously shown a relation between minor neurological dysfunction and perinatal disorders, especially abnormal neonatal neurological condition. We have now investigated the relation between breastfeeding and long-term neurological development. We studied 135 breastfed (for greater than or equal to 3 weeks) and 391 formula-fed children, born at term in the University Hospital Groningen between 1975 and 1979. A standard neonatal neurological examination was used to classify the infants as normal (247), slightly abnormal (213), or frankly abnormal (66). At 9 years of age the children were reexamined. In 1993 their mothers were asked to complete a questionnaire about how the children were fed as infants. After adjustment for obstetric, perinatal, neonatal neurological, and social differences, a small advantageous effect of breastfeeding on neurological status at 9 years of age was found (odds ratio for neurological non-normality 0.54 [95% Cl 0.30-0.97]). Although a retrospective design cannot lead to definite conclusions, our data suggest a beneficial effect of breastfeeding on postnatal neurological development. Longer-chain polyunsaturated fatty acids, which are present in breast-milk but not in most formula-milks, may have a role since they are vital for brain development.	UNIV GRONINGEN HOSP,DEPT PHYSIOL,9713 EZ GRONINGEN,NETHERLANDS; UNIV GRONINGEN,FAC MED,DEPT HLTH SCI,EPIDEMIOL & STAT UNIT,GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen	LANTING, CI (corresponding author), UNIV GRONINGEN HOSP,DEPT OBSTET & GYNAECOL,NUTR & DEV UNIT,9713 EZ GRONINGEN,NETHERLANDS.			Lanting, Caren/0000-0001-9417-7074				BIRCH E, 1993, J PEDIATR OPHTHALMOL, V30, P33; BIRCH EE, 1992, INVEST OPHTH VIS SCI, V33, P3242; BJERVE KS, 1992, NUTRITION, V8, P130; CARLSON SE, 1986, AM J CLIN NUTR, V44, P798, DOI 10.1093/ajcn/44.6.798; CLANDININ MT, 1980, EARLY HUM DEV, V4, P131, DOI 10.1016/0378-3782(80)90016-X; CRAWFORD MA, 1976, CURR MED RES OPIN, V4, P33, DOI 10.1185/03007997609109350; CRAWFORD MA, 1976, LANCET, V1, P452; FARQUHARSON J, 1992, LANCET, V340, P810, DOI 10.1016/0140-6736(92)92684-8; FERGUSSON DM, 1982, SOC SCI MED, V16, P1705, DOI 10.1016/0277-9536(82)90096-X; HADDERSALGRA M, 1988, DEV MED CHILD NEUROL, V30, P482; HADDERSALGRA M, 1988, DEV MED CHILD NEUROL, V30, P472; JURGENSVANDERZEE AD, 1979, EARLY HUM DEV, V3, P141, DOI 10.1016/0378-3782(79)90003-3; Koldovsky O., 1989, Textbook of gastroenterology and nutrition in infancy., P97; LEAF AA, 1992, J PEDIATR GASTR NUTR, V14, P300, DOI 10.1097/00005176-199204000-00011; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MAKRIDES M, 1993, PEDIATR RES, V33, P425; MARTINEZ M, 1974, PEDIATR RES, V8, P93, DOI 10.1203/00006450-197402000-00005; MENKES JH, 1977, DEV MED CHILD NEUROL, V19, P169, DOI 10.1111/j.1469-8749.1977.tb07966.x; Prechtl HFR., 1977, CLIN DEV MED, P63; PUTNAM JC, 1982, AM J CLIN NUTR, V36, P106, DOI 10.1093/ajcn/36.1.106; ROGAN WJ, 1993, EARLY HUM DEV, V31, P181, DOI 10.1016/0378-3782(93)90194-Y; SINCLAIR AJ, 1972, J NEUROCHEM, V19, P1753, DOI 10.1111/j.1471-4159.1972.tb06219.x; TOUWEN BCL, 1980, EARLY HUM DEV, V4, P207, DOI 10.1016/0378-3782(80)90027-4; Touwen BCL., 1979, CLIN DEV MED, P71; UAUY RD, 1990, PEDIATR RES, V28, P485, DOI 10.1203/00006450-199011000-00014; van den Bogaard C, 1991, Fam Med, V23, P510; YAMAMOTO N, 1987, J LIPID RES, V28, P144; 1991, ACTA PAEDIATR SCAND, V80, P887; 1992, UNSATURATED FATTY AC; 1977, FOOD NUTRITION PAPER	30	171	176	2	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1319	1322		10.1016/S0140-6736(94)90692-0	http://dx.doi.org/10.1016/S0140-6736(94)90692-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968027				2022-12-28	WOS:A1994PQ92600008
J	KARET, FE; DICKERSON, JEC; BROWN, J; BROWN, MJ				KARET, FE; DICKERSON, JEC; BROWN, J; BROWN, MJ			BOVRIL AND MOCLOBEMIDE - A NOVEL THERAPEUTIC STRATEGY FOR CENTRAL AUTONOMIC FAILURE	LANCET			English	Note							MONOAMINE-OXIDASE	The consumption of tyramine-containing foods is contraindicated in patients on classic monoamine oxidase (MAO) inhibitors. We report successful therapeutic use of moclobemide (a MAO-A selective inhibitor) plus controlled amounts of Bovril (a tyramine-rich yeast-extract available as a food) in a patient with pure central autonomic failure who was rendered bed-bound by severe postural hypotension. Standing blood pressure is now at least 90/45 mm Hg. The selectivity of moclobemide allows about a tenth of ingested tyramine to reach nerve endings and thus the modest hypertensive effect of this combination re-established day-to-day function by restoring normotension.			KARET, FE (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,CLIN PHARMACOL UNIT,BOX 110,CAMBRIDGE CB2 2QQ,ENGLAND.			Karet, Fiona/0000-0002-2457-2869				AMREIN R, 1989, BRIT J PSYCHIAT, V155, P66, DOI 10.1192/S0007125000297511; BANNISTER R, 1987, OXFORD TXB MED; DOLLERY CT, 1983, CLIN PHARMACOL THER, V34, P651, DOI 10.1038/clpt.1983.228; DOLLERY CT, 1984, MONAMINE OXIDASE DIS, P487; KORN A, 1984, MONOAMINE OXIDASE DI, P429; Oppenheimer D., 1988, AUTONOMIC FAILURE TX, P451; VANINGELGHEM E, 1994, J NEUROL NEUROSUR PS, V57, P745, DOI 10.1136/jnnp.57.6.745	7	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1263	1265		10.1016/S0140-6736(94)90752-8	http://dx.doi.org/10.1016/S0140-6736(94)90752-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967987				2022-12-28	WOS:A1994PP70100010
J	CARNON, AG; SSEMWOGERERE, A; LAMONT, DW; HOLE, DJ; MALLON, EA; GEORGE, WD; GILLIS, CR				CARNON, AG; SSEMWOGERERE, A; LAMONT, DW; HOLE, DJ; MALLON, EA; GEORGE, WD; GILLIS, CR			RELATION BETWEEN SOCIOECONOMIC DEPRIVATION AND PATHOLOGICAL PROGNOSTIC FACTORS IN WOMEN WITH BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							LATE-STAGE DIAGNOSIS; SOCIAL-CLASS; SURVIVAL; RACE; DELAY; AGE	Objective-To investigate the relation between socioeconomic deprivation and pathological prognostic factors in women with breast cancer as a possible explanation for socioeconomic differences in survival. Design-Retrospective analysis of data from cancer registry and from pathology and biochemistry records. Setting-Catchment areas of two large teaching hospitals in Glasgow. Subjects-1361 women aged under 75 who had breast cancer diagnosed between 1980 and 1987. Main outcome measures-Tumour size, axillary lymph node status, histological grade, and oestrogen receptor concentration in relation to deprivation category of area of residence. Results-There was no significant relation between socioeconomic deprivation and four pathological prognostic factors: 93 (32%) women in the most affluent group presented with tumours less than 20 mm in size compared with 91 (31%) women in the most deprived group; 152 (48%) of the most affluent group presented with negative nodes compared with 129 (46%) of the most deprived group; 23 (22%) of the most affluent group presented with grade I tumours compared with 12 (17%) of the most deprived group; and 142 (51%) of the most affluent group had a low oestrogen receptor concentration at presentation compared with 148 (52%) of the most deprived group. None of these differences was statistically significant. Conclusions-Differences in survival from breast cancer by socioeconomic deprivation category could not be accounted for by differences in tumour stage or biology. Other possible explanations, such as differences in treatment or in host response, should be investigated.	RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT PATHOL,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT SURG,GLASGOW G11 6NT,LANARK,SCOTLAND	University of Glasgow; University of Glasgow; University of Glasgow								AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Carstairs V., 1991, DEPRIVATION HLTH SCO; COATES RJ, 1992, JNCI-J NATL CANCER I, V84, P938, DOI 10.1093/jnci/84.12.938; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FARLEY TA, 1989, AM J PUBLIC HEALTH, V79, P1508, DOI 10.2105/AJPH.79.11.1508; GORDON NH, 1992, AM J EPIDEMIOL, V135, P609, DOI 10.1093/oxfordjournals.aje.a116340; KARJALAINEN S, 1990, CANCER-AM CANCER SOC, V66, P819, DOI 10.1002/1097-0142(19900815)66:4<819::AID-CNCR2820660437>3.0.CO;2-E; KEIRN W, 1985, CANCER, V55, P1552, DOI 10.1002/1097-0142(19850401)55:7<1552::AID-CNCR2820550723>3.0.CO;2-E; KOGEVINAS M, 1991, J EPIDEMIOL COMMUN H, V45, P216, DOI 10.1136/jech.45.3.216; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MITTRA I, 1991, EUR J CANCER, V27, P1583; MOHLA S, 1982, CANCER-AM CANCER SOC, V50, P552, DOI 10.1002/1097-0142(19820801)50:3<552::AID-CNCR2820500328>3.0.CO;2-G; NATARAJAN N, 1985, CANCER-AM CANCER SOC, V56, P1704, DOI 10.1002/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L; OWNBY HE, 1985, J NATL CANCER I, V75, P55; RICHARDSON JL, 1992, BRIT J CANCER, V65, P922, DOI 10.1038/bjc.1992.193; TOMATIS L, 1990, CANCER CAUSES OCCURR; VAGERO D, 1987, J EPIDEMIOL COMMUN H, V41, P204, DOI 10.1136/jech.41.3.204; VERNON SW, 1985, CANCER-AM CANCER SOC, V55, P1563, DOI 10.1002/1097-0142(19850401)55:7<1563::AID-CNCR2820550726>3.0.CO;2-1; WELLS BL, 1992, AM J PUBLIC HEALTH, V82, P1383, DOI 10.2105/AJPH.82.10.1383; 1987, TNM CLASSIFICATION M; 1991, BREAST CANCER SCREEN	22	60	61	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1054	1057		10.1136/bmj.309.6961.1054	http://dx.doi.org/10.1136/bmj.309.6961.1054			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN733	7950739	Green Published			2022-12-28	WOS:A1994PN73300022
J	FARRELL, M; WARD, J; MATTICK, R; HALL, W; STIMSON, GV; JARLAIS, DD; GOSSOP, M; STRANG, J				FARRELL, M; WARD, J; MATTICK, R; HALL, W; STIMSON, GV; JARLAIS, DD; GOSSOP, M; STRANG, J			FORTNIGHTLY REVIEW - METHADONE-MAINTENANCE TREATMENT IN OPIATE DEPENDENCE - A REVIEW	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRAVENOUS-DRUG-USERS; HUMAN IMMUNODEFICIENCY VIRUS; NEW-YORK-CITY; RISK-TAKING BEHAVIOR; GENERAL-PRACTITIONERS; HEROIN-ADDICTS; LONG-TERM; NATIONAL SURVEY; FOLLOW-UP; OPIOID DEPENDENCE		UNIV NEW S WALES, NATL DRUG & ALCOHOL RES CTR, KENSINGTON, NSW 2033, AUSTRALIA; CTR RES DRUGS & HLTH BEHAV, LONDON SW7 1RQ, ENGLAND; BETH ISRAEL MED CTR, NEW YORK, NY 10003 USA	University of New South Wales Sydney; Harvard University; Beth Israel Deaconess Medical Center	FARRELL, M (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT, NATL ADDICT CTR, DE CRESPIGNY PK, DENMARK HILL, LONDON SE5 8AF, ENGLAND.		Strang, John/H-5460-2011; Hall, Wayne D/A-3283-2008; Farrell, Michael P/A-4769-2012	Strang, John/0000-0002-5413-2725; Hall, Wayne D/0000-0003-1984-0096; Farrell, Michael P/0000-0001-7008-8130				ABDULQUADER AS, 1987, CONTEMP DRUG PROBL, V14, P425; ABED RT, 1990, BRIT J ADDICT, V85, P131; ANGLIN M, 1984, NIDA RES MONOGRAPH, V51; ANGLIN MD, 1989, ADDICT BEHAV, V14, P307; [Anonymous], 1988, AIDS DRUG MISUSE 1; BAEKELAND F, 1975, PSYCHOL BULL, V82, P738, DOI 10.1037/h0077132; Baillie A J, 1992, Drug Alcohol Rev, V11, P343, DOI 10.1080/09595239200185471; BALE RN, 1980, ARCH GEN PSYCHIAT, V37, P179; Ball J.C., 2012, EFFECTIVENESS METHAD; Battersby M, 1992, Drug Alcohol Rev, V11, P35, DOI 10.1080/09595239200185061; BELL J, 1992, BRIT J ADDICT, V87, P251; BINCHY JM, 1994, BRIT MED J, V308, P1335, DOI 10.1136/bmj.308.6940.1335; BLIX O, 1988, 4TH P INT C AIDS STO; Blum K, 1984, HDB ABUSABLE DRUGS, V1st; BREWER C, 1991, DRUG ADDICTION AIDS, P187; BROWN BS, 1982, AM J DRUG ALCOHOL AB, V9, P129, DOI 10.3109/00952998209002617; BROWN LS, 1989, NEW YORK STATE J MED, V89, P506; CAPLEHORN JRM, 1993, ADDICTION, V88, P119, DOI 10.1111/j.1360-0443.1993.tb02769.x; CAPLEHORN JRM, 1991, MED J AUSTRALIA, V154, P195, DOI 10.5694/j.1326-5377.1991.tb121030.x; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CONDELLI WS, 1993, AM J DRUG ALCOHOL AB, V19, P65, DOI 10.3109/00952999309002666; CRAIG RJ, 1980, INT J ADDICT, V15, P701, DOI 10.3109/10826088009040049; CUSHMAN P, 1978, AM J MED, V65, P46, DOI 10.1016/0002-9343(78)90691-5; CUSHMAN P, 1981, SUBSTANCE ABUSE CLIN; DARKE S, 1992, DRUG ALCOHOL DEPEN, V31, P31, DOI 10.1016/0376-8716(92)90005-W; DARKE S, 1992, DRUG ALCOHOL DEPEN, V29, P263, DOI 10.1016/0376-8716(92)90101-H; DARKE S, 1990, BRIT J ADDICT, V85, P1603; DAUNNO T, 1992, JAMA-J AM MED ASSOC, V267, P253, DOI 10.1001/jama.267.2.253; Des Jarlais D C, 1981, Ann N Y Acad Sci, V362, P231; DOLAN MP, 1987, PUBLIC HEALTH REP, V102, P395; Dole V P, 1978, Ann N Y Acad Sci, V311, P181, DOI 10.1111/j.1749-6632.1978.tb16775.x; DOLE VP, 1977, NEW YORK STATE J MED, V77, P1409; DOLE VP, 1969, NEW ENGL J MED, V280, P1372, DOI 10.1056/NEJM196906192802502; DOLE VP, 1991, AM J PUBLIC HEALTH, V81, P1111, DOI 10.2105/AJPH.81.9.1111; DRUMMER OH, 1990, LANCET, V335, P108, DOI 10.1016/0140-6736(90)90570-U; FARRELL M, 1991, BRIT MED J, V302, P1477, DOI 10.1136/bmj.302.6791.1477; FARRELL M, 1994, BRIT MED J, V308, P609, DOI 10.1136/bmj.308.6929.609; FREEDMAN RR, 1981, DRUG ALCOHOL DEPEN, V8, P215, DOI 10.1016/0376-8716(81)90064-8; GARDNER R, 1970, BRIT J ADDICT, V65, P113; GEARING FR, 1974, AM J EPIDEMIOL, V100, P101, DOI 10.1093/oxfordjournals.aje.a112012; GERSTEIN DR, 1990, TREATING DRUG PROBLE, V1; GLANZ A, 1986, BRIT MED J, V293, P543, DOI 10.1136/bmj.293.6546.543; GLANZ A, 1986, BRIT MED J, V293, P427, DOI 10.1136/bmj.293.6544.427; GLANZ A, 1986, BRIT MED J, V293, P486, DOI 10.1136/bmj.293.6545.486; GOLDSTEIN A, 1973, 5TH P NAT C METH TRE; GOSSOP M, 1991, BRIT J ADDICT, V86, P1151; GUNNE LM, 1981, DRUG ALCOHOL DEPEN, V7, P249, DOI 10.1016/0376-8716(81)90096-X; HANDAL PJ, 1976, INT J ADDICT, V11, P363, DOI 10.3109/10826087609056156; HARFORD RJ, 1978, ARCH GEN PSYCHIAT, V35, P356; HARTGERS C, 1992, AM J PUBLIC HEALTH, V82, P547, DOI 10.2105/AJPH.82.4.547; HARTNOLL RC, 1984, ARCH GEN PSYCHIAT, V37, P882; Hubbard RL, 1989, DRUG ABUSE TREATMENT; IGUCHI MY, 1988, DRUG ALCOHOL DEPEN, V22, P1, DOI 10.1016/0376-8716(88)90030-0; Joe G W, 1991, J Subst Abuse, V3, P73; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; KLEE H, 1991, BRIT J ADDICT, V86, P217; KLEE H, 1990, BRIT J ADDICT, V85, P1125; LIEBSON I, 1973, AM J PSYCHIAT, V130, P483; LING W, 1976, ARCH GEN PSYCHIAT, V33, P709; LOWINSON JH, 1992, SUBSTANCE ABUSE COMP, P550; MADDUX JF, 1991, J SUBST ABUSE TREAT, V8, P195, DOI 10.1016/0740-5472(91)90039-D; MARMOR M, 1987, AIDS, V1, P39; MCGLOTHLIN WH, 1981, ARCH GEN PSYCHIAT, V38, P1055; MCGLOTHLIN WH, 1981, ARCH GEN PSYCHIAT, V38, P885; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; MCLELLAN AT, 1988, J NERV MENT DIS, V176, P423, DOI 10.1097/00005053-198807000-00004; METZGER D, 1991, AM J PSYCHIAT, V148, P636; MILBY JB, 1988, J NERV MENT DIS, V176, P409, DOI 10.1097/00005053-198807000-00003; Newman R G, 1991, Drug Alcohol Rev, V10, P225, DOI 10.1080/09595239100185261; NEWMAN RG, 1991, J PSYCHOACTIVE DRUGS, V23, P115, DOI 10.1080/02791072.1991.10472230; NEWMAN RG, 1979, LANCET, V2, P485; NOLIMAL D, 1990, J SUBST ABUSE TREAT, V7, P219, DOI 10.1016/0740-5472(90)90044-Q; NOVICK DM, 1990, ARCH INTERN MED, V150, P97, DOI 10.1001/archinte.150.1.97; PAYNEJAMES JJ, 1994, J ROY SOC MED, V87, P13; ROSENBAUM M, 1988, CONTEMP DRUG PROBL, V15, P491; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SELWYN PA, 1987, AIDS, V1, P247; SIASSI I, 1977, INT J ADDICT, V12, P993, DOI 10.3109/10826087709027267; SIMPSON DD, 1979, AM J PSYCHIAT, V136, P1449; SIMPSON DD, 1981, ARCH GEN PSYCHIAT, V38, P875; SIMPSON DD, 1982, ADV ALCOHOL SUBSTANC, V0002; Stimmel B, 1978, Ann N Y Acad Sci, V311, P173, DOI 10.1111/j.1749-6632.1978.tb16774.x; STITZER ML, 1986, DRUG ALCOHOL DEPEN, V18, P341, DOI 10.1016/0376-8716(86)90097-9; STRAIN EC, 1993, ANN INTERN MED, V119, P23, DOI 10.7326/0003-4819-119-1-199307010-00004; TENNANT F S JR, 1986, Journal of Substance Abuse Treatment, V3, P195; TORRENS M, 1991, DRUG ALCOHOL DEPEN, V27, P29, DOI 10.1016/0376-8716(91)90083-B; UCHTENHAGEN A, 1990, METHADONE MAINTENANC, P55; VANICHSENI S, 1991, INT J ADDICT, V26, P1313, DOI 10.3109/10826089109062163; WARD J, 1992, KEY ISSUES METHADONE; WILSON P, 1994, BRIT MED J, V309, P641, DOI 10.1136/bmj.309.6955.641; WOLK J, 1990, BRIT J ADDICT, V85, P1445; WU CH, 1990, LANCET, V335, P424, DOI 10.1016/0140-6736(90)90269-B; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185; 1993, AIDS DRUG MISUSE UPD; 1989, AIDS DRUG MISUSE 2	95	278	284	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 15	1994	309	6960					997	1001		10.1136/bmj.309.6960.997	http://dx.doi.org/10.1136/bmj.309.6960.997			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950725	Green Published			2022-12-28	WOS:A1994PM41700027
J	CHEN, C; RAINNIE, DG; GREENE, RW; TONEGAWA, S				CHEN, C; RAINNIE, DG; GREENE, RW; TONEGAWA, S			ABNORMAL FEAR RESPONSE AND AGGRESSIVE-BEHAVIOR IN MUTANT MICE DEFICIENT FOR ALPHA-CALCIUM-CALMODULIN KINASE-II	SCIENCE			English	Article							DORSAL RAPHE NEURONS; RAT-BRAIN; TRYPTOPHAN-HYDROXYLASE; CONDITIONED FEAR; PROTEIN-KINASE; SEROTONIN; PHOSPHORYLATION; DISORDERS; MONOAMINE; SLICES	Mice deficient for the gene encoding alpha-calcium-calmodulin-dependent kinase II (alpha-CaMKII knockout mice) provide a promising tool to link behavioral and cellular abnormalities with a specific molecular lesion. The heterozygous mouse exhibited a well-circumscribed syndrome of behavioral abnormalities, consisting primarily of a decreased fear response and an increase in defensive aggression, in the absence of any measured cognitive deficits. Unlike the heterozygote, the homozygote displayed abnormal behavior in all paradigms tested. At the cellular level, both extracellular and whole-cell patch clamp recordings indicated that serotonin release in putative serotonergic neurons of the dorsal raphe was reduced. Thus, alpha-CaMKII knockout mice, in particular the heterozygote, may provide a model for studying the molecular and cellular basis underlying emotional disorders involving fear and aggression.	MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT PSYCHIAT, BROCKTON, MA 02401 USA; VET ADM MED CTR, BROCKTON, MA 02401 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	CHEN, C (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Rainnie, Donald/L-3853-2016	Rainnie, Donald/0000-0003-0758-0530; Greene, Robert/0000-0003-1355-9797				ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; AGHAJANIAN GK, 1984, BRAIN RES, V305, P181, DOI 10.1016/0006-8993(84)91137-5; BARNETT SA, 1975, RAT STUDY BEHAVIOR; BENTON D, 1985, PHARM BIOCH BEHAV, V23, P979; BOLLES RC, 1970, PSYCHOL REV, V77, P32, DOI 10.1037/h0028589; BRAIN PF, 1989, E M I LIF S, V6, P1; BROWN GL, 1990, J CLIN PSYCHIAT, V51, P31; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CHARNEY DS, 1990, ANN NY ACAD SCI, V600, P558, DOI 10.1111/j.1749-6632.1990.tb16910.x; EHRET M, 1989, J NEUROCHEM, V52, P1886, DOI 10.1111/j.1471-4159.1989.tb07272.x; FANSELOW MS, 1992, BEHAV NEUROSCI, V106, P336, DOI 10.1037/0735-7044.106.2.336; FANSELOW MS, 1986, ANN NY ACAD SCI, V467, P40, DOI 10.1111/j.1749-6632.1986.tb14617.x; FANSELOW MS, 1984, TRENDS NEUROSCI, V7, P460; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GRANT L D, 1973, Pharmacology Biochemistry and Behavior, V1, P77, DOI 10.1016/0091-3057(73)90059-2; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hen R., 1993, Society for Neuroscience Abstracts, V19, P632; HIGLEY JD, 1992, ARCH GEN PSYCHIAT, V49, P436; INOUE T, 1993, PHARMACOL BIOCHEM BE, V44, P371, DOI 10.1016/0091-3057(93)90476-A; ISOBE T, 1991, J MOL BIOL, V217, P125, DOI 10.1016/0022-2836(91)90616-E; KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126; KOOLHAAS M, 1991, NEUROMETHODS, V19, P249; KOSTOWSKI W, 1980, PHYSIOL BEHAV, V25, P161, DOI 10.1016/0031-9384(80)90201-2; KSHAMA D, 1990, BEHAV NEURAL BIOL, V54, P234, DOI 10.1016/0163-1047(90)90617-F; MICZEK KA, 1994, NEUROSCI BIOBEHAV R, V18, P97, DOI 10.1016/0149-7634(94)90040-X; NEVINS ME, 1994, J PHARMACOL EXP THER, V268, P248; NORMAN TR, 1989, INT J CLIN PHARM RES, V9, P151; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; TREIT D, 1993, BEHAV BRAIN RES, V54, P23, DOI 10.1016/0166-4328(93)90045-R; VANDERMAELEN CP, 1983, BRAIN RES, V289, P109, DOI 10.1016/0006-8993(83)90011-2; VANPRAAG HM, 1990, BRIT J PSYCHIAT, V157, P723, DOI 10.1192/bjp.157.5.723; WALLETSCHEK H, 1982, PHYSIOL BEHAV, V28, P697, DOI 10.1016/0031-9384(82)90054-3; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; WESTENBERG HGM, 1989, PSYCHOPATHOLOGY, V22, P68, DOI 10.1159/000284628; WILLIAMS JT, 1988, J NEUROSCI, V8, P3499	36	224	233	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	1994	266	5183					291	294		10.1126/science.7939668	http://dx.doi.org/10.1126/science.7939668			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939668				2022-12-28	WOS:A1994PM13400039
J	ETZKOWITZ, H; KEMELGOR, C; NEUSCHATZ, M; UZZI, B; ALONZO, J				ETZKOWITZ, H; KEMELGOR, C; NEUSCHATZ, M; UZZI, B; ALONZO, J			THE PARADOX OF CRITICAL MASS FOR WOMEN IN SCIENCE	SCIENCE			English	Editorial Material							PERFORMANCE		SUNY COLL PURCHASE,SOCIOL BOARD,PURCHASE,NY 10577; AMER INST PHYS,DIV EDUC & EMPLOYMENT STAT,COLLEGE PK,MD 20740; NORTHWESTERN UNIV,JL KELLOGG GRAD SCH MANAGEMENT,EVANSTON,IL; NEW SCH SOCIAL RES,FAC GRAD,DEPT SOCIOL,NEW YORK,NY 10003	State University of New York (SUNY) System; Northwestern University; The New School			McBee, David J/F-3968-2012					ALEXANDER VD, 1985, SOC FORCES, V64, P332, DOI 10.2307/2578644; BARINAGA M, 1993, SCIENCE, V260, P384, DOI 10.1126/science.260.5106.384; Bielby W.T., 1991, OUTER CIRCLE WOMEN S, P171; BORG A, 1994, JUN WOM ENG PROGR AD; BRAINARD S, 1993, J COLL SCI TEACH, V32, P336; COLE JR, 1987, SCI AM, V256, P119, DOI 10.1038/scientificamerican0287-119; Cole JR., 1979, FAIR SCI WOMEN SCI C; ETZKOWITZ H, 1993, JAN NAT AC SCI COUNC; ETZKOWITZ H, 1994, TECHNOL ACCESS REP, V7; ETZKOWITZ H, 1991, WOMEN SCI ENG IMPROV; Etzkowitz H., 1992, SCI PUBL POLICY, V19, P157, DOI DOI 10.1093/SPP/19.3.157; GRIES D, 1990, COMPUTER, V23, P65, DOI 10.1109/2.58238; Gutek B., 1985, SEX WORKPLACE IMPACT; Kanter R.M., 1977, MEN WOMEN CORPORATIO; KEMELGOR C, 1989, THESIS STATE U NEW Y; KONRAD AM, 1986, THESIS CLAREMONT GRA; LANE N, 1994, RISING TIDE REPORT W; LAZARUS B, UNPUB; MOEN P, 1994, WOMEN HUMAN RESOURCE; NUEVEOKERR L, 1993, J WOMENS HIST, V4, P141; OSBORN M, 1994, SCIENCE, V263, P1389, DOI 10.1126/science.263.5152.1389; PEARSON W, 1994, HUMAN RESOURCES SCI; PORTER B, 1989, AM ASS ADV SCI ANN M; ROSSI A, 1965, SCIENCE, V148, P3674; SOUTH SJ, 1982, AM SOCIOL REV, V47, P687; SPANGLER E, 1978, AM J SOCIOL, V84, P160, DOI 10.1086/226745; TALAPESSY L, 1993, POSITION WOMEN SCI R; WEBSTER BD, 1989, BIOSCIENCE, V39, P96, DOI 10.2307/1310908; 1984, WOMEN MINORITIES SCI	29	166	166	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					51	54		10.1126/science.7939644	http://dx.doi.org/10.1126/science.7939644			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939644				2022-12-28	WOS:A1994PK58200022
J	KUROKAWA, R; DIRENZO, J; BOEHM, M; SUGARMAN, J; GLOSS, B; ROSENFELD, MG; HEYMAN, RA; GLASS, CK				KUROKAWA, R; DIRENZO, J; BOEHM, M; SUGARMAN, J; GLOSS, B; ROSENFELD, MG; HEYMAN, RA; GLASS, CK			REGULATION OF RETINOID SIGNALING BY RECEPTOR POLARITY AND ALLOSTERIC CONTROL OF LIGAND-BINDING	NATURE			English	Article							THYROID-HORMONE; X-RECEPTOR; RESPONSE ELEMENTS; NUCLEAR RECEPTOR; DNA-BINDING; DIRECT REPEAT; AMINO-ACIDS; BETA-GENE; RXR-BETA; RAR	RETINOIC acid receptors (RARs) and retinoid X receptors (RXRs) regulate transcription by binding to response elements in target genes that generally consist of two direct repeat half-sites of consensus sequence AGGTCA (ref. 1). RAR/RXR heterodimers activate transcription in response to all-irans or 9-cis retinoic acid by binding to direct repeats spaced by five base pairs (DR5 elements)(2-8), such that RAR occupies the downstream half-site(9-12). RXR homodimers activate transcription in response to 9-cis retinoic acid by binding to direct repeats spaced by one base pair (DR1 elements)(8,13,14). Although RXR/RAR heterodimers bind to DR1 elements with higher affinity than RXR homodimers, in most contexts they are unable to activate transcription in response to either all-trans or 9-cis retinoic acid(3-5). AS a result, RARs inhibit RXR-dependent transcription from these sites(13,15). We report that the switching of the RAR from an activator to an inhibitor of retinoid-dependent transcription requires that it be bound to the upstream half-site of DR1 elements and that it allosterically block the binding of ligand to the RXR.	UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; LIGAND PHARMACEUT,DEPT CELL BIOL,SAN DIEGO,CA 92121	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Ligand Pharmaceuticals			Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592				DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; GLASS C. K., 1994, ENDOCR REV, V15, P1503; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; KLLEWER SA, 1992, NATURE, V355, P446; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	26	391	403	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					528	531		10.1038/371528a0	http://dx.doi.org/10.1038/371528a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935766				2022-12-28	WOS:A1994PK58900059
J	GREEN, JM				GREEN, JM			SERUM SCREENING FOR DOWNS-SYNDROME - EXPERIENCES OF OBSTETRICIANS IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To assess the experiences of obstetricians in England and Wales of serum screening for Down's syndrome. Design-Postal questionnaire survey. Subjects-Questionnaires were sent to all practising obstetricians in England and Wales with nonacademic appointments who had not participated in an earlier (randomly sampled) survey of obstetricians' attitudes (n = 555). Responses were received from 393 (71%), of which 351 were analysed. The data represent about one third of obstetric consultants in England and Wales. Main outcome measures-The extent of use of serum screening for Down's syndrome, and the problems encountered. Results-Serum screening for Down's syndrome was being offered on some basis by virtually all obstetricians in the survey. Nearly half the sample said that they did not have adequate resources for counselling all the women to whom screening was offered. Many problems were reported, which in all cases were more common than equivalent problems encountered with serum screening for neural tube defects. Over 80% (289) said that women not understanding the test was a problem. Conclusions-There is considerable confusion associated with serum screening for Down's syndrome. The precedent of serum screening for neural tube defects does not seem to have lessened the problems experienced, rather the contrary. Many obstetricians report inadequate resources for counselling, which is consistent with the high prevalence of problems associated with women not understanding the test. There is an urgent need to consider what counselling should consist of and who should undertake it and to ensure that necessary resources are available.			GREEN, JM (corresponding author), UNIV CAMBRIDGE,CTR FAMILY RES,CAMBRIDGE CB2 3RF,ENGLAND.							GREEN JM, 1993, LANCET, V342, P1179, DOI 10.1016/0140-6736(93)92164-O; GREEN JM, 1990, OCCASIONAL PAPERS, V2; GREEN JM, 1994, PRENATAL DIAGNOSIS H, P37; MARTEAU TM, 1992, PUBLIC HEALTH, V106, P131, DOI 10.1016/S0033-3506(05)80390-7; STATHAM H, 1993, BRIT MED J, V307, P174, DOI 10.1136/bmj.307.6897.174; WALD N, 1992, LANCET, V340, P494, DOI 10.1016/0140-6736(92)91822-P; 1994, GENETIC SCREENING ET	7	67	67	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					769	772		10.1136/bmj.309.6957.769	http://dx.doi.org/10.1136/bmj.309.6957.769			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950560	Green Published			2022-12-28	WOS:A1994PJ28200017
J	SPITZER, RL; WILLIAMS, JBW; KROENKE, K; LINZER, M; DEGRUY, FV; HAHN, SR; BRODY, D; JOHNSON, JG				SPITZER, RL; WILLIAMS, JBW; KROENKE, K; LINZER, M; DEGRUY, FV; HAHN, SR; BRODY, D; JOHNSON, JG			UTILITY OF NEW PROCEDURE FOR DIAGNOSING MENTAL-DISORDERS IN PRIMARY-CARE - THE PRIME-MD-1000 STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STRUCTURED CLINICAL INTERVIEW; PSYCHIATRIC-DISORDERS; SERVICE UTILIZATION; GENERAL-PRACTICE; DEPRESSION; HEALTH; RECOGNITION; RELIABILITY; PHYSICIANS; SYMPTOMS	Objective.-To assess the validity and utility of PRIME-MD (Primary Care Evaluation of Mental Disorders), a new rapid procedure for diagnosing mental disorders by primary care physicians. Design.-Survey; criterion standard. Setting.-Four primary care clinics. Subjects.-A total of 1000 adult patients (369 selected by convenience and 631 selected by site-specific methods to avoid sampling bias) assessed by 31 primary care physicians. Main Outcome Measures.-PRIME-MD diagnoses, independent diagnoses made by mental health professionals, functional status measures (Short-Form General Health Survey), disability days, health care utilization, and treatment/ referral decisions. Results.-Twenty-six percent of the patients had a PRIME-MD diagnosis that met full criteria for a specific disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. The average time required of the primary care physician to complete the PRIME-MD evaluation was 8.4 minutes. There was good agreement between PRIME-MD diagnoses and those of independent mental health professionals (for the diagnosis of any PRIME-MD disorder, kappa=0.71; overall accuracy rate=88%). Patients with PRIME-MD diagnoses had lower functioning, more disability days, and higher rates of health care utilization than did patients without PRIME-MD diagnoses (for all measures, P<.005). Nearly half (48%) of 287 patients with a PRIME-MD diagnosis who were somewhat or fairly well-known to their physicians had not been recognized to have that diagnosis before the PRIME-MD evaluation. A new treatment or referral was initiated for 62% of the 125 patients with a PRIME-MD diagnosis who were not already being treated. Conclusion.-PRIME-MD appears to be a useful tool for identifying mental disorders in primary care practice and research.	COLUMBIA UNIV,DEPT PSYCHIAT,NEW YORK,NY 10032; UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20814; TUFTS UNIV NEW ENGLAND MED CTR,DEPT MED,BOSTON,MA 02111; UNIV SO ALABAMA,DEPT FAMILY PRACTICE & COMMUNITY MED,MOBILE,AL 36688; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10467; MERCY CATHOLIC MED CTR,DEPT MED,DARBY,PA	Columbia University; Uniformed Services University of the Health Sciences - USA; Tufts Medical Center; University of South Alabama; Yeshiva University; Albert Einstein College of Medicine	SPITZER, RL (corresponding author), NEW YORK STATE PSYCHIAT INST & HOSP,BIOMETR RES DEPT,UNIT 74,722 W 168 ST,NEW YORK,NY 10032, USA.		anand, amit/A-7222-2009; Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213; Kroenke, Kurt/0000-0002-0114-4669				ANDERSEN SM, 1989, MED CARE, V27, P869, DOI 10.1097/00005650-198909000-00003; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P615; BARRETT JE, 1988, ARCH GEN PSYCHIAT, V45, P1100; BECK AT, 1974, MODERN PROBLEMS PHAR, V7; BORUS JF, 1988, GEN HOSP PSYCHIAT, V10, P317, DOI 10.1016/0163-8343(88)90002-3; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COHEN J., 1983, APPL MULTIPLE REGRES, V2; CYPRESS BK, 1978, ADV DATA VITAL HLTH, V38; ESCOBAR JI, 1987, ARCH GEN PSYCHIAT, V44, P713; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Goldberg DP, 1972, DETECTION PSYCHIAT I; HELZER JE, 1985, ARCH GEN PSYCHIAT, V42, P657; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; KATON W, 1992, GEN HOSP PSYCHIAT, V14, P237, DOI 10.1016/0163-8343(92)90094-Q; KATON W, 1987, J NERV MENT DIS, V175, P12, DOI 10.1097/00005053-198701000-00003; KESSLER LG, 1985, ARCH GEN PSYCHIAT, V42, P583; KROENKE K, 1990, ARCH INTERN MED, V150, P1685, DOI 10.1001/archinte.150.8.1685; MAGRUDERHABIB K, 1990, MED CARE, V28, P239, DOI 10.1097/00005650-199003000-00004; MANDERSCHEID RW, 1993, ARCH GEN PSYCHIAT, V50, P108; ORMEL J, 1991, ARCH GEN PSYCHIAT, V48, P700; ORMEL J, 1993, AM J PUBLIC HEALTH, V83, P385, DOI 10.2105/AJPH.83.3.385; POTTS MK, 1990, J PSYCHIATR RES, V24, P335, DOI 10.1016/0022-3956(90)90005-B; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; ROBINS LN, 1985, ARCH GEN PSYCHIAT, V42, P918; ROBINS LN, 1991, PSYCHIATRIC DISORDER; RYDON P, 1992, J STUD ALCOHOL, V53, P197, DOI 10.15288/jsa.1992.53.197; SCHAPPERT SM, 1992, VITAL HLTH STAT 13, V110; SCHULBERG HC, 1988, GEN HOSP PSYCHIAT, V10, P79, DOI 10.1016/0163-8343(88)90092-8; SCHURMAN RA, 1985, ARCH GEN PSYCHIAT, V42, P89; SHAPIRO S, 1984, ARCH GEN PSYCHIAT, V41, P971; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; SPITZER RL, 1993, INT J EAT DISORDER, V13, P137, DOI 10.1002/1098-108X(199303)13:2&lt;161::AID-EAT2260130204&gt;3.0.CO;2-R; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; VONKORFF M, 1987, ARCH GEN PSYCHIAT, V44, P152; WELLS KB, 1988, J PSYCHIAT RES, V22, P207, DOI 10.1016/0022-3956(88)90006-4; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; WYSHAK G, 1991, MED CARE, V29, P775, DOI 10.1097/00005650-199108000-00010; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P164; IN PRESS DIAGNOSTIC; 1987, DIAGNOSTIC STATISTIC; 1993, PHYSICIANS CURRENT P; 1993, NIH933477 NAT I MENT; [No title captured]; 1993, UNPUB COVERAGE CODIN, P10	47	2168	2185	0	71	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1749	1756		10.1001/jama.272.22.1749	http://dx.doi.org/10.1001/jama.272.22.1749			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PV815	7966923				2022-12-28	WOS:A1994PV81500024
J	MAJEWSKI, S; SKOPINSKA, M; BOLLAG, W; JABLONSKA, S				MAJEWSKI, S; SKOPINSKA, M; BOLLAG, W; JABLONSKA, S			COMBINATION OF ISOTRETINOIN AND CALCITRIOL FOR PRECANCEROUS AND CANCEROUS SKIN-LESIONS	LANCET			English	Letter									F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES,CH-4002 BASEL,SWITZERLAND	Roche Holding	MAJEWSKI, S (corresponding author), WARSAW ACAD MED & HOSP,DEPT DERMATOL,PL-02008 WARSAW,POLAND.							Bollag W., 1994, Retinoids: from basic science to clinical applications., P267; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; RAINA V, 1991, BRIT J CANCER, V63, P463, DOI 10.1038/bjc.1991.108; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307	4	37	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1510	1511		10.1016/S0140-6736(94)90330-1	http://dx.doi.org/10.1016/S0140-6736(94)90330-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968149				2022-12-28	WOS:A1994PT99500052
J	FLETCHER, RH; FLETCHER, SW				FLETCHER, RH; FLETCHER, SW			GLUTATHIONE AND AGING - IDEAS AND EVIDENCE	LANCET			English	Editorial Material									HARVARD UNIV,COMMUNITY HLTH PLAN,BOSTON,MA	Harvard University	FLETCHER, RH (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA, USA.							BUCK C, 1975, INT J EPIDEMIOL, V4, P159, DOI 10.1093/ije/4.3.159; DATTA M, 1993, LANCET, V342, P345, DOI 10.1016/0140-6736(93)91478-5; JULIUS M, 1994, J CLIN EPIDEMIOL, V47, P1021, DOI 10.1016/0895-4356(94)90117-1; LANG CA, 1992, J LAB CLIN MED, V120, P720; LOCK S, 1994, ANN INTERN MED, V121, P60, DOI 10.7326/0003-4819-121-1-199407010-00012; MACLURE M, 1985, AM J EPIDEMIOL, V121, P35; TUKEY JW, 1977, SCIENCE, V198, P679, DOI 10.1126/science.333584	7	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1379	1380		10.1016/S0140-6736(94)90562-2	http://dx.doi.org/10.1016/S0140-6736(94)90562-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968069				2022-12-28	WOS:A1994PR78600003
J	GROTH, CG; KORSGREN, O; TIBELL, A; TOLLEMAR, J; MOLLER, E; BOLINDER, J; OSTMAN, J; REINHOLT, FP; HELLERSTROM, C; ANDERSSON, A				GROTH, CG; KORSGREN, O; TIBELL, A; TOLLEMAR, J; MOLLER, E; BOLINDER, J; OSTMAN, J; REINHOLT, FP; HELLERSTROM, C; ANDERSSON, A			TRANSPLANTATION OF PORCINE FETAL PANCREAS TO DIABETIC-PATIENTS	LANCET			English	Note							ISLET ALLOGRAFT; CELL CLUSTERS; SURVIVAL; MICE	Transplanation of fetal porcine islet-like cell clusters (ICC) reverses diabetes in experimental animals. We have now transplanted porcine ICC to ten insulin-dependent diabetic kidney-transplant patients. A11 patients received standard immunosuppression and, at ICC transplantation, antithymocyte globulin or 15-deoxyspergualin. ICC were injected intraportally or placed under the kidney capsule of the renal graft. Four patients excreted small amounts of porcine C-peptide in urine for 200-400 days. In one renal-graft biopsy specimen, morphologically intact epithelial cells stained positively for insulin and glucagon in the subcapsular space. We conclude that porcine pancreatic endocrine tissue can survive in the human body.	KAROLINSKA INST,HUDDINGE HOSP,DEPT MED,S-14106 HUDDINGE,SWEDEN; KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN IMMUNOL,S-14106 HUDDINGE,SWEDEN; KAROLINSKA INST,HUDDINGE HOSP,DEPT PATHOL,S-14106 HUDDINGE,SWEDEN; UNIV UPPSALA,BIOCTR,DEPT MED CELL BIOL,UPPSALA,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Uppsala University	GROTH, CG (corresponding author), KAROLINSKA INST,HUDDINGE HOSP,DEPT TRANSPLANTAT SURG,S-14106 HUDDINGE,SWEDEN.			Bolinder, Jan/0000-0003-0035-0142; Korsgren, Olle/0000-0002-8524-9547				BJOERSDORFF A, 1992, TRANSPLANT P, V24, P674; GJESSING HJ, 1989, DIABETIC MED, V6, P329, DOI 10.1111/j.1464-5491.1989.tb01174.x; KORSGREN O, 1993, SURGERY, V113, P205; KORSGREN O, 1988, TRANSPLANTATION, V45, P509, DOI 10.1097/00007890-198803000-00001; KORSGREN O, 1991, DIABETOLOGIA, V34, P376; SANDBERG JO, 1993, PHARMACOL TOXICOL, V73, P24, DOI 10.1111/j.1600-0773.1993.tb01952.x; SATAKE M, 1993, CLIN TRANSPLANT, V7, P281; SATAKE M, IN PRESS XENOTRANSPL; SHIZURU JA, 1987, SCIENCE, V237, P278, DOI 10.1126/science.2955518; TOLLEMAR J, 1991, TRANSPLANTATION, V53, P139	10	400	420	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1402	1404		10.1016/S0140-6736(94)90570-3	http://dx.doi.org/10.1016/S0140-6736(94)90570-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968077				2022-12-28	WOS:A1994PR78600011
J	IRVINE, KD; WIESCHAUS, E				IRVINE, KD; WIESCHAUS, E			FRINGE, A BOUNDARY-SPECIFIC SIGNALING MOLECULE, MEDIATES INTERACTIONS BETWEEN DORSAL AND VENTRAL CELLS DURING DROSOPHILA WING DEVELOPMENT	CELL			English	Article							PATTERN-FORMATION; IMAGINAL DISKS; HEDGEHOG GENE; MELANOGASTER; REGENERATION; TRANSCRIPTION; EXPRESSION; PROTEIN; FIELDS	Wing formation in Drosophila requires interactions between dorsal and ventral cells. We describe a new gene, fringe, which is expressed in dorsal cells and encodes for a novel protein that is predicted to be secreted. Wing margin formation and distal wing outgrowth can be induced by the juxtaposition of cells with and without fringe expression, whether at the normal wing margin, at the boundaries of fringe mutant clones in the dorsal wing, or at sites of fringe misexpression in the ventral wing. By contrast, both loss of fringe expression and uniform fringe expression cause wing loss. These observations suggest that fringe encodes a boundary-specific cell-signaling molecule that is responsible for dorsal-ventral cell interactions during wing development.			IRVINE, KD (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022780] Funding Source: NIH RePORTER; NICHD NIH HHS [5R01HD22780] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAKER NE, 1988, DEVELOPMENT, V102, P489; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; BUTTERWORTH FM, 1965, GENETICS, V52, P1153; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN SM, 1993, DEV DROSOPHILA MELAN, P474; COUSO JP, 1994, DEVELOPMENT, V120, P621; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GELBART WM, 1989, DEVELOPMENT, V107, P65; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HAYNIE JL, 1976, NATURE, V259, P659, DOI 10.1038/259659b0; IRVINE KD, 1991, DEVELOPMENT, V111, P407; KARLSSON J, 1980, J EMBRYOL EXP MORPH, V59, P315; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEHMANN R, 1985, THESIS U TUBINGEN TU; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MEINHARDT H, 1982, DEV ORDER ITS ORIGIN, P439; MOHLER J, 1992, DEVELOPMENT, V115, P957; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; ROBERTSON HM, 1988, GENETICS, V118, P461; STEVENS ME, 1986, DEV BIOL, V117, P326, DOI 10.1016/0012-1606(86)90375-1; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILCOX M, 1980, ROUX ARCH DEV BIOL, V188, P157, DOI 10.1007/BF00848808; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WILLIAMS JA, 1993, BIOESSAYS, V15, P567, DOI 10.1002/bies.950150902; XU T, 1993, DEVELOPMENT, V117, P1223	41	296	303	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					595	606		10.1016/0092-8674(94)90545-2	http://dx.doi.org/10.1016/0092-8674(94)90545-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954826				2022-12-28	WOS:A1994PT48100007
J	BARRETT, AJ; HOROWITZ, MM; POLLOCK, BH; ZHANG, MJ; BORTIN, MM; BUCHANAN, GR; CAMITTA, BM; OCHS, J; GRAHAMPOLE, J; ROWLINGS, PA; RIMM, AA; KLEIN, JP; SHUSTER, JJ; SOBOCINSKI, KA; GALE, RP				BARRETT, AJ; HOROWITZ, MM; POLLOCK, BH; ZHANG, MJ; BORTIN, MM; BUCHANAN, GR; CAMITTA, BM; OCHS, J; GRAHAMPOLE, J; ROWLINGS, PA; RIMM, AA; KLEIN, JP; SHUSTER, JJ; SOBOCINSKI, KA; GALE, RP			BONE-MARROW TRANSPLANTS FROM HLA-IDENTICAL SIBLINGS AS COMPARED WITH CHEMOTHERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA IN A 2ND REMISSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LYMPHOCYTIC-LEUKEMIA; PEDIATRIC-ONCOLOGY-GROUP; TOTAL-BODY IRRADIATION; 2ND REMISSION; COMBINATION CHEMOTHERAPY; CYTOSINE-ARABINOSIDE; RELAPSE; THERAPY; 1ST	Background. It is unclear how best to treat children with acute lymphoblastic leukemia who are in a second remission after a bone marrow relapse. For those with HLA-identical siblings, the question of whether to perform a bone marrow transplantation or to continue chemotherapy has not been answered. Methods. We compared the results of treatment with marrow transplants from HLA-identical siblings in 376 children, as reported to the International Bone Marrow Transplant Registry, with the results of chemotherapy in 540 children treated by the Pediatric Oncology Group. A preliminary analysis identified variables associated with treatment failure in both groups. We selected cohorts by matching these variables. A possible bias associated with differences in the interval between remission and treatment was controlled for by choosing matched pairs in which the duration of the second remission in the chemotherapy recipient was at least as long as the time between the second remission and transplantation in the transplant recipient. A total of 255 matched pairs were studied. Results. The mean (+/- SE) probability of a relapse at five years was significantly lower among the transplant recipients than among the chemotherapy recipients (45 +/- 4 percent vs. 80 +/- 3 percent, P < 0.001). At five years the probability of leukemia-free survival was higher after transplantation than after chemotherapy (40 +/- 3 percent vs. 17 +/- 3 percent, P < 0.001). The relative benefit of transplantation as compared with chemotherapy was similar in children with prognostic factors indicating a high or low risk of relapse (the duration of the first remission, age, leukocyte count at the time of the diagnosis, and phenotype of the leukemic cells). Conclusions. For children with acute lymphoblastic leukemia in a second remission, bone marrow transplants from HLA-identical siblings result in fewer relapses and longer leukemia-free survival than does chemotherapy.	MED COLL WISCONSIN, INT BONE MARROW TRANSPLANT REGISTRY, INST HLTH POLICY, MILWAUKEE, WI 53226 USA; NHLBI, BETHESDA, MD USA; MED COLL WISCONSIN, DEPT PEDIAT, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT BIOSTAT, MILWAUKEE, WI USA; UNIV FLORIDA, PEDIAT ONCOL GRP, STAT OFF, GAINESVILLE, FL USA; UNIV FLORIDA, COLL MED, GAINESVILLE, FL USA; UNIV TEXAS, SW MED CTR, DALLAS, TX USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN USA; CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH USA; SALICK HLTH CARE, LOS ANGELES, CA USA	Medical College of Wisconsin; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Medical College of Wisconsin; Medical College of Wisconsin; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; St Jude Children's Research Hospital; Case Western Reserve University			Shuster, Jonathan/ABB-5773-2021; horowitz, Mary/ABH-2173-2021	Shuster, Jonathan/0000-0001-9499-5616; 	NATIONAL CANCER INSTITUTE [U10CA033625, U10CA029139, P01CA040053] Funding Source: NIH RePORTER; NCI NIH HHS [U10-CA-29139, P01-CA-40053, CA-33625] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMADORI S, 1981, SCAND J HAEMATOL, V26, P292; ANDERSEN PK, 1993, STATISTICAL MODELS B, P386; BARRETT AJ, 1989, BLOOD, V74, P862; BARRETT AJ, 1986, BRIT J HAEMATOL, V64, P179, DOI 10.1111/j.1365-2141.1986.tb07585.x; BARRETT AJ, 1992, BONE MARROW TRANSPL, P33; BAUM E, 1983, MED PEDIATR ONCOL, V11, P1, DOI 10.1002/mpo.2950110102; BEGG CB, 1984, J CLIN ONCOL, V2, P369, DOI 10.1200/JCO.1984.2.5.369; BROCHSTEIN JA, 1987, NEW ENGL J MED, V317, P1618, DOI 10.1056/NEJM198712243172602; BUCHANAN GR, 1988, BLOOD, V72, P1286; BUCHANAN GR, 1986, BLOOD S, V68, pA219; BUTTURINI A, 1987, LANCET, V1, P429; CHAMPLIN R, 1989, BLOOD, V73, P2051; CHESSELLS JM, 1979, MED PEDIATR ONCOL, V6, P359, DOI 10.1002/mpo.2950060413; CHESSELLS JM, 1986, LANCET, V1, P1239; CHESSELLS JM, 1992, BLOOD REV, V6, P193, DOI 10.1016/0268-960X(92)90015-I; COCCIA PF, 1988, BLOOD, V71, P888; COX DR, 1972, J R STAT SOC B, V34, P187; DARBYSHIRE PJ, 1990, LANCET, V335, P733, DOI 10.1016/0140-6736(90)90853-W; DOPFER R, 1991, BLOOD, V78, P2780; EKERT H, 1979, MED J AUSTRALIA, V2, P224, DOI 10.5694/j.1326-5377.1979.tb127098.x; HARRIS R, 1987, PROGR BONE MARROW TR, P91; HENZE G, 1991, BLOOD, V78, P1166; HERZIG RH, 1987, LANCET, V1, P786; HOROWITZ MM, 1991, ANN INTERN MED, V115, P13, DOI 10.7326/0003-4819-115-1-13; HOROWITZ MM, 1992, BONE MARROW TRANSPL, P367; JOHNSON FL, 1981, NEW ENGL J MED, V305, P846, DOI 10.1056/NEJM198110083051502; KIMBALL JC, 1980, CANCER, V45, P1093; PINKEL D, 1989, LEUKEMIA, V3, P242; POYNTON CH, 1986, LANCET, V2, P395; RAMSAY NKC, 1990, BLOOD, V75, P815; RIVERA G, 1978, CANCER, V42, P2521, DOI 10.1002/1097-0142(197812)42:6<2521::AID-CNCR2820420603>3.0.CO;2-4; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; SADOWITZ PD, 1993, BLOOD, V81, P602; SANDERS JE, 1987, BLOOD, V70, P324; WINGARD JR, 1990, J CLIN ONCOL, V8, P820, DOI 10.1200/JCO.1990.8.5.820	35	202	208	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1253	1258		10.1056/NEJM199411103311902	http://dx.doi.org/10.1056/NEJM199411103311902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP752	7935682	Bronze			2022-12-28	WOS:A1994PP75200002
J	LEWIN, B				LEWIN, B			CHROMATIN AND GENE-EXPRESSION - CONSTANT QUESTIONS, BUT CHANGING ANSWERS	CELL			English	Review							DROSOPHILA-MELANOGASTER; DNA-REPLICATION; PROTEIN; YEAST; TRANSCRIPTION; REPRESSION; ACTIVATOR; REGULATOR; ENHANCER; DOMAINS											CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; HARRISON DA, 1993, GENE DEV, V7, P1966, DOI 10.1101/gad.7.10.1966; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MORETTI P, 1994, IN PRESS GENES DEV; ONEILL TE, 1993, P NATL ACAD SCI USA, V90, P6203, DOI 10.1073/pnas.90.13.6203; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THOMPSON JS, 1994, COLD SPRING HARB SYM, V58, P247; TRUSS M, 1994, IN PRESS EMBO J; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0	28	117	118	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					397	406		10.1016/0092-8674(94)90249-6	http://dx.doi.org/10.1016/0092-8674(94)90249-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954807				2022-12-28	WOS:A1994PQ48800003
J	NOLAN, JJ; LUDVIK, B; BEERDSEN, P; JOYCE, M; OLEFSKY, J				NOLAN, JJ; LUDVIK, B; BEERDSEN, P; JOYCE, M; OLEFSKY, J			IMPROVEMENT IN GLUCOSE-TOLERANCE AND INSULIN-RESISTANCE IN OBESE SUBJECTS TREATED WITH TROGLITAZONE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; ANTIDIABETIC AGENT CS-045; PIMA-INDIANS; RISK-FACTORS; SENSITIVITY; PARENTS; DEFECTS; NIDDM	Background. Troglitazone decreases insulin resistance and hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM), but its effects on subjects without diabetes are not known. Methods. We performed oral and intravenous glucose-tolerance tests, studies with the euglycemic-hyperinsulinemic clamp, meal-tolerance tests, acid 24-hour blood-pressure measurements at base line and after the administration of troglitazone, 200 mg orally twice daily, or placebo for 12 weeks in 18 nondiabetic obese subjects, 9 of whom had impaired glucose tolerance. Results. The mean (+/-SD) rates of glucose disposal increased from 4.7+/-1.7 to 6.0+/-1.7 mg per kilogram of body weight per minute (P = 0.004) and from 9.0+/-1.8 to 9.9+/-1.3 mg per kilogram per minute (P = 0.02) during insulin infusions of 40 and 300 mU per square meter of body-surface area per minute, respectively, in the troglitazone group. The insulin-sensitivity index, calculated from the results of intravenous glucose-tolerance tests, increased from 0.7+/-0.6 x 10(-4) to 1.6+/-0.9 x 10(-4) in subjects given troglitazone, and their glycemic response to oral glucose and to mixed meals decreased. The mean fasting plasma insulin concentration decreased by 48 percent (P = 0.002), and the plasma insulin response to oral glucose and mixed meals decreased by 40 and 41 percent, respectively. The changes were similar in the subjects with normal glucose tolerance and those with impaired glucose tolerance. Systolic and diastolic blood pressure decreased by 5+/-2 mm Hg (P = 0.05) and 4+/-2 mm Hg (P = 0.04), respectively, after treatment with troglitazone. There were virtually no changes in the placebo group. Conclusions. Troglitazone decreases insulin resistance and improves glucose tolerance in obese subjects with either impaired or normal glucose tolerance. The ability of troglitazone to reduce insulin resistance could be useful in preventing NIDDM.	UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET AFFAIRS MED CTR,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00827] Funding Source: Medline; NIDDK NIH HHS [DK 33651] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGMAN RN, 1987, J CLIN INVEST, V79, P790, DOI 10.1172/JCI112886; CIARALDI TP, 1990, METABOLISM, V39, P1056, DOI 10.1016/0026-0495(90)90166-A; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FINEGOOD DT, 1987, DIABETES, V36, P914, DOI 10.2337/diabetes.36.8.914; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; Goldman R., 1961, TECHNIQUES MEASURING, P78; HAFFNER SM, 1990, DIABETES, V39, P283, DOI 10.2337/diabetes.39.3.283; HO LT, 1990, DIABETIC MED, V7, P31, DOI 10.1111/j.1464-5491.1990.tb01303.x; IWAMOTO Y, 1991, DIABETES CARE, V14, P1083, DOI 10.2337/diacare.14.11.1083; KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; KEEN H, 1982, DIABETOLOGIA, V22, P73, DOI 10.1007/BF00254832; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; KOLTERMAN OG, 1981, J CLIN INVEST, V68, P957, DOI 10.1172/JCI110350; KOSAKA K, 1977, DIABETES, V26, P944, DOI 10.2337/diab.26.10.944; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WELCH S, 1990, J CLIN ENDOCR METAB, V71, P1508, DOI 10.1210/jcem-71-6-1508; 1985, WHO TECH REP SER, V727, P9	21	849	872	1	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1188	1193		10.1056/NEJM199411033311803	http://dx.doi.org/10.1056/NEJM199411033311803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935656				2022-12-28	WOS:A1994PN80600003
J	AYANIAN, JZ; HAUPTMAN, PJ; GUADAGNOLI, E; ANTMAN, EM; PASHOS, CL; MCNEIL, BJ				AYANIAN, JZ; HAUPTMAN, PJ; GUADAGNOLI, E; ANTMAN, EM; PASHOS, CL; MCNEIL, BJ			KNOWLEDGE AND PRACTICES OF GENERALIST AND SPECIALIST PHYSICIANS REGARDING DRUG-THERAPY FOR ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIALS; HEALTH-CARE REFORM; UNSTABLE ANGINA; MANAGEMENT; INFORMATION; SERVICES; DISSEMINATION; GUIDELINES; LIDOCAINE; PATTERNS	Background. The respective roles of generalist and specialist physicians in the care of patients are currently a matter of debate. Information is limited about the knowledge and practices of generalist and specialist physicians regarding conditions that both groups treat, such as myocardial infarction. Methods. We therefore surveyed 1211 cardiologists, internists, and family practitioners in the states of New York and Texas about four treatments demonstrated by randomized clinical trials to be associated with improved survival after myocardial infarction (thrombolytic therapy, immediate and long-term use of aspirin, and long-term use of beta-blockers) and two treatments for which such evidence is lacking (diltiazem for patients with pulmonary congestion and prophylactic lidocaine). We asked physicians about the effect of each treatment on survival and the likelihood that they would prescribe each class of drugs. Results. For the four beneficial treatments, the cardiologists believed more strongly than the internists and family physicians that survival was improved by the treatment, and they were more likely to prescribe these drugs (P<0.001). For example, 94.1 percent of cardiologists said they were very likely to prescribe thrombolytic agents to treat an acute myocardial infarction, as compared with 82.0 percent of internists and 77.3 percent of family practitioners. Conversely, for the two treatments for which trials showed no evidence of a survival benefit, cardiologists were less likely than internists and family practitioners to think there was such a benefit and less likely to prescribe the drugs (P<0.001). For example, 4.7 percent of cardiologists reported that they were very likely to use prophylactic lidocaine, as compared with 13.1 percent of internists, and 16.5 percent of family practitioners. When we used logistic regression to adjust for potential confounders, all the differences between the cardiologists and the internists and family practitioners remained significant (P<0.02). Conclusions. Internists and family practitioners are less aware of or less certain about key advances in the treatment of myocardial infarction than are cardiologists. This finding underscores the need to improve the dissemination of information from clinical trials to generalist physicians, particularly if they are to have an enlarged role in the evolving health care system.	BRIGHAM & WOMENS HOSP, DIV GEN MED, HLTH SERV & POLICY RES SECT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	AYANIAN, JZ (corresponding author), HARVARD UNIV, SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST, PARCEL B, 1ST FL, BOSTON, MA 02115 USA.				AHRQ HHS [HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY LA, 1989, DESIGNING CONDUCTING, P121; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1988, BRIT MED J, V296, P320; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BEHAR S, 1988, EUR HEART J, V9, P354; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; COHEN JJ, 1993, NEW ENGL J MED, V329, P1810, DOI 10.1056/NEJM199312093292412; ELKHATIB A, 1993, CIRCULATION, V88, P608; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P1449, DOI 10.1001/jama.270.12.1449; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GRAVES EJ, 1993, DHHS PHS931250 NAT C; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; Gunnar R M, 1990, Circulation, V82, P664; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; HANSEN JF, 1984, EUR HEART J, V5, P516; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HLATKY MA, 1988, AM J CARDIOL, V61, P510, DOI 10.1016/0002-9149(88)90755-2; HLATKY MA, 1988, AM J CARDIOL, V61, P515, DOI 10.1016/0002-9149(88)90756-4; HUTCHISON SJ, 1987, BRIT MED J, V294, P1261, DOI 10.1136/bmj.294.6582.1261; KIMBALL HR, 1994, JAMA-J AM MED ASSOC, V271, P315, DOI 10.1001/jama.271.4.315; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MITCHELL JRA, 1982, BRIT MED J, V285, P1140, DOI 10.1136/bmj.285.6349.1140; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; NAYLOR CD, 1990, CAN MED ASSOC J, V142, P1069; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136; STINSON ER, 1980, JAMA-J AM MED ASSOC, V243, P140, DOI 10.1001/jama.243.2.140; STROSS JK, 1979, JAMA-J AM MED ASSOC, V241, P2622, DOI 10.1001/jama.241.24.2622; STROSS JK, 1981, JAMA-J AM MED ASSOC, V246, P360, DOI 10.1001/jama.246.4.360; THOMPSON PL, 1992, MED J AUSTRALIA, V157, P87, DOI 10.5694/j.1326-5377.1992.tb137032.x; TOGNONI G, 1990, STAT MED, V9, P17, DOI 10.1002/sim.4780090108; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; YOUNG MJ, 1987, HEALTH SERV RES, V22, P623; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1993, PHYSICIAN CHARACTERI; 1990, SAS STAT USERS GUIDE; 1991, DHHS PHS911232 NAT C; 1993, STATISTICAL ABSTRACT, P33	49	340	340	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1136	1142		10.1056/NEJM199410273311707	http://dx.doi.org/10.1056/NEJM199410273311707			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7935639				2022-12-28	WOS:A1994PN06500007
J	SHELDON, TA; SMITH, P; BOROWITZ, M; MARTIN, S; HILL, RC				SHELDON, TA; SMITH, P; BOROWITZ, M; MARTIN, S; HILL, RC			ATTEMPT AT DERIVING A FORMULA FOR SETTING GENERAL-PRACTITIONER FUNDHOLDING BUDGETS	BRITISH MEDICAL JOURNAL			English	Article							REFORMS	Objective-To explore the possibility of using routine Hospital Episode Statistics, census data, and vital statistics to derive weights for an equitable capitation formula for setting general practitioner fundholding budgets for buying acute hospital services. Design-Analysis of a routine dataset of 9 million hospital episodes-in 1991-2, extracting elective general practitioner fundholding procedures, combined with 1991 census variables, vital statistics, and data on supply of health care at ward level. Costs were attached to each procedure according to the average cost of the relevant ''Mersey'' band category. Main outcome measures-Variation in age and sex adjusted expenditure per head on fundholding procedures across wards modelled for the impact of health and social needs variables after adjusting for variations in supply. Results-No sensible simple model including determinants of use other than age and sex could be derived. The most parsimonious but statistically acceptable model showed that though standardised mortality ratio and self reported illness and several social class variables were associated with utilisation, the signs and the size of the coefficients were contradictory. The most important explanation of variation was provided by age and sex differences between wards. Conclusions-An equitable system of setting general practitioner fundholders' budgets is needed. In the short term age and sex weighted capitation should form the principal basis of fundholder budgets. Utilisation data at ward level are inadequate for developing a formula which adequately adjusts for the differences in the health care needs of populations. A capitation formula based on information derived from individual cohort data may be the only means of promoting equity and efficiency and of avoiding discriminating against patients with known high cost health problems.	UNIV YORK,DEPT ECON & RELATED STUDIES,YORK YO1 5DD,N YORKSHIRE,ENGLAND; BATTELLE MED RES & POLICY CTR,LONDON WC1,ENGLAND; UNIV YORK,SOCIAL SCI RES INST,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK; University of York - UK; University of York - UK	SHELDON, TA (corresponding author), UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Sheldon, Trevor/AAK-7088-2021	Sheldon, Trevor/0000-0002-7479-5913; Smith, Peter/0000-0003-0058-7588				CARRHILL RA, IN PRESS BMJ; COULTER A, 1992, BRIT MED J, V304, P397, DOI 10.1136/bmj.304.6824.397; DIXON J, 1994, BRIT MED J, V308, P772, DOI 10.1136/bmj.308.6931.772; DIXON J, 1994, BRIT MED J, V309, P30, DOI 10.1136/bmj.309.6946.30; Epstein A M, 1988, Health Care Financ Rev, V10, P51; Garfinkel S A, 1988, Health Care Financ Rev, V9, P41; GLENNERSTER H, 1993, HEALTH POLICY, V23, P179, DOI 10.1016/0168-8510(93)90056-U; Godfrey L. G., 1988, MISSPECIFICATION TES; HILL RC, 1994, FORMULA DISTRIBUTING; LERNER C, 1994, 116 CTR HLTH EC DISC; MADDALA G, 1987, ECONOMETRICS; MATSAGANIS M, 1994, J HEALTH ECON, V13, P31, DOI 10.1016/0167-6296(94)90003-5; MAYS N, 1987, 81 SOC ADM OCC PAP; Newhouse J P, 1986, Health Care Financ Rev, P45; PAYNE N, 1994, J EPIDEMIOL COMMUNIT, V48, P74; ROLAND M, 1992, HOSP REFERRALS, P62; SCHEFFLER R, 1989, LANCET, V1, P950; SMITH P, IN PRESS BMJ; Thomas J W, 1986, Health Care Financ Rev, V7, P85; van Vliet R C, 1993, Health Econ, V2, P177, DOI 10.1002/hec.4730020210; VANDEVEN WPM, 1992, HLTH EC WORLDWIDE, P23; VANVLIET RCJA, 1992, SOC SCI MED, V34, P1035, DOI 10.1016/0277-9536(92)90134-C; WILKIN D, 1992, HOSPITAL REFERRALS, P76; Wilson AG., 1974, URBAN REGIONAL MODEL; 1993, PRACTICE MAKES PERFE; 1993, GP FUNDHOLDER BUDGET; 1989, WORKING PATIENTS	27	47	48	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1059	1064		10.1136/bmj.309.6961.1059	http://dx.doi.org/10.1136/bmj.309.6961.1059			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN733	7950741	Green Published			2022-12-28	WOS:A1994PN73300025
J	CHEN, ZW; KOH, M; VANDRIESSCHE, G; VANBEEUMEN, JJ; BARTSCH, RG; MEYER, TE; CUSANOVICH, MA; MATHEWS, FS				CHEN, ZW; KOH, M; VANDRIESSCHE, G; VANBEEUMEN, JJ; BARTSCH, RG; MEYER, TE; CUSANOVICH, MA; MATHEWS, FS			THE STRUCTURE OF FLAVOCYTOCHROME-C SULFIDE DEHYDROGENASE FROM A PURPLE PHOTOTROPHIC BACTERIUM	SCIENCE			English	Article							CHROMATIUM-VINOSUM; SEQUENCE; FLAVIN; FLAVOPROTEIN; KINETICS; SUBUNIT	The structure of the heterodimeric flavocytochrome c sulfide dehydrogenase from Chromatium vinosum was determined at a resolution of 2.53 angstroms. It contains a glutathione reductase-like flavin-binding subunit and a diheme cytochrome subunit. The diheme cytochrome folds as two domains, each resembling mitochondrial cytochrome c, and has an unusual interpropionic acid linkage joining the two heme groups in the interior of the subunit. The active site of the flavoprotein subunit contains a catalytically important disulfide bridge located above the pyrimidine portion of the flavin ring. A tryptophan, threonine, or tyrosine side chain may provide a partial conduit for electron transfer to one of the heme groups located 10 angstroms from the flavin.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; STATE UNIV GHENT,DEPT BIOCHEM PHYSIOL & MICROBIOL,B-9000 GHENT,BELGIUM; UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721	Washington University (WUSTL); Ghent University; University of Arizona					NIGMS NIH HHS [GM-21277, GM-20530] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021277] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cusanovich M, 1991, CHEM BIOCH FLAVOENZY, V2, P377; CUSANOVICH MA, 1985, BIOCHEMISTRY-US, V24, P1281, DOI 10.1021/bi00327a002; DOLATA MM, 1993, J BIOL CHEM, V268, P14426; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; KENNEY WC, 1974, EUR J BIOCHEM, V48, P449, DOI 10.1111/j.1432-1033.1974.tb03785.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MATHEWS FS, 1990, BIOCHEMISTRY-US, V31, P238; MEYER TE, 1991, BIOCHEMISTRY-US, V30, P8840, DOI 10.1021/bi00100a016; MEYER TE, 1991, ARCH BIOCHEM BIOPHYS, V287, P128, DOI 10.1016/0003-9861(91)90397-2; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; REGAN J, 1993, PATHWAYS, V2; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SALEMME FR, 1982, J MOL BIOL, V159, P551, DOI 10.1016/0022-2836(82)90302-3; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; VANBEEUMAN JJ, UNPUB; VANBEEUMEN JJ, 1991, J BIOL CHEM, V266, P12921; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	19	126	133	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					430	432		10.1126/science.7939681	http://dx.doi.org/10.1126/science.7939681			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939681				2022-12-28	WOS:A1994PN27200033
J	DOLLERY, CM; SULLIVAN, ID; BAURAIND, O; BULL, C; MILLA, PJ				DOLLERY, CM; SULLIVAN, ID; BAURAIND, O; BULL, C; MILLA, PJ			THROMBOSIS AND EMBOLISM IN LONG-TERM CENTRAL VENOUS ACCESS FOR PARENTERAL-NUTRITION	LANCET			English	Article							CATHETER; COMPLICATIONS; CHILDREN	Although the use of silicone catheters for long-term central venous access is widespread, little is known about the incidence of pulmonary thromboembolic complications. We studied clinical events, lung perfusion scans, and echocardiographic screens in 34 children and adolescents with gut failure who had received cyclical parenteral nutrition for 2 months to 9 years. Major thrombosis and/or embolism was identified in 12 patients and 4 died as a consequence. Actuarial survival free from thrombosis was 53% at 5 years (95% Cl, 30-77%). Survival free from fatal pulmonary thromboembolic events was 74% at 5 years (48-99%). 3 patients required surgery to remove right atrial thrombus or pulmonary emboli. Major right atrial thrombosis and pulmonary embolism are common and potentially fatal complications of parenteral nutrition by long-term venous access in childhood. Anticoagulation is recommended.	HOSP SICK CHILDREN,CARDIOTHORAC UNIT,LONDON WC1N 3JH,ENGLAND; HOSP SICK CHILDREN,GASTROENTEROL UNIT,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust								BISSET WM, 1992, ARCH DIS CHILD, V67, P109, DOI 10.1136/adc.67.1.109; BRISMAR B, 1982, ARCH SURG-CHICAGO, V117, P1196; EMERY JL, 1961, SURGERY, V50, P309; LEIBY JM, 1989, AM J MED, V86, P228, DOI 10.1016/0002-9343(89)90276-3; MOUKARZEL A, 1991, JPEN-PARENTER ENTER, V15, P551, DOI 10.1177/0148607191015005551; MUGHAL MM, 1989, BRIT J SURG, V76, P15, DOI 10.1002/bjs.1800760107; RYAN JA, 1974, NEW ENGL J MED, V290, P757, DOI 10.1056/NEJM197404042901401; SCHMIDTSOMMERFELD E, 1990, JPEN-PARENTER ENTER, V14, P148, DOI 10.1177/0148607190014002148; SHIBA E, 1992, EUR J SURG, V158, P59	9	120	120	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1043	1045		10.1016/S0140-6736(94)91707-8	http://dx.doi.org/10.1016/S0140-6736(94)91707-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934444				2022-12-28	WOS:A1994PL85200007
J	LITTLE, PS; WILLIAMSON, I				LITTLE, PS; WILLIAMSON, I			CONTROVERSIES IN MANAGEMENT - ARE ANTIBIOTICS APPROPRIATE FOR SORE THROATS - COSTS OUTWEIGH THE BENEFITS	BRITISH MEDICAL JOURNAL			English	Article											LITTLE, PS (corresponding author), UNIV SOUTHAMPTON,ALDERMOOR HLTH CTR,DEPT PRIMARY MED CARE,SOUTHAMPTON SO1 6ST,HANTS,ENGLAND.			Little, Paul/0000-0003-3664-1873				BANKS M, 1985, INT J EPIDEMIOL, V4, P189; BOLME P, 1975, SCAND J INFECT DIS, V7, P141, DOI 10.3109/inf.1975.7.issue-2.11; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; CHAPPLE PAL, 1956, BMJ-BRIT MED J, V1, P705, DOI 10.1136/bmj.1.4969.705; CHARNEY E, 1967, PEDIATRICS, V40, P188; DELMAR C, 1992, MED J AUSTRALIA, V156, P572, DOI 10.5694/j.1326-5377.1992.tb121422.x; DELMAR C, 1992, MED J AUSTRALIA, V156, P644, DOI 10.5694/j.1326-5377.1992.tb121463.x; HERZ MJ, 1988, FAM PRACT, V5, P196, DOI 10.1093/fampra/5.3.196; HODGKIN K, 1978, EARLIER DIAGNOSIS PR; Hoigne R., 1992, P600; HOWIE J, 1980, BRIT MED J, V1, P836; HOWIE JGR, 1985, J ROY COLL GEN PRACT, V35, P223; HOWIE JGR, 1976, BRIT MED J, V2, P1061, DOI 10.1136/bmj.2.6043.1061; Madden T A, 1977, J R Coll Gen Pract, V27, P73; PITTS J, 1987, PRACTITIONER, V231, P1232; TAYLOR B, 1977, BRIT MED J, V2, P553; TAYLOR JL, 1983, J ROY COLL GEN PRACT, V33, P783; WHITE P, 1953, JAMA-J AM MED ASSOC, V33, P783; WHITFIELD MJ, 1981, PRACTITIONER, V225, P234	19	42	45	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					1010	1011		10.1136/bmj.309.6960.1010	http://dx.doi.org/10.1136/bmj.309.6960.1010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950695	Green Published			2022-12-28	WOS:A1994PM41700032
J	MATTE, TD; PROOPS, D; PALAZUELOS, E; GRAEF, J; AVILA, MH				MATTE, TD; PROOPS, D; PALAZUELOS, E; GRAEF, J; AVILA, MH			ACUTE HIGH-DOSE LEAD-EXPOSURE FROM BEVERAGE CONTAMINATED BY TRADITIONAL MEXICAN POTTERY	LANCET			English	Article								Screening and follow-up blood lead measurements in a 7-year-old child of a US Embassy official in Mexico City revealed an increase in blood lead concentration from 1.10 to 4.60 mu mol/L in less than 4 weeks. The cause was traced to fruit punch contaminated with lead leached from traditional ceramic pottery urns. Consumption of the contaminated punch at a picnic was associated with a 20% increase in blood lead concentrations among embassy staff and dependants who were tested 6 weeks after the exposure. This episode highlights the continued health risk, even from brief exposure, posed by traditional pottery in Mexico.	CTR DIS CONTROL & PREVENT,LEAD POISONING PREVENT BRANCH,ATLANTA,GA 30341; US DEPT STATE,WASHINGTON,DC 20520; HOSP ABC,MEXICO CITY,DF,MEXICO; CHILDRENS HOSP,BOSTON,MA 02115; INST NACL SALUD PUBL,CUERNAVACA,MORELOS,MEXICO	Centers for Disease Control & Prevention - USA; Harvard University; Boston Children's Hospital; Instituto Nacional de Salud Publica								AVILA MH, 1991, ENVIRON HEALTH PERSP, V94, P117, DOI 10.2307/3431303; HARRIS JW, 1967, JAMA-J AM MED ASSOC, V202, P544; MERANGER JC, 1973, CAN J PUBLIC HEALTH, V64, P472; RABINOWITZ MB, 1976, J CLIN INVEST, V58, P260, DOI 10.1172/JCI108467; SPIELHOLTZ GI, 1980, TALANTA, V27, P997, DOI 10.1016/0039-9140(80)80134-2	5	28	28	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1064	1065		10.1016/S0140-6736(94)91715-9	http://dx.doi.org/10.1016/S0140-6736(94)91715-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934450				2022-12-28	WOS:A1994PL85200015
J	HASTINGS, GB; RYAN, H; TEER, P; MACKINTOSH, AM				HASTINGS, GB; RYAN, H; TEER, P; MACKINTOSH, AM			CIGARETTE ADVERTISING AND CHILDRENS SMOKING - WHY REG WAS WITHDRAWN	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the appeal of the Embassy Regal ''Reg'' campaign to young people. Design-Three quantitative surveys and one piece of qualitative research: (a) self completion questionnaire administered in classrooms, (b) questionnaire led interviews with children, (c) questionnaire led interviews with adults, and (d) group discussions with children and adults. Settings-(a) Secondary and middle schools in England; (b) north of England, Scotland, and Wales; (c) north of England, Scotland, and Wales; and (d) Glasgow. Subjects-(a) 5451 schoolchildren aged 11-15 recruited by stratified random sampling; (b) 437 children aged 5-10 recruited by quota sampling; (c) 814 adults aged 15-65 recruited by quota sampling; and (d) 12 groups of children aged 10-15, three groups of adults aged 18-24, and three groups of adults aged 35-55. Results-Children were familiar with cigarette advertising and in particular the Reg campaign. Although younger children struggled to understand the creative content of the adverts, older and smoking children could understand and appreciate the humour. They considered Reg to be amusing and could relate to the type of joke used in the advert. In addition Reg's flippant attitude towards serious issues appealed to the children. While adults aged 18-24 understood the campaign they did not identify with it, and 35-55 year olds (the campaign's supposed target) were unappreciative of the campaign. Conclusions-The Reg campaign was getting through to children more effectively than it was to adults and held most appeal for teenagers, particularly 14-15 year old smokers. It clearly contravened the code governing tobacco advertising, which states that advertising must not appeal to children more than it does to adults, and it may have had a direct impact on teenage smoking. In view of these findings the Advertising Standards Authority's decision to withdraw the Reg campaign seems appropriate.	HLTH EDUC AUTHOR,LONDON WC1H 9TX,ENGLAND		HASTINGS, GB (corresponding author), UNIV STRATHCLYDE,CTR SOCIAL MKT,GLASGOW G4 0RQ,LANARK,SCOTLAND.							CHANNON C, 1985, ADVERTISING WORKS 3; HASTINGS GB, 1987, BRIT MED J, V294, P48, DOI 10.1136/bmj.294.6563.48; King S., 1991, J MARKETING MANAGEME, V8, P43, DOI DOI 10.1080/0267257X.1991.9964136; SMEE C, 1993, EUROPEAN COMMISSIONS; 1992, VOLUNTARY AGREEMENT	5	36	36	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 8	1994	309	6959					933	937		10.1136/bmj.309.6959.933	http://dx.doi.org/10.1136/bmj.309.6959.933			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PL781	7950668	Green Published			2022-12-28	WOS:A1994PL78100026
J	HABRAKEN, Y; SUNG, P; PRAKASH, L; PRAKASH, S				HABRAKEN, Y; SUNG, P; PRAKASH, L; PRAKASH, S			HOLIDAY JUNCTION CLEAVAGE BY YEAST RAD1 PROTEIN	NATURE			English	Article							DNA-REPAIR; ESCHERICHIA-COLI; HOLLIDAY JUNCTIONS; ENDONUCLEASE; RESOLUTION	IN Saccharomyces cerevisiae, of the many genes required for excision repair of ultraviolet-damaged DNA, only RAD1 and RAD10 also function in genetic recombination(1). Complex formation between the RAD1 and RAD10 gene products(1) activates an endonucleolytic function that nicks single-stranded DNA(2,3) and negatively supercoiled double-stranded DNA(2). To characterize the recombination role of the proteins Rad1 and Rad10, we have investigated their interaction with the Holliday junction, a four-stranded structure that results from single-stranded crossover between two duplex DNA molecules and whose resolution is obligatory for the generation of mature recombinants. We show that Rad1 binds specifically to a Holliday junction and, in the presence of magnesium, catalyses the endonucleolytic cleavage of the junction. Junction cleavage by Rad1 proceeds sufficiently without Rad10, thus identifying Rad1 as the catalytic subunit of Rad1/Rad10 endonuclease.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444				BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; Egel R., 1989, MOL BIOL FISSION YEA, P31; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; RODEL C, 1992, NUCLEIC ACIDS RES, V20, P6347, DOI 10.1093/nar/20.23.6347; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; TAYLOR AF, 1992, CELL, V69, P1063, DOI 10.1016/0092-8674(92)90626-N; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757	13	41	42	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					531	534		10.1038/371531a0	http://dx.doi.org/10.1038/371531a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935767				2022-12-28	WOS:A1994PK58900060
J	JONES, G; NGUYEN, T; SAMBROOK, P; KELLY, PJ; EISMAN, JA				JONES, G; NGUYEN, T; SAMBROOK, P; KELLY, PJ; EISMAN, JA			PROGRESSIVE LOSS OF BONE IN THE FEMORAL-NECK IN ELDERLY PEOPLE - LONGITUDINAL FINDINGS FROM THE DUBBO OSTEOPOROSIS EPIDEMIOLOGY STUDY	BRITISH MEDICAL JOURNAL			English	Article							MINERAL DENSITY; POSTMENOPAUSAL WOMEN; CIGARETTE-SMOKING; DIETARY-INTAKE; AGE; MEN; CALCIUM; SPINE; MASS; FRACTURES	Objectives-To determine prospectively the rates of change in bone mineral density in elderly people and to examine the relation between lifestyle and demographic factors and these rates of change. Design-Longitudinal population based study. Setting-Dubbo, New South Wales, Australia. Subjects-Representative sample (n = 769) of residents aged greater than or equal to 60 on 1 January 1989. Main outcome measure-Rates of change in bone mineral density measured prospectively (mean scan interval 2.5 years) at the femoral neck and lumbar spine by dual energy x ray absorptiometry. Results-Summary rates of loss in the femoral neck were 0.96% per year (95% confidence interval 0.64% to 1.28%) in women and 0.82% per year (0.52% to 1.12%) in men. Importantly, rates of loss at the femoral neck (both percentage and absolute) increased in both sexes with advancing age. No significant loss was evident in either sex at the lumbar spine, probably because of coexistent osteoarthritis. Lifestyle factors had only modest effects on rates of loss at either site. Conclusions-These data show that bone density of the femoral neck declines at an increasing rate in elderly people, and as this site is predictive of fracture suggest that treatment to minimise bone loss may be important even in very elderly people.	ST VINCENTS HOSP,GARVAN INST MED RES,DIV BONE & MINERAL,DARLINGHURST,NSW 2010,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			Nguyen, Tuan V/B-6147-2008; Nguyen, Tuan V./AAD-9503-2020; Eisman, John A/C-2886-2014	Nguyen, Tuan V/0000-0002-3246-6281; Nguyen, Tuan V./0000-0002-3246-6281; 				ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; ANGUS RM, 1988, BONE MINER, V4, P265; BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; CHRISTIANSEN C, 1987, Lancet, V1, P1105; CUMMING RG, 1990, CALCIFIED TISSUE INT, V47, P194; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DAVIS JW, 1989, J BONE MINER RES, V4, P351; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; GOTFREDSEN A, 1987, J LAB CLIN MED, V110, P362; HANNAN MT, 1992, J BONE MINER RES, V7, P547; HEANEY RP, 1986, BONE MINER, V1, P99; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; HUI SL, 1982, J CHRON DIS, V35, P715, DOI 10.1016/0021-9681(82)90095-9; JONES G, 1994, OSTEOPOROSIS INT, V4, P273; KELLY PJ, 1993, J BONE MINER RES, V8, P11; KRALL EA, 1991, J BONE MINER RES, V6, P331; KROLNER B, 1982, CLIN SCI, V62, P329, DOI 10.1042/cs0620329; LORD SR, 1991, J GERONTOL, V46, pM57; MASAUD T, 1993, BRIT MED J, V307, P172; MAZESS RB, 1987, BONE MINER, V2, P211; MAZESS RB, 1990, J BONE MINER RES, V5, P645; MAZESS RB, 1991, AM J CLIN NUTR, V53, P132, DOI 10.1093/ajcn/53.1.132; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; Myers R., 1990, CLASSICAL MODERN REG; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; NGUYEN T, 1994, IN PRESS J BONE MINE; ORWOLL ES, 1990, J CLIN ENDOCR METAB, V70, P1202, DOI 10.1210/jcem-70-4-1202; POCOCK NA, 1989, BONE, V10, P329, DOI 10.1016/8756-3282(89)90128-2; RIGGS BL, 1981, J CLIN INVEST, V67, P328, DOI 10.1172/JCI110039; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404; SAMBROOK PN, 1987, J BONE MINER RES, V2, P109; SIMONS LA, 1990, AUST NZ J MED, V20, P783, DOI 10.1111/j.1445-5994.1990.tb00423.x; SLEMENDA CW, 1992, ANN INTERN MED, V117, P286, DOI 10.7326/0003-4819-117-4-286; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; STEIGER P, 1992, J BONE MINER RES, V7, P625; VANHEMERT AM, 1990, J CLIN EPIDEMIOL, V43, P579, DOI 10.1016/0895-4356(90)90162-I; 1990, SAS USERS GUIDES STA	39	358	366	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					691	695		10.1136/bmj.309.6956.691	http://dx.doi.org/10.1136/bmj.309.6956.691			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950520	Green Published			2022-12-28	WOS:A1994PH40700013
J	BREWIN, T				BREWIN, T			PRIMUM NON NOCERE	LANCET			English	Editorial Material																		BREWIN TB, 1993, LANCET, V341, P161, DOI 10.1016/0140-6736(93)90019-D; Brouillette J N, 1991, J Fla Med Assoc, V78, P527; CHALMERS TC, 1975, MED CLIN N AM, V59, P1035, DOI 10.1016/S0025-7125(16)32001-6; EISDORFER C, 1989, CARING ELDERLY; GIFFORD RW, 1977, JAMA-J AM MED ASSOC, V238, P589; GILLON R, 1985, BRIT MED J, V291, P130, DOI 10.1136/bmj.291.6488.130; GOODYEARSMITH F, 1993, NEW ZEAL MED J, V106, P416; HILL AB, 1963, BMJ-BRIT MED J, P1043, DOI 10.1136/bmj.1.5337.1043; MILLER WT, 1993, SEMIN ROENTGENOL, V28, P291, DOI 10.1016/S0037-198X(05)80088-4; WARNOCK M, 1994, BRIT MED J, V308, P988; 1992, BAILEY LOVES SHORT P	11	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 26	1994	344	8935					1487	1488						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968126				2022-12-28	WOS:A1994PT99500015
J	MILLER, GJ				MILLER, GJ			THE NATIONS HEALTH DEFICIT AND ITS POLITICAL-ECONOMY	LANCET			English	Editorial Material							DIFFERENTIALS; INEQUALITIES; MORTALITY				MILLER, GJ (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,WOLFSON INST PREVENT MED,MRC,LONDON EC1M 6BQ,ENGLAND.							CHINNOCK A, 1984, HUMAN GROWTH DEV; CHURHILL WS, 1970, PEOPLES RIGHTS; FRIEDMAN M, 1978, HUMAN EVENTS    1118, P14; GALBRAITH JK, 1991, AFFLUENT SOC, P44; GEORGE H, 1938, CRIME POVERTY; Goldthorpe John H., 1987, SOCIAL MOBILITY CLAS; Harrison Fred, 1983, POWER LAND; MARMOT MG, 1984, LANCET, V1, P1003; MORRIS JN, 1990, LANCET, V336, P491, DOI 10.1016/0140-6736(90)92026-E; MOSER KA, 1987, BRIT MED J, V294, P86, DOI 10.1136/bmj.294.6564.86; NORTH F, 1993, BRIT MED J, V306, P361, DOI 10.1136/bmj.306.6874.361; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; PLATT SD, 1989, BRIT MED J, V298, P1673, DOI 10.1136/bmj.298.6689.1673; SMITH GD, 1993, BRIT MED J, V307, P1085, DOI 10.1136/bmj.307.6912.1085; Townsend P, 1992, INEQUALITIES HLTH BL; WILKINSON RG, 1989, J SOC POLICY, V18, P307, DOI 10.1017/S0047279400017591; 1977, URBAN WASTELAND	17	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1419	1420		10.1016/S0140-6736(94)90575-4	http://dx.doi.org/10.1016/S0140-6736(94)90575-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PR786	7968081				2022-12-28	WOS:A1994PR78600016
J	PHAROAH, POD				PHAROAH, POD			FAMILY SPACING, BREAST-FEEDING, AND CONTRACEPTION	LANCET			English	Editorial Material							HEALTH				PHAROAH, POD (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; SCHUFTAN C, 1990, FAM PRACT, V7, P329, DOI 10.1093/fampra/7.4.329; WISNER B, 1988, SOC SCI MED, V26, P963, DOI 10.1016/0277-9536(88)90417-0; 1994, CONTRACEPTION, V50, P55; 1994, CONTRACEPTION, V50, P35	5	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1382	1382		10.1016/S0140-6736(94)90565-7	http://dx.doi.org/10.1016/S0140-6736(94)90565-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PR786	7968072				2022-12-28	WOS:A1994PR78600006
J	ELGOYHEN, AB; JOHNSON, DS; BOULTER, J; VETTER, DE; HEINEMANN, S				ELGOYHEN, AB; JOHNSON, DS; BOULTER, J; VETTER, DE; HEINEMANN, S			ALPHA-9 - AN ACETYLCHOLINE-RECEPTOR WITH NOVEL PHARMACOLOGICAL PROPERTIES EXPRESSED IN RAT COCHLEAR HAIR-CELLS	CELL			English	Article							GUINEA-PIG COCHLEA; FUNCTIONAL EXPRESSION; CALCIUM PERMEABILITY; INSITU HYBRIDIZATION; NICOTINIC RECEPTOR; SEQUENCE-ANALYSIS; XENOPUS OOCYTES; GENE FAMILY; SUBUNIT; BRAIN	We report the isolation and funational characterization of a member of the nicotinic acetylcholine receptor subunit gene family, alpha 9. Xenopus oocytes injected with alpha 9 cRNA express a homomeric receptor-channel complex that is activated by acetylcholine. The alpha 9 receptor displays an unusual mixed nicotinic-muscarinic pharmacological profile. The unique properties of the alpha 9 receptor-channel complex closely match those described for the cholinergic receptor present in vertebrate cochlear hair cells. In situ hybridization studies reveal a restricted pattern of alpha 9 gene expression that includes the outer hair cells of the rat cochlea. Our results suggest that the alpha 9 receptor is involved in the cholinergic efferent innervation of cochlear hair cells and thus may modulate the encoding of auditory stimuli.	SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA	Salk Institute			Vetter, Douglas E./O-8150-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011549] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 11549] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; BOULTER J, 1990, J BIOL CHEM, V265, P4472; BOUVET JF, 1988, NEUROSCI RES, V5, P214, DOI 10.1016/0168-0102(88)90050-8; BROWN MC, 1984, J PHYSIOL-LONDON, V354, P625, DOI 10.1113/jphysiol.1984.sp015396; BUONANNO A, 1989, J BIOL CHEM, V264, P7611; CHANG C. C., 1963, ARCH INTERNATL PHARMACODYN THER, V144, P241; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DECKER ER, 1990, J NEUROSCI, V10, P3413; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; EROSTEGUI C, 1994, HEARING RES, V74, P135, DOI 10.1016/0378-5955(94)90182-1; FLOCK A, 1983, HEARING PHYSL BASES, P2; FUCHS PA, 1992, P ROY SOC B-BIOL SCI, V248, P35, DOI 10.1098/rspb.1992.0039; FUCHS PA, 1992, J NEUROSCI, V12, P800; FUXE K, 1989, PSYCHONEUROENDOCRINO, V14, P19, DOI 10.1016/0306-4530(89)90054-1; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; HOUSLEY GD, 1991, P ROY SOC B-BIOL SCI, V244, P161, DOI 10.1098/rspb.1991.0065; KAKEHATA S, 1993, J PHYSIOL-LONDON, V463, P227, DOI 10.1113/jphysiol.1993.sp019592; KLINKE R, 1986, HEARING RES, V22, P235, DOI 10.1016/0378-5955(86)90100-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LENOIR M, 1980, ANAT EMBRYOL, V160, P253, DOI 10.1007/BF00305106; LIBERMAN MC, 1980, HEARING RES, V3, P189, DOI 10.1016/0378-5955(80)90046-5; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LUETJE CW, 1991, J NEUROSCI, V11, P837; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MULLE C, 1992, NEURON, V8, P135, DOI 10.1016/0896-6273(92)90115-T; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; RAJAN R, 1988, BRAIN RES, V459, P241, DOI 10.1016/0006-8993(88)90640-3; RYAN AF, 1991, HEARING RES, V56, P148, DOI 10.1016/0378-5955(91)90164-5; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SEGUELA P, 1993, J NEUROSCI, V13, P596; SHIRLEY SG, 1992, INT REV NEUROBIOL, V33, P1, DOI 10.1016/S0074-7742(08)60690-X; SHIRVAN MH, 1991, P NATL ACAD SCI USA, V88, P4860, DOI 10.1073/pnas.88.11.4860; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; TAYLOR P, 1990, PHARMACOL BASIS THER, P122; Taylor P., 1990, PHARMACOL BASIS THER, P166; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; WITTKOWSKI WH, 1992, ACTA ENDOCRINOL-COP, V126, P285, DOI 10.1530/acta.0.1260285	50	736	754	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					705	715		10.1016/0092-8674(94)90555-X	http://dx.doi.org/10.1016/0092-8674(94)90555-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954834				2022-12-28	WOS:A1994PT48100017
J	HUNTER, T; PINES, J				HUNTER, T; PINES, J			CYCLINS AND CANCER .2. CYCLIN-D AND CDK INHIBITORS COME OF AGE	CELL			English	Review							MATURATION-PROMOTING FACTOR; CELL-CYCLE; DEPENDENT KINASES; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; MAP KINASE; S-PHASE; HEPATOCELLULAR-CARCINOMA; MAMMALIAN FIBROBLASTS; NITROGEN-MUSTARD		WELLCOME CANC RES CTR INST,CAMBRIDGE CB2 1QR,ENGLAND		HUNTER, T (corresponding author), SALK INST BIOL STUDIES,LA JOLLA,CA 92037, USA.			Pines, Jonathon/0000-0002-5227-6004	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BONETTA L, 1994, NATURE, V370, P180, DOI 10.1038/370180a0; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAKSIS JI, 1994, IN PRESS ONCOGENE; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DILEONARDO A, 1994, IN PRESS GENES DEV; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN KL, 1994, IN PRESS GENES DEV; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANNA Z, 1993, ONCOGENE, V8, P1661; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KHATIB ZA, 1993, CANCER RES, V53, P5535; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEACH FS, 1993, CANCER RES, V53, P1986; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI Y, 1994, ONCOGENE, V9, P2261; LI Y, 1994, IN PRESS CANCER RES; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHIELI P, 1994, CANCER RES, V54, P3391; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MORI T, 1994, CANCER RES, V54, P3396; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKAMOTO A, 1994, IN PRESS P NATL ACAD; OSWALD F, 1994, ONCOGENE, V9, P2029; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARRY D, 1994, IN PRESS EMBO J; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHIMKE RT, 1991, COLD SH Q B, V56, P417; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SETO M, 1992, ONCOGENE, V7, P1401; SEWING A, 1994, J CELL SCI, V107, P581; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHERR CJ, 1994, SCIENCE, V263, P1143; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TAM SW, 1994, ONCOGENE, V9, P2663; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; TSURUTA H, 1993, BIOCHEM BIOPH RES CO, V196, P1529, DOI 10.1006/bbrc.1993.2425; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WIMMEL A, 1994, ONCOGENE, V9, P995; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	150	2174	2284	2	112	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					573	582		10.1016/0092-8674(94)90543-6	http://dx.doi.org/10.1016/0092-8674(94)90543-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954824				2022-12-28	WOS:A1994PT48100005
J	TODD, NW				TODD, NW			IMAGES IN CLINICAL MEDICINE - CHOLESTEATOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											TODD, NW (corresponding author), EMORY UNIV,ATLANTA,GA 30322, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1347	1347						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935704				2022-12-28	WOS:A1994PR21600005
J	KAVANAUGH, A				KAVANAUGH, A			DANAZOL THERAPY IN THROMBOCYTOPENIA ASSOCIATED WITH THE ANTIPHOSPHOLIPID ANTIBODY SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Note							SYSTEMIC LUPUS-ERYTHEMATOSUS; AUTOIMMUNE THROMBOCYTOPENIA; ANTICARDIOLIPIN; PURPURA		DALLAS DEPT VET AFFAIRS MED CTR, DALLAS, TX USA		KAVANAUGH, A (corresponding author), UNIV TEXAS, SW MED CTR DALLAS, DIV RHEUMAT DIS, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.							AHN YS, 1989, ANN INTERN MED, V111, P723, DOI 10.7326/0003-4819-111-9-723; AHN YS, 1987, ANN INTERN MED, V107, P177, DOI 10.7326/0003-4819-107-2-177; AHN YS, 1989, FASEB J, V3, P157, DOI 10.1096/fasebj.3.2.2914627; BOWLES CA, 1990, RHEUM DIS CLIN N AM, V16, P471; CERVERA H, 1993, ARTHRITIS RHEUM, V36, pS92; GEORGE JN, 1990, BLOOD, V76, P859; HARRIS EN, 1986, ARCH INTERN MED, V146, P2153, DOI 10.1001/archinte.146.11.2153; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; MYLVAGANAM R, 1987, CLIN IMMUNOL IMMUNOP, V42, P281, DOI 10.1016/0090-1229(87)90016-X; SCHREIBER AD, 1987, NEW ENGL J MED, V316, P503, DOI 10.1056/NEJM198702263160903; WEST SG, 1988, ANN INTERN MED, V108, P703, DOI 10.7326/0003-4819-108-5-703	11	18	19	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					767	768		10.7326/0003-4819-121-10-199411150-00007	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944055				2022-12-28	WOS:A1994PQ92800007
J	PETERSON, CL				PETERSON, CL			THE SMC FAMILY - NOVEL MOTOR PROTEINS FOR CHROMOSOME CONDENSATION	CELL			English	Review							TOPOISOMERASE-II; CAENORHABDITIS-ELEGANS; MITOTIC CHROMOSOMES; SEQUENCE; GENE; DOSAGE		UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	PETERSON, CL (corresponding author), UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.							ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BUCHENAU P, 1993, J CELL SCI, V104, P1175; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; FALK G, 1988, BIOCHEM J, V254, P109, DOI 10.1042/bj2540109; GASSER SM, 1989, INT REV CYTOL, V119, P57; GUACCI V, 1993, COLD SPRING HARB SYM, V58, P677, DOI 10.1101/SQB.1993.058.01.075; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HODGKIN J, 1983, MOL GEN GENET, V192, P452, DOI 10.1007/BF00392190; Hsu David R., 1993, Seminars in Developmental Biology, V4, P93, DOI 10.1006/sedb.1993.1012; NOTARNICOLA SM, 1991, GENE, V97, P77, DOI 10.1016/0378-1119(91)90012-Z; PLENEFISCH JD, 1989, GENETICS, V121, P57; SAITOH N, 1994, IN PRESS J CELL BIOL, V127; SAKA Y, 1994, IN PRESS EMBO J; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429	19	78	79	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					389	392		10.1016/0092-8674(94)90247-X	http://dx.doi.org/10.1016/0092-8674(94)90247-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954805				2022-12-28	WOS:A1994PQ48800001
J	GONZALEZREYES, A; STJOHNSTON, D				GONZALEZREYES, A; STJOHNSTON, D			ROLE OF OOCYTE POSITION IN ESTABLISHMENT OF ANTERIOR-POSTERIOR POLARITY IN DROSOPHILA	SCIENCE			English	Article							BICOID RNA; LOCALIZATION; OOGENESIS; FOLLICLE; ENCODES; OSKAR; EGG; TRANSPORT; PROTEIN; EMBRYO	The polarized microtubule cytoskeleton of the Drosophila oocyte directs the localization of the maternal determinants which establish the anterior-posterior (AP) axis of the embryo. Because the formation of this microtubule array is dependent on signals from the follicle cells that surround the oocyte, it has been proposed that AP polarity originates in the follicle cells. Here it is shown that the movement of the oocyte to the posterior of the egg chamber early in oogenesis determines AP polarity in the follicle cell layer, and also in the oocyte. Moreover, the generation of AP asymmetry requires signaling from the germ line to the soma and back again.	UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge; University of Cambridge			Gonzalez-Reyes, Acaimo/L-1993-2014; St Johnston, Daniel/C-9568-2009	Gonzalez-Reyes, Acaimo/0000-0003-3048-0968; St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CHASAN R, 1993, GENETICA BIOL DROSOP, V1, P387; CHEUNG HK, 1992, DEVELOPMENT, V114, P653; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; GINIGER E, 1993, ROUX ARCH DEV BIOL, V202, P112, DOI 10.1007/BF00636536; GONZALEZREYES A, UNPUB; GOODE S, 1992, DEVELOPMENT, V116, P177; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JOHNSTON DS, 1992, CELL, V68, P201; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; LOHSSCHARDIN M, 1982, ROUX ARCH DEV BIOL, V191, P28, DOI 10.1007/BF00848543; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; PEIFER M, 1993, DEVELOPMENT, V118, P1191; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUOHOLABAKER H, 1994, TRENDS GENET, V10, P89, DOI 10.1016/0168-9525(94)90231-3; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	27	98	99	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					639	642		10.1126/science.7939717	http://dx.doi.org/10.1126/science.7939717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939717				2022-12-28	WOS:A1994PN80700045
J	WOLPERT, L				WOLPERT, L			DO WE UNDERSTAND DEVELOPMENT	SCIENCE			English	Editorial Material											WOLPERT, L (corresponding author), UCL, DEPT ANAT & DEV BIOL, LONDON, ENGLAND.							BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; GRUNWALD T, 1992, CELL, V68, P271; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KELLER R, 1992, DEVELOPMENT, P81; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lawrence P., 1992, MAKING FLY GENETICS; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; NIESWANDER L, IN PRESS NATURE; OLSEN EN, 1991, GENE DEV, V4, P1454; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WOLPERT L, 1990, BIOL J LINN SOC, V39, P109, DOI 10.1111/j.1095-8312.1990.tb00506.x; WOLPERT L, IN PRESS DEVELOPME S; WOLPERT L, 1989, DEVELOPMENT S, P3	18	70	72	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					571	572		10.1126/science.7939707	http://dx.doi.org/10.1126/science.7939707			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939707				2022-12-28	WOS:A1994PN80700031
J	BLAMEY, RW; WILSON, ARM; PATNICK, J; DIXON, M				BLAMEY, RW; WILSON, ARM; PATNICK, J; DIXON, M			ABC OF BREAST DISEASES - SCREENING FOR BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							TRIAL		NHS BREAST SCREENING PROGRAMME,SHEFFIELD,S YORKSHIRE,ENGLAND; EDINBURGH ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh	BLAMEY, RW (corresponding author), CITY HOSP NOTTINGHAM,HUCKNALL RD,NOTTINGHAM,ENGLAND.							ANDERSON TJ, 1991, BRIT J CANCER, V64, P108, DOI 10.1038/bjc.1991.251; DAY NE, 1991, BRIT MED BULL, V47, P400, DOI 10.1093/oxfordjournals.bmb.a072479; DIXON JM, 1993, HDB DISEASES BREAST, P86; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112	4	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1076	1079		10.1136/bmj.309.6961.1076	http://dx.doi.org/10.1136/bmj.309.6961.1076			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN733	7950747	Green Published			2022-12-28	WOS:A1994PN73300034
J	PETER, M; HERSKOWITZ, I				PETER, M; HERSKOWITZ, I			JOINING THE COMPLEX - CYCLIN-DEPENDENT KINASE INHIBITORY PROTEINS AND THE CELL-CYCLE	CELL			English	Review							SIGNAL-TRANSDUCTION PATHWAY; NEGATIVE REGULATION; TGF-BETA; FAR1; YEAST				PETER, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FLROESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SCHNEIDER KR, 1994, IN PRESS SCIENCE; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3	30	460	477	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					181	184		10.1016/0092-8674(94)90186-4	http://dx.doi.org/10.1016/0092-8674(94)90186-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954786				2022-12-28	WOS:A1994PN63000001
J	DIXON, J; MANSEL, RE				DIXON, J; MANSEL, RE			ABC OF BREAST DISEASES - SYMPTOMS ASSESSMENT AND GUIDELINES FOR REFERRAL	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV WALES COLL MED,CARDIFF,S GLAM,WALES	University of Edinburgh; Cardiff University	DIXON, J (corresponding author), ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND.								0	47	48	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					722	726		10.1136/bmj.309.6956.722	http://dx.doi.org/10.1136/bmj.309.6956.722			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950527	Green Published			2022-12-28	WOS:A1994PH40700028
J	KNIPSCHILD, P				KNIPSCHILD, P			SYSTEMATIC REVIEWS - SAME EXAMPLES	BRITISH MEDICAL JOURNAL			English	Article							PREMENSTRUAL-SYNDROME; COMMON COLD; BACK; PHYSIOTHERAPY; HOMEOPATHT; VITAMIN-B6; TRIALS; PAIN	Reviewing the Literature is a scientific inquiry that needs a clear design to preclude bias. It is a real enterprise if one aims at completeness of the literature on a certain subject. Going through refereed English language journals is not enough. On line databases are helpful, but mainly as a starting point. This article gives examples of systematic reviews on vitamin C and the common cold, pyridoxine against the premenstrual syndrome, homoeopathy, and physiotherapy.			KNIPSCHILD, P (corresponding author), UNIV LIMBURG,DEPT EPIDEMIOL,POB 616,6200 MD MAASTRICHT,NETHERLANDS.							BECKERMAN H, 1991, EFFECTIVITEIT FYSIOT; BERMAN MK, 1990, J AM DIET ASSOC, V90, P859; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; DOLL H, 1989, J ROY COLL GEN PRACT, V39, P364; HEMILA H, 1992, BRIT J NUTR, V67, P3, DOI 10.1079/BJN19920004; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KLEIJNEN J, 1992, PHARM WEEKBLAD, V14, P316, DOI 10.1007/BF01977620; KLEIJNEN J, 1990, BRIT J OBSTET GYNAEC, V97, P847, DOI 10.1111/j.1471-0528.1990.tb02582.x; KLEIJNEN J, 1991, THESIS U LIMBURG MAA; KNIPSCHILD P, 1993, LANCET, V341, P1135, DOI 10.1016/0140-6736(93)93140-V; KNIPSCHILD P, 1990, SOC SCI MED, V31, P625, DOI 10.1016/0277-9536(90)90099-E; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; Pauling L., 1986, LIVE LONGER FEEL BET	15	35	36	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					719	721		10.1136/bmj.309.6956.719	http://dx.doi.org/10.1136/bmj.309.6956.719			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950526	Green Published			2022-12-28	WOS:A1994PH40700026
J	VANDERPOEL, CL; CUYPERS, HT; REESINK, HW				VANDERPOEL, CL; CUYPERS, HT; REESINK, HW			HEPATITIS-C VIRUS 6 YEARS ON	LANCET			English	Review							POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; LIVER-DISEASE; NON-A; HEPATOCELLULAR-CARCINOMA; BLOOD-DONORS; RISK-FACTORS; RNA; THERAPY; TRANSMISSION		NETHERLANDS RED CROSS,BLOOD BANK AMSTERDAM,1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS									AKAHANE Y, 1994, ANN INTERN MED, V120, P748, DOI 10.7326/0003-4819-120-9-199405010-00005; ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; BRESTERS D, 1993, LANCET, V342, P210, DOI 10.1016/0140-6736(93)92300-I; Bresters D., 1994, V61, P121; BUKH J, 1992, P NATL ACAD SCI USA, V89, P187, DOI 10.1073/pnas.89.1.187; BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; BUSCH MP, 1994, TRANSFUSION, V34, P130; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COUROUCE AM, 1994, LANCET, V343, P853; DIBISCEGLIE AM, 1992, HEPATOLOGY, V16, P649, DOI 10.1002/hep.1840160307; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; FERAY C, 1992, J CLIN INVEST, V89, P1361, DOI 10.1172/JCI115723; GORDON SC, 1992, AM J GASTROENTEROL, V87, P1849; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HAGIWARA H, 1993, GASTROENTEROLOGY, V104, P877, DOI 10.1016/0016-5085(93)91025-D; HOUGHTON M, 1991, HEPATOLOGY, V14, P382; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; MAKRIS M, 1993, BLOOD, V81, P1898; MARCELLIN P, 1993, GASTROENTEROLOGY, V104, P272, DOI 10.1016/0016-5085(93)90862-7; MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994; MICHEL G, 1992, LANCET, V339, P267, DOI 10.1016/0140-6736(92)91332-3; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; TILSTON P, 1994, LANCET, V344, P201, DOI 10.1016/S0140-6736(94)92809-6; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; VANDERPOEL C, 1991, TRANSFUSION, V31, P777; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3; ZAAIJER HL, 1994, TRANSFUSION, V34, P184, DOI 10.1046/j.1537-2995.1994.34294143953.x	35	194	201	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1475	1479		10.1016/S0140-6736(94)90293-3	http://dx.doi.org/10.1016/S0140-6736(94)90293-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968123				2022-12-28	WOS:A1994PT99500012
J	HAKE, LE; RICHTER, JD				HAKE, LE; RICHTER, JD			CPEB IS A SPECIFICITY FACTOR THAT MEDIATES CYTOPLASMIC POLYADENYLATION DURING XENOPUS OOCYTE MATURATION	CELL			English	Article							MESSENGER-RNA TRANSLATION; POLY(A) ELONGATION; ZINC FINGERS; PROTEIN; BINDING; ELEMENTS; FERTILIZATION; LAEVIS; PURIFICATION; RECRUITMENT	The translational activation of several maternal mRNAs during Xenopus oocyte maturation is stimulated by cytoplasmic poly(A) elongation, which requires the uridine-rich cytoplasmic polyadenylation element (CPE) and the hexanucleotide AAUAAA. Here, we have enriched a CPE-binding protein (CPEB) by single-step RNA affinity chromatography, have obtained a CPEB cDNA, and have assessed the role of CPEB in cytoplasmic polyadenylation. The 62 kDa CPEB contains two RNA recognition motifs, and within this region, it is 62% identical to orb, an oocyte-specific RNA-binding protein from Drosophila. CPEB mRNA and protein are abundant in oocytes and are not detected in embryos beyond the gastrula stage. During oocyte maturation, CPEB is phosphorylated at a time that corresponds with the induction of polyadenylation. Immunodepletion of CPEB from polyadenylation-proficient egg extracts renders them incapable of adenylating exogenous RNA. Partial restoration of polyadenylation in depleted extracts is achieved by the addition of CPEB, thus demonstrating that this protein is required for cytoplasmic polyadenylation.			HAKE, LE (corresponding author), WORCESTER FDN EXPTL BIOL INC, SHREWSBURY, MA 01545 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREAZZOLI M, 1993, NUCLEIC ACIDS RES, V21, P4218, DOI 10.1093/nar/21.18.4218; BERG JM, 1990, J BIOL CHEM, V265, P6513; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BILGER A, 1994, GENE DEV, V8, P1106, DOI 10.1101/gad.8.9.1106; BOUVET P, 1994, MOL CELL BIOL, V14, P1893, DOI 10.1128/MCB.14.3.1893; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTTIER P, 1992, J GEN VIROL, V73, P1931, DOI 10.1099/0022-1317-73-8-1931; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DWORKIN MB, 1985, P NATL ACAD SCI USA, V82, P7636, DOI 10.1073/pnas.82.22.7636; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX CA, 1992, EMBO J, V11, P5021, DOI 10.1002/j.1460-2075.1992.tb05609.x; GEBAUER F, 1994, IN PRESS EMBO J; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLLINGER TG, 1980, GAMETE RES, V3, P45, DOI 10.1002/mrd.1120030106; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIRBY KS, 1965, BIOCHEM J, V96, P266, DOI 10.1042/bj0960266; LANTZ V, 1994, GENE DEV, V8, P598, DOI 10.1101/gad.8.5.598; LANTZ V, 1992, DEVELOPMENT, V115, P75; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MCGREW LL, 1990, EMBO J, V9, P3743, DOI 10.1002/j.1460-2075.1990.tb07587.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; PARIS J, 1990, DEV BIOL, V140, P221, DOI 10.1016/0012-1606(90)90070-Y; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; PARIS J, 1991, GENE DEV, V5, P1697, DOI 10.1101/gad.5.9.1697; RICHTER JD, 1993, DEV GENET, V14, P407, DOI 10.1002/dvg.1020140602; ROSENTHAL ET, 1987, DEV BIOL, V121, P237, DOI 10.1016/0012-1606(87)90155-2; RUBY SW, 1990, METHOD ENZYMOL, V181, P97; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER M, 1990, EMBO J, V9, P4519, DOI 10.1002/j.1460-2075.1990.tb07903.x; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SIMON R, 1992, GENE DEV, V6, P2580, DOI 10.1101/gad.6.12b.2580; SIMON R, 1994, IN PRESS MOL CELL BI; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; STANDART N, 1993, DEV GENET, V14, P492, DOI 10.1002/dvg.1020140610; STEBBINSBOAZ B, 1994, MOL CELL BIOL, V14, P5870, DOI 10.1128/MCB.14.9.5870; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WANG SS, 1992, MOL CELL BIOL, V12, P2633, DOI 10.1128/MCB.12.6.2633; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756	55	352	360	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					617	627		10.1016/0092-8674(94)90547-9	http://dx.doi.org/10.1016/0092-8674(94)90547-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954828				2022-12-28	WOS:A1994PT48100009
J	KRAUS, JF; PEEK, C; MCARTHUR, DL; WILLIAMS, A				KRAUS, JF; PEEK, C; MCARTHUR, DL; WILLIAMS, A			THE EFFECT OF THE 1992 CALIFORNIA-MOTORCYCLE-HELMET-USE-LAW ON MOTORCYCLE CRASH FATALITIES AND INJURIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NECK INJURIES; HEAD; IMPACT; REPEAL; SEVERITY; DEATHS; TEXAS; COSTS	Objective.-To determine the effects of the California motorcycle helmet use law on statewide fatalities and a large sample of nonfatal injuries before and after law implementation. Design.-Police reports and death certificates were collected for motorcycle crash fatalities in California for 1991 (prelaw) and 1992 (postlaw). Official counts of registered motorcycles provided a statewide basis for exposure to a motorcycle crash. Autopsy results were collected for fatalities in 11 counties. Hospital records were reviewed for nonfatal injuries in 28 hospitals in 10 of the 11 counties. Police reports were linked to injury data for the riders. Subjects and Patients.-A total of 850 fatalities and injury data for 547 fatally injured riders and 3252 nonfatally injured patients. Main outcome Measures.-Changes in number and rates among statewide fatalities were estimated. The number and pattern of head injuries in fatally and nonfatally injured motorcycle riders were evaluated. Results.-After implementation of the helmet use law, statewide motorcycle crash fatalities decreased by 37.5%, from 523 fatalities in 1991 to 327 in 1992, more than 37%, and an estimated 92 to 122 fatalities were prevented. Motorcycle fatality rates were reduced by 26.5%, from 70.1 per 100 000 registered motorcycles in 1991 to 51.5 per 100 000 in 1992. Head injuries decreased significantly among both fatally and nonfatally injured motorcyclists. Conclusion.-Enactment of an unrestricted helmet law significantly reduces the incidence of motorcycle crash fatalities and the number and severity of head injuries.	INSURANCE INST HIGHWAY SAFETY,ARLINGTON,VA		KRAUS, JF (corresponding author), UNIV CALIF LOS ANGELES,SCH PUBL HLTH,SO CALIF INJURY PREVENT RES CTR,CHS 76-078,LOS ANGELES,CA 90024, USA.							[Anonymous], 1990, ABBREVIATED INJURY S; [Anonymous], 1991, FINAL REPORT; BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CHENIER TC, 1987, ACCIDENT ANAL PREV, V19, P133, DOI 10.1016/0001-4575(87)90032-7; COOTER RD, 1988, LANCET, V1, P84; DARE CE, 1978, DOTHS601429 NAT HIGH; DRYSDALE WF, 1975, J TRAUMA, V15, P99, DOI 10.1097/00005373-197502000-00003; FAYON A, 1976, P INT C BIOMECHANICS; FLEMING NS, 1992, MED CARE, V30, P832, DOI 10.1097/00005650-199209000-00007; GABRIEL KR, 1966, J AM STAT ASSOC, V61, P1081, DOI 10.2307/2283202; GOLDSTEIN JP, 1986, EVALUATION REV, V10, P355, DOI 10.1177/0193841X8601000306; HARMS PL, 1984, 1984 P INT C BIOM IN; HURT HH, 1981, P AM ASS AUTOMOTIVE; HUSTON RL, 1981, J BIOMECH ENG-T ASME, V103, P18, DOI 10.1115/1.3138238; KELLY P, 1991, ANN EMERG MED, V20, P852, DOI 10.1016/S0196-0644(05)81426-X; KRANTZ KPG, 1985, INJURY, V16, P253; KRAUS JF, 1975, AM J EPIDEMIOL, V102, P99, DOI 10.1093/oxfordjournals.aje.a112137; KRAUS JF, IN PRESS AM J PUBLIC; LLOYD LE, 1987, TEX MED, V83, P30; LUMMIS ML, 1979, DOTHS804018 NAT HIGH; LUNA GK, 1981, WESTERN J MED, V135, P89; MCHUGH TP, 1985, JSC MED ASS, V6, P588; MCSWAIN NE, 1980, SURG GYNECOL OBSTET, V151, P215; MCSWAIN NE, 1990, J TRAUMA, V30, P1189, DOI 10.1097/00005373-199010000-00002; MCSWAIN NE, 1984, DTN2282 NAT HIGHW TR; MCSWAIN NE, 1984, DOTHS806760 NAT HIGH; Meyer R D, 1977, Med Times, V105, P101; MEYER RD, 1985, J TRAUMA, V24, P329; MOUNCE N, 1992, FEINSTATED COMPREHEN; MUELLEMAN RL, 1992, ANN EMERG MED, V21, P266, DOI 10.1016/S0196-0644(05)80886-8; MURDOCK MA, 1991, WESTERN J MED, V155, P370; ORSAY EM, 1994, ANN EMERG MED, V23, P802, DOI 10.1016/S0196-0644(94)70317-5; RUSSO PK, 1978, NEW ENGL J MED, V299, P1074, DOI 10.1056/NEJM197811092991915; RUTLEDGE R, 1991, HSRCMP74 ASS ADV AUT; SARKAR S, IN PRESS J TRAUMA; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; STRUCKMANJOHNSO.C, 1980, DOTHS902130 NAT HIGH; WATSON GS, 1980, AM J PUBLIC HEALTH, V70, P579, DOI 10.2105/AJPH.70.6.579; WILSON P, 1993, CALIFORNIA MOTORCYCL; 1980, REPORT C EFFECT MOTO; 1991, GAORCED91170 US GEN	42	97	99	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1506	1511		10.1001/jama.272.19.1506	http://dx.doi.org/10.1001/jama.272.19.1506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PQ900	7966842				2022-12-28	WOS:A1994PQ90000029
J	JARVIS, WR				JARVIS, WR			HANDWASHING - THE SEMMELWEIS LESSON FORGOTTEN	LANCET			English	Editorial Material							INTENSIVE-CARE UNITS; INFECTIONS				JARVIS, WR (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,ATLANTA,GA 30341, USA.							ALBERT RK, 1981, NEW ENGL J MED, V304, P1465, DOI 10.1056/NEJM198106113042404; CASEWELL M, 1977, BRIT MED J, V2, P1315, DOI 10.1136/bmj.2.6098.1315; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; DONOWITZ LG, 1987, AM J DIS CHILD, V141, P683, DOI 10.1001/archpedi.1987.04460060099044; DUBBERT PM, 1990, INFECT CONT HOSP EP, V11, P191; GARNER JS, 1986, INFECT CONT HOSP EP, V7, P231; GRAHAM M, 1990, AM J INFECT CONTROL, V18, P78; MEENGS MR, 1994, ANN EMERG MED, V23, P1307, DOI 10.1016/S0196-0644(94)70357-4; RAMMELKAMP CH, 1964, ANN INTERN MED, V60, P753, DOI 10.7326/0003-4819-60-5-753; ROTTER ML, 1984, INFECT CONT HOSP EP, V5, P18, DOI 10.1017/S0195941700058744; SALZMAN TC, 1967, ANTIMICROB AGENTS CH, V2, P97; Semmelweis I., 1861, ETIOLOGY CONCEPT PRO; SIMMONS B, 1990, INFECT CONT HOSP EP, V11, P589	13	129	133	1	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1311	1312		10.1016/S0140-6736(94)90687-4	http://dx.doi.org/10.1016/S0140-6736(94)90687-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968023				2022-12-28	WOS:A1994PQ92600003
J	BUTTERFIELD, JH; GLEICH, GJ				BUTTERFIELD, JH; GLEICH, GJ			INTERFERON-ALPHA TREATMENT OF 6 PATIENTS WITH THE IDIOPATHIC HYPEREOSINOPHILIC-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						HYPEREOSINOPHILIC SYNDROME; INTERFERON ALFA-2B; PREDNISONE; HYDROXYUREA	EOSINOPHILIC ENDOMYOCARDIAL DISEASE; CHRONIC MYELOGENOUS LEUKEMIA; ELEVATED SERUM LEVELS; THERAPY; RESPONSES; RECEPTOR; FEATURES	Objective: To examine the response to interferon-alpha 2B therapy in six patients with the idiopathic hypereosinophilic syndrome. Design: Prospective cohort study. Setting: Tertiary referral center, university hospital inpatient and outpatient clinics, and offices of private practice physicians. Patients: Six patients satisfying the criteria for the hypereosinophilic syndrome, five of whom were resistant to or intolerant of conventional treatment. Intervention: Individualized dosages of interferon-a based on clinical response and side effects. Measurements: Measurements of eosinophilia (peripheral and bone marrow counts), levels of serum eosinophil major basic protein, doses of glucocorticoid and cytotoxic medications, and transfusion requirements. Results: Various dosages of interferon-alpha from 1.5 MU/d to 8 MU/d decreased the total eosinophil count to less than 1000/mm(3) in five of six patients. All patients were able to taper and discontinue prednisone and hydroxyurea. Both patients with incapacitating mucosal ulcers had resolution and no recurrence of these previously resistant lesions. Interferon-alpha was generally well tolerated except for dose-limiting side effects, including thrombocytopenia in one patient and in a second patient, temporary worsening of mucosal lesions and constitutional symptoms. Conclusions: Interferon-a is a valuable agent for patients with the hypereosinophilic syndrome who are resistant to or intolerant of conventional therapy and for patients with this syndrome who have incapacitating mucosal ulcers.	MAYO CLIN & MAYO GRAD SCH MED, ROCHESTER, MN 55905 USA	Mayo Clinic	BUTTERFIELD, JH (corresponding author), MAYO CLIN & MAYO FDN, DIV ALLERG DIS, ROCHESTER, MN 55905 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015231, R37AI009728, R37AI015231, R01AI031155, R01AI009728] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 09728, AI 31155, AI 15231] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCHIMBAUD E, 1988, AM J HEMATOL, V27, P302, DOI 10.1002/ajh.2830270414; BROXMEYER HE, 1983, J IMMUNOL, V131, P1300; BUSCH FW, 1991, ANN INTERN MED, V114, P338, DOI 10.7326/0003-4819-114-4-338_2; BUSH RK, 1978, ARCH INTERN MED, V138, P1244, DOI 10.1001/archinte.138.8.1244; Chambers L A, 1990, Prog Clin Biol Res, V337, P83; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; DALE DC, 1976, J LAB CLIN MED, V87, P487; DASILVA MAP, 1988, CANCER GENET CYTOGEN, V32, P109, DOI 10.1016/0165-4608(88)90317-2; DAVIES J, 1981, BRIT HEART J, V46, P438; DAVIES J, 1983, Q J MED, V52, P23; DINE G, 1992, PRESSE MED, V21, P1776; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; HARDY WR, 1968, ANN INTERN MED, V68, P1220, DOI 10.7326/0003-4819-68-6-1220; KENNEDY BJ, 1972, CANCER-AM CANCER SOC, V29, P1052, DOI 10.1002/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO;2-7; Kobayashi M, 1993, Rinsho Ketsueki, V34, P367; LEIFERMAN KM, 1982, JAMA-J AM MED ASSOC, V247, P1018, DOI 10.1001/jama.247.7.1018; MARSHALL GM, 1989, AM J PEDIAT HEMATOL, V11, P178; MURPHY PT, 1990, BRIT J HAEMATOL, V75, P619, DOI 10.1111/j.1365-2141.1990.tb07811.x; PARRILLO JE, 1978, ANN INTERN MED, V89, P167, DOI 10.7326/0003-4819-89-2-167; PRIN L, 1991, BLOOD, V78, P2626; PRIN L, 1989, CLIN EXP IMMUNOL, V78, P383; RATAIN MJ, 1987, BLOOD, V69, P872; SCHOOLEY RT, 1981, BLOOD, V58, P1021; SMIT AJ, 1991, CANCER-AM CANCER SOC, V67, P2826, DOI 10.1002/1097-0142(19910601)67:11<2826::AID-CNCR2820671119>3.0.CO;2-#; SPRY CJF, 1983, Q J MED, V52, P1; TALPAZ M, 1991, ANN INTERN MED, V114, P532, DOI 10.7326/0003-4819-114-7-532; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; WEMMER U, 1988, HAUTARZT, V39, P42; WYNN SR, 1987, J PEDIATR-US, V111, P94, DOI 10.1016/S0022-3476(87)80352-9; YARBRO JW, 1968, CANCER RES, V28, P1082; ZABEL P, 1991, ANN HEMATOL, V62, P230, DOI 10.1007/BF01729838; ZIELINSKI RM, 1990, ANN INTERN MED, V113, P716, DOI 10.7326/0003-4819-113-9-716	32	104	107	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					648	653		10.7326/0003-4819-121-9-199411010-00003	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944072				2022-12-28	WOS:A1994PN45000003
J	DUBOULE, D				DUBOULE, D			HOW TO MAKE A LIMB	SCIENCE			English	Editorial Material							PATTERN-FORMATION; HOMEOBOX GENES; VERTEBRATE LIMB; HOX GENES; EXPRESSION; EVOLUTION; GROWTH; MICE				DUBOULE, D (corresponding author), UNIV GENEVA, DEPT ZOOL, SCI 3, QUAI ERNEST ANSERMET 30, CH-1211 GENEVA 4, SWITZERLAND.			duboule, denis/0000-0001-9961-2960				AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; AHLBERG PE, 1989, ZOOL J LINN SOC-LOND, V96, P119, DOI 10.1111/j.1096-3642.1989.tb01824.x; COATES M, 1991, NATO ADV SCI I A-LIF, V205, P325; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SHUBIN N, IN PRESS EVOL BIOL; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; TABIN C, 1993, NATURE, V361, P692, DOI 10.1038/361692a0; TABIN CJ, 1992, DEVELOPMENT, V116, P289; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOROGOOD P, 1991, NATO ADV SCI I A-LIF, V205, P347; TICKLE C, 1991, DEVELOPMENT, P113; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	24	88	88	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	1994	266	5185					575	576		10.1126/science.7939709	http://dx.doi.org/10.1126/science.7939709			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939709				2022-12-28	WOS:A1994PN80700033
J	FARKAS, G; GAUSZ, J; GALLONI, M; REUTER, G; GYURKOVICS, H; KARCH, F				FARKAS, G; GAUSZ, J; GALLONI, M; REUTER, G; GYURKOVICS, H; KARCH, F			THE TRITHORAX-LIKE GENE ENCODES THE DROSOPHILA GAGA FACTOR	NATURE			English	Article							POSITION-EFFECT VARIEGATION; BITHORAX COMPLEX; TRANSCRIPTION; MELANOGASTER; CHROMATIN; PROTEINS; ANTIREPRESSION; SEGMENTATION; TRANSPOSON; EXPRESSION	LITTLE is known about the way higher-order chromatin structure influences gene expression and chromosome topology in general. Genetic analysis in Drosophila has led to the discovery of two classes of genes, the regulators of homeotic genes and the modifiers of position-effect variegation, which seem to be good candidates for encoding some of the factors regulating chromatin functions(1,2). The Trithorax-like gene we describe here is required for the normal expression of the homeotic genes and is a modifier of position-effect variegation. We found that Trithorax-like encodes the GAGA factor which is involved in the formation of an accessible chromatin structure at promoter sequences(3). Our genetic analysis suggests that the chromatin modelling function of the GAGA factor is not restricted to promoter regions.	HUNGARIAN ACAD SCI,BIOL RES CTR,INST GENET,H-6701 SZEGED,HUNGARY; UNIV GENEVA,DEPT ZOOL & ANIM BIOL,CH-1224 GENEVA,SWITZERLAND; UNIV HALLE WITTENBERG,INST GENET,D-06108 HALLE,GERMANY	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; University of Geneva; Martin Luther University Halle Wittenberg			Galloni, Mireille/F-2665-2019	Galloni, Mireille/0000-0002-5099-1709				BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; CHI HC, 1991, DNA CELL BIOL, V10, P451, DOI 10.1089/dna.1991.10.451; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIBELLO PR, 1991, GENETICS, V129, P385; DORN R, 1993, GENETICS, V133, P279; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; DUNCAN IM, 1982, GENETICS, V102, P49; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GODT D, 1993, DEVELOPMENT, V119, P799; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; INGHAM PW, 1981, ROUX ARCH DEV BIOL, V190, P365, DOI 10.1007/BF00863275; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; READ D, 1990, MOL CELL BIOL, V10, P4334, DOI 10.1128/MCB.10.8.4334; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; SHEARN A, 1989, GENETICS, V121, P517; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; THUMMEL C, 1989, GENE DEV, V6, P2635; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	27	343	353	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					806	808		10.1038/371806a0	http://dx.doi.org/10.1038/371806a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935842				2022-12-28	WOS:A1994PP01800062
J	STARFIELD, B				STARFIELD, B			IS PRIMARY-CARE ESSENTIAL	LANCET			English	Article							HEALTH-CARE; SERVICES; SYSTEMS				STARFIELD, B (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD 21205 USA.							ALPERT J, 1974, US DHEW PHS HRH74311; BAKWIN H, 1945, NEW ENGL J MED, V232, P691, DOI 10.1056/NEJM194506142322401; BLENDON RJ, 1991, HEALTH AFFAIR, V10, P216, DOI 10.1377/hlthaff.10.3.216; BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; Burner S T, 1992, Health Care Financ Rev, V14, P1; EISENBERG JM, 1986, DOCTORS DECISION COS; ELLIS RP, 1993, J ECON PERSPECT, V7, P135, DOI 10.1257/jep.7.4.135; ESCARCE JJ, 1993, MED CARE, V31, P1106, DOI 10.1097/00005650-199312000-00004; Farmer F L, 1991, J Rural Health, V7, P153; FLOOD AB, 1993, JUN ANN M ASS HLTH S; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GERVAS J, IN PRESS FAM PRACTIC; KIMBALL HR, 1994, JAMA-J AM MED ASSOC, V271, P315, DOI 10.1001/jama.271.4.315; KRISTIANSEN IS, 1993, HEALTH POLICY, V24, P203, DOI 10.1016/0168-8510(93)90040-V; Manning W. G., 1988, HLTH INSURANCE DEMAN; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; MILLIS JS, 1966, REPORT CITIZENS COMM, P37; NOBLE J, 1992, ANN INTERN MED, V116, P482, DOI 10.7326/0003-4819-116-6-482; Roos N P, 1979, Inquiry, V16, P73; RUBLEE DA, 1991, HLTH AFFAIRS     FAL, P187; Schieber G J, 1992, Health Care Financ Rev, V13, P1; SCHIEBER GJ, 1991, HLTH AFFAIRS     FAL, P22; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; SHI L, IN PRESS INT J HLTH; Somers A R, 1983, Inquiry, V20, P301; Starfield B, 1993, J Ambul Care Manage, V16, P27; Starfield B., 1992, PRIMARY CARE CONCEPT; Volpp K G, 1994, JAMA, V271, P1370, DOI 10.1001/jama.271.17.1370; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WILKINSON RG, 1990, SOCIOL HEALTH ILL, V12, P391, DOI 10.1111/1467-9566.ep11340405; 1994, PRIMARY HLTH CARE CH; 1992, REFORM HLTH CARE COM; 1980, US DHHS HRA81651 PUB; 1993, OTABPH116 US C OFF T; 1989, 1989 NAT LEAD C; 1990, ISSUE BRIEF, P2; 1978, IOM7802 PUBLICATION; 1978, PRIMARY HLTH CARE, P25; 1990, MMWR-MORBID MORTAL W, V39, P205	39	609	641	6	35	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 22	1994	344	8930					1129	1133		10.1016/S0140-6736(94)90634-3	http://dx.doi.org/10.1016/S0140-6736(94)90634-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934497	hybrid			2022-12-28	WOS:A1994PN06600013
J	WANG, Q; SCHOENLEIN, RW; PETEANU, LA; MATHIES, RA; SHANK, CV				WANG, Q; SCHOENLEIN, RW; PETEANU, LA; MATHIES, RA; SHANK, CV			VIBRATIONALLY COHERENT PHOTOCHEMISTRY IN THE FEMTOSECOND PRIMARY EVENT OF VISION	SCIENCE			English	Article							CIS-TRANS ISOMERIZATION; 1ST STEP; IMPULSIVE EXCITATION; DYNAMICS; BACTERIORHODOPSIN; RHODOPSIN; PHOTOISOMERIZATION; FEMTOCHEMISTRY; ISORHODOPSIN; SPECTROSCOPY	Femtosecond pump-probe experiments reveal the impulsive production of photoproduct in the primary event in vision. The retinal chromophore of rhodopsin was excited with a 35-femtosecond pulse at 500 nanometers, and transient changes in absorption were measured with 10-femtosecond probe pulses. At probe wavelengths within the photoproduct absorption band, oscillatory features with a period of 550 femtoseconds (60 wavenumbers) were observed whose phase and amplitude demonstrate that they are the result of nonstationary vibrational motion in the ground state of the photoproduct. The observation of coherent vibrational motion of the photoproduct supports the idea that the primary step in vision is a vibrationally coherent process and that the high quantum yield of the cis-->trans isomerization in rhodopsin is a consequence of the extreme speed of the excited-state torsional motion.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley	WANG, Q (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV MAT SCI,BERKELEY,CA 94720, USA.		Schoenlein, Robert W/D-1301-2014; Peteanu, Linda/O-5581-2017	Schoenlein, Robert W/0000-0002-6066-7566; Peteanu, Linda/0000-0003-0075-6521	NATIONAL EYE INSTITUTE [R01EY002051, R37EY002051] Funding Source: NIH RePORTER; NEI NIH HHS [EY-02051] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAGCHI B, 1990, J PHYS CHEM-US, V94, P9, DOI 10.1021/j100364a004; BANIN U, 1993, J CHEM PHYS, V98, P4391, DOI 10.1063/1.465066; DEXHEIMER SL, 1992, CHEM PHYS LETT, V188, P61, DOI 10.1016/0009-2614(92)85089-S; DOUGHERTY TP, 1992, SCIENCE, V258, P770, DOI 10.1126/science.258.5083.770; FRAGNITO HL, 1989, CHEM PHYS LETT, V160, P101, DOI 10.1016/0009-2614(89)87564-5; KOCHENDOERFER G, 1994, 208TH NAT AM CHEM SO; Landau L., 1932, PHYZ SOWJETUNION, V2, P46, DOI DOI 10.1098/RSPA.1932.0165; LOPPNOW GR, 1988, BIOPHYS J, V54, P35, DOI 10.1016/S0006-3495(88)82928-X; MATHIES RA, 1988, SCIENCE, V240, P777, DOI 10.1126/science.3363359; PALINGS I, 1987, BIOCHEMISTRY-US, V26, P2544, DOI 10.1021/bi00383a021; PETEANU LA, 1993, P NATL ACAD SCI USA, V90, P11762, DOI 10.1073/pnas.90.24.11762; POLLARD WT, 1992, J PHYS CHEM-US, V96, P6147, DOI 10.1021/j100194a013; ROSENFELD T, 1977, PURE APPL CHEM, V49, P341, DOI 10.1351/pac197749030341; SCHOENLEIN RW, 1991, APPL PHYS LETT, V58, P801, DOI 10.1063/1.104494; SCHOENLEIN RW, 1993, J PHYS CHEM-US, V97, P12087, DOI 10.1021/j100148a040; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; SENSION RJ, 1993, J CHEM PHYS, V98, P6291, DOI 10.1063/1.464824; VOS MH, 1993, NATURE, V363, P320, DOI 10.1038/363320a0; WARSHEL A, 1982, J AM CHEM SOC, V104, P1469, DOI 10.1021/ja00370a003; WARSHEL A, 1976, NATURE, V260, P679, DOI 10.1038/260679a0; WEISS RM, 1979, J AM CHEM SOC, V101, P6131, DOI 10.1021/ja00514a051; Zener C, 1932, P R SOC LOND A-CONTA, V137, P696, DOI 10.1098/rspa.1932.0165; ZEWAIL AH, 1988, SCIENCE, V242, P1645, DOI 10.1126/science.242.4886.1645; ZEWAIL AH, 1993, J PHYS CHEM-US, V97, P12427, DOI 10.1021/j100150a001	24	553	563	4	167	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					422	424		10.1126/science.7939680	http://dx.doi.org/10.1126/science.7939680			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939680				2022-12-28	WOS:A1994PN27200030
J	STEVENS, CF; WANG, YY				STEVENS, CF; WANG, YY			CHANGES IN RELIABILITY OF SYNAPTIC FUNCTION AS A MECHANISM FOR PLASTICITY	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL SLICES; AREA CA1; PROBABILITY; DEPRESSION; RECORDINGS; INDUCTION; CURRENTS; RELEASE; NEURONS	SYNAPTIC transmission in the hippocampus is rather unreliable, with many presynaptic action potentials failing to release neurotransmitter(1-4). How is this unreliability affected by the alterations in synaptic strength seen in long-term potentiation (LTP)(5) and long-term depression(6,7) (LTD)? We find that LTP increases synaptic reliability, and LTD decreases it, both without a change in the size of those postsynaptic currents that do occur. Thus LTD is a functional inverse of LTP.			STEVENS, CF (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,MOLEC NEUROBIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92110, USA.							ALLEN C, IN PRESS P NATN ACAD; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; Korn S.J., 1991, METHODS NEUROSCIENCE, VVolume 4, P364; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x	18	317	318	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					704	707		10.1038/371704a0	http://dx.doi.org/10.1038/371704a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935816				2022-12-28	WOS:A1994PM77300057
J	BURGER, H; VANDAELE, PLA; ALGRA, D; HOFMAN, A; GROBBEE, DE; SCHUTTE, HE; BIRKENHAGER, JC; POLS, HAP				BURGER, H; VANDAELE, PLA; ALGRA, D; HOFMAN, A; GROBBEE, DE; SCHUTTE, HE; BIRKENHAGER, JC; POLS, HAP			VERTEBRAL DEFORMITIES AS PREDICTORS OF NON-VERTEBRAL FRACTURES	BRITISH MEDICAL JOURNAL			English	Article									ERASMUS UNIV ROTTERDAM,DEPT EPIDEMIOL & BIOSTAT RADIOL & INTERNAL MED,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam			Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; 1991, AM J MED, V90, P107	5	79	82	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					991	992		10.1136/bmj.309.6960.991	http://dx.doi.org/10.1136/bmj.309.6960.991			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950721	Green Published			2022-12-28	WOS:A1994PM41700023
J	WHITE, RR; RIDGWAY, EJ				WHITE, RR; RIDGWAY, EJ			MANAGING INJURIES FROM SHARP INSTRUMENTS IN HEALTH-CARE WORKERS IN MERSEY	BRITISH MEDICAL JOURNAL			English	Article											WHITE, RR (corresponding author), ROYAL LIVERPOOL UNIV HOSP,DEPT MICROBIOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; MANIAN FA, 1992, ANN INTERN MED, V116, P345; Newman C P, 1992, Commun Dis Rep CDR Rev, V2, pR30; 1990, GUIDANCE CLIN HLTH C; 1992, COMMUNICABLE DISEASE, V2, pR97	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					989	990		10.1136/bmj.309.6960.989	http://dx.doi.org/10.1136/bmj.309.6960.989			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950719	Green Published			2022-12-28	WOS:A1994PM41700021
J	GATTI, DL; PALFEY, BA; LAH, MS; ENTSCH, B; MASSEY, V; BALLOU, DP; LUDWIG, ML				GATTI, DL; PALFEY, BA; LAH, MS; ENTSCH, B; MASSEY, V; BALLOU, DP; LUDWIG, ML			THE MOBILE FLAVIN OF 4-OH BENZOATE HYDROXYLASE	SCIENCE			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; CRYSTAL-STRUCTURE; PSEUDOMONAS-FLUORESCENS; CONFORMATIONAL CHANGE; ACTIVE-SITE; RESOLUTION; CHEMISTRY; MECHANISM	Para-hydroxybenzoate hydroxylase inserts oxygen into substrates by means of the labile intermediate, flavin C(4a)-hydroperoxide. This reaction requires transient isolation of the flavin and substrate from the bulk solvent. Previous crystal structures have revealed the position of the substrate para-hydroxybenzoate during oxygenation but not how it enters the active site. In this study, enzyme structures with the flavin ring displaced relative to the protein were determined, and it was established that these or similar flavin conformations also occur in solution. Movement of the flavin appears to be essential for the translocation of substrates and products into the solvent-shielded active site during catalysis.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOPHYS RES,ANN ARBOR,MI 48109; UNIV NEW ENGLAND,DEPT BIOCHEM & MICROBIOL,ARMIDALE,NSW 2351,AUSTRALIA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of New England			dballou@umich.edu, David P/A-1298-2007; Lah, Myoung Soo/E-5885-2010	Lah, Myoung Soo/0000-0001-9517-7519; Palfey, Bruce/0000-0001-5098-259X	NIGMS NIH HHS [GM 20877, GM 11106, GM 16429] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020877, R37GM011106, R01GM011106, R01GM020877] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballou D. P., 1984, FLAVINS FLAVOPROTEIN, P605; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BRUICE TC, 1984, ISRAEL J CHEM, V24, P54; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR VERSION 3 1; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; ENTSCH B, IN PRESS FLAVINS FLA; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GHISLA S, 1986, BIOCHEMISTRY-US, V25, P3282, DOI 10.1021/bi00359a030; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; LAH MS, 1994, BIOCHEMISTRY-US, V33, P1555, DOI 10.1021/bi00172a036; LAH MS, IN PRESS FLAVINS FLA; MERENYI G, 1991, J AM CHEM SOC, V113, P3146, DOI 10.1021/ja00008a051; Mitchell P, 1966, CHEMIOSMOTIC COUPLIN; Ornston L N, 1977, Curr Top Cell Regul, V12, P209; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; SCHREUDER HA, 1992, PROTEINS, V14, P178, DOI 10.1002/prot.340140205; SCHREUDER HA, 1990, BIOCHEMISTRY-US, V29, P3101, DOI 10.1021/bi00464a029; SCHREUDER HA, 1988, J BIOL CHEM, V263, P3131; Schulz GE, 1991, CURR OPIN STRUC BIOL, V1, P883, DOI 10.1016/0959-440X(91)90082-5; SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505; SHOUN H, 1983, J BIOCHEM-TOKYO, V93, P169, DOI 10.1093/oxfordjournals.jbchem.a134151; STEENNIS PJ, 1973, FEBS LETT, V36, P177, DOI 10.1016/0014-5793(73)80363-1; VERVOORT J, 1991, EUR J BIOCHEM, V200, P731, DOI 10.1111/j.1432-1033.1991.tb16238.x; VINOGRADOV AD, 1994, BIOPHYS J, V66, pA12; WIERENGA RK, 1979, J MOL BIOL, V131, P55, DOI 10.1016/0022-2836(79)90301-2; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	34	175	176	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					110	114		10.1126/science.7939628	http://dx.doi.org/10.1126/science.7939628			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939628				2022-12-28	WOS:A1994PK58200035
J	COHEN, D				COHEN, D			MARGINAL ANALYSIS IN PRACTICE - AN ALTERNATIVE TO NEEDS ASSESSMENT FOR CONTRACTING HEALTH-CARE	BRITISH MEDICAL JOURNAL			English	Article								Prioritising health care services on the basis of total needs can lead to inefficient use of resources. A better option is to determine priorities by marginal analysis, which examines the effects of altering the existing balance of expenditure between health care programmes. Resources to support investment are released from disinvestments-that is, the strategy is resource neutral. Thus an increase in total health benefits is achieved independent of any gains that may result from increased spending on health. In 1989 the Welsh Health Planning Forum identified 10 health gain areas, outlining within each one where further investment was likely to produce health gains and where disinvestment might be considered. Ah Welsh districts then attempted, with varying degrees of success, to produce a resource neutral strategy. Mid Glamorgan further explored the possibility of using marginal analysis in producing its strategy and influencing its policy for contracting. Working groups for most health gain areas each proposed 10 programmes for investment and a further 10 for disinvestment, which were then evaluated by a core evaluation team. In the case of maternal and child health the team dropped 10 of the 20 proposals. The remainder were considered by the health authority, which dropped a further proposal. Nine of the original 20 proposals thus formally became policy for 1995.			COHEN, D (corresponding author), UNIV GLAMORGAN,PONTYPRIDD CF37 1DL,M GLAM,WALES.							Cohen DR, 1988, HLTH PREVENTION EC; DONALDSON C, 1991, BRIT MED J, V303, P1529, DOI 10.1136/bmj.303.6816.1529; DONALDSON C, 1993, HEALTH POLICY, V25, P95, DOI 10.1016/0168-8510(93)90105-X; Mooney G., 1992, EC MED HLTH CARE, V2nd ed; MOONEY G, 1992, NAHAT6 NAT ASS HLTH; ROBINSON R, 1993, BMJ-BRIT MED J, V307, P994, DOI 10.1136/bmj.307.6910.994; TWADDLE S, 1994, IMPROVING GYNAECOLOG; 1989, STRATEGIC INTENT DIR; 1992, HLTH NATION; 1993, LOCAL STRATEGY HLTH	10	39	39	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					781	784		10.1136/bmj.309.6957.781	http://dx.doi.org/10.1136/bmj.309.6957.781			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950568	Green Published			2022-12-28	WOS:A1994PJ28200026
J	WALKER, D; WILLIAMS, P; TAWN, J				WALKER, D; WILLIAMS, P; TAWN, J			AUDIT OF REQUESTS FOR PREOPERATIVE CHEST RADIOGRAPHY	BRITISH MEDICAL JOURNAL			English	Article									ROYAL BOURNEMOUTH GEN HOSP,DEPT RADIOL,BOURNEMOUTH BH7 7DW,DORSET,ENGLAND									[Anonymous], 1979, LANCET, V2, P83; POWER KJ, 1992, ANAESTHESIA, V47, P518, DOI 10.1111/j.1365-2044.1992.tb02279.x; 1993, MAKING BEST USE DEP	3	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					772	773		10.1136/bmj.309.6957.772	http://dx.doi.org/10.1136/bmj.309.6957.772			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950561	Green Published			2022-12-28	WOS:A1994PJ28200018
J	HICKS, NR				HICKS, NR			SOME OBSERVATIONS ON ATTEMPTS TO MEASURE APPROPRIATENESS OF CARE	BRITISH MEDICAL JOURNAL			English	Article							QUALITY	There are a growing number of published studies that suggest that much health care is delivered inappropriately. There are calls for measures of appropriateness to be used by purchasers and others to regulate or influence the delivery of health care. This paper explores assumptions inherent in results generated by a leading measure of appropriateness and concludes that there are considerable uncertainties about the measure's meaning, the magnitude of bias that it contains, and the degree to which its application can be generalised. Some of these uncertainties could be resolved if the tacit assumptions inherent in the generation of the criteria could be made explicit. Existing measures of appropriateness are not yet sufficiently robust to be used with confidence to influence or control the delivery of health care. They may have a use as an aid rather than as a constraint in clinical decision making. A randomised controlled trial could resolve whether patients achieve better outcomes if their care is influenced by appropriateness criteria.			HICKS, NR (corresponding author), OXFORDSHIRE HLTH AUTHOR,DEPT PUBL HLTH & HLTH POLICY,OXFORD OX3 9DZ,ENGLAND.			Hicks, Nicholas/0000-0002-7214-9678				BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; BROOK RH, 1994, BRIT MED J, V308, P218, DOI 10.1136/bmj.308.6923.218; BROOK RH, 1988, LANCET, V1, P750; CHALMERS I, 1989, EFFECTIVE CARE PREGN, P38; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; EDDY DM, 1988, HEALTH AFFAIR, V7, P19, DOI 10.1377/hlthaff.7.1.19; Hopkins A, 1993, QUAL HEALTH CARE, V2, P117; KAHN KL, 1988, MED CARE, V26, P415, DOI 10.1097/00005650-198804000-00010; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; MCCLELLAN M, 1992, MED CARE, V30, P565, DOI 10.1097/00005650-199207000-00001; MULLEY AG, 1988, JAMA-J AM MED ASSOC, V260, P540, DOI 10.1001/jama.260.4.540; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; TANEBAUM SJ, 1993, NEW ENGL J MED, V329, P1269; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505	16	115	115	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					730	733		10.1136/bmj.309.6956.730	http://dx.doi.org/10.1136/bmj.309.6956.730			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PH407	7950529	Green Published			2022-12-28	WOS:A1994PH40700030
J	GREENGARD, JS; EICHINGER, S; GRIFFIN, JH; BAUER, KA				GREENGARD, JS; EICHINGER, S; GRIFFIN, JH; BAUER, KA			VARIABILITY OF THROMBOSIS AMONG HOMOZYGOUS SIBLINGS WITH RESISTANCE TO ACTIVATED PROTEIN-C DUE TO AN ARG-]GLN MUTATION IN THE GENE FOR FACTOR-V	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							POOR ANTICOAGULANT RESPONSE; VENOUS THROMBOSIS; PURPURA FULMINANS; DEFICIENCY; THROMBOPHILIA; FRAGMENT; MARKERS; NEWBORN; INFANT		SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, DEPT MED, BOSTON, MA USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, BOSTON, MA USA	Scripps Research Institute; Scripps Research Institute; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School				Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014, R01HL021544] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21544, HL 33014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUER KA, 1984, J CLIN INVEST, V74, P2033, DOI 10.1172/JCI111626; BAUER KA, 1988, BLOOD, V71, P1418; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BRANSON HE, 1983, LANCET, V2, P1165; CONARD J, 1993, BLOOD, V82, P1159; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; GRIFFIN JH, 1993, BLOOD, V82, P1989; HALBMAYER WM, 1994, BLOOD COAGUL FIBRIN, V5, P51, DOI 10.1097/00001721-199402000-00008; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LINDBLOM B, 1988, GENE ANAL TECH, V5, P97, DOI 10.1016/0735-0651(88)90003-9; MAHASANDANA C, 1990, J PEDIATR-US, V117, P750, DOI 10.1016/S0022-3476(05)83335-9; MANNUCCI PM, 1992, THROMB HAEMOSTASIS, V67, P200; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SUN X, 1994, BLOOD, V83, P3120; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TEITEL JM, 1982, BLOOD, V59, P1086; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	24	138	140	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1559	1562		10.1056/NEJM199412083312305	http://dx.doi.org/10.1056/NEJM199412083312305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969326				2022-12-28	WOS:A1994PV29200005
J	GOVAERT, TME; THIJS, CTMCN; MASUREL, N; SPRENGER, MJW; DINANT, GJ; KNOTTNERUS, JA				GOVAERT, TME; THIJS, CTMCN; MASUREL, N; SPRENGER, MJW; DINANT, GJ; KNOTTNERUS, JA			THE EFFICACY OF INFLUENZA VACCINATION IN ELDERLY INDIVIDUALS - A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VOLUNTEERS; REDUCTION; IMMUNIZATION; POPULATION; MORTALITY; PNEUMONIA; EPIDEMIC; VACCINES; ANTIBODY; DISEASE	Objective.-To determine the efficacy of influenza vaccination in elderly people. Design.-Randomized double-blind placebo-controlled trial. Setting.-Fifteen family practices in the Netherlands during influenza season 1991-1992. Participants.-A total of 1838 subjects aged 60 years or older, not known as belonging to those high-risk groups in which vaccination was previously given. Intervention.-Purified split-virion vaccine containing A/Singapore/6/86(H1N1), A/Beijing/353/89(H3N2), B/Beijing/l/87, and B/Panama/45/90 (n=927) or intramuscular placebo containing physiological saline solution (n=911). Main Outcome Measures.-Patients presenting with influenzalike illness up to 5 months after vaccination; self-reported influenza in postal questionnaires 10 weeks and 5 months after vaccination; serological influenza (fourfold increase of antibody titer between 3 weeks and 5 months after vaccination). Results.-The incidence of serological influenza was 4% in the vaccine group and 9% in the placebo group (relative risk [RR], 0.50; 95% confidence interval [CI], 0.35 to 0.61). The incidences of clinical influenza were 2% and 3%, respectively (RR, 0.53; 95% Cl, 0.39 to 0.73), The effect was strongest for the combination of serological and clinical influenza (RR, 0.42; 95% Cl, 0.23 to 0.74). The effect was less pronounced for self-reported influenza. Conclusion.-In the elderly, influenza vaccination may halve the incidence of serological and clinical influenza (in periods of antigenic drift).	UNIV LIMBURG,DEPT GEN PRACTICE,MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT EPIDEMIOL,6200 MD MAASTRICHT,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT VIROL,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,WHO,CTR INFLUENZA,ROTTERDAM,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT INFECT DIS EPIDEMIOL,BILTHOVEN,NETHERLANDS	Hasselt University; Maastricht University; Hasselt University; Erasmus University Rotterdam; Erasmus University Rotterdam; World Health Organization; Netherlands National Institute for Public Health & the Environment			Knottnerus, Johannes A/A-3829-2009; Thijs, Carel/H-8340-2019; Knottnerus, Andre/F-4866-2013	Thijs, Carel/0000-0001-6646-5458; 				BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BARKER WH, 1980, JAMA-J AM MED ASSOC, V244, P2547, DOI 10.1001/jama.244.22.2547; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; BERLIN BS, 1963, VIROLOGY, V21, P665, DOI 10.1016/0042-6822(63)90244-7; DALESSIO DJ, 1969, J AMER MED ASSOC, V210, P485, DOI 10.1001/jama.210.3.485; DIXON WJ, 1981, BMDP STATISTICAL SOF; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; GROSS PA, 1988, ARCH INTERN MED, V148, P562, DOI 10.1001/archinte.148.3.562; HOBSON D, 1973, LANCET, V2, P155; HOSKINS TW, 1979, LANCET, V1, P33; KEREN G, 1988, J MED VIROL, V25, P85, DOI 10.1002/jmv.1890250112; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P477; MASUREL N, 1984, J HYG-CAMBRIDGE, V92, P263, DOI 10.1017/S0022172400064500; MASUREL N, 1981, J HYG-CAMBRIDGE, V87, P201, DOI 10.1017/S0022172400069412; MCDONALD JC, 1955, BRIT MED J, V2, P1232, DOI 10.1136/bmj.2.4950.1232; PALACHE AM, 1993, VACCINE, V11, P3, DOI 10.1016/0264-410X(93)90333-S; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; PYHALA R, 1976, ACTA VIROL, V20, P66; ROTHMAN KJ, 1985, MODERN EPIDEMIOLOGY, P171; SCHOENBA.SC, 1969, B WORLD HEALTH ORGAN, V41, P531; SPRENGER MJW, 1993, INT J EPIDEMIOL, V22, P334, DOI 10.1093/ije/22.2.334; STRASSBURG MA, 1986, VACCINE, V4, P38, DOI 10.1016/S0264-410X(86)80002-0; STUART WH, 1969, J AMER MED ASSOC, V209, P232, DOI 10.1001/jama.209.2.232; THIJS C, 1991, AM J EPIDEMIOL, V134, P186, DOI 10.1093/oxfordjournals.aje.a116071; VOTH DW, 1966, ARCH ENVIRON HEALTH, V13, P576, DOI 10.1080/00039896.1966.10664621; 1944, JAMA-J AM MED ASSOC, V124, P982; 1953, BRIT MED J, V2, P1173; 1991, CONTINUOUS MORBIDITY; 1983, ICHPPC 2 DEFINED INC; 1991, VACCINATION INFLUENZ, P15	30	643	669	2	41	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1661	1665		10.1001/jama.272.21.1661	http://dx.doi.org/10.1001/jama.272.21.1661			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966893				2022-12-28	WOS:A1994PU75900024
J	PASTERIS, NG; CADLE, A; LOGIE, LJ; PORTEOUS, MEM; SCHWARTZ, CE; STEVENSON, RE; GLOVER, TW; WILROY, RS; GORSKI, JL				PASTERIS, NG; CADLE, A; LOGIE, LJ; PORTEOUS, MEM; SCHWARTZ, CE; STEVENSON, RE; GLOVER, TW; WILROY, RS; GORSKI, JL			ISOLATION AND CHARACTERIZATION OF THE FACIOGENITAL DYSPLASIA (AARSKOG-SCOTT SYNDROME) GENE - A PUTATIVE RHO/RAC GUANINE-NUCLEOTIDE EXCHANGE FACTOR	CELL			English	Article							GTP-BINDING PROTEIN; AUTOSOMAL DOMINANT INHERITANCE; HUMAN X-CHROMOSOME; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; RAS; IDENTIFICATION; YEAST; RECEPTOR; GRB2	Faciogenital dysplasia (FGDY), also known as Aarskog-Scott syndrome, is an X-linked developmental disorder characterized by disproportionately short stature and by facial, skeletal, and urogenital anomalies. Molecular genetic analyses mapped FGDY to chromosome Xp11.21. To clone this gene, YAC clones spanning an FGDY-specific translocation breakpoint were isolated. An isolated cDNA, FGD1, is disrupted by the breakpoint, and FGD1 mutations cosegregate with the disease. FGD1 codes for a 961 amino acid protein that has strong homology to Rho/Rac guanine nucleotide exchange factors (GEFs), contains a cysteine-rich zinc finger-like region, and, like the RasGEF mSos, contains two potential SH3-binding sites. These results provide compelling evidence that FGD1 is responsible for FGDY and suggest that FGD1 is a Rho/RacGEF involved in mammalian development.	UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV EDINBURGH,DEPT HUMAN GENET,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; GREENWOOD GENET CTR,GREENWOOD,SC 29646; UNIV TENNESSEE,MEMPHIS HLTH SCI CTR,DEPT PEDIAT,MEMPHIS,TN 38105	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Edinburgh; Greenwood Genetic Center; University of Tennessee System; University of Tennessee Health Science Center					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030771] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00042] Funding Source: Medline; NINDS NIH HHS [NS-30771] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AARSKOG D, 1970, J PEDIATR-US, V77, P856, DOI 10.1016/S0022-3476(70)80247-5; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ARVEILER B, 1991, Technique (Philadelphia), V3, P24; BAWLE E, 1984, AM J MED GENET, V17, P595, DOI 10.1002/ajmg.1320170307; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; DUNCAN PA, 1977, J PEDIATR-US, V91, P769, DOI 10.1016/S0022-3476(77)81038-X; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; European Chromosome 16 Tuberous Sclerosis C., 1993, CELL, V75, P1305; FRYNS JP, 1992, AM J MED GENET, V43, P420, DOI 10.1002/ajmg.1320430164; GLOVER TW, 1993, HUM MOL GENET, V10, P1717; Gorlin RJ, 1990, PLAST RECONSTR SURG; GORSKI JL, 1989, CYTOGENET CELL GENET, V52, P90, DOI 10.1159/000132849; GORSKI JL, 1992, GENOMICS, V14, P657, DOI 10.1016/S0888-7543(05)80165-X; GRIER RE, 1983, AM J MED GENET, V15, P39, DOI 10.1002/ajmg.1320150105; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAFRENIERE RG, 1991, GENOMICS, V11, P352, DOI 10.1016/0888-7543(91)90143-3; LEE JT, 1992, GENOMICS, V12, P526, DOI 10.1016/0888-7543(92)90444-W; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIFSHITZ B, 1988, ONCOGENE, V2, P113; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; MELNICK M, 1976, CLIN GENET, V9, P20; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PASTERIS NG, 1993, NUCLEIC ACIDS RES, V21, P5275, DOI 10.1093/nar/21.22.5275; PORTEOUS MEM, 1992, GENOMICS, V14, P298, DOI 10.1016/S0888-7543(05)80219-8; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sambrook J, 1989, MOL CLONING LABORATO; Scott CIJ, 1971, CLIN DELINEATION BIR, V10, P240; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STEVENSON RE, 1994, IN PRESS AM J MED GE; TOMMERUP N, 1993, J MED GENET, V30, P713, DOI 10.1136/jmg.30.9.713; VANDEVOOREN MJ, 1983, CLIN GENET, V24, P439; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0	57	257	260	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					669	678						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954831				2022-12-28	WOS:A1994PT48100014
J	ANTHONISEN, NR; CONNETT, JE; KILEY, JP; ALTOSE, MD; BAILEY, WC; BUIST, AS; CONWAY, WA; ENRIGHT, PL; KANNER, RE; OHARA, P; OWENS, GR; SCANLON, PD; TASHKIN, DP; WISE, RA				ANTHONISEN, NR; CONNETT, JE; KILEY, JP; ALTOSE, MD; BAILEY, WC; BUIST, AS; CONWAY, WA; ENRIGHT, PL; KANNER, RE; OHARA, P; OWENS, GR; SCANLON, PD; TASHKIN, DP; WISE, RA			EFFECTS OF SMOKING INTERVENTION AND THE USE OF AN INHALED ANTICHOLINERGIC BRONCHODILATOR ON THE RATE OF DECLINE OF FEV(1) - THE LUNG HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; FORCED EXPIRATORY VOLUME; CHRONIC-BRONCHITIS; CLINICAL-TRIAL; ONE 2ND; CANCER; RISK; PARTICIPANTS; DESIGN; MODELS	Objective.-To determine whether a program incorporating smoking intervention and use of an inhaled bronchodilator can slow the rate of decline in forced expiratory volume in 1 second (FEV(1)) in smokers aged 35 to 60 years who have mild obstructive pulmonary disease. Design.-Randomized clinical trial. Participants randomized with equal probability to one of the following groups: (1) smoking intervention plus bronchodilator, (2) smoking intervention plus placebo, or (3) no intervention. Setting.-Ten clinical centers in the United States and Canada. Participants.-A total of 5887 male and female smokers, aged 35 to 60 years, with spirometric signs of early chronic obstructive pulmonary disease. Interventions.-Smoking intervention: intensive 12-session smoking cessation program combining behavior modification and use of nicotine gum, with continuing 5-year maintenance program to minimize relapse. Bronchodilator: ipratropium bromide prescribed three times daily (two puffs per time) from a metered-dose inhaler. Main Outcome Measures.-Rate of change and cumulative change in FEV(1) over a 5-year period. Results.-Participants in the two smoking intervention groups showed significantly smaller declines in FEV(1) than did those in the control group. Most of this difference occurred during the first year following entry into the study and was attributable to smoking cessation, with those who achieved sustained smoking cessation experiencing the largest benefit. The small noncumulative benefit associated with use of the active bronchodilator vanished after the bronchodilator was discontinued at the end of the study. Conclusions.-An aggressive smoking intervention program significantly reduces the age-related decline in FEV(1) in middle-aged smokers with mild airways obstruction. Use of an inhaled anticholinergic bronchodilator results in a relatively small improvement in FEV(1) that appears to be reversed after the drug is discontinued. Use of the bronchodilator did not influence the long-term decline of FEV(1).	UNIV MANITOBA,WINNIPEG,MB,CANADA; UNIV MINNESOTA,MINNEAPOLIS,MN 55455; NHLBI,BETHESDA,MD 20892; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; UNIV ALABAMA,BIRMINGHAM,AL; OREGON HLTH SCI UNIV,PORTLAND,OR 97201; HENRY FORD HOSP,DETROIT,MI 48202; UNIV ARIZONA,TUCSON,AZ; UNIV UTAH,SALT LAKE CITY,UT; UNIV MIAMI,MIAMI,FL 33152; UNIV PITTSBURGH,PITTSBURGH,PA; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905; UNIV CALIF LOS ANGELES,LOS ANGELES,CA; JOHNS HOPKINS UNIV,BALTIMORE,MD	University of Manitoba; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Case Western Reserve University; University of Alabama System; University of Alabama Birmingham; Oregon Health & Science University; Henry Ford Health System; Henry Ford Hospital; University of Arizona; Utah System of Higher Education; University of Utah; University of Miami; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Mayo Clinic; University of California System; University of California Los Angeles; Johns Hopkins University				Connors, Alfred F./0000-0001-7123-3360; Wise, Robert/0000-0002-8353-2349	DIVISION OF LUNG DISEASES [N01HR046002] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00064] Funding Source: Medline; NHLBI NIH HHS [N01-HR-46002] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P814; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P14, DOI 10.1164/arrd.1986.133.1.14; BARTER CE, 1974, AUST NZ J MED, V4, P339, DOI 10.1111/j.1445-5994.1974.tb03201.x; BUIST AS, 1979, AM REV RESPIR DIS, V120, P953; BUIST AS, 1993, CHEST, V103, P1863, DOI 10.1378/chest.103.6.1863; BURROWS B, 1969, AM REV RESPIR DIS, V99, P865; CAMPBELL AH, 1985, THORAX, V40, P741, DOI 10.1136/thx.40.10.741; CONNETT JE, 1993, CONTROL CLIN TRIALS, V14, pS38; CONNETT JE, 1993, CONTROL CLIN TRIALS, V14, pS3; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DURKIN DA, 1993, CONTROL CLIN TRIALS, V14, pS20; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215, DOI 10.1164/ajrccm/143.6.1215; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Fletcher C., 1976, NATURAL HIST BRONCHI; GROSS NJ, 1975, AM REV RESPIR DIS, V112, P823; HALEY NJ, 1983, AM J PUBLIC HEALTH, V73, P1204, DOI 10.2105/AJPH.73.10.1204; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KULLER LH, 1990, AM J EPIDEMIOL, V132, P265, DOI 10.1093/oxfordjournals.aje.a115656; MASSEY KL, 1985, DRUG INTEL CLIN PHAR, V19, P5, DOI 10.1177/106002808501900102; MCCARTHY DS, 1976, AM REV RESPIR DIS, V104, P103; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; OHARA P, 1993, PREV MED, V22, P304, DOI 10.1006/pmed.1993.1025; OSCHERWITZ M, 1972, AM J EPIDEMIOL, V96, P319, DOI 10.1093/oxfordjournals.aje.a121462; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; RUTH KJ, 1991, PREV MED, V20, P574, DOI 10.1016/0091-7435(91)90056-A; SKILLRUD DM, 1986, ANN INTERN MED, V105, P503, DOI 10.7326/0003-4819-105-4-503; SLUITER HJ, 1991, EUR RESPIR J, V4, P479; TASHKIN DP, 1986, AM J MED, V81, P81, DOI 10.1016/0002-9343(86)90468-7; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301, DOI 10.1164/ajrccm/145.2_Pt_1.301; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512; VOLLMER WM, 1985, AM REV RESPIR DIS, V132, P1186; WU MC, 1988, STAT MED, V7, P337, DOI 10.1002/sim.4780070134; XU XP, 1992, AM REV RESPIR DIS, V146, P1345, DOI 10.1164/ajrccm/146.5_Pt_1.1345; 1990, BMDP STATISTICAL SOF, V2, P1207; [No title captured]; 1991, AM REV RESPIR DIS, V144, P1202; 1993, SAS STAT USERS GUIDE; 1988, NOMAD2 REFERENCE MAN	40	1295	1342	1	37	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1497	1505		10.1001/jama.272.19.1497	http://dx.doi.org/10.1001/jama.272.19.1497			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966841				2022-12-28	WOS:A1994PQ90000028
J	SCHABLE, C; ZEKENG, L; PAU, CP; HU, D; KAPTUE, L; GURTLER, L; DONDERO, T; TSAGUE, JM; SCHOCHETMAN, G; JAFFE, H; GEORGE, JR				SCHABLE, C; ZEKENG, L; PAU, CP; HU, D; KAPTUE, L; GURTLER, L; DONDERO, T; TSAGUE, JM; SCHOCHETMAN, G; JAFFE, H; GEORGE, JR			SENSITIVITY OF UNITED-STATES HIV ANTIBODY TESTS FOR DETECTION OF HIV-1 GROUP-O INFECTIONS	LANCET			English	Note								Infections by highly divergent strains of HIV-1, first detected in central Africa and grouped provisionally as group O, have not been reliably detected by certain European HIV screening tests. Serum specimens from eight probable group O infections from Cameroon were tested by ten HIV assays licensed by the US Food and Drug Administration. All assays based on synthetic peptides or recombinant antigens failed to detect at least one of the infections; assays based on whole-virus lysates performed better. Divergent HIV strains may be undetected by current HIV tests. Thus active surveillance for and characterisation of HIV variants to evaluate and, when necessary, modify current tests is urgently needed.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; UNIV YAOUNDE,YAOUNDE,CAMEROON; MAX VON PETTENKOFER INST,W-8000 MUNICH,GERMANY	Centers for Disease Control & Prevention - USA; University of Yaounde I; University of Munich				Gurtler, Lutz/0000-0003-3435-9030				DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; GURTLER LG, 1994, J VIROL, V68, P1581; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; MYERS G, 1993, HUMAN RETROVIRUSES A; NKENGASONG JN, 1993, AIDS, V7, P1536, DOI 10.1097/00002030-199311000-00026; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005	7	110	117	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1333	1334		10.1016/S0140-6736(94)90695-5	http://dx.doi.org/10.1016/S0140-6736(94)90695-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968029				2022-12-28	WOS:A1994PQ92600011
J	WILSON, APR				WILSON, APR			THE DANGERS OF BIPP	LANCET			English	Editorial Material											WILSON, APR (corresponding author), UCL HOSP, DEPT CLIN MICROBIOL, LONDON, ENGLAND.							BLACK B, 1979, CLIN OTOLARYNGOL, V4, P207, DOI 10.1111/j.1365-2273.1979.tb01887.x; Chambers H, 1917, LANCET, V1, P333; CHEVRETTON EB, 1991, J LARYNGOL OTOL, V105, P916, DOI 10.1017/S0022215100117803; Colman G, 1962, BR DENT J, V113, P22; JONES JAH, 1990, ORAL SURG ORAL MED O, V69, P668, DOI 10.1016/0030-4220(90)90344-R; KRUGER G, 1976, LANCET, V2, P485; LEQUESNE PM, 1981, J NEUROL NEUROSUR PS, V44, P1, DOI 10.1136/jnnp.44.1.1; MCRAE RDR, 1992, J LARYNGOL OTOL, V106, P387; MILLER WA, 1974, BRIT DENT J, V137, P278, DOI 10.1038/sj.bdj.4803305; NIGAM A, 1990, CLIN OTOLARYNGOL, V15, P173, DOI 10.1111/j.1365-2273.1990.tb00452.x; OCONNOR AFF, 1977, J LARYNGOL OTOL, V91, P903, DOI 10.1017/S002221510008453X; SHARMA RR, 1994, J NEUROL NEUROSUR PS, V57, P990, DOI 10.1136/jnnp.57.8.990	12	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1313	1314		10.1016/S0140-6736(94)90689-0	http://dx.doi.org/10.1016/S0140-6736(94)90689-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968025				2022-12-28	WOS:A1994PQ92600005
J	SPECTOR, SA; GELBER, RD; MCGRATH, N; WARA, D; BARZILAI, A; ABRAMS, E; BRYSON, YJ; DANKNER, WM; LIVINGSTON, RA; CONNOR, EM; SHEARER, WT; DOYLE, M; HANSON, CG; LAFLEN, J; PELTON, SI; COOPER, ER; REGAN, AM; TOLTZIS, P; ZUCKER, M; CHANCE, M; YOGEV, R; CHADWICK, E; BAKER, RC; SIEGEL, R; PITT, J; GERSHON, AA; KANEM, N; NESHEIM, SR; NAHMIAS, AJ; KEYSERLING, HL; SAWYER, MK; DOSSETT, J; EYSTER, ME; CUBBLE, LJ; YOLKEN, R; MODLIN, J; VINK, P; WARFORD, R; HEATON, S; HODES, D; SACKS, HS; MCSHERRY, G; OLESKE, J; PICARDI, J; COLABELLI, N; GUPTA, A; BORKOWSKY, W; CHANDWANI, S; RIGAUD, M; KAUL, A; BRADY, MT; HUNKLER, JA; CRIM, LB; BONAGURA, VR; VALACER, DJ; BAKSHI, S; GRIECO, MH; RIVERS, J; MCKINLEY, G; FIKRIG, S; VANDYKE, RB; ALCHEDIAK, T; DEVEIKIS, A; WONG, V; CHURCH, J; DORENBAUM, A; PETRU, A; TREBITHICK, D; RICH, K; CHEESEMAN, S; SULLIVAN, JL; LUZURIAGA, K; JONES, CR; GOODROAD, BK; BALFOUR, HH; DIAZ, C; LUGO, L; FLORES, L; RIVERA, C; BURCHETT, SK; MOHAN, K; FOSTER, I; COREY, L; STORCH, G; BREUKLANDER, L; ROYAL, M				SPECTOR, SA; GELBER, RD; MCGRATH, N; WARA, D; BARZILAI, A; ABRAMS, E; BRYSON, YJ; DANKNER, WM; LIVINGSTON, RA; CONNOR, EM; SHEARER, WT; DOYLE, M; HANSON, CG; LAFLEN, J; PELTON, SI; COOPER, ER; REGAN, AM; TOLTZIS, P; ZUCKER, M; CHANCE, M; YOGEV, R; CHADWICK, E; BAKER, RC; SIEGEL, R; PITT, J; GERSHON, AA; KANEM, N; NESHEIM, SR; NAHMIAS, AJ; KEYSERLING, HL; SAWYER, MK; DOSSETT, J; EYSTER, ME; CUBBLE, LJ; YOLKEN, R; MODLIN, J; VINK, P; WARFORD, R; HEATON, S; HODES, D; SACKS, HS; MCSHERRY, G; OLESKE, J; PICARDI, J; COLABELLI, N; GUPTA, A; BORKOWSKY, W; CHANDWANI, S; RIGAUD, M; KAUL, A; BRADY, MT; HUNKLER, JA; CRIM, LB; BONAGURA, VR; VALACER, DJ; BAKSHI, S; GRIECO, MH; RIVERS, J; MCKINLEY, G; FIKRIG, S; VANDYKE, RB; ALCHEDIAK, T; DEVEIKIS, A; WONG, V; CHURCH, J; DORENBAUM, A; PETRU, A; TREBITHICK, D; RICH, K; CHEESEMAN, S; SULLIVAN, JL; LUZURIAGA, K; JONES, CR; GOODROAD, BK; BALFOUR, HH; DIAZ, C; LUGO, L; FLORES, L; RIVERA, C; BURCHETT, SK; MOHAN, K; FOSTER, I; COREY, L; STORCH, G; BREUKLANDER, L; ROYAL, M			CONTROLLED TRIAL OF INTRAVENOUS IMMUNE GLOBULIN FOR THE PREVENTION OF SERIOUS BACTERIAL-INFECTIONS IN CHILDREN RECEIVING ZIDOVUDINE FOR ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-TRIALS; GAMMA-GLOBULIN; IMMUNOGLOBULIN	Background. Serious bacterial infections are common in children infected with the human immunodeficiency virus (HIV). Studies performed before zidovudine became standard therapy found that intravenous immune globulin decreases the number of serious bacterial infections in these children. We designed a multicenter study to evaluate the efficacy of intravenous immune globulin in children with advanced HIV infection who were receiving zidovudine. Methods. In a double-blind trial 255 children between 3 months and 12 years of age who had the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex were randomly assigned to receive either intravenous immune globulin (400 mg per kilogram of body weight) (n = 129) or placebo (0.1 percent albumin) (n = 126) every 28 days. All children received 180 mg of zidovudine per square meter of body-surface area orally four times daily. Treatment assignment was stratified according to whether the patients had a history of one or more serious bacterial infections, had previously been treated with zidovudine, or were currently receiving prophylaxis with trimethoprim-sulfamethoxazole. The median length of follow-up was 30.6 months. Results. The estimated two-year rates of serious bacterial infections with confirmed pathogens were 16.9 percent for the immune globulin group and 24.3 percent for the placebo group (relative risk, 0.60; 95 percent confidence interval, 0.35 to 1.04; P = 0.07). The treatment effect was seen primarily among the 174 children who were not receiving trimethoprim-sulfamethoxazole prophylaxis at entry; the estimated two-year rates of infection were 11.3 percent for the immune globulin group and 26.8 percent for the placebo group (relative risk, 0.45; 95 percent confidence interval, 0.22 to 0.91; P = 0.03). For the 81 children who were receiving trimethoprim-sulfamethoxatele prophylaxis initially, the rates were 27.7 percent in the immune globulin group and 17.7 percent in the placebo group (relative risk, 1.26; 95 percent confidence interval, 0.44 to 3.66; P = 0.67). The two-year survival was similar in the two groups: 79.2 percent among immune globulin recipients and 75.4 percent among placebo recipients (P = 0.41). Conclusions. In children with advanced HIV disease who are receiving zidovudine, intravenous immune globulin decreases the risk of serious bacterial infections. However, this benefit is apparent only in children who are not receiving trimethoprim-sulfamethoxazole as prophylaxis.	HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; MT SINAI HOSP,NEW YORK,NY 10029; COLUMBIA UNIV,NEW YORK,NY; UNIV CALIF LOS ANGELES,LOS ANGELES,CA; JOHNS HOPKINS UNIV,BALTIMORE,MD; UNIV MED & DENT NEW JERSEY,NEWARK,NJ; BAYLOR UNIV,HOUSTON,TX 77030; BOSTON CITY HOSP,BOSTON,MA 02118; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; CHILDRENS MEM HOSP,CHICAGO,IL 60614; CINCINNATI CHILDRENS HOSP,CINCINNATI,OH; EMORY UNIV,ATLANTA,GA 30322; MILTON S HERSHEY MED CTR,HERSHEY,PA; MT SINAI MED CTR,NEW YORK,NY 10029; NEW YORK MED COLL,VALHALLA,NY 10595; NYU,NEW YORK,NY; OHIO STATE UNIV,COLUMBUS,OH 43210; SCHNEIDER CHILDRENS HOSP,NEW HYDE PK,NY; ST LUKES ROOSEVELT HOSP,NEW YORK,NY 10025; SUNY HLTH SCI CTR,BROOKLYN,NY; UNIV ILLINOIS,CHICAGO,IL; UNIV MASSACHUSETTS,WORCESTER,MA 01605; UNIV MINNESOTA,MINNEAPOLIS,MN 55455; UNIV PUERTO RICO,SAN JUAN,PR 00936; UNIV WASHINGTON,SEATTLE,WA 98195; WASHINGTON UNIV,ST LOUIS,MO; TULANE UNIV,NEW ORLEANS,LA 70118	Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Francisco; Icahn School of Medicine at Mount Sinai; Columbia University; University of California System; University of California Los Angeles; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Baylor University; Boston Medical Center; Case Western Reserve University; Ann & Robert H. Lurie Children's Hospital of Chicago; Cincinnati Children's Hospital Medical Center; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Icahn School of Medicine at Mount Sinai; New York Medical College; New York University; University System of Ohio; Ohio State University; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Mount Sinai St. Luke's; Mount Sinai West; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Massachusetts System; University of Massachusetts Worcester; University of Minnesota System; University of Minnesota Twin Cities; University of Puerto Rico; University of Washington; University of Washington Seattle; Washington University (WUSTL); Tulane University	SPECTOR, SA (corresponding author), UNIV CALIF SAN DIEGO,9500 GILMAN DR,LA JOLLA,CA 92093, USA.		yolken, robert/AAW-2556-2021	McGrath, Nuala/0000-0002-1039-0159				AMMANN AJ, 1984, JAMA-J AM MED ASSOC, V251, P1447, DOI 10.1001/jama.251.11.1447; BERNSTEIN LJ, 1985, PEDIATR INFECT DIS J, V4, P472, DOI 10.1097/00006454-198509000-00005; CALVELLI TA, 1986, PEDIATR INFECT DIS J, V5, pS207; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; COX DR, 1972, J R STAT SOC B, V34, P187; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Greenwood M., 1926, REPORTS PUBLIC HLTH, V33, P1; GUPTA A, 1986, AM J DIS CHILD, V140, P143, DOI 10.1001/archpedi.1986.02140160061033; HAGUE RA, 1989, ARCH DIS CHILD, V64, P1146, DOI 10.1136/adc.64.8.1146; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIM K, 1990, BIOMETRICS, V46, P81, DOI 10.2307/2531632; KRASINSKI K, 1988, PEDIATR INFECT DIS J, V7, P323, DOI 10.1097/00006454-198805000-00006; LANE HC, 1985, ANNU REV IMMUNOL, V3, P477, DOI 10.1146/annurev.iy.03.040185.002401; MOFENSON LM, 1992, JAMA-J AM MED ASSOC, V268, P483, DOI 10.1001/jama.268.4.483; MOFENSON LM, 1993, J ACQ IMMUN DEF SYND, V6, P1101; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; ROILIDES E, 1991, PEDIATR INFECT DIS J, V10, P813, DOI 10.1097/00006454-199111000-00004; ROILIDES E, 1991, J PEDIATR-US, V118, P724, DOI 10.1016/S0022-3476(05)80033-2; SIEGAL FP, 1986, CLIN USE INTRAVENOUS, P373; WOOD CC, 1987, PEDIATR INFECT DIS J, V6, P564, DOI 10.1097/00006454-198706000-00015; 1987, MMWR MORB MORTAL S1S, V36, pS3; 1991, NEW ENGL J MED, V325, P73; 1991, MMWR-MORBID MORTAL W, V40, P1; 1987, MMWR-MORBID MORTAL W, V36, P225	24	109	110	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1181	1187		10.1056/NEJM199411033311802	http://dx.doi.org/10.1056/NEJM199411033311802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935655	Green Accepted			2022-12-28	WOS:A1994PN80600002
J	SCHLICHTING, I; BERENDZEN, J; PHILLIPS, GN; SWEET, RM				SCHLICHTING, I; BERENDZEN, J; PHILLIPS, GN; SWEET, RM			CRYSTAL-STRUCTURE OF PHOTOLYZED CARBONMONOXY-MYOGLOBIN	NATURE			English	Article							LIGAND-BINDING; HEME-PROTEINS; MOLECULAR-DYNAMICS; PHOTOPRODUCTS; RESOLUTION; MONOXIDE; RAMAN; CRYSTALLOGRAPHY; DIFFRACTION; REFINEMENT	MYOGLOBIN is a globular haem protein that reversibly binds ligands such as O-2 and CO. Single photons of visible light can break the covalent bond between CO and the haem iron in carbon-monoxy-myoglobin (MbCO) and thus form an unstable intermediate, Mb*CO, with the CO inside the protein(1,2). The ensuing rebinding process has been extensively studied as a model for the interplay of dynamics, structure and function in protein reactions. We have used X-ray crystallography at liquid-helium temperatures to determine the structure of Mb*CO to a resolution of 1.5 Angstrom. The photodissociated CO lies on top of the haem pyrrole ring C. Comparison with the CO-bound and unligated myoglobin structures reveals that on photodissociation of the CO, the haem 'domes', the iron moves partially out of the haem plane, the iron-proximal histidine bond is compressed, the F helix is strained and the distal histidine swings towards the outside of the ligand-binding pocket.	MAX PLANCK INST MED RES,DEPT BIOPHYS,D-69120 HEIDELBERG,GERMANY; RICE UNIV,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77251; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Max Planck Society; Rice University; United States Department of Energy (DOE); Brookhaven National Laboratory			Schlichting, Ilme/I-1339-2013	Berendzen, Joel/0000-0002-9454-9074				AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; AHMED AM, 1991, CHEM PHYS, V158, P329, DOI 10.1016/0301-0104(91)87076-8; ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BARTUNIK HD, 1983, NUCL INSTRUM METHODS, V208, P523, DOI 10.1016/0167-5087(83)91176-6; BRUNGER AT, 1993, XPLOR VERSION 31 MAN; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHENG XD, 1991, J MOL BIOL, V220, P381, DOI 10.1016/0022-2836(91)90020-7; DASGUPTA S, 1986, BIOCHEMISTRY-US, V25, P5941, DOI 10.1021/bi00368a016; GIBSON QH, 1992, J BIOL CHEM, V268, P17908; HONG MK, 1989, THESIS U ILLINOIS UR; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KUCZERA K, 1993, P NATL ACAD SCI USA, V90, P5805, DOI 10.1073/pnas.90.12.5805; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; POWERS L, 1987, BIOCHEMISTRY-US, V26, P4785, DOI 10.1021/bi00389a028; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; ROTHBERG LJ, 1991, P SPIE INT SOC OPT E, V1599, P309; ROUSSEAU DL, 1986, P NATL ACAD SCI USA, V83, P1310, DOI 10.1073/pnas.83.5.1310; SASSAROLI M, 1986, J BIOL CHEM, V261, P3704; STAVROV SS, 1993, BIOPHYS J, V65, P1942, DOI 10.1016/S0006-3495(93)81265-7; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; STRAUB JE, 1991, CHEM PHYS, V158, P221, DOI 10.1016/0301-0104(91)87068-7; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TENG TY, 1987, BIOCHEMISTRY-US, V26, P8066, DOI 10.1021/bi00399a007; TLTON RF, 1982, BIOCHEMISTRY-US, V23, P2849	31	336	338	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					808	812		10.1038/371808a0	http://dx.doi.org/10.1038/371808a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935843				2022-12-28	WOS:A1994PP01800063
J	HOLMES, J				HOLMES, J			CONTROVERSIES IN MANAGEMENT - PSYCHOTHERAPY - A LUXURY THE NHS CANNOT AFFORD - MORE EXPENSIVE NOT TO TREAT	BRITISH MEDICAL JOURNAL			English	Article											HOLMES, J (corresponding author), NO DEVON HLTHCARE TRUST,BARNSTAPLE,DEVON EX31 4RT,ENGLAND.							FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P1053; GUTHRIE E, 1993, BRIT J PSYCHIAT, V163, P315, DOI 10.1192/bjp.163.3.315; Holmes J., 1989, VALUES PSYCHOTHERAPY; KARASU TB, 1986, AM J PSYCHOTHER, V40, P324, DOI 10.1176/appi.psychotherapy.1986.40.3.324; LEFF J, 1984, EPRESSED EMOTION FAM; MCGRATH G, 1986, BRIT J PSYCHIAT, V150, P65; MENZIES D., 1993, PSYCHIATRIC B, V17, P517; ROSENTHAL R, 1990, AM PSYCHOL, V45, P775, DOI 10.1037/0003-066X.45.6.775; STEVENSON J, 1992, AM J PSYCHIAT, V149, P358; 1993, DRUGS THER B, V31, P73	10	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1070	1071		10.1136/bmj.309.6961.1070	http://dx.doi.org/10.1136/bmj.309.6961.1070			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN733	7950744	Green Published			2022-12-28	WOS:A1994PN73300029
J	SONG, YH; CONNOR, E; LI, YX; ZOROVICH, B; BALDUCCI, P; MACLAREN, N				SONG, YH; CONNOR, E; LI, YX; ZOROVICH, B; BALDUCCI, P; MACLAREN, N			THE ROLE OF TYROSINASE IN AUTOIMMUNE VITILIGO	LANCET			English	Article							MELANOCYTE AUTOANTIBODIES; DIABETES-MELLITUS; ANTIBODIES; SEQUENCE; CLONE	Vitiligo is a common depigmenting skin disease, associated with certain autoimmune endocrinopathies, and autoantibodies to several antigens can be found in melanoma cells. We set out to identify the antigens. We examined 26 patients with vitiligo and associated endocrine disease. Of these, 18 patients (77%) and 8 immediate family members had autoantibodies specific for a 69 kDa protein in HTB-70 human melanoma cells that was not seen in control cells. The autoantibody-positive patient sera reacted with recombinant human tyrosinase expressed in Escherichia cell seen by western blots, as did antibodies raised in rabbits against hamster tyrosinase, but not to recombinant tyrosinase-related protein. Not one of 31 normal controls or 8 patients with alopecia or systemic lupus erythematosus had tyrosinase autoantibodies but a small proportion (12%) of 42 patients with autoimmune endocrine disease without a history of vitiligo had them. The results show that tyrosinase, an enzyme important in melanin formation, is a principal autoantigen of autoimmune vitiligo.	UNIV FLORIDA,COLL MED,DEPT PATHOL & LAB MED,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT PEDIAT,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida			Song, Yao-Hua/A-2516-2011	Connor, Ellen/0000-0002-9667-7002	NICHD NIH HHS [R01HD19469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; AUSTIN LM, 1992, CLIN IMMUNOL IMMUNOP, V64, P112, DOI 10.1016/0090-1229(92)90188-T; BADRI M, 1993, J PATHOL, V170, P149; BROSTOFF J, 1969, LANCET, V2, P177; COHEN T, 1990, NUCLEIC ACIDS RES, V18, P2807, DOI 10.1093/nar/18.9.2807; CUI J, 1993, J INVEST DERMATOL, V100, P812, DOI 10.1111/1523-1747.ep12476636; GOUDIE RB, 1990, LANCET, V335, P316, DOI 10.1016/0140-6736(90)90607-7; GOULD IM, 1985, BRIT J DERMATOL, V113, P153, DOI 10.1111/j.1365-2133.1985.tb02057.x; HERTZ KC, 1977, NEW ENGL J MED, V297, P634, DOI 10.1056/NEJM197709222971204; HOWITZ J, 1971, LANCET, V1, P1331; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAMONT SJ, 1981, CLIN IMMUNOL IMMUNOP, V21, P407, DOI 10.1016/0090-1229(81)90229-4; LEPOOLE IC, 1993, J INVEST DERMATOL, V100, P816, DOI 10.1111/1523-1747.ep12476645; LORINI R, 1992, AUTOIMMUNITY, V11, P255, DOI 10.3109/08916939209035163; MACLAREN NK, 1985, DIABETES CARE, V8, P34, DOI 10.2337/diacare.8.1.S34; MOELLMANN GE, 1985, J INVEST DERMATOL, V84, P333; NAUGHTON GK, 1983, J INVEST DERMATOL, V81, P540, DOI 10.1111/1523-1747.ep12522891; NAUGHTON GK, 1983, J EXP MED, V158, P246, DOI 10.1084/jem.158.1.246; NEUFELD M, 1981, MEDICINE, V60, P355, DOI 10.1097/00005792-198109000-00003; NORRIS DA, 1988, J INVEST DERMATOL, V90, P783, DOI 10.1111/1523-1747.ep12461505; Sambrook J, 1989, MOL CLONING LABORATO; SEARLE EA, 1993, PIGM CELL RES, V6, P145, DOI 10.1111/j.1600-0749.1993.tb00594.x	24	151	165	3	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1049	1052		10.1016/S0140-6736(94)91709-4	http://dx.doi.org/10.1016/S0140-6736(94)91709-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934446				2022-12-28	WOS:A1994PL85200009
J	JACKSON, DY; BURNIER, J; QUAN, C; STANLEY, M; TOM, J; WELLS, JA				JACKSON, DY; BURNIER, J; QUAN, C; STANLEY, M; TOM, J; WELLS, JA			A DESIGNED PEPTIDE LIGASE FOR TOTAL SYNTHESIS OF RIBONUCLEASE-A WITH UNNATURAL CATALYTIC RESIDUES	SCIENCE			English	Article							BOVINE PANCREATIC RIBONUCLEASE; AMINO-ACIDS; PROTEINS; DEPENDENCE; ENZYMES	An engineered variant of subtilisin BPN', termed subtilligase, which efficiently ligates esterified peptides in aqueous solution, was used for the complete synthesis of ribonuclease (RNase) A that contains unnatural catalytic residues. Fully active RNase A (124 residues long) was produced in milligram quantities by stepwise ligation of six esterified peptide fragments (each 12 to 30 residues long) at yields averaging 70 percent per ligation. Variants of RNase A were produced in which the catalytic histidines at positions 12 and 119 were substituted with the unnatural amino acid 4-fluorohistidine, which has a pK(a) of 3.5 compared to 6.8 for histidine. Large changes in the profile of the pH as it affects rate occurred for the single and double mutants with surprisingly little change in the k(cat) for either the RNA cleavage or hydrolysis steps. The data indicate that these imidazoles function as general acids and bases, but that the proton transfer steps are not rate-limiting when the imidazoles are present in their correct protonation states. These studies indicate the potential of subtilligase for the blockwise synthesis of large proteins.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOORGAN CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016					ABRAHMSEN L, 1991, BIOCHEMISTRY-US, V30, P4151, DOI 10.1021/bi00231a007; ANSLYN E, 1989, J AM CHEM SOC, V111, P4473, DOI 10.1021/ja00194a050; BLACKBURN P, 1982, ENZYMES, V15; BODANSZKY M, 1984, PRACTICE PEPTIDE SYN, V21; BRESLOW R, 1991, TETRAHEDRON, V47, P2365, DOI 10.1016/S0040-4020(01)81774-9; BROWN TB, 1981, J CHEM SOC CHEM COMM, V408, P648; BRUICE TC, 1963, J AM CHEM SOC, V85, P1659, DOI 10.1021/ja00894a028; CAMPBELL RL, 1987, BIOCHEMISTRY-US, V26, P8579, DOI 10.1021/bi00400a013; CHANG TK, IN PRESS P NATL ACAD; DUNN BM, 1974, J BIOL CHEM, V249, P6295; FINDLAY D, 1962, BIOCHEM J, V85, P139, DOI 10.1042/bj0850139; FINK AL, 1987, BIOCHEMISTRY-US, V26, P8571, DOI 10.1021/bi00400a012; FUJII N, 1981, J CHEM SOC PERK T 1, P804, DOI 10.1039/p19810000804; FUJII N, 1981, J CHEM SOC PERK T 1, P789, DOI 10.1039/p19810000789; FUJII N, 1981, J CHEM SOC PERK T 1, P797, DOI 10.1039/p19810000797; GUTTE B, 1971, J BIOL CHEM, V246, P1922; HIRSCHMANN R, 1969, J AM CHEM SOC, V91, P502; Ipata P L., 1968, FEBS Lett, V1, P29, DOI 10.1016/0014-5793(68)80010-9; KAISER ET, 1989, ACCOUNTS CHEM RES, V22, P47, DOI 10.1021/ar00158a001; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KIRK KL, 1973, J AM CHEM SOC, V95, P4619, DOI 10.1021/ja00795a026; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; KULLMAN W, 1987, ENZYMATIC PEPTIDE SY; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MENDEL D, 1992, SCIENCE, V256, P1798, DOI 10.1126/science.1615324; NAKATSUKA T, 1987, J AM CHEM SOC, V109, P3808, DOI 10.1021/ja00246a064; NEET KE, 1966, P NATL ACAD SCI USA, V56, P1606, DOI 10.1073/pnas.56.5.1606; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; POLGAR L, 1966, J AM CHEM SOC, V88, P3153, DOI 10.1021/ja00965a060; RICO M, 1991, Journal of Biomolecular NMR, V1, P283, DOI 10.1007/BF01875521; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; TAYLOR HC, 1981, J MOL BIOL, V149, P313, DOI 10.1016/0022-2836(81)90305-3; THOMPSON JE, 1994, J AM CHEM SOC, V116, P5467, DOI 10.1021/ja00091a060; TRAUTWEIN K, 1991, FEBS LETT, V281, P275, DOI 10.1016/0014-5793(91)80410-5; USHER DA, 1972, P NATL ACAD SCI USA, V69, P115, DOI 10.1073/pnas.69.1.115; VEBER DF, 1977, J ORG CHEM, V42, P3286, DOI 10.1021/jo00440a018; WONG CH, 1993, J AM CHEM SOC, V115, P5893, DOI 10.1021/ja00067a001; WU Z, 1989, J AM CHEM SOC, V111, P2414	40	244	283	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					243	247		10.1126/science.7939659	http://dx.doi.org/10.1126/science.7939659			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939659				2022-12-28	WOS:A1994PM13400023
J	NESS, DE; ENDE, J				NESS, DE; ENDE, J			DENIAL IN THE MEDICAL INTERVIEW - RECOGNITION AND MANAGEMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; CAGE QUESTIONNAIRE; ILLNESS; ALCOHOLISM; SCALE; HISTORY; DELAY	Denial is a psychological defense in which the individual repudiates some or all of the meanings of an illness, thereby warding off an awareness of painful thoughts and feelings such as fear, grief, depression, and anger. Although it is often viewed as a problem, denial may at times be a healthy and adaptive response to illness. In the medical interview, denial may be exhibited by the patient, the physician, or both. Not all instances of denial can or should be addressed within the interview. The decision to address denial can be made based on how adaptive the denial is, what kind of psychosocial support is available to the patient, and how well prepared the patient is to deal with the fears that underlie denial. In those instances when denial should be addressed, the interviewer can use techniques of clarification, confrontation, and interpretation.	UNIV PENN,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104	University of Pennsylvania	NESS, DE (corresponding author), ALLEGHENY GEN HOSP,MED COLL PENN & HANEMANN UNIV,DEPT PSYCHIAT,ALLEGHENY CAMPUS,320 E NORTH AVE,PITTSBURGH,PA 15212, USA.							BARSKY AJ, 1990, JAMA-J AM MED ASSOC, V264, P1132, DOI 10.1001/jama.264.9.1132; BEISSER AR, 1979, AM J PSYCHIAT, V136, P1026; BILLINGS JA, 1989, CLIN ENCOUNTER GUIDE, P180; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CARSKY M, 1992, J NERV MENT DIS, V180, P458, DOI 10.1097/00005053-199207000-00009; COHENCOLE S, 1991, MED INTERVIEW 3 FUNC, P151; COX A, 1981, BRIT J PSYCHIAT, V139, P144, DOI 10.1192/bjp.139.2.144; COX A, 1981, BRIT J PSYCHIAT, V138, P406; Crouch M A, 1986, Fam Med, V18, P15; CYR MG, 1988, JAMA-J AM MED ASSOC, V259, P51, DOI 10.1001/jama.259.1.51; DEAN C, 1989, J PSYCHOSOM RES, V33, P561, DOI 10.1016/0022-3999(89)90063-9; DOUGLAS CJ, 1987, GEN HOSP PSYCHIAT, V9, P53, DOI 10.1016/0163-8343(87)90102-2; DRUSS RG, 1969, ARCH GEN PSYCHIAT, V20, P419; DRUSS RG, 1988, GEN HOSP PSYCHIAT, V10, P163, DOI 10.1016/0163-8343(88)90015-1; ELLIS SJ, 1993, STROKE, V24, P757, DOI 10.1161/01.STR.24.5.757; ENDE J, 1984, ARCH INTERN MED, V144, P558, DOI 10.1001/archinte.144.3.558; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOWERS BJ, 1992, J PSYCHOSOM RES, V36, P469, DOI 10.1016/0022-3999(92)90007-O; FREUD A, 1966, EGO MECH DEF, P79; FREUD A, 1965, NORMALITY PATHOLOGY, P177; GABBARD GO, 1990, PSYCHODYNAMIC PSYCHI, P79; GOLDSMITH RJ, 1988, J NERV MENT DIS, V176, P614, DOI 10.1097/00005053-198810000-00006; GORLIN R, 1983, NEW ENGL J MED, V308, P1059, DOI 10.1056/NEJM198305053081804; GREENSTEIN R A, 1990, Emergency Medicine Clinics of North America, V8, P429; GREER S, 1990, LANCET, V335, P49, DOI 10.1016/0140-6736(90)90173-3; HACKETT TP, 1973, NEW ENGL J MED, V289, P14, DOI 10.1056/NEJM197307052890104; HACKETT TP, 1974, J PSYCHOSOM RES, V13, P93; HAUSER ST, 1993, DO FAMILIES COPE CHR, P26; JACOBSEN BS, 1992, PSYCHOSOM MED, V54, P372, DOI 10.1097/00006842-199205000-00012; JANNE P, 1991, JAMA-J AM MED ASSOC, P265; KERNBERG OF, 1989, PSYCHODYNAMIC PSYCHO, P11; KUBLERROSS E, 1969, DEATH DYING, P39; LEVENSON JL, 1989, PSYCHOSOM MED, V51, P27, DOI 10.1097/00006842-198901000-00003; LEVINE J, 1987, PSYCHOSOM MED, V49, P109, DOI 10.1097/00006842-198703000-00001; LOWERY BJ, 1992, HEART LUNG, V21, P523; MARTIN AR, 1983, ARCH INTERN MED, V143, P1773, DOI 10.1001/archinte.143.9.1773; MILLER LJ, 1990, HOSP COMMUNITY PSYCH, V41, P1233; Mishler EG, 1984, DISCOURSE MED DIALEC; Moore B. E., 1990, PSYCHOANALYTIC TERMS; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; MOSES R, 1966, ANN NY ACAD SCI, V125, P984, DOI 10.1111/j.1749-6632.1966.tb45450.x; MOSES R, 1983, DENIAL STRESS, P287; PERRY JC, 1986, EMPIRICAL STUDIES EG, P124; PHELAN M, 1992, J ROY SOC MED, V85, P206; QUILL TE, 1989, ANN INTERN MED, V111, P51, DOI 10.7326/0003-4819-111-1-51; REISER DE, 1980, PATIENT INTERVIEWING, P62; SHELP EE, 1985, ARCH INTERN MED, V145, P697, DOI 10.1001/archinte.145.4.697; Shuy R., 1983, SOCIAL ORG DOCTOR PA, P189; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; STRAUSS DH, 1990, AM J PSYCHIAT, V147, P1168; WATSON M, 1984, CANCER-AM CANCER SOC, V53, P2008, DOI 10.1002/1097-0142(19840501)53:9<2008::AID-CNCR2820530934>3.0.CO;2-B; WEST C, 1983, SOCIAL ORG DOCTOR PA, P75; Wool M S, 1988, Adv Psychosom Med, V18, P37; YELLOWLEES PM, 1989, CHEST, V95, P1298, DOI 10.1378/chest.95.6.1298	55	36	36	2	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1777	1781		10.1001/jama.272.22.1777	http://dx.doi.org/10.1001/jama.272.22.1777			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PV815	7966927				2022-12-28	WOS:A1994PV81500028
J	HOROWITZ, HW; VALSAMIS, MP; WICHER, V; ABBRUSCATO, F; LARSEN, SA; WORMSER, GP; WICHER, K				HOROWITZ, HW; VALSAMIS, MP; WICHER, V; ABBRUSCATO, F; LARSEN, SA; WORMSER, GP; WICHER, K			CEREBRAL SYPHILITIC GUMMA CONFIRMED BY THE POLYMERASE CHAIN-REACTION IN A MAN WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; TREPONEMA-PALLIDUM; HIV-INFECTION; NEUROSYPHILIS; DIAGNOSIS; PURIFICATION; INVASION; LESIONS; TISSUES; DNA		NEW YORK MED COLL,DEPT MED,DIV INFECT DIS,VALHALLA,NY 10595; NEW YORK MED COLL,DEPT PATHOL,VALHALLA,NY 10595; NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201; CTR DIS CONTROL & PREVENT,DIV SEXUALLY TRANSMITTED DIS LAB RES,ATLANTA,GA	New York Medical College; New York Medical College; State University of New York (SUNY) System; Wadsworth Center; Centers for Disease Control & Prevention - USA					PHS HHS [A 121833] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERGER JR, 1992, NEUROLOGY, V42, P1282, DOI 10.1212/WNL.42.7.1282; BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BURSTAIN JM, 1991, J CLIN MICROBIOL, V29, P62, DOI 10.1128/JCM.29.1.62-69.1991; DALLAS WS, 1987, INFECT IMMUN, V55, P1106, DOI 10.1128/IAI.55.5.1106-1115.1987; HAY PE, 1990, GENITOURIN MED, V66, P374; HUNTER EF, 1984, ARCH PATHOL LAB MED, V108, P878; ITO F, 1992, J CLIN MICROBIOL, V30, P831, DOI 10.1128/JCM.30.4.831-838.1992; ITO F, 1991, J CLIN MICROBIOL, V29, P444, DOI 10.1128/JCM.29.3.444-448.1991; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; KATZ DA, 1993, ARCH NEUROL-CHICAGO, V50, P614; KATZ DA, 1993, ARCH NEUROL-CHICAGO, V50, P243, DOI 10.1001/archneur.1993.00540030009006; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MORGELLO S, 1989, HUM PATHOL, V20, P808, DOI 10.1016/0046-8177(89)90078-6; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; NOORDHOEK GT, 1991, J CLIN MICROBIOL, V29, P1976, DOI 10.1128/JCM.29.9.1976-1984.1991; PETERS M, 1993, J INFECTION, V27, P57, DOI 10.1016/0163-4453(93)93768-Y; SANCHEZ PJ, 1993, J INFECT DIS, V167, P148, DOI 10.1093/infdis/167.1.148; SOTREL A, 1992, AIDS OTHER MANIFESTA, P543; VOLKENANDT M, 1993, PCR SELECTED PROTOCO, P81; WICHER K, 1992, J CLIN MICROBIOL, V30, P497, DOI 10.1128/JCM.30.2.497-500.1992; WOLTERS EC, 1987, CLIN NEUROPHARMACOL, V10, P143, DOI 10.1097/00002826-198704000-00004; 1993, BLUGENE NONRADIOACTI	23	48	50	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1488	1491		10.1056/NEJM199412013312204	http://dx.doi.org/10.1056/NEJM199412013312204			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969298				2022-12-28	WOS:A1994PU86600004
J	EMANUEL, EJ				EMANUEL, EJ			THE HISTORY OF EUTHANASIA DEBATES IN THE UNITED-STATES AND BRITAIN	ANNALS OF INTERNAL MEDICINE			English	Review							ACTIVE EUTHANASIA; LIFE	Debates about the ethics of euthanasia and physician-assisted suicide date from ancient Greece and Pome. After the development of ether, physicians began advocating the use of anesthetics to relieve the pains of death. In 1870, Samuel Williams first proposed using anesthetics and morphine to intentionally end a patient's life. Over the next 35 years, debates about the ethics of euthanasia raged in the United States and Britain,culminating in 1906 in an Ohio bill to legalize euthanasia, a bill that was ultimately defeated. The arguments propounded for and against euthanasia in the 19th century are identical to contemporary arguments. Such similarities suggest four conclusions: Public interest in euthanasia 1) is not linked with advances in biomedical technology; 2) it flourishes in times of economic recession, in which individualism and social Darwinism are invoked to justify public policy; 3) it arises when physician authority over medical decision making is challenged; and 4) it occurs when terminating life-sustaining medical interventions become standard medical practice and interest develops in extending such practices to include euthanasia.			EMANUEL, EJ (corresponding author), DANA FARBER CANC INST, 44 BINNEY ST, BOSTON, MA 02115 USA.							ALEXANDER L, 1949, NEW ENGL J MED, V241, P39, DOI 10.1056/NEJM194907142410201; AMUNDSEN DW, 1978, HASTINGS CENT REP, V8, P23, DOI 10.2307/3560974; Bach A, 1896, MED LEG J, V14, P103; BACON F, 1924, NEW ATLANTIS; BALDWIN SE, 1899, ST PAUL MED J, V1, P875; Bannister Robert C., 1988, SOCIAL DARWINISM SCI; BINDING K, 1992, ISSUES LAW MED, V8, P231; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; Bullar Joseph, 1866, BRIT MED J, V2, P10; BURNIE WG, 1899, LANCET, V1, P561; Carrick P, 1985, MED ETHICS ANTIQUITY; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; COSTIGAN G, 1906, NY TIMES        0206, P8; Degler C., 1991, SEARCH HUMAN NATURE; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Douglas CE, 1936, BRIT MED J, V1936, P33; DRINK ERP, 1929, JAMA-J AM MED ASSOC, V92, P1658; Edelstein L, 1967, ANCIENT MED SELECTED; EMANUEL EJ, 1991, ENDS HUMAN LIFE; Fleming RA, 1936, BRIT MED J, V1936, P86; FONER E, 1992, SOCIAL DARWINISM AM, pR20; FYE WB, 1978, B HIST MED, V52, P492; GARVER KL, 1991, AM J HUM GENET, V49, P1109; Gillon R., 1969, EUTHANASIA RIGHT DEA; GOUREVITCH D, 1969, Bulletin of the History of Medicine, V43, P501; Griffiths G, 1936, BRIT MED J, V1936, P134; HELME T, 1991, J MED ETHICS, V17, P25, DOI 10.1136/jme.17.1.25; HITCHCOCK FE, 1889, T MAINE MED SOC, V10, P30; Hofstadter Richard, 1992, SOCIAL DARWINISM AM; HUME D, 1854, PHILOS WORKS, V4, P535; JACOBI A, 1912, MED REV REV, V18, P362; KAMISAR Y, 1958, MINN LAW REV, V42, P969; KASS LR, 1989, PUBLIC INTEREST, P25; Lifton R. J., 1986, NAZI DOCTORS MED KIL; Manson JS, 1936, BRIT MED J, V1936, P87; McGarry PJ, 1936, BRIT MED J, V1936, P134; MILLARD CK, 1931, PUBLIC HLTH, V45, P39; MILLARD CK, 1935, BRIT MED J, V2, P1181; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; MORE T, 1984, UTOPIA OTHER WRITING; MUNK W, 1887, EUTHANASIA MED TREAT; PERNICK MS, 1985, CALCULUS SUFFERING; Pfafflin F, 1986, Med Law, V5, P1; PLINY, 1969, LETT PANEGYERICUS, V1, pR22; Proctor Robert N., 1988, RACIAL HYGIENE MED N; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; RACHELS J., 1986, END LIFE EUTHANASIA; REICHEL W, 1989, LANCET, V2, P1321; REISER SJ, 1975, DILEMMAS EUTHANASIA; Richards WG, 1936, BRIT MED J, V1936, P390; ROBINSON V, 1903, MED REV REV, V19, P143; Rosenberg Charles E., 1987, CARE STRANGERS RISE; Rosenberg LJ, 1901, J AMER MED ASSOC, V36, P108; Ross Dorothy, 1992, ORIGINS AM SOCIAL SC; RUPP A, 1906, NY TIMES        0130, P8; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; Starr P, 1982, SOCIAL TRANSFORMATIO; TOLLEMACHE L, 1873, FORTNIGHTLY REV, P218; TOMLINSON A, 1906, NY TIMES        0211, P8; Tredgold AF, 1936, BRIT MED J, V1936, P33; WARREN JC, 1848, ETHERIZATION SURGICA, P69; WELLS SR, 1907, T MED LEGAL SOC YEAR, V4, P1; WILLIAMS CB, 1894, MED REC, V70, P909; WILLIAMS G, 1958, MINN LAW REV, V43, P1; Williams G. L., 1957, SANCTITY LIFE CRIMIN; WILLIAMS SD, 1872, EUTHANASIA; Williamson Jeffrey Gale, 1980, AM INEQUALITY MACROE; WILSON R, 1896, PRACTITIONER, V56, P631; WOLF SM, 1989, HASTINGS CENT REP, V19, pS13; Wood Gordon S., 1991, RADICALISM AM REVOLU; 1906, NY TIMES        0124, P2; 1897, BRIT MED J, V1, P934; 1870, SATURDAY REV, V30, P632; 1871, SPECTATOR, V44, P34; 1904, JAMA-J AM MED ASSOC, V43, P896; 1934, MED REC, V139, P257; 1873, POPULAR SCI MONTHLY, V3, P90; 1935, TIME            1118, P53; 1936, BRIT MED J, V1, P186; 1879, APR P S CAR MED ASS, P14; 1931, PUBLIC HLTH, V45, P33; 1872, SATURDAY REV, V34, P43; 1988, JAMA-J AM MED ASSOC, V259, P272; 1885, JAMA-J AM MED ASSOC, V5, P382; 1935, BRIT MED J, V2, P1168; 1902, SPECTATOR, V88, P134; 1935, TIME            1125, P39; 1873, MED SURGICAL REPORTE, V29, P122; 1899, LANCET, V1, P489; 1914, JAMA-J AM MED ASSOC, V62, P705; 1926, JAMA-J AM MED ASSOC, V87, P1491; 1885, MED LEG J, V2, P312; 1936, MED REC, V143, P177; 1906, MED REC, V69, P184; 1879, MED SURGICAL REPORTE, V41, P479; 1885, MED REC, V28, P322; 1939, LANCET, V2, P1369; 1935, TIME            1202, P34; 1919, JAMA-J AM MED ASSOC, V72, P1557; 1934, PRACTITIONER, V132, P485; 1905, AM MED, V10, P1093; 1906, BRIT MED J, V1, P638; 1903, JAMA-J AM MED ASSOC, V41, P1094; 1935, BRIT MED J, V2, P856; 1899, LANCET, V1, P532; 1936, LANCET, V2, P1215; 1906, NY TIMES        0106, P8; 1935, NEWSWEEK        1116, V6, P40; 1884, BOSTON MED SURGICAL, V110, P19; 1906, ST LOUIS MED REV, V53, P66; 1899, INTERSTATE MED J, V6, P488	111	70	73	1	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					793	802		10.7326/0003-4819-121-10-199411150-00010	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00010			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944057				2022-12-28	WOS:A1994PQ92800010
J	SAWIN, CT; GELLER, A; WOLF, PA; BELANGER, AJ; BAKER, E; BACHARACH, P; WILSON, PWF; BENJAMIN, EJ; DAGOSTINO, RB				SAWIN, CT; GELLER, A; WOLF, PA; BELANGER, AJ; BAKER, E; BACHARACH, P; WILSON, PWF; BENJAMIN, EJ; DAGOSTINO, RB			LOW SERUM THYROTROPIN CONCENTRATIONS AS A RISK FACTOR FOR ATRIAL-FIBRILLATION IN OLDER PERSONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THYROID-STIMULATING-HORMONE; GRAVES-DISEASE; THYROTOXICOSIS; ASSAY; STROKE; TSH; HYPERTHYROIDISM; PREVALENCE; EMBOLISM; CARE	Background, Low serum thyrotropin concentrations are a sensitive indicator of hyperthyroidism but can also occur in persons who have no clinical manifestations of the disorder. We studied whether low serum thyrotropin concentrations in clinically euthyroid older persons are a risk factor for Subsequent atrial fibrillation. Methods. We studied 2007 persons (814 men and 1193 women) 60 years of age or older who did not have atrial fibrillation in order to determine the frequency of this arrhythmia during a 10-year follow-up period. The subjects were classified according to their serum thyrotropin concentrations: those with low values (less than or equal to 0.1 mU per liter; 61 subjects); those with slightly low values (> 0.1 to 0.4 mU per liter; 187 subjects); those with normal values (> 0.4 to 5.0 mU per liter; 1576 subjects); and those with high values (> 5.0 mU per liter; 183 subjects). Results. During the 10-year follow-up period, atrial fibrillation occurred in 13 persons with low initial values for serum thyrotropin, 23 with slightly low values, 133 with normal values, and 23 with high values. The cumulative incidence of atrial fibrillation at 10 years was 28 percent among the subjects with low serum thyrotropin values (less than or equal to 0.1 mU per liter), as compared with 11 percent among those with normal values; the age-adjusted incidence of atrial fibrillation was 28 per 1000 person-years among those with low values and 10 per 1000 person-years among those with normal values (P = 0.005). After adjustment for other known risk factors, the relative risk of atrial fibrillation in elderly subjects with low serum thyrotropin concentrations, as compared with those with normal concentrations, was 3.1 (95 percent confidence interval, 1.7 to 5.5; P < 0.001), The 10-year incidence of atrial fibrillation in the groups with slightly low and high serum thyrotropin values was not significantly different from that in the group with normal values. Conclusions. Among people 60 years of age or older, a low serum thyrotropin concentration is associated with a threefold higher risk that atrial fibrillation will develop in the subsequent decade.	VET AFFAIRS MED CTR,MED RES SERV,BOSTON,MA; BOSTON UNIV,EVANS MEM DEPT CLIN RES,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA; BOSTON UNIV,DEPT NEUROL,BOSTON,MA; BOSTON UNIV,DEPT MATH,BOSTON,MA; BOSTON UNIV,DEPT MED,BOSTON,MA; FRAMINGHAM HEART DIS EPIDEMIOL STUDY,FRAMINGHAM,MA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston University; Boston University; Boston University; Boston University; Framingham Heart Study	SAWIN, CT (corresponding author), VET AFFAIRS MED CTR,MED SERV,150 S HUNTINGTON AVE,BOSTON,MA 02130, USA.		Wilson, Peter W.F./J-2455-2016; Benjamin, Emelia/E-7103-2011	Wolf, Philip/0000-0002-3628-301X; Benjamin, Emelia/0000-0003-4076-2336	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL40423-04, N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-R01-NS-17950-12] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAGCHI N, 1990, ARCH INTERN MED, V150, P785, DOI 10.1001/archinte.150.4.785; COX DR, 1972, J R STAT SOC B, V34, P187; DALY JG, 1982, BMJ-BRIT MED J, V285, P1574; EGGERTSEN R, 1988, BRIT MED J, V297, P1586, DOI 10.1136/bmj.297.6663.1586; FAGERBERG B, 1990, CLIN CHEM, V36, P620; FRIEDMAN D, 1992, AGE, V15, P9, DOI 10.1007/BF02434907; FURSZYFER J, 1970, MAYO CLIN PROC, V45, P636; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI, P199; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; LUNDGREN E, 1990, CLIN ENDOCRINOL, V33, P133, DOI 10.1111/j.1365-2265.1990.tb00473.x; NORDYKE RA, 1988, ARCH INTERN MED, V148, P626, DOI 10.1001/archinte.148.3.626; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PEKARY AE, 1975, J CLIN ENDOCR METAB, V41, P676, DOI 10.1210/jcem-41-4-676; PETERSEN P, 1988, STROKE, V19, P15, DOI 10.1161/01.STR.19.1.15; PETERSEN P, 1984, ACTA MED SCAND, V216, P5; PHILLIPS DIW, 1985, CLIN ENDOCRINOL, V23, P283, DOI 10.1111/j.1365-2265.1985.tb00225.x; PRESTI CF, 1989, AM HEART J, V117, P976, DOI 10.1016/0002-8703(89)90642-X; ROSS DS, 1990, J CLIN ENDOCR METAB, V71, P764, DOI 10.1210/jcem-71-3-764; SANDLER G, 1959, Q J MED, V52, P347; SAWIN CT, 1991, ARCH INTERN MED, V151, P165, DOI 10.1001/archinte.151.1.165; SIEBERS MJ, 1992, ARCH INTERN MED, V152, P2063, DOI 10.1001/archinte.152.10.2063; SINGER DE, 1992, NEW ENGL J MED, V327, P1451, DOI 10.1056/NEJM199211123272009; STAFFURTH JS, 1977, BRIT MED J, V2, P688, DOI 10.1136/bmj.2.6088.688; SUNDBECK G, 1991, ARCH INTERN MED, V151, P549, DOI 10.1001/archinte.151.3.549; TENERZ A, 1990, J INTERN MED, V228, P229; TIBALDI JM, 1986, AM J MED, V81, P619, DOI 10.1016/0002-9343(86)90547-4; WEEKS I, 1984, CLIN ENDOCRINOL, V20, P489, DOI 10.1111/j.1365-2265.1984.tb03446.x; White PD, 1918, ARCH INTERN MED, V22, P766; WOLF PA, 1983, STROKE, V14, P664, DOI 10.1161/01.STR.14.5.664; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	32	855	889	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1249	1252		10.1056/NEJM199411103311901	http://dx.doi.org/10.1056/NEJM199411103311901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP752	7935681				2022-12-28	WOS:A1994PP75200001
J	WELLS, PS; HOLBROOK, AM; CROWTHER, NR; HIRSH, J				WELLS, PS; HOLBROOK, AM; CROWTHER, NR; HIRSH, J			INTERACTIONS OF WARFARIN WITH DRUGS AND FOOD	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; STEREOSELECTIVE INTERACTION; RACEMIC WARFARIN; ATRIAL-FIBRILLATION; ANTICOAGULANT-THERAPY; SEPARATED ENANTIOMORPHS; ORAL ANTICOAGULANTS; STEREOCHEMICAL CONSIDERATIONS; HYPOPROTHROMBINEMIC RESPONSE; COUMARIN ANTICOAGULANTS	Purpose: To evaluate the quality of studies about drugs and food interactions with warfarin and their clinical relevance. Data Sources: MEDLINE and TOXLINE databases from 1966 to October 1993 using the Medical Subject Headings warfarin, drug interactions, and English only. Study Selection: Ail articles reporting original data on drug and food interactions with warfarin. Data Extraction: Each report, rated independently by at least two investigators (using causality assessment), received a summary score indicating the level of assurance (level 1 = highly probable, level 2 = probable, level 3 = possible, and level 4 = doubtful) that a clinically important interaction had or had not occurred. Inter-rater agreement was assessed using a weighted kappa statistic. Results: Of 793 retrieved citations, 120 contained original reports on 186 interactions. The weighted kappa statistic was 0.67, representing substantial agreement. Of 86 different drugs and foods appraised, 43 had level 1 evidence. Of these, 26 drugs and foods did interact with warfarin. Warfarin's anticoagulant effect was potentiated by 6 antibiotics (cotrimoxazole, erythromycin, fluconazole, isoniazid, metronidazole, and miconazole); 5 cardiac drugs (amiodarone, clofibrate, propafenone, propranolol, and sulfinpyrazone); phenylbutazone; piroxicam; alcohol (only with concomitant liver disease); cimetidine; and omeprazole. Three patients had a hemorrhage at the time of a potentiating interaction (caused by alcohol, isoniazid, and phenylbutazone). Warfarin's anticoagulant effect was inhibited by 3 antibiotics (griseofulvin, rifampin, and nafcillin); 3 drugs active on the central nervous system (barbiturates, carbamazepine, and chlordiazepoxide); cholestyramine; sucralfate; foods high in vitamin K; and large amounts of avocado. Conclusions: Many drugs and foods interact with warfarin, including antibiotics, drugs affecting the central nervous system, and cardiac medications. Many of these drug interactions increase warfarin's anticoagulant effect.	ST JOSEPHS HOSP, CTR EVALUAT MED, HAMILTON L8N 4A6, ON, CANADA; MCMASTER UNIV, HAMILTON, ON, CANADA; HAMILTON CIV HOSP, RES CTR, HAMILTON L8V 1C3, ON, CANADA	McGill University; McMaster University; McMaster University; McMaster University								AGGELER PM, 1967, NEW ENGL J MED, V276, P496, DOI 10.1056/NEJM196703022760904; AHMAD S, 1990, ARCH INTERN MED, V150, P2407, DOI 10.1001/archinte.150.11.2407; AHMAD S, 1990, CHEST, V98, P1041, DOI 10.1378/chest.98.4.1041b; ALMOG S, 1985, EUR J CLIN PHARMACOL, V28, P257, DOI 10.1007/BF00543320; ALTMAN R, 1991, J THORAC CARDIOV SUR, V101, P427; ANGARAN DM, 1987, ANN SURG, V206, P155, DOI 10.1097/00000658-198708000-00007; [Anonymous], 1969, Br Med J, V1, P335; ANTLITZ AM, 1968, CURR THER RES CLIN E, V10, P501; BACHMANN K, 1984, PHARMACOLOGY, V28, P171, DOI 10.1159/000137958; BAX NDS, 1984, BRIT J CLIN PHARMACO, V17, pS85, DOI 10.1111/j.1365-2125.1984.tb02433.x; BELL WR, 1986, ARCH INTERN MED, V146, P2325, DOI 10.1001/archinte.146.12.2325; BENEDEK IH, 1992, J CLIN PHARMACOL, V32, P558, DOI 10.1177/009127009203200612; Benichou C, 1991, DRUG INF J, V25, P251; BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; BIANCO TM, 1992, PHARMACOTHERAPY, V12, P435; BLACK D, 1992, CLIN PHARMACOL THER, V51, P52; BLICKSTEIN D, 1991, LANCET, V337, P914, DOI 10.1016/0140-6736(91)90244-J; BRASS C, 1982, ANTIMICROB AGENTS CH, V21, P151, DOI 10.1128/AAC.21.1.151; BRECKENRIDGE A, 1971, ANN NY ACAD SCI, V179, P421, DOI 10.1111/j.1749-6632.1971.tb46919.x; BRECKENRIDGE A, 1978, SEMIN HEMATOL, V15, P19; BUCKLEY NA, 1992, MED J AUSTRALIA, V157, P479, DOI 10.5694/j.1326-5377.1992.tb137313.x; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHANG HJ, 1990, ARCH INTERN MED, V150, P83, DOI 10.1001/archinte.150.1.83; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COOK DJ, 1992, CHEST, V102, pS305; COURNOT A, 1988, J CLIN PHARMACOL, V28, P1120, DOI 10.1002/j.1552-4604.1988.tb05727.x; CULLEN SI, 1967, J AMER MED ASSOC, V199, P582, DOI 10.1001/jama.199.8.582; DALE J, 1977, AM HEART J, V94, P101, DOI 10.1016/S0002-8703(77)80351-7; DANOS EA, 1992, CLIN PHARMACY, V11, P806; DAVIS RL, 1991, J PEDIATR-US, V118, P300, DOI 10.1016/S0022-3476(05)80508-6; DELEPELEIRE I, 1990, INT J CLIN PHARM RES, V10, P167; DRAPKIN A, 1972, J AMER MED ASSOC, V222, P541, DOI 10.1001/jama.222.5.541; DUURSEMA L, 1992, DRUG INVEST, V4, P395, DOI 10.1007/BF03258417; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; GAW A, 1992, LANCET, V340, P979, DOI 10.1016/0140-6736(92)92872-D; GOLDBERG RJ, 1985, AM HEART J, V109, P616, DOI 10.1016/0002-8703(85)90581-2; GRIND M, 1993, CLIN PHARMACOL THER, V54, P381, DOI 10.1038/clpt.1993.164; HANSEN JM, 1971, CLIN PHARMACOL THER, V12, P539; HARDY JL, 1986, CAN MED ASSOC J, V135, P1372; HAWORTH E, 1977, BRIT MED J, V2, P866, DOI 10.1136/bmj.2.6091.866-a; HAYNES RB, 1991, ANN INTERN MED S1, V114; HEIMARK LD, 1992, CLIN PHARMACOL THER, V51, P398, DOI 10.1038/clpt.1992.39; HEIMARK LD, 1987, CLIN PHARMACOL THER, V42, P388, DOI 10.1038/clpt.1987.168; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; Hunt C E, 1989, J Perinatol, V9, P184; HUTCHINSON TA, 1989, J CLIN EPIDEMIOL, V42, P5, DOI 10.1016/0895-4356(89)90020-6; JAHNCHEN E, 1978, BRIT J CLIN PHARMACO, V5, P437, DOI 10.1111/j.1365-2125.1978.tb01651.x; JAIN A, 1979, CLIN PHARMACOL THER, V25, P61; JOHNSON KC, 1991, J FAM PRACTICE, V33, P338; JONES JK, 1989, PHARMACOEPIDEM DR S, P275; KAMADA AK, 1990, DICP ANN PHARMAC, V24, P27, DOI 10.1177/106002809002400106; KATES RE, 1987, CLIN PHARMACOL THER, V42, P305, DOI 10.1038/clpt.1987.152; KELLY JG, 1979, CLIN PHARMACOKINET, V4, P1, DOI 10.2165/00003088-197904010-00001; KEMPIN SJ, 1983, NEW ENGL J MED, V308, P1229; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOCHWESE.J, 1971, NEW ENGL J MED, V285, P487, DOI 10.1056/NEJM197108262850905; KOCHWESE.J, 1971, NEW ENGL J MED, V285, P547, DOI 10.1056/NEJM197109022851005; KOCHWESER J, 1968, ANN INTERN MED, V68, P511, DOI 10.7326/0003-4819-68-3-511; KRAMER P, 1984, CLIN PHARMACOL THER, V35, P416, DOI 10.1038/clpt.1984.52; KRSTENANSKY PM, 1987, CLIN PHARMACY, V6, P804; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LANDEFELD CS, 1992, ANN INTERN MED, V116, P829, DOI 10.7326/0003-4819-116-10-829; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LEIZOROVICZ A, 1983, EUR J CLIN PHARMACOL, V24, P333, DOI 10.1007/BF00610050; LEOR J, 1987, ANN INTERN MED, V107, P601, DOI 10.7326/0003-4819-107-4-601_2; LEOR J, 1988, ANN INTERN MED, V109, P761, DOI 10.7326/0003-4819-109-9-761_1; LEVINE M, 1984, CLIN PHARMACY, V3, P200; LEVINE MA, 1992, ANN INTERN MED S1, V116; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; LEWIS RJ, 1974, J CLIN INVEST, V53, P1607, DOI 10.1172/JCI107711; LINVILLE T, 1989, ANN INTERN MED, V110, P751, DOI 10.7326/0003-4819-110-9-751_2; LIPSKY BA, 1984, ANN INTERN MED, V100, P835, DOI 10.7326/0003-4819-100-6-835; LODWICK R, 1987, BRIT MED J, V295, P1141, DOI 10.1136/bmj.295.6606.1141-b; LORENTZ SM, 1985, CLIN PHARMACY, V4, P332; MACLEOD SM, 1976, DRUGS, V11, P461, DOI 10.2165/00003495-197611060-00006; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MIESZCZAK C, 1993, EUR J CLIN PHARMACOL, V44, P205, DOI 10.1007/BF00315483; MITCHELL AA, 1972, NEW ENGL J MED, V287, P1153; MOK CK, 1985, CIRCULATION, V72, P1059, DOI 10.1161/01.CIR.72.5.1059; MOTT FE, 1989, ANN INTERN MED, V111, P542, DOI 10.7326/0003-4819-111-6-542_2; MUNGALL D, 1983, ANN INTERN MED, V98, P557, DOI 10.7326/0003-4819-98-4-557_2; MUNGALL DR, 1984, J CLIN PHARMACOL, V24, P264, DOI 10.1002/j.1552-4604.1984.tb02783.x; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; NENCI GG, 1981, BRIT MED J, V282, P1361, DOI 10.1136/bmj.282.6273.1361; NIPPER H, 1981, J CLIN PHARMACOL, V21, P654, DOI 10.1002/j.1552-4604.1981.tb05678.x; O'Reilly R A, 1987, Adv Exp Med Biol, V214, P205; OKINO K, 1986, DRUG INTEL CLIN PHAR, V20, P291, DOI 10.1177/106002808602000417; OREILLY RA, 1974, ANN INTERN MED, V81, P337, DOI 10.7326/0003-4819-81-3-337; OREILLY RA, 1987, CLIN PHARMACOL THER, V42, P290, DOI 10.1038/clpt.1987.149; OREILLY RA, 1984, ARCH INTERN MED, V144, P989, DOI 10.1001/archinte.144.5.989; OREILLY RA, 1980, CLIN PHARMACOL THER, V28, P187, DOI 10.1038/clpt.1980.149; OREILLY RA, 1979, AM J MED SCI, V277, P189, DOI 10.1097/00000441-197903000-00007; OREILLY RA, 1981, CLIN PHARMACOL THER, V29, P332, DOI 10.1038/clpt.1981.45; OREILLY RA, 1976, NEW ENGL J MED, V295, P354, DOI 10.1056/NEJM197608122950702; OREILLY RA, 1980, NEW ENGL J MED, V302, P33, DOI 10.1056/NEJM198001033020106; OREILLY RA, 1992, CLIN PHARMACOL THER, V51, P656, DOI 10.1038/clpt.1992.78; OREILLY RA, 1981, ARCH INTERN MED, V141, P458, DOI 10.1001/archinte.141.4.458; OREILLY RA, 1972, THROMB DIATH HAEMOST, V27, P309; OREILLY RA, 1982, CIRCULATION, V65, P202, DOI 10.1161/01.CIR.65.1.202; OREILLY RA, 1980, J CLIN INVEST, V65, P746, DOI 10.1172/JCI109722; ORME M, 1976, BRIT MED J, V1, P200, DOI 10.1136/bmj.1.6003.200; ORME M, 1976, NEW ENGL J MED, V295, P1482; OSTLERE LS, 1991, BRIT J DERMATOL, V124, P505, DOI 10.1111/j.1365-2133.1991.tb00637.x; PARR M D, 1982, Clinical Pharmacy, V1, P274; PETERSEN P, 1989, LANCET, V1, P175; PORTER RS, 1986, APPLIED PHARMACOKINE, P1057; PYORALA K, 1965, ANN MED EXP BIOL FEN, V43, P95; QURESHI GD, 1984, ANN INTERN MED, V100, P527, DOI 10.7326/0003-4819-100-4-527; QURESHI GD, 1981, ARCH INTERN MED, V141, P507, DOI 10.1001/archinte.141.4.507; RHODES RS, 1985, DRUG INTEL CLIN PHAR, V19, P556, DOI 10.1177/106002808501900711; RINDONE JP, 1991, CLIN PHARMACY, V10, P136; ROBINSON DS, 1971, CLIN PHARMACOL THER, V12, P491; ROOS J, 1980, LANCET, V2, P989; ROSENTHAL AR, 1977, JAMA-J AM MED ASSOC, V238, P2177, DOI 10.1001/jama.238.20.2177; ROWE H, 1978, LIFE SCI, V23, P807, DOI 10.1016/0024-3205(78)90515-5; RUBIN RN, 1984, CLIN RES, V32, pA698; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P30; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; SAX MJ, 1987, CLIN PHARMACY, V6, P492; SCHULMAN S, 1989, BRIT J RHEUMATOL, V28, P46; SCOTT AK, 1989, PHARMACOL THERAPEUT, V42, P429, DOI 10.1016/0163-7258(89)90034-X; SCOTT AK, 1984, BRIT J CLIN PHARMACO, V17, P559, DOI 10.1111/j.1365-2125.1984.tb02390.x; SERLIN MJ, 1981, BRIT J CLIN PHARMACO, V12, P791, DOI 10.1111/j.1365-2125.1981.tb01308.x; SERLIN MJ, 1980, CLIN PHARMACOL THER, V28, P493, DOI 10.1038/clpt.1980.193; SERLIN MJ, 1979, LANCET, V2, P317; SERLIN MJ, 1983, DRUGS, V25, P610, DOI 10.2165/00003495-198325060-00004; SHOVICK VA, 1991, DICP ANN PHARMAC, V25, P598, DOI 10.1177/106002809102500605; SINGLETON JD, 1992, AM J MED, V92, P217, DOI 10.1016/0002-9343(92)90116-S; SIORIS LJ, 1980, ARCH INTERN MED, V140, P546, DOI 10.1001/archinte.140.4.546; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SMITH R, 1984, DRUG INTEL CLIN PHAR, V18, P822, DOI 10.1177/106002808401801011; SNYDER DS, 1988, ANN INTERN MED, V108, P311, DOI 10.7326/0003-4819-108-2-311_1; SUTCLIFF FA, 1987, Q REV DRUGS MET DRUG, V5, P225; SUTFIN T, 1989, THER DRUG MONIT, V11, P176, DOI 10.1097/00007691-198903000-00010; SYLVEN C, 1983, BRIT MED J, V286, P1181, DOI 10.1136/bmj.286.6372.1181; TALBERT RL, 1985, DICP ANN PHARMAC, V19, P59; TOON S, 1987, EUR J CLIN PHARMACOL, V32, P165, DOI 10.1007/BF00542190; TOON S, 1986, BRIT J CLIN PHARMACO, V21, P245, DOI 10.1111/j.1365-2125.1986.tb05186.x; TOON S, 1987, CLIN PHARMACOL THER, V42, P33, DOI 10.1038/clpt.1987.104; TOON S, 1990, BRIT J CLIN PHARMACO, V30, P743, DOI 10.1111/j.1365-2125.1990.tb03845.x; TOON S, 1986, CLIN PHARMACOL THER, V39, P15, DOI 10.1038/clpt.1986.3; TREWIN VF, 1988, PHARM J         0618, P781; TURPIE AGG, 1988, LANCET, V1, P1242; UDALL JA, 1975, CURR THER RES CLIN E, V17, P67; WALKER FB, 1984, ARCH INTERN MED, V144, P2089, DOI 10.1001/archinte.144.10.2089; WATSON PG, 1982, BRIT MED J, V285, P1045, DOI 10.1136/bmj.285.6347.1045-b; WEIBERT RT, 1989, CLIN PHARMACY, V8, P210; WEINER B, 1984, DRUG INTEL CLIN PHAR, V18, P904, DOI 10.1177/106002808401801112; WESTFALL LK, 1980, AM J HOSP PHARM, V37, P1620, DOI 10.1093/ajhp/37.12.1620a; YEH J, 1990, BRIT MED J, V301, P669, DOI 10.1136/bmj.301.6753.669-b; 1973, JAMA-J AM MED ASSOC, V225, P724; 1993, DRUG INFORMATION HLT, P244	153	403	429	1	31	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					676	683		10.7326/0003-4819-121-9-199411010-00009	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944078				2022-12-28	WOS:A1994PN45000009
J	HAY, RJ				HAY, RJ			OF IMAGING AND SKIN	LANCET			English	Editorial Material											HAY, RJ (corresponding author), GUYS HOSP,ST JOHNS INST DERMATOL,LONDON,ENGLAND.							DERIGAL J, 1989, J INVEST DERMATOL, V93, P621, DOI 10.1111/1523-1747.ep12319741; GASSENMAIER G, 1990, HAUTARZT, V41, P360; GOETTMANN S, 1994, BRIT J DERMATOL, V130, P701, DOI 10.1111/j.1365-2133.1994.tb03405.x; KIRSNER RS, 1993, BRIT J DERMATOL, V128, P99, DOI 10.1111/j.1365-2133.1993.tb00156.x; PEREDNIA DA, 1991, J AM ACAD DERMATOL, V25, P89, DOI 10.1016/0190-9622(91)70178-5	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1174	1174		10.1016/S0140-6736(94)90504-5	http://dx.doi.org/10.1016/S0140-6736(94)90504-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934536				2022-12-28	WOS:A1994PN80300005
J	MARK, DB; NAYLOR, CD; HLATKY, MA; CALIFF, RM; TOPOL, EJ; GRANGER, CB; KNIGHT, JD; NELSON, CL; LEE, KL; CLAPPCHANNING, NE; SUTHERLAND, W; PILOTE, L; ARMSTRONG, PW				MARK, DB; NAYLOR, CD; HLATKY, MA; CALIFF, RM; TOPOL, EJ; GRANGER, CB; KNIGHT, JD; NELSON, CL; LEE, KL; CLAPPCHANNING, NE; SUTHERLAND, W; PILOTE, L; ARMSTRONG, PW			USE OF MEDICAL RESOURCES AND QUALITY-OF-LIFE AFTER ACUTE MYOCARDIAL-INFARCTION IN CANADA AND THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDEX	Background. Much attention has been directed to the use of medical resources and to patients' outcomes in Canada as compared with the United States. We compared U.S. and Canadian patients with respect to their use of medical resources and their quality of life during the year after acute myocardial infarction. Methods. A total of 2600 U.S. and 400 Canadian patients were randomly selected from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. Base-line data from their initial hospitalizations were analyzed, and the patients were then interviewed by telephone 30 days, 6 months, and 1 year after myocardial infarction to determine their use of medical care and quality of life. Results. The Canadian patients typically stayed in the hospital one day longer (P = 0.009) than the U.S. patients but had a much lower rate of cardiac catheterization (25 percent vs. 72 percent, P<0.001), coronary angioplasty (11 percent vs. 29 percent, P<0.001), and coronary bypass surgery (3 percent vs. 14 percent, P<0.001). At one year 24 percent of the Canadian and 53 percent of the U.S. patients had undergone angioplasty or bypass surgery at least once (P<0.001). The Canadians had more visits to physicians during the follow-up year (P<0.001), but fewer visits to specialists (P<0.001). At 30 days, functional status was equivalent in the patients from the two countries. However, after one year the U.S. patients had substantially more improvement than the Canadian patients (P<0.001). The prevalence of chest pain and dyspnea at one year was higher among the Canadian patients (34 percent vs. 21 percent and 45 percent vs. 29 percent, respectively; P<0.001). Conclusions. The Canadian patients had more cardiac symptoms and worse functional status one year after acute myocardial infarction than the U.S. patients. The Canadian patients also underwent fewer invasive cardiac procedures and had fewer visits to specialist physicians. These results suggest, but do not prove, that the more aggressive pattern of care in the United States may have been responsible for the better quality of life.	DUKE UNIV, MED CTR, CLIN TRIALS COORDINATING CTR, DURHAM, NC 27708 USA; DUKE UNIV, MED CTR, DIV CARDIOL, DURHAM, NC 27708 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27708 USA; DUKE UNIV, MED CTR, DEPT FAMILY & COMMUNITY MED, DIV BIOMETRY, DURHAM, NC 27708 USA; UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; INST CLIN EVALUAT SCI, TORONTO, ON, CANADA; UNIV ALBERTA, DEPT MED, EDMONTON, AB, CANADA; STANFORD UNIV, MED CTR, DEPT HLTH RES & POLICY, DIV HLTH SERV RES, STANFORD, CA 94305 USA; CLEVELAND CLIN, DEPT CARDIOL, CLEVELAND, OH USA	Duke University; Duke University; Duke University; Duke University; University of Toronto; University of Toronto; University of Alberta; Stanford University; Cleveland Clinic Foundation	MARK, DB (corresponding author), DUKE UNIV, MED CTR, ECON & QUAL LIFE RES GRP, POB 3485, DURHAM, NC 27708 USA.		Granger, Christopher B/D-3458-2014	Granger, Christopher B/0000-0002-0045-3291; Topol, Eric/0000-0002-1478-4729; Mark, Daniel/0000-0001-6340-8087; Armstrong, Paul/0000-0002-0460-3445; Hlatky, Mark/0000-0003-4686-9441; Pilote, Louise/0000-0002-6159-0628	AHRQ HHS [HS-05635, HS-06503] Funding Source: Medline; NHLBI NIH HHS [HL-36587] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036587] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; COX DR, 1972, J R STAT SOC B, V34, P187; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; KOENIG HG, 1992, INT J PSYCHIAT MED, V22, P183, DOI 10.2190/M1F5-F40P-C4KD-YPA3; MARK DB, IN PRESS ACUTE CORON; PILOTE L, 1994, ARCH INTERN MED, V154, P1090, DOI 10.1001/archinte.154.10.1090; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; TSEVAT J, 1990, J CLIN EPIDEMIOL, V43, pS73, DOI 10.1016/0895-4356(90)90224-D; 1991, CIRCULATION S5, V84, P1; 1992, DHHS PHS921232 NAT C	16	319	322	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1130	1135		10.1056/NEJM199410273311706	http://dx.doi.org/10.1056/NEJM199410273311706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7935638				2022-12-28	WOS:A1994PN06500006
J	YANG, YD; BLAKE, R				YANG, YD; BLAKE, R			BROAD TUNING FOR SPATIAL-FREQUENCY OF NEURAL MECHANISMS UNDERLYING VISUAL-PERCEPTION OF COHERENT MOTION	NATURE			English	Article								NEURAL events underlying perception of coherent motion are generally believed to be hierarchical(1,2): information about local motion is registered by spatio-temporal coincidence detectors(3-5) whose outputs are cooperatively integrated at a subsequent stage(6,7). There is disagreement, however, concerning the spatial scale of the neural filters underlying these operations. According to one class of models, motion registration is initially accomplished in parallel at multiple spatial scales(3-5), with filters tuned to lower spatial frequencies responsive to larger motion displacements than filters tuned to higher frequencies. According to another scheme, motion analysis involves a single, broadly tuned spatial filter, with optimal displacement dependent on spacing of local elements(8). Here we use a masking procedure to measure the extent to which dynamic noise depicted at one spatial scale interferes with detection of coherent motion conveyed by image features at another spatial scale. Our results indicate that a single filter, broadly tuned for spatial frequency, is mediating detection of coherent motion. This finding dovetails with known physiological properties of neurons at an intermediate stage of motion processing.			YANG, YD (corresponding author), VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240, USA.							ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ADELSON EH, 1991, OPTICS PHOTONICS NEW, V2, P24; ANDERSON SJJ, 1985, VISION RES, V13, P1147; BRADDICK O, 1993, TRENDS NEUROSCI, V16, P263, DOI 10.1016/0166-2236(93)90179-P; BRITTEN KH, 1993, VISUAL NEUROSCI, V10, P1157, DOI 10.1017/S0952523800010269; CHANG JJ, 1984, VISION RES, V24, P1781, DOI 10.1016/0042-6989(84)90009-9; CLEARY R, 1990, VISION RES, V30, P303, DOI 10.1016/0042-6989(90)90045-M; MORGAN MJ, 1992, NATURE, V355, P344, DOI 10.1038/355344a0; MOVSHON A, 1990, IMAGES UNDERSTANDING; NAWROT M, 1990, VISION RES, V30, P1439, DOI 10.1016/0042-6989(90)90025-G; SMITH AT, 1994, VISION RES, V34, P2425, DOI 10.1016/0042-6989(94)90286-0; VANDEGRIND WA, 1992, EXP BRAIN RES, V91, P135, DOI 10.1007/BF00230022; VANSANTEN JPH, 1984, J OPT SOC AM A, V1, P451, DOI 10.1364/JOSAA.1.000451; WATSON AB, 1986, J OPT SOC AM A, V3, P300, DOI 10.1364/JOSAA.3.000300; WERKHOVEN P, 1993, VISION RES, V33, P463, DOI 10.1016/0042-6989(93)90253-S; WILLIAMS DW, 1984, VISION RES, V24, P55, DOI 10.1016/0042-6989(84)90144-5; WILSON HR, 1994, VISION RES, V34, P1835, DOI 10.1016/0042-6989(94)90308-5; YANG Y, 1991, VISION RES, V31, P1177	19	35	35	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					793	796		10.1038/371793a0	http://dx.doi.org/10.1038/371793a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935839				2022-12-28	WOS:A1994PP01800058
J	CARRHILL, RA; SHELDON, TA; SMITH, P; MARTIN, S; PEACOCK, S; HARDMAN, G				CARRHILL, RA; SHELDON, TA; SMITH, P; MARTIN, S; PEACOCK, S; HARDMAN, G			ALLOCATING RESOURCES TO HEALTH AUTHORITIES - DEVELOPMENT OF METHOD FOR SMALL-AREA ANALYSIS OF USE OF INPATIENT SERVICES	BRITISH MEDICAL JOURNAL			English	Article							NHS; CRITIQUE	Every year about pound 22 billion is allocated to health authorities for hospital and community services in England. The distribution of most of these funds is based on a formula developed to reflect the population's needs, but the existing formula has been criticised on several grounds. This paper describes the development of a method to determine the health needs for small geographical areas. Data from the hospital episodes statistics and 1991 census together with information on vital statistics and supply of health care facilities were used in the model. Two stage least squares regression was used to identify true indicators of need, and these were entered into a multilevel model to take account of variations in practice in different health authorities. The resulting formula should be more statistically robust and more sensitive to needs than previous approaches.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV YORK,DEPT ECON & RELATED STUDIES,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV YORK,SOCIAL SCI RES INST,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV YORK,YORK HLTH ECON CONSORTIUM,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK; University of York - UK; University of York - UK; University of York - UK			Sheldon, Trevor/AAK-7088-2021; Peacock, Stuart J/P-2437-2018	Sheldon, Trevor/0000-0002-7479-5913; Peacock, Stuart J/0000-0002-8243-8721; Smith, Peter/0000-0003-0058-7588				CLARKE A, 1992, BRIT MED J, V305, P1307, DOI 10.1136/bmj.305.6865.1307; COOPERS, 1988, INTEGRATED ANAL REV; CROMWELL J, 1986, J HEALTH ECON, V5, P293, DOI 10.1016/0167-6296(86)90006-8; GATSONIS C, 1993, MED CARE, V31, pYS54, DOI 10.1097/00005650-199305001-00008; Godfrey L. G., 1988, MISSPECIFICATION TES; HANCOCK KE, 1991, APPL ECON, V23, P1623, DOI 10.1080/00036849100000127; HENDRY DF, 1987, ADV ECONOMETRICS 5TH; MADDALS GS, 1987, ECONOMETRICS; MAYS N, 1989, COMMUNITY MED, V11, P173; MAYS N, 1987, 81 SOC ADM OCC PAP; MORGAN M, 1987, J EPIDEMIOL COMMUN H, V41, P269, DOI 10.1136/jech.41.4.269; Paterson L, 1991, BRIT EDUC RES J, V17, P387, DOI [DOI 10.1080/0141192910170408, 10.1080/0141192910170408]; SHELDON TA, 1993, BRIT MED J, V306, P835, DOI 10.1136/bmj.306.6881.835; SHELDON TA, 1992, J ROY STAT SOC A STA, V155, P403, DOI 10.2307/2982891; SMITH P, 1994, BRIT MED J, V309, P1050, DOI 10.1136/bmj.309.6961.1050; Smith P., 1994, FORMULA DISTRIBUTING; Wilson AG., 1974, URBAN REGIONAL MODEL; 1993, HOSPITAL EPISODE STA, V1; 1976, SHARING RESOURCES HL; 1986, REV RESOURCE ALLOCAT; 1988, REV RESOURCE ALLOCAT	21	86	88	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1046	1049		10.1136/bmj.309.6961.1046	http://dx.doi.org/10.1136/bmj.309.6961.1046			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN733	7950737	Green Published			2022-12-28	WOS:A1994PN73300020
J	HAMMOND, C; HELENIUS, A				HAMMOND, C; HELENIUS, A			FOLDING OF VSV G-PROTEIN - SEQUENTIAL INTERACTION WITH BIP AND CALNEXIN	SCIENCE			English	Article							STOMATITIS-VIRUS-G; CHAIN BINDING-PROTEIN; ER; TRANSPORT	The endoplasmic reticulum (ER) contains molecular chaperones that facilitate the folding of proteins in mammalian cells. Biosynthetic labeling was used to study the interactions of two chaperones, BiP and calnexin, with vesicular stomatitis virus (VSV) glycoprotein (G protein). Coimmunoprecipitation of G protein with the chaperones showed that BiP bound maximally to early folding Intermediates of G protein, whereas calnexin bound after a short lag to more folded molecules. Castanospermine, an inhibitor of ER glucosidases, blocked the binding of proteins to calnexin and inhibited G protein folding. Interaction with calnexin was necessary for efficient folding of G protein and for retention of partially folded forms.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University					NCI NIH HHS [P01 CA46128] Funding Source: Medline; NIGMS NIH HHS [R01 GM38346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DUNIGAN DD, 1983, J VIROL, V45, P618, DOI 10.1128/JVI.45.2.618-626.1983; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GEHTING MJ, 1992, NATURE, V355, P33; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SARASTE J, 1991, J CELL SCI, V100, P415; SCHLESINGER S, 1984, J BIOL CHEM, V259, P7597; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8	24	285	286	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					456	458		10.1126/science.7939687	http://dx.doi.org/10.1126/science.7939687			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939687				2022-12-28	WOS:A1994PN27200040
J	STRASSER, A; HARRIS, AW; JACKS, T; CORY, S				STRASSER, A; HARRIS, AW; JACKS, T; CORY, S			DNA-DAMAGE CAN INDUCE APOPTOSIS IN PROLIFERATING LYMPHOID-CELLS VIA P53-INDEPENDENT MECHANISMS INHIBITABLE BY BCL-2	CELL			English	Article							WILD-TYPE P53; MYELOID-LEUKEMIA CELLS; DEATH GENE CED-3; CYCLE CONTROL; ERYTHROLEUKEMIA-CELLS; MICE DEFICIENT; STRAND BREAKS; MUTANT P53; PRE-B; PROTEIN	The roles of p53 as an inducer and Bcl-2 as an inhibitor of apoptotic death were explored in lymphoid cells. Lymphocytes from p53(-/-) mice were radioresistant, but unexpectedly, cycling T lymphoma cells and mitogenically activated T lymphocytes from these animals underwent apoptosis after irradiation or genotoxic drug treatment. Hence, p53 is not the only mediator of apoptosis provoked by DNA damage. Irradiated p53(-/-) lymphoblasts expressing Bcl-2 were subject to growth arrest but resisted apoptosis. Their accumulation in G1 as well as G2 is suggestive of a p53-independent DNA-damage G1 checkpoint. Since Bcl-2 increased the clonogenic survival of the irradiated cells, expression of survival genes may pose a greater impediment to genotoxic cancer therapy than loss of p53.	MIT,HOWARD HUGHES MED INST,CTR CANC RES,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	STRASSER, A (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA.		Strasser, Andreas/C-7581-2013; Cory, Suzanne/E-1642-2013	Strasser, Andreas/0000-0002-5020-4891; Cory, Suzanne/0000-0002-6818-3451	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CAMPOS L, 1993, BLOOD, V81, P3091; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DELALUNA S, 1992, METHOD ENZYMOL, V216, P376; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FISHER TC, 1993, CANCER RES, V53, P3321; FRITSCHE M, 1993, ONCOGENE, V8, P307; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; GORCZYCA W, 1993, CANCER RES, V53, P1945; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; IKEGAKI N, 1994, CANCER RES, V54, P6; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KAMESAKI S, 1993, CANCER RES, V53, P4251; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIMPENS J, 1991, ONCOGENE, V6, P2271; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MANOME Y, 1993, ONCOL RES, V5, P139; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MERRITT AJ, 1994, CANCER RES, V54, P614; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1992, CANCER RES, V52, P5407; PETTERSSON M, 1992, BLOOD, V79, P495; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PURDIE CA, 1994, ONCOGENE, V9, P603; RAMQVIST T, 1993, ONCOGENE, V8, P1495; REED JC, 1991, CANCER RES, V51, P6529; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAYLOR IW, 1980, J HISTOCHEM CYTOCHEM, V28, P1021, DOI 10.1177/28.9.6157714; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WANG YS, 1993, ONCOGENE, V8, P3427; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZUTTER M, 1991, BLOOD, V78, P1062	71	672	687	2	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					329	339		10.1016/0092-8674(94)90201-1	http://dx.doi.org/10.1016/0092-8674(94)90201-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954799				2022-12-28	WOS:A1994PN63000016
J	YU, YG; KING, DS; SHIN, YK				YU, YG; KING, DS; SHIN, YK			INSERTION OF A COILED-COIL PEPTIDE FROM INFLUENZA-VIRUS HEMAGGLUTININ INTO MEMBRANES	SCIENCE			English	Article							CONFORMATIONAL CHANGE; FUSION ACTIVITY; GLYCOPROTEIN; AGGREGATION; MUTANTS	The trimeric protein hemagglutinin (HA) of the influenza viral envelope is essential for cell entry. To investigate the interaction of HA with membranes, two 40-residue, cysteine-substituted peptides comprising the loop region and the first part of the coiled-coil stem were synthesized and modified with a nitroxide spin label. Electron paramagnetic resonance analysis revealed that the peptide inserts reversibly into phospholipid vesicles under endosomal pH conditions. This result suggests that some or all of the long coiled-coil trimer of HA may insert into membranes, which could bring the viral and cell membranes closer together and facilitate fusion.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV STRUCT BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley								ALTENBACH C, 1988, PROTEINS, V3, P230, DOI 10.1002/prot.340030404; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ARCHER SJ, 1991, BIOPHYS J, V60, P389, DOI 10.1016/S0006-3495(91)82064-1; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DOMS RW, 1985, J BIOL CHEM, V260, P2973; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KEMBLE GW, 1992, J VIROL, V66, P4940, DOI 10.1128/JVI.66.8.4940-4950.1992; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	19	107	108	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					274	276		10.1126/science.7939662	http://dx.doi.org/10.1126/science.7939662			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939662				2022-12-28	WOS:A1994PM13400033
J	BLACK, DG; BIRCHALL, AD; TRIMBLE, IMG				BLACK, DG; BIRCHALL, AD; TRIMBLE, IMG			NON-FUNDHOLDING IN NOTTINGHAM - A VISION OF THE FUTURE	BRITISH MEDICAL JOURNAL			English	Article								The 1991 health service reforms introduced the internal market and gave individual fundholding practices budgets with which they could attempt to secure preferential access to secondary health care for their patients. In the view of many doctors this undermined the principle of equity on which the NHS was founded. In Nottingham 200 non-fundholding general practitioners have joined together to act in liaison with their purchasing health authority. A committed representative group of general practitioners can collectively offer more time and knowledge to the contracting process while minimising the impact on clinical workload. As a large purchaser with low management costs the group has secured access to quality secondary care which is equitably available to all patients, preventing the development of a local two tier service. Nottingham's non-fundholding model of commissioning is equitable and efficient.			BLACK, DG (corresponding author), NOTTINGHAM NONFUNDHOLDERS SHERWOOD HLTH CTR,NOTTINGHAM NG5 4AD,ENGLAND.							BOTTOMLEY V, 1994, BRIT MED J, V308, P338, DOI 10.1136/bmj.308.6924.338; 1994, HLTH 2000 HLTH WEALT	2	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 8	1994	309	6959					930	932		10.1136/bmj.309.6959.930	http://dx.doi.org/10.1136/bmj.309.6959.930			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7950667	Green Published			2022-12-28	WOS:A1994PL78100025
J	WILLIAMS, EC; KIRKMAN, RJE; ELSTEIN, M				WILLIAMS, EC; KIRKMAN, RJE; ELSTEIN, M			PROFILE OF YOUNG PEOPLES ADVICE CLINIC IN REPRODUCTIVE HEALTH, 1988-93	BRITISH MEDICAL JOURNAL			English	Article								For an unprepared sexually active teenager the 1990s present a minefield of potential problems in addition to the most obvious problems of unplanned pregnancy and sexually transmitted disease. Promoting the importance of a healthy sexual and reproductive life to young people requires openness, better sex education, realistic discussion of related issues, and provision of contraception, as well as support if things go wrong. The Woodhouse Park Clinic in south Manchester opened in October 1988 with the aim of providing weekly advice sessions to young people up to the age of 18. Advice is given on topics such as substance misuse and smoking as wed as on family planning. Attendance has steadily increased over the years; from April to June 1993 the average number of attenders per session was 39, one third of whom were young men.	MANCUNIAN COMMUNITY HLTH NHS TRUST,MANCHESTER M20 9LJ,ENGLAND; UNIV MANCHESTER,DEPT OBSTET & GYNAECOL,MANCHESTER M20 8LR,ENGLAND	University of Manchester								Doppenberg H, 1993, BR J FAMILY PLANNING, V18, P123; JONES EF, 1985, FAM PLANN PERSPECT, V17, P53, DOI 10.2307/2135261; 1990, HDB CONTRACEPTIVE PR; 1994, 1991 CENSUS WORD CIV; 1992, HLTH NATION STRATEGY; 1993, PUBLIC HLTH COMMON D; 1993, 19923 PAL CTR ANN RE; 1992, BAC1991 BROOK ADV CT	8	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					786	788		10.1136/bmj.309.6957.786	http://dx.doi.org/10.1136/bmj.309.6957.786			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950570	Green Published			2022-12-28	WOS:A1994PJ28200029
J	ASHWORTH, TG				ASHWORTH, TG			THE FUTURE FOR HISTOPATHOLOGY - PROTECTIONISM OR PRUDENCE	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					417	417		10.1136/bmj.309.6951.417	http://dx.doi.org/10.1136/bmj.309.6951.417			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	7950509	Green Published			2022-12-28	WOS:A1994PB31600082
J	SILVERSTEIN, MD; REED, CE; OCONNELL, EJ; MELTON, LJ; OFALLON, WM; YUNGINGER, JW				SILVERSTEIN, MD; REED, CE; OCONNELL, EJ; MELTON, LJ; OFALLON, WM; YUNGINGER, JW			LONG-TERM SURVIVAL OF A COHORT OF COMMUNITY RESIDENTS WITH ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD ASTHMA; RECENT INCREASE; MORTALITY; DEATHS; EPIDEMIOLOGY; PROGNOSIS; RATES; POPULATION; ACCURACY; RECORD	Background. Reports of an increase in asthma-related mortality have been based on studies of death certificates from the general U.S. population on which asthma was listed as an underlying cause of death. We addressed the issue in a different way by analyzing longterm survival in a defined, population-based cohort of patients with asthma. Methods. We identified all residents of Rochester, Minnesota, in whom asthma was diagnosed from January 1, 1964, through December 31, 1983, by reviewing the medical records of ail patients with asthma and associated diagnoses, using explicit predefined criteria. The patients' vital status at last follow-up was ascertained. Medical records, death certificates, and autopsy reports were reviewed to classify deaths as due either to asthma or to other conditions. Results. We identified 2499 patients with definite or probable asthma. The mean duration of follow-up was 14 years (range, 0 to 29). There were 140 deaths during 32,605 person-years of follow-up. Overall survival was not significantly different from the survival that was expected for residents of Rochester, Survival was less than expected in patients who were 35 years of age or older when their asthma was diagnosed and who also had another lung disease (predominantly chronic obstructive pulmonary disease). Four percent of all deaths in the study cohort were due to asthma, and all were among adults. Survival was not related to the year of onset of asthma. Conclusions. Survival among patients with asthma but no other lung disease was not significantly different from expected survival, However, patients 35 or older who had asthma associated with chronic obstructive pulmonary disease did have worse than expected survival. Asthma was classified as the cause of death in only 4 percent of the patients, and there was no evidence of an increased risk of death among patients with a more recent diagnosis of asthma. These results provide assurance that community-based patients with asthma usually have a good prognosis.	MAYO CLIN & MAYO FDN,DIV ALLERG DIS & INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PEDIAT & ADOLESCENT MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic	SILVERSTEIN, MD (corresponding author), MAYO CLIN & MAYO FDN,DIV AREA GEN INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905, USA.		Silverstein, Marc D/D-8592-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25187] Funding Source: Medline; NIAMS NIH HHS [AR 30582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALMIND M, 1992, DAN MED BULL, V39, P561; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; [Anonymous], 1984, Thorax, V39, P505; BARGER LW, 1988, ANN ALLERGY, V60, P31; BEARD CM, 1992, J CLIN EPIDEMIOL, V45, P1013; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P389, DOI 10.1016/0091-6749(87)90056-X; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; HANNAWAY PJ, 1988, PEDIATR ASTHMA ALLER, V2, P99; HUNT LW, 1993, JAMA-J AM MED ASSOC, V269, P1947, DOI 10.1001/jama.269.15.1947; JONSSON JA, 1987, ACTA PAEDIATR SCAND, V76, P950, DOI 10.1111/j.1651-2227.1987.tb17270.x; KAPLAN KM, 1993, PUBLIC HEALTH REP, V108, P66; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; MALVEAUX FJ, 1988, J ALLERGY CLIN IMMUN, V81, P306; MAO Y, 1987, CAN MED ASSOC J, V137, P620; MARKOWE HLJ, 1987, BRIT MED J, V295, P949, DOI 10.1136/bmj.295.6604.949; MUSK AW, 1987, MED J AUSTRALIA, V147, P423, DOI 10.5694/j.1326-5377.1987.tb133582.x; PAULOZZI LJ, 1986, ANN ALLERGY, V56, P392; RACHELEFKSY GS, 1987, J ALLERGY CLIN IMMUN, V79, P183; RYSSING E, 1959, Acta Paediatr, V48, P255; SCHACHTER EN, 1984, CHEST, V85, P623, DOI 10.1378/chest.85.5.623; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P383, DOI 10.1016/0091-6749(87)90055-8; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	27	108	109	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1537	1541		10.1056/NEJM199412083312301	http://dx.doi.org/10.1056/NEJM199412083312301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969322				2022-12-28	WOS:A1994PV29200001
J	NABER, SP				NABER, SP			MOLECULAR PATHOLOGY - DETECTION OF NEOPLASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											NABER, SP (corresponding author), BAYSTATE MED CTR,DEPT PATHOL,SPRINGFIELD,MA 01199, USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ROSENTHAL N, 1994, NEW ENGL J MED, V331, P315, DOI 10.1056/NEJM199408043310508; SKLAR J, 1992, CANCER, V70, P1710, DOI 10.1002/1097-0142(19920915)70:4+<1710::AID-CNCR2820701610>3.0.CO;2-J; WAINSCOAT JS, 1990, CANCER RES, V50, P1355	4	34	50	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1508	1510		10.1056/NEJM199412013312208	http://dx.doi.org/10.1056/NEJM199412013312208			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969302				2022-12-28	WOS:A1994PU86600008
J	PAUKER, SG; KOPELMAN, RI				PAUKER, SG; KOPELMAN, RI			SOME FAMILIAR TRADE-OFFS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							PULMONARY-EMBOLISM; VENOUS THROMBOSIS; HEPARIN-THERAPY; ANTICOAGULATION; PREVENTION; MANAGEMENT; DIAGNOSIS; WARFARIN		TUFTS UNIV,SCH MED,NEW ENGLAND MED CTR,DIV GEN INTERNAL MED,BOSTON,MA	Tufts Medical Center; Tufts University	PAUKER, SG (corresponding author), TUFTS UNIV,SCH MED,NEW ENGLAND MED CTR,DIV CLIN DECIS MAKING,BOX 302,750 WASHINGTON ST,BOSTON,MA 02111, USA.							ALPERT JS, 1994, HEART ARTERIES VEINS, V2, P1875; BECKER DM, 1992, ARCH INTERN MED, V152, P1985, DOI 10.1001/archinte.152.10.1985; CLAGETT GP, 1992, CHEST, V102, pS391, DOI 10.1378/chest.102.4_Supplement.391S; COHEN AM, 1993, CANC PRINCIPLES PRAC, V1, P929; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; DORFMAN GS, 1992, RADIOL CLIN N AM, V30, P879; ECKMAN MH, 1990, JAMA-J AM MED ASSOC, V263, P1513, DOI 10.1001/jama.263.11.1513; GOLDHABER SZ, 1992, JAMA-J AM MED ASSOC, V268, P1727, DOI 10.1001/jama.268.13.1727; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HIRSH J, 1992, CHEST, V102, pS337, DOI 10.1378/chest.102.4.337S; HIRSH J, 1992, CHEST S4, V102, pS321; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL RD, 1992, ARCH INTERN MED, V152, P1589, DOI 10.1001/archinte.152.8.1589; HYERS TM, 1992, CHEST, V102, pS408, DOI 10.1378/chest.102.4_Supplement.408S; HYERS TM, 1993, CHEST, V103, P1636, DOI 10.1378/chest.103.5.1636a; JAFFIN BW, 1987, AM J MED, V83, P269, DOI 10.1016/0002-9343(87)90697-8; KILLEWICH LA, 1993, J VASC SURG, V17, P934, DOI 10.1016/0741-5214(93)90043-L; LANDEFELD CS, 1989, AM J MED, V87, P153; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; MOSER KM, 1994, HARRISONS PRINCIPLES, P1214; PAUKER SG, 1993, NEW ENGL J MED, V328, P1621, DOI 10.1056/NEJM199306033282209; PRINS MH, 1994, ARCH INTERN MED, V154, P1310, DOI 10.1001/archinte.154.12.1310; QUINN DA, 1992, JAMA-J AM MED ASSOC, V268, P1689, DOI 10.1001/jama.268.13.1689; SARASIN FP, 1993, J GEN INTERN MED, V8, P476, DOI 10.1007/BF02600108; SENIOR RM, 1992, CECIL TXB MED, P421; 1990, JAMA-J AM MED ASSOC, V263, P2753	28	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1511	1514		10.1056/NEJM199412013312209	http://dx.doi.org/10.1056/NEJM199412013312209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969303				2022-12-28	WOS:A1994PU86600009
J	VANSCHOOTEN, FJ; MOONEN, EJC; RHIJNSBURGER, E; VANAGEN, B; THIJSSEN, HHW; KLEINJANS, JCS				VANSCHOOTEN, FJ; MOONEN, EJC; RHIJNSBURGER, E; VANAGEN, B; THIJSSEN, HHW; KLEINJANS, JCS			DERMAL UPTAKE OF POLYCYCLIC AROMATIC-HYDROCARBONS AFTER HAIRWASH WITH COAL-TAR SHAMPOO	LANCET			English	Letter							COKE-OVEN WORKERS		UNIV LIMBURG,DEPT PHARMACOL,6200 MD MAASTRICHT,NETHERLANDS	Hasselt University	VANSCHOOTEN, FJ (corresponding author), UNIV LIMBURG,DEPT HLTH RISK ANAL & TOXICOL,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Kleinjans, Jos C.S./E-7241-2015	van Schooten, Frederik Jan/0000-0001-8111-8198				BERTRAND JP, 1987, BRIT J IND MED, V44, P559; DENNIS MJ, 1983, FOOD CHEM TOXICOL, V21, P569, DOI 10.1016/0278-6915(83)90142-4; JONGENEELEN FJ, 1990, BRIT J IND MED, V47, P454; VANROOIJ JGM, 1993, BRIT J IND MED, V50, P623; 1986, MONORAPHS POLYCYCL 1, V38	5	23	23	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1505	1506		10.1016/S0140-6736(94)90323-9	http://dx.doi.org/10.1016/S0140-6736(94)90323-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968140				2022-12-28	WOS:A1994PT99500042
J	VLADECK, BC				VLADECK, BC			PHYSICIAN INVOLVEMENT WITH MEDICAID HOME-BASED AND COMMUNITY-BASED SERVICES WAIVER PROGRAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1569	1569		10.1001/jama.272.20.1569	http://dx.doi.org/10.1001/jama.272.20.1569			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966855				2022-12-28	WOS:A1994PR40500003
J	SHERR, CJ				SHERR, CJ			G1 PHASE PROGRESSION - CYCLING ON CUE	CELL			English	Review							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASES; PROTEIN-KINASE; S-PHASE; RETINOBLASTOMA PROTEIN; DNA-REPLICATION; FIBROBLASTS; INHIBITION; SUBUNIT				SHERR, CJ (corresponding author), ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, DEPT TUMOR CELL BIOL, 332 N LAUDERDALE, MEMPHIS, TN 38104 USA.		Sherr, Charles J/N-8074-2018	Sherr, Charles J/0000-0002-5516-6206				AXTON JM, 1994, EMBO J, V13, P462, DOI 10.1002/j.1460-2075.1994.tb06281.x; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARDWELL L, 1994, IN PRESS DEV BIOL; BATES S, 1994, ONCOGENE, V9, P1633; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2261; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3883; TAM SW, 1994, ONCOGENE, V9, P2663; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	59	2603	2653	0	76	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 18	1994	79	4					551	555		10.1016/0092-8674(94)90540-1	http://dx.doi.org/10.1016/0092-8674(94)90540-1			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954821				2022-12-28	WOS:A1994PT48100002
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PROPOSES SPECIAL LABELING AND PACKAGING TO PREVENT CHILDHOOD IRON POISONING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1488	1488						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966836				2022-12-28	WOS:A1994PQ90000021
J	DIETZ, V; COLOMBO, G; JENSEN, L				DIETZ, V; COLOMBO, G; JENSEN, L			LOCOMOTOR-ACTIVITY IN SPINAL MAN	LANCET			English	Article							SPASTICITY	We studied whether spinal locomotor centres of patients with paraplegia can be activated by external stimuli. In patients with complete paraplegia, coordinated stepping movements were induced by weight support and standing on a moving treadmill. The pattern of leg muscle electromyographic (EMG) activity was similar to that seen in healthy subjects although EMG amplitude was smaller. With daily training the amplitude of gastrocnemius EMG activity increased during the weight-bearing phase of stepping and the degree of inappropriate tibialis anterior activity decreased. Patients with incomplete paraplegia profited from the training programme in that their walking on a stationary surface improved even when unsupported. Our results may suggest new ways to improve mobility of patients with paraplegia.			DIETZ, V (corresponding author), UNIV HOSP BALGRIST,CTR PARAPLEG,CH-8008 ZURICH,SWITZERLAND.							BARBEAU H, 1987, BRAIN RES, V437, P83, DOI 10.1016/0006-8993(87)91529-0; DIETZ V, 1992, EXP BRAIN RES, V89, P229; DIETZ V, 1987, J PHYSIOL-LONDON, V386, P149, DOI 10.1113/jphysiol.1987.sp016527; DIETZ V, 1992, PHYSIOL REV, V72, P33, DOI 10.1152/physrev.1992.72.1.33; DIETZ V, 1981, BRAIN, V104, P431, DOI 10.1093/brain/104.3.431; Grillner S., 1981, HDB PHYSL NERVOUS SY, P1179, DOI DOI 10.1002/CPHY.CP010226; HORSTMANN GA, 1988, ELECTROEN CLIN NEURO, V70, P447, DOI 10.1016/0013-4694(88)90022-3; KUHN RA, 1950, BRAIN, V73, P1, DOI 10.1093/brain/73.1.1; MEINCK HM, 1989, J NEUROL, V236, P120, DOI 10.1007/BF00314410; WERNIG A, 1992, PARAPLEGIA, V30, P229, DOI 10.1038/sc.1992.61	10	298	301	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1260	1263		10.1016/S0140-6736(94)90751-X	http://dx.doi.org/10.1016/S0140-6736(94)90751-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967986				2022-12-28	WOS:A1994PP70100009
J	SMITH, P; SHELDON, TA; CARRHILL, RA; MARTIN, S; PEACOCK, S; HARDMAN, G				SMITH, P; SHELDON, TA; CARRHILL, RA; MARTIN, S; PEACOCK, S; HARDMAN, G			ALLOCATING RESOURCES TO HEALTH AUTHORITIES - RESULTS AND POLICY IMPLICATIONS OF SMALL-AREA ANALYSIS OF USE OF INPATIENT SERVICES	BRITISH MEDICAL JOURNAL			English	Article							CRITIQUE	A study designed to identify the principal determinants of use of inpatient facilities in NHS hospitals in England used the data and methods outlined in the previous paper. The model for the psychiatric sector contains mortality, self reported morbidity, and social variables indicating deprivation and the level of care at home. The non-acute model contains mortality and several socioeconomic variables. The models lay less weight on age than the current formula, and a national formula based on these models would, in the acute sector, redistribute resources to poorer areas compared with the current formula.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV YORK,SOCIAL SCI RES INST,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV YORK,YORK HLTH ECON CONSORTIUM,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK; University of York - UK; University of York - UK	SMITH, P (corresponding author), UNIV YORK,DEPT ECON & RELATED STUDIES,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Peacock, Stuart J/P-2437-2018; Sheldon, Trevor/AAK-7088-2021	Peacock, Stuart J/0000-0002-8243-8721; Sheldon, Trevor/0000-0002-7479-5913; Smith, Peter/0000-0003-0058-7588				CARRHILL RA, 1994, BRIT MED J, V309, P1046, DOI 10.1136/bmj.309.6961.1046; CARRHILL RA, 1990, HLTH POLY, V13, P135; CARRHILL RA, 1994, FORMUAL DISTRIBUTING; MAYS N, 1989, COMMUNITY MED, V11, P173; SHELDON TA, 1992, J ROY STAT SOC A STA, V155, P403, DOI 10.2307/2982891	5	66	67	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1050	1054		10.1136/bmj.309.6961.1050	http://dx.doi.org/10.1136/bmj.309.6961.1050			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN733	7950738	Green Published			2022-12-28	WOS:A1994PN73300021
J	ARBER, S; HALDER, G; CARONI, P				ARBER, S; HALDER, G; CARONI, P			MUSCLE LIM PROTEIN, A NOVEL ESSENTIAL REGULATOR OF MYOGENESIS, PROMOTES MYOGENIC DIFFERENTIATION	CELL			English	Article							TRANSCRIPTIONAL ACTIVATION; DOMAIN; MYOD; GENE; COMMITMENT; REPRESSION; BINDING; MOTIF; RNAS; JUN	Muscle LIM protein (MLP) is a novel positive regulator of myogenesis. Its expression and that of its Drosophila homolog DMLP1 are enriched in striated muscle and coincide with myogenic differentiation. in the absence of MLP, induced C2 cells express myogenin but fail to exit from the cell cycle and to differentiate. Overexpression of MLP in C2 myoblasts potentiates myogenic differentiation and reduces its sensitivity to TGF beta. Like MLP, single LIM domain deletion mutants of MLP and nonmuscle LIM-only proteins promote myogenic differentiation. In 3T3 fibroblasts, the same LIM proteins prevent phorbol ester-induced inhibition of DNA replication. These results establish MLP as an essential promoter of myogenesis and suggest that LIM-only proteins act via similar mechanisms to regulate aspects of cell differentiation.	UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND	University of Basel	ARBER, S (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.		Halder, Georg/F-2966-2015	Halder, Georg/0000-0001-7580-3236; Arber, Silvia/0000-0002-6261-250X				ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FISCHBACH GD, 1972, DEV BIOL, V28, P407, DOI 10.1016/0012-1606(72)90023-1; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; LASSAR AB, 1992, TRANSCRIPTIONAL REGU, P1037; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LYONS GE, 1992, SEM DEV BIOL, V3, P243; MARTIN JF, 1992, J BIOL CHEM, V267, P10956; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MIZUNO K, 1994, ONCOGENE, V9, P1605; NGUYEN HT, 1983, CELL, V34, P281, DOI 10.1016/0092-8674(83)90159-9; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; RUBENSTEIN JLR, 1990, NUCLEIC ACIDS RES, V18, P4833, DOI 10.1093/nar/18.16.4833; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WANG XK, 1992, J BIOL CHEM, V267, P9176; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503	30	389	407	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					221	231		10.1016/0092-8674(94)90192-9	http://dx.doi.org/10.1016/0092-8674(94)90192-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954791				2022-12-28	WOS:A1994PN63000007
J	VAJANAPHANICH, M; SCHULTZ, C; RUDOLF, MT; WASSERMAN, M; ENYEDI, P; CRAXTON, A; SHEARS, SB; TSIEN, RY; BARRETT, KE; TRAYNORKAPLAN, A				VAJANAPHANICH, M; SCHULTZ, C; RUDOLF, MT; WASSERMAN, M; ENYEDI, P; CRAXTON, A; SHEARS, SB; TSIEN, RY; BARRETT, KE; TRAYNORKAPLAN, A			LONG-TERM UNCOUPLING OF CHLORIDE SECRETION FROM INTRACELLULAR CALCIUM LEVELS BY INS(3,4,5,6)P-4	NATURE			English	Article							EPITHELIAL-CELL LINE; INOSITOL TETRAKISPHOSPHATE; RAT-LIVER; PURIFICATION; PHOSPHATES; TRANSPORT	OSMOREGULATION, inhibitory neurotransmission and pH balance depend on chloride ion (Cl-) flux. In intestinal epithelial cells, apical Cl- channels control salt and fluid secretion and are, in turn, regulated by agonists acting through cyclic nucleotides and internal calcium ion concentration ([Ca2+](i))(1-3). Recently, we found that muscarinic pretreatment prevents [Ca2+](i) increases from eliciting Cl- secretion in T-84 colonic epithelial cells(4). By studying concomitant inositol phosphate metabolism, ae have now identified D-myo-inositol 3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P-4), as the inositol phosphate most likely to mediate this uncoupling. A novel, membrane-permeant ester prepared by total synthesis delivers Ins(3,4,5,6)P-4 intracellularly and confirms that this emerging messenger(5) does inhibit Cl- flux resulting from thapsigargin- or histamine-induced [Ca2+](i) elevations.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED 8414,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV BREMEN,INST ORGAN CHEM,W-2800 BREMEN,GERMANY; NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of Bremen; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Barrett, Kim Elaine/AAE-7762-2019; Shears, Stephen B/C-6335-2019; Barrett, Kim/AAE-2794-2022	Barrett, Kim Elaine/0000-0002-6704-998X; Shears, Stephen B/0000-0001-7309-8916; Schultz, Carsten/0000-0002-5824-2171				ABDULLAH M, 1992, J BIOL CHEM, V267, P22340; ANGYAL SJ, 1965, J CHEM SOC, P6949, DOI 10.1039/jr9650006949; CRAXTON A, 1994, J BIOL CHEM, V269, P4337; DHARMASATHAPHOR.K, 1984, AM J PHYSIOL, V9, pG204; DHARMSATHAPHORN K, 1989, AM J PHYSIOL, V256, pC1224, DOI 10.1152/ajpcell.1989.256.6.C1224; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; DHARMSATHAPHORN K, 1991, TXB INTERNAL MED, P398; FRIZZELL RA, 1986, ION TRANSPORT EPITHE, V36, P137; KACHINTORN U, 1993, BRIT J PHARMACOL, V109, P510, DOI 10.1111/j.1476-5381.1993.tb13599.x; KACHINTORN U, 1993, AM J PHYSIOL, V264, pC671, DOI 10.1152/ajpcell.1993.264.3.C671; MANDEL KG, 1986, J BIOL CHEM, V261, P704; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; PITTET D, 1989, J BIOL CHEM, V264, P18489; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; SCHULTZ C, 1993, J BIOL CHEM, V268, P6316; TRAYNORKAPLAN AE, IN PRESS AM J PHYSL; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; WONG NS, 1988, BIOCHEM J, V252, P1	20	171	174	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					711	714		10.1038/371711a0	http://dx.doi.org/10.1038/371711a0			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935818				2022-12-28	WOS:A1994PM77300059
J	ALTMAN, DG; BLAND, JM				ALTMAN, DG; BLAND, JM			QUARTILES, QUINTILES, CENTILES, AND OTHER QUANTILES	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	St Georges University London	ALTMAN, DG (corresponding author), IMPERIAL CANC RES FUND,POB 123,LONDON WC2A 3PX,ENGLAND.							Altman DG, 1991, PRACTICAL STAT MED R, P419; CAMPBELL MJ, 1989, STATISTICS CONFIDENC, P71; COLE TJ, 1994, BMJ-BRIT MED J, V308, P641, DOI 10.1136/bmj.308.6929.641	3	111	113	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					996	996		10.1136/bmj.309.6960.996	http://dx.doi.org/10.1136/bmj.309.6960.996			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950724	Green Published, Bronze			2022-12-28	WOS:A1994PM41700026
J	KAISER, J				KAISER, J			BREAST-CANCER - ARMY DOLES OUT ITS FIRST 210-MILLION-DOLLARS	SCIENCE			English	Editorial Material																		1994, SCIENCE, V264, P1068	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					212	212		10.1126/science.7939652	http://dx.doi.org/10.1126/science.7939652			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939652				2022-12-28	WOS:A1994PM13400011
J	MORRISON, D				MORRISON, D			14-3-3 - MODULATORS OF SIGNALING PROTEINS	SCIENCE			English	Editorial Material							AERUGINOSA EXOENZYME-S; PSEUDOMONAS-AERUGINOSA; FAMILY; RAS				MORRISON, D (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,MOLEC MECHANISMS CARCINOGENESIS LAB,FREDERICK,MD 21702, USA.							AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BOHEN SP, 1994, BIOL HEAT SHOCK PROT; COBURN J, 1989, J BIOL CHEM, V264, P9004; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; Moore B. E., 1967, PHYSL BIOCH ASPECTS; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; SMITH BL, 1991, J BIOL CHEM, V266, P14866; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJEK AB, 1993, CELL, V74, P205; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	26	192	197	4	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					56	57		10.1126/science.7939645	http://dx.doi.org/10.1126/science.7939645			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939645	Green Submitted			2022-12-28	WOS:A1994PK58200024
J	AUGARTEN, A; YAHAV, Y; KEREM, BS; HALLE, D; LAUFER, J; SZEINBERG, A; DOR, J; MASHIACH, S; GAZIT, E; MADGAR, I				AUGARTEN, A; YAHAV, Y; KEREM, BS; HALLE, D; LAUFER, J; SZEINBERG, A; DOR, J; MASHIACH, S; GAZIT, E; MADGAR, I			CONGENITAL BILATERAL ABSENCE OF VAS-DEFERENS IN THE ABSENCE OF CYSTIC-FIBROSIS	LANCET			English	Note							MEN	The high frequency of mutations in the cystic fibrosis gene in patients with congenital bilateral absence of vas deferens (CBAVD) has raised the question whether all of them have a genital form of cystic fibrosis. We investigated 47 CBAVD patients by ultrasonography, 10 (21%) had renal malformations and 37 (79%) did not. In the former group, no cystic fibrosis mutations were found and sweat chloride concentrations were normal. In the latter group, 18 patients (49%) carried at least one cystic fibrosis mutation and sweat chloride was high in 17 of 26 tested (65%). Our findings suggest that CBAVD patients with renal malformations do not necessarily have cystic fibrosis.	CHAIM SHEBA MED CTR,DEPT GYNAECOL,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,DEPT UROL,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,TISSUE TYPING LAB,IL-52621 TEL HASHOMER,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL; HEBREW UNIV JERUSALEM,DEPT GENET,IL-91904 JERUSALEM,ISRAEL	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem	AUGARTEN, A (corresponding author), CHAIM SHEBA MED CTR,DEPT PAEDIAT,IL-52621 TEL HASHOMER,ISRAEL.							AMOS JA, 1992, PEDIAT PULMON S, V8, P142; ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; DUMUR V, 1990, LANCET, V336, P512, DOI 10.1016/0140-6736(90)92066-Q; OATES RD, 1994, J ANDROL, V15, P1; OATES RD, 1993, WORLD J UROL, V11, P82; OSBORNE LR, 1993, HUM MOL GENET, V2, P1605, DOI 10.1093/hmg/2.10.1605; RUBIN SO, 1975, SCAND J UROL NEPHROL, V9, P94, DOI 10.3109/00365597509180913; 1992, LANCET, V339, P1328	8	96	97	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1473	1474		10.1016/S0140-6736(94)90292-5	http://dx.doi.org/10.1016/S0140-6736(94)90292-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968122				2022-12-28	WOS:A1994PT99500011
J	LEE, PR				LEE, PR			MODELS OF EXCELLENCE	LANCET			English	Article							PHYSICIANS				LEE, PR (corresponding author), US DEPT HHS, OFF ASSISTANT SECRETARY HLTH, 200 INDEPENDENCE AVE, WASHINGTON, DC 20201 USA.							BOUFFORD JI, 1994, CHANGING HLTH CARE S; ENGLE GL, 1977, SCIENCE, V196, P127; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FRY J, 1978, NEW APPROACH MED; GREENLICK MR, 1992, JAMA-J AM MED ASSOC, V267, P1645, DOI 10.1001/jama.267.12.1645; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; LASKER RD, 1994, 54TH ANN M AM DIAB A; LEE PR, 1993, AM FAM PHYSICIAN, V47, P323; LIGHT DW, 1994, LANCET, V344, P1197, DOI 10.1016/S0140-6736(94)90512-6; MANT D, 1994, LANCET, V344, P1343, DOI 10.1016/S0140-6736(94)90698-X; MILLIS JS, 1966, GRADUATE ED PHYSICIA; ORTON P, 1994, LANCET, V344, P1413; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGH BM, 1984, BRIT MED J, V289, P726, DOI 10.1136/bmj.289.6447.726; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; TERRIS M, 1983, J PUBL HLTH POLI MAR; VANWEEL C, 1994, LANCET, V344, P1276, DOI 10.1016/S0140-6736(94)90756-0	18	12	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 26	1994	344	8935					1484	1486		10.1016/S0140-6736(94)90295-X	http://dx.doi.org/10.1016/S0140-6736(94)90295-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968125				2022-12-28	WOS:A1994PT99500014
J	MCANULTY, JM; FLEMING, DW; GONZALEZ, AH				MCANULTY, JM; FLEMING, DW; GONZALEZ, AH			A COMMUNITY-WIDE OUTBREAK OF CRYPTOSPORIDIOSIS ASSOCIATED WITH SWIMMING AT A WAVE POOL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; GIARDIA; IMMUNOCOMPETENT; CONTAMINATION; TRANSMISSION; DIARRHEA; GEORGIA; CALVES	Objective.-To determine the cause of a community-wide outbreak of cryptosporidiosis. Design.-A matched case-control study. Setting.-General community of Lane County, Oregon. Patients and Other Participants.-Persons with Cryptosporidium detected in their stool from June to October 1992 were identified by contacting laboratories serving the area. Exposures of the first 18 case patients identified were compared with those of 18 age- and neighborhood-matched controls selected from a reverse telephone directory. Main Outcome Measures.-Reported exposures to risk factors for cryptosporidiosis and abatement of cryptosporidiosis outbreak. Results.-Fifty-five patients with cryptosporidiosis were detected, including 37 who were the first individuals ill in their households. The case-control study involving the first 18 case patients showed no association between illness and attendance at day care or drinking municipal water or drinking untreated surface waters (river or lake water) in the 2 weeks before onset of illness. However, nine of 18 case patients reported swimming at a local wave pool, compared with none of 18 controls. We ultimately identified 17 case patients who reported swimming at the same wave pool during their incubation periods, whose exposure dates spanned a 2-month period. Inspection of the pool's filtration system did not detect any abnormalities. The outbreak subsided after the pool water was drained and replaced. Conclusions.-This prolonged outbreak of cryptosporidiosis was likely caused by exposure to fecally contaminated wave pool water. Since Cryptosporidium is highly chlorine resistant and inadequately removed by sand filters, such outbreaks may represent an unrecognized hazard of wave pools, where the likelihood of inadvertent water ingestion is high. Such outbreaks may go undetected in areas where cryptosporidiosis is not reportable or laboratory screening is infrequent.	CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; OREGON MED LABS,EUGENE,OR	Centers for Disease Control & Prevention - USA	MCANULTY, JM (corresponding author), OREGON HLTH DIV,CTR DIS CONTROL & PREVENT,800 NE OREGON ST,PORTLAND,OR 97232, USA.							ADDISS DG, 1991, PEDIATR INFECT DIS J, V10, P907, DOI 10.1097/00006454-199112000-00005; CASEMORE DP, 1989, J INFECTION, V19, P101, DOI 10.1016/S0163-4453(89)91764-7; CRAWFORD FG, 1988, PEDIATR INFECT DIS J, V7, P806, DOI 10.1097/00006454-198811000-00013; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; DEAN AG, 1994, EPI INFO VERSION 6; FERSON MJ, 1992, MED J AUSTRALIA, V156, P813, DOI 10.5694/j.1326-5377.1992.tb121578.x; GARCIA LS, 1988, DIAGNOSTIC MED PARAS, P389; GREENSMITH CT, 1988, PEDIATR INFECT DIS J, V7, P91, DOI 10.1097/00006454-198802000-00005; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; JOCE RE, 1991, EPIDEMIOL INFECT, V107, P497, DOI 10.1017/S0950268800049190; KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423, DOI 10.1128/AEM.56.5.1423-1428.1990; LECHEVALLIER MW, 1991, GIARDIA CRYPTOSPORID; MEISEL JL, 1976, GASTROENTEROLOGY, V70, P1156; MILLER RA, 1990, J INFECT DIS, V161, P312, DOI 10.1093/infdis/161.2.312; MIRON D, 1991, PEDIATR INFECT DIS J, V10, P438, DOI 10.1097/00006454-199106000-00004; NAVIN TR, 1984, REV INFECT DIS, V6, P313; NIME FA, 1976, GASTROENTEROLOGY, V70, P592; PORTER JD, 1988, AM J PUBLIC HEALTH, V78, P659, DOI 10.2105/AJPH.78.6.659; REIF JS, 1989, AM J PUBLIC HEALTH, V79, P1528, DOI 10.2105/AJPH.79.11.1528; ROSE JB, 1991, ENVIRON SCI TECHNOL, V25, P1393, DOI 10.1021/es00020a005; SCHULER PF, 1990, J AM WATER WORKS ASS, V82, P67; SMITH HV, 1989, EPIDEMIOL INFECT, V103, P703, DOI 10.1017/S0950268800031101; SORVILLO FJ, 1992, AM J PUBLIC HEALTH, V82, P742, DOI 10.2105/AJPH.82.5.742; Sterling C.R., 1990, P51; TANGERMANN RH, 1991, AM J EPIDEMIOL, V133, P471, DOI 10.1093/oxfordjournals.aje.a115914; WEBER J, 1983, NEW ENGL J MED, V309, P1326; WOLFSON JS, 1985, NEW ENGL J MED, V312, P1278, DOI 10.1056/NEJM198505163122002; 1993, CD SUMMARY, V42, P1; 1994, MMWR-MORBID MORTAL W, V43, P561; 1984, MMWR-MORBID MORTAL W, V33, P599	31	64	68	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1597	1600		10.1001/jama.272.20.1597	http://dx.doi.org/10.1001/jama.272.20.1597			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966870				2022-12-28	WOS:A1994PR40500026
J	STERN, RS				STERN, RS			DRUG PROMOTION FOR AN UNLABELED INDICATION - THE CASE OF TOPICAL TRETINOIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	STERN, RS (corresponding author), BETH ISRAEL HOSP,DEPT DERMATOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							DELOZIER JE, 1987, DHHS PHS821364 NAT C; HOROWITZ GL, 1981, NEW ENGL J MED, V305, P924, DOI 10.1056/NEJM198110153051605; KESSLER DA, 1991, NEW ENGL J MED, V325, P201, DOI 10.1056/NEJM199107183250310; KRIPKE ML, 1980, J AM ACAD DERMATOL, V2, P439, DOI 10.1016/S0190-9622(80)80373-2; LIMERICK Z, 1977, READERS GUIDE PERIOD, V36; RANDALL T, 1991, JAMA-J AM MED ASSOC, V266, P11, DOI 10.1001/jama.266.1.11; SCHAPPERT SM, 1993, DHHS PHS931250 NAT C; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P527, DOI 10.1001/jama.259.4.527; Weiss JS, 1988, JAMA-J AM MED ASSOC, V260, P926; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P3274; 1987, DRUG TOPICS RED BOOK; 1985, J AM ACAD DERMATOL, V13, pA60; 1989, J AM ACAD DERMATOL, V20, pA100; 1980, VITAL HLTH STATIST 2, V90; 1991, DRUG TOPICS RED BOOK; 1991, FDC REPORTS PINK SHE, V53; 1978, NY TIMES INDEX BOOK, V65; 1978, FDA DRUG B, V8, P26	18	13	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1348	1349		10.1056/NEJM199411173312006	http://dx.doi.org/10.1056/NEJM199411173312006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935705				2022-12-28	WOS:A1994PR21600006
J	HUYSMANS, DAKC; HERMUS, ARMM; CORSTENS, FHM; BARENTSZ, JO; KLOPPENBORG, PWC				HUYSMANS, DAKC; HERMUS, ARMM; CORSTENS, FHM; BARENTSZ, JO; KLOPPENBORG, PWC			LARGE, COMPRESSIVE GOITERS TREATED WITH RADIOIODINE	ANNALS OF INTERNAL MEDICINE			English	Article						IODINE RADIOISOTOPES; GOITER, NODULAR; AGED; SURGERY, OPERATIVE; LEVOTHYROXINE	MULTINODULAR NONTOXIC GOITER; RADIOACTIVE IODINE; TOXIC GOITER; THERAPY; HYPERTHYROIDISM; THYROIDECTOMY; MANAGEMENT; THYROXINE; DISEASE	Objective: To evaluate the effectiveness of radioiodine therapy as an alternative for surgery in elderly patients with a large, compressive goiter using objective methods for measuring thyroid volume and tracheal compression. Design: Prospective study. Setting: University hospital in the Netherlands. Patients: 19 patients (mean age +/- SD, 66 +/- 14 years) with a large, compressive multinodular goiter who had a high operative risk or refused to have thyroid surgery. Intervention: A single intravenous dose of I-131 at 2.6 +/- 1.0 GBq (70 +/- 28 mCi) (3.7 MBq or 100 mu Ci/g of thyroid tissue), followed by daily administration of L-thyroxine in doses that did not suppress thyroid-stimulating hormone. Measurements: Clinical evaluation and measurements of thyroid volume, maximal tracheal deviation, and the smallest cross-sectional area of the tracheal lumen with magnetic resonance imaging before and 1 year after I-131 treatment. Results: No exacerbation of compressive symptoms after I-131 therapy was observed. Thyroid volume was 269 +/- 153 mL before treatment and 154 +/- 73 mL 1 year after treatment (P < 0.001). Thyroid volume was reduced 40% +/- 15% (range, 19% to 68%). Maximal tracheal deviation (1.9 +/- 0.8 cm before and 1.5 +/- 0.7 cm 1 year after therapy) had decreased by 20% +/- 20% (range, -4% to 73%; P < 0.001), and the smallest cross-sectional area of the tracheal lumen (0.78 +/- 0.38 cm(2) before and 1.04 +/- 0.48 cm(2) 1 year after therapy) had increased by 36% +/- 38% (range, -3% to 125%; P < 0.001). Clinical signs and symptoms improved in 8 of 12 patients with dyspnea and inspiratory strider and in both patients with compression of the superior vena cava. Conclusions:Therapy with I-131 is an effective alternative to surgery for elderly patients with a large, compressive multinodular goiter.	UNIV NIJMEGEN HOSP, DEPT ENDOCRINOL, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen	HUYSMANS, DAKC (corresponding author), DEWEEZENLANDEN HOSP, DEPT NUCL MED, POB 10500, 8000 GM ZWOLLE, NETHERLANDS.		Barentsz, Jelle/D-3515-2009; Hermus, A.R.M.M./H-8043-2014	Hermus, A.R.M.M./0000-0003-1075-2655				BERDING G, 1990, NUKLEARMED, V29, P158; BERGHOUT A, 1989, CLIN ENDOCRINOL, V31, P193, DOI 10.1111/j.1365-2265.1989.tb01242.x; BERGHOUT A, 1988, CLIN ENDOCRINOL, V28, P409, DOI 10.1111/j.1365-2265.1988.tb03672.x; BERGHOUT A, 1990, LANCET, V336, P193, DOI 10.1016/0140-6736(90)91730-X; BLIDDAL H, 1982, ACTA ENDOCRINOL-COP, V99, P517, DOI 10.1530/acta.0.0990517; Cooper DS, 1991, WERNER INGBARS THYRO, P887; DeGroot LJ, 1975, THYROID ITS DISEASES, P314; DOERING P, 1958, Strahlentherapie, V105, P245; FOSTER RS, 1978, SURG GYNECOL OBSTET, V146, P423; FREY KW, 1979, FORTSCHR RONTG NEUEN, V130, P172; GEERDSEN JP, 1984, CLIN ENDOCRINOL, V21, P529, DOI 10.1111/j.1365-2265.1984.tb01391.x; HAMBURGER JI, 1985, J NUCL MED, V26, P888; HEGEDUS L, 1990, DAN MED BULL, V37, P249; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HUYSMANS DAKC, 1994, BRIT J RADIOL, V67, P519, DOI 10.1259/0007-1285-67-798-519; KAY TWH, 1987, ANN INTERN MED, V107, P857, DOI 10.7326/0003-4819-107-6-857; KAY TWH, 1988, AM J MED, V84, P19, DOI 10.1016/0002-9343(88)90003-4; KEIDERLING W, 1964, DEUT MED WOCHENSCHR, V89, P453, DOI 10.1055/s-0028-1111038; MILLER MR, 1990, Q J MED, V74, P177; NYGAARD B, 1993, BRIT MED J, V307, P828, DOI 10.1136/bmj.307.6908.828; Rohrer F, 1915, PFLUG ARCH GES PHYS, V162, P225, DOI 10.1007/BF01681259; SAILER R, 1986, CHIRURGIE SCHILDDRUS, P77; SHIMAOKA K, 1974, AM J MED, V57, P576, DOI 10.1016/0002-9343(74)90009-6; STUDLEY J, 1993, SURG ENDOCRINOLOGY, P231; TAMMELING GJ, 1979, CONTOURS BREATHING, V1, P76; VERELST J, 1990, ACTA ENDOCRINOL-COP, V122, P417, DOI 10.1530/acta.0.1220417; WEITENSFELDER W, 1989, CHIRURG, V60, P29	27	115	115	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					757	762		10.7326/0003-4819-121-10-199411150-00005	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944053				2022-12-28	WOS:A1994PQ92800005
J	WOOLF, GM; PETROVIC, LM; ROJTER, SE; WAINWRIGHT, S; VILLAMIL, FG; KATKOV, WN; MICHIELETTI, P; WANLESS, IR; STERMITZ, FR; BECK, JJ; VIERLING, JM				WOOLF, GM; PETROVIC, LM; ROJTER, SE; WAINWRIGHT, S; VILLAMIL, FG; KATKOV, WN; MICHIELETTI, P; WANLESS, IR; STERMITZ, FR; BECK, JJ; VIERLING, JM			ACUTE HEPATITIS ASSOCIATED WITH THE CHINESE HERBAL PRODUCT JIN BU HUAN	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS, TOXIC; JIN BU HUAN; MEDICINE, HERBAL; QUALITY CONTROL	VENO-OCCLUSIVE DISEASE; MEDICINE; TOXICITY; HEPATOTOXICITY; MEDICATION; LIVER	Objective: To describe the hepatotoxicity associated with ingestion of the Chinese herbal product Jin Bu Huan Anodyne Tablets (Lycopodium serratum) and to propose possible mechanisms of injury. Design: Retrospective analysis. Setting: Academic hepatology units and private practice facilities. Patients: Seven previously healthy patients. Measurements: Clinical, laboratory, radiologic, and histologic studies. Results: Acute hepatitis occurred after a mean of 20 weeks (range, 7 to 52 weeks) of Jin Bu Huan ingestion and resolved in six patients within a mean of 8 weeks (range, 2 to 30 weeks); another patient is currently improving. Hepatitis was associated with symptoms of fever, fatigue, nausea, pruritus, and abdominal pain and with signs of jaundice and hepatomegaly. Biopsy specimens showed that one patient had hepatitis with eosinophils (consistent with a drug reaction) and the other had mild hepatitis, moderate fibrosis, and microvesicular steatosis. Decreasing the Jin Bu Huan dose in one patient improved liver test results. Reusing Jin Bu Huan in two other patients caused abrupt recrudescence of hepatitis. Conclusion: Jin Bu Huan can cause liver injury. Although the hepatotoxic mechanisms are not defined, they may include hypersensitive or idiosyncratic reactions or direct toxicity to active metabolites. Hepatotoxicity caused by herbal products underscores the importance of national surveillance programs and quality control of the manufacture of these products.	CEDARS SINAI MED CTR, LIVER TRANSPLANTAT PROGRAM, LOS ANGELES, CA 90048 USA; CTR DIS CONTROL & PREVENT, NATL CTR ENVIRONM HLTH, DIV ENVIRONM HAZARDS & HLTH EFFECTS, ATLANTA, GA 30341 USA; TORONTO HOSP, DIV GEN, DIV GASTROENTEROL, TORONTO M5G 2C4, ON, CANADA; ST JOHNS HOSP, DIV GASTROENTEROL, SANTA MONICA, CA 90404 USA; COLORADO STATE UNIV, DEPT CHEM, FT COLLINS, CO 80523 USA	Cedars Sinai Medical Center; Centers for Disease Control & Prevention - USA; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Colorado State University	WOOLF, GM (corresponding author), CEDARS SINAI MED CTR, HEPATOL PROGRAM, 8700 BEVERLY BLVD, SUITE 7511, LOS ANGELES, CA 90048 USA.							BEUERS U, 1991, LANCET, V337, P372, DOI 10.1016/0140-6736(91)91012-J; CASTOT A, 1992, GASTROEN CLIN BIOL, V16, P916; CHAN H, 1977, CLIN TOXICOL, V10, P273, DOI 10.3109/15563657708992423; CHAN MY, 1989, AM J CHINESE MED, V17, P165, DOI 10.1142/S0192415X89000255; CHANG HM, 1986, PHARM APPLICATIONS C, P552; Clark F., 1992, Morbidity and Mortality Weekly Report, V41, P812; DHARMANANDA S, 1993, I TRADITIONAL MED, P1; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; HARVEY J, 1981, BRIT MED J, V282, P186, DOI 10.1136/bmj.282.6259.186; Horowitz R. S., 1993, Morbidity and Mortality Weekly Report, V42, P633; HUXTABLE RJ, 1986, NEW ENGL J MED, V315, P1095; KATZ M, 1990, J CLIN GASTROENTEROL, V12, P203, DOI 10.1097/00004836-199004000-00021; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; LARREY D, 1992, ANN INTERN MED, V117, P129, DOI 10.7326/0003-4819-117-2-129; LIU GQ, 1982, ARCH INT PHARMACOD T, V258, P39; LOEPER J, 1994, GASTROENTEROLOGY, V106, P464, DOI 10.1016/0016-5085(94)90606-8; MACGREGOR FB, 1989, BRIT MED J, V299, P1156, DOI 10.1136/bmj.299.6708.1156; MATTOCKS AR, 1968, NATURE, V217, P723, DOI 10.1038/217723a0; MCGEE JO, 1976, J CLIN PATHOL, V29, P788, DOI 10.1136/jcp.29.9.788; MOHABBAT O, 1976, LANCET, V2, P269; RIES CA, 1975, JAMA-J AM MED ASSOC, V231, P352, DOI 10.1001/jama.231.4.352; SMITH BC, 1993, AUST NZ J MED, V23, P526, DOI 10.1111/j.1445-5994.1993.tb01846.x; TANDON BN, 1976, LANCET, V2, P271; VERHOEF MJ, 1990, CAN MED ASSOC J, V142, P121; Woolf G. M., 1993, Morbidity and Mortality Weekly Report, V42, P920; YEONG ML, 1993, INT J EXP PATHOL, V74, P211; Zimmerman H. J., 1978, HEPATOTOXICITY ADVER; 1993, UNSUBSTANTIATED CLAI; 1991, IMPORTANT INFORMATIO	29	155	157	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					729	735		10.7326/0003-4819-121-10-199411150-00001	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944049				2022-12-28	WOS:A1994PQ92800001
J	ROLLS, MM; WEBSTER, P; BALBA, NH; ROSE, JK				ROLLS, MM; WEBSTER, P; BALBA, NH; ROSE, JK			NOVEL INFECTIOUS PARTICLES GENERATED BY EXPRESSION OF THE VESICULAR STOMATITIS-VIRUS GLYCOPROTEIN FROM A SELF-REPLICATING RNA	CELL			English	Article							SEMLIKI FOREST VIRUS; CELL-SURFACE; ANIMAL-CELLS; SINDBIS VIRUS; RABIES VIRUS; G-PROTEIN; TRANSPORT; MEMBRANE; MUTANTS; VECTORS	Self-propagating infectious particles were produced in animal cells transfected with an RNA replicon encoding a single viral structural protein, the vesicular stomatitis virus glycoprotein (VSV-G). The replicon is derived from an alphavirus, Semliki Forest virus (SFV), and encodes the SFV RNA replicase, but none of the SFV structural proteins. After transfection of the replicon into tissue culture cells, expression of G protein spread from small foci throughout the culture. Supernatants from the cells contained infectious, virus-like particles that could be passaged and were neutralized by anti-VSV serum. The majority of the infectious particles were smaller and less dense than either VSV or SFV. Characterization by electron microscopy showed membrane-enveloped vesicles that contained the VSV-G protein. Infectious particles were apparently generated by budding of vesicles containing VSV-G protein and the RNA replicon. These experiments reveal that an enveloped infectious agent can be much simpler than previously thought.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University			Rolls, Melissa/G-6402-2014	Rolls, Melissa/0000-0002-5021-4360; Webster, Paul/0000-0002-1980-6931	NIAID NIH HHS [AI-24345] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024345, R37AI024345] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN T, 1993, CURRENT PROTOCOLS MO; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FLORKIEWICZ RZ, 1984, SCIENCE, V225, P721, DOI 10.1126/science.6087454; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; GRAHAM JM, 1988, BIOCHEM J, V252, P437, DOI 10.1042/bj2520437; GRIMLEY PM, 1968, J VIROL, V2, P1326, DOI 10.1128/JVI.2.11.1326-1338.1968; HARTFORD SL, 1975, P NATL ACAD SCI USA, V72, P1202, DOI 10.1073/pnas.72.3.1202; KAARIAINEN L, 1969, ANN MED EXP BIOL FEN, V47, P235; Kelley J M, 1972, J Virol, V10, P1231; KNIPE DM, 1977, J VIROL, V21, P1149, DOI 10.1128/JVI.21.3.1149-1158.1977; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MATLIN KS, 1982, J MOL BIOL, V156, P609, DOI 10.1016/0022-2836(82)90269-8; MCCOMBS RM, 1966, J BACTERIOL, V91, P803, DOI 10.1128/JB.91.2.803-812.1966; METSIKKO K, 1986, EMBO J, V5, P1913, DOI 10.1002/j.1460-2075.1986.tb04444.x; OWENS RJ, 1993, J VIROL, V67, P360, DOI 10.1128/JVI.67.1.360-365.1993; PAUL NL, 1993, AIDS RES HUM RETROV, V9, P963, DOI 10.1089/aid.1993.9.963; RICE CM, 1987, J VIROL, V61, P3809, DOI 10.1128/JVI.61.12.3809-3819.1987; RIEDEL H, 1984, EMBO J, V3, P1477, DOI 10.1002/j.1460-2075.1984.tb01999.x; ROSE J, 1987, RHABDOVIRUSES; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1982, J VIROL, V43, P361, DOI 10.1128/JVI.43.1.361-364.1982; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SCHLESINGER MJ, 1986, TOGAVIRIDAE FLAVIVIR; SIMONS K, 1980, J GEN VIROL, V50, P1, DOI 10.1099/0022-1317-50-1-1; Strauss EG, 1986, TOGAVIRIDAE FLAVIVIR; SUOMALAINEN M, 1992, J VIROL, V66, P4737, DOI 10.1128/JVI.66.8.4737-4747.1992; WHITT MA, 1989, J VIROL, V63, P3569, DOI 10.1128/JVI.63.9.3569-3578.1989; WHITT MA, 1991, VIROLOGY, V185, P681, DOI 10.1016/0042-6822(91)90539-N; WHITT MA, 1990, J VIROL, V64, P4907, DOI 10.1128/JVI.64.10.4907-4913.1990; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607; ZAVADA J, 1982, J GEN VIROL, V63, P15, DOI 10.1099/0022-1317-63-1-15; ZHAO HX, 1992, J VIROL, V66, P7089, DOI 10.1128/JVI.66.12.7089-7095.1992	34	109	124	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					497	506		10.1016/0092-8674(94)90258-5	http://dx.doi.org/10.1016/0092-8674(94)90258-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954815				2022-12-28	WOS:A1994PQ48800012
J	ZHU, LY; SAGE, JT; CHAMPION, PM				ZHU, LY; SAGE, JT; CHAMPION, PM			OBSERVATION OF COHERENT REACTION DYNAMICS IN HEME-PROTEINS	SCIENCE			English	Article							GEMINATE RECOMBINATION; IMPULSIVE EXCITATION; OPTICAL SPECTROSCOPY; CO BINDING; RELAXATION; ABSORPTION; MYOGLOBIN; RAMAN; MOTION; MODEL	Femtosecond laser pulses, resonant with the Soret band of the nitric oxide complex of myoglobin (MbNO), were used to probe coherent, low-frequency nuclear motion of the heme group after photolysis. Distinct oscillations with periods of 430 and 150 femtoseconds were observed and are attributed to heme doming and iron-histidine motion, respectively. These results verify that the nuclear motion of the heme is strongly coupled to the ligand binding reaction and demonstrate that such motion is not determined by overdamped (diffusive) dynamics. The relative phases and frequencies of the nuclear motion of the photoproduct suggest that the coherence arises from impulsive electronic forces associated with the spin-state change of the heme iron atom and the depopulation of its d(z)2 orbital during the bond-breaking event.	NORTHEASTERN UNIV,DEPT PHYS,BOSTON,MA 02115	Northeastern University					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035090] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-35090] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; AGMON N, 1992, J CHEM PHYS, V97, P7270, DOI 10.1063/1.463500; AHMED AM, 1991, CHEM PHYS, V158, P329, DOI 10.1016/0301-0104(91)87076-8; BANIN U, 1993, J CHEM PHYS, V98, P4391, DOI 10.1063/1.465066; BERLIN YA, 1992, CHEM PHYS LETT, V197, P81, DOI 10.1016/0009-2614(92)86026-E; CHAMPION PM, 1992, J RAMAN SPECTROSC, V23, P557, DOI 10.1002/jrs.1250231008; CHERNOFF DA, 1980, P NATL ACAD SCI USA, V77, P5606, DOI 10.1073/pnas.77.10.5606; DEXHEIMER SL, 1992, CHEM PHYS LETT, V188, P61, DOI 10.1016/0009-2614(92)85089-S; DHAR L, 1994, CHEM REV, V94, P157, DOI 10.1021/cr00025a006; FINDSEN EW, 1985, J AM CHEM SOC, V107, P3355, DOI 10.1021/ja00297a056; FRAGNITO HL, 1989, CHEM PHYS LETT, V160, P101, DOI 10.1016/0009-2614(89)87564-5; FRANKE G, 1894, ARCH LARYNGOL RHINOL, V1, P230; GU YG, 1994, J CHEM PHYS, V100, P2547, DOI 10.1063/1.467232; LEE D, 1985, ADV INFRARED RAMAN S, V12, P179; LI XY, 1992, CHEM PHYS LETT, V188, P16, DOI 10.1016/0009-2614(92)85081-K; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; MUKAMEL S, 1990, ANNU REV PHYS CHEM, V41, P647, DOI 10.1146/annurev.pc.41.100190.003243; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; POLLARD WT, 1992, ANNU REV PHYS CHEM, V43, P497, DOI 10.1146/annurev.physchem.43.1.497; PUGLIANO N, 1993, J CHEM PHYS, V99, P7273, DOI 10.1063/1.465422; ROSKER MJ, 1988, J CHEM PHYS, V89, P6113, DOI 10.1063/1.455427; ROSKER MJ, 1986, PHYS REV LETT, V57, P321, DOI 10.1103/PhysRevLett.57.321; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; RUHMAN S, 1987, J CHEM PHYS, V86, P6563, DOI 10.1063/1.452400; SCHEIDT WR, 1976, J AM CHEM SOC, V98, P1913, DOI 10.1021/ja00423a044; SCHERER NF, 1992, J CHEM PHYS, V96, P5544, DOI 10.1063/1.462693; SRAJER V, 1988, J AM CHEM SOC, V110, P6656, DOI 10.1021/ja00228a009; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P7390, DOI 10.1021/bi00244a005; SRAJER V, 1986, PHYS REV LETT, V57, P1267, DOI 10.1103/PhysRevLett.57.1267; VOS MH, 1993, NATURE, V363, P320, DOI 10.1038/363320a0; WALTERS MA, 1982, BIOCHEMISTRY-US, V21, P6989, DOI 10.1021/bi00269a057; WISE FW, 1987, IEEE J QUANTUM ELECT, V23, P1116, DOI 10.1109/JQE.1987.1073483; ZEWAIL AH, 1988, SCIENCE, V242, P1645, DOI 10.1126/science.242.4886.1645; ZHU L, 1994, PHYS REV LETT, V72, P301, DOI 10.1103/PhysRevLett.72.301	35	178	179	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					629	632		10.1126/science.7939716	http://dx.doi.org/10.1126/science.7939716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939716				2022-12-28	WOS:A1994PN80700041
J	WHITE, RJ; KHOO, BCE; INOSTROZA, JA; REINBERG, D; JACKSON, SP				WHITE, RJ; KHOO, BCE; INOSTROZA, JA; REINBERG, D; JACKSON, SP			DIFFERENTIAL REGULATION OF RNA POLYMERASE-I, POLYMERASE-II, AND POLYMERASE-III BY THE TBP-BINDING REPRESSOR DR1	SCIENCE			English	Article							TRANSCRIPTION FACTOR-TFIIIB; FUNCTIONAL DOMAINS; TATA-LESS; PROTEIN; COMPLEX; COMPONENTS; ACTIVATION; MECHANISM; PROMOTER; HOMOLOGY	RNA polymerases I, II, and III each use the TATA-binding protein (TBP). Regulators that target this shared factor may therefore provide a means to coordinate the activities of the three nuclear RNA polymerases; The repressor Dr1 binds to TBP and blocks the interaction of TBP with polymerase II- and polymerase III-specific factors. This enables Drl to coordinately regulate transcription by RNA polymerases II and III, Under the same conditions, Dr1 does not inhibit polymerase I transcription. By selectively repressing polymerases II and III, Drl may shift the physiological balance of transcriptional output in favor of polymerase I.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; UNIV MED & DENT NEW JERSEY,DEPT BIOCHEM,PISCATAWAY,NJ 08854	University of Cambridge; Rutgers State University New Brunswick; Rutgers State University Medical Center	WHITE, RJ (corresponding author), UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND.		Khoo, Bernard/B-1247-2009; Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Khoo, Bernard/0000-0002-4223-9736; Jackson, Stephen Philip/0000-0001-9317-7937; Reinberg, Danny/0000-0003-4288-2016	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; Gill Grace, 1992, Current Biology, V2, P565, DOI 10.1016/0960-9822(92)90046-D; GODDARD JP, 1983, NUCLEIC ACIDS RES, V11, P2551, DOI 10.1093/nar/11.9.2551; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; INOSTROZA JA, 1992, CELL, V70, P477; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KHOO BCE, IN PRESS GENES DEV; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; WERNER M, 1993, J BIOL CHEM, V268, P20721; White R.C., UNPUB; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	43	56	58	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					448	450		10.1126/science.7939686	http://dx.doi.org/10.1126/science.7939686			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939686				2022-12-28	WOS:A1994PN27200038
J	FOX, R				FOX, R			RED-LIGHT ON CALCUTTA - HEALTH VIA SCHOOLS IN ANDHRA-PRADESH	LANCET			English	Editorial Material																		JANA S, 1994, 10TH INT C AIDS YOK	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1038	1038		10.1016/S0140-6736(94)91705-1	http://dx.doi.org/10.1016/S0140-6736(94)91705-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PL852	7934442				2022-12-28	WOS:A1994PL85200005
J	SOUTHERN, DA; READ, MS				SOUTHERN, DA; READ, MS			LESSON OF THE WEEK - OVERDOSAGE OF OPIATE FROM PATIENT-CONTROLLED ANALGESIA DEVICES	BRITISH MEDICAL JOURNAL			English	Article											SOUTHERN, DA (corresponding author), UNIV WALES HOSP,CARDIFF CF4 4XW,S GLAM,WALES.							GREY TC, 1988, JAMA-J AM MED ASSOC, V259, P2240, DOI 10.1001/jama.1988.03720150022025; GROVER ER, 1992, ANAESTHESIA, V47, P402, DOI 10.1111/j.1365-2044.1992.tb02221.x; KEERISZANTO M, 1971, CAN ANAESTH SOC J, V18, P581, DOI 10.1007/BF03026023; NORTCUTT WG, 1992, BRIT J ANAESTH, V69, P95; THOMAS DW, 1988, ANAESTHESIA, V43, P770, DOI 10.1111/j.1365-2044.1988.tb05753.x	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					1002	1002		10.1136/bmj.309.6960.1002	http://dx.doi.org/10.1136/bmj.309.6960.1002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950692	Green Published			2022-12-28	WOS:A1994PM41700029
J	TUFFNELL, DJ; NUTTALL, K; RAISTRICK, J; JACKSON, TL				TUFFNELL, DJ; NUTTALL, K; RAISTRICK, J; JACKSON, TL			USE OF TRANSLATED WRITTEN MATERIAL TO COMMUNICATE WITH NON-ENGLISH SPEAKING PATIENTS	BRITISH MEDICAL JOURNAL			English	Article											TUFFNELL, DJ (corresponding author), BRADFORD ROYAL INFIRM,DEPT OBSTET,BRADFORD BD9 6RJ,W YORKSHIRE,ENGLAND.							1994, LEEDS BANGLADESHI CO; 1994, WHAT SEEMS BE MATTER; 1993, A Z QUALITY GUIDE IN	3	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					992	992		10.1136/bmj.309.6960.992	http://dx.doi.org/10.1136/bmj.309.6960.992			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950722	Green Published			2022-12-28	WOS:A1994PM41700024
J	CARR, CM; KIM, PS				CARR, CM; KIM, PS			FLU VIRUS INVASION - HALFWAY THERE	SCIENCE			English	Editorial Material							HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; INFLUENZA-VIRUS; FUSION; MECHANISM; PROTEIN				CARR, CM (corresponding author), MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142, USA.							BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; JUNANKAR PR, 1986, BIOCHIM BIOPHYS ACTA, V854, P198, DOI 10.1016/0005-2736(86)90111-2; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; LAZAROWITZ SG, 1971, VIROLOGY, V46, P830, DOI 10.1016/0042-6822(71)90084-5; LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8; RAMALHOSANTOS J, 1993, BIOCHEMISTRY-US, V32, P2771, DOI 10.1021/bi00062a006; SKEHEL JJ, 1975, P NATL ACAD SCI USA, V72, P93, DOI 10.1073/pnas.72.1.93; SPRUCE AE, 1989, NATURE, V342, P555, DOI 10.1038/342555a0; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WEBER T, 1994, J BIOL CHEM, V269, P18353; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; YU YG, 1994, SCIENCE, V266, P274, DOI 10.1126/science.7939662	22	47	49	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					234	236		10.1126/science.7939658	http://dx.doi.org/10.1126/science.7939658			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939658				2022-12-28	WOS:A1994PM13400021
J	MCGUIRE, W; HILL, AVS; ALLSOPP, CEM; GREENWOOD, BM; KWIATKOWSKI, D				MCGUIRE, W; HILL, AVS; ALLSOPP, CEM; GREENWOOD, BM; KWIATKOWSKI, D			VARIATION IN THE TNF-ALPHA PROMOTER REGION ASSOCIATED WITH SUSCEPTIBILITY TO CEREBRAL MALARIA	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; MAJOR HISTOCOMPATIBILITY COMPLEX; B-CELL LINES; FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; GENE-REGULATION; T-CELL; POLYMORPHISM; PROTECTION; CACHECTIN	TUMOUR-necrosis factor-alpha (TNF-alpha) is believed to have an important role in the pathogenesis of severe infectious disease(1) and fatal cerebral malaria is associated with high circulating levels of this cytokine(2,3). In a large case-control study in Cambian children we find that homozygotes for the TNF2 allele, a variant of the TNF-alpha gene promoter region(4), have a relative risk of 7 for death or severe neurological sequelae due to cerebral malaria. Although the TNF2 allele is in linkage disequilibrium with several neighbouring HLA alleles, we show that this disease association is independent of HLA class I and class II variation. These data suggest that regulatory polymorphisms of cytokine genes can affect the outcome of severe infection. The maintenance of the TNF2 allele at a gene frequency of 0.16 in The Gambia implies that the increased risk of cerebral malaria in homozygotes is counterbalanced by some biological advantage.	JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND; MRC LABS,FAJARA,SENEGAL	University of Oxford	MCGUIRE, W (corresponding author), JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND.		HILL, Adrian V>S>/C-1306-2008	Kwiatkowski, Dominic/0000-0002-5023-0176; McGuire, William/0000-0001-8572-3467	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALFONSO SD, 1994, IMMUNOGENETICS, V30, P150; ALLSOPP CEM, 1991, HUM IMMUNOL, V30, P105, DOI 10.1016/0198-8859(91)90078-N; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; CLARK IA, 1987, PARASITOL TODAY, V3, P300, DOI 10.1016/0169-4758(87)90187-6; CLARK IA, 1992, LANCET, V340, P8994; DUNHAM I, 1987, P NATL ACAD SCI USA, V84, P7237, DOI 10.1073/pnas.84.20.7237; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918; GRAU GE, 1992, TUMOUR NECROSIS FACT, V1, P329; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HILL AVS, 1992, P NATL ACAD SCI USA, V89, P2277, DOI 10.1073/pnas.89.6.2277; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233; KERN P, 1989, AM J MED, V87, P139, DOI 10.1016/S0002-9343(89)80688-6; KWIATKOWSKI D, 1989, CLIN EXP IMMUNOL, V77, P361; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; KWIATKOWSKI D, 1992, CURR OPIN IMMUNOL, V4, P425, DOI 10.1016/S0952-7915(06)80034-8; MOLVIG J, 1988, SCAND J IMMUNOL, V27, P7025; NEDOSPASOV SA, 1986, COLD SPRING HARB SYM, V51, P611, DOI 10.1101/SQB.1986.051.01.073; PICOT F, 1993, EUR J IMMUNOL, V23, P224; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; TITUS RG, 1991, PARASITOL TODAY, V12, pA13; Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353; WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557; WILSON AG, 1994, BR J RHEUMATOL S1, V33, P89; WONG FHW, 1992, TUMOR NECROSIS FACTO, V1, P371	30	1050	1078	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					508	511		10.1038/371508a0	http://dx.doi.org/10.1038/371508a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935762				2022-12-28	WOS:A1994PK58900053
J	DIXON, JM; MANSEL, RE				DIXON, JM; MANSEL, RE			ABC OF BREAST DISEASES - CONGENITAL PROBLEMS AND ABERRATIONS OF NORMAL BREAST DEVELOPMENT AND INVOLUTION	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV WALES COLL MED,CARDIFF,S GLAM,WALES	University of Edinburgh; Cardiff University	DIXON, JM (corresponding author), EDINBURGH ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND.								0	38	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					797	800		10.1136/bmj.309.6957.797	http://dx.doi.org/10.1136/bmj.309.6957.797			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950574	Green Published			2022-12-28	WOS:A1994PJ28200035
J	KRUM, H; CONWAY, EL; BROADBEAR, JH; HOWES, LG; LOUIS, WJ				KRUM, H; CONWAY, EL; BROADBEAR, JH; HOWES, LG; LOUIS, WJ			POSTURAL HYPOTENSION IN ELDERLY PATIENTS GIVEN CARVEDILOL	BRITISH MEDICAL JOURNAL			English	Article									AUSTIN HOSP,DEPT CLIN PHARMACOL & THERAPEUT,HEIDELBERG,VIC 3084,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health			Broadbear, Jillian/ABC-6569-2020; Broadbear, Jillian/A-6864-2011; Howes, Laurence/M-4551-2019	Broadbear, Jillian/0000-0003-3342-5868; Broadbear, Jillian/0000-0003-3342-5868; Howes, Laurence/0000-0002-1507-8260				LOUIS W J, 1987, Journal of Cardiovascular Pharmacology, V10, pS89, DOI 10.1097/00005344-198706111-00016; LOUIS WJ, 1990, DOSE RESPONSE RELATI, P67; MCTAVISH D, 1993, DRUGS, V45, P232, DOI 10.2165/00003495-199345020-00006; Rittinghausen R, 1988, Drugs, V36 Suppl 6, P92; SENN S, 1993, CROSS TRIALS CLIN RE	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					775	776		10.1136/bmj.309.6957.775	http://dx.doi.org/10.1136/bmj.309.6957.775			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950564	Green Published			2022-12-28	WOS:A1994PJ28200021
J	ORMEL, J; VONKORFF, M; USTUN, TB; PINI, S; KORTEN, A; OLDEHINKEL, T				ORMEL, J; VONKORFF, M; USTUN, TB; PINI, S; KORTEN, A; OLDEHINKEL, T			COMMON MENTAL-DISORDERS AND DISABILITY ACROSS CULTURES - RESULTS FROM THE WHO COLLABORATIVE STUDY ON PSYCHOLOGICAL-PROBLEMS IN GENERAL HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPRESSIVE SYMPTOMATOLOGY; PSYCHIATRIC-DISORDERS; POPULATION; SYMPTOMS; ANXIETY; PREVALENCE; OUTCOMES; SCHEDULE; ILLNESS; ILL	Objective.-To examine the impact of common mental illness on functional disability and the cross-cultural consistency of this relationship while controlling for physical illness. A secondary objective was to determine the level of disability associated with specific psychiatric disorders. Design.-A cross-sectional sample selected by two-stage sampling. Setting.-Primary health care facilities in 14 countries covering most major cultures and languages. Patients.-A total of 25916 consecutive attenders of these facilities were screened for psychopathology using the General Health Questionnaire (96% response). Screened patients were sampled from the General Health Questionnaire score strata for the second-stage Composite International Diagnostic Interview administered to 5447 patients (62% response). Main outcome Measures.-Patient-reported physical disability, number of disability days, and interviewer-rated occupational role functioning. Results.-After controlling for physical disease severity, psychopathology was consistently associated with increased disability. Physical disease severity was an independent, although weaker, contributor to disability. A dose-response relationship was found between severity of mental illness and disability. Disability was most prominent among patients with major depression, panic disorder, generalized anxiety, and neurasthenia; disorder-specific differences were modest after controlling for psychiatric comorbidity. Results were consistent across disability measures and across centers. Conclusions. The consistent relationship of psychopathology and disability indicates the compelling personal and socioeconomic impact of common mental illnesses across cultures. This suggests the importance of impairments of higher-order human capacities (eg, emotion, motivation, and cognition) as determinants of functional disability.	UNIV GRONINGEN,DEPT HLTH SCI,9700 RB GRONINGEN,NETHERLANDS; GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101; WHO,COLLABORAT STUDY,CH-1211 GENEVA,SWITZERLAND; UNIV VERONA,INST PSYCHIAT,I-37100 VERONA,ITALY; AUSTRALIAN NATL UNIV,SOCIAL PSYCHIAT RES UNIT,CANBERRA,ACT,AUSTRALIA	University of Groningen; Group Health Cooperative; World Health Organization; University of Verona; Australian National University	ORMEL, J (corresponding author), UNIV GRONINGEN,DEPT PSYCHIAT,POB 30001,9700 RB GRONINGEN,NETHERLANDS.		ormel, johan/AAC-5584-2019; Pini, Stefano/AAH-4968-2020; Ormel, Johan/C-6094-2013	ormel, johan/0000-0002-5463-037X; Pini, Stefano/0000-0001-9092-9144; VonKorff, Michael/0000-0001-5386-8477				[Anonymous], 1980, INT CLASSIFICATION I; BARRETT JE, 1988, ARCH GEN PSYCHIAT, V45, P1100; BARSKY AJ, 1988, PSYCHOSOM MED, V50, P510, DOI 10.1097/00006842-198809000-00007; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; BLACKER CVR, 1987, BRIT J PSYCHIAT, V150, P737, DOI 10.1192/bjp.150.6.737; BLUMENTHAL MD, 1975, ARCH GEN PSYCHIAT, V32, P985; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; CASEY PR, 1985, SOC PSYCHIATR, V20, P5, DOI 10.1007/BF00595042; COOPER B, 1969, BRIT J PREV SOC MED, V23, P210; CRAIG TJ, 1983, AM J PSYCHIAT, V140, P598; DOHRENWEND BS, 1983, ARCH GEN PSYCHIAT, V40, P1174; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; HANKIN J, 1979, ADM78661 US DEP HLTH; HANKIN JR, 1982, AM J PUBLIC HEALTH, V29, P2; HECHT H, 1990, J AFFECT DISORDERS, V18, P137, DOI 10.1016/0165-0327(90)90070-O; HOEPER EW, 1979, INT J MENT HEALTH, V8, P6, DOI 10.1080/00207411.1979.11448829; HURRY J, 1981, WHAT IS CASE; Jablensky A, 1992, PSYCHOL MED S, V20; KATON W, 1990, Journal of Clinical Psychiatry, V51, P3; KESSLER LG, 1985, ARCH GEN PSYCHIAT, V42, P583; LEFF J, 1992, PSYCHOL MED, V22, P131, DOI 10.1017/S0033291700032797; LEFLEY HP, 1990, HOSP COMMUNITY PSYCH, V41, P177; MANN AH, 1981, PSYCHOL MED, V11, P535, DOI 10.1017/S0033291700052855; MURPHY JM, 1986, PSYCHOL MED, V16, P117, DOI 10.1017/S0033291700057809; ORMEL J, 1993, AM J PUBLIC HEALTH, V83, P385, DOI 10.2105/AJPH.83.3.385; ORMEL J, 1990, PSYCHOL MED, V20, P909, DOI 10.1017/S0033291700036606; PAYKEL ES, 1973, ARCH GEN PSYCHIAT, V28, P659; REGIER DA, 1985, PSYCHOL MED, V15, P265, DOI 10.1017/S0033291700023540; RODIN G, 1986, AM J PSYCHIAT, V143, P696; SARTORIUS N, 1993, ARCH GEN PSYCHIAT, V50, P819; SCHULBERG HC, 1987, J GEN INTERN MED, V2, P312, DOI 10.1007/BF02596165; SHEPHERD M, 1966, PSYCHIATRIC ILLNESS; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STOUDEMIRE A, 1986, GEN HOSP PSYCHIAT, V8, P387, DOI 10.1016/0163-8343(86)90018-6; SUSSER M, 1990, PSYCHOL MED, V20, P471, DOI 10.1017/S0033291700016974; TURNER RJ, 1990, J NERV MENT DIS, V178, P343, DOI 10.1097/00005053-199006000-00001; USTUN TB, IN PRESS MENTAL ILLN; VONKORFF M, 1987, ARCH GEN PSYCHIAT, V44, P152; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; VONKORFF M, IN PRESS MENTAL ILLN; VONKORFF M, IN PRESS J CLIN EPID; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WIERSMA D, 1988, INT J REHABIL RES, V11, P213, DOI 10.1097/00004356-198809000-00001; WOHLFARTH TD, 1993, BRIT J PSYCHIAT, V163, P37, DOI 10.1192/bjp.163.1.37; 1989, MNHNAT89 WHO DIV MEN	45	732	740	1	67	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1741	1748		10.1001/jama.272.22.1741	http://dx.doi.org/10.1001/jama.272.22.1741			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PV815	7966922				2022-12-28	WOS:A1994PV81500023
J	DEC, GW; FUSTER, V				DEC, GW; FUSTER, V			IDIOPATHIC DILATED CARDIOMYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONGESTIVE-HEART-FAILURE; POLYMERASE CHAIN-REACTION; CONVERTING-ENZYME-INHIBITION; PLACEBO-CONTROLLED TRIAL; COXSACKIEVIRUS B3 RNA; LOW-DOSE AMIODARONE; TERM BETA-BLOCKADE; VENTRICULAR ARRHYTHMIAS; CARDIAC TRANSPLANTATION; CLINICAL COURSE				DEC, GW (corresponding author), MASSACHUSETTS GEN HOSP, CARDIAC UNIT, BULFINCH 211, BOSTON, MA 02114 USA.		McKenna, William J/C-3243-2008; Fuster, Valentin/H-4319-2015	McKenna, William J/0000-0001-7994-2460; Fuster, Valentin/0000-0002-9043-9986				AKAGI T, 1991, AM HEART J, V121, P1502, DOI 10.1016/0002-8703(91)90158-E; ANDERSON JL, 1982, LANCET, V2, P1124; [Anonymous], 1990, Lancet, V336, P1; ANSARI AA, 1991, AM J PATHOL, V139, P337; ARCHARD LC, 1987, EUR HEART J, V8, P437, DOI 10.1093/eurheartj/8.suppl_J.437; Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; BAGGER JP, 1984, BRIT HEART J, V52, P327; BENDER JR, 1991, CIRCULATION, V83, P704, DOI 10.1161/01.CIR.83.2.704; BOWLES NE, 1989, CIRCULATION, V80, P1128, DOI 10.1161/01.CIR.80.5.1128; BREMBILLAPERROT B, 1991, AM HEART J, V121, P1124, DOI 10.1016/0002-8703(91)90672-5; BRISTOW MR, 1993, J AM COLL CARDIOL, V22, pA61, DOI 10.1016/0735-1097(93)90465-D; BRISTOW MR, 1991, CIRCULATION, V84, P1024, DOI 10.1161/01.CIR.84.3.1024; CAFORIO ALP, 1992, CIRCULATION, V85, P1734, DOI 10.1161/01.CIR.85.5.1734; CANNON RO, 1987, J AM COLL CARDIOL, V10, P1190, DOI 10.1016/S0735-1097(87)80118-3; CARLQUIST JF, 1991, CIRCULATION, V83, P515, DOI 10.1161/01.CIR.83.2.515; CLELAND JGF, 1987, BRIT HEART J, V57, P436; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COUGHLIN SS, 1990, AM J EPIDEMIOL, V131, P48, DOI 10.1093/oxfordjournals.aje.a115484; DAS SK, 1986, AM J CARDIOL, V58, P998, DOI 10.1016/S0002-9149(86)80026-1; DASGUPTA P, 1989, CIRCULATION S2, V80, P117; DEC GW, 1990, J AM COLL CARDIOL, V16, P97, DOI 10.1016/0735-1097(90)90463-Y; DEC GW, 1985, NEW ENGL J MED, V312, P885, DOI 10.1056/NEJM198504043121404; DEC GW, 1991, TRANSPL P, V23, P2095; DEMARIA R, 1992, AM J CARDIOL, V69, P1451, DOI 10.1016/0002-9149(92)90900-J; DIAZ RA, 1987, BRIT HEART J, V58, P393; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; DIES F, 1986, CIRCULATION, V74, P38; DILENARDA A, 1990, CIRCULATION, V82, P387; DOI YL, 1991, AM J CARDIOL, V67, P188, DOI 10.1016/0002-9149(91)90443-O; DOUGLAS PS, 1989, J AM COLL CARDIOL, V13, P311, DOI 10.1016/0735-1097(89)90504-4; DUNKMAN WB, 1993, CIRCULATION, V87, P94; EICHHORN EJ, 1990, CIRCULATION, V82, P473, DOI 10.1161/01.CIR.82.2.473; ELEFTERIADES JA, 1993, J AM COLL CARDIOL, V22, P1411, DOI 10.1016/0735-1097(93)90551-B; EVANGELISTAMASIP A, 1992, AM J CARDIOL, V69, P373, DOI 10.1016/0002-9149(92)90236-R; EVANS RW, 1986, JAMA-J AM MED ASSOC, V255, P1892; FALK RH, 1992, AM HEART J, V123, P136, DOI 10.1016/0002-8703(92)90757-M; FAZIO G, 1991, PACE, V14, P1905, DOI 10.1111/j.1540-8159.1991.tb02788.x; FEILD BJ, 1973, CIRCULATION, V47, P1022, DOI 10.1161/01.CIR.47.5.1022; FELDMAN AM, 1991, AM J CARDIOL, V68, P1203, DOI 10.1016/0002-9149(91)90194-P; FELDMAN AM, 1993, NEW ENGL J MED, V329, P149, DOI 10.1056/NEJM199307153290301; FERRANS VJ, 1989, AM J CARDIOL, V64, pC9, DOI 10.1016/0002-9149(89)90677-2; FIGULLA HR, 1985, CIRCULATION, V71, P1095, DOI 10.1161/01.CIR.71.6.1095; FRANCIOSA JA, 1983, AM J CARDIOL, V51, P831, DOI 10.1016/S0002-9149(83)80141-6; FRIEDMAN RA, 1991, J AM COLL CARDIOL, V18, P152, DOI 10.1016/S0735-1097(10)80233-5; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GAVAZZI A, 1993, AM HEART J, V125, P410; GERLI R, 1986, AM HEART J, V112, P350, DOI 10.1016/0002-8703(86)90274-7; GHEORGHIADE M, 1991, CIRCULATION, V84, P2181, DOI 10.1161/01.CIR.84.5.2181; GILBERT EM, 1989, CIRCULATION S2, V80, P428; GILLUM RF, 1986, AM HEART J, V111, P752, DOI 10.1016/0002-8703(86)90111-0; GLAMANN DB, 1992, ARCH INTERN MED, V152, P769, DOI 10.1001/archinte.152.4.769; GOLDMAN S, 1993, CIRCULATION, V87, P24; GOLDSTEIN S, 1988, JAMA-J AM MED ASSOC, V259, P539; GOSSINGER HD, 1990, INT J CARDIOL, V29, P215, DOI 10.1016/0167-5273(90)90224-S; GRADMAN A, 1989, J AM COLL CARDIOL, V14, P564, DOI 10.1016/0735-1097(89)90093-4; GRASSO M, 1992, AM J CARDIOL, V69, P658, DOI 10.1016/0002-9149(92)90160-Z; GRIFFIN BP, 1991, AM J CARDIOL, V67, P848, DOI 10.1016/0002-9149(91)90618-U; GRIFFIN ML, 1988, J AM COLL CARDIOL, V11, P139, DOI 10.1016/0735-1097(88)90179-9; HAMER AWF, 1989, J AM COLL CARDIOL, V14, P1768, DOI 10.1016/0735-1097(89)90030-2; HAMMOND EH, 1987, AM HEART J, V114, P1055, DOI 10.1016/0002-8703(87)90180-3; HARE JM, 1992, J AM COLL CARDIOL, V20, P1318, DOI 10.1016/0735-1097(92)90243-G; HARTZ AJ, 1984, NEW ENGL J MED, V311, P1201, DOI 10.1056/NEJM198411083111901; HJALMARSON A, 1991, EUR HEART J, V12, P63, DOI 10.1093/eurheartj/12.suppl_F.63; HOFMANN T, 1988, AM HEART J, V116, P1455, DOI 10.1016/0002-8703(88)90728-4; HOLMES J, 1985, AM J CARDIOL, V55, P146, DOI 10.1016/0002-9149(85)90317-0; IKRAM H, 1987, BRIT HEART J, V57, P521; JOHNSON RA, 1982, NEW ENGL J MED, V307, P1051, DOI 10.1056/NEJM198210213071704; JOHNSON RA, 1982, NEW ENGL J MED, V307, P1119, DOI 10.1056/NEJM198210283071804; KANDOLF R, 1987, P NATL ACAD SCI USA, V84, P6272, DOI 10.1073/pnas.84.17.6272; KAYE MP, 1992, J HEART LUNG TRANSPL, V11, P599; KEELING PJ, 1992, BRIT HEART J, V68, P554; KELLY DP, 1994, NEW ENGL J MED, V330, P913; KELLY TL, 1990, AM HEART J, V119, P1111, DOI 10.1016/S0002-8703(05)80242-X; KEMP D L, 1992, Journal of the American College of Cardiology, V19, p107A; KEOGH AM, 1990, AM J CARDIOL, V65, P903, DOI 10.1016/0002-9149(90)91434-8; KEREN A, 1990, CIRCULATION, V81, P506, DOI 10.1161/01.CIR.81.2.506; KLEBER FX, 1992, BRIT HEART J, V67, P289; KLEIN R, 1984, CLIN EXP IMMUNOL, V58, P283; KOMAJDA M, 1990, EUR HEART J, V11, P824, DOI 10.1093/oxfordjournals.eurheartj.a059803; KUBO SH, 1992, CIRCULATION, V85, P942, DOI 10.1161/01.CIR.85.3.942; KUHN H, 1982, Z KARDIOL, V71, P497; LATHAM RD, 1989, AM HEART J, V117, P876, DOI 10.1016/0002-8703(89)90626-1; LEE WH, 1986, CIRCULATION, V73, P257, DOI 10.1161/01.CIR.73.2.257; LEWIS AB, 1991, AM J CARDIOL, V68, P365, DOI 10.1016/0002-9149(91)90833-7; LEWIS JF, 1993, J AM COLL CARDIOL, V21, P649, DOI 10.1016/0735-1097(93)90097-K; LIEM LB, 1988, AM J CARDIOL, V62, P611, DOI 10.1016/0002-9149(88)90665-0; LIKOFF MJ, 1987, AM J CARDIOL, V59, P634; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; LUBBE WF, 1992, J AM COLL CARDIOL, V19, P1622, DOI 10.1016/0735-1097(92)90629-2; LUU M, 1989, CIRCULATION, V80, P1675, DOI 10.1161/01.CIR.80.6.1675; MAGNUSSON Y, 1990, J CLIN INVEST, V86, P1658, DOI 10.1172/JCI114888; MANCINI DM, 1991, CIRCULATION, V83, P778, DOI 10.1161/01.CIR.83.3.778; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MASON JW, 1989, CIRCULATION, V79, P971, DOI 10.1161/01.CIR.79.5.971; MASSIE B, 1985, CIRCULATION, V71, P963, DOI 10.1161/01.CIR.71.5.963; MEINERTZ T, 1984, AM J CARDIOL, V53, P902, DOI 10.1016/0002-9149(84)90522-8; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MIDDLEKAUFF HR, 1993, J AM COLL CARDIOL, V21, P110, DOI 10.1016/0735-1097(93)90724-F; MUDGE GH, 1993, J AM COLL CARDIOL, V22, P21, DOI 10.1016/0735-1097(93)90812-F; MUIR P, 1989, LANCET, V1, P804; NERI R, 1986, POSTGRAD MED J, V62, P593, DOI 10.1136/pgmj.62.728.593; NERI R, 1987, AM HEART J, V113, P707, DOI 10.1016/0002-8703(87)90711-3; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; OCONNELL JB, 1981, CIRCULATION, V64, P780, DOI 10.1161/01.CIR.64.4.780; OLSHAUSEN KV, 1988, AM J CARDIOL, V61, P146, DOI 10.1016/0002-9149(88)91321-5; PACKER M, 1992, CIRCULATION, V85, P50; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PARRILLO JE, 1989, NEW ENGL J MED, V321, P1061, DOI 10.1056/NEJM198910193211601; PODRID PJ, 1990, AM J CARDIOL, V66, P451, DOI 10.1016/0002-9149(90)90704-5; POLL DS, 1986, AM J CARDIOL, V58, P992, DOI 10.1016/S0002-9149(86)80025-X; POPMA JJ, 1989, AM J CARDIOL, V63, P955, DOI 10.1016/0002-9149(89)90147-1; PRATT CM, 1989, AM HEART J, V118, P433, DOI 10.1016/0002-8703(89)90254-8; QUIGLEY PJ, 1987, EUR HEART J, V8, P39, DOI 10.1093/eurheartj/8.suppl_J.39; RAE AP, 1987, AM J CARDIOL, V59, P291, DOI 10.1016/0002-9149(87)90801-0; RAYNOLDS MV, 1993, LANCET, V342, P1073, DOI 10.1016/0140-6736(93)92061-W; RECTOR TS, 1987, AM HEART J, V114, P148, DOI 10.1016/0002-8703(87)90318-8; REGAN TJ, 1984, PROG CARDIOVASC DIS, V27, P141, DOI 10.1016/0033-0620(84)90001-X; ROBERTS WC, 1987, AM J CARDIOL, V60, P1340, DOI 10.1016/0002-9149(87)90618-7; ROMEO F, 1989, CLIN CARDIOL, V12, P387, DOI 10.1002/clc.4960120708; ROMEO F, 1989, AM J CARDIOL, V63, P138, DOI 10.1016/0002-9149(89)91103-X; ROUILLARD V M, 1991, Journal of the American College of Cardiology, V17, p219A; SAXON LA, 1993, AM J CARDIOL, V72, P62, DOI 10.1016/0002-9149(93)90220-7; SCHOELLER R, 1993, AM J CARDIOL, V71, P720, DOI 10.1016/0002-9149(93)91017-C; SCHULTHEISS HP, 1990, INT C NEW TRENDS CAR, P221; Shah P M, 1988, J Am Soc Echocardiogr, V1, P20; Stevenson L W, 1988, Cardiol Clin, V6, P187; STEVENSON LW, 1991, J HEART LUNG TRANSPL, V10, P468; STEWART RAH, 1990, Q J MED, V74, P309; STRAUSS RH, 1987, AM J CARDIOL, V59, P892, DOI 10.1016/0002-9149(87)91114-3; SUGRUE DD, 1992, ANN INTERN MED, V117, P117, DOI 10.7326/0003-4819-117-2-117; SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TALIERCIO CP, 1985, J AM COLL CARDIOL, V6, P1126, DOI 10.1016/S0735-1097(85)80319-3; TAMBURRO P, 1992, Journal of the American College of Cardiology, V19, p366A; TAZELAAR HD, 1986, AM J SURG PATHOL, V10, P405, DOI 10.1097/00000478-198606000-00005; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; TRACY S, 1990, J MOL CELL CARDIOL, V22, P403, DOI 10.1016/0022-2828(90)91476-N; UNVERFERTH DV, 1984, AM J CARDIOL, V54, P147, DOI 10.1016/0002-9149(84)90320-5; URETSKY BF, 1990, CIRCULATION, V82, P774, DOI 10.1161/01.CIR.82.3.774; WAAGSTEIN F, 1989, CIRCULATION, V80, P551, DOI 10.1161/01.CIR.80.3.551; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WALLIS DE, 1984, J AM COLL CARDIOL, V4, P674, DOI 10.1016/S0735-1097(84)80392-7; WEISS LM, 1991, AM J PATHOL, V138, P497; WILENSKY RL, 1988, AM J CARDIOL, V62, P276, DOI 10.1016/0002-9149(88)90225-1; WILLIAMS DG, 1985, BRIT HEART J, V54, P153; WOODRUFF JF, 1980, AM J PATHOL, V101, P425; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZEECHENG CS, 1984, J AM COLL CARDIOL, V3, P63, DOI 10.1016/S0735-1097(84)80431-3; 1992, NEW ENGL J MED, V327, P1768; 1980, BRIT HEART J, V44, P672; 1990, LANCET, V336, P698	155	623	677	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1564	1575		10.1056/NEJM199412083312307	http://dx.doi.org/10.1056/NEJM199412083312307			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969328				2022-12-28	WOS:A1994PV29200007
J	POLLACK, IF				POLLACK, IF			BRAIN-TUMORS IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROSPECTIVE RANDOMIZED TRIAL; PEDIATRIC-ONCOLOGY-GROUP; CENTRAL-NERVOUS-SYSTEM; RADIATION-THERAPY; ADJUVANT CHEMOTHERAPY; INTRACRANIAL EPENDYMOMA; HYPOTHALAMIC GLIOMAS; PROGNOSTIC FACTORS; IMPROVED SURVIVAL; STEM GLIOMAS		UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	POLLACK, IF (corresponding author), CHILDRENS HOSP PITTSBURGH, DEPT NEUROSURG, 3705 5TH AVE, PITTSBURGH, PA 15213 USA.							ALBRIGHT AL, 1993, CA-CANCER J CLIN, V43, P272, DOI 10.3322/canjclin.43.5.272; ALBRIGHT AL, 1993, NEUROSURGERY, V33, P1026; Albright AL, 1985, CONT NEUROSURG, V7, P1; ALVORD EC, 1988, J NEUROSURG, V68, P85, DOI 10.3171/jns.1988.68.1.0085; BACKLUND EO, 1989, ACTA NEUROCHIR, V99, P11, DOI 10.1007/BF01407771; BERGER MS, 1991, J NEUROSURG, V74, P872, DOI 10.3171/jns.1991.74.6.0872; BERGER MS, 1992, PEDIATRIC NEUROONCOL; BOURNE JP, 1992, J NEURO-ONCOL, V14, P263; BRUCE DA, 1993, PEDIATR NEUROSURG, V19, P322; CARMEL PW, 1985, NEUROSURGERY, V1, P905; DEUTSCH M, 1991, P AN M AM SOC CLIN, V10, P124; DUFFNER PK, 1993, NEW ENGL J MED, V328, P1725, DOI 10.1056/NEJM199306173282401; DUFFNER PK, 1985, CANCER-AM CANCER SOC, V56, P2189, DOI 10.1002/1097-0142(19851101)56:9<2189::AID-CNCR2820560909>3.0.CO;2-I; DUFFNER PK, 1986, NEUROLOGY, V36, P597, DOI 10.1212/WNL.36.5.597; ELLENBERG L, 1987, NEUROSURGERY, V21, P638, DOI 10.1227/00006123-198711000-00006; EPSTEIN FJ, 1989, PEDIATRIC NEUROSURGE, P357; EVANS AE, 1990, J NEUROSURG, V72, P572, DOI 10.3171/jns.1990.72.4.0572; FINLAY J, 1994, PROG P AM SOC CLIN O, V13, P176; FINLAY J, 1991, P AN M AM SOC CLIN, V10, P308; FINLAY JL, 1992, PEDIATRIC NEUROONCOL, P278; FISCHER EG, 1990, J NEUROSURG, V73, P534, DOI 10.3171/jns.1990.73.4.0534; GJERRIS F, 1978, J NEUROSURG, V49, P179, DOI 10.3171/jns.1978.49.2.0179; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; HIRSCH JF, 1989, J NEUROSURG, V70, P568, DOI 10.3171/jns.1989.70.4.0568; HOFFMAN HJ, 1993, PEDIATR NEUROSURG, V19, P186, DOI 10.1159/000120729; HOFFMAN HJ, 1992, J NEUROSURG, V76, P47, DOI 10.3171/jns.1992.76.1.0047; HOROWITZ ME, 1988, NEUROSURGERY, V22, P687, DOI 10.1227/00006123-198804000-00011; JENKIN D, 1990, INT J RADIAT ONCOL, V19, P265, DOI 10.1016/0360-3016(90)90533-P; JENKIN RDT, 1987, J NEUROSURG, V66, P227, DOI 10.3171/jns.1987.66.2.0227; KELLY PJ, 1989, NEUROSURGERY, V25, P185, DOI 10.1227/00006123-198908000-00006; KOVNAR EH, 1990, J CLIN ONCOL, V8, P330, DOI 10.1200/JCO.1990.8.2.330; KRETSCHMAR CS, 1993, CANCER-AM CANCER SOC, V72, P1404, DOI 10.1002/1097-0142(19930815)72:4<1404::AID-CNCR2820720441>3.0.CO;2-G; KRISCHER JP, 1991, J NEUROSURG, V74, P905, DOI 10.3171/jns.1991.74.6.0905; LEFKOWITZ I, 1989, P AN M AM SOC CLIN, V8, P87; LIVESEY EA, 1990, BRIT J CANCER, V61, P622, DOI 10.1038/bjc.1990.138; LUNSFORD LD, 1990, ARCH NEUROL-CHICAGO, V47, P169, DOI 10.1001/archneur.1990.00530020071018; NAZAR GB, 1990, J NEUROSURG, V72, P408, DOI 10.3171/jns.1990.72.3.0408; PACKER RJ, 1991, J NEUROSURG, V74, P433, DOI 10.3171/jns.1991.74.3.0433; PACKER RJ, 1993, J CLIN ONCOL, V11, P850, DOI 10.1200/JCO.1993.11.5.850; PACKER RJ, 1993, CANCER-AM CANCER SOC, V72, P1414, DOI 10.1002/1097-0142(19930815)72:4<1414::AID-CNCR2820720442>3.0.CO;2-C; PACKER RJ, 1992, PEDIATRIC NEUROONCOL; PENDERGRASS TW, 1987, J CLIN ONCOL, V5, P1221, DOI 10.1200/JCO.1987.5.8.1221; PETRONIO J, 1991, J NEUROSURG, V74, P701, DOI 10.3171/jns.1991.74.5.0701; PIERCE SM, 1990, CANCER, V65, P45, DOI 10.1002/1097-0142(19900101)65:1<45::AID-CNCR2820650111>3.0.CO;2-Z; POLLACK IF, 1994, J NEUROSURG, V80, P681, DOI 10.3171/jns.1994.80.4.0681; POLLACK IF, IN PRESS J NEUROSURG; PROBERT JC, 1973, CANCER, V32, P634, DOI 10.1002/1097-0142(197309)32:3<634::AID-CNCR2820320316>3.0.CO;2-A; RADCLIFFE J, 1992, ANN NEUROL, V32, P551, DOI 10.1002/ana.410320411; Rorke L, 1989, PEDIAT NEUROSURGERY, P335; RORKE LB, 1983, J NEUROPATH EXP NEUR, V42, P1, DOI 10.1097/00005072-198301000-00001; RUBINSTEIN LJ, 1985, J NEUROSURG, V62, P795, DOI 10.3171/jns.1985.62.6.0795; SALAZAR OM, 1983, J NEUROSURG, V59, P652, DOI 10.3171/jns.1983.59.4.0652; SPOSTO R, 1989, J NEURO-ONCOL, V7, P165, DOI 10.1007/BF00165101; SUTTON LN, 1991, PEDIATR NEUROSURG, V16, P57, DOI 10.1159/000120509; TAIT DM, 1990, EUR J CANCER, V26, P464; TORRES CF, 1994, NEW ENGL J MED, V330, P892, DOI 10.1056/NEJM199403313301303; VANUYTSEL LJ, 1992, INT J RADIAT ONCOL, V23, P313, DOI 10.1016/0360-3016(92)90747-6; WISOFF JH, 1993, J NEUROSURG, V78, pA344; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7	59	325	329	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1500	1507		10.1056/NEJM199412013312207	http://dx.doi.org/10.1056/NEJM199412013312207			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969301				2022-12-28	WOS:A1994PU86600007
J	EDLIN, BR; IRWIN, KL; FARUQUE, S; MCCOY, CB; WORD, C; SERRANO, Y; INCIARDI, JA; BOWSER, BP; SCHILLING, RF; HOLMBERG, SD; ELBASSEL, N; CABRERA, A; FLORES, Y; GUZMAN, N; HOGAN, R; MELENDEZ, N; NIEVES, E; OCASIO, A; RIVERA, G; RIZZOLO, A; STEELE, F; TURSO, S; BIDASSIE, B; KUOHSIEN, S; STRAUSS, D; MCCOY, HV; MCBRIDE, DC; WEATHERBY, N; RIVERS, JE; ALONSO, E; ARISTIDE, G; ASHELY, M; BOWENS, S; BUCKWALDEN, D; COMERFORD, S; DEVEAUXSHEPARD, V; DYER, E; GALVEZ, M; GRIFFIN, J; JONES, M; LOCASCIO, V; MAGILNER, L; MENDEZ, N; MCKAY, C; MCQUEEN, L; MILES, C; MIRANDA, R; PAGAN, L; PIERRE, RM; SALAS, R; SEOANE, L; SHABAZZ, B; WALDEN, E; FLECHER, MA; GARCIAMORALES, R; EVANS, PE; WORD, CO; BALLESTEROS, C; BYRD, S; CURTIS, W; DOGAN, D; GARNER, A; GRIFFIN, M; HAWKINS, C; HUNTERGAMBLE, D; IREGUI, C; JUSTICE, M; LEE, M; LODICO, M; MCGILROY, J; PATTERSON, V; PENN, S; PERKINS, C; PERSAUD, M; RICHARDSON, C; ROBERTSON, N; BACK, A; LARSEN, S; SCHMIDT, DS; BYERS, RH; LUDWIG, D; JOHNSON, R; WONG, L; DUSHKU, J				EDLIN, BR; IRWIN, KL; FARUQUE, S; MCCOY, CB; WORD, C; SERRANO, Y; INCIARDI, JA; BOWSER, BP; SCHILLING, RF; HOLMBERG, SD; ELBASSEL, N; CABRERA, A; FLORES, Y; GUZMAN, N; HOGAN, R; MELENDEZ, N; NIEVES, E; OCASIO, A; RIVERA, G; RIZZOLO, A; STEELE, F; TURSO, S; BIDASSIE, B; KUOHSIEN, S; STRAUSS, D; MCCOY, HV; MCBRIDE, DC; WEATHERBY, N; RIVERS, JE; ALONSO, E; ARISTIDE, G; ASHELY, M; BOWENS, S; BUCKWALDEN, D; COMERFORD, S; DEVEAUXSHEPARD, V; DYER, E; GALVEZ, M; GRIFFIN, J; JONES, M; LOCASCIO, V; MAGILNER, L; MENDEZ, N; MCKAY, C; MCQUEEN, L; MILES, C; MIRANDA, R; PAGAN, L; PIERRE, RM; SALAS, R; SEOANE, L; SHABAZZ, B; WALDEN, E; FLECHER, MA; GARCIAMORALES, R; EVANS, PE; WORD, CO; BALLESTEROS, C; BYRD, S; CURTIS, W; DOGAN, D; GARNER, A; GRIFFIN, M; HAWKINS, C; HUNTERGAMBLE, D; IREGUI, C; JUSTICE, M; LEE, M; LODICO, M; MCGILROY, J; PATTERSON, V; PENN, S; PERKINS, C; PERSAUD, M; RICHARDSON, C; ROBERTSON, N; BACK, A; LARSEN, S; SCHMIDT, DS; BYERS, RH; LUDWIG, D; JOHNSON, R; WONG, L; DUSHKU, J			INTERSECTING EPIDEMICS - CRACK COCAINE USE AND HIV-INFECTION AMONG INNER-CITY YOUNG-ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; SEXUALLY-TRANSMITTED DISEASES; DRUG-USERS; RISK; SEX; PROSTITUTION; SYPHILIS; SMOKERS; AIDS	Background and Methods. The smoking of ''crack'' cocaine is thought to be associated with high-risk sexual practices that accelerate the spread of infection with the human immunodeficiency virus (HIV). We studied 2323 young adults, 18 to 29 years of age, who smoked crack regularly or who had never smoked crack. The study participants, recruited from the streets of inner-city neighborhoods in New York, Miami, and San Francisco, were interviewed and tested for HIV. This report presents the findings for the 1967 participants (85 percent) who had never injected drugs. Results. Of the 1137 crack smokers, 15.7 percent were positive for HIV antibody, as compared with 5.2 percent of the 830 nonsmokers (prevalence ratio adjusted for the city, 2.4; 99 percent confidence interval, 1.7 to 3.6). The prevalence of HIV was highest among the crack-smoking women in New York (29.6 percent) and Miami (23.0 percent). In these two cities, of the 283 women who had sex in exchange for money or drugs, 30.4 percent were infected with HIV as compared with 9.1 percent of the 286 other women (prevalence ratio, 3.1; 99 percent confidence interval, 1.9 to 5.1); of the 91 men who had anal sex with other men, 42.9 percent were infected with HIV as compared with 9.3 percent of the 582 men who did not have anal sex with other men (prevalence ratio, 4.7; 99 percent confidence interval, 3.0 to 7.4). In multivariable analyses, these high-risk sexual practices accounted for the higher prevalence of HIV infection among the crack smokers, as compared with those who did not smoke crack. Women who had recently had unprotected sex in exchange for money or drugs were as likely to be infected as men who had had sex with men (40.9 percent vs. 42.9 percent). Conclusions. In poor, inner-city communities young smokers of crack cocaine, particularly women who have sex in exchange for money or drugs, are at high risk for HIV infection. Crack use promotes the heterosexual transmission of HIV.	ASSOC DRUG ABUSE PREVENT & TREATMENT,NEW YORK,NY; UNIV MIAMI,MIAMI,FL 33152; BAYVIEW HUNTERS POINT FDN,SAN FRANCISCO,CA; UNIV DELAWARE,NEWARK,DE; CALIF STATE UNIV HAYWARD,HAYWARD,CA 94542; COLUMBIA UNIV,NEW YORK,NY	University of Miami; University of Delaware; California State University System; California State University East Bay; Columbia University	EDLIN, BR (corresponding author), CTR DIS CONTROL & PREVENT,DIV HIV AIDS E45,1600 CLIFTON RD,ATLANTA,GA 30333, USA.		Edlin, Brian/F-2966-2018	Edlin, Brian/0000-0001-8172-8797	PHS HHS [U64/CCU904-453, U64/CCU404539, U64/CCU204582] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN DF, 1987, COCAINE CRISIS, P15; ANTHONY JC, 1991, J DRUG ISSUES, V21, P739, DOI 10.1177/002204269102100405; BOOTH RE, 1993, AM J PUBLIC HEALTH, V83, P1144, DOI 10.2105/AJPH.83.8.1144; Bourgois P., 1989, CONTEMP DRUG PROBL, V16, P619; BOWSER BP, 1989, J NATL MED ASSOC, V81, P538; Breiman L., 1984, CLASSIFICATION REGRE; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; CHIRGWIN K, 1991, AM J PUBLIC HEALTH, V81, P1576, DOI 10.2105/AJPH.81.12.1576; COHEN S, 1987, COCAINE CRISIS, P27; DUNLAP E, 1992, J PSYCHOACTIVE DRUGS, V24, P307, DOI 10.1080/02791072.1992.10471656; DUPONT RL, 1991, OFFICE SUBSTANCE ABU, V9; EDLIN BR, 1992, J PSYCHOACTIVE DRUGS, V24, P363, DOI 10.1080/02791072.1992.10471660; ELLERBROCK TV, 1992, NEW ENGL J MED, V327, P1704, DOI 10.1056/NEJM199212103272402; FARLEY TA, 1990, SEX TRANSM DIS, V17, P163, DOI 10.1097/00007435-199010000-00003; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; HAMID A, 1992, J PSYCHOACTIVE DRUGS, V24, P337, DOI 10.1080/02791072.1992.10471658; Inciardi J., 1993, WOMEN CRACK COCAINE, P147; Inciardi J. A., 1987, CONTEMP DRUG PROBL, V14, P461; INCIARDI JA, 1986, WAR DRUGS HEROIN COC, P121; MARX R, 1991, SEX TRANSM DIS, V18, P92, DOI 10.1097/00007435-199118020-00008; RATNER MS, 1993, CRACK PIPE PIMP ETHN; Rinfret M, 1991, NIDA Res Monogr, V110, P297; ROLFS RT, 1990, AM J PUBLIC HEALTH, V80, P853, DOI 10.2105/AJPH.80.7.853; SANCHEZMARTINEZ D, 1991, J INFECT DIS, V164, P1196, DOI 10.1093/infdis/164.6.1196; SMART RG, 1991, AM J DRUG ALCOHOL AB, V17, P13, DOI 10.3109/00952999108992806; WASHTON AM, 1987, COCAINE CRISIS, P45; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; 1987, LANCET, V2, P1061; 1990, SAS STAT USERS GUIDE; 1993, 4 DEP HLTH HUM SERV; 1991, DHHS ADM921887 DEP H	31	460	466	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1422	1427		10.1056/NEJM199411243312106	http://dx.doi.org/10.1056/NEJM199411243312106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PU533	7969281				2022-12-28	WOS:A1994PU53300006
J	GOLDSTEIN, RS; GORT, EH; STUBBING, D; AVENDANO, MA; GUYATT, GH				GOLDSTEIN, RS; GORT, EH; STUBBING, D; AVENDANO, MA; GUYATT, GH			RANDOMIZED CONTROLLED TRIAL OF RESPIRATORY REHABILITATION	LANCET			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; HEALTH-STATUS	Disability associated with chronic obstructive pulmonary disease has led to the development of rehabilitation programmes that aim to increase exercise tolerance and improve quality of life. Many reports of the benefits of rehabilitation have been from uncontrolled trials and unsupervised programmes. In view of asked of patients, their families, professionals, rehabilitation should be justified by a demonstration of sustained improvement over conventional treatment. We undertook a prospective randomised controlled trial of respiratory rehabilitation in 89 subjects (44 men, 45 women) aged 66 (SD 7) years with severe but stable chronic obstructive pulmonary disease who received rehabilitation or conventional community care. The treatment group were rehabilitated as inpatients for 8 weeks and supervised as outpatients for 16 weeks. Primary outcome measures of exercise tolerance and quality of life were made at baseline and repeated at 12, 18, and 24 weeks. The difference between baseline and last follow-up was significant for 6 min walk distance (37.9 m [95% CI 10.8-65.0], p=0.0067) and submaximal cycle time (4.7 min [2.1-7.3]), There were also significant differences in questionnaire (p=0.0061), emotional function (p=0.0150), mastery (p=0.0002), and dyspnoea index (p=0.0053). Improvements in exercise tolerance and quality of life can be achieved and sustained for 6 months in patients undergoing respiratory rehabilitation compared with those receiving conventional care.	UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; MCMASTER UNIV, DEPT MED, TORONTO, ON, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL, TORONTO, ON, CANADA	University of Toronto; McMaster University; McMaster University								[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1299; ATKINS CJ, 1984, J CONSULT CLIN PSYCH, V52, P591, DOI 10.1037/0022-006X.52.4.591; BLACK LF, 1969, AM REV RESPIR DIS, V99, P696; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BRUNDIN A, 1974, SCAND J RESPIR DIS, V55, P25; BURROWS B, 1969, NEW ENGL J MED, V280, P397, DOI 10.1056/NEJM196902202800801; BURROWS B, 1971, CHEST, V60, P25; DONNER CF, 1992, EUR RESPIR J, V5, P266; DUDLEY DL, 1980, CHEST, V77, P413, DOI 10.1378/chest.77.3.413; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GUYATT GH, 1987, AM REV RESPIR DIS, V135, P1069; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; GUYATT GH, 1984, THORAX, V39, P818, DOI 10.1136/thx.39.11.818; HAAS A, 1969, MED CLIN N AM, V53, P593, DOI 10.1016/S0025-7125(16)32756-0; ISAWA T, 1978, AM REV RESPIR DIS, V118, P55; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Jones NL., 1988, CLIN EXERCISE TESTIN, V3rd edn; LERTZMAN MM, 1976, AM REV RESPIR DIS, V114, P1145; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; MCGAVIN CR, 1977, THORAX, V32, P307, DOI 10.1136/thx.32.3.307; MUNGALL IPF, 1979, THORAX, V34, P254, DOI 10.1136/thx.34.2.254; PAEZ PN, 1967, AM REV RESPIR DIS, V95, P944; PETTY TL, 1970, CHEST, V57, P204, DOI 10.1378/chest.57.2.204; ROCHESTER DF, 1985, AM REV RESPIR DIS, V132, P42; SAHN S A, 1980, Chest, V77, P311, DOI 10.1378/chest.77.2_Supplement.311; SERGYSELS R, 1979, RESPIRATION, V38, P105, DOI 10.1159/000194066; SINCLAIR DJM, 1980, BMJ-BRIT MED J, V280, P519, DOI 10.1136/bmj.280.6213.519; TOSHIMA MT, 1990, HEALTH PSYCHOL, V9, P237, DOI 10.1037/0278-6133.9.3.237; WIJKSTRA PJ, 1994, EUR RESPIR J, V7, P269, DOI 10.1183/09031936.94.07020269; 1981, J R COLL PHYSICIANS, V15, P69; 1980, BRIT MED J, V1, P519	33	356	363	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 19	1994	344	8934					1394	1397		10.1016/S0140-6736(94)90568-1	http://dx.doi.org/10.1016/S0140-6736(94)90568-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968075				2022-12-28	WOS:A1994PR78600009
J	JONES, P; RODGERS, B; MURRAY, R; MARMOT, M				JONES, P; RODGERS, B; MURRAY, R; MARMOT, M			CHILD DEVELOPMENTAL RISK-FACTORS FOR ADULT SCHIZOPHRENIA IN THE BRITISH 1946 BIRTH COHORT	LANCET			English	Article							DISORDER; LIFE	Schizophrenia has been linked with childhood psychological abnormalities since it was first described, but studies of associations have not used population samples and so may be subject to bias. We have studied associations between adult-onset schizophrenia and childhood sociodemographic, neurodevelopmental, cognitive, and behavioural factors within a cohort of 5362 people born in the week March 3-9, 1946. Childhood data were gathered prospectively and case ascertainment was independent of routine follow-up of this cohort. 30 cases of schizophrenia arose between ages 16 and 43 years (cumulative risk 0.63% [95% CI 0.41-0.86%]). Milestones of motor development were reached later in cases than in controls, particularly walking (difference in means 1.2 months [0.1-2.3], p = 0.005), and up to age 15, cases had more speech problems than had controls (odds ratio 2.8 [0.9-7.8], p = 0.04). Low educational test scores at ages 8, 11, and 15 years were a risk factor, with significant linear trends across population distributions; risk was not confined to very low scores. Solitary play preference at ages 4 and 6 years predicted schizophrenia (odds ratios 2.1, 2.5, p = 0.05). At 13 years cases rated themselves as less socially confident (p for trend, 0.04). At 15 years, teachers rated cases as being more anxious in social situations (p for trend 0.003), independent of intelligence quotient. A health visitor's rating of the mother as having below average mothering skills and understanding of her child at age 4 years was a predictor of schizophrenia in that child (odds ratio 5.8 [0.8-31.8], p = 0.02). Differences between children destined to develop schizophrenia as adults and the general population were found across a range of developmental domains. As with some other adult illnesses, the origins of schizophrenia may be found in early life.	UCL, DEPT EPIDEMIOL & PUBL HLTH, MRC, NATL SURVEY HLTH & DEV, LONDON, ENGLAND	University of London; University College London	JONES, P (corresponding author), INST PSYCHIAT, DEPT PSYCHOL MED, DE CRESPIGNY PK, LONDON SE5 8AF, ENGLAND.		Rodgers, Bryan/B-2090-2013; Marmot, M G/Y-3920-2019; murray, robin/F-8658-2012	Rodgers, Bryan/0000-0002-2863-3737; Marmot, M G/0000-0002-2431-6419; Jones, Peter Brian/0000-0002-0387-880X; murray, robin/0000-0003-0829-0519	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], 1970, CLASSIFICATION OCCUP; AYLWARD E, 1984, SCHIZOPHRENIA BULL, V10, P430, DOI 10.1093/schbul/10.3.430; DONE DJ, 1994, BRIT MED J, V309, P699, DOI 10.1136/bmj.309.6956.699; DONE DJ, 1991, BRIT MED J, V302, P1576, DOI 10.1136/bmj.302.6792.1576; FISH B, 1992, ARCH GEN PSYCHIAT, V49, P221; GITTELMA.R, 1969, J PSYCHIAT RES, V7, P35, DOI 10.1016/0022-3956(69)90010-7; LEWIS G, 1992, LANCET, V340, P137, DOI 10.1016/0140-6736(92)93213-7; Lewis SW, 1989, SCHIZOPHRENIA, P56; MCGUIRE PK, 1993, LANCET, V342, P703, DOI 10.1016/0140-6736(93)91707-S; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P188; MURRAY RM, 1987, BRIT MED J, V295, P681, DOI 10.1136/bmj.295.6600.681; PIDGEON DA, 1968, ALL OUR FUTURES, P194; PIDGEON DA, 1964, HOME SCH, P129; ROBERTS GW, 1990, BRIT J PSYCHIAT, V157, P1; Robins L. N., 1966, DEVIANT CHILDREN GRO; RODGERS B, 1978, DEV MED CHILD NEUROL, V20, P421, DOI 10.1111/j.1469-8749.1978.tb15242.x; RODGERS B, 1990, J CHILD PSYCHOL PSYC, V31, P393, DOI 10.1111/j.1469-7610.1990.tb01577.x; RODGERS B, 1986, PSYCHOL MED, V16, P689, DOI 10.1017/S0033291700010436; RODGERS B, 1990, BRIT J PSYCHIAT, V157, P539, DOI 10.1192/bjp.157.4.539; Rose G., 1992, STRATEGY PREVENTIVE; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983; TIENARI P, 1987, SCHIZOPHRENIA BULL, V13, P477, DOI 10.1093/schbul/13.3.477; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300; WALKER E, 1990, AM J PSYCHIAT, V147, P1052; WATT NF, 1978, ARCH GEN PSYCHIAT, V35, P160; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; 1987, DIAGNOSTIC STATISTIC; 1948, MATERNITY GB	30	988	1002	0	60	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1398	1402		10.1016/S0140-6736(94)90569-X	http://dx.doi.org/10.1016/S0140-6736(94)90569-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968076				2022-12-28	WOS:A1994PR78600010
J	GO, ES; URBAN, C; BURNS, J; KREISWIRTH, B; EISNER, W; MARIANO, N; MOSINKASNIPAS, K; RAHAL, JJ				GO, ES; URBAN, C; BURNS, J; KREISWIRTH, B; EISNER, W; MARIANO, N; MOSINKASNIPAS, K; RAHAL, JJ			CLINICAL AND MOLECULAR EPIDEMIOLOGY OF ACINETOBACTER INFECTIONS SENSITIVE ONLY TO POLYMYXIN-B AND SULBACTAM	LANCET			English	Article							CALCOACETICUS BIOTYPE ANITRATUS; IMIPENEM-RESISTANT; ANTIBIOTIC-RESISTANCE; NOSOCOMIAL INFECTIONS; SUSCEPTIBILITY; BAUMANNII	A nosocomial outbreak of infections due to imipenem-resistant Acinetobacter baumannii occurred in a New York hospital after increased use of imipenem for cephalosporin-resistant klebsiella infections. We identified all A baumannii isolates over 12 months, reviewed corresponding patient records, and compared strains with different antibiotic susceptibility patterns by restriction endonuclease analysis. Environmental surveillance cultures were done before and after institution of control measures. 59 patients harboured imipenem-resistant A baumannii, and 18 were infected, isolates from patients were resistant to all routinely tested antibiotics, including imipenem. Further studies showed susceptibility to polymyxin B and sulbactam. These isolates were identical by restriction endonuclease analysis to A baumannii isolates susceptible to imipenem alone, or to imipenem and amikacin, but differed from broadly susceptible isolates. Surveillance cultures showed hand and environmental colonisation by imipenem-resistant strains. Infection and colonisation were eliminated by intensive infection control measures, and irrigation of wounds with polymyxin B. Increased use of imipenem against cephalosporin-resistant klebsiella may lead to imipenem resistance among other species, particularly acinetobacter. Such resistance appears to derive from a prior multi-resistant clone, in contrast to one which retains susceptibility to several antibiotics.	CORNELL UNIV,SCH MED,DEPT MED,NEW YORK,NY 10021; CORNELL UNIV,SCH MED,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,NEW YORK HOSP,MED CTR QUEENS,DEPT MED,INFECT DIS SECT,NEW YORK,NY; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY; NEW YORK CITY DEPT HLTH,BUR LABS,NEW YORK,NY 10013	Cornell University; Cornell University; Cornell University; NewYork-Presbyterian Hospital; Cornell University; New York City Department of Health & Mental Hygiene								ALKHOJA MS, 1979, J CLIN PATHOL, V32, P497, DOI 10.1136/jcp.32.5.497; ALLARDETSERVENT A, 1989, J CLIN MICROBIOL, V27, P2057, DOI 10.1128/JCM.27.9.2057-2061.1989; BECKSAGUE CM, 1990, AM J EPIDEMIOL, V132, P723, DOI 10.1093/oxfordjournals.aje.a115714; BUXTON AE, 1978, AM J MED, V65, P507, DOI 10.1016/0002-9343(78)90777-5; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DECHAMPS C, 1993, J CLIN MICROBIOL, V31, P123, DOI 10.1128/JCM.31.1.123-127.1993; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GAYNES RP, 1992, INFECT CONT HOSP EP, V13, P10, DOI 10.1086/646417; GEHRLEIN M, 1991, CHEMOTHERAPY, V37, P405, DOI 10.1159/000238887; GLEW RH, 1977, MEDICINE, V56, P79, DOI 10.1097/00005792-197703000-00001; HARSTEIN AI, 1988, AM J MED, V85, P624; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; LEVY SB, 1993, JAMA-J AM MED ASSOC, V269, P1840, DOI 10.1001/jama.269.14.1840; MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Paton R, 1993, Int J Antimicrob Agents, V2, P81, DOI 10.1016/0924-8579(93)90045-7; PATTERSON JE, 1991, AM J MED, V91, P479, DOI 10.1016/0002-9343(91)90183-X; RAIMONDI A, 1991, ANTIMICROB AGENTS CH, V35, P1174, DOI 10.1128/AAC.35.6.1174; ROLSTON KVI, 1986, ANTIMICROB AGENTS CH, V30, P769, DOI 10.1128/AAC.30.5.769; SATO K, 1991, J ANTIMICROB CHEMOTH, V28, P35, DOI 10.1093/jac/28.1.35; SEIFERT H, 1993, ANTIMICROB AGENTS CH, V37, P750, DOI 10.1128/AAC.37.4.750; TAPLIN D, 1963, JAMA-J AM MED ASSOC, V186, P952; TRAUB WH, 1989, ANTIMICROB AGENTS CH, V33, P1617, DOI 10.1128/AAC.33.9.1617; URBAN C, 1993, J INFECT DIS, V167, P448, DOI 10.1093/infdis/167.2.448; WOOD CA, 1993, J INFECT DIS, V168, P1602, DOI 10.1093/infdis/168.6.1602	25	284	305	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1329	1332		10.1016/S0140-6736(94)90694-7	http://dx.doi.org/10.1016/S0140-6736(94)90694-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968028				2022-12-28	WOS:A1994PQ92600010
J	HIGGINS, CF				HIGGINS, CF			FLIP-FLOP - THE TRANSMEMBRANE TRANSLOCATION OF LIPIDS	CELL			English	Review							MULTIDRUG TRANSPORTER; CARRIER PROTEIN; CELLS; SITE		UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN BIOCHEM,OXFORD OX3 9DU,ENGLAND	University of Oxford	HIGGINS, CF (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND.							DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Henderson PJF, 1991, CURR OPIN STRUC BIOL, V1, P590, DOI 10.1016/S0959-440X(05)80082-X; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, NUCLEIC ACIDS MOL BI, V6, P67; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHULDINER S, 1977, P NATL ACAD SCI USA, V74, P1851, DOI 10.1073/pnas.74.5.1851; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; WADZINSKI BE, 1990, BIOCHEM J, V272, P151, DOI 10.1042/bj2720151	15	126	128	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					393	395		10.1016/0092-8674(94)90248-8	http://dx.doi.org/10.1016/0092-8674(94)90248-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954806				2022-12-28	WOS:A1994PQ48800002
J	HOLMES, L; LOUGHEAD, K; TREASURE, T; GALLIVAN, S				HOLMES, L; LOUGHEAD, K; TREASURE, T; GALLIVAN, S			WHICH PATIENTS WILL NOT BENEFIT FROM FURTHER INTENSIVE-CARE AFTER CARDIAC-SURGERY	LANCET			English	Article							UNIT PATIENTS; PREDICTION	In intensive care units, a predictive model that identified patients who are certain to die would spare suffering and free resources for more productive work. In a prospective study to determine factors which might predict the outcome of a protracted stay in intensive care units, information was collected for 162 patients who remained in intensive care longer than 48 hours after cardiac surgery. Of these patients, 21% presented as emergencies, 35% as urgent cases, and 44% as elective cases. They were drawn from 2256 adult patients operated upon during a 12-month period in three UK centres. 115 patients (71%) who were in intensive care for more than 48 hours survived to be discharged. The median duration of stay was 6 days (range 3-90 days) and the median duration of hospital stay was 21 days (7-111 days). An existing algorithm developed and calibrated to predict outcome for general patients in intensive care was applied to forecast outcomes. Contrary to expectations, the algorithm performed well for patients after cardiac surgery. In identifying deaths in intensive care and before hospital discharge, the specificities for death at various intervals after admission were all 97% or more. There is little scope for improving the algorithm's ability to forecast longer term outcome. Furthermore, if it were to be introduced to aid decisions a bout withdrawal of treatment, the potential saving in intensive care bed-days would be small-less than 3% overall.	ST GEORGE HOSP,CARDIOTHORAC UNIT,LONDON SW17 0QT,ENGLAND	St Georges University London			Taylor, Kathryn/ABG-1422-2020					CHANG RWS, 1988, CRIT CARE MED, V16, P34, DOI 10.1097/00003246-198801000-00007; CHANG RWS, 1986, LANCET, V1, P1483; CHANG RWS, 1989, LANCET, V2, P143; COHEN SL, 1993, WHOSE LIFE IS IT ANY; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619	7	33	33	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1200	1202		10.1016/S0140-6736(94)90513-4	http://dx.doi.org/10.1016/S0140-6736(94)90513-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934545				2022-12-28	WOS:A1994PN80300014
J	VIRGOLINI, I; RADERER, M; KURTARAN, A; ANGELBERGER, P; BANYAI, S; YANG, Q; LI, SR; BANYAI, M; PIDLICH, J; NIEDERLE, B; SCHEITHAUER, W; VALENT, P				VIRGOLINI, I; RADERER, M; KURTARAN, A; ANGELBERGER, P; BANYAI, S; YANG, Q; LI, SR; BANYAI, M; PIDLICH, J; NIEDERLE, B; SCHEITHAUER, W; VALENT, P			VASOACTIVE INTESTINAL PEPTIDE-RECEPTOR IMAGING FOR THE LOCALIZATION OF INTESTINAL ADENOCARCINOMAS AND ENDOCRINE TUMORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WATERY-DIARRHEA SYNDROME; VIP RECEPTORS; T-CELLS; SOMATOSTATIN; SCINTIGRAPHY	Background. Intestinal adenocarcinomas and various endocrine tumors express large numbers of high-affinity receptors for vasoactive intestinal peptide (VIP). We have evaluated the usefulness of scanning with VIP labeled with iodine-123 for tumor localization in patients with gastrointestinal tumors. Methods. Radioiodinated VIP was purified by high-pressure liquid chromatography and administered as a single intravenous bolus injection (300 pmol [1 mu g]). Scanning with radiolabeled VIP was compared with computed tomography and scanning with somatostatin analogues in 79 patients with colorectal cancer, pancreatic carcinoma, gastric cancer, carcinoid tumor, or insulinoma. Results. Visualization of gastrointestinal tumors and metastases was obtained with radiolabeled VIP. Binding of the labeled peptide by primary tumors and metastases was visible shortly after the injection and was still demonstrable at 24 hours. In patients with colorectal adenocarcinomas, primary or recurrent tumors were visualized in 10 of 10, liver metastases in 15 of 18, lung metastases in 2 of 3, and lymph-node metastases in 4 of 4. Primary pancreatic adenocarcinomas were visualized by imaging in 10 of 12 patients, and liver metastases were seen in 7 of 7. Primary or recurrent gastric adenocarcinomas were visualized in five of five patients, and liver metastases were seen in two of two patients. VIP scans were positive in 9 of 10 patients with carcinoid tumors and in 4 of 4 patients with insulinomas. Some tumors with positive VIP scans were also visualized with somatostatin analogues (4 of 17 colorectal adenocarcinomas, 8 of 9 carcinoids, and 2 of 2 insulinomas). In vitro binding studies confirmed the presence of VIP receptors on gastrointestinal tumors. Conclusions. Scanning with radiolabeled VIP can visualize intestinal tumors and metastases that express receptors for VIP.	UNIV VIENNA,DEPT CLIN PHARMACOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DIV ONCOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DIV HEMATOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DIV INTERNAL MED 1,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DIV GASTROENTEROL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DIV INTERNAL MED 4,A-1090 VIENNA,AUSTRIA; RES CTR SEIBERSDORF,DEPT RADIOCHEM,SEIBERSDORF,AUSTRIA; UNIV VIENNA,DEPT SURG,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna; University of Vienna; University of Vienna; University of Vienna; University of Vienna	VIRGOLINI, I (corresponding author), UNIV VIENNA,DEPT NUCL MED,WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA.		Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019; Test, PV/U-9451-2019; Test, Test/Y-7921-2019	Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; LI, Shuren/0000-0001-7827-8051; Niederle, Bruno/0000-0001-8107-4068				BLOOM SR, 1973, LANCET, V2, P14; BLUM AM, 1992, J NEUROIMMUNOL, V39, P101, DOI 10.1016/0165-5728(92)90179-O; COUVINEAU A, 1985, J CLIN ENDOCR METAB, V61, P50, DOI 10.1210/jcem-61-1-50; ELBATTARI A, 1988, J BIOL CHEM, V263, P17685; FISCHMAN AJ, 1993, J NUCL MED, V34, P2253; KRENNING EP, 1993, EUR J NUCL MED, V20, P716, DOI 10.1007/BF00181765; KRENNING EP, 1989, LANCET, V1, P242; KRENNING EP, 1992, J NUCL MED, V33, P652; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; ODORISIO MS, 1985, J IMMUNOL, V135, pS792; OTTAWAY CA, 1984, J EXP MED, V160, P1054, DOI 10.1084/jem.160.4.1054; PAUL S, 1987, J BIOL CHEM, V262, P158; SAID SI, 1975, NEW ENGL J MED, V293, P155, DOI 10.1056/NEJM197507242930401; SCHWARTZ CJ, 1974, J CLIN INVEST, V54, P536, DOI 10.1172/JCI107790; SREEDHARAN SP, 1991, P NATL ACAD SCI USA, V88, P4986, DOI 10.1073/pnas.88.11.4986; SVOBODA M, 1988, EUR J BIOCHEM, V176, P707, DOI 10.1111/j.1432-1033.1988.tb14334.x; VERNER JV, 1958, AM J MED, V25, P374, DOI 10.1016/0002-9343(58)90075-5; VIRGOLINI I, 1991, J NUCL MED, V32, P2132; VIRGOLINI I, 1994, CANCER RES, V54, P690	19	247	261	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1116	1121		10.1056/NEJM199410273311703	http://dx.doi.org/10.1056/NEJM199410273311703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7935635				2022-12-28	WOS:A1994PN06500003
J	SCHWOB, E; BOHM, T; MENDENHALL, MD; NASMYTH, K				SCHWOB, E; BOHM, T; MENDENHALL, MD; NASMYTH, K			THE B-TYPE CYCLIN KINASE INHIBITOR P40(SIC1) CONTROLS THE G1 TO S TRANSITION IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							YEAST-CELL CYCLE; SIGNAL-TRANSDUCTION PATHWAY; MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; CDC28; GENE; FAR1; PROTEOLYSIS; EXPRESSION	When yeast cells reach a critical size, they initiate bud formation, spindle pole body duplication, and DNA replication almost simultaneously. All three events depend on activation of Cdc28 protein kinase by the G1 cyclins Cln1, -2, and -3. We show that DNA replication also requires activation of Cdc28 by B-type (Clb) cyclins. A sextuple clb1-6 mutant arrests as multibudded G1 cells that resemble cells lacking the Cdc34 ubiquitin-conjugating enzyme. cdc34 mutants cannot enter S phase because they fail to destroy p40(SIC1), which is a potent inhibitor of Clb but not Cln forms of the Cdc28 kinase. In wild-type cells, p40(SIC1) protein appears at the end of mitosis and disappears shortly before S phase. Proteolysis of a cyclin-specific inhibitor of Cdc28 is therefore an essential aspect of the G1 to S phase transition.	UNIV KENTUCKY,LUCILLE P MARKEY CANC CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky	SCHWOB, E (corresponding author), IMP RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Schwob, Etienne/H-4678-2015; Schwob, Etienne/AAC-3050-2020	Schwob, Etienne/0000-0002-9369-6419; Nasmyth, Kim/0000-0001-7030-4403				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; YOCHEM J, 1987, J MOL BIOL, V195, P223	40	793	805	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					233	244		10.1016/0092-8674(94)90193-7	http://dx.doi.org/10.1016/0092-8674(94)90193-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954792				2022-12-28	WOS:A1994PN63000008
J	KLEIN, C; STRUHL, K				KLEIN, C; STRUHL, K			INCREASED RECRUITMENT OF TATA-BINDING PROTEIN TO THE PROMOTER BY TRANSCRIPTIONAL ACTIVATION DOMAINS IN-VIVO	SCIENCE			English	Article							RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; YEAST; CHROMATIN; MECHANISM; DNA; NUCLEOSOME; INVITRO; REPLICATION	The rate at which the TATA-binding protein (TBP) interacts with the TATA element and promotes transcription by RNA polymerase II was determined in yeast cells. A TBP derivative with altered TATA-element specificity was rapidly induced, and transcription from promoters with appropriately mutated TATA elements was measured. Without a functional activator protein, basal transcription was observed only after a lag of several hours. In contrast, GCN4-activated transcription occurred rapidly upon induction of the TBP derivative. These results suggest that accessibility of TBP to the chromatin template in vivo is rate limiting and that activation domains increase recruitment of TBP to the promoter.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030186, R37GM030186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; Croston GE, 1993, CURR OPIN CELL BIOL, V5, P417, DOI 10.1016/0955-0674(93)90006-C; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRECO MA, 1990, J BACTERIOL, V172, P317, DOI 10.1128/JB.172.1.317-325.1990; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEIN C, UNPUB; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRIOLEAU MN, 1994, CELL, V77, P439, DOI 10.1016/0092-8674(94)90158-9; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; SIKORSKI RS, 1989, GENETICS, V122, P19; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1993, CURR BIOL, V3, P220, DOI 10.1016/0960-9822(93)90338-O; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; STRUHL K, 1987, MOL CELL BIOL, V7, P104, DOI 10.1128/MCB.7.1.104; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; ZAWEL L, 1993, INITIATION TRANSCRIP, V2	47	113	114	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					280	282		10.1126/science.7939664	http://dx.doi.org/10.1126/science.7939664			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939664				2022-12-28	WOS:A1994PM13400035
J	HILEY, CMH; MORLEY, CJ				HILEY, CMH; MORLEY, CJ			EVALUATION OF GOVERNMENTS CAMPAIGN TO REDUCE RISK OF COT DEATH	BRITISH MEDICAL JOURNAL			English	Article									UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT PAEDIAT,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge				Morley, Colin/0000-0001-5388-0214				FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; MCKENNA JJ, 1990, AM J PHYS ANTHROPOL, V83, P331, DOI 10.1002/ajpa.1330830307; 1991, SLEEPING POSITION IN; 1993, OPCS MONITOR	4	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					703	704		10.1136/bmj.309.6956.703	http://dx.doi.org/10.1136/bmj.309.6956.703			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PH407	7950523	Green Published			2022-12-28	WOS:A1994PH40700016
J	GOODMAN, RA; JENKINS, EL; MERCY, JA				GOODMAN, RA; JENKINS, EL; MERCY, JA			WORKPLACE-RELATED HOMICIDE AMONG HEALTH-CARE WORKERS IN THE UNITED-STATES, 1980 THROUGH 1990	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							OCCUPATIONAL INJURIES	Objective.-To improve understanding of the epidemiology of fatal violence directed toward physicians and other health care workers (HCWs) in health care settings. Design.-Analyses of data for 1980 through 1990 from the National Traumatic Occupational Fatalities surveillance system. Main Outcome Measures.-Overall occurrence of occupational injury deaths and occurrence of workplace-related homicides among HCWs. Results.-From 1980 through 1990, a total of 522 HCWs died from injuries sustained while working. The most common causes of death were motor vehicle crashes (122 [23.4%1]), homicide (106 [20.3%]), and suicide (88 [16.9%]). Firearms were used in the greatest number (78 [73.6%]) of workplace-related homicides among HCWs. Conclusions.-These findings highlight the need for strengthened surveillance and more accurate estimates of the risks of workplace-related violent injury for HCWs in the United States.	CTR DIS CONTROL & PREVENT,NIOSH,DIV SAFETY RES,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,DIV VIOLENCE PREVENT,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Centers for Disease Control & Prevention - USA	GOODMAN, RA (corresponding author), CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF MSC08,ATLANTA,GA 30333, USA.							BELL CA, 1990, JAMA-J AM MED ASSOC, V263, P3047, DOI 10.1001/jama.263.22.3047; CARMEL H, 1989, HOSP COMMUNITY PSYCH, V40, P41; CASTILLO DN, 1994, J OCCUP ENVIRON MED, V36, P125, DOI 10.1097/00043764-199402000-00006; GOETZ RR, 1991, ANN EMERG MED, V20, P8, DOI 10.1016/S0196-0644(05)81109-6; JENKINS EL, 1993, DHHS NIOSH93108, P93; JENKINS EL, 1992, J AM ASS OCCUP HLTH, V40, P215; Keep N, 1992, J Emerg Nurs, V18, P433; Kenya, 1984, EMPLOYMENT EARNINGS; LAVOIE FW, 1988, ANN EMERG MED, V17, P1227, DOI 10.1016/S0196-0644(88)80076-3; Lipscombe J, 1992, J AM ASS OCCUP HLTH, V40, P219; MASTRANGELO R, 1994, ADVANCE, V2, P16; SCOTT K, 1993, US MED, V29, P12; SCOTT K, 1993, US MED, V29, P2; STOUT NA, 1992, SCAND J WORK ENV HEA, V18, P88; 1988, EMERGENCY DEPT VIOLE; 1993, GUIDELINES SECUIRTY; 1992, JAMA-J AM MED ASSOC, V18, P399; 1992, INJURY MORTALITY NAT	18	47	48	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1686	1688		10.1001/jama.272.21.1686	http://dx.doi.org/10.1001/jama.272.21.1686			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PU759	7966897				2022-12-28	WOS:A1994PU75900028
J	LINK, AS; TOOLE, JF				LINK, AS; TOOLE, JF			PRESIDENTIAL DISABILITY AND THE 25TH-AMENDMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									WAKE FOREST UNIV, BOWMAN GRAY SCH MED, CTR STROKE RES, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT NEUROL, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, COY C CARPENTER LIB, HIST MED SECT, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center								Abrams Herbert L., 1992, PRESIDENT HAS BEEN S; ALVAREZ WC, 1966, LITTLE STROKES, P34; BAILEY TA, 1945, W WILSON GRET BETRAY; BAKER RS, 1920, COLLIERS        0313, P19; BRUENN HG, 1970, ANN INTERN MED, V72, P579, DOI 10.7326/0003-4819-72-4-579; EISENHOWER DD, 1964, WHITE HOUSE YEARS, V2, P227; FEERICK JD, 1992, 25TH AMENDENT ITS CO; Ferrell R, 1992, ILL ADVISED PRESIDEN; GRAYSON CT, 1960, W WILSON INTIMATE ME, P81; LINK AS, IN PRESS P AM PHILOS; LINK AS, 1988, PAPERS W WILSON, V58; LINK AS, 1988, PAPERS W WILSON, V58, P6037; MCCULLOUGH D, 1992, TRUMAN, P327; PARK BE, 1986, IMPACT ILLNESS WORLD, P225; PARK BE, 1991, AILING AGING ADDICTE, P217; POST JM, 1993, ILLNESS TRIKES LEADE; PRICHARD RW, 1951, SURG GYNECOL OBSTET, V92, P625; ROSENBERG CE, 1968, TRIAL ASSASSIN GUITE, P1; SCARLETT EP, 1966, ARCH INTERN MED, V118, P603, DOI 10.1001/archinte.118.6.603; Weinstein Edwin A., 1981, W WILSON MED PSYCHOL; 1966, CHURCHILL TAKEN DIAR, pR10; 1988, REPORT MILLER CTR CO	22	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1694	1697		10.1001/jama.272.21.1694	http://dx.doi.org/10.1001/jama.272.21.1694			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966898				2022-12-28	WOS:A1994PU75900030
J	ENTMAN, SS; GLASS, CA; HICKSON, GB; GITHENS, PB; WHETTENGOLDSTEIN, K; SLOAN, FA				ENTMAN, SS; GLASS, CA; HICKSON, GB; GITHENS, PB; WHETTENGOLDSTEIN, K; SLOAN, FA			THE RELATIONSHIP BETWEEN MALPRACTICE CLAIMS HISTORY AND SUBSEQUENT OBSTETRIC CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY IMPROVEMENT TOOL	Objective.-To determine the relationship between prior malpractice claims experience and the quality of clinical obstetric care. Design.-Historical cohort study of obstetricians, classified by their prior malpractice claims experience, with blinded review of medical records from their practices 5 to 10 years later. Setting.-Florida obstetricians who lost, settled, or defended malpractice claims between 1977 and 1983 and who were still practicing obstetrics in 1987. Main Outcome Measures.-Objective and subjective assessment of quality of clinical care of patients attended by obstetricians with different histories of malpractice claims. Results.-No differences were found in any of the objective or subjective measures of the quality of clinical care provided to patients of obstetricians who were classified into one of four groups according to their prior claims history. Conclusions.-No relationship was found between prior malpractice claims experience and the technical quality of practice by Florida obstetricians. Strategies that attempt to identify physicians at risk for future clinical errors by using data on prior malpractice claims (such as the National Practitioner Data Bank) may be misjudging the likelihood that substandard clinical care will be provided by physicians with prior claims.	VANDERBILT UNIV,MED CTR,DEPT PEDIAT,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT ECON,NASHVILLE,TN 37232; DUKE UNIV,CTR HLTH POLICY RES & EDUC,DURHAM,NC	Vanderbilt University; Vanderbilt University; Duke University	ENTMAN, SS (corresponding author), VANDERBILT UNIV,MED CTR,DEPT OBSTET & GYNECOL,B-1100 MED CTR N,NASHVILLE,TN 37232, USA.		Whetten, Kathryn/C-8572-2009	Whetten, Kathryn/0000-0002-4841-7695	AHRQ HHS [HSO6499] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		CETRULO CL, 1990, ASSESSMENT CARE FETU, P961; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; HICKSON GB, 1994, JAMA-J AM MED ASSOC, V272, P1583, DOI 10.1001/jama.272.20.1583; KRAVITZ RL, 1991, JAMA-J AM MED ASSOC, V266, P2087, DOI 10.1001/jama.266.15.2087; LOCALIO AR, 1993, JAMA-J AM MED ASSOC, V269, P366, DOI 10.1001/jama.269.3.366; ROLPH JE, 1991, JAMA-J AM MED ASSOC, V266, P2093, DOI 10.1001/jama.266.15.2093; ROLPH JE, 1993, INQUIRY-J HEALTH CAR, V30, P441; SACHS BP, 1989, MED PROFESSIONAL LIA, V2, P27; SLOAN FA, 1989, JAMA-J AM MED ASSOC, V262, P3291, DOI 10.1001/jama.262.23.3291; TARAGIN MI, 1994, MED CARE, V32, P661, DOI 10.1097/00005650-199407000-00001; VANTUINEN I, 1992, UNNECESSARY CESAREAN	11	104	104	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1588	1591		10.1001/jama.272.20.1588	http://dx.doi.org/10.1001/jama.272.20.1588			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966868				2022-12-28	WOS:A1994PR40500024
J	HEICHMAN, KA; ROBERTS, JM				HEICHMAN, KA; ROBERTS, JM			RULES TO REPLICATE BY	CELL			English	Review							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; MAMMALIAN FIBROBLASTS; YEAST; TRANSCRIPTION; CDC7; CLB5				HEICHMAN, KA (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; AXELROD A, 1991, MOL CELL BIOL, V11, P1080, DOI 10.1128/MCB.11.2.1080; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; CRAIG NL, 1991, MOL MICROBIOL, V5, P2569, DOI 10.1111/j.1365-2958.1991.tb01964.x; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HENRICKSEN LA, 1994, IN PRESS J BIOL CHEM; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LI R, 1994, IN PRESS NATURE; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MICKLEM G, 1993, NATURE, V312, P247; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Roberts JM, 1993, CURR OPIN CELL BIOL, V5, P201, DOI 10.1016/0955-0674(93)90103-W; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STRAUSFELD UP, 1994, IN PRESS CURR BIOL; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351; [No title captured]	40	239	242	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					557	562		10.1016/0092-8674(94)90541-X	http://dx.doi.org/10.1016/0092-8674(94)90541-X			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954822				2022-12-28	WOS:A1994PT48100003
J	IGLEHART, JK				IGLEHART, JK			RAPID CHANGES FOR ACADEMIC MEDICAL-CENTERS .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		ANDERS G, 1994, WALL STREET J   1221, pA12; DOBSON A, 1994, ANAL TEACHING HOSPIT; GOSSELIN PG, 1994, BOSTON GLOBE    0612, P1; HILZENRATH D, 1994, WASHINGTON POST 0606, pA12; HILZENRATH DS, 1994, WASH POST       0712, pA1; IGLEHART JK, 1993, NEW ENGL J MED, V329, P1052, DOI 10.1056/NEJM199309303291428; IGLEHART JK, 1994, NEW ENGL J MED, V330, P1167, DOI 10.1056/NEJM199404213301628; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1370, DOI 10.1056/NEJM199411173312010; Kosterlitz J, 1994, Natl J (Wash), V26, P1970; LEWIS C, 1994, WASH POST       0821, pC2; MORGAN D, 1994, WASHINGTON POST 0924, pA4; PETERSDORF RG, 1991, ACAD MED, V66, P595, DOI 10.1097/00001888-199110000-00007; SCHWARTZ WB, 1994, HEALTH AFFAIR, V13, P70, DOI 10.1377/hlthaff.13.3.70; WOOLSEY C, 1994, BUSINESS INSURA 0905, P49	14	94	94	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1391	1395		10.1056/NEJM199411173312025	http://dx.doi.org/10.1056/NEJM199411173312025			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935726				2022-12-28	WOS:A1994PR21600037
J	ESRIG, D; ELMAJIAN, D; GROSHEN, S; FREEMAN, JA; STEIN, JP; CHEN, SC; NICHOLS, PW; SKINNER, DG; JONES, PA; COTE, RJ				ESRIG, D; ELMAJIAN, D; GROSHEN, S; FREEMAN, JA; STEIN, JP; CHEN, SC; NICHOLS, PW; SKINNER, DG; JONES, PA; COTE, RJ			ACCUMULATION OF NUCLEAR P53 AND TUMOR PROGRESSION IN BLADDER-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE PROGRESSION; ALTERED EXPRESSION; GENE-PRODUCT; MUTATIONS; PROTEIN; OVEREXPRESSION; CHEMOTHERAPY; CYSTECTOMY; CARCINOMA	Background. We have previously demonstrated a strong association between nuclear accumulation of p53 protein, as determined by immunohistochemical analysis, and mutations in the p53 gene. The purpose of this study was to determine the relation between nuclear accumulation of p53 and tumor progression in transitional-cell carcinoma of the bladder. Methods. Histologic specimens of transitional-cell carcinoma of the bladder (stages Pa, noninvasive disease, to P4, disease with direct extension into adjacent organs or structures) from 243 patients who were treated by radical cystectomy were examined for the immunohistochemical detection of p53 protein. Nuclear p53 reactivity was then analyzed in relation to time to recurrence and overall survival. Results. The detection of nuclear p53 was significantly associated with an increased risk of recurrence of bladder cancer (P < 0.001) and with decreased overall survival (P < 0.001). In patients with cancer confined to the bladder, the rates of recurrence for stage P1, P2, and P3a tumors that had no detectable nuclear p53 reactivity at five years were 7, 12, and 11 percent, respectively, as compared with 62, 56, and 80 percent, respectively, for tumors that had p53 immunoreactivity. Similar results were obtained when the presence or absence of p53 in the nuclei of the tumor cells was studied in relation to overall survival. In a multivariable analysis stratified according to grade, pathological stage, and lymph-node status, nuclear p53 status was an independent predictor (and in cancer confined to the bladder, the only independent predictor) of recurrence and overall survival (P < 0.001). Conclusions. In patients with transitional-cell carcinoma confined to the bladder, an accumulation of p53 in the tumor-cell nuclei detected by immunohistochemical methods predicts a significantly increased risk of recurrence and death, independently of tumor grade, stage, and lymph-node status. Patients with transitional-cell carcinoma confined to the bladder that demonstrates nuclear p53 reactivity should be considered for protocols of adjuvant treatment.	UNIV SO CALIF,KENNETH NORRIS JR COMPREHENS CANC CTR,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT UROL,LOS ANGELES,CA; UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA	University of Southern California; University of Southern California; University of Southern California					NCI NIH HHS [P30 CA 14089, R35 CA49758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049758, P30CA014089] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergkvist A, 1965, Acta Chir Scand, V130, P371; CORDONCARDO C, 1994, CANCER RES, V54, P794; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; ESRIG D, 1993, AM J PATHOL, V143, P1389; FIENBERG SE, 1977, ANAL CROSS CLASSIFIE, P9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; HERMANEK P, 1987, TNM CLASSIFICATION M, P133; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIPPONEN PK, 1993, INT J CANCER, V53, P365, DOI 10.1002/ijc.2910530304; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; MILLER RG, 1981, SURVIVAL ANAL, P44; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; SARKIS AS, 1993, INT J ONCOL, V3, P355; SARKIS AS, 1993, J NATL CANCER I, V85, P53, DOI 10.1093/jnci/85.1.53; SIDRANSKY D, 1992, UROL CLIN N AM, V19, P629; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SKINNER DG, 1982, J UROLOGY, V128, P34, DOI 10.1016/S0022-5347(17)52740-8; SKINNER DG, 1991, J UROLOGY, V145, P459, DOI 10.1016/S0022-5347(17)38368-4; SPRUCK CH, 1994, CANCER RES, V54, P784; STOCKLE M, 1992, J UROLOGY, V148, P302, DOI 10.1016/S0022-5347(17)36578-3	23	673	682	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1259	1264		10.1056/NEJM199411103311903	http://dx.doi.org/10.1056/NEJM199411103311903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP752	7935683				2022-12-28	WOS:A1994PP75200003
J	FINE, PEM; STERNE, JAC; PONNIGHAUS, JM; REES, RJW				FINE, PEM; STERNE, JAC; PONNIGHAUS, JM; REES, RJW			DELAYED-TYPE HYPERSENSITIVITY, MYCOBACTERIAL VACCINES AND PROTECTIVE IMMUNITY	LANCET			English	Article							NORTHERN MALAWI; LEPROSY VACCINE; TUBERCULOSIS; LEPRAE	There is a longstanding debate over the implications of natural and vaccine-induced delayed type hypertensivity for protective immunity to mycobacterial infections. The identification of correlates of vaccine-induced protective immunity should help explain the inconsistent behaviour of BCG vaccines in different populations and assist in efforts to devise improved vaccines. More than 70 000 subjects in Karonga District, northern Malawi were skin tested with soluble antigens of the tubercle and leprosy bacilli, and then followed up for five years for tuberculosis and leprosy incidence. Incidence rate ratios were calculated to compare subjects with different levels of prior shin test sensitivity, after controlling for the effects of age, sex and previous BCG vaccination. BCG vaccination protected against leprosy without persistent delayed-type hypersensitivity to tuberculin or to soluble antigens of the leprosy bacillus. In subjects who had not received BCG, hypersensitivity to tuberculin or to antigens of the leprosy bacillus was associated with strong protection against leprosy. In BCG-vaccinated and unvaccinated subjects, there was a J-shaped relation between hypersensitivity to tuberculin and subsequent rates of tuberculosis, with lowest rates associated with low grade sensitivity (induration 1-10 mm). This study shows that delayed-type hypersensitivity to antigens has different implications for and leprosy: low-level hypersensitivity (probably attributable to environmental mycobacteria) is associated with protection, but persistent vaccine-associated hypersensitivity to mycobacterial antigens is not a correlate of vaccine-derived protection against mycobacterial diseases.	LEPRA,CHILUMBA,MALAWI; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	FINE, PEM (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND.		Sterne, Jonathan/Z-3106-2019	Sterne, Jonathan/0000-0001-8496-6053				[Anonymous], 1972, B WORLD HEALTH ORGAN, V46, P371; BECHELLI LM, 1973, B WORLD HEALTH ORGAN, V48, P323; COMSTOCK GW, 1988, AM REV RESPIR DIS, V138, P479, DOI 10.1164/ajrccm/138.2.479; DANNENBERG AM, 1989, REV INFECT DIS, V11, pS369; DRAPER P, 1994, J GEN MICROBIOL, V69, P313; FINE PEM, 1993, TUBERCULOSIS BACK FU, P53; GILL HK, 1986, B WORLD HEALTH ORGAN, V64, P121; GUPTE MD, 1990, LEPROSY REV, V61, P132; HART P. D'A., 1967, Tubercle, V48, P201, DOI 10.1016/S0041-3879(67)80024-2; MACKANESS GB, 1991, INT P US DHEW, V14, P69; PALMER CE, 1967, ARCH ENVIRON HEALTH, V15, P792, DOI 10.1080/00039896.1967.10664998; PALMER CE, 1957, B INT UNION TUBERC, V27, P106; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; PONNIGHAUS JM, 1987, INT J LEPROSY, V55, P454; PONNIGHAUS JM, 1986, INT J LEPROSY, V54, P25; PONNIGHAUS JM, 1987, LEPROSY REV, V58, P359; PONNIGHAUS JM, 1994, INT J LEPROSY, V61, P10; SHEPARD CC, 1980, BRIT J EXP PATHOL, V61, P376; STANLEY SJ, 1981, J HYG CAMB, V87, P235; Youmans G.P., 1979, TUBERCULOSIS, P302; 3RD IMMLEP SCI WORK, P20	21	147	149	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1245	1249		10.1016/S0140-6736(94)90748-X	http://dx.doi.org/10.1016/S0140-6736(94)90748-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967984				2022-12-28	WOS:A1994PP70100006
J	IGLEHART, JK				IGLEHART, JK			HEALTH-POLICY REPORT - PHYSICIANS AND THE GROWTH OF MANAGED CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		BERENSON RA, 1994, HEALTH AFFAIR, V13, P185, DOI 10.1377/hlthaff.13.2.185; CHOLLET D, 1994, HEALTH AFFAIR, V13, P315, DOI 10.1377/hlthaff.13.1.315; DEMARIA AN, 1994, J AM COLL CARDIOL, V23, P1245, DOI 10.1016/0735-1097(94)90617-3; EMMONS DW, 1993, PHYSICIAN MARKETPLAC; GABEL J, 1994, HEALTH AFFAIR, V13, P327, DOI 10.1377/hlthaff.13.1.327; HILLMAN AL, 1991, HEALTH AFFAIR, V10, P138, DOI 10.1377/hlthaff.10.4.138; IGLEHART JK, 1994, NEW ENGL J MED, V331, P63, DOI 10.1056/NEJM199407073310129; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1151, DOI 10.1056/NEJM199410273311709; LEONHARDT D, 1994, WASHINGTON POST 0720, V20, pB1; MECHANIC D, 1994, INQUIRY-J HEALTH CAR, V31, P124; RELMAN AS, 1993, NEW ENGL J MED, V328, P133, DOI 10.1056/NEJM199301143280212; SCHROEDER SA, 1994, JAMA-J AM MED ASSOC, V272, P239, DOI 10.1001/jama.272.3.239; STOUT H, 1994, WALL STREET J   0210, pA1; WERINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WINKENWERDER W, 1994, PRIMARY CARE SPECIAL; WINSLOW R, 1994, WALL STREET J   0621, pA2; 1993, MONOGRAPH AM COLLEGE, V1	18	75	75	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1167	1171		10.1056/NEJM199410273311719	http://dx.doi.org/10.1056/NEJM199410273311719			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7935653				2022-12-28	WOS:A1994PN06500030
J	ELLIOTT, MJ; MAINI, RN; FELDMANN, M; LONGFOX, A; CHARLES, P; BIJL, H; WOODY, JN				ELLIOTT, MJ; MAINI, RN; FELDMANN, M; LONGFOX, A; CHARLES, P; BIJL, H; WOODY, JN			REPEATED THERAPY WITH MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) IN PATIENTS WITH RHEUMATOID-ARTHRITIS	LANCET			English	Note								Our in-vitro, animal, and early clinical data suggest that tumour necrosis factor or (TNF alpha) is an important target for specific biological therapy in rheumatoid arthritis. We report the results of repealed treatment with a chimeric monoclonal antibody to TNF alpha (cA2) in patients having disease flares. 7 patients originally enrolled in an open-label trial completed two to four cycles, each of which was followed by a good clinical response, with median improvements in the swollen-joint count and C-reactive protein exceeding 80%, cA2 may be useful therapy in the control of acute disease flares in rheumatoid arthritis and treatment programmes including cA2 may be effective in the long-term management of this disease.	KENNEDY INST,LONDON W6 7DW,ENGLAND; CHARING CROSS & WESTMINSTER MED SCH,ACAD DEPT RHEUMATOL,LONDON,ENGLAND; CENTOCOR INC,MALVERN,PA 19355	University of Oxford; Imperial College London; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc								ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ELLIOTT MJ, 1994, INT ARCH ALLERGY IMM, V104, P112, DOI 10.1159/000236718; FELDMANN M, 1993, TUMOR NECROSIS FACTOR : MOLECULAR AND CELLULAR BIOLOGY AND CLINICAL RELEVANCE, P144; ISSACS JD, 1992, LANCET, V340, P748; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; PAULUS HE, 1990, ARTHRITIS RHEUM, V33, P477, DOI 10.1002/art.1780330403; WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762	8	584	693	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1125	1127		10.1016/S0140-6736(94)90632-7	http://dx.doi.org/10.1016/S0140-6736(94)90632-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934495				2022-12-28	WOS:A1994PN06600011
J	POTAMITIS, T; AGGARWAL, RK; TSALOUMAS, M; RENE, C; MCLAUGHLIN, J; ONEILL, E				POTAMITIS, T; AGGARWAL, RK; TSALOUMAS, M; RENE, C; MCLAUGHLIN, J; ONEILL, E			DRIVING, GLAUCOMA, AND THE LAW	BRITISH MEDICAL JOURNAL			English	Article											POTAMITIS, T (corresponding author), BIRMINGHAM & MIDLAND EYE HOSP,BIRMINGHAM B3 2NS,W MIDLANDS,ENGLAND.							KIRN MM, 1978, AM JOPHTHALMOL, V85, P28; NORTH RV, 1985, OPHTHAL PHYSL OPT, V5, P205, DOI 10.1111/j.1475-1313.1985.tb00657.x	2	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1057	1058		10.1136/bmj.309.6961.1057	http://dx.doi.org/10.1136/bmj.309.6961.1057			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN733	7950740	Green Published			2022-12-28	WOS:A1994PN73300023
J	ANDREASEN, NC; ARNDT, S; SWAYZE, V; CIZADLO, T; FLAUM, M; OLEARY, D; EHRHARDT, JC; YUH, WTC				ANDREASEN, NC; ARNDT, S; SWAYZE, V; CIZADLO, T; FLAUM, M; OLEARY, D; EHRHARDT, JC; YUH, WTC			THALAMIC ABNORMALITIES IN SCHIZOPHRENIA VISUALIZED THROUGH MAGNETIC-RESONANCE IMAGE AVERAGING	SCIENCE			English	Article							STRUCTURAL ABNORMALITIES; ATTENTION; CORTEX; NEUROPATHOLOGY; TOMOGRAPHY; ANATOMY; REGION; BRAIN; PET	Schizophrenia is a complex illness characterized by multiple types of symptoms involving many aspects of cognition and emotion. Most efforts to identify its underlying neural substrates have focused on a strategy that relates a single symptom to a single brain region. An alternative hypothesis, that the variety of symptoms could be explained by a lesion in midline neural circuits mediating attention and information processing, is explored. Magnetic resonance images from patients and controls were transformed with a ''bounding box'' to produce an ''average schizophrenic brain'' and an ''average normal brain.'' After image subtraction of the two averages, the areas of difference were displayed as an effect size map. Specific regional abnormalities were observed in the thalamus and adjacent white matter. An abnormality in the thalamus and related circuitry explains the diverse symptoms of schizophrenia parsimoniously because they could all result from a defect in filtering or gating sensory input, which is one of the primary functions of the thalamus in the human brain.	UNIV IOWA, COLL MED, DEPT PSYCHIAT, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT RADIOL, IOWA CITY, IA 52242 USA; UNIV IOWA HOSP & CLIN, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	ANDREASEN, NC (corresponding author), UNIV IOWA, COLL MED, MENTAL HLTH CLIN RES CTR, IOWA CITY, IA 52242 USA.		Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204; Swayze, Victor/0000-0002-6434-3606; O'Leary, Daniel/0000-0003-1959-6521	NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH043271, P50MH043271, R37MH031593, R01MH040856, R01MH031593] Funding Source: NIH RePORTER; NIMH NIH HHS [MH40856, MHCRC 43271, MH31593] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDREASEN N, 1986, ARCH GEN PSYCHIAT, V43, P136; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P615; ANDREASEN NC, 1994, P NATL ACAD SCI USA, V91, P93, DOI 10.1073/pnas.91.1.93; ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; ANDREASEN NC, 1993, J NEUROPSYCH CLIN N, V5, P121; ANDREASEN NC, 1990, ARCH GEN PSYCHIAT, V47, P35; ANDREASEN NC, 1993, 23RD SOC NEUR ANN M; Arndt S, 1994, Neuroimage, V1, P191, DOI 10.1006/nimg.1994.1004; BARTA PE, 1990, AM J PSYCHIAT, V147, P1457; BAUMER H, 1954, J HIRNFORSCH, V1, P157; BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P996; BENES FM, 1987, ARCH GEN PSYCHIAT, V44, P608; Bleuler E., 1950, DEMENTIA PRAECOX; BOGERTS B, 1993, SCHIZOPHRENIA BULL, V19, P431, DOI 10.1093/schbul/19.2.431; BRAFF DL, 1993, SCHIZOPHRENIA BULL, V19, P233, DOI 10.1093/schbul/19.2.233; Broadbent D.E., 1958, PERCEPTION COMMUNICA; BUCHSBAUM MS, 1990, SCHIZOPHRENIA BULL, V16, P379, DOI 10.1093/schbul/16.3.379; CARLSSON M, 1990, SCHIZOPHRENIA BULL, V16, P425, DOI 10.1093/schbul/16.3.425; COHEN G, 1992, PSYCHIAT RES-NEUROIM, V45, P33, DOI 10.1016/0925-4927(92)90012-S; Cohen J., 1988, STATISTICAL POWER AN, DOI DOI 10.1234/12345678; Evans A C, 1992, Neuroimage, V1, P43, DOI 10.1016/1053-8119(92)90006-9; EVANS AC, 1988, J CEREBR BLOOD F MET, V8, P513, DOI 10.1038/jcbfm.1988.92; FLAUM M, IN PRESS AM J PSYCHI; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; FRITH CD, 1991, NEUROPSYCHOLOGIA, V29, P1137, DOI 10.1016/0028-3932(91)90029-8; Fuster J.M., 1989, PREFRONTAL CORTEX; GOLDMANRAKIC PS, 1990, BRAIN RES PREFRONTAL, P325; GUR RE, 1993, SCHIZOPHRENIA BULL, V19, P337, DOI 10.1093/schbul/19.2.337; HOLZMAN PS, 1976, ARCH GEN PSYCHIAT, V33, P1415; JONES EG, 1970, BRAIN, V93, P37, DOI 10.1093/brain/93.1.37; Jones EG, 1985, THALAMUS; KARSON CN, 1993, AM J PSYCHIAT, V150, P454; KLEIST K, 1960, J MENT SCI, V106, P246, DOI 10.1192/bjp.106.442.246; Kraepelin E., 1919, CUTTING SHEPHERD; LESCH A, 1984, EUR ARCH PSY CLIN N, V234, P212, DOI 10.1007/BF00381351; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; MCGHIE A, 1961, BRIT J MED PSYCHOL, V34, P103, DOI 10.1111/j.2044-8341.1961.tb00936.x; PAKKENBERG B, 1992, ACTA NEUROL SCAND, V85, P20, DOI 10.1111/j.1600-0404.1992.tb05034.x; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; POSNER MI, 1984, J NEUROSCI, V4, P1863; Russ J.C, 1992, IMAGE PROCESSING HDB; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; STEVENS JR, 1973, ARCH GEN PSYCHIAT, V29, P177; Talairach J., 1988, COPLANAR STEREOTAXIC; TREFF W M, 1958, J Hirnforsch, V4, P314; VOLKOW ND, 1985, J CEREB BLOOD FLOW M, V5, P199; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767	51	610	624	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	1994	266	5183					294	298		10.1126/science.7939669	http://dx.doi.org/10.1126/science.7939669			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939669				2022-12-28	WOS:A1994PM13400040
J	SMIDER, V; RATHMELL, WK; LIEBER, MR; CHU, G				SMIDER, V; RATHMELL, WK; LIEBER, MR; CHU, G			RESTORATION OF X-RAY RESISTANCE AND V(D)J RECOMBINATION IN MUTANT-CELLS BY KU CDNA	SCIENCE			English	Article							STRAND BREAK REPAIR; PROTEIN; DNA; AUTOANTIBODIES; OVERLAP; SUBUNIT; ANTIGEN	Three genetic complementation groups of rodent cells are defective for both repair of x-ray-induced double-strand breaks and V(D)J recombination. Cells from one group lack a DNA end-binding activity that is biochemically and antigenically similar to the Ku autoantigen. Transfection of complementary DNA (cDNA) that encoded the 86-kilodalton subunit of Ku rescued these mutant cells for DNA end-binding activity, x-ray resistance, and V(D)J recombination activity. These results establish a role for Ku in DNA repair and recombination. Furthermore, as a component of a DNA-dependent protein kinase, Ku may initiate a signaling pathway induced by DNA damage.	STANFORD UNIV,MED CTR,DEPT MED,STANFORD,CA 94305; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Stanford University; Washington University (WUSTL)				Lieber, Michael/0000-0001-8809-0909; Smider, Vaughn/0000-0003-3488-6383; Lieber, Michael/0000-0003-3700-6345				ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BLIER PR, 1993, J BIOL CHEM, V268, P7594; CAL QQ, 1994, CYTOGENET CELL GENET, V65, P221; CHEN DJ, 1994, GENOMICS, V21, P423, DOI 10.1006/geno.1994.1287; COLLINS AR, 1993, MUTAT RES, V293, P99, DOI 10.1016/0921-8777(93)90062-L; FALZON M, 1993, J BIOL CHEM, V268, P10546; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HAFEZPARAST M, 1993, SOMAT CELL MOLEC GEN, V19, P413, DOI 10.1007/BF01233246; HAMILTON AA, 1987, MOL CELL BIOL, V7, P1409, DOI 10.1128/MCB.7.4.1409; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOORE PD, 1986, MUTAT RES, V160, P149, DOI 10.1016/0027-5107(86)90038-2; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; REEVES WH, 1989, J BIOL CHEM, V264, P5047; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Taccioli G E, 1992, Curr Top Microbiol Immunol, V182, P107; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; YANEVA M, 1989, J BIOL CHEM, V264, P13407	27	329	333	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					288	291		10.1126/science.7939667	http://dx.doi.org/10.1126/science.7939667			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939667				2022-12-28	WOS:A1994PM13400038
J	TOWNSEND, J; RODERICK, P; COOPER, J				TOWNSEND, J; RODERICK, P; COOPER, J			CIGARETTE-SMOKING BY SOCIOECONOMIC GROUP, SEX, AND AGE - EFFECTS OF PRICE, INCOME, AND HEALTH PUBLICITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; TOBACCO	Objective-To assess effects of price, income, and health publicity on cigarette smoking by age, sex, and socioeconomic group. Design-Econometric multiple regression analysis of data on cigarette smoking from the British general household survey. Subjects-Random sample of adult population in Britain interviewed for biennial general household surveys 1972-90. Main outcome measures-Changes in cigarette consumption and prevalence of smoking. Results-Price elasticities of demand for cigarettes (percentage change in cigarette consumption for a 1% change in price) were significant at -0.5 (95% confidence interval -0.8 to -0.1) for men and -0.6 (-0.9 to -0.3) for women, were highest in socioeconomic group V (-1.0 for men and -0.9 for women), and lowest (not significantly different from zero) in socioeconomic groups I and II. The gradient in price elasticities by socioeconomic group was significant for men (F=5.6, P=0.02) and for women (F=6.1, P=0.02). Price was a significant factor in cigarette consumption by age for women in every age group and for men aged 25-34. Cigarette consumption by young men aged 16-34 increased with income. There was a significant decrease in smoking over time by women in socioeconomic groups I and II and by men in all age and social groups except socioeconomic group V attributable to health publicity. Price significantly affected smoking prevalence in socioeconomic group V (-0.6 for men and -0.5 for women) and for all women (-0.2). Conclusions-Men and women in lower socioeconomic groups are more responsive than are those in higher socioeconomic groups to changes in the price of cigarettes and less to health publicity. Women of all ages, including teenagers, appear to have been less responsive to health publicity than have men but more responsive to price. Response to health publicity decreased linearly with age. Real price increases in cigarettes could narrow differences between socioeconomic groups in smoking and the related inequalities in health, but specific measures would be necessary to ameliorate effects on the most deprived families that may include members who continue to smoke. The use of a policy to steadily increase cigarette tax is likely to help achieve the government's targets for smoking and smoking related diseases.			TOWNSEND, J (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL, WOLFSON INST PREVENT MED, MRC, LONDON EC1M 6BQ, ENGLAND.							ATKINSON AB, 1994, HOUSEHOLD EXPENDITUR; BAKER P, 1990, SIMULATION INDIRECT; BLANE D, 1990, BRIT MED J, V301, P429, DOI 10.1136/bmj.301.6749.429; Borren P, 1992, Health Econ, V1, P245, DOI 10.1002/hec.4730010406; BOSANQUET N, 1992, BRIT MED J, V304, P370, DOI 10.1136/bmj.304.6823.370; CHAPMAN S, 1993, BMJ-BRIT MED J, V307, P518, DOI 10.1136/bmj.307.6903.518; COHEN S, 1990, HEALTH PSYCHOL, V9, P466, DOI 10.1037/0278-6133.9.4.466; FOX AJ, 1982, LONGITUDINAL STUDY 1; FRY V, 1988, CHANGING PATTERNS SM; GODFREY C, 1988, BRIT MED J, V297, P339, DOI 10.1136/bmj.297.6644.339; GRAHAM H, 1994, LIFES DRAG; Lewitt E M, 1982, J Health Econ, V1, P121; MARMOT MG, 1986, LANCET, V2, P274; Marsh A, 1994, POOR SMOKERS, VPolicy Studies Institute; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; PARROTT A, 1994, ADDICTION, V89, P142, DOI 10.1111/j.1360-0443.1994.tb00870.x; RAMSEY JB, 1969, J ROY STAT SOC B, V31, P350; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; THOMAS M, 1993, SMOKING SECONDARY SC; TOWNSEND J, 1988, PRICE TAX SMOKING YO; TOWNSEND J, IN PRESS TACKING INE; TOWNSEND J, 1978, NEW SOC          MAR; Townsend J, 1988, PRICE TAX SMOKING EU; TOWNSEND J, 1987, APPLIED EC, V19, P335; WALD N, 1991, UK SMOKING STATISTIC; WASSERMAN J, 1991, J HEALTH ECON, V10, P43, DOI 10.1016/0167-6296(91)90016-G; 1986, SERIES DS, V6; 1992, HLTH NATION STRATEGY; 1972, NATIONAL INCOME EXPE; 1978, REGISTRAR GENERALS D; SAS USERS GUIDE STAT, P243; 1991, SMOKING SECONDARY SC; 1992, EFFECT TOBACCO ADVER; 1972, GENERAL HOUSEHOLD SU; 1992, SMOKING YOUNG LONDON	35	286	289	0	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	1994	309	6959					923	927		10.1136/bmj.309.6959.923	http://dx.doi.org/10.1136/bmj.309.6959.923			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7950662	Green Published			2022-12-28	WOS:A1994PL78100019
J	KIRSCHNER, MW; MARINCOLA, E; TEISBERG, EO				KIRSCHNER, MW; MARINCOLA, E; TEISBERG, EO			THE ROLE OF BIOMEDICAL-RESEARCH IN HEALTH-CARE REFORM	SCIENCE			English	Editorial Material							DISEASE		AMER SOC CELL BIOL,BETHESDA,MD 20814; HARVARD UNIV,SCH BUSINESS,BUSINESS GOVT & COMPETIT AREA,BOSTON,MA 02163	Harvard University	KIRSCHNER, MW (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,25 SHATTUCK ST,BOSTON,MA 02115, USA.							ALPER J, 1993, SCIENCE, V260, P159, DOI 10.1126/science.8469968; BLOOM BS, 1993, J CLIN GASTROENTEROL, V17, P333, DOI 10.1097/00004836-199312000-00015; EVANS RW, 1992, TRANSPLANTATION, V53, P1041, DOI 10.1097/00007890-199205000-00014; FENNERTY MB, 1994, ARCH INTERN MED, V154, P721, DOI 10.1001/archinte.154.7.721; KURATA J, 1994, J CLIN GASTROENTEROL, V18, P245; LUDLUM DB, 1977, CANCER COMPREHENSIVE, P285; PHIBBS CS, 1993, J PEDIATR-US, V123, P953, DOI 10.1016/S0022-3476(05)80394-4; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SELKOE DJ, COMMUNICATION; TEISBERG EO, 1994, HARV BUS REV     JUL, P131; WEINER CP, 1991, AM J OBSTET GYNECOL, V165, P1302; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; 1993, HLTH US 1993, P142; 1993, NIH931261 PUB; 1994, REDUCING DEFICIT SPE	15	36	36	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					49	51		10.1126/science.7939643	http://dx.doi.org/10.1126/science.7939643			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PK582	7939643				2022-12-28	WOS:A1994PK58200021
J	BUCHER, HC; WEINBACHER, M; GYR, K				BUCHER, HC; WEINBACHER, M; GYR, K			INFLUENCE OF METHOD OF REPORTING STUDY RESULTS ON DECISION OF PHYSICIANS TO PRESCRIBE DRUGS TO LOWER CHOLESTEROL CONCENTRATION	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; TRIAL; RISK	Objective-To determine whether the reporting of study results by using reductions in relative or absolute risk and the number needed to treat affects the views of physicians about the effectiveness of drugs to lower lipid concentrations and decisions about treatment. Design-Random allocation of two questionnaires presenting the results of three end points of the Helsinki heart study as results from separate trials by using reduction in either relative or absolute risk. In both questionnaires one end point was also presented by showing person years of treatment needed to prevent one myocardial infarction. The effectiveness of lipid lowering drugs was assessed for all end points on an 11 point scale. For each study result the likelihood to treat hypercholesterolaemia of 7.5 mmol/l in a healthy man had to be indicated on a seven point scale. Subjects-Random sample of 802 internists and general practitioners representative of providers of primary care in Switzerland. Results-The response rate was 69.6% (558), For the prevention of fatal and non-fatal myocardial infarction the mean ratings of effectiveness of lipid lowering drugs were 0.45 (95% confidence interval 0.21 to 0.69) and 1.39 (1.09 to 1.68) scale points lower when the reduction of absolute risk or number needed to treat were reported instead of the relative risk reduction (both P<0.001). Physicians receiving trial results for identical end points in form of absolute reduction of risk or number needed to treat were less inclined to treat hypercholesterolaemia (both P<0.001). Conclusions-Physicians' views of the effectiveness of lipid lowering drugs and the decision to prescribe such drugs is affected by the predominant use of reduction of relative risk in trial reports and advertisements.	UNIV BASEL,KANTONSSPITAL,MED POLIKLIN,CH-4031 BASEL,SWITZERLAND	Kantonsspital Aarau AG (KSA); University of Basel								BRETT AS, 1989, NEW ENGL J MED, V13, P764; DUNNIGAN MG, 1993, BRIT MED J, V306, P1355, DOI 10.1136/bmj.306.6889.1355; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GARATTINI S, 1993, LANCET, V342, P1191, DOI 10.1016/0140-6736(93)92181-R; GUTZWILLER F, 1989, B MED SUISSE, V70, P1; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MAGNANI HN, 1992, SCRIPS 1991 HYPOLIPA; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; 1988, SPSS PC PLUS V3 0 SY	15	140	143	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					761	764		10.1136/bmj.309.6957.761	http://dx.doi.org/10.1136/bmj.309.6957.761			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950558	Green Published			2022-12-28	WOS:A1994PJ28200014
J	DONE, DJ; CROW, TJ; JOHNSTONE, EC; SACKER, A				DONE, DJ; CROW, TJ; JOHNSTONE, EC; SACKER, A			CHILDHOOD ANTECEDENTS OF SCHIZOPHRENIA AND AFFECTIVE-ILLNESS - SOCIAL-ADJUSTMENT AT AGES 7 AND 11	BRITISH MEDICAL JOURNAL			English	Article							ADULT SCHIZOPHRENICS	Objective-To investigate the social adjustment in childhood of people who as adults have psychiatric disorders. Design-Subjects in a prospectively followed up cohort (the national child development study) who had been admitted as adults to psychiatric hospitals were compared with the rest of the cohort on ratings of social behaviour made by teachers at the ages of 7 and 11 years. Subjects-40 adult patients with schizophrenic illnesses, 35 with affective psychoses, and 79 with neurotic illness who had been admitted for psychiatric reasons by the age of 28. 1914 randomly selected members of the cohort who had never been admitted for psychiatric treatment. Main outcome measures-Overall scores and scores for overreaction (externalising behaviour) and underreaction (internalising behaviour) with the Bristol social adjustment guide at ages 7 and 11. Results-At the age of 7 children who developed schizophrenia were rated by their teachers as manifesting more social maladjustment than controls (overall score 4.3 (SD 2.4) v 3.1 (2.0); P < 0.01). This was more apparent in the boys (5 (2.6)) than the girls (3.4 (1.8)) and related to overreactive rather than underreactive behaviour. At both ages prepsychotic (affective) children differed little from normal controls. By the age of 11 preneurotic children, particularly the girls, had an increased rating of maladjustment (including overreactions and underreactions). Conclusion-Abnormalities of social adjustment are detectable in childhood in some people who develop psychotic illness. Sex and the rate of development of different components of the capacity for social interaction are important determinants of the risk of psychosis and other psychiatric disorders in adulthood.	CLIN RES CTR,DIV PSYCHIAT,HARROW HA1 3UJ,MIDDX,ENGLAND; ROYAL EDINBURGH & ASSOCIATED HOSP,DEPT PSYCHIAT,EDINBURGH EH10 5HF,SCOTLAND	Royal Infirmary of Edinburgh	DONE, DJ (corresponding author), UNIV HERTFORDSHIRE,DEPT PSYCHOL,HATFIELD AL10 9AB,HERTS,ENGLAND.		crow, timothy J/M-8327-2014	crow, timothy J/0000-0002-5482-6655; Sacker, Amanda/0000-0001-8796-5398				AMBELAS A, 1992, BRIT J PSYCHIAT, V160, P401, DOI 10.1192/bjp.160.3.401; CANNONSPOOR HE, 1982, SCHIZOPHRENIA BULL, V8, P470, DOI 10.1093/schbul/8.3.470; DONE DJ, 1991, BRIT MED J, V302, P1576, DOI 10.1136/bmj.302.6792.1576; Gotlib IH., 1992, PSYCHOL ASPECTS DEPR; HARTMANN E, 1984, ARCH GEN PSYCHIAT, V41, P1050; LANE EA, 1965, AM J ORTHOPSYCHIAT, V35, P747, DOI 10.1111/j.1939-0025.1965.tb00447.x; MCCREADIE RG, 1982, BRIT J PSYCHIAT, V140, P582, DOI 10.1192/bjp.140.6.582; OFFORD DR, 1974, BRIT J PSYCHIAT, V125, P12, DOI 10.1192/bjp.125.1.12; RUTTER ML, RISK PROTECTIVE FACT, P181; Stott GH, 1987, SOCIAL ADJUSTMENT CH; Tabachnick B.G., 2019, USING MULTIVARIATE S, V7th; WATT NF, 1978, ARCH GEN PSYCHIAT, V35, P160; WATT NF, 1970, AM J ORTHOPSYCHIAT, V40, P637, DOI 10.1111/j.1939-0025.1970.tb00721.x; Wing JK, 1974, DESCRIPTION CLASSIFI; 1960, CLASSIFICATION OCCUP; 1986, USERS GUIDE SPSSX RE; [No title captured]	17	377	380	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					699	703		10.1136/bmj.309.6956.699	http://dx.doi.org/10.1136/bmj.309.6956.699			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PH407	7950522	Green Published, Green Submitted			2022-12-28	WOS:A1994PH40700015
J	ANDREASEN, NC; FLASHMAN, L; FLAUM, M; ARNDT, S; SWAYZE, V; OLEARY, DS; EHRHARDT, JC; YUH, WTC				ANDREASEN, NC; FLASHMAN, L; FLAUM, M; ARNDT, S; SWAYZE, V; OLEARY, DS; EHRHARDT, JC; YUH, WTC			REGIONAL BRAIN ABNORMALITIES IN SCHIZOPHRENIA MEASURED WITH MAGNETIC-RESONANCE-IMAGING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBRAL BLOOD-FLOW; DORSOLATERAL PREFRONTAL CORTEX; TEMPORAL-LOBE; STRUCTURAL ABNORMALITIES; PHYSIOLOGIC DYSFUNCTION; COMPUTED-TOMOGRAPHY; NEGATIVE SYMPTOMS; MONOZYGOTIC TWINS; CORPUS-CALLOSUM; DISORDER	Objective.-To determine general and regional indices of structural brain abnormality in schizophrenia. Design.-Case-control comparison study. Subjects.-Fifty-two patients diagnosed as having schizophrenia according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, were compared with 90 healthy volunteers recruited from the community. Measurements.-Structural brain images were acquired using magnetic resonance; measurements were obtained using three-dimensional visualization of volume-rendered brains and an automated atlas-based dissection of specific regions. General measures included the volume of total brain tissue, total cerebrospinal fluid (CSF), and CSF within the ventricular system. Regional measures included the volume of tissue and CSF in the frontal; temporal, parietal, and occipital lobes and the cerebellum. Results.-Compared with the controls, the patients had a smaller average volume of total brain tissue and a greater average volume of total and ventricular CSF. A specific relative decrease in brain tissue was found only in the frontal lobes, although the volume of CSF was greater in patients than in controls in all brain regions. Conclusion.-In addition to the generalized brain abnormalities observed in schizophrenia, a regional abnormality may be present in frontal regions. Since the frontal lobes integrate multimodality information and perform a variety of ''higher'' cognitive and emotional functions that are impaired in schizophrenia, the frontal abnormality noted is consistent with the clinical presentation of the illness. Impaired frontal function and a disruption in its complex circuitry (including thalamocortical projections) may explain why patients with schizophrenia often have significant deficits in formulating concepts and organizing their thinking and behavior.	UNIV IOWA HOSP & CLIN, DEPT RADIOL, IOWA CITY, IA 52242 USA	University of Iowa	ANDREASEN, NC (corresponding author), UNIV IOWA HOSP & CLIN, MENTAL HLTH CLIN RES CTR, DEPT PSYCHIAT, 200 HAWKINS DR, 2911 JPP, IOWA CITY, IA 52242 USA.		Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204; O'Leary, Daniel/0000-0003-1959-6521; Swayze, Victor/0000-0002-6434-3606	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH031593, R37MH031593, P50MH043271, P30MH043271, R01MH040856] Funding Source: NIH RePORTER; NIMH NIH HHS [MHCRC 43271, MH40856, MH31593] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDREASEN N, 1986, ARCH GEN PSYCHIAT, V43, P136; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P615; ANDREASEN NC, 1994, P NATL ACAD SCI USA, V91, P93, DOI 10.1073/pnas.91.1.93; ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125; ANDREASEN NC, 1994, SCIENCE, V266, P294, DOI 10.1126/science.7939669; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; ANDREASEN NC, 1993, J NEUROPSYCH CLIN N, V5, P121; ANDREASEN NC, 1990, ARCH GEN PSYCHIAT, V47, P35; ANDREASEN NC, 1988, SCIENCE, V239, P1381, DOI 10.1126/science.3279509; ANDREASEN NC, 1994, AUTOMATED ATLAS BASE; Arndt S, 1994, Neuroimage, V1, P191, DOI 10.1006/nimg.1994.1004; ARNDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; BARTA PE, 1990, AM J PSYCHIAT, V147, P1457; Becker T, 1990, Eur Neuropsychopharmacol, V1, P83, DOI 10.1016/0924-977X(90)90018-6; BERMAN KF, 1986, ARCH GEN PSYCHIAT, V43, P126; BLEUJER E, 1950, DEMENTIA PRAECOX GRO; BOGERTS B, 1993, SCHIZOPHRENIA BULL, V19, P431, DOI 10.1093/schbul/19.2.431; BOGERTS B, 1990, PSYCHIAT RES-NEUROIM, V35, P1; BUCHSBAUM MS, 1990, SCHIZOPHRENIA BULL, V16, P379, DOI 10.1093/schbul/16.3.379; BUCHSBAUM MS, 1984, ARCH GEN PSYCHIAT, V41, P1159; BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P935; CIZADLO T, 1994, SPIE INT SOC OPTICAL, V2168, P423; CLEGHORN JM, 1989, PSYCHIAT RES, V28, P119, DOI 10.1016/0165-1781(89)90040-1; COHEN G, 1992, PSYCHIAT RES-NEUROIM, V45, P33, DOI 10.1016/0925-4927(92)90012-S; DEGREEF G, 1992, AM J NEURORADIOL, V13, P835; DEGREEF G, 1992, ARCH GEN PSYCHIAT, V49, P531; DELISI LE, 1988, SCHIZOPHRENIA BULL, V14, P185, DOI 10.1093/schbul/14.2.185; DELISI LE, 1991, BIOL PSYCHIAT, V29, P159, DOI 10.1016/0006-3223(91)90044-M; DELISI LE, 1989, COMPR PSYCHIAT, V30, P197, DOI 10.1016/0010-440X(89)90038-2; DEMYER MK, 1988, SCHIZOPHRENIA BULL, V14, P21, DOI 10.1093/schbul/14.1.21; DEVOUS MD, 1985, J CEREB BLOOD FLO S1, V5, pS201; FEINBERG I, 1983, J PSYCHIAT RES, V17, P319, DOI 10.1016/0022-3956(82)90038-3; FLAUM M, 1990, AM J PSYCHIAT, V147, P1327; FLAUM M, IN PRESS AM J PSYCHI; FRANZEN G, 1975, J PSYCHIAT RES, V12, P199, DOI 10.1016/0022-3956(75)90027-8; Fuster J.M., 1989, PREFRONTAL CORTEX; GOLDMANRAKIC PS, 1990, PROG BRAIN RES, V85, P325; GUR RE, 1993, SCHIZOPHRENIA BULL, V19, P337, DOI 10.1093/schbul/19.2.337; GUR RE, 1994, AM J PSYCHIAT, V151, P343; GUR RE, 1991, ARCH GEN PSYCHIAT, V48, P407; HOFF AL, 1992, SCHIZOPHRENIA BULL, V18, P257, DOI 10.1093/schbul/18.2.257; JERNIGAN TL, 1991, ARCH GEN PSYCHIAT, V48, P881; KELSOE JR, 1988, ARCH GEN PSYCHIAT, V45, P533; KLEIST K, 1960, J MENT SCI, V106, P246, DOI 10.1192/bjp.106.442.246; Kraepelin E., 1919, CUTTING SHEPHERD; LIDDLE PF, 1990, BRIT J PSYCHIAT, V157, P558, DOI 10.1192/bjp.157.4.558; MCNEIL TF, 1993, BRIT J PSYCHIAT, V162, P517, DOI 10.1192/bjp.162.4.517; NASRALLAH HA, 1986, BIOL PSYCHIAT, V21, P274, DOI 10.1016/0006-3223(86)90048-X; NYBACK H, 1982, ACTA PSYCHIAT SCAND, V65, P403, DOI 10.1111/j.1600-0447.1982.tb00864.x; PEARLSON GD, 1993, AM PSYCHIATRIC PRESS, V12, P347; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; PFEFFERBAUM A, 1990, SCHIZOPHRENIA BULL, V16, P453, DOI 10.1093/schbul/16.3.453; PFEFFERBAUM A, 1991, SCHIZOPHR RES, V4, P193, DOI 10.1016/0920-9964(91)90033-N; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; ROSSI A, 1990, BIOL PSYCHIAT, V27, P61, DOI 10.1016/0006-3223(90)90020-3; RUBIN P, 1991, ARCH GEN PSYCHIAT, V48, P987; SCHULZ SC, 1983, AM J PSYCHIAT, V140, P1592; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; SUDDATH RL, 1989, AM J PSYCHIAT, V146, P464; SWAYZE VW, 1990, ARCH GEN PSYCHIAT, V47, P1054; SWAYZE VW, 1990, ARCH NEUROL-CHICAGO, V47, P805, DOI 10.1001/archneur.1990.00530070103018; Talairach J., 1988, COPLANAR STEREOTAXIC; TURNER SW, 1986, PSYCHOL MED, V16, P219, DOI 10.1017/S003329170000266X; VOLKOW ND, 1986, J NEUROL NEUROSUR PS, V49, P1199, DOI 10.1136/jnnp.49.10.1199; WEINBERGER DR, 1992, AM J PSYCHIAT, V149, P890; WEINBERGER DR, 1982, ARCH GEN PSYCHIAT, V39, P778; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WILLIAMSON P, 1991, BRIT J PSYCHIAT, V159, P130, DOI 10.1192/bjp.159.1.130; WOLKIN A, 1992, ARCH GEN PSYCHIAT, V49, P959; WOOD FB, 1990, SCHIZOPHRENIA BULL, V16, P413, DOI 10.1093/schbul/16.3.413; ZIPURSKY RB, 1992, ARCH GEN PSYCHIAT, V49, P195; 1987, DIAGNOSTIC STATISTIC	73	273	280	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1763	1769		10.1001/jama.272.22.1763	http://dx.doi.org/10.1001/jama.272.22.1763			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV815	7966925				2022-12-28	WOS:A1994PV81500026
J	WEBER, BL				WEBER, BL			SUSCEPTIBILITY GENES FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											WEBER, BL (corresponding author), UNIV PENN,MED CTR,PHILADELPHIA,PA 19104, USA.							EASTON DF, 1993, AM J HUM GENET, V52, P678; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	5	19	19	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1523	1524		10.1056/NEJM199412013312214	http://dx.doi.org/10.1056/NEJM199412013312214			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969307				2022-12-28	WOS:A1994PU86600014
J	TAGLIAVINI, F; PRELLI, F; PORRO, M; ROSSI, G; GIACCONE, G; FARLOW, MR; DLOUHY, SR; GHETTI, B; BUGIANI, O; FRANGIONE, B				TAGLIAVINI, F; PRELLI, F; PORRO, M; ROSSI, G; GIACCONE, G; FARLOW, MR; DLOUHY, SR; GHETTI, B; BUGIANI, O; FRANGIONE, B			AMYLOID FIBRILS IN GERSTMANN-STRAUSSLER-SCHEINKER DISEASE (INDIANA AND SWEDISH KINDREDS) EXPRESS ONLY PRP PEPTIDES ENCODED BY THE MUTANT ALLELE	CELL			English	Article							CREUTZFELDT-JAKOB DISEASE; HEREDITARY CEREBRAL-HEMORRHAGE; PROTEIN MISSENSE VARIANT; PRION PROTEIN; NEUROFIBRILLARY TANGLES; SPONGIFORM ENCEPHALOPATHIES; ALZHEIMERS-DISEASE; DUTCH TYPE; PLAQUES; SCRAPIE	Gerstmann-Straussler-Scheinker (GSS) disease is a cerebral amyloidosis linked to mutations of the PRNP gene. We previously reported that the amyloid protein in the Indiana kindred of GSS is an internal fragment of prion protein (PrP). To investigate whether this fragment originates only from mutant or from both mutant and wild-type PrP, we have characterized amyloid proteins purified from patients of the Indiana and Swedish GSS families. These patients were heterozygous for the Met-Val polymorphism at PRNP codon 129 and carried a mutation at PRNP codon 198 (Phe-->Ser) and codon 217 (Gln-->Arg), respectively. The smallest amyloid subunit was a 7 kDa peptide spanning residues similar to 81 to similar to 150 in the Indiana patient and similar to 81 to similar to 146 in the Swedish patient. In both patients, only Val was present at position 129. Since Val-129 was in coupling phase with Ser-198 and Arg-217, our findings indicate that only the mutant PrP is involved in amyloid formation in both kindreds.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; INDIANA UNIV,SCH MED,DEPT MED & MOLEC GENET,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PATHOL & LAB MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT NEUROL,INDIANAPOLIS,IN 46202	New York University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	TAGLIAVINI, F (corresponding author), IST NAZL NEUROL CARLO BESTA,VIA CELORIA 11,I-20133 MILAN,ITALY.		Tagliavini, Fabrizio/AAO-7891-2021; giaccone, giorgio/AAB-9978-2019; Giaccone, Giorgio/J-6212-2012; Rossi, Giacomina/I-2783-2012	Tagliavini, Fabrizio/0000-0003-1039-7315; giaccone, giorgio/0000-0002-4803-0802; Rossi, Giacomina/0000-0001-6680-2725	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030455, R01NS029822] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30455, NS29822] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BROWN P, 1992, REV NEUROL, V148, P317; BUGIANI O, 1993, J NEUROPATH EXP NEUR, V52, P64, DOI 10.1097/00005072-199301000-00008; Castano EM, 1991, BRAIN PATHOL, V1, P263, DOI 10.1111/j.1750-3639.1991.tb00669.x; DEGLOIA L, 1994, J BIOL CHEM, V269, P7859; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; FARLOW MR, 1991, HDB CLIN NEUROLOGY H, V16, P619; FORLONI G, 1994, EUR J NEUROSCI, V6, P1415, DOI 10.1111/j.1460-9568.1994.tb01003.x; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GAJDUSEK DC, 1990, VIROLOGY, P2289; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Gerstmann J., 1936, Z NEUROL, V154, P736, DOI [10.1007/BF02865827, DOI 10.1007/BF02865827]; GHETTI B, 1989, NEUROLOGY, V39, P1453, DOI 10.1212/WNL.39.11.1453; GHETTI B, 1994, MOL NEUROBIOL, V8, P41, DOI 10.1007/BF02778006; GHETTI B, 1992, PRION DISEASES HUMAN, P153; GHISO J, 1990, BIOCHEM J, V272, P827, DOI 10.1042/bj2720827; GIACCONE G, 1992, P NATL ACAD SCI USA, V89, P9349, DOI 10.1073/pnas.89.19.9349; GIACCONE G, 1990, BRAIN RES, V530, P325, DOI 10.1016/0006-8993(90)91304-Y; GOLDFARB LG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91198-4; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; GOREVIC PD, 1989, J CLIN INVEST, V83, P836, DOI 10.1172/JCI113966; HOUGHTEN RA, 1983, METHOD ENZYMOL, V91, P549; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1992, NAT GENET, V1, P68, DOI 10.1038/ng0492-68; HSIAO KK, 1991, NEUROLOGY, V41, P681, DOI 10.1212/WNL.41.5.681; IKEDA S, 1992, NEURODEGENERATION, V1, P281; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KITAMOTO T, 1991, NEUROLOGY, V41, P306, DOI 10.1212/WNL.41.2_Part_1.306; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V191, P709, DOI 10.1006/bbrc.1993.1275; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V192, P525, DOI 10.1006/bbrc.1993.1447; KITAMOTO T, 1986, ANN NEUROL, V57, P230; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; PRAS M, 1981, J EXP MED, V154, P989, DOI 10.1084/jem.154.3.989; PRELLI F, 1987, BIOCHEMISTRY-US, V26, P8251, DOI 10.1021/bi00399a035; PRELLI F, 1990, BIOCHEM BIOPH RES CO, V170, P301, DOI 10.1016/0006-291X(90)91274-V; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12277, DOI 10.1021/bi00164a001; ROGERS M, 1991, J IMMUNOL, V147, P3568; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; TAGLIAVINI F, 1993, BRAIN RES, V616, P325, DOI 10.1016/0006-8993(93)90226-D; TATEISHI J, 1988, ANN NEUROL, V24, P35, DOI 10.1002/ana.410240108; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I	51	137	139	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					695	703		10.1016/0092-8674(94)90554-1	http://dx.doi.org/10.1016/0092-8674(94)90554-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954833				2022-12-28	WOS:A1994PT48100016
J	HIRANO, T; MITCHISON, TJ				HIRANO, T; MITCHISON, TJ			A HETERODIMERIC COILED-COIL PROTEIN REQUIRED FOR MITOTIC CHROMOSOME CONDENSATION IN-VITRO	CELL			English	Article							TOPOISOMERASE-II; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; METAPHASE CHROMOSOMES; DNA TOPOISOMERASES; DROSOPHILA EMBRYO; EXTRACTS; INVITRO; CHROMATIN; PURIFICATION	We report here a chromosomal protein that plays an essential role in mitotic chromosome condensation in Xenopus egg extracts. Two polypeptides, designated XCAP-C and XCAP-E, were found to associate with each other in the extracts, presumably forming a heterodimer. During chromosome assembly in mitotic extracts, XCAP-C/E was recruited to the chromatin and formed a discrete internal structure within assembled chromosomes. Antibody blocking experiments showed that XCAP-C function is required for both assembly and structural maintenance of mitotic chromosomes in vitro. Deduced amino acid sequences revealed that the two polypeptides share common structural motifs, consisting of an N-terminal NTP-binding domain, two central coiled-coil regions, and a C-terminal conserved domain. These motifs are highly conserved in a protein family, members of which have been identified recently in both prokaryotes and eukaryotes.			HIRANO, T (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143, USA.		Hirano, Tatsuya/F-6008-2011	Hirano, Tatsuya/0000-0002-4219-6473				ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BELMONT AS, 1989, CHROMOSOMA, V98, P129, DOI 10.1007/BF00291049; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; Earnshaw WC, 1991, CURR OPIN STRUC BIOL, V1, P237, DOI 10.1016/0959-440X(91)90068-5; GASSER SM, 1987, EXP CELL RES, V173, P85, DOI 10.1016/0014-4827(87)90334-X; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HADLACZKY G, 1981, CHROMOSOMA, V81, P557, DOI 10.1007/BF00285849; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; Kreis T., 1993, GUIDEBOOK CYTOSKELET; LAEMMLI UK, 1978, COLD SPRING HARB SYM, V42, P351; LARIONOV VL, 1985, CURR GENET, V10, P15, DOI 10.1007/BF00418488; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NOTARNICOLA SM, 1991, GENE, V97, P77, DOI 10.1016/0378-1119(91)90012-Z; OHNUKI Y, 1968, CHROMOSOMA, V25, P402, DOI 10.1007/BF02327721; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; PAULSON JR, 1989, CHROMOSOMA, V97, P289, DOI 10.1007/BF00371968; RATTNER JB, 1985, CELL, V42, P291, DOI 10.1016/S0092-8674(85)80124-0; SAITOH N, 1994, IN PRESS J CELL BIOL; SAKA Y, 1994, IN PRESS EMBO J; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHIRAHIGE K, 1993, MOL CELL BIOL, V13, P5043, DOI 10.1128/MCB.13.8.5043; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	36	425	440	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					449	458		10.1016/0092-8674(94)90254-2	http://dx.doi.org/10.1016/0092-8674(94)90254-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954811				2022-12-28	WOS:A1994PQ48800008
J	LU, DS; WILLARD, D; PATEL, IR; KADWELL, S; OVERTON, L; KOST, T; LUTHER, M; CHEN, WB; WOYCHIK, RP; WILKISON, WO; CONE, RD				LU, DS; WILLARD, D; PATEL, IR; KADWELL, S; OVERTON, L; KOST, T; LUTHER, M; CHEN, WB; WOYCHIK, RP; WILKISON, WO; CONE, RD			AGOUTI PROTEIN IS AN ANTAGONIST OF THE MELANOCYTE-STIMULATING-HORMONE RECEPTOR	NATURE			English	Article							MOLECULAR-CLONING; MELANOCORTIN RECEPTOR; EXPRESSION; LOCUS; ASSAY; CELLS; MICE	THE genetic loci agouti and extension control the relative amounts of eumelanin (brown-black) and phaeomelanin (yellow-red) pigments in mammals(1): extension encodes the receptor for melanocyte-stimulating hormone (MSH)(2) and agouti encodes a novel 131-amino-acid protein containing a signal sequence(3,4). Agouti, which is produced in the hair follicle(5), acts on follicular melanocytes(6) to inhibit alpha-MSH-induced eumelanin production, resulting in the subterminal band of phaeomelanin often visible in mammalian fur. Here we use partially purified agouti protein to demonstrate that agouti is a high-affinity antagonist of the MSH receptor and blocks alpha-MSH stimulation of adenylyl cyclase, the effector through which alpha-MSH induces eumelanin synthesis, Agouti was also found to be an antagonist of the melanocortin-4 receptor(7,8), a related MSH-binding receptor. Consequently, the obesity caused by ectopic expression of agouti in the lethal yellow (A(y)) mouse(9) may be due to the inhibition of melanocortin reteptor(s) outside the hair follicle.	GLAXO INC, RES INST, DIV MOLEC SCI, RES TRIANGLE PK, NC 27709 USA; OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA; OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA	GlaxoSmithKline; Oregon Health & Science University; United States Department of Energy (DOE); Oak Ridge National Laboratory			Woychik, Richard P/C-8345-2019; Chen, Wenbiao/ABG-1276-2020	Woychik, Richard P/0000-0001-8196-1732; Chen, Wenbiao/0000-0002-0750-8275				BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; CONKLIN BR, 1993, NATURE, V364, P110, DOI 10.1038/364110b0; DESARNAUD F, 1994, BIOCHEM J, V299, P367, DOI 10.1042/bj2990367; DICKERSON GE, 1947, SCIENCE, V105, P496, DOI 10.1126/science.105.2732.496-a; FRAZIER AL, 1990, MOL ENDOCRINOL, V4, P1264, DOI 10.1210/mend-4-8-1264; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANZ I, 1993, J BIOL CHEM, V268, P8246; JACKSON IJ, 1993, NATURE, V362, P587, DOI 10.1038/362587a0; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KWON HY, IN PRESS P NATN ACAD; LAMOREUX ML, 1975, DEV BIOL, V46, P160, DOI 10.1016/0012-1606(75)90094-9; Little C., 1957, INHERITANCE COAT COL; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Mountjoy K.G., 1992, SCIENCE, V257, P543; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; RAINEY WE, 1989, J BIOL CHEM, V264, P21474; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SIEGRIST W, 1988, J RECEPTOR RES, V8, P323, DOI 10.3109/10799898809048996; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SUMMERS MD, 1987, TEXAS AGR EXP ST B, V1555	25	892	937	4	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	1994	371	6500					799	802		10.1038/371799a0	http://dx.doi.org/10.1038/371799a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935841				2022-12-28	WOS:A1994PP01800060
J	ELLIOTT, MJ; MAINI, RN; FELDMANN, M; KALDEN, JR; ANTONI, C; SMOLEN, JS; LEEB, B; BREEDVELD, FC; MACFARLANE, JD; BIJL, H; WOODY, JN				ELLIOTT, MJ; MAINI, RN; FELDMANN, M; KALDEN, JR; ANTONI, C; SMOLEN, JS; LEEB, B; BREEDVELD, FC; MACFARLANE, JD; BIJL, H; WOODY, JN			RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS	LANCET			English	Article							DISEASE; MICE	Tumour necrosis factor a (TNF alpha) is a critical inflammatory mediator in rheumatoid arthritis, and may therefore be a useful target for specific immunotherapy. In support of this hypothesis, we previously observed beneficial responses in patients with active rheumatoid arthritis after open-label administration of a chimeric monoclonal antibody to TNF alpha (cA2). We now report the results of a four-centre, randomised double-blind trial of a single infusion of 1 or 10 mg/kg cA2 compared with placebo in 73 patients with active rheumatoid arthritis. The primary endpoint of the study was the achievement at week 4 of a Paulus 20% response, an amalgam of six clinical, observational, and laboratory variables. Intention-to-treat analysis of data from individual patients showed only 2 of 24 placebo recipients responding at this time, compared with 11 of 25 patients treated with low-dose cA2 (p=0.0083) and 19 of 24 patients treated with high-dose cA2 (p<0.0001). Over half of the high-dose cA2 patients responded by the more stringent 50% Paulus criteria at this time (p=0.0005). The magnitude of these responses was impressive, with maximum mean improvements in individual disease-activity assessments, such as tender or swollen-joint counts and in serum C-reactive protein, exceeding 60% for patients on high-dose treatment. There were two severe adverse events. 1 patient on 1 mg/kg cA2 developed pneumonia (''possibly'' treatment-related) and 1 on 10 mg/kg had a fracture (''probably not'' treatment-related). The results provide the first good evidence that specific cytokine blockade can be effective in human inflammatory disease and define a new direction for the treatment of rheumatoid arthritis.	KENNEDY INST,LONDON W6 7DW,ENGLAND; CHARING CROSS & WESTMINSTER MED SCH,ACAD DEPT RHEUMATOL,LONDON,ENGLAND; INST CLIN IMMUNOL & RHEUMATOL,DEPT INTERNAL MED 3,ERLANGEN,GERMANY; HOSP LAINZ,DEPT MED 2,CTR RHEUMAT DIS,VIENNA,AUSTRIA; LUDWIG BOLTZMANN INST RHEUMATOL,VIENNA,AUSTRIA; LEIDEN UNIV HOSP,DEPT RHEUMATOL,LEIDEN,NETHERLANDS; CENTOCOR INC,MALVERN,PA 19355	University of Oxford; Imperial College London; University of Erlangen Nuremberg; Ludwig Boltzmann Institute; Leiden University; Leiden University Medical Center (LUMC); Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc			Leeb, Burkhard F./AAD-9985-2020					ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BRENNAN FM, 1989, LANCET, V2, P244; BROOKS PM, 1993, LANCET, V341, P286, DOI 10.1016/0140-6736(93)92628-7; COPE AP, 1994, J CLIN INVEST, V94, P749, DOI 10.1172/JCI117394; DERKX B, 1993, LANCET, V342, P173, DOI 10.1016/0140-6736(93)91375-V; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; ELLIOTT MJ, 1994, INT ARCH ALLERGY IMM, V104, P112, DOI 10.1159/000236718; FELDMANN M, 1993, TUMOR NECROSIS FACTOR : MOLECULAR AND CELLULAR BIOLOGY AND CLINICAL RELEVANCE, P144; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; HAVELL EA, 1989, J IMMUNOL, V143, P2894; HAWORTH C, 1991, EUR J IMMUNOL, V21, P2575, DOI 10.1002/eji.1830211039; JOHNSON RA, 1989, BLOOD, V74, P130; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; MAINI RN, 1993, CLIN EXP RHEUMATOL, V11, pS173; MORELAND L, 1993, ARTHRITIS RHEUM, V36, pS39; PAULUS HE, 1990, ARTHRITIS RHEUM, V33, P477, DOI 10.1002/art.1780330403; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; ROODMAN GD, 1987, BLOOD CELLS, V13, P171; SEWELL KL, 1993, ARTHRITIS RHEUM-US, V36, P1223, DOI 10.1002/art.1780360907; SMOLEN JS, 1994, RHEUMATOL EUR, V23, P37; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; THORBECKE GJ, 1992, P NATL ACAD SCI USA, V89, P7375, DOI 10.1073/pnas.89.16.7375; VANDERLUBBE PA, IN PRESS ARTHRITIS R; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784	25	1502	1617	1	47	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1105	1110		10.1016/S0140-6736(94)90628-9	http://dx.doi.org/10.1016/S0140-6736(94)90628-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934491				2022-12-28	WOS:A1994PN06600007
J	SCHMEICHEL, KL; BECKERLE, MC				SCHMEICHEL, KL; BECKERLE, MC			THE LIM DOMAIN IS A MODULAR PROTEIN-BINDING INTERFACE	CELL			English	Article							INSULIN GENE; MOTIF; IDENTIFICATION; DIMERIZATION; HOMEODOMAIN; REGULATORS; ZYXIN	LIM domains are zinc-binding protein sequences that are found in a growing number of proteins, including certain transcriptional regulators, proto-oncogene products, and adhesion plaque constituents. Here we define the biological activity of the LIM domain through studies of an adhesion plaque protein called zyxin that displays three C-terminal LIM domains. We have used our ability to reconstitute complexes between zyxin and its two known binding partners, alpha-actinin and the cysteine-rich protein (CRP), to examine the involvement of LIM domains in protein-protein interactions. We have determined that one of the three LIM domains of zyxin is necessary and sufficient to support the association of zyxin with CRP. Our findings demonstrate that the LIM domain functions as a specific protein-binding interface.			SCHMEICHEL, KL (corresponding author), UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112, USA.				NCI NIH HHS [CA42014, CA09602] Funding Source: Medline; NIGMS NIH HHS [GM50877, R01 GM050877] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014, T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050877] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOEHM T, 1990, ONCOGENE, V5, P1103; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	31	427	438	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					211	219		10.1016/0092-8674(94)90191-0	http://dx.doi.org/10.1016/0092-8674(94)90191-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954790				2022-12-28	WOS:A1994PN63000006
J	BOSHOFF, C; RUSTIN, G; BEGENT, R; OLIVER, T; NEWLANDS, E; HOLDEN, L; ONG, J				BOSHOFF, C; RUSTIN, G; BEGENT, R; OLIVER, T; NEWLANDS, E; HOLDEN, L; ONG, J			TREATMENT OF GOOD-RISK, STAGE-II, NONSEMINOMATOUS TESTIS CANCER	LANCET			English	Letter									CHARING CROSS HOSP,DEPT MED ONCOL,LONDON W6 8RF,ENGLAND; ROYAL FREE HOSP,ACAD DEPT ONCOL,LONDON NW3 2QG,ENGLAND	Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	BOSHOFF, C (corresponding author), UNIV LONDON LONDON HOSP,DEPT MED ONCOL,LONDON E1 2AD,ENGLAND.		Rustin, Gordon J. S./J-9763-2019					BOSHOFF C, 1994, P ASCO; HORWICH A, 1994, J UROLOGY, V151, P72, DOI 10.1016/S0022-5347(17)34874-7; OSTERLIND A, 1991, J NATL CANCER I, V83, P1391, DOI 10.1093/jnci/83.19.1391; RUSTIN GJS, 1983, NEW ENGL J MED, V308, P473, DOI 10.1056/NEJM198303033080901; SHAMBERGER RC, 1981, CANCER TREAT REP, V65, P739	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1085	1086		10.1016/S0140-6736(94)91740-X	http://dx.doi.org/10.1016/S0140-6736(94)91740-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934464				2022-12-28	WOS:A1994PL85200042
J	CARDON, LR; SMITH, SD; FULKER, DW; KIMBERLING, WJ; PENNINGTON, BF; DEFRIES, JC				CARDON, LR; SMITH, SD; FULKER, DW; KIMBERLING, WJ; PENNINGTON, BF; DEFRIES, JC			QUANTITATIVE TRAIT LOCUS FOR READING-DISABILITY ON CHROMOSOME-6	SCIENCE			English	Article							MULTIPLE-REGRESSION ANALYSIS; DEVELOPMENTAL DYSLEXIA; IMMUNE DISORDERS; LINKAGE ANALYSIS; LEFT-HANDEDNESS; TWIN DATA; ETIOLOGY	Interval mapping of data from two independent samples of sib pairs, at least one member of whom was reading disabled, revealed evidence for a quantitative trait locus (QTL) on chromosome 6. Results obtained from analyses of reading performance from 114 sib pairs genotyped for DNA markers localized the QTL to 6p21.3. Analyses of corresponding data from an independent sample of 50 dizygotic twin pairs provided evidence for linkage to the same region. In combination, the replicate samples yielded a chi(2) value of 16.73 (P = 0.0002). Examination of twin and kindred siblings with more extreme deficits in reading performance yielded even stronger evidence for a QTL (chi(2) = 27.35, P < 0.00001). The position of the QTL was narrowly defined with a 100:1 confidence interval to a 2-centimorgan region within the human leukocyte antigen complex.	SRI INT,HLTH SCI PROGRAM,MENLO PK,CA 94025; STANFORD UNIV,DEPT MATH,STANFORD,CA 94305; BOYS TOWN NATL RES HOSP,CTR HEREDITARY COMMUN DISORDERS,OMAHA,NE 68131; UNIV COLORADO,INST BEHAV GENET,BOULDER,CO 80309; UNIV DENVER,DEPT PSYCHOL,DENVER,CO 80208	SRI International; Stanford University; Boys Town National Research Hospital; University of Colorado System; University of Colorado Boulder; University of Denver					NHGRI NIH HHS [HG-00085] Funding Source: Medline; NICHD NIH HHS [HD-11681, HD-27802] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P50HD027802] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD011681] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [F32HG000085] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BROWN BS, 1978, DYSLEXIA APPRAISAL C, pR5; CARDON LR, 1994, AM J HUM GENET, V55, P825; CAREY G, 1991, AM J HUM GENET, V49, P786; DEFRIES JC, 1988, ACTA GENET MED GEMEL, V37, P205, DOI 10.1017/S0001566000003810; DEFRIES JC, 1987, NATURE, V329, P537, DOI 10.1038/329537a0; DEFRIES JC, 1985, BEHAV GENET, V15, P467, DOI 10.1007/BF01066239; DEFRIES JC, 1991, READING BRAIN BIOL B, P53; DEFRIES JC, 1993, NATURE NURTURE PSYCH, P121; Dunn LM, 1970, EXPANDED MANUAL PEAB; FROSTER U, 1993, LANCET, V342, P178, DOI 10.1016/0140-6736(93)91385-Y; FULKER DW, 1991, READ WRIT, V3, P299, DOI 10.1007/BF00354964; FULKER DW, 1994, AM J HUM GENET, V54, P1092; GESCHWIND N, 1982, P NATL ACAD SCI-BIOL, V79, P5097, DOI 10.1073/pnas.79.16.5097; GILGER JW, 1992, NEUROPSYCHOLOGIA, V30, P209, DOI 10.1016/0028-3932(92)90001-3; HALEY CS, 1992, HEREDITY, V69, P315, DOI 10.1038/hdy.1992.131; HANSEN O, 1986, HEREDITAS, V105, P165, DOI 10.1111/j.1601-5223.1986.tb00656.x; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; HUGDAHL K, 1990, NEUROPSYCHOLOGIA, V28, P673, DOI 10.1016/0028-3932(90)90122-5; HUGDAHL K, 1988, PSYCHONEUROENDOCRINO, V13, P1; LANDER ES, 1989, GENETICS, V121, P185; PENNINGTON BF, 1987, ARCH NEUROL-CHICAGO, V44, P634, DOI 10.1001/archneur.1987.00520180054016; PENNINGTON BF, 1991, JAMA-J AM MED ASSOC, V266, P1527, DOI 10.1001/jama.266.11.1527; PENNINGTON BF, 1990, J CHILD PSYCHOL PSYC, V31, P193, DOI 10.1111/j.1469-7610.1990.tb01561.x; PLOMIN R, 1994, BEHAV GENET, V24, P107, DOI 10.1007/BF01067815; RABIN M, 1993, LANCET, V342, P178, DOI 10.1016/0140-6736(93)91384-X; SMITH SD, 1990, J AM ACAD CHILD PSY, V29, P204, DOI 10.1097/00004583-199003000-00008; SMITH SD, 1983, SCIENCE, V219, P1345, DOI 10.1126/science.6828864; SMITH SD, 1991, READING DISABILITIES; URION DK, 1988, ANN NEUROL, V24, P267, DOI 10.1002/ana.410240215	29	437	444	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					276	279		10.1126/science.7939663	http://dx.doi.org/10.1126/science.7939663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PM134	7939663				2022-12-28	WOS:A1994PM13400034
J	KAMIYA, H; ZUCKER, RS				KAMIYA, H; ZUCKER, RS			RESIDUAL CA2+ AND SHORT-TERM SYNAPTIC PLASTICITY	NATURE			English	Article							FROG NEUROMUSCULAR-JUNCTION; SQUID GIANT SYNAPSE; TRANSMITTER RELEASE; POSTTETANIC POTENTIATION; CALCIUM CHELATORS; INTRACELLULAR CALCIUM; NERVE-TERMINALS; DM-NITROPHEN; FACILITATION; CA-2+	AT many synapses, the amount of transmitter released by action potentials increases progressively during a train of spikes. This enhancement of evoked transmitter release grows during tetanic stimulation with several time constants, each bearing a different name (facilitation: tens to hundreds of milliseconds; augmentation: several seconds; potentiation: several minutes), and the enhancement of release to test spikes after a tetanus decays with similar time constants. All these processes depend on presynaptic Ca2+ influx during the conditioning tetanus(1). It has often been proposed that these forms of synaptic plasticity are due to residual Ca2+ present in nerve terminals following conditioning activity(2). We tested this idea directly by using photolabile Ca2+ chelators to reduce residual Ca2+ following conditioning stimulation or to generate an artificial elevation in Ca2+ concentration, and observed the effects on synaptic transmission at crayfish neuromuscular junctions. We found that facilitation, augmentation and potentiation are caused by the continuing action of residual Ca2+. Augmentation and potentiation seem to arise from Ca2+ acting at a separate site from facilitation, and these sites are different from the molecular target triggering neurosecretion.	UNIV CALIF BERKELEY, DIV NEUROBIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Zucker, Robert S/J-9995-2012; Kamiya, Haruyuki/E-7199-2010	Zucker, Robert S/0000-0003-1068-2343; Kamiya, Haruyuki/0000-0002-2618-3146				ADAMS SR, 1989, J AM CHEM SOC, V111, P7957, DOI 10.1021/ja00202a042; ADLER EM, 1991, J NEUROSCI, V11, P1496; BAIN AI, 1992, J PHYSIOL-LONDON, V455, P383, DOI 10.1113/jphysiol.1992.sp019307; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BITTNER GD, 1981, BRAIN RES, V210, P431, DOI 10.1016/0006-8993(81)90922-7; DELANEY K, 1991, J NEUROSCI, V11, P2631; DELANEY KR, 1989, J NEUROSCI, V9, P3558; DELANEY KR, IN PRESS J NEUROSCI; HOCHNER B, 1991, NEUROSCI LETT, V125, P215, DOI 10.1016/0304-3940(91)90032-O; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; LANDO L, 1994, J NEUROPHYSIOL, V72, P825, DOI 10.1152/jn.1994.72.2.825; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; MAGLEBY KL, 1982, J GEN PHYSIOL, V80, P613, DOI 10.1085/jgp.80.4.613; MINTA A, 1989, J BIOL CHEM, V264, P8171; MULKEY RM, 1992, J NEUROSCI, V12, P4327; MULKEY RM, 1993, J PHYSIOL-LONDON, V462, P243, DOI 10.1113/jphysiol.1993.sp019553; REGEHR WG, 1994, J NEUROSCI, V14, P523; ROBITAILLE R, 1991, ANN NY ACAD SCI, V635, P492, DOI 10.1111/j.1749-6632.1991.tb36537.x; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; TANABE N, 1989, NEUROSCI LETT, V99, P147, DOI 10.1016/0304-3940(89)90280-2; TANABE N, 1992, J PHYSIOL-LONDON, V455, P271, DOI 10.1113/jphysiol.1992.sp019301; VANDERKLOOT W, 1993, J NEUROPHYSIOL, V69, P717, DOI 10.1152/jn.1993.69.3.717; VANDERKLOOT W, 1994, J NEUROSCI, V14, P5722; YAMADA WM, 1992, BIOPHYS J, V61, P671, DOI 10.1016/S0006-3495(92)81872-6; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P175, DOI 10.1085/jgp.76.2.175; ZENGEL JE, 1981, J GEN PHYSIOL, V77, P503, DOI 10.1085/jgp.77.5.503; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1992, CELL CALCIUM, V13, P29, DOI 10.1016/0143-4160(92)90027-P; ZUCKER RS, 1974, J PHYSIOL-LONDON, V241, P91, DOI 10.1113/jphysiol.1974.sp010642; ZUCKER RS, 1993, CELL CALCIUM, V14, P87, DOI 10.1016/0143-4160(93)90079-L	30	278	280	1	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 13	1994	371	6498					603	606		10.1038/371603a0	http://dx.doi.org/10.1038/371603a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935792				2022-12-28	WOS:A1994PL55900051
J	ANDERSONHUNT, M; DENNERSTEIN, L				ANDERSONHUNT, M; DENNERSTEIN, L			INCREASED FEMALE SEXUAL-RESPONSE AFTER OXYTOCIN	BMJ-BRITISH MEDICAL JOURNAL			English	Letter											ANDERSONHUNT, M (corresponding author), UNIV MELBOURNE, KEY CTR WOMENS HLTH SOC, CARLTON, VIC 3053, AUSTRALIA.							ANDERSONHUNT M, IN PRESS LEARNING SE; CARTER CS, 1992, NEUROSCI BIOBEHAV R, V16, P131, DOI 10.1016/S0149-7634(05)80176-9; INSEL TR, 1992, PSYCHONEUROENDOCRINO, V17, P3, DOI 10.1016/0306-4530(92)90073-G; Pedersen CA, 1992, ANN NY ACAD SCI, V652, P1; Reynolds J.E.F., 1993, MARTINDALE THE EXTRA	5	41	44	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	1994	309	6959					929	929		10.1136/bmj.309.6959.929	http://dx.doi.org/10.1136/bmj.309.6959.929			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7950665	Green Published			2022-12-28	WOS:A1994PL78100022
J	HANNEDOUCHE, T; LANDAIS, P; GOLDFARB, B; ELESPER, N; FOURNIER, A; GODIN, M; DURAND, D; CHANARD, J; MIGNON, F; SUC, JM; GRUNFELD, JP				HANNEDOUCHE, T; LANDAIS, P; GOLDFARB, B; ELESPER, N; FOURNIER, A; GODIN, M; DURAND, D; CHANARD, J; MIGNON, F; SUC, JM; GRUNFELD, JP			RANDOMIZED CONTROLLED TRIAL OF ENALAPRIL AND BETA-BLOCKERS IN NONDIABETIC CHRONIC-RENAL-FAILURE	BRITISH MEDICAL JOURNAL			English	Article							CONVERTING ENZYME-INHIBITORS; BLOOD-PRESSURE; KIDNEY-FUNCTION; ANGIOTENSIN-II; PROGRESSION; DISEASE; HYPERTENSION; NEPHROPATHY; PROTEINURIA; CAPTOPRIL	Objective-To compare the ability of angiotensin converting enzyme inhibitors and beta blockers to slow the development of end stage renal failure in nondiabetic patients with chronic renal failure. Design-Open randomised multicentre trial with three year follow up. Setting-Outpatient departments of six French hospitals. Patients-100 hypertensive patients with chronic renal failure (initial serum creatinine 200-400 mu mol/l). 52 randomised to enalapril and 48 to beta blockers (conventional treatment). Interventions-Enalapril or beta blocker was combined with frusemide and, if necessary, a calcium blocker or centrally acting drug in patients whose diastolic pressure remained above 90 mm Hg. Results-17 patients receiving conventional treatment and 10 receiving enalapril developed end stage renal failure. The cumulative renal survival rate was significantly better in the enalapril group than in the conventional group P<0.05). The slope of the reciprocal serum creatinine concentration was steeper in the conventionally treated patients (-6.89 x 10(-5)l/mu mol/month) than in the enalapril group (-4.17 x 10(-5)l/mu mol/month; P<0.05). No difference in blood pressure was found between groups. Conclusion-In hypertensive patients with chronic renal failure enalapril slows progression towards end stage renal failure compared with P blockers. This effect was probably not mediated through controlling blood pressure,	HOP NECKER ENFANTS MALAD,DEPT NEPHROL,PARIS,FRANCE; HOP NECKER ENFANTS MALAD,BIOSTAT LAB,PARIS,FRANCE; HOP SUD,DEPT NEPHROL,AMIENS,FRANCE; HOP BOIS GUILLAUME,ROUEN,FRANCE; HOP RANGUEIL,TOULOUSE,FRANCE; HOP MAISON BLANCHE,REIMS,FRANCE; HOP TERON,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; CHU de Rouen; CHU de Toulouse; CHU de Reims								ALVESTRAND A, 1988, NEPHROL DIAL TRANSPL, V3, P624, DOI 10.1093/oxfordjournals.ndt.a091717; ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528; BJORCK S, 1992, BMJ-BRIT MED J, V304, P339, DOI 10.1136/bmj.304.6823.339; BRAZY PC, 1990, KIDNEY INT, V37, P1113, DOI 10.1038/ki.1990.93; BRAZY PC, 1989, KIDNEY INT, V35, P670, DOI 10.1038/ki.1989.37; CAMERON JS, 1990, AM J NEPHROL, V10, P81; DAVIES DF, 1950, J CLIN INVEST, V29, P491, DOI 10.1172/JCI102285; DIXON WJ, 1988, BMDP STATISTICAL SOF; FENOY FJ, 1991, HYPERTENSION, V17, P1038, DOI 10.1161/01.HYP.17.6.1038; HANNEDOUCHE T, 1989, KIDNEY INT, V35, P95, DOI 10.1038/ki.1989.13; HANNEDOUCHE T, 1993, AM J KIDNEY DIS, V21, P131, DOI 10.1016/0272-6386(93)70104-7; HEEG JE, 1989, KIDNEY INT, V36, P272, DOI 10.1038/ki.1989.190; HEEG JE, 1987, KIDNEY INT, V32, P78, DOI 10.1038/ki.1987.174; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; KAMPER AL, 1992, AM J HYPERTENS, V5, P423, DOI 10.1093/ajh/5.7.423; LEVEY AS, 1988, ANNU REV MED, V39, P465, DOI 10.1146/annurev.me.39.020188.002341; MANN JFE, 1990, NEPHRON, V55, P38; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; MEYER TW, 1987, KIDNEY INT, V31, P752, DOI 10.1038/ki.1987.62; MOORHEAD JF, 1982, LANCET, V2, P1309; NORMAN JT, 1991, RENAL PHYSIOL BIOCH, V14, P175; PARVING HH, 1988, BRIT MED J, V297, P1086, DOI 10.1136/bmj.297.6656.1086; Pocock SJ., 1983, CLIN TRIALS PRACTICA; ROSENBERG ME, 1990, J CLIN INVEST, V85, P1144, DOI 10.1172/JCI114546; RUILOPE LM, 1989, AM J KIDNEY DIS, V13, P120, DOI 10.1016/S0272-6386(89)80129-5; YOSHIDA Y, 1989, KIDNEY INT, V36, P626, DOI 10.1038/ki.1989.239; YOSHIDA Y, 1989, KIDNEY INT, V35, P654, DOI 10.1038/ki.1989.35; 1989, SAS STAT USERS GUIDE; 1991, CONTROL CLIN TRIAL, V12, P566	29	224	226	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					833	837		10.1136/bmj.309.6958.833	http://dx.doi.org/10.1136/bmj.309.6958.833			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7950612	Green Published			2022-12-28	WOS:A1994PK50100018
J	EYSENCK, HJ				EYSENCK, HJ			SYSTEMATIC REVIEWS - METAANALYSIS AND ITS PROBLEMS	BRITISH MEDICAL JOURNAL			English	Article							TOBACCO-SMOKE; LUNG-CANCER; INTEGRATION; EXPOSURE	Including all relevant material-good, bad, and indifferent-in meta-analysis admits the subjective judgments that meta-analysis was designed to avoid. Several problems arise in meta-analysis: regressions are often non-linear; effects are often multivariate rather than univariate; coverage can be restricted; bad studies may be included; the data summarised may not be homogeneous; grouping different causal factors may lead to meaningless estimates of effects; and the theory-directed approach may obscure discrepancies. Meta-analysis may not be the one best method for studying the diversity of fields for which it has been used.	UNIV LONDON,LONDON,ENGLAND	University of London	EYSENCK, HJ (corresponding author), INST PSYCHIAT,DE CRESPIGNY PK, DENMARK HILL,LONDON SE5 8AF,ENGLAND.							[Anonymous], 1986, ENV TOBACCO SMOKE ME; Eysenck H.J., 1991, ADULT EPQ R; EYSENCK HJ, 1978, AM PSYCHOL, V33, P517, DOI 10.1037/0003-066X.33.5.517.a; EYSENCK HJ, 1984, J SPEC EDUC, V18, P41, DOI 10.1177/002246698401800106; EYSENCK HJ, 1992, PHARM MED, V6, P113; EYSENCK HJ, 1987, THEORETICAL F BEHAVI; EYSENCK HJ, 1981, MODEL PERSONALITY; FLEISS JL, 1991, J CLIN EPIDEMIOL, V44, P127, DOI 10.1016/0895-4356(91)90261-7; FLEISS JL, 1991, J CLIN EPIDEMIOL, V44, P439; Glass G.V., 1979, EDUC EVAL POLICY AN, V1, P2, DOI [10.3102/01623737001001002, DOI 10.3102/01623737001001002]; Hedges L, 1985, STATISTICAL METHODS; Huque MF, 1988, PROC BIOPHARM SECT A, V2, P28; JANERICH DT, 1990, NEW ENGL J MED, V323, P632, DOI 10.1056/NEJM199009063231003; KNIPSCHILD P, 1994, BRIT MED J, V309, P719, DOI 10.1136/bmj.309.6956.719; LEE PN, 1988, MISCLASSIFICATION SM; SCHMALE AH, 1971, SOC SCI MED, V5, P95, DOI 10.1016/0037-7856(71)90090-4; SLAVIN RE, 1986, EDUC RES, V15, P9; Smith M. L., 1980, BENEFITS PSYCHOTHERA; SPITZER WO, 1991, J CLIN EPIDEMIOL, V44, P103, DOI 10.1016/0895-4356(91)90258-B; STEIN RA, 1988, P BIOPHARMACEUT SECT, V2, P34; WITTMANN WW, 1986, PSYCHOL RUNDSCH, V37, P20	21	181	184	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					789	792		10.1136/bmj.309.6957.789	http://dx.doi.org/10.1136/bmj.309.6957.789			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PJ282	7950571	Green Published			2022-12-28	WOS:A1994PJ28200030
J	TATTERSFIELD, AE				TATTERSFIELD, AE			CONTROVERSIES IN MANAGEMENT .4. USE OF BETA(2) AGONISTS IN ASTHMA - MUCH ADO ABOUT NOTHING - STILL CAUSE FOR CONCERN	BRITISH MEDICAL JOURNAL			English	Article							SALBUTAMOL; BRONCHODILATOR; RESPONSIVENESS; TERBUTALINE; FENOTEROL; DEATH				TATTERSFIELD, AE (corresponding author), CITY HOSP,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND.							CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; VATHENEN AS, 1988, LANCET, V1, P554; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; WONG CS, 1990, LANCET, V336, P1396, DOI 10.1016/0140-6736(90)93099-B; WONG CS, 1993, ROLE BETA RECEPTOR A, P201	10	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					794	795		10.1136/bmj.309.6957.794	http://dx.doi.org/10.1136/bmj.309.6957.794			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950572	Green Published			2022-12-28	WOS:A1994PJ28200032
J	LANG, DM; POLANSKY, M				LANG, DM; POLANSKY, M			PATTERNS OF ASTHMA MORTALITY IN PHILADELPHIA FROM 1969 TO 1991	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD ASTHMA; AIR-POLLUTION; CHILDREN; DEATHS; PREDICTORS; RISK; CITY; RACE	Background. The rate of mortality from asthma has increased substantially in the United States since 1978. We analyzed the patterns of the rates of death from asthma in Philadelphia between 1969 and 1991. Methods. The rates of death from asthma were analyzed and compared with trends in the concentrations of major air pollutants: ozone, carbon monoxide, nitrogen dioxide, particulate matter (particles <10 mu m in diameter), and sulfur dioxide. Univariate and multivariate analyses were used to study the rates of death from asthma from 1985 to 1991 and their association with race, poverty, sex, and other factors. Results. The rate of death from asthma decreased from 1.68 per 100,000 people in 1969 to 0.68 per 100,000 in 1977, but then increased to 0.92 per 100,000 in 1978 and 2.41 per 100,000 in 1991. Between 1965 and 1990, the concentrations of major air pollutants declined substantially. From 1985 to 1991, 258 people were identified for whom asthma was the primary cause of death. According to multivariate analysis, the rates of death from asthma from 1985 to 1991 were significantly higher in census tracts with higher percentages of blacks (P = 0.032), Hispanics (P = 0.013), female residents (P<0.001), and people with incomes in the poverty range (P<0.001). Conclusions. The rates of death from asthma have increased in Philadelphia, whereas concentrations of major air pollutants have declined. The rates are highest in census tracts with the highest percentages of poor people and minority residents, particularly blacks. Public health efforts should target urban areas where the risk of death from asthma is highest.	HAHNEMANN UNIV,DEPT MED,DIV ALLERGY & IMMUNOL,PHILADELPHIA,PA 19102; HAHNEMANN UNIV,DEPT HUMAN SOCIAL SCI & BIOMETR,PHILADELPHIA,PA 19102	Drexel University; Drexel University								Aitken M, 1989, STATISTICAL MODELLIN, P217; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; COULTAS DB, 1994, AM J RESP CRIT CARE, V149, pS93, DOI 10.1164/ajrccm/149.3_Pt_2.S93; DRECHSLERPARKS DM, 1987, RES REP HLTH EFF I, V6, P1; Gadde JN, 1993, BRONCHIAL ASTHMA MEC, P1154; GIRSH LS, 1967, J ALLERGY, V39, P347, DOI 10.1016/0021-8707(67)90047-0; GREENBERGER PA, 1993, ALLERGY PROC, V14, P321, DOI 10.2500/108854193778773994; GREENLAND S, 1980, AM J EPIDEMIOL, V112, P564, DOI 10.1093/oxfordjournals.aje.a113025; HUNT LW, 1993, JAMA-J AM MED ASSOC, V269, P1947, DOI 10.1001/jama.269.15.1947; KAPLAN KM, 1993, PUBLIC HEALTH REP, V108, P66; MALVEAUX FJ, 1989, J ALLERGY CLIN IMMUN, V83, P1029, DOI 10.1016/0091-6749(89)90443-0; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; MARGOLIS PA, 1992, AM J PUBLIC HEALTH, V82, P1119, DOI 10.2105/AJPH.82.8.1119; MASSICOT JG, 1986, J ALLERGY CLIN IMMUN, V78, P954, DOI 10.1016/0091-6749(86)90284-8; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721, DOI 10.1164/ajrccm/139.3.721; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; PLAUT TF, 1991, JAMA-J AM MED ASSOC, V265, P725, DOI 10.1001/jama.1991.03460060054021; POMA PA, 1988, J NATL MED ASSOC, V80, P1275; SAMET JM, 1987, AM REV RESPIR DIS, V136, P1486, DOI 10.1164/ajrccm/136.6.1486; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STRUNK RC, 1989, J ALLERGY CLIN IMMUN, V83, P477, DOI 10.1016/0091-6749(89)90137-1; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOOLSON RF, 1987, STAT METHODS ANAL BI, P366; 1991, EPA450491023 PUBL; 1990, VITAL STATISTICS REP; 1993, CURRENT POPULATI P60, V185	34	227	228	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1542	1546		10.1056/NEJM199412083312302	http://dx.doi.org/10.1056/NEJM199412083312302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PV292	7969323	Bronze			2022-12-28	WOS:A1994PV29200002
J	ROBERTS, SB; FUSS, P; HEYMAN, MB; EVANS, WJ; TSAY, R; RASMUSSEN, H; FIATARONE, M; CORTIELLA, J; DALLAL, GE; YOUNG, VR				ROBERTS, SB; FUSS, P; HEYMAN, MB; EVANS, WJ; TSAY, R; RASMUSSEN, H; FIATARONE, M; CORTIELLA, J; DALLAL, GE; YOUNG, VR			CONTROL OF FOOD-INTAKE IN OLDER MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLY LABELED WATER; ENERGY-EXPENDITURE; NATIONAL COHORT; BODY-WEIGHT; ADULTS; NUTRITION; HUMANS	Objective.-To investigate the effects of aging on mechanisms of body energy regulation and thereby determine the causes of unexplained weight loss in older persons, a factor predisposing to premature death and disability. Design.-Dietary intervention study. Setting.-Metabolic ward and outpatient. Participants.-The subjects were 35 healthy younger and older men of normal body weight consuming a diet of typical composition and performing usual activities. Main Outcome Measures.-Subjects were either overfed by a mean (+/-SD) of 4.09 (+/-0.26) MJ/d (n=17) or underfed by 3.17 (+/-0.68) MJ/d (n=18) for 21 days. Measurements were made of changes in body weight, body composition, and energy expenditure during overfeeding or underfeeding, and of subsequent voluntary nutrient intakes and changes in body weight. Results.-There was no significant effect of aging on changes in body composition, body weight, or energy expenditure with overfeeding or underfeeding. However, following overfeeding, younger men exhibited spontaneous hypophagia, whereas the older men did not (mean [+/-SD] changes in energy intake relative to control values were -2.11 [+/-2.18] and 1.55 [+/-2.11] MJ/d, respectively; P=.006). As a result, the younger men lost the excess body weight gained during overfeeding but the older men did not. Similarly, following underfeeding, the younger men exhibited hyperphagia while the older men did not (mean [+/-SD] changes in energy intake relative to control values were 1.88 [+/-2.31] and -0.52 [+/-1.54] MJ/d, respectively; P=.02), and as a result the older men failed to regain the weight lost during underfeeding. Conclusions.-These results in 35 men suggest that aging may be associated with a significant impairment in the ability to control food intake following overeating or undereating. Since overeating and undereating occur routinely as part of the normal pattern of energy regulation, the findings reported herein may help to explain the vulnerability of older persons to unexplained weight gain and weight loss.	MIT, CLIN RES CTR, CAMBRIDGE, MA 02139 USA; UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA	Massachusetts Institute of Technology (MIT); University of California System; University of California San Francisco	ROBERTS, SB (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, ENERGY METAB LAB, 711 WASHINGTON ST, BOSTON, MA 02111 USA.				NATIONAL INSTITUTE ON AGING [R37AG007388] Funding Source: NIH RePORTER; NIA NIH HHS [AG07388] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DELMI M, 1990, LANCET, V335, P1013, DOI 10.1016/0140-6736(90)91073-J; DIPIETRO L, 1992, INT J OBESITY, V16, P745; DOTY RL, 1984, SCIENCE, V226, P1441, DOI 10.1126/science.6505700; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; EDHOLM OG, 1970, BRIT J NUTR, V24, P1091, DOI 10.1079/BJN19700112; Energy and protein requirements, 1985, TECHNICAL REPORT SER, V724; FANELLI MT, 1989, ANN NY ACAD SCI, V561, P94; FISCHER J, 1990, J AM DIET ASSOC, V90, P1697; GLICK Z, 1990, GERIATRIC NUTRITION, P27; GOSNELL BA, 1983, LIFE SCI, V32, P2793, DOI 10.1016/0024-3205(83)90401-0; LEAF A, 1984, NEW ENGL J MED, V311, P791, DOI 10.1056/NEJM198409203111209; LEIBOWITZ SF, 1988, NEUROBIOL AGING, V9, P20, DOI 10.1016/S0197-4580(88)80007-1; LIPSCHITZ DA, 1991, SEMIN DERMATOL, V10, P273; MILLER DK, 1990, J AM GERIATR SOC, V38, P645, DOI 10.1111/j.1532-5415.1990.tb01423.x; Morley J., 1990, GERIATRIC NUTRITION, P89; MORLEY JE, 1988, NEUROBIOL AGING, V9, P9, DOI 10.1016/S0197-4580(88)80004-6; MOWE M, 1994, AM J CLIN NUTR, V59, P317, DOI 10.1093/ajcn/59.2.317; NELSON RC, 1989, MED CLIN N AM, V73, P1531, DOI 10.1016/S0025-7125(16)30615-0; PACE N, 1945, J BIOL CHEM, V158, P685; PAMUK ER, 1992, AM J EPIDEMIOL, V136, P686, DOI 10.1093/oxfordjournals.aje.a116548; RABIN DL, 1987, LONG TERM CARE ELDER; ROBERTS SB, 1990, AM J PHYSIOL, V259, pR461, DOI 10.1152/ajpregu.1990.259.3.R461; ROBERTS SB, 1989, CAN J PHYSIOL PHARM, V67, P1190, DOI 10.1139/y89-189; ROBERTS SB, 1992, INT J OBESITY, V16, P969; ROBERTS SB, 1992, AM J PHYSIOL, V263, pR250; ROLLS BJ, 1992, NUTR REV, V50, P422, DOI 10.1111/j.1753-4887.1992.tb02496.x; ROSENBERG IH, 1992, NUTR REV, V50, P349; RUDMAN D, 1990, GERIATRIC NUTRITION, P325; SCHIFFMAN SS, 1989, ANN NY ACAD SCI, V561, P267, DOI 10.1111/j.1749-6632.1989.tb20988.x; SCHOELLER DA, 1988, J NUTR, V118, P1278, DOI 10.1093/jn/118.11.1278; Schutz Y., 1984, HUMAN ENERGY METABOL, P169; SHIMOKATA H, 1989, J GERONTOL, V44, pM66, DOI 10.1093/geronj/44.2.M66; SILVER AJ, 1988, PEPTIDES, V9, P221, DOI 10.1016/0196-9781(88)90254-9; STEEN B, 1988, NUTR REV, V46, P45, DOI 10.1111/j.1753-4887.1988.tb05386.x; TAYBACK M, 1990, ARCH INTERN MED, V150, P1065, DOI 10.1001/archinte.150.5.1065; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; 1990, PHS901232 US DEP HLT; 1983, PHS831681 US DEP HLT; 1991, EXTENDING LIFE ENHAN	39	290	297	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1601	1606		10.1001/jama.272.20.1601	http://dx.doi.org/10.1001/jama.272.20.1601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966871				2022-12-28	WOS:A1994PR40500027
J	SHAFER, T; SCHKADE, LL; WARNER, HE; EAKIN, M; OCONNOR, K; SPRINGER, J; JANKIEWICZ, T; REITSMA, W; STEELE, J; KEENDENTON, K				SHAFER, T; SCHKADE, LL; WARNER, HE; EAKIN, M; OCONNOR, K; SPRINGER, J; JANKIEWICZ, T; REITSMA, W; STEELE, J; KEENDENTON, K			IMPACT OF MEDICAL EXAMINER CORONER PRACTICES ON ORGAN RECOVERY IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSPLANTATION; DONORS	Objective.-The object of this research is to determine the nature and extent of the loss of donor organs during a 3-year period that are otherwise medically suitable for organ transplantation owing to nonrelease by a local medical examiner or coroner. Design and Data Sources.-In a retrospective study of the effects of medical examiner/coroner donor release practices, a detailed survey was mailed to every organ procurement organization (OPO) in the United States. This survey collected specific data (eg, number of cases denied per year), as well as descriptive information. Results.-Of the 2670 organ donors reported by 39 OPO respondents in 1990, 62.1% were medical examiner cases, and 129 (7.2%) of these cases were denied recovery by the local medical examiner/coroner. The number of denials increased to 181 (9.6% of medical examiner cases) in 1991 and to 251 (11.4% of medical examiner cases) in 1992. It is estimated that the population of medical examiner/coroner denials from 1990 through 1992 may be as many as 884. Twenty percent of the OPO respondents reported that no cases were denied recovery by a local medical examiner/coroner. A comparative analysis reveals that the proportion of total reported potential medical examiner/coroner cases that were denied increased by 65% from 1990 to 1992, while medical examiner/coroner cases released declined slightly. Conclusions.-Since an average of 3.37 organs were recovered per donor in 1992, it is possible that as many as 2979 people may have been denied transplants from 1990 through 1992 owing to medical examiners'/coroners' denials. There were no donor denials in 10 geographical areas of the United States, nor was there any instance of violation of case law or any documentation of flawed autopsies or collection of forensic evidence in donor cases released. These two factors suggest that the loss of human life from denials is not needed to protect the judicial process. Increased cooperation between medical examiner offices and OPOs could significantly increase the availability of transplantable organs.	UNIV TEXAS,DEPT INFORMAT SYST,ARLINGTON,TX 76019; NEW ENGLAND ORGAN BANK INC,NEWTON,MA; COLORADO ORGAN RECOVERY SYST INC,DENVER,CO; TRANSLIFE,ORLANDO,FL; NEW JERSEY ORGAN SHARING NETWORK,SPRINGFIELD,NJ; SACRED HEART ORGAN PROCUREMENT ORG,SPOKANE,WA; NW ORGAN PROCUREMENT AGCY,SEATTLE,WA	University of Texas System; University of Texas Arlington	SHAFER, T (corresponding author), LIFEGIFT ORGAN DONAT CTR N TEXAS,1701 RIVER RUN,SUITE 500,FT WORTH,TX 76107, USA.		Shafer, Teresa/HGT-9439-2022					ALEXANDER JW, 1991, TRANSPLANTATION, V51, P135, DOI 10.1097/00007890-199101000-00021; BRENT L, 1975, BRIT MED J, V1, P251; DAVIS JH, 1977, J FORENSIC SCI, V22, P824; Evans R W, 1990, Clin Transpl, P319; EVANS RW, 1993, JAMA-J AM MED ASSOC, V269, P3113, DOI 10.1001/jama.269.24.3113; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; EVANS RW, 1992, TRANSPLANT P, V24, P2152; Hauser J E, 1969, J Forensic Sci, V14, P501; JOHNSON HK, 1984, TRANSPLANT P, V16, P122; KEETON WP, 1984, PROSSER KEETON LAW T, P164, DOI DOI 10.1056/NEJMP1006114; Miracle KL, 1993, J TRANSPLANT COORDIN, V3, P23; PAPROCKI S, 1992, TRANSPLANTATION, V54, P381; STRAWN J, 1990, UNOS MONTHLY ACTIVIT; 1991, P REPORT SURGEON GEN; 1993, MONTHLY VOLUNTARY SU; 1993, GAOHRD9356 US GEN AC; 1977, BRIT MED J, V1, P1418	17	29	30	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1607	1613		10.1001/jama.272.20.1607	http://dx.doi.org/10.1001/jama.272.20.1607			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966872				2022-12-28	WOS:A1994PR40500028
J	KAPLAN, NM				KAPLAN, NM			MANAGEMENT OF HYPERTENSIVE EMERGENCIES	LANCET			English	Article							CEREBRAL BLOOD-FLOW; SODIUM-NITROPRUSSIDE; RENOVASCULAR HYPERTENSION; INTRAVENOUS LABETALOL; DANISH MULTICENTER; ORAL NIFEDIPINE; GRADE-III; PRESSURE; TRIAL; FENOLDOPAM				KAPLAN, NM (corresponding author), UNIV TEXAS,SW MED CTR,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ANGELI P, 1991, ARCH INTERN MED, V151, P678, DOI 10.1001/archinte.151.4.678; BARNETT AJ, 1973, MED J AUSTRALIA, V2, P960, DOI 10.5694/j.1326-5377.1973.tb129861.x; BARRY DI, 1989, AM J CARDIOL, V63, pC14, DOI 10.1016/0002-9149(89)90399-8; BING RF, 1986, J HYPERTENS, V4, pS42; BURNETT CF, 1955, NEW ENGL J MED, V253, P395, DOI 10.1056/NEJM195509082531001; CALHOUN DA, 1990, NEW ENGL J MED, V323, P1177; CHITWOOD WR, 1992, ANN THORAC SURG, V54, P517, DOI 10.1016/0003-4975(92)90446-B; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COTTRELL JE, 1978, J NEUROSURG, V48, P329, DOI 10.3171/jns.1978.48.3.0329; DAVIS BA, 1979, NEW ENGL J MED, V301, P1273, DOI 10.1056/NEJM197912063012307; DUNN FG, 1983, CLIN PHARMACOL THER, V33, P139, DOI 10.1038/clpt.1983.21; DUSTAN HP, 1958, CIRCULATION, V18, P644, DOI 10.1161/01.CIR.18.4.644; FELDMAN JM, 1987, J CLIN PHARMACOL, V27, P288, DOI 10.1002/j.1552-4604.1987.tb03015.x; GIFFORD RW, 1991, JAMA-J AM MED ASSOC, V266, P829, DOI 10.1001/jama.266.6.829; HARRINGTON M, 1959, BRIT MED J, V2, P978; HOOD B, 1970, ACTA MED SCAND, V187, P291; ISLES CG, 1984, Q J MED, V51, P439; Kaplan N, 1994, CLIN HYPERTENSION, P389; Kaplan NM., 1994, CLIN HYPERTENSION, P281; Keith NM, 1939, AM J MED SCI, V197, P332, DOI 10.1097/00000441-193903000-00006; KROGSGAARD AR, 1986, ACTA MED SCAND, V220, P25; MACMAHON S, 1993, CLIN EXP HYPERTENS, V15, P967, DOI 10.3109/10641969309037085; MAHARAJ B, 1992, AM HEART J, V124, P720, DOI 10.1016/0002-8703(92)90283-2; MANN SJ, 1992, ANN INTERN MED, V117, P845, DOI 10.7326/0003-4819-117-10-845; MCDONALD AJ, 1993, AM J EMERG MED, V11, P460, DOI 10.1016/0735-6757(93)90083-N; MCNAIR A, 1986, ACTA MED SCAND, V220, P15; OMVIK P, 1980, HYPERTENSION, V2, P515, DOI 10.1161/01.HYP.2.4.515; PERRY HM, 1958, ARCH INTERN MED, V102, P418, DOI 10.1001/archinte.1958.00030010418011; PHILLIPS SJ, 1994, HYPERTENSION, V23, P131, DOI 10.1161/01.HYP.23.1.131; PILMER BL, 1993, J CLIN PHARMACOL, V33, P549, DOI 10.1002/j.1552-4604.1993.tb04702.x; SCHWARTZ M, 1990, ARCH INTERN MED, V150, P686, DOI 10.1001/archinte.150.3.686; SHEPHERD AMM, 1986, J CARDIOVASC PHARM, V8, P527, DOI 10.1097/00005344-198605000-00014; SHUSTERMAN NH, 1993, AM J MED, V95, P161, DOI 10.1016/0002-9343(93)90256-O; SIMPSON F O, 1958, Scott Med J, V3, P1; STRANDGAARD S, 1989, AM J HYPERTENS, V2, P486, DOI 10.1093/ajh/2.6.486; STRANDGAARD S, 1973, BMJ-BRIT MED J, V1, P507, DOI 10.1136/bmj.1.5852.507; THULIN T, 1993, J HYPERTENS, V11, P83, DOI 10.1097/00004872-199301000-00012; WALLIN JD, 1989, ARCH INTERN MED, V149, P2662, DOI 10.1001/archinte.149.12.2662; WEBSTER J, 1993, Q J MED, V96, P485; WILSON DJ, 1983, AM J MED, V75, P95, DOI 10.1016/0002-9343(83)90141-9	40	60	62	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1335	1338		10.1016/S0140-6736(94)90696-3	http://dx.doi.org/10.1016/S0140-6736(94)90696-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968030				2022-12-28	WOS:A1994PQ92600012
J	WATTERS, JK				WATTERS, JK			BEHAVIORAL-SCIENCE IN THE AIDS EPIDEMIC	LANCET			English	Editorial Material							SAN-FRANCISCO; MEN		UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	WATTERS, JK (corresponding author), UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143, USA.							BOOTH RE, 1994, AIDS, V8, P1515, DOI 10.1097/00002030-199411000-00001; Brown B. S., 1993, HDB RISK AIDS INJECT; FRIEDMAN SR, 1994, 10TH INT C AIDS YOK; MCKUSICK L, 1985, AM J PUBLIC HEALTH, V75, P493, DOI 10.2105/AJPH.75.5.493; MORRIS M, 1994, AM J EPIDEMIOL, V140, P217, DOI 10.1093/oxfordjournals.aje.a117241; NELSON KE, 1991, JAMA-J AM MED ASSOC, V266, P2250; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; VARMUS, 1994, LANCET          1029, P1215; WATTERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115, DOI 10.1001/jama.271.2.115; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; 1994, WORKSHOP NEEDLE EXCH; 1990, MMWR-MORBID MORTAL W, V39, P529; 1994, LANCET, V344, P535; 1994, AIDS RISK BEHAVIOR I	14	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1312	1313		10.1016/S0140-6736(94)90688-2	http://dx.doi.org/10.1016/S0140-6736(94)90688-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PQ926	7968024				2022-12-28	WOS:A1994PQ92600004
J	HUNTINGTON, J; CONNELL, FA				HUNTINGTON, J; CONNELL, FA			FOR EVERY DOLLAR SPENT - THE COST SAVINGS ARGUMENT FOR PRENATAL-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LOW-BIRTH-WEIGHT; MEDICAID; PROJECT; IMPACT; INFANT; BARRIERS; WOMEN		UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,SEATTLE,WA 98112	University of Washington; University of Washington Seattle; Group Health Cooperative					PHS HHS [MCJ 9043] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUESCHER PA, 1987, AM J OBSTET GYNECOL, V156, P204, DOI 10.1016/0002-9378(87)90239-0; CURRY M, 1987, ACCESS PRENATAL CARE; ENKIN M, 1982, CLIN DEV MED, V81, P266; GORSKY RD, 1989, HEALTH SERV RES, V24, P583; GUYER B, 1990, JAMA-J AM MED ASSOC, V264, P2264, DOI 10.1001/jama.264.17.2264; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; HALL MH, 1980, LANCET, V2, P78; Huntington JL, 1913, BOSTON MED SURG J, V169, P763, DOI 10.1056/NEJM191311201692108; KORENBROT CC, 1984, MOBIUS, V4, P34; Lazarus E S, 1990, Med Anthropol, V12, P269; Leavitt J.W., 1986, BROUGHT BED CHILDBEA; Lennie J A, 1987, Health Care Financ Rev, V8, P83; LEPPERT PC, 1985, J NURSE-MIDWIFERY, V30, P285, DOI 10.1016/0091-2182(85)90044-8; LEVENO KJ, 1985, OBSTET GYNECOL, V66, P599; MOORE TR, 1986, AM J OBSTET GYNECOL, V154, P29, DOI 10.1016/0002-9378(86)90387-X; Morales W J, 1985, J Fla Med Assoc, V72, P852; OAKLEY A, 1990, BRIT J OBSTET GYNAEC, V97, P155, DOI 10.1111/j.1471-0528.1990.tb01741.x; PEOPLES MD, 1984, AM J PUBLIC HEALTH, V74, P549, DOI 10.2105/AJPH.74.6.549; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; POLAND ML, 1987, AM J OBSTET GYNECOL, V157, P297, DOI 10.1016/S0002-9378(87)80156-4; SARDELL A, 1990, J HEALTH POLIT POLIC, V15, P271, DOI 10.1215/03616878-15-2-271; SCHRAMM WF, 1992, PUBLIC HEALTH REP, V107, P647; SCHWARTZ RM, 1989, FAM PLANN PERSPECT, V21, P170, DOI 10.2307/2135808; SOKOL RJ, 1980, OBSTET GYNECOL, V56, P150; STCLAIR PA, 1990, PUBLIC HEALTH REP, V105, P264; STROBINO DM, 1986, AM J PUBLIC HEALTH, V76, P274, DOI 10.2105/AJPH.76.3.274; Thompson JE, 1990, NEW PERSPECTIVES PAR, P9; Wertz Richard W., 1989, LYING HIST CHILDBIRT; WILSON AL, 1992, AM J PERINAT, V9, P281, DOI 10.1055/s-2007-994790; 1988, OTAH345 OFF TECHN AS; [No title captured]	31	70	71	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1303	1307		10.1056/NEJM199411103311910	http://dx.doi.org/10.1056/NEJM199411103311910			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP752	7935689				2022-12-28	WOS:A1994PP75200010
J	GUI, D; CASSETTA, E; ANASTASIO, G; BENTIVOGLIO, AR; MARIA, G; ALBANESE, A				GUI, D; CASSETTA, E; ANASTASIO, G; BENTIVOGLIO, AR; MARIA, G; ALBANESE, A			BOTULINUM TOXIN FOR CHRONIC ANAL-FISSURE	LANCET			English	Note								Botulinum toxin can chemically denervate striated muscle. Botulinum toxin A (15 U) was used to treat ten patients with chronic anal fissure by injection in the internal sphincter. In seven patients, the lesion healed at 2 months after treatment; one relapsed at 3 months. In one patient the lesion healed at 1 month, but partly relapsed a month later. Mild faecal incontinence lasting for 1 day was observed in one patient. We propose that botulinum toxin injections in the internal anal sphincter be considered an alternative approach to surgical therapy of anal fissure.	UNIV CATTOLICA SACRO CUORE,IST NEUROL,I-00168 ROME,ITALY; UNIV CATTOLICA SACRO CUORE,IST CLIN CHIRURG,I-00168 ROME,ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli			Albanese, Alberto/K-7396-2016; Bentivoglio, Anna Rita/K-3752-2018; Brisinda, Giuseppe/G-6436-2010	Albanese, Alberto/0000-0002-5864-0006; Brisinda, Giuseppe/0000-0001-8820-9471; Bentivoglio, Anna Rita/0000-0002-9663-095X; Cassetta, Emanuele/0000-0003-1442-1458				ABCARIAN H, 1982, DIS COLON RECTUM, V25, P525, DOI 10.1007/BF02564159; ALBANESE A, 1992, EUR NEUROL, V32, P112, DOI 10.1159/000116805; FLESHMAN JW, 1993, SURG CLIN N AM, V73, P1245; GIBBONS CP, 1986, BRIT J SURG, V73, P443, DOI 10.1002/bjs.1800730609; GOLLIGHER JC, 1980, SURGERY ANUS RECTUM, P136; HSU TC, 1984, DIS COLON RECTUM, V27, P475, DOI 10.1007/BF02555546; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; KLOSTERHALFEN B, 1989, DIS COLON RECTUM, V32, P43, DOI 10.1007/BF02554725; PASRICHA PJ, 1993, LANCET, V341, P244, DOI 10.1016/0140-6736(93)90109-T; PESCATORI M, 1989, COLOPROCTOLOGY, V11, P120	10	138	140	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1127	1128		10.1016/S0140-6736(94)90633-5	http://dx.doi.org/10.1016/S0140-6736(94)90633-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934496				2022-12-28	WOS:A1994PN06600012
J	BRENNWALD, P; KEARNS, B; CHAMPION, K; KERANEN, S; BANKAITIS, V; NOVICK, P				BRENNWALD, P; KEARNS, B; CHAMPION, K; KERANEN, S; BANKAITIS, V; NOVICK, P			SEC9 IS A SNAP-25-LIKE COMPONENT OF A YEAST SNARE COMPLEX THAT MAY BE THE EFFECTOR OF SEC4 FUNCTION IN EXOCYTOSIS	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; GTP-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; SECRETORY VESICLES; SYNAPTIC VESICLES; PLASMA-MEMBRANE; PATHWAY; FUSION; FAMILY	To identify potential Sec4 effecters, we isolated high copy suppressors of a Sec4 effector domain mutant. The most potent of these was found to be SEC9, a gene required for post-Golgi transport. The sole essential domain of Sec9 has significant sequence similarity to the neuronal protein SNAP-25, a component of the SNARE complex, that is implicated in vesicle targeting and fusion. Analogous to SNAP-25, Sec9 is bound to the yeast plasma membrane and is absent from post-Golgi vesicles. Furthermore, Sec9 is physically associated with two proteins that are homologous to components of the neuronal SNARE complex. Our results identify Sec9 as the yeast cognate of SNAP-25 and suggest that SNARE complexes acting at specific stages of vesicular transport serve as the ultimate targets of regulation by members of the Sec4/Ypt1/Rab family of GTPases.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA; UNIV ALABAMA, DEPT CELL BIOL, BIRMINGHAM, AL 35294 USA; UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA; VTT BIOTECHNOL & FOOD RES, SF-02044 ESPOO, FINLAND	Yale University; University of Alabama System; University of Alabama Birmingham; University of Illinois System; University of Illinois Urbana-Champaign; VTT Technical Research Center Finland					NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035370, R01GM044530, R01GM035370] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NIGMS NIH HHS [GM44530, GM35370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; INOUE A, 1992, J BIOL CHEM, V267, P10613; KIBBE WA, 1993, RAS SUPERFAMILY GTPA, P367; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; RINE J, 1991, METHOD ENZYMOL, V194, P239; RISINGER C, 1993, P NATL ACAD SCI USA, V90, P10598, DOI 10.1073/pnas.90.22.10598; RISINGER C, 1993, J BIOL CHEM, V268, P24408; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SCHLAVO G, 1993, J BIOL CHEM, V288, P23784; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	33	305	308	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					245	258		10.1016/0092-8674(94)90194-5	http://dx.doi.org/10.1016/0092-8674(94)90194-5			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954793				2022-12-28	WOS:A1994PN63000009
J	CLARKE, MJ; STEWART, LA				CLARKE, MJ; STEWART, LA			SYSTEMATIC REVIEWS - OBTAINING DATA FROM RANDOMIZED CONTROLLED TRIALS - HOW MUCH DO WE NEED FOR RELIABLE AND INFORMATIVE METAANALYSES	BRITISH MEDICAL JOURNAL			English	Article							ACTIVE-SPECIFIC IMMUNOTHERAPY; HUMAN COLORECTAL-CANCER; CLINICAL-TRIALS; PATIENT	Many randomised controlled trials compare treatments that will produce only moderate differences in outcome, but these differences can be clinically important. However, they are difficult to assess reliably and require a large amount of randomised evidence. This can be achieved through large prospective randomised trials which will accrue future patients, the meta-analysis of results from randomised trials involving patients from the past, or-ideally-both. The techniques require that all possible biases are minimised, and in meta-analyses this can best be achieved by ensuring that all of the randomised evidence-both trials and participants in those trials-is included. The meta-analysis of individual patient data has been described as the gold standard for this approach. It will remove many of the problems associated with relying solely on published data and some of the problems arising from a reliance on aggregate data, and will also add to the analyses that can be performed. Such projects, however, require considerable time and effort.	RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC STUDIES UNIT,OXFORD OX2 6HE,ENGLAND; MRC,CANC TRIALS OFF,CAMBRIDGE CB2 2BW,ENGLAND	Radcliffe Infirmary; University of Oxford	CLARKE, MJ (corresponding author), RADCLIFFE INFIRM,CLIN TRIAL SERV UNIT,OXFORD OX2 6HE,ENGLAND.			Stewart, Lesley/0000-0003-0287-4724				[Anonymous], 1984, Lancet, V2, P1205; CHALMERS I, 1933, ANN NY ACAD SCI, V703, P156; DICKERSIN K, IN PRESS BMJ; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; GREGORY WM, 1992, J CLIN ONCOL, V10, P334, DOI 10.1200/JCO.1992.10.2.334; HOOVER HC, 1985, CANCER, V55, P1236, DOI 10.1002/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#; HOOVER HC, 1993, J CLIN ONCOL, V11, P390, DOI 10.1200/JCO.1993.11.3.390; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PETO R, 1993, ANN NY ACAD SCI, V703, P314, DOI 10.1111/j.1749-6632.1993.tb26369.x; PIGNON JP, 1993, LANCET, V341, P964; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; STEWART LA, 1994, P AN M AM SOC CLIN, V13, P336; 1994, BRIT MED J, V308, pR1; 1991, BRIT MED J, V303, P884; 1992, LANCET, V339, P71	16	89	90	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					1007	1010		10.1136/bmj.309.6960.1007	http://dx.doi.org/10.1136/bmj.309.6960.1007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950694	Green Published			2022-12-28	WOS:A1994PM41700031
J	SHIINA, N; GOTOH, Y; KUBOMURA, N; IWAMATSU, A; NISHIDA, E				SHIINA, N; GOTOH, Y; KUBOMURA, N; IWAMATSU, A; NISHIDA, E			MICROTUBULE SEVERING BY ELONGATION-FACTOR 1-ALPHA	SCIENCE			English	Article							POLYPEPTIDE-CHAIN ELONGATION; SEA-URCHIN EGGS; STABLE MICROTUBULES; BINDING PROTEIN; FACTOR-1-ALPHA; IDENTIFICATION; DICTYOSTELIUM; EF-1-ALPHA; EXTRACTS; MITOSIS	An activity that severs stable microtubules is thought to be involved in microtubule reorganization during the cell cycle. Here, a 48-kilodalton microtubule-severing protein was purified from Xenopus eggs and identified as translational elongation factor 1 alpha (EF-1 alpha). Bacterially expressed human EF-1 alpha also displayed microtubule-severing activity in vitro and, when microinjected into fibroblasts, induced rapid and transient fragmentation of cytoplasmic microtubule arrays. Thus, EF-1 alpha, an essential component of the eukaryotic translational apparatus, appears to have a second role as a regulator of cytoskeletal rearrangements.	KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	Kyoto University; Kirin Brewery Company Limited				Shiina, Nobuyuki/0000-0002-1854-4239				BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; COPPARD NJ, 1991, J CELL BIOL, V112, P237, DOI 10.1083/jcb.112.2.237; DJE MK, 1990, NUCLEIC ACIDS RES, V18, P3489, DOI 10.1093/nar/18.12.3489; HARLOW E, 1988, ANTIBODIES; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KARSENTI E, 1993, CURR BIOL, V3, P208, DOI 10.1016/0960-9822(93)90334-K; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V8, P106, DOI 10.1002/cm.970080203; KURIYAMA R, 1990, J CELL SCI, V95, P231; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; NISHIDA E, 1987, J BIOL CHEM, V262, P16200; OHTA K, 1990, J BIOL CHEM, V265, P3240; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; SHIINA N, 1992, EMBO J, V11, P4723, DOI 10.1002/j.1460-2075.1992.tb05577.x; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; SHIINA N, UNPUB; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	24	228	237	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					282	285		10.1126/science.7939665	http://dx.doi.org/10.1126/science.7939665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939665				2022-12-28	WOS:A1994PM13400036
J	COLLINS, EJ; GARBOCZI, DN; WILEY, DC				COLLINS, EJ; GARBOCZI, DN; WILEY, DC			3-DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING FROM ONE END OF A CLASS-I MHC BINDING-SITE	NATURE			English	Article							VIRAL PEPTIDES; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURES; ANTIGEN; COMPLEXES; MOLECULES; HLA-B27; H-2K(B); HLA-A2	CLASS I major histocompatibility complex (MHC) molecules present peptides to CD8(+) T cells for immunological surveillance (reviewed in ref. 1). The structures of complexes of class I MHC molecules with octamer, nonamer and decamer peptides determined until now(2-8) show a common binding mode, with both peptide termini bound in conserved pockets at the ends of the peptide binding site. Length variations were accommodated by the peptide bulging(5,6) or zig-zagging(4) in the middle. Here we describe the structure of a decamer peptide which binds with the carboxy-terminal residue positioned outside the peptide binding site. Several protein side chains have rearranged to allow the peptide to exit. The structure suggests that even longer peptides could bind. The energetic effect of the altered mode of binding has been assessed by measuring the stability of the complex to thermal denaturation. Peptides bound in this novel manner are stable at physiological temperature, raising questions about their role in T-cell recognition and their production by proteolytic processing.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University								BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 0 M; CHEN Y, 1994, J IMMUNOL, V152, P2874; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GARBOCZI DN, 1994, J MOL BIOL, V239, P581, DOI 10.1006/jmbi.1994.1398; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; OLSEN AC, 1994, EUR J IMMUNOL, V24, P3585; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	25	195	199	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					626	629		10.1038/371626a0	http://dx.doi.org/10.1038/371626a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935798				2022-12-28	WOS:A1994PL55900058
J	JONSSON, J; CARLSSON, L; EDLUND, T; EDLUND, H				JONSSON, J; CARLSSON, L; EDLUND, T; EDLUND, H			INSULIN-PROMOTER-FACTOR-1 IS REQUIRED FOR PANCREAS DEVELOPMENT IN MICE	NATURE			English	Article							MAMMALIAN PANCREAS; GENE; EXPRESSION; CELLS	THE mammalian pancreas is a mixed exocrine and endocrine gland that, in most species, arises from ventral and dorsal buds which subsequently merge to form the pancreas. In both mouse and rat the first histological sign of morphogenesis of the dorsal pancreas is a dorsal evagination of the duodenum ai the level of the liver at around the 22-25-somite stage, and shortly thereafter a ventral evagination appears as a derivative of the liver diverticulum(1-3). Low levels of insulin gene transcripts are already present and restricted to the dorsal foregut endoderm at 20 somites, suggesting that pancreas- or insulin gene-specific transcriptional factors are present in this region before the onset of morphogenesis(4). Insulin-promoter-factor 1 (IPF1) is a homeodomain protein which, in the adult mouse pancreas, is selectively expressed in the beta-cells and binds to and transactivates the insulin promoter(5). In mouse embryos, IPF1 expression is restricted to the developing pancreatic anlagen and is initiated when the foregut endoderm is committed to a pancreatic fate(5). We now show that mice homozygous for a targeted mutation in the Ipf1 gene selectively lack a pancreas. The mutant pups survive fetal development but die within a few days after birth. The gastrointestinal part and all other internal organs were normal in appearance. No pancreatic tissue and no ectopic expression of insulin or pancreatic amylase could be detected in mutant embryos and neonates. These findings show that IPF1 is needed for the formation of the pancreas and suggest that it acts to determine the fate of common pancreatic precursor cells and/or to regulate their propagation.	UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN	Umea University				Edlund, Helena/0000-0002-3553-7348				GITHENS S, 1989, HUMAN GASTROINTESTIN, P669; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; HOGAN B, 1986, MANIPULATING MOUSE E, P194; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Pictet R., 1972, HDB PHYSL, P25; SPOONER BS, 1970, J CELL BIOL, V47, P235, DOI 10.1083/jcb.47.1.235; SPOONER BS, 1977, DEV BIOL, V61, P119, DOI 10.1016/0012-1606(77)90285-8; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WESSELLS NK, 1967, DEV BIOL, V15, P237, DOI 10.1016/0012-1606(67)90042-5; WRIGHT CVE, 1988, DEVELOPMENT, V104, P787	14	1467	1542	0	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					606	609		10.1038/371606a0	http://dx.doi.org/10.1038/371606a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935793				2022-12-28	WOS:A1994PL55900052
J	BURR, DC; MORRONE, MC; ROSS, J				BURR, DC; MORRONE, MC; ROSS, J			SELECTIVE SUPPRESSION OF THE MAGNOCELLULAR VISUAL PATHWAY DURING SACCADIC EYE-MOVEMENTS	NATURE			English	Article							MOTION PERCEPTION; MACAQUE MONKEY; SENSITIVITY; CONTRAST; IMAGE	VISUAL scientists have long sought to explain why the world remains stable during saccades, the ballistic eye-movements that continually displace the retinal image at fast but resolvable(1) velocities. An early suggestion was that vision may be actively suppressed during saccades(2), but experimental support has been variable(3-5). Here we present evidence that saccadic suppression does occur, but that it is selective for patterns modulated in luminance at low spatial frequencies. Patterns of higher Spatial frequency, and equiluminant patterns (modulated only in colour) at all spatial frequencies were not suppressed during saccades, but actually enhanced. The selectivity of the suppression suggests that it is confined to the colour-blind magnocellular stream (which provides the dominant input to motion centres and areas involved with attention), where it could dull the otherwise disturbing sense of Past low-spatial-frequency image motion. Masking studies suggest that the suppression precedes the site of contrast masking and may therefore occur early in visual processing, possibly as early as the lateral geniculate nucleus.	UNIV ROME, DEPT PSYCHOL, I-00185 ROME, ITALY; UNIV WESTERN AUSTRALIA, DEPT PSYCHOL, NEDLANDS, WA 6009, AUSTRALIA	Sapienza University Rome; University of Western Australia	BURR, DC (corresponding author), CNR, IST NEUROFISIOL, VIA S ZENO 51, I-56127 PISA, ITALY.		Morrone, Maria Concetta/C-6756-2014	Morrone, Maria Concetta/0000-0002-1025-0316; Burr, David/0000-0003-1541-8832				BONDS AB, 1991, NONLINEAR VISION DET, P329; Burr D. C., 1982, VISION RES, V23, P3567, DOI [10.1016/0042-6989(82)90196-1, DOI 10.1016/0042-6989(82)90196-1]; BURR DC, 1993, J OPT SOC AM A, V10, P1706, DOI 10.1364/JOSAA.10.001706; BURR DC, 1982, J PHYSIOL-LONDON, V333, P1; CORBETTA M, 1993, J NEUROSCI, V13, P1202; CROPPER SJ, 1988, PERCEPTION, V17, P353; DERRINGTON AM, 1984, VISION RES, V24, P1965, DOI 10.1016/0042-6989(84)90031-2; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; Grusser O.J., 1991, VISION VISUAL DYSFUN, V12; Holt EB, 1903, PSYCHOL REV-MONOGR S, V4, P3; ILG UJ, 1993, VISION RES, V33, P211, DOI 10.1016/0042-6989(93)90159-T; KRAUSKOPF J, 1966, AM J PSYCHOL, V79, P73, DOI 10.2307/1420709; LATOUR PL, 1962, VISION RES, V2, P261, DOI 10.1016/0042-6989(62)90031-7; MACKAY DM, 1970, NATURE, V225, P90, DOI 10.1038/225872a0; MATIN E, 1974, PSYCHOL BULL, V81, P899, DOI 10.1037/h0037368; MAUNSELL JHR, 1990, J NEUROSCI, V10, P3323; MERIGAN WH, 1991, J NEUROSCI, V11, P3422; MERIGAN WH, 1991, J NEUROSCI, V11, P994; MERIGAN WH, 1993, ANNU REV NEUROSCI, V16, P369, DOI 10.1146/annurev.ne.16.030193.002101; MERIGAN WH, 1991, NATO ADV SCI I A-LIF, V203, P117; OHZAWA I, 1982, NATURE, V298, P5871; RIGGS LA, 1974, VISION RES, V14, P997, DOI 10.1016/0042-6989(74)90169-2; SCHILLER PH, 1990, NATURE, V343, P68, DOI 10.1038/343068a0; SCLAR G, 1990, VISION RES, V30, P1, DOI 10.1016/0042-6989(90)90123-3; SHIOIRI S, 1989, VISION RES, V29, P915, DOI 10.1016/0042-6989(89)90106-5; UCHIKAWA K, IN PRESS J OPT SOC A; UNGERLEIDER LG, 1986, J COMP NEUROL, V248, P147, DOI 10.1002/cne.902480202; WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828; [No title captured]	29	484	492	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					511	513		10.1038/371511a0	http://dx.doi.org/10.1038/371511a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935763				2022-12-28	WOS:A1994PK58900054
J	HEIDELBERGER, R; HEINEMANN, C; NEHER, E; MATTHEWS, G				HEIDELBERGER, R; HEINEMANN, C; NEHER, E; MATTHEWS, G			CALCIUM-DEPENDENCE OF THE RATE OF EXOCYTOSIS IN A SYNAPTIC TERMINAL	NATURE			English	Article							SQUID GIANT SYNAPSE; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; CHROMAFFIN CELLS; GOLDFISH RETINA; BIPOLAR CELLS; SECRETION; CHANNELS; INFLUX; CHELATORS	RAPID calcium-dependent exocytosis underlies neurotransmitter release from nerve terminals. Despite the fundamental importance of this process, neither the relationship between presynaptic intracellular calcium ion concentration ([Ca2+](i)) and rate of exocytosis, nor the maximal rate of secretion is known quantitatively. To provide this information, we have used flash photolysis of caged Ca2+ to elevate [Ca2+](i) rapidly and uniformly in synaptic terminals, while measuring membrane capacitance as ao index of exocytosis and monitoring [Ca2+](i) with a Ca2+-indicator dye. When [Ca2+](i) was abruptly increased to > 10 mu M, capacitance rose at a rate that increased steeply with [Ca2+](i). The steepness suggested that at least four calcium ions must bind to activate synaptic vesicle fusion. Half-saturation was at 194 mu M, and the maximal rate constant was 2,000-3,000 s(-1). A given synaptic vesicle can exocytose with high probability within a few hundred microseconds, if [Ca2+](i) rises above 100 mu M These properties provide for the extremely rapid signalling required for neuronal communication.	SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	HEIDELBERGER, R (corresponding author), MAX PLANCK INST BIOPHYS CHEM,MEMBRANBIOPHYS ABT,FASSBERG,W-3400 GOTTINGEN,GERMANY.		Neher, Erwin/A-2109-2013	Heidelberger, Ruth/0000-0002-8033-2050				ADLER EM, 1991, J NEUROSCI, V11, P1496; ALMERS W, 1994, NATURE, V367, P682; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DELANEY KR, 1990, J PHYSIOL-LONDON, V426, P473, DOI 10.1113/jphysiol.1990.sp018150; DOWLING JE, 1987, RETINA APPROACHABLE, P42; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIDELBERGER R, 1992, J PHYSIOL-LONDON, V447, P235, DOI 10.1113/jphysiol.1992.sp019000; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; HEINEMANN C, IN PRESS BIOPHYS J; HERRINGTON J, 1993, PULSE CONTROL V3 0 I; ISHIDA AT, 1980, J COMP NEUROL, V191, P315, DOI 10.1002/cne.901910302; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P483, DOI 10.1098/rspb.1965.0016; KONISHI M, 1991, J GEN PHYSIOL, V97, P271, DOI 10.1085/jgp.97.2.271; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MCCRAY J, 1992, BIOCHEMISTRY-US, V37, P8856; PARNAS H, 1986, PFLUG ARCH EUR J PHY, V406, P121, DOI 10.1007/BF00586672; ROBERTS WM, 1990, J NEUROSCI, V10, P3664; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; YAZULLA S, 1987, BRAIN RES, V411, P400, DOI 10.1016/0006-8993(87)91095-X; ZUCKER RS, 1993, CELL CALCIUM, V14, P87, DOI 10.1016/0143-4160(93)90079-L; ZUCKER RS, 1986, P NATL ACAD SCI USA, V83, P3032, DOI 10.1073/pnas.83.9.3032	30	620	628	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					513	515		10.1038/371513a0	http://dx.doi.org/10.1038/371513a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935764				2022-12-28	WOS:A1994PK58900055
J	ABUAREFEH, I; RUSSELL, G				ABUAREFEH, I; RUSSELL, G			PREVALENCE OF HEADACHE AND MIGRAINE IN SCHOOLCHILDREN	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; EPIDEMIOLOGY; CRITERIA	Objectives-To determine the prevalence rates of the various causes of severe headache in school-children, with special emphasis on migraine and its impact on school attendance. Design-Population based study in two stages, comprising an initial screening questionnaire followed by clinical interviews and examination of children with symptoms and a control group of asymptomatic children matched for age and sex. Setting-67 primary and secondary schools in the city of Aberdeen. Subjects-2165 children, representing a random sample of 10% of schoolchildren in Aberdeen aged 5-15 years. Main outcome measures-(a) the prevalence of migraine (International Headache Society criteria) and of other types of headache; (b) the impact of migraine on school attendance. Results-The estimated prevalence rates of migraine and tension headache were 10.6% (95% confidence interval 9.1 to 12.3) and 0.9% (0.5 to 1.5) respectively. The estimated prevalence rates for migraine without aura and migraine with aura were 7.8% (95% confidence interval 6.5 to 9.3) and 2.8% (2.0 to 3.8) respectively. In addition, 10 children (0.7%) had headaches which, though lasting less than two hours, also fulfilled the International Headache Society criteria for migraine, 14 (0.9%) had tension headaches, and 20 (1.3%) had non-specific recurrent headache. The prevalence of migraine increased with age, with male preponderance in children under 12 and female preponderance thereafter. Children with migraine lost a mean of 7.8 school days a year due to all illnesses (2.8 days (range 0-80) due to headache) as compared with a mean of 3.7 days lost by controls. Conclusions-Migraine is a common cause of headache in children and causes significantly reduced school attendance.	ROYAL ABERDEEN CHILDRENS HOSP,DEPT MED PAEDIAT,ABERDEEN AB9 2ZG,SCOTLAND	University of Aberdeen			Abu-Arafeh, Ishaq/H-7417-2019	Abu-Arafeh, Ishaq/0000-0003-1252-0153				BARLOW C, 1984, HEADACHE MIGRAINE CH, P172; BILLE B, 1962, ACTA PAED STOCK S136, V51, P1, DOI DOI 10.1111/J.1651-2227.1962.TB06591.X; CHEN TC, 1990, ARCH NEUROL-CHICAGO, V47, P1227, DOI 10.1001/archneur.1990.00530110087022; DALSGAAR.T, 1970, DAN MED BULL, V17, P138; DEUNBER DC, 1977, HEADACHE, V17, P173; GARDNER S, 1989, CONFIDENCE INTERVAL; GREEN JE, 1975, MIGRAINE NEWS    SEP, P30; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; HENRY P, 1992, CEPHALALGIA, V12, P229, DOI 10.1046/j.1468-2982.1992.1204229.x; Hockaday J.M., 1988, MIGRAINE CHILDHOOD, P5; HOCKADAY JM, 1991, MATERN CHILD HLTH J, V16, P246; MORTIMER MJ, 1992, DEV MED CHILD NEUROL, V34, P1095; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; RASMUSSEN BK, 1992, CEPHALALGIA, V12, P221, DOI 10.1046/j.1468-2982.1992.1204221.x; ROSSI LN, 1992, DEV MED CHILD NEUROL, V34, P516; SILLANPAA M, 1983, HEADACHE, V23, P15; SPARKS JP, 1978, PRACTITIONER, V221, P407; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; VAHLQUIST B, 1949, ACTA PAEDIATR, V38, P622, DOI 10.1111/j.1651-2227.1949.tb17914.x; 1962, JAMA-J AM MED ASSOC, V179, P717; 1993, SPSS WINDOWS RELEASE; 1991, WKLY EPIDEMIOL REC, V66, P324	23	548	561	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					765	769		10.1136/bmj.309.6957.765	http://dx.doi.org/10.1136/bmj.309.6957.765			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950559	Green Published			2022-12-28	WOS:A1994PJ28200016
J	WILSON, PWF; MYERS, RH; LARSON, MG; ORDOVAS, JM; WOLF, PA; SCHAEFER, EJ				WILSON, PWF; MYERS, RH; LARSON, MG; ORDOVAS, JM; WOLF, PA; SCHAEFER, EJ			APOLIPOPROTEIN-E ALLELES, DYSLIPIDEMIA, AND CORONARY-HEART-DISEASE - THE FRAMINGHAM OFFSPRING STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; E POLYMORPHISM; ARTERY DISEASE; E PHENOTYPE; MYOCARDIAL-INFARCTION; INCREASED PREVALENCE; LOVASTATIN TREATMENT; TRIGLYCERIDE LEVELS; ALZHEIMERS-DISEASE	Objective.-To describe the association between apolipoprotein E alleles (epsilon 2, epsilon 3, and epsilon 4), dyslipidemias, and coronary heart disease (CHD). Design.-Cross-sectional prevalence study. Setting and Participants.-Community-based sample of men (n=1034) and women (n=916) aged 40 to 77 years who are participating in a long-term study of cardiovascular disease. Study participants underwent fasting lipid measurements, coronary risk factor determinations, and a comprehensive evaluation for the presence of current or previous CHD. Results.-Compared with the epsilon 3 allele, the epsilon 4 allele was associated with elevated low-density lipoprotein cholesterol values (greater than or equal to 4.14 mmol/L [160 mg/dL]) in women, the epsilon 2 and epsilon 4 alleles were associated with moderately elevated triglyceride values (greater than or equal to 2.82 mmol/L [250 mg/dL]) in men, and the epsilon 2 allele was associated with severely elevated triglyceride values (greater than or equal to 5.64 mmol/L [500 mg/dL]) in men. The apolipoprotein E alleles were not associated with hypertension, obesity, smoking, or diabetes, but the epsilon 4 allele frequency was reduced in women after 60 years of age. The age-adjusted prevalence of CHD was associated with the epsilon 4 allele in both men (relative odds=1.53, P=.04) and women (relative odds=1.99, P=.05). In analyses for women and for both sexes combined, this relation persisted after adjustment by hypertension, smoking, obesity, diabetes, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. Conclusions.-Apolipoprotein E alleles are important genetic markers for dyslipidemia and CHD. The estimated CHD odds associated with the epsilon 4 allele appears to be greater than that for any other known genetic lipid abnormality, and the association of the epsilon 4 allele with CHD remains significant in women and both sexes combined after adjustment by traditional coronary risk factors and lipids.	BOSTON UNIV,MED CTR,BOSTON,MA; TUFTS UNIV,USDA,HUMAN NUTR RES CTR,BOSTON,MA 02111	Boston University; Tufts University; United States Department of Agriculture (USDA)	WILSON, PWF (corresponding author), FRAMINGHAM HEART DIS EPIDEMIOL STUDY,5 THURBER ST,FRAMINGHAM,MA 01701, USA.		Wilson, Peter W.F./J-2455-2016; Ordovas, Jose/B-8727-2013	Wolf, Philip/0000-0002-3628-301X; Larson, Martin/0000-0002-9631-1254; Myers, Richard/0000-0002-8365-2674; Ordovas, Jose/0000-0002-7581-5680				ASSMANN G, 1984, CLIN CHEM, V30, P641; BOEMI M, 1993, DIABETOLOGIA, V36, P229, DOI 10.1007/BF00399955; BOERWINKLE E, 1987, ANN HUM GENET, V51, P211, DOI 10.1111/j.1469-1809.1987.tb00874.x; BOERWINKLE E, 1988, AM J HUM GENET, V42, P104; BREWER HB, 1983, ANN INTERN MED, V98, P623, DOI 10.7326/0003-4819-98-5-623; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CARMENA R, 1993, METABOLISM, V42, P895, DOI 10.1016/0026-0495(93)90066-W; CHIVOT L, 1990, ATHEROSCLEROSIS, V82, P205, DOI 10.1016/0021-9150(90)90042-H; COBB MM, 1992, CIRCULATION, V86, P849, DOI 10.1161/01.CIR.86.3.849; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CUMMING AM, 1984, CLIN GENET, V25, P310; CUPPPLES LA, 1987, FRAMINGHAM STUDY EPI; DALLONGEVILLE J, 1992, J LIPID RES, V33, P447; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DEKNIJFF P, 1990, ATHEROSCLEROSIS, V83, P89; DESPRES JP, 1993, DIABETES, V42, P1474, DOI 10.2337/diabetes.42.10.1474; EHNHOLM C, 1986, J LIPID RES, V27, P227; EICHNER JE, 1990, ARTERIOSCLEROSIS, V10, P379, DOI 10.1161/01.ATV.10.3.379; EICHNER JE, 1993, AM J CARDIOL, V71, P160, DOI 10.1016/0002-9149(93)90732-R; ETO M, 1989, CLIN GENET, V36, P183; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Funke Harald, 1993, Current Opinion in Lipidology, V4, P453, DOI 10.1097/00041433-199312000-00006; GHISELLI G, 1982, J CLIN INVEST, V70, P474, DOI 10.1172/JCI110638; GLUECK CJ, 1976, METABOLISM, V25, P1269, DOI 10.1016/S0026-0495(76)80010-8; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1533, DOI 10.1172/JCI107331; HIXSON JE, 1991, ARTERIOSCLER THROMB, V11, P1237, DOI 10.1161/01.ATV.11.5.1237; JANUS ED, 1985, ATHEROSCLEROSIS, V57, P249, DOI 10.1016/0021-9150(85)90038-3; KAMBOH MI, 1993, ATHEROSCLEROSIS, V98, P201, DOI 10.1016/0021-9150(93)90129-I; KUUSI T, 1989, ARTERIOSCLEROSIS, V9, P237, DOI 10.1161/01.ATV.9.2.237; LENZEN HJ, 1986, CLIN CHEM, V32, P778; LOUHIJA J, 1994, ARTERIOSCLER THROMB, V14, P1084, DOI 10.1161/01.ATV.14.7.1084; MAHLEY RW, 1991, JAMA-J AM MED ASSOC, V265, P78, DOI 10.1001/jama.265.1.78; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; NIEMINEN MS, 1992, ARTERIOSCLER THROMB, V12, P58, DOI 10.1161/01.ATV.12.1.58; OJALA JP, 1991, J INTERN MED, V230, P397, DOI 10.1111/j.1365-2796.1991.tb00464.x; OMALLEY JP, 1990, METABOLISM, V39, P150, DOI 10.1016/0026-0495(90)90068-N; ORDOVAS JM, 1987, J LIPID RES, V28, P371; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RUST S, 1992, CIRCULATION, V86, P420; SCHAEFER EJ, 1994, ARTERIOSCLER THROMB, V14, P1105, DOI 10.1161/01.ATV.14.7.1105; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P234; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHMITZ G, 1993, ARTERIOSCLER THROMB, V13, P1053, DOI 10.1161/01.ATV.13.7.1053; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SING CF, 1985, AM J HUM GENET, V37, P268; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1993, NEUROLOGY, V43, P1467; STUYT PMJ, 1991, SCAND J CLIN LAB INV, V51, P425, DOI 10.3109/00365519109091636; UKKOLA O, 1993, ATHEROSCLEROSIS, V101, P9, DOI 10.1016/0021-9150(93)90096-D; UTERMANN G, 1984, HUM GENET, V65, P237, DOI 10.1007/BF00286509; UTERMANN G, 1979, CLIN GENET, V15, P37; UTERMANN G, 1979, CLIN GENET, V15, P63; VANBOCKXMEER FM, 1992, LANCET, V340, P879, DOI 10.1016/0140-6736(92)93288-X; WALDEN CC, 1994, ANN INTERN MED, V120, P1026, DOI 10.7326/0003-4819-120-12-199406150-00009; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; WILSON PWF, 1980, ACCEL TAPES, V12, P1; YAMAMOTO A, 1990, ANN NY ACAD SCI, V598, P58, DOI 10.1111/j.1749-6632.1990.tb42276.x; YAMAMURA T, 1990, JPN CIRC J, V54, P448, DOI 10.1253/jcj.54.448; 1993, JAMA-J AM MED ASSOC, V269, P505; 1974, NIH75628 LIP RES CLI; 1993, JAMA-J AM MED ASSOC, V269, P3015	64	423	428	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1666	1671		10.1001/jama.272.21.1666	http://dx.doi.org/10.1001/jama.272.21.1666			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966894				2022-12-28	WOS:A1994PU75900025
J	SOLOMON, R; WERNER, C; MANN, D; DELIA, J; SILVA, P				SOLOMON, R; WERNER, C; MANN, D; DELIA, J; SILVA, P			EFFECTS OF SALINE, MANNITOL, AND FUROSEMIDE ON ACUTE DECREASES IN RENAL-FUNCTION INDUCED BY RADIOCONTRAST AGENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAJOR ANGIOGRAPHY; CARDIAC-CATHETERIZATION; CONTRAST NEPHROPATHY; CORONARY ANGIOGRAPHY; RISK-FACTORS; FAILURE; DYSFUNCTION; INSUFFICIENCY; MEDIA; NEPHROTOXICITY	Background. Injections of radiocontrast agents are a frequent cause of acute decreases in renal function, occurring most often in patients with chronic renal insufficiency and diabetes mellitus. Methods. We prospectively studied 78 patients with chronic renal insufficiency (mean [+/-SD] serum creatinine concentration, 2.1+/-0.6 mg per deciliter [186+/-53 mu mol per liter]) who underwent cardiac angiography. The patients were randomly assigned to receive 0.45 percent saline alone for 12 hours before and 12 hours after angiography, saline plus mannitol, or saline plus furosemide. The mannitol and furosemide were given just before angiography. Serum creatinine was measured before and far 48 hours after angiography, and urine was collected for 24 hours after angiography. An acute radiocontrast-induced decrease in renal function was defined as an increase in the base-line serum creatinine concentration of at least 0.5 mg per deciliter (44 mu mol per liter) within 48 hours after the injection of radiocontrast agents. Results. Twenty of the 78 patients (26 percent) had an increase in the serum creatinine concentration of at least 0.5 mg per deciliter after angiography. Among the 28 patients in the saline group, 3 (11 percent) had such an increase in serum creatinine, as compared with 7 of 25 in the mannitol group (28 percent) and 10 of 25 in the furosemide group (40 percent) (P = 0.05). The mean increase in serum creatinine 48 hours after angiography was significantly greater in the furosemide group (P = 0.01) than in the saline group. Conclusions. In patients with chronic renal insufficiency who are undergoing cardiac angiography, hydration with 0.45 percent saline provides better protection against acute decreases in renal function induced by radiocontrast agents than does hydration with 0.45 percent saline plus mannitol or furosemide.	NEW ENGLAND DEACONESS HOSP,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	SOLOMON, R (corresponding author), JOSLIN DIABET CTR,1 JOSLIN PL,BOSTON,MA 02215, USA.			D'Elia, John/0000-0001-9482-581X				ANTO HR, 1981, ARCH INTERN MED, V141, P1652, DOI 10.1001/archinte.141.12.1652; BARRETT BJ, 1992, KIDNEY INT, V41, P1274, DOI 10.1038/ki.1992.189; BERNS AS, 1989, KIDNEY INT, V36, P730, DOI 10.1038/ki.1989.254; BERONIADE VC, 1981, 8TH INT C NEPHR ATH, P380; Brown RS, 1990, J AM SOC NEPHROL, V1, p330A; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; CRONIN RE, 1978, KIDNEY INT, V14, P187, DOI 10.1038/ki.1978.106; DAVIDSON CJ, 1989, ANN INTERN MED, V110, P119, DOI 10.7326/0003-4819-110-2-119; DELIA JA, 1982, AM J MED, V72, P719, DOI 10.1016/0002-9343(82)90536-8; EISENBERG RL, 1980, AM J MED, V68, P43, DOI 10.1016/0002-9343(80)90163-1; GOMES AS, 1989, RADIOLOGY, V170, P65, DOI 10.1148/radiology.170.1.2909121; GUSSENHOVEN MJE, 1991, J CARDIOVASC SURG, V32, P81; HEYMAN SN, 1991, KIDNEY INT, V40, P632, DOI 10.1038/ki.1991.255; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; LAUTIN EM, 1991, AM J ROENTGENOL, V157, P49, DOI 10.2214/ajr.157.1.2048539; LEVY E, 1993, J AM SOC NEPHROL, V4, pA319; MANSKE CL, 1990, AM J MED, V89, P615, DOI 10.1016/0002-9343(90)90180-L; MARTINPAREDERO V, 1983, ARCH SURG-CHICAGO, V118, P1417; MASON RA, 1985, JAMA-J AM MED ASSOC, V253, P1001, DOI 10.1001/jama.253.7.1001; MENASHE PI, 1988, CRIT CARE MED, V16, P1106, DOI 10.1097/00003246-198811000-00005; MORRIS CR, 1972, J CLIN INVEST, V51, P1555, DOI 10.1172/JCI106952; NORA N, 1989, KIDNEY INT, V35, P414; OGUAGHA C, 1981, 8TH INT C NEPHR ATH, P290; OLD CW, 1981, CLIN RES, V29, pA470; PERNEGER TV, 1993, J AM SOC NEPHROL, V4, pA256; PORTER GA, 1989, AM J CARDIOL, V64, pE22, DOI 10.1016/0002-9149(89)90730-3; RICH MW, 1990, ARCH INTERN MED, V150, P1237, DOI 10.1001/archinte.150.6.1237; SWARTZ RD, 1978, AM J MED, V65, P31, DOI 10.1016/0002-9343(78)90689-7; TALIERCIO CP, 1986, ANN INTERN MED, V104, P501, DOI 10.7326/0003-4819-104-4-501; VOSNIDES G, 1981, 8TH INT C NEPHR ATH, P306; WEINRAUCH LA, 1977, ANN INTERN MED, V86, P56, DOI 10.7326/0003-4819-86-1-56; WEINSTEIN JM, 1992, NEPHRON, V62, P413, DOI 10.1159/000187090; WEISBERG LS, 1994, KIDNEY INT, V45, P259, DOI 10.1038/ki.1994.32	33	865	922	0	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1416	1420		10.1056/NEJM199411243312104	http://dx.doi.org/10.1056/NEJM199411243312104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7969280				2022-12-28	WOS:A1994PU53300004
J	OSHAUGHNESSY, MV; SCHECHTER, MT				OSHAUGHNESSY, MV; SCHECHTER, MT			LEARNING ABOUT HIV-2	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS; RETROVIRUS				OSHAUGHNESSY, MV (corresponding author), UNIV BRITISH COLUMBIA,ST PAULS HOSP,BRITISH COLUMBIA CTR EXCELLENCE HIV AIDS,VANCOUVER,BC,CANADA.			Schechter, Martin/0000-0001-6063-2155				ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; BARIN F, 1985, LANCET, V2, P1387; CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; Kanki PJ, 1994, AIDS S1, V8, pS85; LOONEY DJ, 1990, J ACQ IMMUN DEF SYND, V3, P649; SIMON F, 1994, SCIENCE, V26, P1587; THOMAS FP, 1994, J VIROL, V68, P7099, DOI 10.1128/JVI.68.11.7099-7107.1994	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1380	1381		10.1016/S0140-6736(94)90563-0	http://dx.doi.org/10.1016/S0140-6736(94)90563-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968070				2022-12-28	WOS:A1994PR78600004
J	ROSENBLUM, LS; CASTRO, KG; DOOLEY, S; MORGAN, M; COLBERT, G				ROSENBLUM, LS; CASTRO, KG; DOOLEY, S; MORGAN, M; COLBERT, G			EFFECT OF HIV-INFECTION AND TUBERCULOSIS ON HOSPITALIZATIONS AND COST OF CARE FOR YOUNG-ADULTS IN THE UNITED-STATES, 1985 TO 1990	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; INTRAVENOUS DRUG-USERS; CLINICAL-FEATURES; MEDICAL-CARE; OUTBREAK; AIDS; TRANSMISSION; MANAGEMENT; IMPACT	Objective: To evaluate the effect of human immunodeficiency virus (HIV) infection and tuberculosis on hospitalizations and the cost of care. Design: National Hospital Discharge Survey, a nationally representative survey of discharges from U.S. nonfederal short-stay hospitals, and statewide billing information. Patients: Patients 15 to 44 years of age with a listed diagnosis of HIV infection (n = 418 200) or active tuberculosis (n = 77 700) during 1985-1990. Results: During 1985-1990, hospitalizations related to HIV infection increased sixfold, from 18 to 102 per 100 000 persons; during 1988-1990, hospitalizations related to-tuberculosis increased twofold, from 8 to 16 per 100 000 persons. The prevalence of tuberculosis among HIV-infected patients increased from 2.4% in 1985-1988 to 5.1% in 1989-1990 (P = 0.003). The prevalence of HIV infection among patients with tuberculosis increased from 11% in 1985-1988 to 28% in 1989 to 39% in 1990 (P < 0.001). Infection with HIV was more prevalent among patients with extrapulmonary tuberculosis (31%) than among those with pulmonary tuberculosis (18%) (P = 0.01). An increase in the duration of hospital stay was associated with both tuberculosis and HIV infection. From 1985 to 1990, inpatient care costs increased 7.7-fold and 3.2-fold for HIV and tuberculosis hospitalizations, respectively. During this period, HIV and tuberculosis hospitalizations resulted in 5 793 000 and 1 107 900 days of care, respectively, with an estimated direct cost of $5.7 to $7.4 billion and $0.89 to $1.07 billion, respectively. Estimated national costs of inpatient care for HIV infection or tuberculosis or both totaled $6.4 to $8.1 billion, 5% of which was for patients with both HIV infection and tuberculosis. Conclusions: This is the first study to use a nationally representative sample of hospitals, combined with cost data, to estimate hospitalizations and their costs for HIV and tuberculosis care. Our findings suggest that the convergence of the HIV and tuberculosis epidemics has had an increasing effect on morbidity and the cost of care among young adults in the United States. The increasing prevalence of comorbidity of HIV infection and tuberculosis in inpatients underscores the need for strict infection control of tuberculosis on the part of hospitals, increased attention to prevention, and early identification and treatment of HIV infection and tuberculosis to reduce morbidity, hospitalizations, and the cost of care.	CTR DIS CONTROL & PREVENT, DIV HIV AIDS, SURVEILLANCE BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA			Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				ANDRULIS DP, 1992, JAMA-J AM MED ASSOC, V267, P2482, DOI 10.1001/jama.267.18.2482; ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P784, DOI 10.1001/jama.262.6.784; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1994, MMWR MORB MORTAL WKL; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BURWEN D, 1993, MAY AM LUNG ASS AM T; Centers for Disease Control and Prevention, 1987, MMWR-MORBID MORTAL W, V36, p1S; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P718; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FARNHAM PG, 1994, IN PRESS READINGS PU; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HAUPT BJ, 1992, VITAL HLTH STATI 111, V13; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RAVIGLIONE MC, 1992, B WORLD HEALTH ORGAN, V70, P515; ROSENBLUM L, 1993, AM J PUBLIC HEALTH, V83, P1457, DOI 10.2105/AJPH.83.10.1457; ROSENBLUM LS, 1992, J ACQ IMMUN DEF SYND, V5, P497; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, AIDS, V3, pS201, DOI 10.1097/00002030-198901001-00029; SHAH BY, 1981, SESUDAAN STANDARD ER, P1; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; 1980, DHHS PHS801260 PUB; 1992, TUBERCULOSIS STATIST, P14; 1990, MMWR-MORBID MORTAL W, V39, P110; 1990, MMWR-MORBID MORTAL W, V39, P9; 1993, MMWR-MORBID MORTAL W, V42, P696; 1989, MMWR-MORBID MORTAL W, V38, P243; 1989, AIDS PUBLIC INFORMAT; 1993, MMWR-MORBID MORTAL W, V42, P11; 1989, MMWR-MORBID MORTAL W, V38, P236; 1993, MMWR-MORBID MORTAL W, V42, P703; 1989, CURRENT POPULATI P25, V1044, P13; 1986, SUGI SUPPLEMENTAL LI, P269; 1992, STATISTICAL ABSTRACT, P471	45	40	40	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					786	792		10.7326/0003-4819-121-10-199411150-00009	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944056				2022-12-28	WOS:A1994PQ92800009
J	AMOUYEL, P; VIDAL, O; LAUNAY, JM; LAPLANCHE, JL				AMOUYEL, P; VIDAL, O; LAUNAY, JM; LAPLANCHE, JL			THE APOLIPOPROTEIN-E ALLELES AS MAJOR SUSCEPTIBILITY FACTORS FOR CREUTZFELDT-JAKOB-DISEASE	LANCET			English	Article							FAMILIAL ALZHEIMER-DISEASE; TYPE-4 ALLELE; GENE; REGENERATION; EXPRESSION; RECEPTORS; NERVE	Creutzfeldt-Jakob disease (CJD) is a rapid progressive mental and neurological disorder characterised by dementia and is both infectious and genetic. Pathogenic mutations and a predisposing polymorphism have been described in the prion protein gene and an abnormal prion product accumulates in the brain of affected patients. Apolipoprotein E (APOE), a protein of lipid metabolism, has been detected in some prion protein deposits. This ApoE exists as three common isoforms, coded by specific allele (epsilon 2, epsilon 3, epsilon 4). The presence of at least one epsilon 4 allele was described as a major risk factor for Alzheimer's disease, another neurodegenerative disorder. From a series of 61 patients with CJD we found that epsilon 4 allele of the APOE gene was a risk factor for the disease (p < 0.01). This association was observed in both definite and probable cases, and for patients with and without prion protein gene mutations. Moreover, in affected subjects, epsilon 2 allele of the APOE gene delayed occurrence of death (p < 0.01) independently of other known mutations influencing the phenotype of the disease. These effects on neurodegenerative disease associated with APOE alleles suggest a strong involvement of the APOE locus in brain metabolism.	INST PASTEUR, INSERM, U325, F-59019 LILLE, FRANCE; HOP ST LOUIS, SERV BIOCHIM, PARIS, FRANCE; HOP ST LOUIS, FRA CLAUDE BERNARD, PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	AMOUYEL, P (corresponding author), INST PASTEUR, SERV EPIDEMIOL & SANTE PUBL, 1 RUE CALMETTE, F-59019 LILLE, FRANCE.		LAPLANCHE, Jean-Louis/S-8707-2016	Amouyel, Philippe/0000-0001-9088-234X; LAPLANCHE, Jean-Louis/0000-0003-2836-2903				AMOUYEL P, 1993, LANCET, V342, P1309; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BROUSSEAU T, 1994, NEUROLOGY, V44, P342, DOI 10.1212/WNL.44.2.342; BROWN P, 1991, EUR J EPIDEMIOL, V7, P469, DOI 10.1007/BF00143124; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; DOHURA K, 1991, NATURE, V353, P801, DOI 10.1038/353801b0; HIXSON JE, 1990, J LIPID RES, V31, P545; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; LAPLANCHE JL, IN PRESS NEUROLOGY; LUC G, 1994, ARTERIOSCLER THROMB, V14, P1412, DOI 10.1161/01.ATV.14.9.1412; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1993, ARCH NEUROL-CHICAGO, V50, P1129, DOI 10.1001/archneur.1993.00540110011002; REBECK GW, 1993, NEURON, V11, P575; RIPOLL L, 1993, NEUROLOGY, V43, P1934, DOI 10.1212/WNL.43.10.1934; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SCHELLENBERG GD, 1987, J NEUROGENET, V4, P97, DOI 10.3109/01677068709102337; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; 1988, SAS P179 SAS I INC T, P49; 1993, LANCET, V342, P737	29	139	145	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	1994	344	8933					1315	1318		10.1016/S0140-6736(94)90691-2	http://dx.doi.org/10.1016/S0140-6736(94)90691-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968026				2022-12-28	WOS:A1994PQ92600007
J	MANT, D				MANT, D			PREVENTION	LANCET			English	Article							HYPERTENSION				MANT, D (corresponding author), UNIV SOUTHAMPTON,FAC MED,ALDERMOOR HLTH CTR,SOUTHAMPTON SO16 5ST,HANTS,ENGLAND.							ALLSOP J, 1986, EMPERORS NEW CLOTHES; BUNTINX F, 1992, SEARCH GOOD QUALITY; COCKBURN J, 1992, BRIT MED J, V304, P691, DOI 10.1136/bmj.304.6828.691; DIETRICH A, 1994, BRIT MED J, V304, P687; ECCLES M, 1991, BMJ-BRIT MED J, V302, P91, DOI 10.1136/bmj.302.6768.91; ELWOOD JM, 1984, BRIT MED J, V289, P891, DOI 10.1136/bmj.289.6449.891; FULLARD E, 1984, BRIT MED J, V289, P1585, DOI 10.1136/bmj.289.6458.1585; Hart, 1988, NEW KIND DOCTOR; LEES KR, 1992, BMJ-BRIT MED J, V304, P713, DOI 10.1136/bmj.304.6828.713-a; MCCORMICK J, 1988, LANCET, V2, P839; PARKIN DM, 1981, PUBLIC HEALTH, V95, P311, DOI 10.1016/S0033-3506(81)80003-0; ROBSON J, 1989, BMJ-BRIT MED J, V298, P433, DOI 10.1136/bmj.298.6671.433; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; The South-East London Screening Study Group, 1977, INT J EPIDEMIOL, V6, P357; WILBER JA, 1972, AM J MED, V52, P653, DOI 10.1016/0002-9343(72)90055-1; 1994, BRIT MED J, V308, P313; 1985, LANCET, V2, P363; 1994, BRIT MED J, V308, P308; 1994, CERVICAL CYTOLOGY EN; 1981, RCGP20 ROYAL COLL GE	20	25	25	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1343	1346		10.1016/S0140-6736(94)90698-X	http://dx.doi.org/10.1016/S0140-6736(94)90698-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968032				2022-12-28	WOS:A1994PQ92600014
J	GEORGE, JN; ELHARAKE, MA; RASKOB, GE				GEORGE, JN; ELHARAKE, MA; RASKOB, GE			CURRENT CONCEPTS - CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IMMUNE THROMBOCYTOPENIA; IMMUNOGLOBULIN-G; GAMMA-GLOBULIN; ANTI-D; ADULT; THERAPY; SPLENECTOMY; AUTOANTIBODIES; TRANSMISSION; MANAGEMENT		UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOSTAT & EPIDEMIOL, OKLAHOMA CITY, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	GEORGE, JN (corresponding author), UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, HEMATOL ONCOL SECT, POB 26901, OKLAHOMA CITY, OK 73190 USA.							ANDERSEN JC, 1994, NEW ENGL J MED, V330, P1560, DOI 10.1056/NEJM199406023302203; ANDREW M, 1992, J PEDIATR-US, V120, P522, DOI 10.1016/S0022-3476(10)80001-0; BALLEM PJ, 1987, J CLIN INVEST, V80, P33, DOI 10.1172/JCI113060; BALLEM PJ, 1993, OBSTETRIC TRANSFUSIO, P49; BAUMANN MA, 1986, ANN INTERN MED, V104, P808, DOI 10.7326/0003-4819-104-6-808; BERCHTOLD P, 1993, BLOOD, V81, P1246; BLANCHETTE VS, 1992, SEMIN HEMATOL, V29, P72; BURROWS RF, 1993, NEW ENGL J MED, V329, P1463, DOI 10.1056/NEJM199311113292005; BUSSEL JB, 1991, BLOOD, V77, P1884; BUSSEL JB, 1988, BLOOD, V72, P121; CARPENTER AF, 1959, JAMA-J AM MED ASSOC, V171, P1911, DOI 10.1001/jama.1959.03010320001001; CARR JM, 1986, AM J MED, V80, P1051, DOI 10.1016/0002-9343(86)90664-9; CORTELAZZO S, 1991, BLOOD, V77, P31; DENOTTOLANDER GJ, 1984, SCAND J HAEMATOL, V32, P101; DIFINO SM, 1980, AM J MED, V69, P430, DOI 10.1016/0002-9343(80)90016-9; DOAN CA, 1960, ANN INTERN MED, V53, P861, DOI 10.7326/0003-4819-53-5-861; EYSTER ME, 1993, BLOOD, V81, P828; FABRIS F, 1989, ACTA HAEMATOL-BASEL, V81, P28; FACON T, 1992, AM J HEMATOL, V41, P184, DOI 10.1002/ajh.2830410308; FIGUEROA M, 1993, NEW ENGL J MED, V328, P1226, DOI 10.1056/NEJM199304293281703; FRIEND PJ, 1990, NEW ENGL J MED, V323, P807, DOI 10.1056/NEJM199009203231207; FUJISAWA K, 1992, BLOOD, V79, P1441; FUJISAWA K, 1993, BLOOD, V81, P2872; GEORGE JN, 1990, BLOOD, V76, P859; George JN, 1994, WILLIAMS HEMATOLOGY, P1315; GUTHRIE TH, 1988, AM J MED SCI, V296, P17, DOI 10.1097/00000441-198807000-00004; HARRINGTON WJ, 1951, J LAB CLIN MED, V38, P1; HE RY, 1994, BLOOD, V83, P1024; IKKALA E, 1978, ANN CLIN RES, V10, P83; JACOBS P, 1986, Q J MED, V58, P153; JIJI RM, 1973, ARCH INTERN MED, V132, P380, DOI 10.1001/archinte.132.3.380; JULIA A, 1990, BRIT J HAEMATOL, V76, P250, DOI 10.1111/j.1365-2141.1990.tb07880.x; KAUFMAN DW, 1993, BLOOD, V82, P2714; KURATA Y, 1994, THROMB HAEMOSTASIS, V71, P184; LACEY JV, 1977, SEMIN THROMB HEMOST, V3, P160; MCCRAE KR, 1992, BLOOD, V80, P2697; MEYERS MC, 1961, AM J MED SCI, V242, P295, DOI 10.1097/00000441-196109000-00004; NAJEAN Y, 1989, CANCER, V64, P2506, DOI 10.1002/1097-0142(19891215)64:12<2506::AID-CNCR2820641217>3.0.CO;2-J; NAJEAN Y, 1990, BRIT J HAEMATOL, V74, P203, DOI 10.1111/j.1365-2141.1990.tb02566.x; OSKI FA, 1966, NEW ENGL J MED, V275, P352, DOI 10.1056/NEJM196608182750703; PICOZZI VJ, 1980, AM J MED, V69, P690, DOI 10.1016/0002-9343(80)90419-2; PIZZUTO J, 1984, BLOOD, V64, P1179; QUIQUANDON I, 1990, BRIT J HAEMATOL, V74, P223, DOI 10.1111/j.1365-2141.1990.tb02569.x; SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404; Shulman N R, 1965, Trans Assoc Am Physicians, V78, P374; SUAREZ JG, 1992, AM J HEMATOL, V39, P146, DOI 10.1002/ajh.2830390215; THOMPSON RL, 1972, ARCH INTERN MED, V130, P730, DOI 10.1001/archinte.130.5.730; WATSONWILLIAMS EJ, 1958, LANCET, V2, P221	48	216	221	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1207	1211		10.1056/NEJM199411033311807	http://dx.doi.org/10.1056/NEJM199411033311807			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935660				2022-12-28	WOS:A1994PN80600007
J	LIGHT, DW				LIGHT, DW			MANAGED CARE - FALSE AND REAL SOLUTIONS	LANCET			English	Article							HEALTH-CARE				LIGHT, DW (corresponding author), UNIV MED & DENT NEW JERSEY, DIV BEHAV & SOCIAL MED, CAMDEN, NJ 08103 USA.							BERK ML, 1992, HEALTH AFFAIR, V11, P145, DOI 10.1377/hlthaff.11.4.145; BROWN SA, 1993, META ANAL PROCESS CA; DEANGELIS CD, 1994, JAMA-J AM MED ASSOC, V271, P868, DOI 10.1001/jama.271.11.868; Enthoven A.C., 1985, REFLECTIONS MANAGEME; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; Enthoven Alain C., 1988, THEORY PRACTICE MANA; FARMER A, 1993, BRITAINS HLTH SYSTEM, P57; Fox D., 1993, POWER ILLNESS FAILUR; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; FRY J, 1994, REVIVING PRIMARY CAR; LIGHT D, 1993, BRITAINS HLTH SYSTEM, pCH15; LIGHT D, 1993, BRITAINS HLTH SYSTEM; Light D. W, 1993, EUROPEAN J PUBLIC HL, V3, P281; LIGHT DW, 1991, LANCET, V338, P102, DOI 10.1016/0140-6736(91)90088-7; LIGHT DW, 1994, STRATEGIC CHALLENGES; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; REED RR, 1987, JAMA-J AM MED ASSOC, V258, P3279, DOI 10.1001/jama.258.22.3279; ROBINSON JC, 1994, MILBANK Q, V72, P259, DOI 10.2307/3350296; 1994, CAPITATED HLTH CARE; 1994, PARTNERSHIPS QUALITY; 1994, HLTH MANAGEMENT GUID, V5, P1; [No title captured]	22	22	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 29	1994	344	8931					1197	1199		10.1016/S0140-6736(94)90512-6	http://dx.doi.org/10.1016/S0140-6736(94)90512-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934544				2022-12-28	WOS:A1994PN80300013
J	NAVARRO, V; REUBEN, A				NAVARRO, V; REUBEN, A			IMAGES IN CLINICAL MEDICINE - BLEEDING ESOPHAGEAL-VARICES	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											NAVARRO, V (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06510, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1129	1129						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7935637				2022-12-28	WOS:A1994PN06500005
J	BEGG, N; NICOLL, A				BEGG, N; NICOLL, A			MYTHS IN MEDICINE .1. IMMUNIZATION	BRITISH MEDICAL JOURNAL			English	Article							FALSE CONTRAINDICATIONS; MEASLES IMMUNIZATION; ANTIBODY-RESPONSE; PARENTS BELIEFS; VACCINATION; INFANTS; RETROVIRUSES; ORIGIN; AIDS				BEGG, N (corresponding author), PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND.							Dalphinis J, 1986, Health Visit, V59, P342; DEFOREST A, 1973, J PEDIATR-US, V83, P93, DOI 10.1016/S0022-3476(73)80323-3; ELLIMAN D, 1990, BRIT MED J, V301, P551, DOI 10.1136/bmj.301.6751.551; GARRETT AJ, 1993, LANCET, V342, P932, DOI 10.1016/0140-6736(93)91982-R; Harding C M, 1985, Community Med, V7, P87; HARDING CM, 1985, CHILD CARE HLTH DEV, V11, P21, DOI 10.1111/j.1365-2214.1985.tb00446.x; HULL D, 1981, BRIT MED J, V283, P1231, DOI 10.1136/bmj.283.6301.1231; HULL D, 1984, LANCET, V2, P1215; JOHN TJ, 1976, PEDIATRICS, V57, P47; KINDER J, 1992, BRIT J GEN PRACT, V42, P160; KLEIN N, 1989, BRIT MED J, V298, P1687, DOI 10.1136/bmj.298.6689.1687; KROBER MS, 1991, JAMA-J AM MED ASSOC, V265, P2095, DOI 10.1001/jama.265.16.2095; KYLE WS, 1992, LANCET, V339, P600, DOI 10.1016/0140-6736(92)90876-5; LECATSAS G, 1992, LANCET, V339, P1427, DOI 10.1016/0140-6736(92)91256-8; LINGAM S, 1986, BRIT MED J, V292, P939, DOI 10.1136/bmj.292.6525.939; NICOLL A, 1985, LANCET, V1, P679; PUGH EJ, 1986, COMMUNITY MED, V8, P340; RITCHIE LD, 1992, BRIT MED J, V304, P816, DOI 10.1136/bmj.304.6830.816; SCHULZ TF, 1992, LANCET, V339, P867, DOI 10.1016/0140-6736(92)90307-O; STEVENS D, 1989, BRIT MED J, V299, P257; STEWART GT, 1977, LANCET, V1, P234; STRICKER RB, 1993, LANCET, V343, P52; WELSH JK, 1979, J PEDIATR-US, V94, P1, DOI 10.1016/S0022-3476(79)80340-6; WILKINSON JR, 1985, PUBLIC HEALTH, V99, P198, DOI 10.1016/S0033-3506(85)80021-4; 1984, IMMUNISATION INFECTI; 1984, WEEKLY EPIDEMIOLOGIC, V3, P13; 1985, HN8519 DEP HLTH SOC; 1992, IMMUNISATION INFECTI; 1990, IMMUNISATION INFECTI; 1981, WHOOPING COUGH REPOR; 1989, MANUAL INFECTIONS IM; 1980, BRIT MED J, V280, P1555; 1988, IMMUNISATION INFECTI; 1991, WEEKLY EPIDEMIOLOGIC, V25, P181	34	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1073	1075		10.1136/bmj.309.6961.1073	http://dx.doi.org/10.1136/bmj.309.6961.1073			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN733	7950746	Green Published			2022-12-28	WOS:A1994PN73300032
J	KUMAR, L				KUMAR, L			DONOR LEUKOCYTE INFUSIONS FOR RELAPSE IN CHRONIC MYELOGENOUS LEUKEMIA	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; LEUKOCYTE INFUSIONS; IMMUNOTHERAPY; TRANSFUSIONS				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,DEPT MED ONCOL,NEW DELHI,INDIA.							ANTIN JH, 1993, BLOOD, V82, P2273; ARCESE W, 1993, BLOOD, V82, P3211; BAR BMAM, 1993, J CLIN ONCOL, V11, P513; CULLIS JO, 1992, BLOOD, V79, P1379; DROBYSKI WR, 1993, BLOOD, V82, P2310; HERTENSTEIN B, 1993, TRANSPLANTATION, V56, P1114, DOI 10.1097/00007890-199311000-00013; KOLB HJ, 1993, SEMIN HEMATOL, V30, P37; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; KUMAR L, 1994, J CLIN ONCOL, V12, P1710, DOI 10.1200/JCO.1994.12.8.1710; MRSIC M, 1992, BONE MARROW TRANSPL, V9, P269; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204	11	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1101	1102		10.1016/S0140-6736(94)90624-6	http://dx.doi.org/10.1016/S0140-6736(94)90624-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934489				2022-12-28	WOS:A1994PN06600003
J	MARKS, I				MARKS, I			UNEVALUATED OR INEFFICIENT APPROACHES ARE HARD TO JUSTIFY	BRITISH MEDICAL JOURNAL			English	Article							DISORDER; EXPOSURE				MARKS, I (corresponding author), INST PSYCHIAT,DE CRESPIGNY PK, DENMARK HILL,LONDON SE5 8AF,ENGLAND.							DURHAM RC, 1993, BRIT J PSYCHIAT, V163, P19, DOI 10.1192/bjp.163.1.19; FAIRBURN CG, 1993, ARCH GEN PSYCHIAT, V50, P419; FOA EB, 1991, J CONSULT CLIN PSYCH, V59, P715, DOI 10.1037/0022-006X.59.5.715; GHOSH A, 1988, BRIT J PSYCHIAT, V152, P234, DOI 10.1192/bjp.152.2.234; LITTMAN AB, 1993, PSYCHOTHER PSYCHOSOM, V60, P148, DOI 10.1159/000288689; MARKS IM, 1993, BRIT J PSYCHIAT, V162, P776, DOI 10.1192/bjp.162.6.776; MARKS IM, 1987, FEARS PHOBIAS; SHAPIRO DA, IN PRESS J CONSULT C; SHEA MT, 1992, ARCH GEN PSYCHIAT, V49, P782, DOI 10.1001/archpsyc.1992.01820100026006; TREASURE J, 1994, BMJ-BRIT MED J, V308, P686, DOI 10.1136/bmj.308.6930.686	10	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1071	1072		10.1136/bmj.309.6961.1071	http://dx.doi.org/10.1136/bmj.309.6961.1071			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN733	7950745	Green Published			2022-12-28	WOS:A1994PN73300030
J	SAMPSON, JH; NEATON, J				SAMPSON, JH; NEATON, J			ON BEING POOR WITH HIV	LANCET			English	Editorial Material							AIDS		UNIV MINNESOTA,SCH PUBL HLTH,DIV BIOSTAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	SAMPSON, JH (corresponding author), OREGON SW WASHINGTON COMMUNITY PROGRAMS CLIN RES,RES & EDUC GRP,PORTLAND,OR, USA.							CURTIS JR, 1993, AM J PUBLIC HEALTH, V83, P1425, DOI 10.2105/AJPH.83.10.1425; ELSADR W, 1992, JAMA-J AM MED ASSOC, V267, P954, DOI 10.1001/jama.267.7.954; FRANKEL DH, 1994, LANCET, V344, P741, DOI 10.1016/S0140-6736(94)92221-7; GRAHAM NMH, 1994, J CLIN EPIDEMIOL, V47, P1003, DOI 10.1016/0895-4356(94)90115-5; SORLIE P, 1992, LANCET, V340, P346, DOI 10.1016/0140-6736(92)91413-3; [No title captured]; 1994, LANCET, V344, P1120	7	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1100	1101		10.1016/S0140-6736(94)90623-8	http://dx.doi.org/10.1016/S0140-6736(94)90623-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934488				2022-12-28	WOS:A1994PN06600002
J	STEEN, N; HUTCHINSON, A; MCCOLL, E; ECCLES, MP; HEWISON, J; MEADOWS, KA; BLADES, SM; FOWLER, P				STEEN, N; HUTCHINSON, A; MCCOLL, E; ECCLES, MP; HEWISON, J; MEADOWS, KA; BLADES, SM; FOWLER, P			DEVELOPMENT OF A SYMPTOM BASED OUTCOME MEASURE FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE; CARE	Measuring symptom specific health outcome is complex, but the methodologies now exist to develop measures with the appropriate properties. As one element of a major programme to develop multidomain health outcome measures for chronic disease, a symptom based measure for asthma care has been developed for use in general practice and outpatient departments. This article outlines the development process, which used a framework recently described in the theoretical literature to show the constraints that scientific criteria place on the development of outcome measures and the means of overcoming such limiting factors. Although substantial effort is required to undertake a rigorous process of development, useful tools are the result. Two five item, symptom based outcome measures for adult asthma are described.	UNIV HULL,DEPT PUBL HLTH MED,KINGSTON HULL,N HUMBERSIDE,ENGLAND; UNIV NEWCASTLE UPON TYNE,CTR HLTH SERV RES,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND; UNIV LEEDS,LEEDS,W YORKSHIRE,ENGLAND	University of Hull; Newcastle University - UK; University of Leeds			Eccles, Martin P/AAD-4029-2020					AITKIN M, 1989, STATISTICAL MODELLIN; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Deyo RA, 1991, CONTROLLED CLIN TRIA, V12, P142; FITZPATRICK R, 1992, BRIT MED J, V305, P1074, DOI 10.1136/bmj.305.6861.1074; Fletcher Astrid, 1992, British Medical Journal, V305, P1145; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; KINSMAN RA, 1973, PSYCHOSOM MED, V35, P250, DOI 10.1097/00006842-197305000-00008; KIRKWOOD BR, 1988, ESSENTIALS MED STATI; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCOLL AJ, 1993, POPULATION HLTH OUTC; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; PARKERSON GR, 1993, J CLIN EPIDEMIOL, V46, P379, DOI 10.1016/0895-4356(93)90153-R; Streiner DL., 2001, HLTH MEASUREMENT SCA, V2nd; USHERWOOD TP, 1990, ARCH DIS CHILD, V65, P779, DOI 10.1136/adc.65.7.779; WILKIN D, 1992, MEASURES NEED OUTCOM	16	82	84	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1065	1068		10.1136/bmj.309.6961.1065	http://dx.doi.org/10.1136/bmj.309.6961.1065			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN733	7950742	Green Published			2022-12-28	WOS:A1994PN73300027
J	HAUGWITZ, M; NOEGEL, AA; KARAKESISOGLOU, J; SCHLEICHER, M				HAUGWITZ, M; NOEGEL, AA; KARAKESISOGLOU, J; SCHLEICHER, M			DICTYOSTELIUM AMEBAS THAT LACK G-ACTIN-SEQUESTERING PROFILINS SHOW DEFECTS IN F-ACTIN CONTENT, CYTOKINESIS, AND DEVELOPMENT	CELL			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; HEAVY-CHAIN GENE; POLYMORPHONUCLEAR LEUKOCYTES; BINDING-PROTEINS; HOMOLOGOUS RECOMBINATION; MONOCLONAL-ANTIBODIES; CELL MOTILITY; DISCOIDEUM; MYOSIN; THYMOSIN-BETA-4	To study in vivo functions of the ubiquitous actin-binding protein profilin, we generated by antisense and gene disruption techniques Dictyostelium mutants that lack one or both of the profilin isoforms. Whereas the single mutants showed an essentially unchanged phenotype, the behavior of the double mutant was drastically altered. Motility was significantly reduced, single cells were up to 10 times larger than wild-type cells and showed a broad rim of filamentous actin below the plasma membrane, the filamentous actin concentration was increased by about 60%-70%, and development was blocked prior to fruiting body formation. Furthermore, double mutants could not be grown in shaking culture under normal conditions, reflecting an impaired cytokinesis. The aberrant phenotype could be rescued by reintroducing a functional profilin I or profilin II gene. The data in this study suggest that profilin functions in Dictyostelium amoebae primarily as an actin-sequestering protein.	UNIV MUNICH, INST ZELLBIOL, D-80366 MUNICH, GERMANY; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	University of Munich; Max Planck Society								ADAMS AEM, 1993, MOL BIOL CELL, V4, P459, DOI 10.1091/mbc.4.5.459; Brown SS, 1993, CURR OPIN CELL BIOL, V5, P129, DOI 10.1016/S0955-0674(05)80018-3; BUSS F, 1992, CELL MOTIL CYTOSKEL, V22, P51, DOI 10.1002/cm.970220106; CANO ML, 1992, J CELL BIOL, V116, P1123, DOI 10.1083/jcb.116.5.1123; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; CLAVIEZ M, 1982, EMBO J, V1, P1017, DOI 10.1002/j.1460-2075.1982.tb01287.x; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; EARLY A, 1988, DEV GENET, V9, P383, DOI 10.1002/dvg.1020090419; EDAMATSU M, 1992, J BIOCHEM-TOKYO, V112, P637, DOI 10.1093/oxfordjournals.jbchem.a123952; EGELHOFF TT, 1989, MOL CELL BIOL, V9, P1965, DOI 10.1128/MCB.9.5.1965; FAIX J, 1992, J CELL SCI, V102, P203; FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; FISHER PR, 1989, J CELL BIOL, V108, P973, DOI 10.1083/jcb.108.3.973; FUKUI Y, 1993, INT REV CYTOL, V144, P85, DOI 10.1016/S0074-7696(08)61514-4; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GREGG JH, 1982, EXP CELL RES, V142, P229, DOI 10.1016/0014-4827(82)90427-X; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HARTWIG JH, 1989, J CELL BIOL, V109, P1571, DOI 10.1083/jcb.109.4.1571; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HAUGWITZ M, 1991, J CELL SCI, V100, P481; ISENBERG G, 1991, J MUSCLE RES CELL M, V12, P136, DOI 10.1007/BF01774032; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MAGDOLEN V, 1993, FEBS LETT, V316, P41, DOI 10.1016/0014-5793(93)81733-G; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; NOEGEL A, 1985, J MOL BIOL, V185, P447, DOI 10.1016/0022-2836(85)90416-4; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLENZ RS, 1992, CELL, V69, P951, DOI 10.1016/0092-8674(92)90614-I; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SCHLEICHER M, 1992, NEW BIOL, V4, P461; SCHLEICHER M, 1984, EMBO J, V3, P2095, DOI 10.1002/j.1460-2075.1984.tb02096.x; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SOUTHWICK FS, 1990, J CELL BIOL, V110, P1965, DOI 10.1083/jcb.110.6.1965; STAIGER CJ, 1994, CURR BIOL, V4, P215, DOI 10.1016/S0960-9822(00)00050-6; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VANHAASTERT PJM, 1991, EUR J BIOCHEM, V195, P289; VINSON VK, 1993, J CELL BIOL, V122, P1277, DOI 10.1083/jcb.122.6.1277; WADDELL DR, 1988, DEV GENET, V9, P673, DOI 10.1002/dvg.1020090443; WILCZYNSKA Z, 1994, IN PRESS PLASMID; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS KL, 1976, GENETICS, V82, P287; Witke W., 1993, Molecular Biology of the Cell, V4, p149A; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x; WITKE W, 1992, CELL, V68, P53, DOI 10.1016/0092-8674(92)90205-Q; ZARBOCK J, 1990, BIOCHEMISTRY-US, V29, P7814, DOI 10.1021/bi00486a006	72	194	199	2	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					303	314		10.1016/0092-8674(94)90199-6	http://dx.doi.org/10.1016/0092-8674(94)90199-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954798				2022-12-28	WOS:A1994PN63000014
J	DELONG, EF; WU, KY; PREZELIN, BB; JOVINE, RVM				DELONG, EF; WU, KY; PREZELIN, BB; JOVINE, RVM			HIGH ABUNDANCE OF ARCHAEA IN ANTARCTIC MARINE PICOPLANKTON	NATURE			English	Article							MICROBIAL ECOLOGY; RIBOSOMAL-RNA; DIVERSITY; ARCHAEBACTERIA; EVOLUTION	ARCHAEA (archaebacteria) constitute one of the three major evolutionary lineages of life on Earth(1-3). Previously these prokaryotes were thought to predominate in only a few unusual and disparate niches, characterized by hypersaline, extremely hot, or strictly anoxic conditions(4-7). Recently, novel (uncultivated) phylotypes of Archaea have been detected in coastal(8) and subsurface(9,10) marine waters, but their abundance, distribution, physiology and ecology remain largely undescribed. Here we report exceptionally high archaeal abundance in frigid marine surface waters of Antarctica. Pelagic Archaea constituted up to 34% of the prokaryotic biomass in coastal Antarctic surface waters, and they were also abundant in a variety of other cold, pelagic marine environments. Because they can make up a significant fraction of picoplankton biomass in the vast habitats encompassed by cold and deep marine waters, these pelagic Archaea represent an unexpectedly abundant component of the Earth's biota.			DELONG, EF (corresponding author), UNIV CALIF SANTA BARBARA,DEPT BIOL,DIV ECOL EVOLUT & MARINE BIOL,SANTA BARBARA,CA 93106, USA.							BARNS SM, 1994, P NATL ACAD SCI USA, V91, P1609, DOI 10.1073/pnas.91.5.1609; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5585; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FUHRMAN JA, 1992, NATURE, V356, P148, DOI 10.1038/356148a0; FUHRMAN JA, 1993, APPL ENVIRON MICROB, V59, P1294, DOI 10.1128/AEM.59.5.1294-1302.1993; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; HUBER R, 1990, NATURE, V345, P179, DOI 10.1038/345179a0; JONES WJ, 1987, MICROBIOL REV, V51, P135, DOI 10.1128/MMBR.51.1.135-177.1987; LARSEN N, 1993, NUCLEIC ACIDS RES, V21, P2021; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; OLSEN GJ, 1986, ANNU REV MICROBIOL, V40, P337, DOI 10.1146/annurev.mi.40.100186.002005; OLSEN GJ, 1993, FASEB J, V7, P113, DOI 10.1096/fasebj.7.1.8422957; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; RASKIN L, 1994, APPL ENVIRON MICROB, V60, P1232, DOI 10.1128/AEM.60.4.1232-1240.1994; SAKAI RK, 1988, SCIENCE, V239, P487; Stahl D.A., 1991, NUCL ACID TECHNIQUES, P205; STAHL DA, 1988, APPL ENVIRON MICROB, V54, P1079, DOI 10.1128/AEM.54.5.1079-1084.1988; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; TINDALL BJ, 1992, PROKARYOTES HDB BIOL, P768; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1994, MICROBIOL REV, V58, P1; [No title captured]	24	424	446	1	58	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					695	697		10.1038/371695a0	http://dx.doi.org/10.1038/371695a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935813				2022-12-28	WOS:A1994PM77300053
J	JACOB, F				JACOB, F			LWOFF,ANDRE (1902-1994)	NATURE			English	Item About an Individual											JACOB, F (corresponding author), INST PASTEUR,DEPT MOLEC BIOL,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							LWOFF A, PUBLICATION LIST	1	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					653	653		10.1038/371653a0	http://dx.doi.org/10.1038/371653a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935808	Bronze			2022-12-28	WOS:A1994PM77300027
J	ROBERTS, SGE; GREEN, MR				ROBERTS, SGE; GREEN, MR			ACTIVATOR-INDUCED CONFORMATIONAL CHANGE IN GENERAL TRANSCRIPTION FACTOR TFIIB	NATURE			English	Article							RNA POLYMERASE-II; FUNCTIONAL DOMAINS; DNA-BINDING	TRANSCRIPTIONAL activator proteins (activators) function, at least in part, by increasing preinitiation complex assembly (for reviews see refs 1-4). Previous studies have shown that an acidic activator forms a contact with the general transcription factor TFIIB (refs 5-7) and recruits it into the preinitiation complex(5,8,9). Mutational studies indicate that this interaction between the acidic activator and TFIIB is required for transcriptional stimulation(5-7,10,11). We show here that the acidic activator-TFIIB interaction has an additional function in preinitiation complex assembly. We provide evidence that in native TFIIB the amino- and carboxy-terminal domains are engaged in an intramolecular interaction. The acidic activator disrupts this intramolecular interaction to expose binding sites for general transcription factors that enter the preinitiation complex through association with TFIIB. Thus, the acidic activator induces a conformational change in TFIIB that drives preinitiation complex assembly forward.			ROBERTS, SGE (corresponding author), UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.		Roberts, Stefan GE/R-5537-2016	Roberts, Stefan GE/0000-0002-7535-6365				BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; JIANG Y, 1994, J BIOL CHEM, V269, P5505; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	24	155	158	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					717	720		10.1038/371717a0	http://dx.doi.org/10.1038/371717a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935820				2022-12-28	WOS:A1994PM77300061
J	MANSEL, RE				MANSEL, RE			ABC OF BREAST DISEASES - BREAST PAIN	BRITISH MEDICAL JOURNAL			English	Article											MANSEL, RE (corresponding author), UNIV WALES COLL MED,CARDIFF,S GLAM,WALES.								0	34	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					866	868		10.1136/bmj.309.6958.866	http://dx.doi.org/10.1136/bmj.309.6958.866			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7950621	Green Published			2022-12-28	WOS:A1994PK50100032
J	SMITH, DK; SHAW, RW; MARTEAU, TM				SMITH, DK; SHAW, RW; MARTEAU, TM			INFORMED CONSENT TO UNDERGO SERUM SCREENING FOR DOWNS-SYNDROME - THE GAP BETWEEN POLICY AND PRACTICE	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH,PSYCHOL & GENET RES GRP,LONDON SE1 9RT,ENGLAND; UNIV WALES COLL MED,CARDIFF CF4 4XN,S GLAM,WALES	University of London; King's College London; Cardiff University				Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		MARTEAU TM, 1992, PUBLIC HEALTH, V106, P131, DOI 10.1016/S0033-3506(05)80390-7; ROUND A, 1993, BRIT MED J, V307, P1211, DOI 10.1136/bmj.307.6913.1211-c; SMITH DK, IN PRESS PRENAT DIAG; Weinman J, 1988, TOPICS HLTH PSYCHOL, P205; 1993, REPORT RCOG WORKING	5	89	89	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					776	776		10.1136/bmj.309.6957.776	http://dx.doi.org/10.1136/bmj.309.6957.776			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PJ282	7950565	Green Published			2022-12-28	WOS:A1994PJ28200022
J	ADUEN, J; BERNSTEIN, WK; KHASTGIR, T; MILLER, JA; KERZNER, R; BHATIANI, A; LUSTGARTEN, J; BASSIN, AS; DAVISON, L; CHERNOW, B				ADUEN, J; BERNSTEIN, WK; KHASTGIR, T; MILLER, JA; KERZNER, R; BHATIANI, A; LUSTGARTEN, J; BASSIN, AS; DAVISON, L; CHERNOW, B			THE USE AND CLINICAL IMPORTANCE OF A SUBSTRATE-SPECIFIC ELECTRODE FOR RAPID-DETERMINATION OF BLOOD LACTATE CONCENTRATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CRITICALLY ILL PATIENTS; SEVERELY TRAUMATIZED PATIENTS; RESPIRATORY-DISTRESS-SYNDROME; HUMAN SEPTIC SHOCK; OXYGEN DELIVERY; CIRCULATORY SHOCK; LACTIC-ACIDOSIS; ARTERIAL BLOOD; CRITICAL CARE	Objective.-To determine the validity and clinical importance of a newly developed amperometric, enzymatic, substrate-specific electrode for the rapid measurement of circulating lactate concentrations. Design.-A prospective multiexperiment study. Setting.-The critical care medicine research laboratory, intensive care unit (ICU), emergency department (ED), and general wards of a university-affiliate hospital. Patients.-A total of 1218 patients and control subjects were studied on one or more occasions. Interventions.-Blood lactate concentrations, descriptive data, physiological parameters, and outcome results were determined in various patient populations. Main Outcome Measures and Results.-Experiment 1: Lactate determinations performed with the new substrate-specific electrode were compared with two laboratory reference methods. Blood samples from 80 ICU patients and 165 ED patients formed the basis of this first experiment. There was excellent agreement between the test instrument and the two reference methods as reflected by bias (with reference method 1, 0.19 mmol/L; reference method 2, 0.09 mmol/L), precision (with reference method 1, +/-0.47 mmol/L; reference method 2, +/-0.34 mmol/L), and correlation data (with reference method 1, r=.92; reference method 2, r=.98). Experiment 2: The new test microchemistry instrument was used to analyze blood samples from 927 patients. The mean (SE) blood lactate concentrations in the various patient populations were 1.26 (0.04) mmol/L for control subjects (n=85), 1.52 (0.03) mmol/L for general ward patients (n=489; P<.001 vs normal subjects), 2.34 (0.15) mmol/L for ICU patients (n=180; P<.001 vs normal subjects and general ward patients), and 2.44 (0.15) mmol/L for ED patients (n=173; P<.001 vs normal subjects and general ward patients). None of the normal subjects and only one (0.2%) of 489 nonhypotensive general ward patients had a blood lactate value greater than 4 mmol/L. Circulating lactate concentrations greater than 4 mmol/L were 98.2% specific in predicting the need for hospital admission in patients presenting to the ED. Furthermore, lactate concentrations greater than 4 mmol/L were 96% specific in predicting mortality in hospitalized nonhypotensive patients. Experiment 3: Blood samples from 46 hypotensive ICU and ED patients and from 353 nonhypotensive ICU and ED patients (the latter samples were derived from experiment 2) were analyzed. A statistically significant difference was noted between the mean (SE) lactate concentration in hypotensive patients in the ICU and ED (4.75 [0.75] mmol/L) when compared with nonhypotensive ICU and ED patients (2.28 [0.10] mmol/L; P<.001). Furthermore, blood lactate values greater than 4 mmol/L were 87.5% specific in predicting mortality in hypotensive patients. Conclusions.-Lactate determinations performed using the new test instrument are precise and accurate. Blood lactate concentrations greater than 4 mmol/L are unusual in normal and noncritically ill hospitalized patients and warrant concern. In hospitalized (non-ICU) nonhypotensive subjects, as well as in critically ill patients, a blood lactate concentration greater than 4 mmol/L may portend a poor prognosis.	SINAI HOSP, DEPT MED, BALTIMORE, MD 21215 USA; SINAI HOSP, DEPT PATHOL, BALTIMORE, MD 21215 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ANESTHESIA & CRIT CARE, BALTIMORE, MD 21205 USA	Sinai Hospital of Baltimore; Sinai Hospital of Baltimore; Johns Hopkins University; Johns Hopkins University								ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; ALMENOFF PL, 1989, CRIT CARE MED, V17, P870, DOI 10.1097/00003246-198909000-00004; ASTIZ ME, 1987, CRIT CARE MED, V15, P26, DOI 10.1097/00003246-198701000-00005; ASTIZ ME, 1988, CRIT CARE MED, V16, P655, DOI 10.1097/00003246-198807000-00001; BAKKER J, 1991, CHEST, V99, P956, DOI 10.1378/chest.99.4.956; Barker SB, 1941, J BIOL CHEM, V138, P535; BERNSTEIN WK, 1994, CRIT CARE MED, V22, pA227; BISHOP MH, 1993, CRIT CARE MED, V21, P56, DOI 10.1097/00003246-199301000-00013; BLAIR E, 1965, Am Surg, V31, P537; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BRODER G, 1964, SCIENCE, V143, P1457, DOI 10.1126/science.143.3613.1457; Cady L D Jr, 1973, Crit Care Med, V1, P75, DOI 10.1097/00003246-197303000-00003; CHERNOW B, 1990, CHEST, V97, pS183, DOI 10.1378/chest.97.5_Supplement.183S; CHERNOW B, 1993, CRIT CARE MED, V21, P481, DOI 10.1097/00003246-199304000-00001; CHERNOW B, 1991, CRIT CARE MED, V19, P313; COWAN BN, 1984, ANAESTHESIA, V39, P759; DUNHAM CM, 1991, CRIT CARE MED, V19, P231, DOI 10.1097/00003246-199102000-00020; FALK JL, 1985, ACUTE CARE, V11, P212; FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175; GAGLIO G, 1886, ARCH ANAT PHYSL ABT, V10, P400; GREENBURG AG, 1993, CRIT CARE MED, V21, P954, DOI 10.1097/00003246-199307000-00003; GROENEVELD ABJ, 1987, CIRC SHOCK, V22, P35; GUTIERREZ G, 1992, CRIT CARE MED, V20, P451, DOI 10.1097/00003246-199204000-00004; HENNING RJ, 1982, CIRC SHOCK, V9, P307; HOTCHKISS RS, 1992, JAMA-J AM MED ASSOC, V267, P1503, DOI 10.1001/jama.267.11.1503; HUCKABEE WE, 1961, AM J MED, V30, P833, DOI 10.1016/0002-9343(61)90171-1; KESSLER KM, 1987, AM HEART J, V113, P1540, DOI 10.1016/0002-8703(87)90696-X; KRUSE JA, 1990, INTENS CARE MED, V16, P1, DOI 10.1007/BF01706317; KRUSE JA, 1990, CHEST, V98, P959, DOI 10.1378/chest.98.4.959; LANDOW L, 1993, CRIT CARE MED, V21, pS84, DOI 10.1097/00003246-199302001-00015; LEAVY JA, 1988, JAMA-J AM MED ASSOC, V260, P662, DOI 10.1001/jama.260.5.662; MAVRIC Z, 1991, AM J CARDIOL, V67, P565, DOI 10.1016/0002-9149(91)90892-O; MEERBAUM S, 1975, P423; NIMMO GR, 1992, ANAESTHESIA, V47, P1023, DOI 10.1111/j.1365-2044.1992.tb04194.x; NIMMO GR, 1993, CLIN INTENSIVE CARE, V4, P8; PARKER MM, 1987, CRIT CARE MED, V15, P923, DOI 10.1097/00003246-198710000-00006; PERETZ DI, 1964, CAN MED ASSOC J, V90, P673; PERRET C, 1979, LACTATE ACUTE CONDIT, P69; PRENTICE A, 1990, INTENS CARE MED, V16, P28, DOI 10.1007/BF01706321; RACINE P, 1975, Z KLIN CHEM KLIN BIO, V13, P533; RASHKIN MC, 1985, CHEST, V87, P580, DOI 10.1378/chest.87.5.580; RONCO JJ, 1993, AM REV RESPIR DIS, V147, P25, DOI 10.1164/ajrccm/147.1.25; RONCO JJ, 1993, JAMA-J AM MED ASSOC, V270, P1724, DOI 10.1001/jama.270.14.1724; ROUMEN RMH, 1993, J TRAUMA, V35, P349, DOI 10.1097/00005373-199309000-00004; SALEM M, 1991, Journal of the American Medical Association, V266, P382, DOI 10.1001/jama.266.3.382; SCHIMASS.H, 1965, ANN NY ACAD SCI, V119, P1013, DOI 10.1111/j.1749-6632.1965.tb47458.x; SCHOEN I, 1989, AM J CLIN PATHOL, V91, P172, DOI 10.1093/ajcp/91.2.172; SCHUSTER HP, 1984, RESUSCITATION, V11, P141, DOI 10.1016/0300-9572(84)90011-X; SHEPS DS, 1979, AM J CARDIOL, V44, P1276, DOI 10.1016/0002-9149(79)90441-7; SHOEMAKER WC, 1993, CRIT CARE MED, V21, P977, DOI 10.1097/00003246-199307000-00010; SIEGEL JH, 1990, ARCH SURG-CHICAGO, V125, P498; SILVERMAN HJ, 1991, CHEST, V100, P1012, DOI 10.1378/chest.100.4.1012; STACPOOLE PW, 1993, ENDOCRIN METAB CLIN, V22, P221, DOI 10.1016/S0889-8529(18)30163-4; TOFFALETTI J, 1992, CLIN CHEM, V38, P2430; TUCHSCHMIDT J, 1989, CRIT CARE MED, V17, P719, DOI 10.1097/00003246-198908000-00001; VINCENT JL, 1983, CRIT CARE MED, V11, P449, DOI 10.1097/00003246-198306000-00012; WEIL MH, 1970, CIRCULATION, V41, P989, DOI 10.1161/01.CIR.41.6.989; WEIL MH, 1985, CRIT CARE MED, V13, P888, DOI 10.1097/00003246-198511000-00005; WEIL MH, 1987, CRIT CARE MED, V15, P489	59	142	148	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1678	1685		10.1001/jama.272.21.1678	http://dx.doi.org/10.1001/jama.272.21.1678			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966896				2022-12-28	WOS:A1994PU75900027
J	MOSER, RH				MOSER, RH			ASPARTAME AND MEMORY LOSS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MOSER, RH (corresponding author), UNIV NEW MEXICO,SCH MED,ALBUQUERQUE,NM 87131, USA.							TOLLEFSON L, 1993, REGUL TOXICOL PHARM, V18, P32, DOI 10.1006/rtph.1993.1042	1	10	10	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1543	1543						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966850				2022-12-28	WOS:A1994PQ90000037
J	STAMLER, JF				STAMLER, JF			THE SILENT MAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1475	1475						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966826				2022-12-28	WOS:A1994PQ90000001
J	GELMON, K				GELMON, K			THE TAXOIDS - PACLITAXEL AND DOCETAXEL	LANCET			English	Article							CELL LUNG-CANCER; PHASE-II; BREAST-CANCER; AGENT; TRIAL				GELMON, K (corresponding author), BRITISH COLUMBIA CANC AGCY,600 W 10TH AVE,VANCOUVER V5Z 4E6,BC,CANADA.							AAPRO M, 1993, P AN M AM SOC CLIN, V12, P256; AAPRO MS, 1992, ANN ONCOL, V3, P53; ARBUCK S, 1993, P AN M AM SOC CLIN, V12, P138; BISSERY MC, 1991, CANCER RES, V51, P4845; CABRAL FR, 1983, J CELL BIOL, V97, P22, DOI 10.1083/jcb.97.1.22; CHANG AY, 1993, J NATL CANCER I, V85, P388, DOI 10.1093/jnci/85.5.388; EISENHAUER E, 1994, ANN ONCOL          S, V5, P506; ETTINGER DS, 1993, P AN M AM SOC CLIN, V12, P329; Fisherman J S, 1993, J Natl Cancer Inst Monogr, P189; FORASTIERE AA, 1993, P AN M AM SOC CLIN, V12, P277; FOSSELLA FV, 1994, ANN ONCOL S5, V5, P510; FROMES Y, 1992, P AACR, V33, P551; GELMON K, 1994, ANN ONCOL S5, V5, P493; GREENBERGER LM, 1987, J BIOL CHEM, V262, P1; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HOLMES FA, 1994, ANN ONCOL S5, V5, P489; HOROWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; HUIZING MT, 1993, J CLIN ONCOL, V11, P2127, DOI 10.1200/JCO.1993.11.11.2127; LAVELLE F, 1989, P AM ASSOC CANC RES, V30, P417; LIEBMANN JE, 1993, BRIT J CANCER, V68, P1104, DOI 10.1038/bjc.1993.488; MARKMAN M, 1992, J CLIN ONCOL, V10, P1485, DOI 10.1200/JCO.1992.10.9.1485; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MURPHY WK, 1993, J NATL CANCER I, V85, P384, DOI 10.1093/jnci/85.5.384; Onetto N, 1993, J Natl Cancer Inst Monogr, P131; PICCART MJ, 1993, P ASCO, V12, P258; RIGAS J, 1993, NOV EUR C CLIN ONC M; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SEIDMAN AD, 1993, SEMIN ONCOL, V20, P40; SLEDGE G, 1993, P AN M AM SOC CLIN, V12, P71; SLICHENMYER W, 1993, P AN M AM SOC CLIN, V12, P160; SWENERTON K, 1993, P AN M AM SOC CLIN, V12, P256; TISHLER RB, 1992, CANCER RES, V52, P3495; TRUDEAU ME, 1993, P AN M AM SOC CLIN, V12, P64; VALERO V, 1994, 8TH NCI EORTC S NEW; VERWEIJ J, 1994, ANN ONCOL S5, V5, P364; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WERNIK PH, 1993, J NATL CANCER I, V15, P185; WILSON WH, 1993, P AN M AM SOC CLIN, V12, P134	38	191	213	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1267	1272		10.1016/S0140-6736(94)90754-4	http://dx.doi.org/10.1016/S0140-6736(94)90754-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967989				2022-12-28	WOS:A1994PP70100012
J	SCHAFFER, JE; LODISH, HF				SCHAFFER, JE; LODISH, HF			EXPRESSION CLONING AND CHARACTERIZATION OF A NOVEL ADIPOCYTE LONG-CHAIN FATTY-ACID TRANSPORT PROTEIN	CELL			English	Article							RAT-HEART MYOCYTES; ACYL-COA SYNTHETASE; BINDING-PROTEIN; MEMBRANE-PROTEIN; PLASMA-MEMBRANE; ESCHERICHIA-COLI; PREADIPOCYTE DIFFERENTIATION; FUNCTIONAL-ANALYSIS; 3T3-L1 ADIPOCYTES; CELLS	Long chain fatty acids (LCFAs) are an important energy substrate used by cardiac myocytes and other cells, but the mechanism whereby these molecules cross the plasma membrane is poorly understood. We used an expression cloning strategy and a cDNA library from 3T3-L1 adipocytes to identify a cDNA that, when expressed in cultured cells, augments uptake of LCFAs. This cDNA encodes a novel 646 amino acid fatty acid transport protein (FATP) with six predicted membrane-spanning regions and that is integrally associated with membranes. Immunocytochemistry and subcellular fractionation of 3T3-L1 adipocytes show that FATP is localized to the plasma membrane. We propose that FATP is a plasma membrane transporter for LCFAs.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute					NHLBI NIH HHS [HL41484, HL02696] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1991, AM J PHYSIOL, V261, pE76, DOI 10.1152/ajpendo.1991.261.1.E76; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; BLACK PN, 1992, J BIOL CHEM, V267, P25513; CLAFFEY KP, 1987, BIOCHEMISTRY-US, V26, P7900, DOI 10.1021/bi00398a054; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEGRELLA RF, 1980, J BIOL CHEM, V255, P9731; DEGRELLA RF, 1980, J BIOL CHEM, V255, P9739; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; EDMOND J, 1987, J NEUROSCI RES, V18, P551, DOI 10.1002/jnr.490180407; FROST SC, 1985, J BIOL CHEM, V260, P2646; FUJII S, 1987, LIPIDS, V22, P544, DOI 10.1007/BF02540374; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JACOBS AEM, 1987, INT J BIOCHEM, V19, P1049, DOI 10.1016/0020-711X(87)90305-3; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KELLY DP, 1994, NEW ENGL J MED, V330, P913; KIM CM, 1992, J BIOL CHEM, V267, P23113; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIM K, 1989, BIOTECHNIQUES, V7, P576; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MANGROO D, 1993, BIOCHEM CELL BIOL, V71, P51, DOI 10.1139/o93-008; MATARESE V, 1989, PROG LIPID RES, V28, P245, DOI 10.1016/0163-7827(89)90001-5; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NEELY J R, 1972, Progress in Cardiovascular Diseases, V15, P289, DOI 10.1016/0033-0620(72)90029-1; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; PINES G, 1992, NATURE, V360, P768, DOI 10.1038/360768a0; RUSSO JJ, 1990, AM J PHYSIOL, V259, pC968, DOI 10.1152/ajpcell.1990.259.6.C968; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUDUBRAY JM, 1992, NEW DEV FATTY ACID O; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SPECTOR AA, 1971, BIOCHEMISTRY-US, V10, P3229; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; STREMMEL W, 1988, J CLIN INVEST, V82, P2001, DOI 10.1172/JCI113820; STREMMEL W, 1988, J CLIN INVEST, V81, P844, DOI 10.1172/JCI113393; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TOSCANI A, 1990, J BIOL CHEM, V265, P5722; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; TROTTER PJ, 1991, J LIPID RES, V32, P293; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEIDEMANN MJ, 1969, BIOCHEM J, V112, P149, DOI 10.1042/bj1120149; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WOSILAIT WD, 1976, COMPUT PROG BIOMED, V6, P142, DOI 10.1016/0010-468X(76)90020-9; ZHOU SL, 1992, J BIOL CHEM, V267, P14456	62	716	740	2	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					427	436		10.1016/0092-8674(94)90252-6	http://dx.doi.org/10.1016/0092-8674(94)90252-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954810				2022-12-28	WOS:A1994PQ48800006
J	KINOSIAN, B; GLICK, H; GARLAND, G				KINOSIAN, B; GLICK, H; GARLAND, G			CHOLESTEROL AND CORONARY HEART-DISEASE - PREDICTING RISKS BY LEVELS AND RATIOS	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; CHOLESTEROL; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; PRACTICE GUIDELINES	DENSITY LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR-DISEASE; PREVALENCE; WOMEN; FAT	Objective: Comparison of four measures of cholesterol for predicting men and women who will develop coronary heart disease within 8 to 10 years. Design: Cohort study. Patients: 1898 men who received placebo (the placebo group of the Lipid Research Clinics [LRC] Coronary Primary Prevention Trial [CPPT]), 1025 men and 1442 women who participated in the 1970-1971 Framingham Heart Study biennial examination, and 1911 men and 1767 women without coronary heart disease who were from the LRC Population Prevalence Study. Measurements: Total cholesterol, low-density lipoprotein (LDL) cholesterol, ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol, and the ratio of LDL to HDL. Outcomes were coronary heart disease in the CPPT and Framingham studies and death from coronary heart disease in the Prevalence Study. Results: independent information in the total cholesterol/HDL ratio added risk-discriminating ability to total Cholesterol and LDL cholesterol measures (P < 0.02), but the reverse was not true. Among women, a high-risk threshold of 5.6 for the total cholesterol/HDL ratio identified a 0% to 15% larger group at 25% to 45% greater risk in the Prevalence and Framingham studies, respectively, than did current guidelines. Among men in the same studies, a risk threshold of 6.4 for the total cholesterol/HDL ratio identified a 69% to 95% larger group at 2% to 14% greater risk than did LDL cholesterol levels alone. Eight-year likelihood ratios for coronary heart disease ranged from 0.32 to 3.11 in men and from 0.59 to 2.98 in women for total cholesterol/HDL ratios (grouped from < 3 to greater than or equal to 9). Conclusions: The total cholesterol/HDL ratio is a superior measure of risk for coronary heart disease compared with either total cholesterol or LDL cholesterol levels. Current practice guidelines could be more efficient if risk stratification was based on this ratio rather than primarily on the LDL cholesterol level.	UNIV PENN, DEPT ECON, PHILADELPHIA, PA 19104 USA; DEPT VET AFFAIRS MED CTR, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	KINOSIAN, B (corresponding author), UNIV PENN, RALSTON PENN CTR, DIV GEN INTERNAL MED, ROOM 230, 3615 CHESTNUT ST, PHILADELPHIA, PA 19104 USA.				NATIONAL INSTITUTE ON AGING [R29AG009837] Funding Source: NIH RePORTER; NIA NIH HHS [NIA R29-AG09837-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BARRETTCONNOR E, 1987, CORONARY HEART DISEA, P117; BASS KM, 1993, ARCH INTERN MED, V153, P2209, DOI 10.1001/archinte.153.19.2209; BROOKSTEIN L, JAMA-J AM MED ASSOC, V150, P1653; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COOPER GR, 1992, JAMA-J AM MED ASSOC, V267, P1652, DOI 10.1001/jama.267.12.1652; GLICK H, 1993, MED DECIS MAKING, V13, P386; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GROVER SA, 1994, ARCH INTERN MED, V154, P679, DOI 10.1001/archinte.154.6.679; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HALL WH, 1993, JAMA-J AM MED ASSOC, V269, P505; HEISS G, 1980, CIRCULATION, V61, P302, DOI 10.1161/01.CIR.61.2.302; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; KANNEL WB, 1992, AM HEART J, V124, P768, DOI 10.1016/0002-8703(92)90288-7; LANDIS JR, 1978, INT STAT REV, V46, P237, DOI 10.2307/1402373; LEVY D, 1990, AM HEART J, V119, P712, DOI 10.1016/S0002-8703(05)80050-X; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RIFKIND BM, 1983, J CHRON DIS, V36, P467; SACKS FM, 1991, NEW ENGL J MED, V325, P1740, DOI 10.1056/NEJM199112123252411; SACKS FM, 1986, ARCH INTERN MED, V146, P1573, DOI 10.1001/archinte.146.8.1573; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SHURTLEFF D, 1974, US DHHS DHEW NIH7559; WILLIAMS OD, 1980, CIRCULATION, V62, P18; 1980, US DHHS NIH801527 PU	27	375	389	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					641	647		10.7326/0003-4819-121-9-199411010-00002	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944071				2022-12-28	WOS:A1994PN45000002
J	KRAMER, MR; SPRINGER, C; BERKMAN, N; BARYISHAY, E; AVITAL, A; MANDELBERG, A; EFFRON, D; GODFREY, S				KRAMER, MR; SPRINGER, C; BERKMAN, N; BARYISHAY, E; AVITAL, A; MANDELBERG, A; EFFRON, D; GODFREY, S			EFFECT OF NATURAL OXYGEN ENRICHMENT AT LOW-ALTITUDE ON OXYGEN-DEPENDENT PATIENTS WITH END-STAGE LUNG-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						QUALITY OF LIFE; LUNG DISEASES; RESPIRATORY FUNCTION TESTS; ALTITUDE; ANOXEMIA	OBSTRUCTIVE PULMONARY-DISEASE; LONG-TERM OXYGEN; 60 MM HG; COR-PULMONALE; OXYHEMOGLOBIN DESATURATION; SUPPLEMENTAL OXYGEN; HYPOXEMIC PATIENTS; EXERCISE CAPACITY; THERAPY; HEMODYNAMICS	Objective: To assess the effect of lowering altitude to that of the lowest place on earth (Dead Sea) on arterial oxygenation and exercise performance in patients with hypoxemia and end-stage lung disease. Design: A cohort of 10 patients. Setting: Pulmonary function laboratories in Jerusalem, Israel, and at the Dead Sea. Patients: 10 patients with end-stage lung disease who were receiving long-term oxygen therapy. The 4 males and 6 females were 12 to 77 years old. Four patients had chronic obstructive pulmonary disease; 2 had cystic fibrosis; 3 had pulmonary fibrosis; and 1 had pulmonary hypertension (thromboembolic). Mean forced vital capacity was 1.54 L (54% of predicted value) and mean forced expiratory volume in 1 second was 0.85 L (35% of predicted value). Measurements: Spirometry, blood gas analysis, progressive exercise testing, and sleep oximetry were done in Jerusalem (altitude, 800 m above sea level; barometric pressure, 696 mm Hg); the same measurements were done 6 days after arrival at the Dead Sea (altitude, 402 m below sea level; barometric pressure, 800 mm Hg) and then 7 to 14 days later in Jerusalem. Results: Arterial oxygenation increased from a median partial pressure of arterial oxygen of 51.6 mm Hg in Jerusalem to 67.0 mm Hg at the Dead Sea, an increase of 15.2 mm Hg (95% CI of paired difference, 4.1 to 20.4 mm Hg; P = 0.001). Partial pressure of arterial carbon dioxide increased from a median of 43.2 to 45.9 mm Hg, an increase of 2.7 mm Hg (CI, 0.5 to 6.4 mm Hg; P = 0.004), with a borderline significant change in the alveolar-arterial gradient. Arterial oxygen saturation increased from a median of 87.7% to 92.8%, a change of 4.8% (CI, 1.9% to 9.8%; P = 0.003). Exercise performance also improved as maximum oxygen uptake increased from a median of 827 mL/min to 1056 mL/min, an increase of 203 mL/min (CI, 54 to 388 mL/min; P = 0.006). Sleep oximetry also improved as median arterial oxygen saturation measured during sleep increased from 85% to 90%, a change of 5% (CI, 2% to 7%; P = 0.005), and percentage of sleep time with an oxygen saturation rate of 90% or more increased from a median of 24% to 73%, a change of 49% (CI, 20% to 87%; P = 0.02). No change in spirometry was noted. All patients felt less dyspneic and reported improved functional capacity with reduced need for oxygen. Conclusion: Descent to low altitude can improve arterial oxygenation, exercise performance, and sleep oximetry and consequently the quality of life in patients with hypoxemia and advanced lung disease.			KRAMER, MR (corresponding author), HADASSAH UNIV HOSP, INST PULMONOL, POB 12000, IL-91120 JERUSALEM, ISRAEL.							ABRAHAM AS, 1968, CIRC RES, V23, P147, DOI 10.1161/01.RES.23.1.147; [Anonymous], 1980, Ann Intern Med, V93, P391; ASHUTOSH K, 1983, AM REV RESPIR DIS, V127, P399, DOI 10.1164/arrd.1983.127.4.399; BLOCK AJ, 1979, CHEST, V75, P109, DOI 10.1378/chest.75.2.109; BRADLEY BL, 1978, AM REV RESPIR DIS, V118, P239; COTE TR, 1993, CHEST, V103, P1194, DOI 10.1378/chest.103.4.1194; COTES JE, 1956, LANCET, V270, P872; FISHMAN AP, 1976, CIRC RES, V38, P221, DOI 10.1161/01.RES.38.4.221; FLENLEY DC, 1981, LANCET, V1, P681; FLETCHER EC, 1992, AM REV RESPIR DIS, V145, P1070, DOI 10.1164/ajrccm/145.5.1070; FLETCHER EC, 1989, CHEST, V95, P757, DOI 10.1378/chest.95.4.757; FLETCHER EC, 1984, CHEST, V85, P6, DOI 10.1378/chest.85.1.6; FLETCHER EC, 1987, CHEST, V92, P604, DOI 10.1378/chest.92.4.604; KAWAKAMI Y, 1983, NEW ENGL J MED, V308, P1045, DOI 10.1056/NEJM198305053081801; LEVINE BE, 1967, ANN INTERN MED, V66, P639, DOI 10.7326/0003-4819-66-4-639; LIGHT RW, 1989, CHEST, V95, P751, DOI 10.1378/chest.95.4.751; MCCULLOUGH RE, 1977, ARCH ENVIRON HEALTH, V32, P36, DOI 10.1080/00039896.1977.10667251; MOORE LG, 1982, AM REV RESPIR DIS, V126, P225; MORRISON DA, 1992, CHEST, V102, P542, DOI 10.1378/chest.102.2.542; MORRISON DA, 1987, J AM COLL CARDIOL, V9, P1219, DOI 10.1016/S0735-1097(87)80459-X; NEFF TA, 1970, ANN INTERN MED, V72, P621, DOI 10.7326/0003-4819-72-5-621; ODONOHUE WJ, 1991, CHEST, V100, P968, DOI 10.1378/chest.100.4.968; PETTY TL, 1985, AM REV RESPIR DIS, V131, P930; PETTY TL, 1968, AM J MED, V45, P242, DOI 10.1016/0002-9343(68)90042-9; RENZETTI AD, 1966, AM J MED, V41, P115, DOI 10.1016/0002-9343(66)90009-X; TIMMS RM, 1985, ANN INTERN MED, V102, P29, DOI 10.7326/0003-4819-102-1-29; Wasserman K., 1987, PRINCIPLES EXERCISE	27	18	18	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					658	662		10.7326/0003-4819-121-9-199411010-00005	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944074				2022-12-28	WOS:A1994PN45000005
J	DAVIS, G; DRIVER, J				DAVIS, G; DRIVER, J			PARALLEL DETECTION OF KANIZSA SUBJECTIVE FIGURES IN THE HUMAN VISUAL-SYSTEM	NATURE			English	Article							ILLUSORY CONTOURS; APPARENT DEPTH; SEARCH	SUBJECTIVE figures, seen in the absence of luminance gradients (Fig. 1), provide a phenomenal illusion that can be related to the properties of single cells in the visual cortex(1), offering a rare bridge between brain function and visual awareness. It remains controversial whether subjective figures arise from intelligent cognitive mechanisms(2-4), or from lower-level processes in early vision(5,6). The cognitive account implies that the perception of subjective figures may require serial attentive processing, whereas on the low-level account they should arise in parallel at earlier visual stages. Physiological evidence apparently fits a low-level account(7,8) and indicates that some types of subjective contour may be detected earlier than the conventional Kanizsa(9) type. Here we report that even Kanizsa subjective figures can be detected without focal attention at parallel stages of the human visual system.			DAVIS, G (corresponding author), UNIV CAMBRIDGE,DEPT EXPTL PSYCHOL,DOWNING ST,CAMBRIDGE CB2 3EA,ENGLAND.		Driver, Jon/A-4779-2010; Davis, Gregory/G-9954-2012					BRIGNER WL, 1974, PERCEPT MOTOR SKILL, V38, P1047, DOI 10.2466/pms.1974.38.3c.1047; BROADBENT DE, 1985, MODELLING COGNITION, P169; COREN S, 1972, PSYCHOL REV, V79, P359, DOI 10.1037/h0032940; DeValois RL, 1990, SPATIAL VISION; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; ENNS JT, 1990, SCIENCE, V247, P721, DOI 10.1126/science.2300824; ENNS JT, 1990, BEHAV RES METH INSTR, V22, P118, DOI 10.3758/BF03203130; GINSBURG AP, 1975, NATURE, V257, P219, DOI 10.1038/257219a0; GINSBURG AP, 1987, PERCEPTION ILLUSORY, P126; GRABOWECKY M, 1989, Investigative Ophthalmology and Visual Science, V30, P457; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GROSOF DH, 1993, NATURE, V365, P550, DOI 10.1038/365550a0; GURNSEY R, 1992, PERCEPT PSYCHOPHYS, V52, P263, DOI 10.3758/BF03209144; Kanizsa G., 1955, RIV PSICOL, V49, P7; PETERHANS E, 1991, TRENDS NEUROSCI, V14, P112, DOI 10.1016/0166-2236(91)90072-3; PRADZNY K, 1983, PERCEPT PSYCHOPHYS, V34, P403; Ramachandran V. S., 1987, PERCEPTION ILLUSORY, P93, DOI 10.1007/978-1-4612-4760-9_10; ROCK I, 1979, PERCEPTION, V8, P665, DOI 10.1068/p080665; SMITH AT, 1977, NATURE, V257, P581; TOWNSEND JT, 1971, PERCEPT PSYCHOPHYS, V10, P161, DOI 10.3758/BF03205778; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; WARM JS, 1986, PERCEPT PSYCHOPHYS, V39, P219	23	127	128	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					791	793		10.1038/371791a0	http://dx.doi.org/10.1038/371791a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PP018	7935838				2022-12-28	WOS:A1994PP01800057
J	PAUSE, A; BELSHAM, GJ; GINGRAS, AC; DONZE, O; LIN, TA; LAWRENCE, JC; SONENBERG, N				PAUSE, A; BELSHAM, GJ; GINGRAS, AC; DONZE, O; LIN, TA; LAWRENCE, JC; SONENBERG, N			INSULIN-DEPENDENT STIMULATION OF PROTEIN-SYNTHESIS BY PHOSPHORYLATION OF A REGULATOR OF 5'-CAP FUNCTION	NATURE			English	Article							5' NONCODING REGION; SECONDARY STRUCTURE; INITIATION; TRANSLATION; MECHANISM; CELLS; EXPRESSION; VIRUS	The cloning is described of two related human complementary DNAs encoding polypeptides that interact specifically with the translation initiation factor eIF-4E, which binds to the messenger RNA 5'-cap structure. Interaction of these proteins with eIF-4E inhibits translation but treatment of cells with insulin causes one of them to become hyperphosphorylated and dissociate from eIF-4E, thereby relieving the translational inhibition. The action of this new regulator of protein synthesis is therefore modulated by insulin, which acts to stimulate the overall rate of translation and promote cell growth.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,PQ,CANADA; BBSRC,INST ANIM HLTH,WOKING GU24 0NF,SURREY,ENGLAND; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	McGill University; McGill University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Washington University (WUSTL)			Belsham, Graham/J-3132-2019; Gingras, Anne-Claude/ABA-8341-2020; Gingras, Anne-Claude/E-9982-2010; Belsham, Graham J./H-8589-2019	Belsham, Graham/0000-0003-1187-4873; Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437; Belsham, Graham J./0000-0003-1187-4873				AVRUCH J, 1985, MOL BASIS INSULIN AC, P67; BELSHAM GJ, 1980, DIABETOLOGIA, V18, P307; BELSHAM GJ, 1982, BIOCHEM J, V204, P345, DOI 10.1042/bj2040345; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; DENTON RM, 1981, DIABETOLOGIA, V21, P347; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, REV BIOCH, V60, P717; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; LARARISKARATZAS A, 1990, NATURE, V345, P544; LYONS RT, 1980, J BIOL CHEM, V255, P6330; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; MORGAN HE, 1971, J BIOL CHEM, V246, P2163; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SHANTZ LM, 1994, CANCER RES, V54, P2313; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; Sonenberg Nahum, 1993, Gene Expression, V3, P317; STIREWAL.WS, 1967, P NATL ACAD SCI USA, V57, P1885, DOI 10.1073/pnas.57.6.1885	31	1031	1058	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					762	767		10.1038/371762a0	http://dx.doi.org/10.1038/371762a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7935836				2022-12-28	WOS:A1994PP01800049
J	SMITH, L; FOLKARD, S; POOLE, CJM				SMITH, L; FOLKARD, S; POOLE, CJM			INCREASED INJURIES ON NIGHT-SHIFT	LANCET			English	Article							PERFORMANCE	Concern over safety has resulted in legislation by, for example, the Commission of the European Union, to limit the number of hours worked at night, There is, however, no direct evidence that injuries a re more frequent at night. We analysed all 4645 injury incidents reported for a year on a rotating three-shift system in a large engineering company where the a-priori accident risk appeared to be constant. The relative risk of sustaining an injury was 1.23 (95% CI 1.14-1.31) higher on the night shift than on the morning shift, which showed the lowest incidence. The type of work (machine versus self-paced) affected the pattern and nature of injuries; for self-paced work the relative risk of more serious injury on the night shift compared with the morning shift was 1.82 (1.30-2.34).	DUDLEY HLTH AUTHOR,DEPT OCCUPAT HLTH,DUDLEY,W MIDLANDS,ENGLAND		SMITH, L (corresponding author), UNIV COLL SWANSEA,DEPT PSYCHOL,BODY RHYTHMS & SHIFTWORK CTR,SWANSEA SA2 8PP,W GLAM,WALES.							BARTON J, IN PRESS OCCU ENV ME; CARTER FA, 1982, SHIFTWORK ACCIDENTS; Drury C. G., 1990, EVALUATION HUMAN WOR; FOLKARD S, 1990, PHILOS T ROY SOC B, V327, P543, DOI 10.1098/rstb.1990.0097; FOLKARD S, 1979, HUM FACTORS, V21, P483, DOI 10.1177/001872087902100410; HARRINGTON JM, 1978, SHIFT WORK HLTH CRIT; KNAUTH P, 1993, ERGONOMICS, V36, P15, DOI 10.1080/00140139308967850; LAVIE P, 1991, SLEEP SLEEPINESS PER, P65; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; ONG CN, 1987, APPL ERGON, V18, P51, DOI 10.1016/0003-6870(87)90070-6; Waterhouse J.M, 1992, SHIFTWORK HLTH SAFET, P1978; 1993, DIRECTIVE WORKING TI; 1993, B EUR STUD TIME, V6, P46	13	160	162	3	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1137	1139		10.1016/S0140-6736(94)90636-X	http://dx.doi.org/10.1016/S0140-6736(94)90636-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN066	7934499				2022-12-28	WOS:A1994PN06600015
J	COUSO, JP; ARIAS, AM				COUSO, JP; ARIAS, AM			NOTCH IS REQUIRED FOR WINGLESS SIGNALING IN THE EPIDERMIS OF DROSOPHILA	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; GENE SERRATE ENCODES; NEUROGENIC GENES; CELL FATE; TRANSMEMBRANE PROTEIN; EXPRESSION; LOCUS; MELANOGASTER; MUTATIONS; RECEPTOR	Mutations in the Notch (N) gene affect many processes during the development of Drosophila. Some alleles of Notch affect only particular processes, suggesting that the Notch protein (N) has more than one functional domain. We have found a series of N mutant phenotypes that are similar to those produced by the loss of function of the segment polarity gene wingless (wg) in the embryo and the adult. In addition, we observe that mutations in N behave as dominant enhancers of wg and that there exist allele-specific interactions between the two loci. Our results suggest that the product of wg is a ligand for N.			COUSO, JP (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.		Martinez Arias, Alfonso/F-1966-2010; Couso, Juan Pablo/ABH-5860-2020		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHBURNER M, 1989, DROSOPHILA LABORATO; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BATE M, 1993, DEVELOPMENT S, V119, P149; BLAIR SS, 1994, DEV BIOL, V162, P229, DOI 10.1006/dbio.1994.1081; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; CHOU TB, 1992, GENETICS, V131, P643; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DECELIS JF, 1993, P NATL ACAD SCI USA, V90, P4037, DOI 10.1073/pnas.90.9.4037; DECELIS JF, 1994, GENETICS, V136, P183; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; JACK J, 1992, GENETICS, V131, P353; JIMENEZ F, 1982, ROUX ARCH DEV BIOL, V191, P191, DOI 10.1007/BF00848335; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Muller H.J, 1932, P 6 INT C GEN, V1, P213; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; ORTEGA JAC, 1993, DEV DROSOPHILA MELAN, P1091; PEIFER M, 1994, DEVELOPMENT, V120, P369; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; PORTIN P, 1981, HEREDITAS, V95, P247; PORTIN P, 1977, HEREDITAS, V87, P77; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; RABINOW L, 1990, GENETICS, V125, P41; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SIMPSON P, 1993, DEVELOPMENT S, V119, P29; STERN CURT, 1954, AMER SCI, V42, P213; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; THOMAS U, 1991, DEVELOPMENT, V111, P749; TSAKONAS SA, 1991, TRENDS GENET, V7, P403; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1992, DEVELOPMENT, V115, P913	63	168	176	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					259	272		10.1016/0092-8674(94)90195-3	http://dx.doi.org/10.1016/0092-8674(94)90195-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954794				2022-12-28	WOS:A1994PN63000010
J	FORTINI, ME; ARTAVANISTSAKONAS, S				FORTINI, ME; ARTAVANISTSAKONAS, S			THE SUPPRESSOR OF HAIRLESS PROTEIN PARTICIPATES IN NOTCH RECEPTOR SIGNALING	CELL			English	Article							DEVELOPING DROSOPHILA EYE; CELL-FATE; BINDING-PROTEIN; NEGATIVE COMPLEMENTATION; NEUROGENIC GENES; LOCUS; MELANOGASTER; SEQUENCE; ENCODES; DELTA	In a genetic screen for mutations that attenuate Notch signaling in the developing Drosophila eye, we isolated rare, gain-of-function alleles of Suppressor of Hairless (Su(H)), the fly homolog of the mammalian C promoter-binding factor 1 (CBF1) gene. Su(H) exhibits numerous allele-specific genetic interactions with Notch as well as with Delta, deltex, and mastermind. In cultured Drosophila cells, the Su(H) protein is sequestered in the cytoplasm when coexpressed with Notch protein and is translocated to the nucleus when Notch binds to its ligand Delta. Cytoplasmic retention of Su(H) requires the intracellular cdc10/ankyrin repeats of Notch, which associate with SU(H) protein in the yeast interaction trap assay. These results indicate that Notch activity may regulate nuclear events by controlling the activity of a DNA-binding protein.	YALE UNIV,HOWARD HUGHES MED INST,DEPT CELL BIOL,NEW HAVEN,CT 06536	Howard Hughes Medical Institute; Yale University	FORTINI, ME (corresponding author), YALE UNIV,HOWARD HUGHES MED INST,DEPT BIOL,NEW HAVEN,CT 06536, USA.				NINDS NIH HHS [NS26084] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026084, R01NS026084] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ASHBURNER M, 1982, GENETICS, V101, P447; BANG AG, 1992, GENE DEV, V6, P1752, DOI 10.1101/gad.6.9.1752; BUSSEAU I, 1994, GENETICS, V136, P585; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; DELACONCHA A, 1988, GENETICS, V118, P499; DELIDAKIS C, 1991, GENETICS, V129, P803; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FOSTER GG, 1975, GENETICS, V81, P99; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOOH PJ, 1993, DEVELOPMENT, V117, P493; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MAIER D, 1992, MECH DEVELOP, V38, P143, DOI 10.1016/0925-4773(92)90006-6; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; NASH D, 1970, GENETICS, V64, P471; NASH D, 1965, GENET RES, V6, P175, DOI 10.1017/S0016672300004079; PARODY TR, 1993, GENETICS, V135, P527; Plunkett CR, 1926, J EXP ZOOL, V46, P181, DOI 10.1002/jez.1400460204; PORTIN P, 1975, GENETICS, V81, P121; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SHELLENBARGER DL, 1975, GENETICS, V81, P143; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Thummel CS, 1992, DROS INF SERV, V71, P150; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	48	473	482	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					273	282		10.1016/0092-8674(94)90196-1	http://dx.doi.org/10.1016/0092-8674(94)90196-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954795				2022-12-28	WOS:A1994PN63000011
J	SYM, M; ROEDER, GS				SYM, M; ROEDER, GS			CROSSOVER INTERFERENCE IS ABOLISHED IN THE ABSENCE OF A SYNAPTONEMAL COMPLEX PROTEIN	CELL			English	Article							MEIOTIC CHROMOSOME SYNAPSIS; CHIASMA MAINTENANCE; ELECTROPHORETIC KARYOTYPE; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; RECOMBINATION NODULES; ASPERGILLUS-NIDULANS; GEL-ELECTROPHORESIS; DESYNAPTIC MUTANT; FISSION YEAST	In the zip1 mutant, meiotic chromosomes fail to synapse, owing to the absence of a structural component of the synaptonemal complex (SC). This mutant has been analyzed for the ability to carry out several functions that have been proposed for the SC. The data presented show that the zip1 mutation does not affect chiasma function and confers only modest defects in meiotic recombination and sister chromatid cohesion. In contrast, crossover interference is completely abolished in the absence of Zip1. These data are the first to establish a molecular link between cytological observations of the SC and the genetic phenomenon of interference.			SYM, M (corresponding author), YALE UNIV, DEPT BIOL, POB 6666, NEW HAVEN, CT 06520 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904, T32GM007223] Funding Source: NIH RePORTER; NIGMS NIH HHS [2 T32 GM07223-18, GM28904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; BHARGAVA J, 1992, GENETICS, V130, P59; BRODY H, 1989, P NATL ACAD SCI USA, V86, P6260, DOI 10.1073/pnas.86.16.6260; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1975, P NATL ACAD SCI USA, V72, P3186, DOI 10.1073/pnas.72.8.3186; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; CLARKE L, 1983, NATURE, V305, P23, DOI 10.1038/305023a0; CLUTTERBUCK AJ, 1992, ASPERGILLUS BIOL IND, P3; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; EGEL R, 1978, HEREDITY, V41, P233, DOI 10.1038/hdy.1978.92; EGELMITANI M, 1982, HEREDITAS, V97, P179, DOI 10.1111/j.1601-5223.1982.tb00870.x; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; ENGEBRECHT JA, 1989, GENETICS, V121, P237; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; FOSS E, 1993, GENETICS, V133, P681; GAME JC, 1980, GENETICS, V94, P51; HALDANE J. B. S., 1931, CYTOLOGIA, V3, P54; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLM PB, 1980, CARLSBERG RES COMMUN, V45, P483, DOI 10.1007/BF02932921; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES G H, 1987, P213; JONES GH, 1974, HEREDITY, V32, P375, DOI 10.1038/hdy.1974.45; JONES GH, 1967, CHROMOSOMA, V22, P69, DOI 10.1007/BF00291287; KABACK DB, 1989, P NATL ACAD SCI USA, V86, P3694, DOI 10.1073/pnas.86.10.3694; KABACK DB, 1992, SCIENCE, V256, P228, DOI 10.1126/science.1566070; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KING JS, 1990, GENETICS, V126, P1127; KLAPHOLZ S, 1985, GENETICS, V110, P187; LAURIE DA, 1981, HEREDITY, V47, P409, DOI 10.1038/hdy.1981.102; MAGUIRE M P, 1978, Chromosoma (Berlin), V65, P173, DOI 10.1007/BF00329469; MAGUIRE MP, 1979, CHROMOSOMA, V70, P313, DOI 10.1007/BF00328769; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MAGUIRE MP, 1988, J THEOR BIOL, V134, P565, DOI 10.1016/S0022-5193(88)80058-4; MAGUIRE MP, 1993, GENOME, V36, P797, DOI 10.1139/g93-105; MAGUIRE MP, 1991, GENOME, V34, P879, DOI 10.1139/g91-135; Mather K, 1940, J GENET, V39, P205, DOI 10.1007/BF02982836; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; MENEES TM, 1989, GENETICS, V123, P675; MOENS PB, 1994, BIOESSAYS, V16, P101, DOI 10.1002/bies.950160206; Mortimer R.R., 1974, MECH RECOMBINATION, P263, DOI [10.1007/978-1-4684-2133-0_23, DOI 10.1007/978-1-4684-2133-0_23]; MORTIMER RK, 1991, MOL CELLULAR BIOL YE, P737; Muller HJ, 1916, AM NAT, V50, P193, DOI 10.1086/279534; Munz P, 1989, MOL BIOL FISSION YEA, P1; NICKLAS RB, 1974, GENETICS, V78, P205; OLSON LW, 1978, HEREDITAS, V89, P189; Olson M., 1991, MOL CELLULAR BIOL YE, P1; PAPAZIAN HP, 1952, GENETICS, V37, P175; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; ROCKMILL B, 1990, GENETICS, V126, P563; ROCKMILL B, 1994, GENETICS, V136, P65; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sherman F., 1986, METHODS YEAST GENETI; SMITH CL, 1987, NUCLEIC ACIDS RES, V15, P4481, DOI 10.1093/nar/15.11.4481; SNOW R, 1979, GENETICS, V92, P231; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRICKLAND WN, 1958, PROC R SOC SER B-BIO, V149, P82, DOI 10.1098/rspb.1958.0053; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; THOMPSON EA, 1989, MOL GEN GENET, V218, P293, DOI 10.1007/BF00331281; VOLLRATH D, 1987, NUCLEIC ACIDS RES, V15, P7865, DOI 10.1093/nar/15.19.7865; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6	64	233	236	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					283	292		10.1016/0092-8674(94)90197-X	http://dx.doi.org/10.1016/0092-8674(94)90197-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954796				2022-12-28	WOS:A1994PN63000012
J	FENTON, WA; KASHI, Y; FURTAK, K; HORWICH, AL				FENTON, WA; KASHI, Y; FURTAK, K; HORWICH, AL			RESIDUES IN CHAPERONIN GROEL REQUIRED FOR POLYPEPTIDE BINDING AND RELEASE	NATURE			English	Article							MOLECULAR CHAPERONE; ATP HYDROLYSIS; PROTEINS; COOPERATIVITY; CELL	CHAPERONINS are king-shaped protein complexes that are essential in the cell, mediating ATP-dependent polypeptide folding in a variety of compartments(1-3). Recent studies suggest that they function through multiple rounds of binding and release of non-native proteins: with each round of ATP-driven release into the bulk solution, a substrate protein kinetically partitions between folding to the native state or rebinding to another chaperonin molecule(4-6). To gain further insight into the mechanism of polypeptide binding and release by the chaperonin GroEL from Escherichia coli, we have undertaken a mutational analysis that relates the functional properties of GroEL to its crystal structure(7). Our functional tests identify a putative polypeptide-binding site on the inside surface of the apical domain, facing the central channel, consisting of hydrophobic residues. These same residues are essential for binding of the co-chaperonin GroES, which is required for productive polypeptide release. A highly conserved residue, Asp 87, positioned within a putative nucleotide-binding pocket in the top of the equatorial domain, is essential for ATP hydrolysis and polypeptide release.	YALE UNIV,SCH MED,BOYER CTR,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,BOYER CTR,DEPT GENET,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University			Kashi, Yechezkel/D-5433-2013					AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	22	576	588	0	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					614	619		10.1038/371614a0	http://dx.doi.org/10.1038/371614a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935796				2022-12-28	WOS:A1994PL55900055
J	PETO, R				PETO, R			SMOKING AND DEATH - THE PAST 40 YEARS AND THE NEXT 40	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY				PETO, R (corresponding author), RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,IMPERIAL CANC RES FUND,CANC STUDIES UNIT,OXFORD OX2 6HE,ENGLAND.							[Anonymous], 1962, SMOKING HLTH; Department of Health, 1992, POL REQ AV COMP SPEC; DOLL R, 1964, BMJ-BRIT MED J, V1, P1460, DOI 10.1136/bmj.1.5396.1460; DOLL R, 1964, BRIT MED J, V1, P1399, DOI 10.1136/bmj.1.5395.1399; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; DOLL R, 1954, BMJ-BRIT MED J, V1, P1451, DOI 10.1136/bmj.1.4877.1451; DOLL R, 1994, BMJ, V309; DOLL RICHARD, 1966, NAT CANCER INST MONOGR, V19, P205; Fletcher CM, 1976, NATURAL HIST CHRONIC; HAMMOND EC, 1954, JAMA-J AM MED ASSOC, V155, P1316, DOI 10.1001/jama.1954.03690330020006; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; PETO R, 1994, MORTALITY SMOKING; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; 1989, DHHS CDC898411 US DE; 1964, PHS PUBLICATION, V1103	16	185	193	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 8	1994	309	6959					937	939		10.1136/bmj.309.6959.937	http://dx.doi.org/10.1136/bmj.309.6959.937			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7950669	Green Published			2022-12-28	WOS:A1994PL78100027
J	CROFT, P; SCHOLLUM, J; SILMAN, A				CROFT, P; SCHOLLUM, J; SILMAN, A			POPULATION STUDY OF TENDER POINT COUNTS AND PAIN AS EVIDENCE OF FIBROMYALGIA	BRITISH MEDICAL JOURNAL			English	Article							FATIGUE; SLEEP; FIBROSITIS; SCALE	Objective-To determine the relation between tender points, complaints of pain, and symptoms of depression, fatigue, and sleep quality in the general population. Design-Two stage cross sectional study with an initial questionnaire about pain to classify those eligible for an examination oftender points. Setting-Two general practices in north west England. Subjects-Stratified random sample of adults from age-sex registers. Of the responders, 250 were selected for examination of tender points on the basis of their reported pain complaints; 177 subsequently participated. Main outcome measures-Tender point count (0 to 18) grouped into four categories with the highest (greater than or equal to 11) corresponding to the criteria of the American College of Rheumatology for fibromyalgia. Assessment of pain (chronic widespread, regional, none). Measures of depression, fatigue, and difficulty with sleeping. Results-Women had a higher median tender point count (six) than did men (three). Counts were higher in those with pain than in those who had no pain and in those with widespread compared with regional pain. Most subjects with chronic widespread pain, however, had fewer than 11 tender points (27/45; 60%). Two people with counts of 11 or more were in the group reporting no pain. Mean symptom scores for depression, fatigue, and sleep problems increased as the tender point count rose (P value for trend < 0.001). These trends were independent of pain complaints. Conclusions-Tender points are a measure of general distress. They are related to pain complaints but are separately associated with fatigue and depression. Sleep problems are associated with tender points, although prospective studies are needed to determine whether they cause tenderness to develop. Fibromyalgia does not seem to be a distinct disease entity.			CROFT, P (corresponding author), UNIV MANCHESTER,ARTHRITIS & RHEUMATISM COUNCIL,EPIDEMIOL RES UNIT,STOPFORD BLDG,MANCHESTER M13 9PT,ENGLAND.							CAMPBELL SM, 1983, ARTHRITIS RHEUM, V26, P817, DOI 10.1002/art.1780260701; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; COHEN ML, 1993, LANCET, V342, P906, DOI 10.1016/0140-6736(93)91950-Q; CROFT P, 1993, J RHEUMATOL, V20, P710; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; GOLDENBERG DL, 1990, ARTHRITIS RHEUM, V33, P381, DOI 10.1002/art.1780330311; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; LEIGH TJ, 1990, SCAND J RHEUMATOL, V19, P5, DOI 10.3109/03009749009092616; MOLDOFSKY H, 1976, PSYCHOSOM MED, V38, P35, DOI 10.1097/00006842-197601000-00006; REILLY PA, 1993, ANN RHEUM DIS, V52, P249, DOI 10.1136/ard.52.4.249; RIDSDALE L, 1993, BMJ-BRIT MED J, V307, P103, DOI 10.1136/bmj.307.6896.103; SMYTHE H A, 1977, Bulletin on the Rheumatic Diseases, V28, P928; WALL PD, 1993, PROGR FIBROMYALGIA M; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; WOLFE F, 1990, RHEUM DIS CLIN N AM, V16, P681; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2; YUNUS MB, 1992, J RHEUMATOL, V19, P846; YUNUS MB, 1991, ARTHRITIS RHEUM, V34, P15, DOI 10.1002/art.1780340104	18	244	248	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					696	699		10.1136/bmj.309.6956.696	http://dx.doi.org/10.1136/bmj.309.6956.696			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950521	Green Published			2022-12-28	WOS:A1994PH40700014
J	MILLINER, DS; EICKHOLT, JT; BERGSTRALH, EJ; WILSON, DM; SMITH, LH				MILLINER, DS; EICKHOLT, JT; BERGSTRALH, EJ; WILSON, DM; SMITH, LH			RESULTS OF LONG-TERM TREATMENT WITH ORTHOPHOSPHATE AND PYRIDOXINE IN PATIENTS WITH PRIMARY HYPEROXALURIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR-FILTRATION RATE; GLYOXYLATE AMINOTRANSFERASE; KIDNEY-TRANSPLANTATION; RENAL-TRANSPLANTATION; PEROXISOMAL ALANINE; OXALATE DYNAMICS; PRIMARY OXALOSIS; HEPATIC ALANINE; TYPE-1; URINARY	Background. The prognosis for patients with primary hyperoxaluria has been ominous, with the expectation of renal failure, poor results with transplantation, and early death. Methods. We studied the long-term effects of orthophosphate and pyridoxine therapy in 25 patients with primary hyperoxaluria who were treated for an average of 10 years (range, 0.3 to 26). Their mean age at the start of treatment was 12 years (median, 6; range, 0.5 to 32). We also studied the effect of orthophosphate and pyridoxine on urinary supersaturation with calcium oxalate, crystal inhibition using a seeded growth system, and crystal formation using scanning electron microscopy in 12 patients during three-day stays in the clinical research center. Results. The mean (+/-SD) glomerular filtration rate at the start of treatment was 91+/-26 ml per minute per 1.73 m(2). The median decline in glomerular filtration rates was 1.4 ml per minute per 1.73 m(2) of body-surface area per year. The actuarial survival free of end-stage renal disease was 96, 89, 74, and 74 percent at 5, 10, 15, and 20 years, respectively. Treatment with orthophosphate and pyridoxine reduced urinary supersaturation with calcium oxalate from 8.3+/-3.0 to 2.1+/-1.7 kJ per mole at 38 degrees C (P<0.001), increased the inhibition of calcium oxalate formation from 63+/-11 to 108+/-10 inhibitor units per 24 hours (P<0.001), and improved the crystalluria score from 2.6+/-0.3 to 0.6+/-0.1 (P<0.001). Conclusions. Treatment of patients with primary hyperoxaluria with orthophosphate and pyridoxine decreases urinary calcium oxalate crystallization and appears to preserve renal function.	MAYO CLIN & MAYO FDN,DEPT PEDIAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	MILLINER, DS (corresponding author), MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV NEPHROL,ROCHESTER,MN 55905, USA.				NCRR NIH HHS [5M01-RR0585-23] Funding Source: Medline; NIADDK NIH HHS [AM20605] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLSOP J, 1987, CLIN CHIM ACTA, V170, P187, DOI 10.1016/0009-8981(87)90127-6; BARRATT TM, 1988, OXALATE METABOLISM R, P84; BRIGMAN J, 1978, INVEST UROL, V15, P496; BROYER M, 1990, NEPHROL DIAL TRANSPL, V5, P332, DOI 10.1093/ndt/5.5.332; CHALMERS RA, 1972, ANALYST, V97, P958, DOI 10.1039/an9729700958; CHLEBECK PT, 1994, AM J KIDNEY DIS, V23, P255, DOI 10.1016/S0272-6386(12)80981-4; COOPER PJ, 1988, J HISTOCHEM CYTOCHEM, V36, P1285, DOI 10.1177/36.10.3418107; DANPURE CJ, 1987, LANCET, V1, P289; DANPURE CJ, 1989, J INHERIT METAB DIS, V12, P210, DOI 10.1007/BF01800727; DANPURE CJ, 1991, AM J KIDNEY DIS, V17, P366, DOI 10.1016/S0272-6386(12)80624-X; DANPURE CJ, 1986, FEBS LETT, V201, P20, DOI 10.1016/0014-5793(86)80563-4; DANPURE CJ, 1989, J CELL BIOL, V108, P1345, DOI 10.1083/jcb.108.4.1345; DENT CE, 1970, ARCH DIS CHILD, V45, P735, DOI 10.1136/adc.45.244.735; FOLIN O, 1905, J BIOL CHEM, V1, P131; FREDERICK EW, 1963, NEW ENGL J MED, V269, P821, DOI 10.1056/NEJM196310172691601; GIBBS DA, 1969, J LAB CLIN MED, V73, P901; GIBBS DA, 1970, CLIN SCI, V38, P277, DOI 10.1042/cs0380277; HELIN I, 1980, SCAND J UROL NEPHROL, V14, P61, DOI 10.3109/00365598009181192; HOCKADAY TD, 1964, MEDICINE, V43, P315, DOI 10.1097/00005792-196405000-00010; HOLMGREN G, 1978, UPSALA J MED SCI, V83, P65, DOI 10.3109/03009737809179114; KATZ A, 1992, KIDNEY INT, V42, P1408, DOI 10.1038/ki.1992.434; KOEHL C, 1976, CLIN CHIM ACTA, V70, P71, DOI 10.1016/0009-8981(76)90006-1; LATTA K, 1990, EUR J PEDIATR, V149, P518, DOI 10.1007/BF01957682; LEUMANN E, 1993, PEDIATR NEPHROL, V7, P207, DOI 10.1007/BF00864405; MCDONALD JC, 1989, NEW ENGL J MED, V321, P1100, DOI 10.1056/NEJM198910193211607; MEYER JL, 1975, INVEST UROL, V13, P36; MISTRY J, 1988, BIOCHEM SOC T, V16, P626, DOI 10.1042/bst0160626; NATELSON S, 1948, J BIOL CHEM, V175, P745; OLTHUIS FMFG, 1977, CLIN CHIM ACTA, V75, P123, DOI 10.1016/0009-8981(77)90507-1; OTT NT, 1975, MAYO CLIN PROC, V50, P664; SCHEINMAN JI, 1984, KIDNEY, V17, P13; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; SCHWARTZ GJ, 1985, J PEDIATR-US, V106, P522, DOI 10.1016/S0022-3476(85)80697-1; SLACK TK, 1976, MAYO CLIN PROC, V51, P296; SMITH LH, 1967, MOD TREAT, V4, P522; SMITH LH, 1976, UROLITHIASIS RES, P199; WATTS RWE, 1987, LANCET, V2, P474; WATTS RWE, 1991, AM J MED, V90, P179; WATTS RWE, 1985, CLIN SCI, V69, P87, DOI 10.1042/cs0690087; WATTS RWE, 1984, CLIN SCI, V66, P591, DOI 10.1042/cs0660591; WERNESS PG, 1981, J CRYST GROWTH, V53, P166, DOI 10.1016/0022-0248(81)90063-4; WERNESS PG, 1985, J UROLOGY, V134, P1242, DOI 10.1016/S0022-5347(17)47703-2; WILL EJ, 1979, METABOLISM, V28, P542, DOI 10.1016/0026-0495(79)90195-1; WILLIAMS HE, 1968, NEW ENGL J MED, V278, P233, DOI 10.1056/NEJM196802012780502; WILLIAMS HE, 1978, METABOLIC BASIS INHE, P182; WILSON DM, 1991, CLIN CHEM, V37, P1229	46	147	148	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1553	1558		10.1056/NEJM199412083312304	http://dx.doi.org/10.1056/NEJM199412083312304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969325	Bronze			2022-12-28	WOS:A1994PV29200004
J	BANERJEE, A; JONES, R				BANERJEE, A; JONES, R			WHITHER IMMEDIATE FLUID RESUSCITATION	LANCET			English	Editorial Material											BANERJEE, A (corresponding author), ROTHERHAM DIST GEN HOSP,DEPT GEN SURG,ROTHERHAM,S YORKSHIRE,ENGLAND.		Banerjee, Anjan Kumar/AAL-6375-2020	Banerjee, Anjan Kumar/0000-0002-5935-3404				BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1; CRAWFORD ES, 1991, J VASC SURG, V13, P348; DEMETRIADES D, 1993, BRIT J SURG, V80, P1534, DOI 10.1002/bjs.1800801213; DILLON J, 1966, ARCH SURG-CHICAGO, V93, P537; JACOBS LM, 1994, NEW ENGL J MED, V331, P1153, DOI 10.1056/NEJM199410273311710; SHIRES T, 1964, ARCH SURG-CHICAGO, V88, P688; SIRINEK KR, 1990, ARCH SURG-CHICAGO, V125, P844; 1993, ADV TRAUMA LIFE SUPP, P75	9	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1450	1451		10.1016/S0140-6736(94)90283-6	http://dx.doi.org/10.1016/S0140-6736(94)90283-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968115				2022-12-28	WOS:A1994PT99500002
J	LEVINE, A; TENHAKEN, R; DIXON, R; LAMB, C				LEVINE, A; TENHAKEN, R; DIXON, R; LAMB, C			H2O2 FROM THE OXIDATIVE BURST ORCHESTRATES THE PLANT HYPERSENSITIVE DISEASE RESISTANCE RESPONSE	CELL			English	Article							CELL-SUSPENSION CULTURES; DNA-BINDING ACTIVITY; PHASEOLUS-VULGARIS; DEFENSE RESPONSE; MESSENGER-RNA; INDUCTION; ELICITOR; GENE; PROTEIN; ELICITATION	Microbial elicitors or attempted infection with an avirulent pathogen strain causes the rapid production of reactive oxygen intermediates. We report here that H2O2 from this oxidative bu rst not only drives the crosslinking of cell wall structural proteins, but also functions as a local trigger of programmed death in challenged cells and as a diffusible signal for the induction in adjacent cells of genes encoding cellular protectants such as glutathione S-transferase and glutathione peroxidase. Thus, H2O2 from the oxidative burst plays a key role in the orchestration of a localized hypersensitive response during the expression of plant disease resistance.	SALK INST BIOL STUDIES, PLANT BIOL LAB, LA JOLLA, CA 92037 USA; SAMUEL ROBERTS NOBLE FDN INC, DIV PLANT BIOL, ARDMORE, OK 73402 USA	Salk Institute; Noble Research Institute			Tenhaken, Raimund/O-6556-2019; Levine, Alex/A-6867-2008	Tenhaken, Raimund/0000-0002-6764-4826; 				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; ATKINSON MM, 1990, PLANT PHYSIOL, V92, P215, DOI 10.1104/pp.92.1.215; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BABIYCHUK E, 1994, P NATL ACAD SCI USA, V91, P3299, DOI 10.1073/pnas.91.8.3299; BAKER CJ, 1993, PHYSIOL MOL PLANT P, V43, P81, DOI 10.1006/pmpp.1993.1042; BECKER F, 1993, PLANT J, V3, P875, DOI 10.1111/j.1365-313X.1993.00875.x; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; BRISSON LF, 1994, IN PRESS PLANT CELL; BULTKE TM, 1994, TODAY, V15, P7; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CREELMAN RA, 1992, P NATL ACAD SCI USA, V89, P4938, DOI 10.1073/pnas.89.11.4938; CRIQUI MC, 1992, PLANT MOL BIOL, V18, P623, DOI 10.1007/BF00040684; CZARNECKA E, 1988, MOL CELL BIOL, V8, P1113, DOI 10.1128/MCB.8.3.1113; DAVIS D, 1993, PHYTOCHEMISTRY, V32, P607, DOI 10.1016/S0031-9422(00)95144-6; DEVLIN WS, 1992, PLANT PHYSIOL, V100, P1189, DOI 10.1104/pp.100.3.1189; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DIXON RA, 1983, PLANT PHYSIOL, V71, P251, DOI 10.1104/pp.71.2.251; EDWARDS K, 1985, P NATL ACAD SCI USA, V82, P6731, DOI 10.1073/pnas.82.20.6731; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FELIX G, 1994, P NATL ACAD SCI USA, V91, P952, DOI 10.1073/pnas.91.3.952; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HAHN MG, 1992, MOL PLANT PATHOL, V2, P231; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAVIR EA, 1992, PLANT PHYSIOL, V99, P533, DOI 10.1104/pp.99.2.533; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HEROUART D, 1993, P NATL ACAD SCI USA, V90, P3108, DOI 10.1073/pnas.90.7.3108; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITZHAKI H, 1993, PLANT MOL BIOL, V22, P43, DOI 10.1007/BF00038994; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KEEN NT, 1991, THEOR APPL GENET, V81, P133, DOI 10.1007/BF00226123; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KIEDROWSKI S, 1992, EMBO J, V11, P4677, DOI 10.1002/j.1460-2075.1992.tb05572.x; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; LI YM, 1992, P NATL ACAD SCI USA, V89, P11867, DOI 10.1073/pnas.89.24.11867; MAUCH F, 1993, PLANT PHYSIOL, V102, P1193, DOI 10.1104/pp.102.4.1193; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; OLSON PD, 1993, PLANT J, V4, P887, DOI 10.1046/j.1365-313X.1993.04050887.x; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROOT RK, 1975, J CLIN INVEST, V55, P945, DOI 10.1172/JCI108024; RYALS J, 1994, PLANT PHYSIOL, V104, P1109, DOI 10.1104/pp.104.4.1109; RYDER TB, 1984, P NATL ACAD SCI-BIOL, V81, P5724, DOI 10.1073/pnas.81.18.5724; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; TURNER JG, 1974, PHYTOPATHOLOGY, V64, P885, DOI 10.1094/Phyto-64-885; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	59	2168	2366	6	271	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					583	593		10.1016/0092-8674(94)90544-4	http://dx.doi.org/10.1016/0092-8674(94)90544-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954825				2022-12-28	WOS:A1994PT48100006
J	NYVAD, O; DANIELSEN, H; MADSEN, S				NYVAD, O; DANIELSEN, H; MADSEN, S			INTRAVENOUS IRON-SUCROSE COMPLEX TO REDUCE EPOETIN DEMAND IN DIALYSIS PATIENTS	LANCET			English	Letter											NYVAD, O (corresponding author), VIBORG CTY HOSP,DEPT NEPHROL,DK-8800 VIBORG,DENMARK.		Danielsen, Havard e/A-7540-2014; Danielsen, Havard/AAK-8489-2020					BAROSI G, 1993, ACTA HAEMATOL-BASEL, V90, P13; MacDougall I. C., 1993, Journal of the American Society of Nephrology, V4, P428; TERUEL JL, 1994, AM J NEPHROL, V14, P95, DOI 10.1159/000168696	3	55	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1305	1306		10.1016/S0140-6736(94)90797-8	http://dx.doi.org/10.1016/S0140-6736(94)90797-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7968018				2022-12-28	WOS:A1994PP70100058
J	KATO, JY; MATSUOKA, M; POLYAK, K; MASSAGUE, J; SHERR, CJ				KATO, JY; MATSUOKA, M; POLYAK, K; MASSAGUE, J; SHERR, CJ			CYCLIC-AMP-INDUCED G1 PHASE ARREST MEDIATED BY AN INHIBITOR (P27(KIP1)) OF CYCLIN-DEPENDENT KINASE-4 ACTIVATION	CELL			English	Article							STIMULATING FACTOR-I; CELL-CYCLE; PROTEIN-KINASE; CATALYTIC SUBUNIT; P34CDC2 KINASE; TGF-BETA; S-PHASE; PHOSPHORYLATION; CDC2; IDENTIFICATION	Cyclic AMP (cAMP) blocks the mitogenic effects of colony-stimulating factor 1 (CSF-1) in macrophages, inducing cell cycle arrest in mid-G1 phase. Complexes between cyclin D1 and cyclin-dependent kinase 4 (cdk4) assemble in growth arrested cells, but cdk4 is not phosphorylated in vivo by the cdk-activating kinase (CAK) and remains inactive. Although undetectable in lysates of cAMP-treated cells, active CAK is recovered after antibody precipitation, indicating that it is not the direct target of inhibition. Levels of the cdk inhibitor p27(Kip1) increase in cAMP-treated cells, and its immunodepletion from inhibitory lysates restores CAK-mediated cdk4 activation. Kip1 does not bind to CAK, but its association with cyclin D-cdk4 prevents CAK from phosphorylating and activating the holoenzyme.	ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, TUMOR CELL BIOL LAB, MEMPHIS, TN 38105 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM GENET & CELL BIOL, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Memorial Sloan Kettering Cancer Center			Sherr, Charles J/N-8074-2018	Sherr, Charles J/0000-0002-5516-6206; Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [P30CA021765, R35CA047064] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765, CA-47064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FLEIG UN, 1992, MOL CELL BIOL, V12, P2295, DOI 10.1128/MCB.12.5.2295; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAMILTON JA, 1983, J CELL PHYSIOL, V115, P67, DOI 10.1002/jcp.1041150111; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; JIANG W, 1993, ONCOGENE, V8, P3447; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORICE WG, 1993, J BIOL CHEM, V268, P22737; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHACTER E, 1988, METHOD ENZYMOL, V159, P3; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SUTHERLAND EW, 1958, J BIOL CHEM, V232, P1077; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VALLANCE SJ, 1994, HYBRIDOMA, V13, P37, DOI 10.1089/hyb.1994.13.37; WALSH DA, 1968, J BIOL CHEM, V243, P3763; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	57	741	756	1	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 4	1994	79	3					487	496		10.1016/0092-8674(94)90257-7	http://dx.doi.org/10.1016/0092-8674(94)90257-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954814				2022-12-28	WOS:A1994PQ48800011
J	SCHIMMEL, TW; CRUMM, KF				SCHIMMEL, TW; CRUMM, KF			IMAGES IN CLINICAL MEDICINE - MICROSURGICAL FERTILIZATION AND BLASTOMERE REMOVAL FOR GENETIC-ANALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											SCHIMMEL, TW (corresponding author), UNITED HOSP,IVF AMER PROGRAM,PORT CHESTER,NY 10573, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1200	1200						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935658				2022-12-28	WOS:A1994PN80600005
J	KIMBLE, J				KIMBLE, J			AN ANCIENT MOLECULAR MECHANISM FOR ESTABLISHING EMBRYONIC POLARITY	SCIENCE			English	Editorial Material							C-ELEGANS EMBRYOS; BICOID PROTEIN; DROSOPHILA; NANOS; GRANULES; PATTERN; ENCODES; SKN-1				KIMBLE, J (corresponding author), UNIV WISCONSIN, HOWARD HUGHES MED INST, MOLEC BIOL LAB, MADISON, WI 53706 USA.							BLACKLER AW, 1966, DEV BIOL, V14, P330; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; HUTTER H, 1994, DEVELOPMENT, V120, P2051; JACOB F, 1982, POSSIBLE ACTUAL JESS; KENYON C, 1994, CELL, V78, P175, DOI 10.1016/0092-8674(94)90288-7; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; MOSKOWITZ IPG, 1994, DEVELOPMENT, V120, P3325; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SIDOW A, 1994, CURR BIOL, V4, P596, DOI 10.1016/S0960-9822(00)00131-7; STJOHNSTON D, 1992, CELL, V68, P201; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1992, SEMIN DEV BIOL, V3; WOOD WB, 1994, TRENDS GENET, V10, P49, DOI 10.1016/0168-9525(94)90148-1	25	18	19	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	1994	266	5185					577	578		10.1126/science.7939710	http://dx.doi.org/10.1126/science.7939710			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939710				2022-12-28	WOS:A1994PN80700034
J	NUSSLEINVOLHARD, C				NUSSLEINVOLHARD, C			OF FLIES AND FISHES	SCIENCE			English	Editorial Material							DROSOPHILA-MELANOGASTER; LARVAL CUTICLE; ZYGOTIC LOCI; 2ND CHROMOSOME; MUTATIONS; ZEBRAFISH; PATTERN; EMBRYO; CELLS				NUSSLEINVOLHARD, C (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,TUBINGEN,GERMANY.							ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; GOFF DJ, 1992, GENOMICS, V14, P200, DOI 10.1016/S0888-7543(05)80309-X; HALPERN ME, 1993, CELL, V75, P1; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; JACOBS H, COMMUNICATION; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; LIN S, 1994, SCIENCE, V265, P666, DOI 10.1126/science.8036514; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; POSTLETHWAIT JH, 1994, SCIENCE, V264, P699, DOI 10.1126/science.8171321; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; SCHUPBACH T, 1989, GENETICS, V121, P101; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; STREISINGER G, 1981, NATURE, V291, P293, DOI 10.1038/291293a0; WALKER C, 1983, GENETICS, V103, P125; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158	21	100	104	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					572	574		10.1126/science.7939708	http://dx.doi.org/10.1126/science.7939708			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939708				2022-12-28	WOS:A1994PN80700032
J	TRENITE, DGAKN				TRENITE, DGAKN			VIDEO-GAME EPILEPSY	LANCET			English	Editorial Material							PHOTOSENSITIVITY				TRENITE, DGAKN (corresponding author), INST EPILEPSIEBESTRIJDING MEER & BOSCH CRUQUIUSHOEVE,HEEMSTEDE,NETHERLANDS.		Trenite, Dorothee Nolst/ABG-5804-2020					FERRIE CD, 1994, J NEUROL NEUROSUR PS, V57, P925, DOI 10.1136/jnnp.57.8.925; FISH DR, 1994, NATIONAL SURVEY PHOT; GRAF WD, 1994, PEDIATRICS, V93, P551; HARDING GFA, 1993, BROADCASTING ADVERTI, V1; Jeavons P, 1975, PHOTOSENSITIVE EPILE; JEAVONS PM, 1986, EPILEPSIA, V27, P569, DOI 10.1111/j.1528-1157.1986.tb03586.x; TRENITE DGA, 1989, ACTA NEUROL SCAND, V47, P163; TRENITE DGAK, 1987, J NEUROL NEUROSUR PS, V50, P1546, DOI 10.1136/jnnp.50.11.1546; WILKINS AJ, 1979, ELECTROEN CLIN NEURO, V47, P163, DOI 10.1016/0013-4694(79)90218-9; WOLF P, 1986, J NEUROL NEUROSUR PS, V49, P1386, DOI 10.1136/jnnp.49.12.1386	10	18	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1102	1103		10.1016/S0140-6736(94)90625-4	http://dx.doi.org/10.1016/S0140-6736(94)90625-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934490				2022-12-28	WOS:A1994PN06600004
J	MARX, J				MARX, J			8 GET THE CALL TO STOCKHOLM - MEDICINE - A SIGNAL AWARD FOR DISCOVERING G-PROTEINS	SCIENCE			English	Note																		1989, SCIENCE, V244, P1446	1	3	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					368	369		10.1126/science.7939678	http://dx.doi.org/10.1126/science.7939678			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939678				2022-12-28	WOS:A1994PN27200017
J	VU, TH; HOFFMAN, AR				VU, TH; HOFFMAN, AR			PROMOTER-SPECIFIC IMPRINTING OF THE HUMAN INSULIN-LIKE GROWTH FACTOR-II GENE	NATURE			English	Article							ALLELE-SPECIFIC METHYLATION; BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; IGF2 GENE; MOUSE; RELAXATION; EMBRYOGENESIS; CANCER	GENOMIC imprinting is a mechanism whereby only one of the two parental alleles is expressed. Loss or relaxation of genomic imprinting has been proposed as an epigenetic mechanism for oncogenesis in a variety of human tumours(1-6). Although the mechanism of imprinting is unknown, differential CpG methylation of the parental alleles has been implicated(7-12). The human insulinlike growth factor-II (IGF2) gene, which is transcribed from four promoters, P1-P4 (ref. 13), is imprinted in fetal liver(14,15) but biallelic expression occurs in adult liver(16). Like most tissues, fetal liver uses primarily promoters P3 and P4 (ref. 17). Adult liver, however, transcribes IGF2 from promoter P1, and it has been suggested that the recruitment of P1 may be responsible for the absence of imprinting in human liver, and in choroid plexus and leptomeninges(18). We report here that in liver and chondrocytes, IGF2 transcripts from promoter P1 are always derived from both parental alleles, whereas transcripts from promoters P2, P3 and P4 are always from one parental allele. These findings demonstrate that imprinting and a lack of imprinting can both occur within a single gene in a single tissue, suggesting that regional imprinting factors may be important.	STANFORD UNIV,DEPT MED,PALO ALTO,CA 94304	Stanford University	VU, TH (corresponding author), VET ADM MED CTR,MED SERV,3801 MIRANDA AVE,PALO ALTO,CA 94304, USA.			Hoffman, Andrew/0000-0002-0145-1917				BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CATTANACH BM, 1990, DEVELOPMENT, P63; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EKSBERG R, 1993, NAT GENET, V5, P143; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9	24	208	212	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					714	717		10.1038/371714a0	http://dx.doi.org/10.1038/371714a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935819				2022-12-28	WOS:A1994PM77300060
J	CLEGG, JB				CLEGG, JB			TRAVELS WITH DNA IN THE PACIFIC	LANCET			English	Article											CLEGG, JB (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MRC,MOLEC HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.							BELLWOOD P, 1991, SCI AM           JUL, P70; Belwood P, 1985, PREHISTORY INDOMALAY; DIAMOND JM, 1988, NATURE, V336, P307, DOI 10.1038/336307a0; FLINT J, 1986, NATURE, V321, P744, DOI 10.1038/321744a0; HAGELBERG E, 1993, P ROY SOC B-BIOL SCI, V252, P163, DOI 10.1098/rspb.1993.0061; HILL AVS, 1989, COLONISATION PACIFIC; NEEL JV, 1962, AM J HUM GENET, V14, P353; Terrell J., 1986, PREHISTORY PACIFIC I; ZIMMET P, 1991, DIABETES ANN, V6, P1; ZIMMET PZ, 1992, DIABETES CARE, V15, P232, DOI 10.2337/diacare.15.2.232	10	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1070	1072		10.1016/S0140-6736(94)91718-3	http://dx.doi.org/10.1016/S0140-6736(94)91718-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934453				2022-12-28	WOS:A1994PL85200018
J	CUPPLES, ME; MCKNIGHT, A				CUPPLES, ME; MCKNIGHT, A			RANDOMIZED CONTROLLED TRIAL OF HEALTH PROMOTION IN GENERAL-PRACTICE FOR PATIENTS AT HIGH CARDIOVASCULAR RISK	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PREVENTION PROJECT; LIFE-STYLE; MEN; DIET	Objective-To assess the value of health education for patients with angina in reducing risk factors for cardiovascular disease and lessening the effect of angina on everyday activities. Design-Randomised controlled trial of personal health education given every four months. Setting-18 general practices in the greater Belfast area. Subjects-688 patients aged less than 75 years and known to have had angina for at least six months; 342 randomised to receive education and 346 to no education. Main outcome measures-Restriction of everyday activities, dietary habit, smoking habit, frequency of physical exercise; blood pressure, body mass index, and serum total cholesterol concentration at entry to trial and after two years. Results-317 in the intervention group and 300 in the control group completed the trial. At the two year review more of the intervention group (140, 44%) reported taking daily physical exercise than the control group (70, 24%). The intervention group also reported eating a healthier diet than the control group and less restriction by angina in any everyday activity. No significant differences were found between the groups in smoking habit, systolic or diastolic blood pressure, cholesterol concentration, or body mass index. Conclusion-Despite having no significant effect on objective cardiovascular risk factors, personal health education of patients with angina seems to increase exercise and improve dietary habits and is effective in lessening the restriction of everyday activities.			CUPPLES, ME (corresponding author), QUEENS UNIV BELFAST,DUNLUCE HLTH CTR,DEPT GEN PRACTICE,BELFAST BT9 7HR,ANTRIM,NORTH IRELAND.			Cupples, Margaret/0000-0002-4248-9700				BINGHAM SA, 1987, NUTR ABSTR REV A, V57, P720; BORKAN GA, 1986, AM J EPIDEMIOL, V124, P410, DOI 10.1093/oxfordjournals.aje.a114411; CAMPBELL MJ, 1984, J EPIDEMIOL COMMUN H, V38, P17, DOI 10.1136/jech.38.1.17; CONNOR SL, 1992, J AM DIET ASSOC, V92, P41; DALY LE, 1986, BRIT MED J, V293, P653, DOI 10.1136/bmj.293.6548.653; DAWBER TR, 1980, FRAMINGHAM STUDY EPI, P76; GIBBINS RL, 1993, BMJ-BRIT MED J, V306, P1652, DOI 10.1136/bmj.306.6893.1652; KORNITZER M, 1983, LANCET, V1, P1066; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; NEILL WA, 1985, ARCH INTERN MED, V145, P1642, DOI 10.1001/archinte.145.9.1642; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; ROSE G, 1983, LANCET, V1, P1062; ROSE G, 1977, LANCET, V1, P105; ROSENBERG L, 1985, NEW ENGL J MED, V313, P1511, DOI 10.1056/NEJM198512123132404; SHAPER AG, 1986, BRIT MED J, V293, P474, DOI 10.1136/bmj.293.6545.474; SILAGY C, 1993, BRIT MED J, V306, P1657, DOI 10.1136/bmj.306.6893.1657; THOROGOOD M, 1990, BRIT MED J, V300, P1297, DOI 10.1136/bmj.300.6735.1297; TODD IC, 1992, BRIT HEART J, V68, P560; 1994, BRIT MED J, V308, P313; 1985, BRIT MED J, V291, P97; 1993, DHSS199293 ANN REP; 1992, RES NUTRITION NO IRE; 1986, CHANGE HEART STRATEG; 1994, BRIT MED J, V308, P308; 1982, BRIT MED J, V285, P1319	25	135	135	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					993	996		10.1136/bmj.309.6960.993	http://dx.doi.org/10.1136/bmj.309.6960.993			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950723	Green Published			2022-12-28	WOS:A1994PM41700025
J	SAAVEDRA, JM; BAUMAN, NA; OUNG, I; PERMAN, JA; YOLKEN, RH				SAAVEDRA, JM; BAUMAN, NA; OUNG, I; PERMAN, JA; YOLKEN, RH			FEEDING OF BIFIDOBACTERIUM-BIFIDUM AND STREPTOCOCCUS-THERMOPHILUS TO INFANTS IN-HOSPITAL FOR PREVENTION OF DIARRHEA AND SHEDDING OF ROTAVIRUS	LANCET			English	Article							FECAL FLORA; BREAST; GASTROENTERITIS; CHILDREN; HUMANS	Acute diarrhoea is a serious cause of infant morbidity and mortality, and the development of preventive measures remains an important goal. Bifidobacteria (which constitute the predominant intestinal flora of breastfed infants), as well as other lactic-acid-producing organisms such as Streptococcus thermophilus, are thought to have a protective effect against acute diarrhoeal disease. However, their efficacy has not been assessed in controlled trials. In a double-blind, placebo-controlled trial, infants aged 5-24 months who were admitted to a chronic medical care hospital were randomised to receive a standard infant formula or the same formula supplemented with Bifidobacterium bifidum and S thermophilus. Patients were evaluated daily for occurrence of diarrhoea, and faecal samples, obtained weekly, were analysed for rotavirus antigen by enzyme immunoassay. Faecal samples were also obtained during an episode of diarrhoea for virological and bacteriological analyses. 55 subjects were evaluated for a total of 4447 patient-days during 17 months. 8 (31%) of the 26 patients who received the control formula and 2 (7%) of 29 who received the supplemented formula developed diarrhoea during the course of the study (p=0.035, Fisher's exact test, two-tailed). 10 (39%) of the subjects who received the control formula and 3 (10%) of those who received the supplemented formula shed rotavirus at some time during the study (p=0.025). The supplementation of infant formula with B bifidum and S thermophilus can reduce the incidence of acute diarrhoea and rotavirus shedding in infants admitted to hospital.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; MT WASHINGTON PEDIAT HOSP,BALTIMORE,MD	Johns Hopkins University			yolken, robert/AAW-2556-2021	Saavedra, Jose M./0000-0003-4343-7176	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040540] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 40540] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNO Y, 1984, MICROBIOL IMMUNOL, V28, P975, DOI 10.1111/j.1348-0421.1984.tb00754.x; BOUHNIK Y, 1992, GASTROENTEROLOGY, V102, P875, DOI 10.1016/0016-5085(92)90172-U; BULLEN CL, 1971, BRIT MED J, V3, P338, DOI 10.1136/bmj.3.5770.338; BULLEN CL, 1977, J MED MICROBIOL, V10, P403, DOI 10.1099/00222615-10-4-403; DUFFY LC, 1986, AM J DIS CHILD, V140, P1164, DOI 10.1001/archpedi.1986.02140250090041; DUFFY LC, 1993, PEDIATR RES, V33, P983; HO MS, 1988, JAMA-J AM MED ASSOC, V260, P3281, DOI 10.1001/jama.260.22.3281; KAPIKIAN AZ, 1989, REV INFECT DIS S, V3, pS539; LEVESQUE J, 1990, ARCH FRANCAISES PEDI, V17, P533; MARTEAU P, 1990, BRIT J NUTR, V64, P71, DOI 10.1079/BJN19900010; MIDDLETON PJ, 1977, AM J DIS CHILD, V131, P733, DOI 10.1001/archpedi.1977.02120200015004; PUHAN Z, 1990, Cultured Dairy Products Journal, V25, P4; SNYDER JD, 1982, B WORLD HEALTH ORGAN, V60, P605; TASOVATZ B, 1964, ANN PEDIATRIE, V22, P291; YOLKEN RH, 1991, TXB HUMAN VIROLOGY, P804	15	706	772	1	36	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1046	1049		10.1016/S0140-6736(94)91708-6	http://dx.doi.org/10.1016/S0140-6736(94)91708-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934445	hybrid			2022-12-28	WOS:A1994PL85200008
J	COHEN, J				COHEN, J			LABORATORY WASTES - TOXIC DISPUTE COSTS STANFORD 1-MILLION-DOLLARS	SCIENCE			English	Editorial Material																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					213	213		10.1126/science.7939653	http://dx.doi.org/10.1126/science.7939653			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939653				2022-12-28	WOS:A1994PM13400013
J	MOY, VT; FLORIN, EL; GAUB, HE				MOY, VT; FLORIN, EL; GAUB, HE			INTERMOLECULAR FORCES AND ENERGIES BETWEEN LIGANDS AND RECEPTORS	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPY; ACTIN FILAMENT; STREPTAVIDIN; CELLS	The recognition mechanisms and dissociation pathways of the avidin-biotin complex and of actin monomers in actin filaments were investigated. The unbinding forces of discrete complexes of avidin or streptavidin with biotin analogs are proportional to the enthalpy change of the complex formation but independent of changes in the free energy. This result indicates that the unbinding process is adiabatic and that entropic changes occur after unbinding. On the basis of the measured forces and binding energies, an effective rupture length of 9.5 +/- 1 angstroms was calculated for all biotin-avidin pairs and approximately 1 to 3 angstroms for the actin monomer-monomer interaction. A model for the correlation among binding forces, intermolecular potential, and molecular function is proposed.	TECH UNIV MUNICH,DEPT PHYS,D-85748 GARCHING,GERMANY	Technical University of Munich								[Anonymous], 1992, INTERMOLECULAR SURFA; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BINNIG G, 1987, REV MOD PHYS, V59, P615, DOI 10.1103/RevModPhys.59.615; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1966, BIOCHEM J, V101, P774, DOI 10.1042/bj1010774; HANSMA PK, 1988, SCIENCE, V242, P209, DOI 10.1126/science.3051380; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; LECKBAND DE, 1994, BIOCHEMISTRY-US, V33, P4611, DOI 10.1021/bi00181a023; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; MIYAMOTO S, 1993, PROTEINS, V16, P226, DOI 10.1002/prot.340160303; MOY VT, 1993, REV SCI INSTRUM, V64, P403; OOSAWA F, 1977, BIORHEOLOGY, V14, P11; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; SENDEN TJ, 1994, LANGMUIR, V10, P1003, DOI 10.1021/la00016a600; SHETERLINE P, 1994, ACTIN, V1; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WEBER PC, 1992, J AM CHEM SOC, V114, P3197, DOI 10.1021/ja00035a004	24	763	784	2	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					257	259		10.1126/science.7939660	http://dx.doi.org/10.1126/science.7939660			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939660				2022-12-28	WOS:A1994PM13400027
J	PUTTERMAN, DM				PUTTERMAN, DM			TRADE AND THE BIODIVERSITY CONVENTION	NATURE			English	Editorial Material											PUTTERMAN, DM (corresponding author), US AGCY INT DEV,RM 509,SA-18,WASHINGTON,DC 20523, USA.							Janzen D. H., 1993, Biodiversity prospecting: using genetic resources for sustainable development., P131; MANFREDI KP, 1991, J MED CHEM, V34, P3402, DOI 10.1021/jm00116a011; 1991, 133 WORLD BANK TECH; 1994, SCRIP            JAN, P32	4	9	9	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					553	554		10.1038/371553a0	http://dx.doi.org/10.1038/371553a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PL559	7935783				2022-12-28	WOS:A1994PL55900023
J	STEINHOFF, HJ; MOLLAAGHABABA, R; ALTENBACH, C; HIDEG, K; KREBS, M; KHORANA, HG; HUBBELL, WL				STEINHOFF, HJ; MOLLAAGHABABA, R; ALTENBACH, C; HIDEG, K; KREBS, M; KHORANA, HG; HUBBELL, WL			TIME-RESOLVED DETECTION OF STRUCTURAL-CHANGES DURING THE PHOTOCYCLE OF SPIN-LABELED BACTERIORHODOPSIN	SCIENCE			English	Article							HALOBACTERIUM-HALOBIUM; CONFORMATIONAL-CHANGES; PROTON TRANSLOCATION; LIGHT; DIFFRACTION; PROTEIN; MUTANTS; SPECTROSCOPY; MECHANISM; RHODOPSIN	Bacteriorhodopsin was selectively spin labeled at residues 72, 101, or 105 after replacement of the native amino acids by cysteine. Only the electron paramagnetic resonance spectrum of the label at 101 was time-dependent during the photocycle. The spectral change rose with the decay of the M intermediate and fell with recovery of the ground state. The transient signal is interpreted as the result of movement in the C-D or E-F interhelical loop, or in both, coincident with protonation changes at the key aspartate 96 residue. These results link the optically characterized intermediates with localized conformational changes in bacteriorhodopsin during the photocycle.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; RUHR UNIV BOCHUM,INST BIOPHYS,D-44780 BOCHUM,GERMANY; UNIV CALIF LOS ANGELES,JULES STEIN EYE INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV PECS,CENT RES LAB,H-7643 PECS,HUNGARY	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Ruhr University Bochum; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Pecs			Steinhoff, Heinz-Juergen/H-3791-2014	Steinhoff, Heinz-Juergen/0000-0002-5888-0157; Krebs, Mark/0000-0001-9017-6066	NATIONAL EYE INSTITUTE [R37EY005216, R01EY005216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER; NEI NIH HHS [EY05216] Funding Source: Medline; NIGMS NIH HHS [GM28289] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXIEV U, 1994, BIOPHYS J, V66, pA44; ALEXIEV U, UNPUB; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; GREENHALGH DA, 1991, P NATL ACAD SCI USA, V88, P8626, DOI 10.1073/pnas.88.19.8626; HENDERSON RD, COMMUNICATION; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; KREBS MP, 1993, J BACTERIOL, V175, P1555, DOI 10.1128/JB.175.6.1555-1560.1993; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P1987, DOI 10.1073/pnas.90.5.1987; LOZIER RH, 1975, BIOPHYS J, V15, P955, DOI 10.1016/S0006-3495(75)85875-9; OESTERHELT D, 1991, Q REV BIOPHYS, V24, P425, DOI 10.1017/S0033583500003863; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; ROTHSCHILD KJ, 1993, J BIOL CHEM, V268, P27046; SOUVIGNIER G, 1992, BIOPHYS J, V63, P1393, DOI 10.1016/S0006-3495(92)81722-8; STOECKENIUS W, 1979, BIOCHIM BIOPHYS ACTA, V505, P215, DOI 10.1016/0304-4173(79)90006-5; SUBRAMANIAM S, 1993, EMBO J, V12, P1; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312	22	148	149	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					105	107		10.1126/science.7939627	http://dx.doi.org/10.1126/science.7939627			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939627				2022-12-28	WOS:A1994PK58200033
J	LI, R; WAGA, S; HANNON, GJ; BEACH, D; STILLMAN, B				LI, R; WAGA, S; HANNON, GJ; BEACH, D; STILLMAN, B			DIFFERENTIAL-EFFECTS BY THE P21 CDK INHIBITOR ON PCNA-DEPENDENT DNA-REPLICATION AND REPAIR	NATURE			English	Article							LAGGING STRAND SYNTHESIS; CELL NUCLEAR ANTIGEN; POLYMERASE-DELTA; EXCISION REPAIR; AUXILIARY PROTEIN; INVITRO; KINASES; P53; SUBUNIT; EPSILON	IN mammalian cells, DNA damage increases the levels of the nuclear tumour-suppressor p53, resulting io elevated synthesis of p21, an inhibitor oi cyclin-dependent kinases (CDK)(1-6). p21 may also directly block DNA replication by inhibiting the proliferating-cell nuclear antigen (PCNA)(7), an essential DNA replication protein. However PCNA is also required for nucleotide-excision repair of DNA(8), an intrinsic part of the cellular response to ultraviolet irradiation. Using an in vitro system(9) we now show that p21 does not block PCNA-dependent nucleotide-excision repair, in contrast to its inhibition of simian virus 40 DNA replication(7) Furthermore, the short gap-filling DNA synthesis by PCNA-dependent DNA polymerases delta and epsilon is less sensitive to inhibition by p21 than is long primer-extension synthesis. The ability of p21 to inhibit the role of PCNA in DNA replication but not in DNA repair rationalizes in vivo data showing that genetic damage leads to inactivation of chromosomal replication while allowing damage-responsive repair.			LI, R (corresponding author), COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,POB 100,COLD SPRING HARBOR,NY 11724, USA.		Hannon, Gregory/AAB-3568-2019	Waga, Shou/0000-0003-4986-8735; Stillman, Bruce/0000-0002-9453-4091				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; [Anonymous], 1985, DNA REPAIR; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEE SH, 1991, J BIOL CHEM, V266, P2207; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MELENDY T, 1992, NUCLEIC ACIDS MOL BI, V6, P129; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WELSER T, 1991, J BIOL CHEM, V266, P10420; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; ZENG XR, 1994, J BIOL CHEM, V269, P13748	29	634	656	4	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					534	537		10.1038/371534a0	http://dx.doi.org/10.1038/371534a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935768				2022-12-28	WOS:A1994PK58900061
J	WILKINSON, G				WILKINSON, G			CONTROVERSIES IN MANAGEMENT - CAN SUICIDE BE PREVENTED - BETTER TREATMENT OF MENTAL-ILLNESS IS MORE APPROPRIATE AIM .5.	BRITISH MEDICAL JOURNAL			English	Article							TREATMENT-OF-DEPRESSION; GENERAL-PRACTITIONERS; EDUCATIONAL-PROGRAM; PREDICTION; DISORDERS; GOTLAND				WILKINSON, G (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,LONDON E1 2AD,ENGLAND.							BLOCH S, 1981, PSYCHIATRIC ETHICS; DOLL R, 1983, BMJ-BRIT MED J, V286, P445, DOI 10.1136/bmj.286.6363.445; Donne John, 1930, BIATHANATOS; GOLDSTEIN RB, 1991, ARCH GEN PSYCHIAT, V48, P418; MACDONALD A, 1992, BRIT J PSYCHIAT, V161, P574, DOI 10.1192/bjp.161.4.574a; MURPHY GE, 1983, ARCH GEN PSYCHIAT, V40, P343; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; RUTZ W, 1992, ACTA PSYCHIAT SCAND, V85, P83, DOI 10.1111/j.1600-0447.1992.tb01448.x; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V79, P19, DOI 10.1111/j.1600-0447.1989.tb09229.x; RUTZ W, 1992, ACTA PSYCHIAT SCAND, V85, P457, DOI 10.1111/j.1600-0447.1992.tb03212.x; 1993, TIMES           1116, P17; 1992, HLTH NATION; 1986, CAN J PSYCHIAT, V31, P104; 1994, BRIT MED J, V308, P7; 1985, TARGETS HLTH ALL TAR	15	36	36	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					860	861		10.1136/bmj.309.6958.860	http://dx.doi.org/10.1136/bmj.309.6958.860			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK501	7950618	Green Published			2022-12-28	WOS:A1994PK50100029
J	WRAY, J; POTMEES, C; ZEITLIN, H; RADLEYSMITH, R; YACOUB, M				WRAY, J; POTMEES, C; ZEITLIN, H; RADLEYSMITH, R; YACOUB, M			COGNITIVE FUNCTION AND BEHAVIORAL STATUS IN PEDIATRIC HEART AND HEART-LUNG TRANSPLANT RECIPIENTS - THE HAREFIELD EXPERIENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; ADJUSTMENT; DEFECTS; DISEASE	Objective-To assess the psychological impact of cardiac and cardiopulmonary transplantation on children. Design-Retrospective cross sectional study. Setting-One British centre performing paediatric heart and heart-lung transplant operations, four cardiac units in London, three London schools, two London health centres, and the dental department of a London children's hospital. Subjects-65 children who had been given heart or heart-lung transplants and two reference groups of 52 children who had had other types of cardiac surgery and 45 healthy children. Main outcome measures-Development, cognition, and behaviour at home and at school as assessed by measures with proved validity and reliability. Results-Developmental and cognitive measures indicated that children given transplants had significantly lower scores on several parameters, particularly in terms of development in children under 41/2 years of age. Performance on all tests, however, was within the normal range. There were no significant differences in behavioural ratings between the transplant and reference groups, though problem behaviour at home was more prevalent in the transplant group. Conclusions-Though cognitive development may be within the normal range, there are adverse psychological effects associated with cardiac and cardiopulmonary transplantation. These data indicate the need for a controlled prospective study in which children and their families are seen before and at regular intervals after transplantation. Interventions should he-developed that are tailored to the particular needs of this very specialised group of paediatric patients and their families.	WESTMINSTER MED SCH & HOSP, CHARING CROSS & WESTMINSTER MED SCH, DEPT PSYCHIAT, LONDON SW1P 2NS, ENGLAND	Imperial College London	WRAY, J (corresponding author), HAREFIELD HOSP, CARDIOTHORAC UNIT, HAREFIELD UB9 6UJ, MIDDX, ENGLAND.			Wray, Jo/0000-0002-4769-1211				APLEY J, 1967, BMJ-BRIT MED J, V1, P103, DOI 10.1136/bmj.1.5532.103; ARAM DM, 1985, J AM COLL CARDIOL, V6, P889; Banner, 1989, TRANSPLANT REV, V3, P1, DOI [10.1016/S0955-470X(89)80003-5, DOI 10.1016/S0955-470X(89)80003-5]; BANNER NR, 1989, ASSISTED CIRCULATION, V3, P448; BERNSTEIN DM, 1977, GIFT LIFE SOCIAL PSY, P119; DANILOWICZ DA, 1971, AM J PSYCHIAT, V128, P185, DOI 10.1176/ajp.128.2.185; Elliot C. D., 1983, BRIT ABILITY SCALES; FRICKER FJ, 1987, PEDIATRICS, V79, P138; FULTON M, 1987, LANCET, V1, P1221; GARRALDA ME, 1988, J CHILD PSYCHOL PSYC, V29, P79, DOI 10.1111/j.1469-7610.1988.tb00691.x; Griffiths R., 1970, ABILITIES YOUNG CHIL; HELLER A, 1985, AM J DIS CHILD, V139, P257, DOI 10.1001/archpedi.1985.02140050051021; KONG SG, 1986, AUST PAEDIATR J, V22, P101; KORSCH BM, 1973, J PEDIATR-US, V83, P399, DOI 10.1016/S0022-3476(73)80262-8; LAWRENCE KS, 1987, J HEART TRANSPLANT, V6, P329; LINDE LM, 1970, ACTA PAEDIATR SCAND, V59, P169, DOI 10.1111/j.1651-2227.1970.tb08984.x; LINDE LM, 1967, J PEDIATR-US, V71, P198, DOI 10.1016/S0022-3476(67)80072-6; NEWBURGER JW, 1984, NEW ENGL J MED, V310, P1495, DOI 10.1056/NEJM198406073102303; ODOUGHERTY M, 1983, CHILD DEV, V54, P1129, DOI 10.1111/j.1467-8624.1983.tb00534.x; PAHL E, 1988, TRANSPLANT P, V20, P743; PENNINGTON DG, 1985, HEART TRANSPLANT, V4, P441; PLESS IB, 1975, CHILD HLTH COMMUNITY, P41; POTMEES C, 1989, PSYCHOSOCIAL AFFECTS; RICHMAN N, 1971, J CHILD PSYCHOL PSYC, V12, P5, DOI 10.1111/j.1469-7610.1971.tb01047.x; ROSENTHAL A, 1975, PROG CARDIOVASC DIS, V18, P27, DOI 10.1016/0033-0620(75)90005-5; RUTTER M, 1970, ED HLTH BEHAVIOR; SCHONELL FJ, 1949, DIAGNOSTIC ATTAINMEN; UZARK K, 1989, PROG CARDIOVASC NURS, V46, P382	28	39	39	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	1994	309	6958					837	841		10.1136/bmj.309.6958.837	http://dx.doi.org/10.1136/bmj.309.6958.837			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7950613	Green Published			2022-12-28	WOS:A1994PK50100019
J	DONALDSON, C				DONALDSON, C			POSSIBLE ROAD TO EFFICIENCY IN THE HEALTH-SERVICE - COMMENTARY	BRITISH MEDICAL JOURNAL			English	Note											DONALDSON, C (corresponding author), UNIV ABERDEEN,DEPT PUBL HLTH,HLTH ECON RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND.			Donaldson, Cam/0000-0003-4670-5340				DONALDSON C, 1993, HEALTH POLICY, V25, P95, DOI 10.1016/0168-8510(93)90105-X	1	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					784	785		10.1136/bmj.309.6957.784	http://dx.doi.org/10.1136/bmj.309.6957.784			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950569	Green Published			2022-12-28	WOS:A1994PJ28200027
J	COMPSTON, JE				COMPSTON, JE			THE THERAPEUTIC USE OF BISPHOSPHONATES	BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; PAGETS-DISEASE; INTERMITTENT; ETIDRONATE; PAMIDRONATE; PREVENTION; APD				COMPSTON, JE (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMI S, 1993, OSTEOPOROSIS INT, V3, pS21; ADAMSON BB, 1993, LANCET, V342, P1459, DOI 10.1016/0140-6736(93)92935-M; ALEXANDRE C, 1990, OSTEOPOROSIS, P1441; BONNEKAMP PM, 1986, BONE MINER, V1, P27; BOYCE BF, 1984, LANCET, V1, P821; COMPSTON JE, 1992, BRIT MED BULL, V48, P309, DOI 10.1093/oxfordjournals.bmb.a072549; FLEISCH H, 1993, OSTEOPOROSIS INT, V3, pS15; FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495-199142060-00003; FROST HM, 1984, CALCIFIED TISSUE INT, V36, P349, DOI 10.1007/BF02405344; GALLACHER SJ, 1992, THORAX, V47, P932, DOI 10.1136/thx.47.11.932; HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X; Kanis J.A., 1991, PATHOPHYSIOLOGY TREA; MULDER H, 1994, BRIT J RHEUMATOL, V33, P348; MUNDY GR, 1991, BONE, V12, pS1, DOI 10.1016/8756-3282(91)90057-P; OTT SM, 1993, J BONE MINER RES, V8, pS597; OTT SM, 1990, OSTEOPOROSIS 1990, P1318; PAPAPOULOS SE, 1992, BONE, V13, pS41, DOI 10.1016/S8756-3282(09)80009-4; PATEL S, 1991, DRUGS, V46, P594; RALSTON SH, 1989, LANCET, V2, P1180; REGINSTER JY, 1989, LANCET, V2, P1469; REID IR, 1988, LANCET, V2, P1144; REID IR, 1988, LANCET, V1, P143; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; STORM T, 1993, J BONE MINER RES, V8, P199; VALKEMA R, 1989, BONE MINER, V5, P183, DOI 10.1016/0169-6009(89)90095-0; VIJVOET OLM, 1993, OSTEOPOROS INT S1, V3, pS230; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201	27	48	50	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					711	715		10.1136/bmj.309.6956.711	http://dx.doi.org/10.1136/bmj.309.6956.711			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950525	Green Published			2022-12-28	WOS:A1994PH40700021
J	OLDHAM, JM				OLDHAM, JM			PERSONALITY-DISORDERS - CURRENT PERSPECTIVES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DSM-III-R; AXIS-I; SAMPLE; CLASSIFICATION; SCHIZOPHRENIA; DIMENSIONS; MANAGEMENT; COMMUNITY; DIAGNOSIS; ADOPTION	Personality disorders are estimated to occur in at least 10% of the population. They can be major sources of long-term disability, and they frequently exist in conjunction with other major psychiatric disorders or with general medical conditions. Not infrequently, patients with personality disorders seek help from primary care physicians for physical complaints, rather than seeking psychiatric help. When a personality disorder is present, treatment of other coexisting psychiatric or medical conditions is frequently more complicated, lengthier, or less successful, a pattern that may at times be due to lack of recognition of the personality disorder. When a personality disorder is diagnosed, more effective treatment may be prescribed, particularly in light of improved treatment strategies for these conditions.	COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY 10032	Columbia University	OLDHAM, JM (corresponding author), NEW YORK STATE PSYCHIAT INST & HOSP,722 W 168TH ST,NEW YORK,NY 10032, USA.							ADLER G, 1989, AM PSYCHIATRIC PRESS, V8; Andreoli A., 1989, J PERSONALITY DISORD, V3, P307, DOI DOI 10.1521/PEDI.1989.3.4.307; [Anonymous], 1990, PERSONALITY ADULTHOO; [Anonymous], 1967, MINNESOTA MULTIPHASI; Beck A.T., 2015, COGNITIVE THERAPY PE; BENJAMIN LS, 1992, BORDERLINE PERSONALI; BINDWELL BG, 1993, ARCH INTERN MED, V153, P1991; BLACK DW, 1993, PSYCHOSOMATICS, V34, P131, DOI 10.1016/S0033-3182(93)71903-9; CADORET RJ, 1990, EUR ARCH PSY CLIN N, V239, P231, DOI 10.1007/BF01738577; CLARKIN JF, 1992, BORDERLINE PERSONALI; CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573; CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975, DOI 10.1001/archpsyc.1993.01820240059008; COCARRO EF, 1991, HOSP COMMUNITY PSYCH, V42, P1029; COCCARO EF, 1993, J PERS DISORD, V7, P181; COCCARO EF, 1994, ARCH GEN PSYCHIAT, V51, P318; Costa P.T., 1990, J PERS DISORD, V4, P362, DOI [https://doi.org/10.1521/pedi.1990.4.4.362, DOI 10.1521/PEDI.1990.4.4.362]; COSTA PT, 1992, J PERS DISORD, V6, P343, DOI 10.1521/pedi.1992.6.4.343; DAHL AA, 1986, ACTA PSYCHIAT SCAND, V73, P61, DOI 10.1111/j.1600-0447.1986.tb10526.x; DAHL AA, 1993, J PERS DISORD, V7, P86; DAWSON DF, 1988, CAN J PSYCHIAT, V33, P370, DOI 10.1177/070674378803300511; DYCE JA, 1994, J PERS DISORD, V8, P77, DOI 10.1521/pedi.1994.8.1.77; FLEMING B, 1990, ADV BEHAVIOR THERAPY; FORD CV, 1992, SPINE, V17, pS338, DOI 10.1097/00007632-199210001-00001; FREEMAN A, 1988, COMPREHENSIVE HDB CO; GERINGER ES, 1986, PSYCHOSOMATICS, V27, P251, DOI 10.1016/S0033-3182(86)72700-X; GROVE WM, 1991, J PERS DISORD, V5, P31, DOI 10.1521/pedi.1991.5.1.31; GROVES JE, 1978, NEW ENGL J MED, V298, P883, DOI 10.1056/NEJM197804202981605; Gunderson J, 1984, BORDERLINE PERSONALI; GUNDERSON JG, 1991, J PERS DISORD, V5, P60, DOI 10.1521/pedi.1991.5.1.60; JACKSON HJ, 1991, ACTA PSYCHIAT SCAND, V83, P206, DOI 10.1111/j.1600-0447.1991.tb05526.x; KAGAN J, 1988, SCIENCE, V240, P167, DOI 10.1126/science.3353713; KAGAN J, 1971, CHANGE CONTINUITY IN; KAHANA RJ, 1964, PSYCHIATRY MED PRACT; KAVOUSSI RJ, 1991, PERSONALITY DISORDER; KENDLER KS, 1982, AM J PSYCHIAT, V139, P1185; KENDLER KS, 1981, ARCH GEN PSYCHIAT, V38, P982; Kernberg O., 1984, SEVERE PERSONALITY D; KERNBERG OF, 1993, PSYCHODYNAMIC PSYCHO; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KILZIEH N, 1993, J PERS DISORD, V7, P100; Klerman G., 1993, NEW APPLICATIONS INT; LINEHAM MM, 1993, COGNITIVE BEHAVIORAL; LIVESLEY WJ, 1991, J PERS DISORD, V5, P52, DOI 10.1521/pedi.1991.5.1.52; LIVESLEY WJ, 1993, AM J PSYCHIAT, V150, P1826; LORANGER AW, 1982, ARCH GEN PSYCHIAT, V39, P795, DOI 10.1001/archpsyc.1982.04290070031007; MAIER W, 1992, J PERS DISORD, V6, P187, DOI 10.1521/pedi.1992.6.3.187; MARTIN RL, 1993, PERSONALITY DISORDER; MERIKANGAS KR, 1986, AM PSYCHIATRIC ASS A, V5; MUSKIN PR, IN PRESS PSYCHODYNAM; NAKAO K, 1992, J PERS DISORD, V6, P24, DOI 10.1521/pedi.1992.6.1.24; NAPOLEON A, 1993, ANN PLAS SURG, V31, P193, DOI 10.1097/00000637-199309000-00001; OLDHAM JM, 1992, AM J PSYCHIAT, V149, P213; Oldham JM, 1990, PERSONALITY SELF POR; OLDHAM JM, IN PRESS AM J PSYCHI; PARIS J, 1993, J PERS DISORD, V7, P255, DOI 10.1521/pedi.1993.7.3.255; Paris J., 1993, BORDERLINE PERSONALI; REICH J, 1989, INT J PSYCHIAT MED, V19, P1; REICH J, 1989, SOC PSYCH PSYCH EPID, V24, P12, DOI 10.1007/BF01788194; REICH JH, 1993, J NERV MENT DIS, V181, P475, DOI 10.1097/00005053-199308000-00002; REICH JH, 1990, J NERV MENT DIS, V178, P592; Robins LN, 1991, PSYCHIAT DISORDERS A, P328; SEARIGHT HR, 1992, J FAM PRACTICE, V34, P605; SHEA MT, 1993, J PERS DISORD, V7, P167; SIEVER LJ, 1991, AM J PSYCHIAT, V148, P1647; SIEVER LJ, 1990, ARCH GEN PSYCHIAT, V47, P634; SIEVER LJ, 1992, J PERS DISORD, V2, P301; SIEVER LJ, 1994, AM PSYCHIATRIC PRESS, V13; SIGVARDSSON S, 1987, J CHILD PSYCHOL PSYC, V28, P929, DOI 10.1111/j.1469-7610.1987.tb00680.x; SKODOL AE, 1993, FUNCTIONAL IMPAIRMEN; SOLOFF PH, 1993, BORDERLINE PERSONALI; Soloff PH, 1990, J PERSONALITY DISORD, V4, P233; Stone M. H, 1990, FATE BORDERLINE PATI; Stone MH, 1993, ABNORMALITIES PERSON; SVRAKIC DM, 1993, ARCH GEN PSYCHIAT, V50, P991; Thomas A., 1977, TEMPERAMENT DEV; TORGERSEN AM, 1985, BIOL BASIS PERSONALI; VANREEKUM R, 1993, BORDERLINE PERSONALI; WEISSMAN MM, 1993, J PERS DISORD, V7, P44; WESTON SC, 1993, J PERS DISORD, V7, P129; WIDIGER TA, 1985, ARCH GEN PSYCHIAT, V42, P615; WIDIGER TA, 1991, J PERS DISORD, V5, P386, DOI 10.1521/pedi.1991.5.4.386; WIDIGER TA, 1991, J ABNORM PSYCHOL, V100, P399, DOI 10.1037/0021-843X.100.3.399; ZIMMERMAN M, 1989, ARCH GEN PSYCHIAT, V46, P682; ZIMMERMAN M, 1994, ARCH GEN PSYCHIAT, V51, P225; ZIMMERMAN M, 1990, ARCH GEN PSYCHIAT, V47, P525; Zuckerman M., 1991, PSYCHOBIOLOGY PERSON; 1980, DIAGNOSTIC STATISTIC; 1987, DIAGNOSTIC STATISTIC; 1994, DIAGNOSTIC STATISTIC	89	32	33	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1770	1776		10.1001/jama.272.22.1770	http://dx.doi.org/10.1001/jama.272.22.1770			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PV815	7966926				2022-12-28	WOS:A1994PV81500027
J	DESJARLAIS, DC; PADIAN, NS; WINKELSTEIN, W				DESJARLAIS, DC; PADIAN, NS; WINKELSTEIN, W			TARGETED HIV-PREVENTION PROGRAMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN IMMUNODEFICIENCY VIRUS; 2 DIVISIVE ISSUES; AIDS POLICY; DRUG-USERS; INFECTION; HEALTH; RISK		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94105; UNIV CALIF BERKELEY,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California Berkeley	DESJARLAIS, DC (corresponding author), NATL DEV & RES INST INC,BETH ISRAEL MED CTR,11 BEACH ST,NEW YORK,NY 10013, USA.							[Anonymous], 1988, RATIONAL CHOICE UNCE; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DESJARLAIS DC, 1993, 9 INT C AIDS BERL; DICLEMENTE RJ, 1994, PREVENTING AIDS THEO; EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106; FENNER F, 1982, REV INFECT DIS, V4, P916; FIFE D, 1992, J ACQ IMMUN DEF SYND, V5, P1111; GAGNON J, 1994, NY TIMES        0106, pA23; HEATHCOTE H, 1984, LECTURE NOTES BIOMAT, V56; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HU DJ, 1993, 9TH INT C AIDS BERL; JONSON AR, 1993, SOCIAL IMPACT AIDS U; KELLY JA, 1991, AM J PUBLIC HEALTH, V81, P168, DOI 10.2105/AJPH.81.2.168; Lurie P, 1993, PUBLIC HLTH IMPACT N; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; ROGERS DE, 1993, JAMA-J AM MED ASSOC, V270, P494; Rogers R. W., 1983, SOCIAL PSYCHOPHYSIOL, P153, DOI DOI 10.1093/DEAFED/ENT031; ROJANAPITHAYAKO.W, 1994, MAY AD HOC TECHN ADV; STRYKER J, 1993, JAMA-J AM MED ASSOC, V270, P2436, DOI 10.1001/jama.270.20.2436; VANWIJNGAARDEN JK, 1992, AIDS IND DEMOCRACIES, P252; WALLACE R, IN PRESS SOC SCI MED; WASSER SC, 1993, J ACQ IMMUN DEF SYND, V6, P1035; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; 1993, AIDS EXPANDING TRAGE; 1994, HIV AIDS SURVEILLANC	26	43	44	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1451	1453		10.1056/NEJM199411243312112	http://dx.doi.org/10.1056/NEJM199411243312112			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7969287				2022-12-28	WOS:A1994PU53300012
J	ALONSO, PL; SMITH, T; SCHELLENBERG, JRMA; MASANJA, H; MWANKUSYE, S; URASSA, H; DEAZEVEDO, IB; CHONGELA, J; KOBERO, S; MENENDEZ, C; HURT, N; THOMAS, MC; LYIMO, E; WEISS, NA; HAYES, R; KITUA, AY; LOPEZ, MC; KILAMA, WL; TEUSCHER, T; TANNER, M				ALONSO, PL; SMITH, T; SCHELLENBERG, JRMA; MASANJA, H; MWANKUSYE, S; URASSA, H; DEAZEVEDO, IB; CHONGELA, J; KOBERO, S; MENENDEZ, C; HURT, N; THOMAS, MC; LYIMO, E; WEISS, NA; HAYES, R; KITUA, AY; LOPEZ, MC; KILAMA, WL; TEUSCHER, T; TANNER, M			RANDOMIZED TRIAL OF EFFICACY OF SPF66 VACCINE AGAINST PLASMODIUM-FALCIPARUM MALARIA IN CHILDREN IN SOUTHERN TANZANIA	LANCET			English	Article							SYNTHETIC VACCINE; SAFETY; IMMUNOGENICITY; SPOROZOITES; CHLOROQUINE	Effective, safe antimalarial vaccines have proved elusive. The synthetic polypeptide SPf66 vaccine is based on preerythrocytic acid asexual blood-stage proteins of Plasmodium falciparum. We report here a randomised double-blind placebo-controlled trial of the efficacy of the SPf66 vaccine against clinical P falciparum malaria in Idete, southern Tanzania, an area of intense perennial malaria transmission. 586 children aged 1-5 years received three doses of vaccine (n=274) or placebo (n=312). The incidence and density of parasitaemia were assessed through repeated cross-sectional surveys on subgroups of children. Morbidity was monitored over a 1 year period through passive case detection in all children plus active case detection in a subgroup of 191. An episode of clinical malaria was defined as measured fever (greater than or equal to 37.5 degrees C) and parasite density >20 000/mu L. No severe side-effects were seen and the frequency of mild side-effects after the third dose was less than 6%. The vaccine was highly immunogenic and after three doses all vaccine recipients had detectable anti-SPf66 antibodies: the geometric mean index of response was 8.3 in the vaccine group and 0.7 in the placebo group. The incidence of parasitaemia was similar in both groups. 123 children had at feast one episode of clinical malaria during the follow-up period after the third dose and annual incidence rates were 0.25 in the vaccine group and 0.35 in the placebo group. Estimated vaccine efficacy was 31% (95% confidence interval 0-52%; p=0.046). After the third dose there were 6 deaths among the study cohort (1 vaccine, 5 placebo). This study confirms that SPf66 is safe, immunogenic and reduces the risk of clinical malaria among children exposed to intense P falciparum transmission.	NATL INST MED RES,IFAKARA CTR,TABORA,TANZANIA; NATL INST MED RES,NIMR HEADQUARTERS,TABORA,TANZANIA; CSIC,INST PARASITOL & BIOMED,GRANADA,SPAIN; UNIV LONDON LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON,ENGLAND; SWISS TROP INST,DEPT EPIDEMIOL & PUBL HLTH,BASEL,SWITZERLAND	Ifakara Health Institute; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); University of London; London School of Hygiene & Tropical Medicine; University of Basel; Swiss Tropical & Public Health Institute	ALONSO, PL (corresponding author), HOSP CLIN BARCELONA,FDN REC BIOMED,UNIDAD EPIDEMIOL & BIOESTAD,VILLARROEL 170,E-08036 BARCELONA,SPAIN.		Smith, Thomas/B-5569-2015; Lopez, Manuel/Z-5641-2019; Menéndez, Clara/Q-3446-2016; Alonso, Pedro L/AAZ-3645-2020; Thomas, María Carmen PhD/D-9065-2016	Smith, Thomas/0000-0002-3650-9381; Menéndez, Clara/0000-0002-2641-6907; Alonso, Pedro L/0000-0003-3292-3443; Lopez, Manuel Carlos/0000-0003-0002-3678; Hayes, Richard/0000-0002-1729-9892; Thomas, M Carmen/0000-0003-3586-9657; Schellenberg, Joanna/0000-0002-0708-3676				ALONSO PL, 1994, VACCINE, V12, P181, DOI 10.1016/0264-410X(94)90058-2; AMADOR R, 1992, VACCINE, V10, P179, DOI 10.1016/0264-410X(92)90009-9; BABIKER HA, IN PRESS PARASITOLOG; BALLOU WR, 1987, LANCET, V1, P1277; BETSCHART B, 1986, ACTA TROP, V43, P125; BOYD MARK F., 1936, AMER JOUR TROP MED, V16, P317; CLYDE DF, 1975, AM J TROP MED HYG, V24, P397, DOI 10.4269/ajtmh.1975.24.397; FRIES LF, 1992, INFECT IMMUN, V60, P1834, DOI 10.1128/IAI.60.5.1834-1839.1992; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KOELLA JC, 1990, T ROY SOC TROP MED H, V84, P662, DOI 10.1016/0035-9203(90)90135-2; LOPEZ MC, 1994, VACCINE, V12, P585, DOI 10.1016/0264-410X(94)90261-5; MORENO A, 1989, BLOOD, V74, P537; NOYA O, 1994, J INFECT DIS, V170, P396, DOI 10.1093/infdis/170.2.396; PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0; SALCEDO M, 1991, CLIN EXP IMMUNOL, V84, P122, DOI 10.1111/j.1365-2249.1991.tb08134.x; SCHELLENBERG JRMA, 1994, PARASITOL TODAY, V10, P439, DOI 10.1016/0169-4758(94)90179-1; SEMPERTEGUI F, 1994, VACCINE, V12, P337, DOI 10.1016/0264-410X(94)90098-1; Shute G. T., 1988, Malaria: principles and practice of malariology. Volume 1., P781; SMITH T, 1993, ACTA TROP, V54, P55, DOI 10.1016/0001-706X(93)90068-M; SMITH T, IN PRESS STAT MED; STUERCHLER D, 1989, PARASITOL TODAY, V5, P39; Tanner M., 1991, DIS MORTALITY SUBSAH; TEUSCHER T, 1994, VACCINE, V12, P328, DOI 10.1016/0264-410X(94)90097-3; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W	25	304	310	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1175	1181		10.1016/S0140-6736(94)90505-3	http://dx.doi.org/10.1016/S0140-6736(94)90505-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934537				2022-12-28	WOS:A1994PN80300006
J	AIBA, A; CHEN, C; HERRUP, K; ROSENMUND, C; STEVENS, CF; TONEGAWA, S				AIBA, A; CHEN, C; HERRUP, K; ROSENMUND, C; STEVENS, CF; TONEGAWA, S			REDUCED HIPPOCAMPAL LONG-TERM POTENTIATION AND CONTEXT-SPECIFIC DEFICIT IN ASSOCIATIVE LEARNING IN MGLUR1 MUTANT MICE	CELL			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; CENTRAL-NERVOUS-SYSTEM; CALCIUM CURRENTS; BRAIN-FUNCTION; NEURONS; RAT; DEPRESSION; INDUCTION; BLOCKADE; CHANNELS	We generated a novel strain of mutant mouse with a deletion in the gene encoding metabotropic glutamate receptor 1 (mGluR1). Gross anatomy of the hippocampus, excitatory synaptic transmission, long-term depression, and short-term potentiation in the hippocampal CA1 region are all apparently normal in the mutant mice. In contrast, long-term potentiation (LTP) is substantially reduced, and a moderate level of impairment is observed in context-specific associative learning. We propose that mGluR1 is not ''in line'' in LTP production, but rather modulates the plasticity process, and hence affects context-specific associative learning.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; CASE WESTERN RESERVE UNIV,SCH MED,ALZHEIMERS RES LABS,CLEVELAND,OH 44106; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Massachusetts Institute of Technology (MIT); Case Western Reserve University; Howard Hughes Medical Institute; Salk Institute	AIBA, A (corresponding author), MIT,HOWARD HUGHES MED INST,CTR LEARNING & MEMORY,CAMBRIDGE,MA 02139, USA.		Rosenmund, Christian/AAC-3596-2020; Herrup, Karl/C-5313-2014	Rosenmund, Christian/0000-0002-3905-2444; Aiba, Atsu/0000-0002-8192-0778; Herrup, Karl/0000-0001-7786-5844	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020591, R01NS032925] Funding Source: NIH RePORTER; NINDS NIH HHS [NS20591, R01 NS32925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BIRSE EF, 1993, NEUROSCIENCE, V52, P481, DOI 10.1016/0306-4522(93)90400-A; BLANTON M, 1990, J NEUROSCI METH, V30, P203; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BONHOEFFER T, 1990, COLD SH Q B, V55, P137; BORTOLOTTO ZA, 1994, NATURE, V368, P740, DOI 10.1038/368740a0; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CHARPAK S, 1991, P ROY SOC B-BIOL SCI, V243, P221, DOI 10.1098/rspb.1991.0035; CHINESTRA P, 1993, J NEUROPHYSIOL, V70, P2684, DOI 10.1152/jn.1993.70.6.2684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; DESAI MA, 1991, J NEUROPHYSIOL, V66, P40, DOI 10.1152/jn.1991.66.1.40; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; FOTUHI M, 1993, J NEUROSCI, V13, P2001; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; HOGAN B, 1986, MANIPULATING MOUSE E; KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; MANZONI OJ, 1994, EUR J NEUROSCI, V6, P1050, DOI 10.1111/j.1460-9568.1994.tb00599.x; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MUSGRAVE MA, 1993, NEUROREPORT, V4, P712; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; RIEDEL G, 1994, NEUROSCI LETT, V167, P141, DOI 10.1016/0304-3940(94)91047-2; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; SAHARA Y, 1993, J NEUROSCI, V13, P3041; SAYER RJ, 1992, J NEUROPHYSIOL, V68, P833, DOI 10.1152/jn.1992.68.3.833; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SWARTZ KJ, 1992, J NEUROSCI, V12, P4358; Westbrook Gary L., 1994, Current Opinion in Neurobiology, V4, P337, DOI 10.1016/0959-4388(94)90094-9; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9; ZHENG F, 1992, NEURON, V9, P163, DOI 10.1016/0896-6273(92)90231-2	53	350	365	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					365	375		10.1016/0092-8674(94)90204-6	http://dx.doi.org/10.1016/0092-8674(94)90204-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954802				2022-12-28	WOS:A1994PN63000019
J	NEWMEYER, DD; FARSCHON, DM; REED, JC				NEWMEYER, DD; FARSCHON, DM; REED, JC			CELL-FREE APOPTOSIS IN XENOPUS EGG EXTRACTS - INHIBITION BY BCL-2 AND REQUIREMENT FOR AN ORGANELLE FRACTION ENRICHED IN MITOCHONDRIA	CELL			English	Article							DEATH GENE CED-3; NUCLEAR-ENVELOPE; GRANULOSA-CELLS; PORE COMPLEX; MAP KINASE; RAT-LIVER; PROTEIN; ONCOPROTEIN; INVITRO; DNA	Apoptotic cell death involves a ritual series of morphological changes, presumably reflecting a conserved molecular pathway. We now report that the nuclear events typical of apoptosis can be reproduced in ''apoptotic'' Xenopus egg extracts. In this cell-free system, nuclear assembly and protein import are initially normal; after 2-4 hr, however, a process of nuclear destruction ensues involving chromatin condensation and the shrinkage and fragmentation of the nuclei. This apoptotic process, which also occurs in nuclei added exogenously, is blocked by the addition of baculovirus-expressed Bcl-2 protein. To block the disintegration of nuclei that are added later, Bcl-2 must be present during this latent period. ''Apoptosis'' in these extracts requires a dense organelle fraction enriched in mitochondria. The cell-free system described here provides a novel tool for understanding intracellular events in apoptosis and the inhibitory function of Bcl-2.	LA JOLLA INST ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA	La Jolla Institute for Immunology	NEWMEYER, DD (corresponding author), LA JOLLA CANC RES FDN, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA060181, R01CA047956] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47956, CA-60181] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; CROMPTON M, 1988, BIOCHEM J, V255, P357; DABAUVALLE MC, 1991, J CELL BIOL, V112, P1073, DOI 10.1083/jcb.112.6.1073; DEJONG D, 1994, CANCER RES, V54, P256; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GONG JP, 1993, J CELL PHYSIOL, V157, P263; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HENNET T, 1993, CANCER RES, V53, P1456; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUGHES FM, 1991, ENDOCRINOLOGY, V129, P2415, DOI 10.1210/endo-129-5-2415; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN BT, 1994, J BIOL CHEM, V269, P5968; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; RICHTER C, 1993, TOXICOL LETT, V67, P119, DOI 10.1016/0378-4274(93)90050-8; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SATO T, 1994, IN PRESS P NATL ACAD; SCHLEGEL J, 1992, BIOCHEM J, V285, P65, DOI 10.1042/bj2850065; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHWARTZMAN RA, 1991, ENDOCRINOLOGY, V128, P1190, DOI 10.1210/endo-128-2-1190; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SMITH LD, 1991, METHOD CELL BIOL, V36, P45; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG HG, 1994, ONCOGENE, V9, P2751; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929	60	490	511	2	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					353	364		10.1016/0092-8674(94)90203-8	http://dx.doi.org/10.1016/0092-8674(94)90203-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954801				2022-12-28	WOS:A1994PN63000018
J	KILPATRICK, ES; RUMLEY, AG; DOMINICZAK, MH; SMALL, M				KILPATRICK, ES; RUMLEY, AG; DOMINICZAK, MH; SMALL, M			GLYCATED HEMOGLOBIN VALUES - PROBLEMS IN ASSESSING BLOOD-GLUCOSE CONTROL IN DIABETES-MELLITUS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FETAL HEMOGLOBIN	Objective-To see whether two measures of glycated haemoglobin concentration-the haemoglobin A(1) (HbA(1)) value and the haemoglobin A1c (HbA(1c) value-assess blood glucose control differently in diabetes. Design-Diabetic patients had glycaemic control assessed on the basis of HbA(1) and HbA(1c) values measured by the same high performance liquid chromatography instrument and on the basis of HbA(1) measured by electrophoresis. Setting-A diabetic outpatient clinic. Subjects-208 diabetic patients and 106 nondiabetic controls. Main outcome measures-Glycated haemoglobin concentrations classified according to European guidelines as representing good, borderline, or poor glycaemic control by using standard deviations from a reference mean. Results-Fewer patients were in good control (25;12%) and more poorly controlled (157;75%) as assessed by the HbA(1c) value compared with both HbA(1) assays (39 (19%) and 130 (63%) respectively when using highperformance liquid chromatography; 63 (30%) acid 74 (36%) when using electrophoresis). The median patient value was 8.0 SD from the reference mean when using HbA(1c), 5.9 when using HbA(1) measured by the same high performance liquid chromatography method, and 4.1 when using HbA(1) measured by electrophoresis. Conclusions-Large differences exist between HbA(1) and HbA(1c) in the classification of glycaemic control in diabetic patients. The HbA(1c) value may suggest a patient is at a high risk of long term diabetic complications when the HbA(1) value may not. Better standardisation of glycated haemoglobin measurements is advisable.	GARTNAVEL ROYAL HOSP, DIABET UNIT, GLASGOW G12 0YN, LANARK, SCOTLAND	Gartnavel Royal Hospital	KILPATRICK, ES (corresponding author), GARTNAVEL ROYAL HOSP, DEPT PATHOL BIOCHEM, LIPID & DIABET LAB, GLASGOW G12 0YN, LANARK, SCOTLAND.							ALBERTI KGMM, 1988, DIABETIC MED, V5, P275, DOI 10.1111/j.1464-5491.1988.tb00984.x; AMER DIABET ASSOC, 1993, DIABETES, V42, P1555; ANTSIFEROV M, 1993, DIABETIC MED, V10, P990; GOLDSTEIN DE, 1986, CLIN CHEM, V32, pB64; JOHN WG, 1992, DIABETIC MED, V9, P15, DOI 10.1111/j.1464-5491.1992.tb01708.x; KILPATRICK ES, 1993, CLIN CHEM, V39, P833; PAGE SR, 1993, DIABETIC MED, V10, P793, DOI 10.1111/j.1464-5491.1993.tb00168.x; RUMLEY AG, 1993, DIABETIC MED, V10, P976, DOI 10.1111/j.1464-5491.1993.tb00016.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; WYSOCKI T, 1989, J BEHAV MED, V12, P183, DOI 10.1007/BF00846550; YATSCOFF RW, 1983, CLIN CHEM, V29, P543	11	36	36	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 15	1994	309	6960					983	986		10.1136/bmj.309.6960.983	http://dx.doi.org/10.1136/bmj.309.6960.983			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950717	Green Published			2022-12-28	WOS:A1994PM41700019
J	JIMENEZ, JA; HUGHES, KA; ALAKS, G; GRAHAM, L; LACY, RC				JIMENEZ, JA; HUGHES, KA; ALAKS, G; GRAHAM, L; LACY, RC			AN EXPERIMENTAL-STUDY OF INBREEDING DEPRESSION IN A NATURAL HABITAT	SCIENCE			English	Article							POPULATIONS	Inbreeding is known to lead to decreased survival and reproduction in captive populations of animals. It is also important to know whether inbreeding has deleterious effects in natural habitats. An estimate was made of the effects of inbreeding in white-footed mice, Peromyscus leucopus noveboracensis, derived from a wild population. This study demonstrates that inbreeding had a significant detrimental effect on the survivorship of mice reintroduced into a natural habitat. This effect was more severe than the effect observed in laboratory studies of the population.	CHICAGO ZOOL SOC, DEPT CONSERVAT BIOL, BROOKFIELD, IL 60513 USA; UNIV ILLINOIS, DEPT BIOL SCI, CHICAGO, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Peng, Bo/A-6920-2009	Peng, Bo/0000-0001-8225-2284				Akaike H, 1973, P 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15; [Anonymous], 1982, ESTIMATION ANIMAL AB; BARRETT SCH, 1991, GENETICS AND CONSERVATION OF RARE PLANTS, P3; BREWER BA, 1990, J HERED, V81, P257, DOI 10.1093/oxfordjournals.jhered.a110988; CHARLESWORTH D, 1987, ANNU REV ECOL SYST, V18, P237, DOI 10.1146/annurev.es.18.110187.001321; CHEN XF, 1993, HEREDITY, V71, P456, DOI 10.1038/hdy.1993.163; CLARK TW, 1989, CONSERVATION BIOL BL; Falconer D. S., 1989, Introduction to quantitative genetics.; GILBERT DG, 1989, IUBIO ARCH MOL GENER; Kleiman D.G., 1986, P959; LACY RC, 1993, NATURAL HIST INBREED, P252; LEBRETON JD, 1992, ECOL MONOGR, V62, P67, DOI 10.2307/2937171; LIVELY CM, 1990, NATURE, V344, P864, DOI 10.1038/344864a0; MORTON NE, 1956, P NATL ACAD SCI USA, V42, P855, DOI 10.1073/pnas.42.11.855; Pradel R., 1993, USERS MANUAL PROGRAM; QUATTRO JM, 1989, SCIENCE, V245, P976, DOI 10.1126/science.2772650; Ralls K., 1983, P164; RALLS K, 1988, Conservation Biology, V2, P185, DOI 10.1111/j.1523-1739.1988.tb00169.x; RYMAN N, 1970, HEREDITAS-GENETISK A, V65, P159; SEAL US, 1989, CONSERVATION BIOL BL; Shields William M., 1993, P143; SHIELDS WM, 1979, PHILOPATRY INBREEDIN; SITTMANN K, 1966, GENETICS, V54, P371; Templeton A.R., 1983, P241; Wright S, 1977, EXPT RESULTS EVOLUTI, V3	25	291	300	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 14	1994	266	5183					271	273		10.1126/science.7939661	http://dx.doi.org/10.1126/science.7939661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939661				2022-12-28	WOS:A1994PM13400032
J	SUN, H; TONKS, NK; BARSAGI, D				SUN, H; TONKS, NK; BARSAGI, D			INHIBITION OF RAS-INDUCED DNA-SYNTHESIS BY EXPRESSION OF THE PHOSPHATES MKP-1	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASES; IMMEDIATE-EARLY GENE; MAP KINASE; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; PROLIFERATION; PATHWAY; DOMAIN	Mitogen-activated protein kinases (MAP kinases) are common components of signaling pathways induced by diverse growth stimuli. Although the guanidine nucleotide-binding Ras proteins are known to be upstream activators of MAP kinases, the extent to which MAP kinases directly contribute to the mitogenic effect of Ras is as yet undefined. In this study, inhibition of MAP kinases by the MAP kinase phosphatase MKP-1 blocked the induction of DNA synthesis in quiescent rat embryonic fibroblast REF-52 cells by an activated mutant of Ras, V(12)Ras. These results suggest an essential role for activation of MAP kinases in the transition from the quiescent to the DNA replication phase of the eukaryotic cell cycle.			SUN, H (corresponding author), COLD SPRING HARBOR LAB,1 BUNGTOWN RD,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA53840, CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053840, R01CA055360, R01CA053840, R37CA055360, R56CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ALESSI DR, 1993, ONCOGENE, V8, P2015; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHARLES CH, 1992, ONCOGENE, V7, P187; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINSHULL J, IN PRESS CELL; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Sun H., UNPUB; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	30	223	234	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1994	266	5183					285	288		10.1126/science.7939666	http://dx.doi.org/10.1126/science.7939666			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM134	7939666				2022-12-28	WOS:A1994PM13400037
J	HILL, D; WHITTET, H; SIMPSON, H				HILL, D; WHITTET, H; SIMPSON, H			HEARING-LOSS AND TINNITUS WITH CARBIMAZOLE	BMJ-BRITISH MEDICAL JOURNAL			English	Letter							PROPYLTHIOURACIL				HILL, D (corresponding author), ROYAL BERKSHIRE HOSP, READING RG1 5AN, BERKS, ENGLAND.							BARNA BP, 1988, LARYNGOSCOPE, V98, P251; FONG PC, 1991, HORM RES, V35, P132, DOI 10.1159/000181888; HORTON RC, 1989, LANCET, V2, P568; SMITH A, 1989, BRIT MED J, V298, P1253, DOI 10.1136/bmj.298.6682.1253-b; SMITH KE, 1972, ARCHIV OTOLARYNGOL, V96, P368	5	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	1994	309	6959					929	929		10.1136/bmj.309.6959.929a	http://dx.doi.org/10.1136/bmj.309.6959.929a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7950664	Green Published			2022-12-28	WOS:A1994PL78100023
J	COOPERPATRICK, L; CRUM, RM; FORD, DE				COOPERPATRICK, L; CRUM, RM; FORD, DE			IDENTIFYING SUICIDAL IDEATION IN GENERAL MEDICAL PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY CARE; PSYCHIATRIC DIAGNOSES; COLLEGE-STUDENTS; UNITED-STATES; RISK-FACTORS; DISORDERS; MODEL; DEPRESSION; BEHAVIOR; HOPELESSNESS	Objectives.-To describe characteristics of general medical patients with suicidal ideation and to develop an efficient clinical strategy for identifying these patients. Design.-Cross-sectional analysis of data without intervention. Setting.-A representative sample of community respondents interviewed as part of the National Institute of Mental Health Epidemiologic Catchment Area surveys. Subjects.-A total of 6041 individuals who reported receiving care in general medical settings in the 6 months preceding the baseline interview. Main Outcome Measure.-Suicidal ideation within the year preceding the baseline interview. Results.-A total of 154 patients(2.6%) had experienced suicidal thoughts within the previous year. In multivariate analyses, the following sociodemographic factors were significantly associated with having suicidal ideation: being white (odds ratio [OR], 2.8; P<.001) relative to African American, separated or divorced (OR, 1.8; P=.03) relative to married, and aged 18 to 30 years (OR, 2.3; P=.02) or aged 31 to 50 years (OR, 2.1; P=.03) relative to those older than 65 years. Gender, educational level, and socioeconomic status were not statistically associated with suicidal ideation. Psychiatric disorders significantly associated with suicidal ideation were major depression (OR, 10.3; P<.001),panic disorder (OR, 5.2; P<.001), alcohol disorder (OR, 2.0; P=.04), and phobic disorder (OR, 1.6; P=.02) within the previous year. However, only 34% of respondents with suicidal ideation met criteria for major depression. With the aid of stepwise logistic regression, a four-item screening questionnaire, the Suicidal Ideation Screening Questionnaire, was developed to predict patients with suicidal ideation. Likelihood ratios for suicidal ideation increased from 0.21 to 32.8 with more positive responses to questions concerning symptoms of hopelessness, guilt, depressed mood, and sleep disturbances. Conclusions.-If the results from the four-item screen are reproduced in a clinical setting, general medical patients with a high likelihood for suicidal ideation may be identified with a brief screening questionnaire. This screen would have greater sensitivity than would be achieved by assessing suicidal ideation only in those patients who meet criteria for a distinct psychiatric disorder.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV INTERNAL MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MENTAL HYG,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Maryland Department of Health & Mental Hygiene					NIAAA NIH HHS [AA00168] Funding Source: Medline; NIMH NIH HHS [MH46967, MH47447] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047447, R29MH046967] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BARRACLOUGH B, 1972, SOC SCI MED, V6, P661, DOI 10.1016/0037-7856(72)90039-X; Beck A., 1979, J CONSULT CLIN PSYCH, V47, P559; BECT AT, 1989, J CONSULT CLIN PSYCH, V57, P308; BLACKER CVR, 1987, BRIT J PSYCHIAT, V150, P737, DOI 10.1192/bjp.150.6.737; BONNER RL, 1988, SUICIDE LIFE-THREAT, V18, P245; BONNER RL, 1987, SUICIDE LIFE-THREAT, V17, P50; BORUS JF, 1988, GEN HOSP PSYCHIAT, V10, P317, DOI 10.1016/0163-8343(88)90002-3; BUZAN RD, 1992, ANNU REV MED, V43, P37, DOI 10.1146/annurev.med.43.1.37; CARLSON GA, 1991, J AFFECT DISORDERS, V21, P127, DOI 10.1016/0165-0327(91)90059-2; COOMBS DW, 1992, SUICIDE LIFE-THREAT, V22, P289; DELONG WB, 1961, AM J PSYCHIAT, V117, P695, DOI 10.1176/ajp.117.8.695; DIEKSTRA RFW, 1989, ACTA PSYCHIAT SCAND, V79, P268, DOI 10.1111/j.1600-0447.1989.tb10257.x; Eaton W.M., 1985, EPIDEMIOLOGIC FIELD; GARRISON CZ, 1993, AM J PUBLIC HEALTH, V83, P179, DOI 10.2105/AJPH.83.2.179; GOLDBERG RJ, 1988, J GEN INTERN MED, V3, P491, DOI 10.1007/BF02595928; GUZE SB, 1970, BRIT J PSYCHIAT, V117, P437, DOI 10.1192/bjp.117.539.437; HAMDI E, 1991, ACTA PSYCHIAT SCAND, V83, P406, DOI 10.1111/j.1600-0447.1991.tb05565.x; HENRIKSSON MM, 1993, AM J PSYCHIAT, V150, P935; HESSELBROCK M, 1988, J STUD ALCOHOL, V49, P436, DOI 10.15288/jsa.1988.49.436; HOLDEN RR, 1989, J CONSULT CLIN PSYCH, V57, P500, DOI 10.1037/0022-006X.57.4.500; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; KATON W, 1987, INT J PSYCHIAT MED, V17, P93, DOI 10.2190/XE8W-GLCJ-KEM6-39FH; KESSLER LG, 1985, ARCH GEN PSYCHIAT, V42, P583; KESSLER LG, 1987, AM J PUBLIC HEALTH, V77, P18, DOI 10.2105/AJPH.77.1.18; KIENHORST CWM, 1990, BRIT J PSYCHIAT, V156, P243, DOI 10.1192/bjp.156.2.243; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; LIN EHB, 1989, J GEN INTERN MED, V4, P1, DOI 10.1007/BF02596482; MANNING WG, 1992, MED CARE, V30, P541, DOI 10.1097/00005650-199206000-00007; MOSCICKI EK, 1989, SUICIDE LIFE-THREAT, V19, P131; MOSCICKI EK, 1988, YALE J BIOL MED, V9, P51; MOTTO J A, 1979, American Journal of Psychiatry, V136, P516; MURPHY GE, 1975, ANN INTERN MED, V82, P301, DOI 10.7326/0003-4819-82-3-301; MURPHY GE, 1986, SUICIDE, P171; MURPHY GE, 1975, ANN INTERN MED, V83, P305; ORMEL J, 1990, PSYCHOL MED, V20, P909, DOI 10.1017/S0033291700036606; PAYKEL ES, 1974, BRIT J PSYCHIAT, V124, P460, DOI 10.1192/bjp.124.5.460; PEREZSTABLE EJ, 1990, ARCH INTERN MED, V150, P1083, DOI 10.1001/archinte.150.5.1083; PETRONIS KR, 1990, SOC PSYCH PSYCH EPID, V25, P193; REGIER DA, 1978, ARCH GEN PSYCHIAT, V35, P685; RICH AR, 1987, SUICIDE LIFE-THREAT, V17, P265; RICH AR, 1992, SUICIDE LIFE-THREAT, V22, P364; RICH CL, 1992, ACTA PSYCHIAT SCAND, V86, P335, DOI 10.1111/j.1600-0447.1992.tb03276.x; ROBINS E, 1959, AM J PSYCHIAT, V115, P724, DOI 10.1176/ajp.115.8.724; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; RUNESON B, 1991, J NERV MENT DIS, V179, P153, DOI 10.1097/00005053-199103000-00007; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P119; SEAGER CP, 1986, SUICIDE, P113; WEISSMAN MM, 1989, NEW ENGL J MED, V321, P1209, DOI 10.1056/NEJM198911023211801; WETZEL RD, 1980, J CLIN PSYCHIAT, V41, P159; Whitlock F., 1986, SUICIDE, V4, P151; 1990, PHS9150213 US DEP HL; 1980, DIAGNOSTIC STATISTIC; 1994, DIAGNOSTIC STATISTIC; 1990, PHS901102 US DEP HLT	55	102	104	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1757	1762		10.1001/jama.272.22.1757	http://dx.doi.org/10.1001/jama.272.22.1757			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PV815	7966924				2022-12-28	WOS:A1994PV81500025
J	WECHSLER, H; DAVENPORT, A; DOWDALL, G; MOEYKENS, B; CASTILLO, S				WECHSLER, H; DAVENPORT, A; DOWDALL, G; MOEYKENS, B; CASTILLO, S			HEALTH AND BEHAVIORAL CONSEQUENCES OF BINGE-DRINKING IN COLLEGE - A NATIONAL SURVEY OF STUDENTS AT 140 CAMPUSES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL-USE; PATTERNS; VALIDITY	Objective.-To examine the extent of binge drinking by college students and the ensuing health and behavioral problems that binge drinkers create for themselves and others on their campus. Design.-Self-administered survey mailed to a national representative sample of US 4-year college students. Setting.-One hundred forty US 4-year colleges in 1993. Participants.-A total of 17 592 college students. Main Outcome Measures.-Self-reports of drinking behavior, alcohol-related health problems, and other problems. Results.-Almost half (44%) of college students responding to the survey were binge drinkers, including almost one fifth (19%) of the students who were frequent binge drinkers. Frequent binge drinkers are more likely to experience serious health and other consequences of their drinking behavior than other students. Almost half (47%) of the frequent binge drinkers experienced five or more different drinking-related problems, including injuries and engaging in unplanned sex, since the beginning of the school year. Most binge drinkers do not consider themselves to be problem drinkers and have not sought treatment for an alcohol problem. Binge drinkers create problems for classmates who are not binge drinkers. Students who are not binge drinkers at schools with higher binge rates were more likely than students at schools with lower binge rates to experience problems such as being pushed, hit, or assaulted or experiencing an unwanted sexual advance. Conclusions.-Binge drinking is widespread on college campuses. Programs aimed at reducing this problem should focus on frequent binge drinkers, refer them to treatment or educational programs, and emphasize the harm they cause for students who are not binge drinkers.	HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	WECHSLER, H (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH & SOCIAL BEHAV, 667 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Fahimifar, Sepideh/M-5303-2019					Berkowitz A D, 1986, J Am Coll Health, V35, P21; BRENNAN AF, 1986, INT J ADDICT, V21, P449, DOI 10.3109/10826088609083536; COOPER AM, 1981, INT J ADDICT, V16, P401, DOI 10.3109/10826088109038841; ENGS RC, 1985, J ALCOHOL DRUG EDUC, V31, P65; HANSON DJ, 1992, PSYCHOL REP, V71, P39, DOI 10.2466/PR0.71.5.39-39; HAWORTHHOEPPNER S, 1989, INT J ADDICT, V24, P829, DOI 10.3109/10826088909047315; HUGHES S, 1983, J COLL STUDENT PERS, V20, P257; JOHNSTON LD, 1991, ADM911835 US DEP HLT; LILJESTRAND P, 1993, J ALCOHOL DRUG EDUC, V38, P1; MIDANIK LT, 1988, BRIT J ADDICT, V83, P1019; OHARE TM, 1990, J STUD ALCOHOL, V51, P536, DOI 10.15288/jsa.1990.51.536; Presley CA., 1993, ALCOHOL DRUGS AM COL, VI; REINISCH OJ, 1991, RAND N3189CHF PUBL; ROOM R, 1971, DRINKING DRUG PRACTI, V3, P15; ROOM R, 1991, ALCOHOL AM DRINKING, P26; Saltz R, 1986, CONTEMP DRUG PROBL, V13, P117; Straus R, 1953, DRINKING IN COLLEGE; WECHSLER H, 1992, Journal of the American Medical Association, V267, P2929, DOI 10.1001/jama.267.21.2929; WECHSLER H, 1979, J STUD ALCOHOL, V40, P969, DOI 10.15288/jsa.1979.40.969; 1990, ALCOHOL HLTH; 1992, BARRONS PROFILES AM; 1994, RETHINKING RITES PAS; 1993, DIGEST ED STATISTICS, P180; 1993, SUBSTANCE ABUSE NATI; 1988, SAS STAT USERS GUIDE; 1990, CAMPUS LIFE SEARCH C	26	1339	1346	1	191	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1672	1677		10.1001/jama.272.21.1672	http://dx.doi.org/10.1001/jama.272.21.1672			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966895				2022-12-28	WOS:A1994PU75900026
J	RAE, D; PORTER, J; BEECHEYNEWMAN, N; SUMAR, N; BENNETT, D; HERMONTAYLOR, J				RAE, D; PORTER, J; BEECHEYNEWMAN, N; SUMAR, N; BENNETT, D; HERMONTAYLOR, J			TYPE-1 PROPHOSPHOLIPASE A(2) PROPEPTIDE IN ACUTE LUNG INJURY	LANCET			English	Note							RESPIRATORY-DISTRESS SYNDROME; NEUTROPHILS	Neutrophil sequestration and activation in the pulmonary vasculature and interstitium are important in acute lung injury. Phospholipase A(2) plays an important part in the production of potent inflammatory mediators in this syndrome. We used our ELISA for type 1 prophospholipase A(2) activation peptides, which have the aminoacid sequence Asp-Ser-Gly-Ile-Ser-Pro-Arg (DSGISPR), to show that DSGISPR concentrations in plasma and urine are a sensitive and specific marker of acute lung injury in patients admitted to intensive care. The detection of DSGISPR in the plasma of 11 of 50 unselected patients had a sensitivity of 100% and a specificity of 93% for the presence or future development of acute lung injury.	ST GEORGE HOSP,SCH MED,DEPT SURG,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,INTENS CARE UNIT,LONDON SW17 0RE,ENGLAND	St Georges University London; St Georges University London			Porter, Joanna/C-7162-2009	Porter, Joanna/0000-0002-7307-169X				CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980; GRATAROLI R, 1982, EUR J BIOCHEM, V122, P111, DOI 10.1111/j.1432-1033.1982.tb05855.x; HEFFNER JE, 1987, AM REV RESPIR DIS, V135, P482; OFFENSTADT G, 1981, INTENS CARE MED, V7, P285, DOI 10.1007/BF01709723; RAE D, IN PRESS CLIN BIOCH; RINTALA EM, 1993, CLIN INFECT DIS, V17, P864, DOI 10.1093/clinids/17.5.864; ROMASCHIN AD, 1992, CLIN BIOCHEM, V25, P55, DOI 10.1016/0009-9120(92)80046-J; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; WEINBERG PF, 1984, AM REV RESPIR DIS, V130, P791; WEISS SJ, 1989, NEW ENGL J MED, V320, P365	10	45	45	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1472	1473		10.1016/S0140-6736(94)90291-7	http://dx.doi.org/10.1016/S0140-6736(94)90291-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968121				2022-12-28	WOS:A1994PT99500010
J	OFVERSTEDT, LG; ZHANG, K; TAPIO, S; SKOGLUND, U; ISAKSSON, LA				OFVERSTEDT, LG; ZHANG, K; TAPIO, S; SKOGLUND, U; ISAKSSON, LA			STARVATION IN-VIVO FOR AMINOACYL-TRANSFER-RNA INCREASES THE SPATIAL SEPARATION BETWEEN THE 2 RIBOSOMAL-SUBUNITS	CELL			English	Article							ESCHERICHIA-COLI RIBOSOME; ELECTRON-MICROSCOPE TOMOGRAPHY; 3-DIMENSIONAL IMAGE-RECONSTRUCTION; ELONGATION-FACTOR TU; TRANSFER-RNA BINDING; X-RAY; IMMUNOELECTRON MICROSCOPY; CONFORMATIONAL CHANGE; PUROMYCIN BINDING; SINGLE PARTICLES	Structures in situ of individual ribosomes in E. coli have been determined by computer-aided electron microscope tomography using a tilt series of positively stained embedded cellular sections. Amino acid starvation of a bacterial culture, causing a deficiency for aminoacyl-tRNA, induces a spatial separation between the ribosomal subunits compared with ribosomes in exponentially growing cells. Eight ribosomes from each growth condition were aligned to each other, and the two average structures were determined. Comparison of these suggests that the distance between the two subunits increases by similar to 3 nm upon starvation for aminoacyl-tRNA during protein synthesis. Ribosomes in most other states of the translational elongation cycle in exponentially growing cells show a more compact structure than previously realized.	UNIV STOCKHOLM,DEPT MICROBIOL,S-10691 STOCKHOLM,SWEDEN	Stockholm University	OFVERSTEDT, LG (corresponding author), KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOLEC BIOL,S-17177 STOCKHOLM,SWEDEN.		Öfverstedt, Lars-Göran/J-3518-2013; Tapio, Soile/CAJ-5871-2022; Tapio, Soile/M-7358-2014; Skoglund, Ulf/B-5829-2015	Öfverstedt, Lars-Göran/0000-0002-1796-2199; Tapio, Soile/0000-0001-9860-3683; Skoglund, Ulf/0000-0002-3407-0053				ARAD T, 1987, BIOCHIMIE, V69, P1001, DOI 10.1016/0300-9084(87)90234-3; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERKOVITCHYELLIN Z, 1992, CRIT REV BIOCHEM MOL, V27, P403, DOI 10.3109/10409239209082568; BRACEWELL RN, 1967, ASTROPHYS J, V150, P427, DOI 10.1086/149346; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; FRANK J, 1988, TRENDS BIOCHEM SCI, V13, P123, DOI 10.1016/0968-0004(88)90063-1; FRANK J, 1990, RIBOSOME, P107; GILBERT PFC, 1972, PROC R SOC SER B-BIO, V182, P89, DOI 10.1098/rspb.1972.0068; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; GLAUERT AM, 1958, J BIOPHYS BIOCHEM CY, V4, P191, DOI 10.1083/jcb.4.2.191; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; HART RG, 1968, SCIENCE, V159, P1464, DOI 10.1126/science.159.3822.1464; HOPPE W, 1986, J MOL BIOL, V192, P291, DOI 10.1016/0022-2836(86)90366-9; ISAKSSON LA, 1977, MOL GEN GENET, V156, P223; KIRSEBOM LA, 1986, MOL GEN GENET, V205, P240, DOI 10.1007/BF00430434; KLUG A, 1972, NATURE, V238, P435, DOI 10.1038/238435a0; KNAUER V, 1983, J MOL BIOL, V163, P409, DOI 10.1016/0022-2836(83)90066-9; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAKE JA, 1977, P NATL ACAD SCI USA, V74, P1903, DOI 10.1073/pnas.74.5.1903; LAKE JA, 1985, ANNU REV BIOCHEM, V54, P507, DOI 10.1146/annurev.biochem.54.1.507; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; LAUGHREA M, 1992, BIOCHEMISTRY-US, V31, P12035, DOI 10.1021/bi00163a011; LAUGHREA M, 1994, IN PRESS MOL MICROBI, V11; LILJAS A, 1982, PROG BIOPHYS MOL BIO, V40, P161, DOI 10.1016/0079-6107(82)90013-X; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; LODMELL JS, 1993, BIOCHEMISTRY-US, V32, P4067, DOI 10.1021/bi00066a030; LONNROTH A, 1993, J MICROSC-OXFORD, V170, P173; LUFT JH, 1972, P ELECTRON MICROSC S, V30, P132; LUHRMANN R, 1981, P NATL ACAD SCI-BIOL, V78, P7276, DOI 10.1073/pnas.78.12.7276; LUTHER PK, 1988, ULTRAMICROSCOPY, V24, P7, DOI 10.1016/0304-3991(88)90322-1; MAUGUEN Y, 1982, NATURE, V297, P162, DOI 10.1038/297162a0; MCEWEN BF, 1986, P NATL ACAD SCI USA, V83, P9040, DOI 10.1073/pnas.83.23.9040; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MEISENBERGER O, 1984, BIOCHIM BIOPHYS ACTA, V781, P225, DOI 10.1016/0167-4781(84)90087-3; Miller J. H, 1972, EXPT MOL GENETICS; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; NORDESTGAARD BG, 1985, MICRON MICROSC ACTA, V16, P65, DOI 10.1016/0739-6260(85)90035-8; ODOM OW, 1990, BIOCHEMISTRY-US, V29, P10734, DOI 10.1021/bi00500a004; OETTL H, 1983, J MOL BIOL, V163, P431, DOI 10.1016/0022-2836(83)90067-0; OFENGAND J, 1986, STRUCTURE FUNCTION G, P473; OLSON HM, 1982, J BIOL CHEM, V257, P2649; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; SERDYUK I, 1992, BIOCHIMIE, V74, P299, DOI 10.1016/0300-9084(92)90107-P; SKOGLUND U, 1986, TRENDS BIOCHEM SCI, V11, P499, DOI 10.1016/0968-0004(86)90077-0; SKOGLUND U, 1986, NATURE, V319, P560, DOI 10.1038/319560a0; SPIRIN A, 1987, BIOCHIMIE, V69, P949, DOI 10.1016/0300-9084(87)90228-8; SPIRIN AS, 1987, J MOL BIOL, V194, P119, DOI 10.1016/0022-2836(87)90720-0; SPIRIN AS, 1983, FEBS LETT, V156, P217, DOI 10.1016/0014-5793(83)80499-2; SPIRIN AS, 1989, BIOL CELL, V66, P215, DOI 10.1016/0248-4900(89)90174-3; SRIVASTAVA S, 1985, FEBS LETT, V186, P17, DOI 10.1016/0014-5793(85)81330-2; STOFFLER G, 1984, ANNU REV BIOPHYS BIO, V13, P303, DOI 10.1146/annurev.bb.13.060184.001511; STOFFLER G, 1980, RIBOSOMES STRUCTURE, P171; TARDIEU A, 1982, EMBO J, V1, P35, DOI 10.1002/j.1460-2075.1982.tb01120.x; VASILIEV VD, 1983, FEBS LETT, V155, P167, DOI 10.1016/0014-5793(83)80232-4; WAGENKNECHT T, 1989, BIOPHYS J, V55, P455, DOI 10.1016/S0006-3495(89)82839-5; WILLIAMS RC, 1970, J MOL BIOL, V52, P121, DOI 10.1016/0022-2836(70)90181-6; WITTMANN HG, 1983, ANNU REV BIOCHEM, V52, P35, DOI 10.1146/annurev.bi.52.070183.000343; WOWER J, 1991, BIOCHIMIE, V73, P961, DOI 10.1016/0300-9084(91)90137-P; YONATH A, 1993, CURR OPIN STRUC BIOL, V3, P175, DOI 10.1016/S0959-440X(05)80149-6; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; YONATH A, 1990, RIBOSOME, P134	69	39	39	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					629	638		10.1016/0092-8674(94)90548-7	http://dx.doi.org/10.1016/0092-8674(94)90548-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954829				2022-12-28	WOS:A1994PT48100010
J	HAKIM, RM; WINGARD, RL; PARKER, RA				HAKIM, RM; WINGARD, RL; PARKER, RA			EFFECT OF THE DIALYSIS MEMBRANE IN THE TREATMENT OF PATIENTS WITH ACUTE-RENAL-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRITICALLY-ILL PATIENTS; RISK-FACTORS; APACHE-II; HEMODIALYSIS; RAT; SURVIVAL; BIOCOMPATIBILITY; PREDICTION; VARIABLES; RECOVERY	Background. The mortality rate among patients with acute renal failure remains high, and the role of the biocompatibility of the dialysis membrane in the resolution of this disorder is not known. Methods. We prospectively studied 72 patients with acute renal failure who required hemodialysis and assigned them to two treatment groups. One group underwent dialysis with the widely used cuprophane dialysis membrane, which activates the complement system and leukocytes, and the other group underwent dialysis with a synthetic polymethyl methacrylate membrane, which has a more limited effect on complement and leukocytes. Scores on the Acute Physiology, Age, and Chronic Health Evaluation (APACHE II) were calculated at the initiation of dialysis. Survival and the recovery of renal function were determined with the use of proportional-hazards and exact logistic-regression analyses. Results. When dialysis was initiated, the patients in the two groups were similar in terms of age, APACHE II scores, the prevalence of oliguria, and biochemical indexes of renal failure. Twenty-three of the 37 patients (62 percent) in the group undergoing dialysis with the polymethyl methacrylate membrane recovered renal function, as compared with 13 of the 35 patients (37 percent) in the group undergoing dialysis with the cuprophane membrane (P = 0.04 after adjustment for the APACHE II score). The median number of dialysis treatments required before the recovery of renal function was 5 in the former group and 17 in the latter group (P = 0.02). Twenty-one patients (57 percent) undergoing dialysis with the polymethyl methacrylate membrane survived, as compared with 13 patients (37 percent) undergoing dialysis with the cuprophane membrane (P = 0.11). Of the 20 patients in each group who initially had nonoliguric acute renal failure, the survival rates were 80 percent with the polymethyl methacrylate membrane and 40 percent with the cuprophane membrane (P = 0.01). Conclusions. Among patients with acute renal failure requiring hemodialysis, the use of the polymethyl methacrylate membrane, as compared with the cuprophane membrane, resulted in improved recovery of renal function.	VANDERBILT UNIV,MED CTR,DEPT MED,DIV NEPHROL,NASHVILLE,TN; VANDERBILT UNIV,MED CTR,DEPT PREVENT MED,DIV BIOSTAT,NASHVILLE,TN	Vanderbilt University; Vanderbilt University					NHLBI NIH HHS [1R01-HL-36015-9] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036015] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADR KF, 1988, J CLIN INVEST, V81, P1702, DOI 10.1172/JCI113509; BARTLETT RH, 1986, SURGERY, V100, P400; BREZIS M, 1991, J CLIN INVEST, V88, P390, DOI 10.1172/JCI115316; BREZIS M, 1993, ANNU REV MED, V44, P27, DOI 10.1146/annurev.me.44.020193.000331; BULLOCK ML, 1985, AM J KIDNEY DIS, V5, P97, DOI 10.1016/S0272-6386(85)80003-2; CHEUNG AK, 1986, KIDNEY INT, V29, P799, DOI 10.1038/ki.1986.69; CHEW SL, 1993, NEPHROL DIAL TRANSPL, V8, P101; CIOFFI WG, 1984, ANN SURG, V200, P205, DOI 10.1097/00000658-198408000-00015; CONGER JD, 1990, SEMIN DIALYSIS, V3, P146, DOI 10.1111/j.1525-139X.1990.tb00031.x; CONGER JD, 1991, KIDNEY INT, V39, P1087, DOI 10.1038/ki.1991.138; CORWIN HL, 1987, AM J NEPHROL, V7, P8, DOI 10.1159/000167421; DAVENPORT A, 1993, KIDNEY INT, V43, pS230; FISCHEREDER M, 1994, SEMIN NEPHROL, V14, P41; HAKIM RM, 1993, KIDNEY INT, V44, P484, DOI 10.1038/ki.1993.272; HARRIS KPG, 1989, KIDNEY INT, V36, P210, DOI 10.1038/ki.1989.181; HIMMELFARB J, 1993, J AM SOC NEPHROL, V4, P178; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LIAFIO F, 1989, NEPHRON, V51, P307; LIEN J, 1985, ARCH INTERN MED, V145, P2067, DOI 10.1001/archinte.145.11.2067; LINAS SL, 1992, KIDNEY INT, V42, P610, DOI 10.1038/ki.1992.325; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MAHER ER, 1989, Q J MED, V72, P857; McCarthy James T., 1993, Journal of the American Society of Nephrology, V4, P367; MENASHE PI, 1988, CRIT CARE MED, V16, P1106, DOI 10.1097/00003246-198811000-00005; MYERS BD, 1986, NEW ENGL J MED, V314, P97; RASMUSSEN HH, 1985, ARCH INTERN MED, V145, P2015, DOI 10.1001/archinte.145.11.2015; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; SCHULMAN G, 1991, KIDNEY INT, V40, P1069, DOI 10.1038/ki.1991.316; SPIEGEL DM, 1991, AM J NEPHROL, V11, P44, DOI 10.1159/000168271; STRASSER T, 1991, KLIN WOCHENSCHR, V69, P808, DOI 10.1007/BF01744274; TURNEY JH, 1990, LANCET, V335, P971, DOI 10.1016/0140-6736(90)91033-7; WOODROW G, 1992, NEPHROL DIAL TRANSPL, V7, P230, DOI 10.1093/oxfordjournals.ndt.a092111; YOSHIOKA T, 1989, AM J PHYSIOL, V257, pF53, DOI 10.1152/ajprenal.1989.257.1.F53	33	332	338	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1338	1342		10.1056/NEJM199411173312003	http://dx.doi.org/10.1056/NEJM199411173312003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935703				2022-12-28	WOS:A1994PR21600003
J	SEKSCENSKI, ES; SANSOM, S; BAZELL, C; SALMON, ME; MULLAN, F				SEKSCENSKI, ES; SANSOM, S; BAZELL, C; SALMON, ME; MULLAN, F			STATE PRACTICE ENVIRONMENTS AND THE SUPPLY OF PHYSICIAN ASSISTANTS, NURSE PRACTITIONERS, AND CERTIFIED NURSE-MIDWIVES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARE; REFORM	Background. Most proposals to increase access to primary care in the United States emphasize increasing the proportion of generalist physicians. Another approach is to increase the number of physician assistants, nurse practitioners, and certified nurse-midwives. Methods. We analyzed variations in the regulation of nurse practitioners, physician assistants, and certified nurse-midwives in all 50 states and the District of Columbia. Using a 100-point scoring system, we assigned numerical values to specific characteristics of the practice environment in each state for each group of practitioners, awarding a maximum of 20 points for legal status, 40 points for reimbursement for services, and 40 points for the authority to write prescriptions. We calculated coefficients for the correlation of summary measures of these values within states with estimates of the supply of practitioners per 100,000 population. Results. There was wide variation among states in both practice-environment scores and practitioner-to-population ratios for all three groups of practitioners. We found positive correlations within states between the supply of physician assistants, nurse practitioners, and certified nurse-midwives and the practice-environment score for the state (Spearman rank-correlation coefficients, 0.63 [P < 0.001], 0.41 [P = 0.003], and 0.51 [P < 0.001], respectively). Positive associations were also found in the stales between the supply of generalist physicians and the supply of physician assistants (r = 0.54, P < 0.001) and nurse practitioners (r = 0.35, P = 0.014). Nevertheless, in the 17 states with the greatest shortages of primary care physicians, favorable practice-environment scores were still associated with higher practitioner-to-population ratios for physician assistants (r = 0.68, P = 0.003), nurse practitioners (r = 0.54, P = 0.026), and certified nurse-midwives (r = 0.42, P = 0.09). Conclusions. State regulation of physician assistants, nurse practitioners, and certified nurse-midwives varies widely. Favorable practice environments are strongly associated with a larger supply of these practitioners.			SEKSCENSKI, ES (corresponding author), US DEPT HHS, HLTH RESOURCES & SERV ADM, BUR HLTH PROFESS, RM 8-47, 5600 PARKLAWN DR, ROCKVILLE, MD 20857 USA.							BARICKMAN C, 1992, J NURSE-MIDWIFERY, V37, P207; BROWN S, 1993, NURSE PRACTITIONERS; BUDETTI PP, 1993, JAMA-J AM MED ASSOC, V269, P498, DOI 10.1001/jama.269.4.498; CLAWSON DK, 1993, ROLES PHYSICIAN ASSI; FOWKES V, 1993, ROLES PHYSICIAN ASSI, P69; GARA N, 1993, PHYSICIAN ASSISTANT; Gibbons JD., 1976, NONPARAMETRIC METHOD, DOI [10.1080/00401706.1974.10489221, DOI 10.1080/00401706.1974.10489221]; GINZBERG E, 1992, HEALTH AFFAIR, V11, P193, DOI 10.1377/hlthaff.11.2.193; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; KLEINBAUM DG, 1978, APPLIED REGRESSION A; Morgan W A, 1993, Nurse Pract, V18, P65; MUNDINGER MO, 1994, NEW ENGL J MED, V330, P211, DOI 10.1056/NEJM199401203300314; Nichols L M, 1992, Nurs Econ, V10, P343; Pearson L J, 1993, Nurse Pract, V18, P23, DOI 10.1097/00006205-199301000-00006; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; ROBACK G, 1993, PHYSICIAN CHARACTERI; Safriet B.J., 1992, YALE J REGUL, V9; SCHAFT GE, 1987, PHYSICIAN ASSISTANTS; SCUPHOLME A, 1992, J NURSE-MIDWIFERY, V37, P341, DOI 10.1016/0091-2182(92)90241-T; Starfield B., 1992, PRIMARY CARE CONCEPT; Willis J., 1993, JAAPA, V6, P418; 1991, PROPOSED STRATEGIE 2; 1994, SURVEY CERTIFIED NUR; 1993, 1992 SAMPLE SURVEY R; 1993, GENERAL CENSUS DATA; 1993, PRIMARY CARE WORKFOR; 1993, ED NURSE MIDWIVES ST; 1993, AREA RESOURCE FILE; 1993, MON VITAL STAT REP S, V42, P1; 1992, SURVEY CERTIFIED NUR; 1993, 1993 ANN REP C; 1992, NURSE MIDWIFERY TODA; 1993, HLTH PROFESSIONS SHO	33	77	78	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1266	1271		10.1056/NEJM199411103311905	http://dx.doi.org/10.1056/NEJM199411103311905			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP752	7935685				2022-12-28	WOS:A1994PP75200005
J	GEIERSTANGER, BH; MRKSICH, M; DERVAN, PB; WEMMER, DE				GEIERSTANGER, BH; MRKSICH, M; DERVAN, PB; WEMMER, DE			DESIGN OF A G-CENTER-DOT-C-SPECIFIC DNA MINOR GROOVE-BINDING PEPTIDE	SCIENCE			English	Article							SEQUENCE-SPECIFIC RECOGNITION; TWO-DIMENSIONAL NMR; MOLECULAR RECOGNITION; DISTAMYCIN-A; N-METHYLPYRROLECARBOXAMIDE; 2-DIMENSIONAL NMR; DYNAMIC ASPECTS; NUCLEIC-ACIDS; NETROPSIN; COMPLEX	A four-ring tripeptide containing alternating imidazole and pyrrole carboxamides specifically binds six-base pair 5'-(A,T)GCGC(A,T)-3' sites in the minor groove of DNA. The designed peptide has a specificity completely reversed from that of the tripyrrole distamycin, which binds A,T sequences. Structural studies with nuclear magnetic resonance revealed that two peptides bound side-by-side and in an antiparallel orientation in the minor groove. Each of the four imidazoles in the 2:1 ligand-DNA complex recognized a specific guanine amino group in the GCGC core through a hydrogen bond. Targeting a designated four- base pair G-C tract by this synthetic ligand supports the generality of the 2:1 peptide-DNA motif for sequence-specific minor groove recognition of DNA.	CALTECH,ARNOLD & MABEL BECKMAN LABS CHEM SYNTHESIS,PASADENA,CA 91125; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,GRAD GRP BIOPHYS,BERKELEY,CA 94720	California Institute of Technology; University of California System; University of California Berkeley; University of California System; University of California Berkeley			Mrksich, Milan/G-2469-2011	Mrksich, Milan/0000-0002-4964-796X	NIGMS NIH HHS [GM-27681, GM-43129] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043129, R37GM027681, R01GM027681] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; BURCKHARDT G, 1989, BIOCHIM BIOPHYS ACTA, V1009, P11, DOI 10.1016/0167-4781(89)90072-9; CHEN X, 1994, NAT STRUCT BIOL, V1, P169, DOI 10.1038/nsb0394-169; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DWYER TJ, 1993, J AM CHEM SOC, V115, P9900, DOI 10.1021/ja00075a005; DWYER TJ, 1992, J AM CHEM SOC, V114, P5911, DOI 10.1021/ja00041a001; GEIERSTANGER BH, 1993, J AM CHEM SOC, V115, P4474, DOI 10.1021/ja00064a009; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P3055, DOI 10.1021/bi00176a039; GEIERSTANGER BH, UNPUB; HARTLEY JA, 1988, ACTA ONCOL, V27, P503, DOI 10.3109/02841868809093578; KISSINGER K, 1987, BIOCHEMISTRY-US, V26, P5590, DOI 10.1021/bi00392a002; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P3296, DOI 10.1021/bi00359a032; KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; LEE M, 1993, BIOCHEMISTRY-US, V32, P4237, DOI 10.1021/bi00067a011; LEE M, 1988, J BIOMOL STRUCT DYN, V5, P1059, DOI 10.1080/07391102.1988.10506449; LEE M, 1988, BIOCHEMISTRY-US, V27, P445, DOI 10.1021/bi00401a066; Lee M, 1989, J Mol Recognit, V2, P84, DOI 10.1002/jmr.300020206; LOWN JW, 1986, BIOCHEMISTRY-US, V25, P7408, DOI 10.1021/bi00371a024; MRKSICH M, 1994, J AM CHEM SOC, V116, P3663, DOI 10.1021/ja00087a088; MRKSICH M, 1993, J AM CHEM SOC, V115, P9892, DOI 10.1021/ja00075a004; MRKSICH M, 1993, J AM CHEM SOC, V115, P2572, DOI 10.1021/ja00060a004; MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586; MRKSICH M, UNPUB; PELTON JG, 1988, BIOCHEMISTRY-US, V27, P8088, DOI 10.1021/bi00421a018; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; PELTON JG, 1990, J AM CHEM SOC, V112, P1393, DOI 10.1021/ja00160a016; SCHULTZ PG, 1984, J BIOMOL STRUCT DYN, V1, P1133, DOI 10.1080/07391102.1984.10507508; SKLENAR V, 1987, FEBS LETT, V216, P249, DOI 10.1016/0014-5793(87)80699-3; TAYLOR JS, 1984, TETRAHEDRON, V40, P457, DOI 10.1016/0040-4020(84)85050-4; WADE WS, 1992, J AM CHEM SOC, V114, P8783, DOI 10.1021/ja00049a006; WADE WS, 1993, BIOCHEMISTRY-US, V32, P11385, DOI 10.1021/bi00093a015; WADE WS, 1987, J AM CHEM SOC, V109, P1574, DOI 10.1021/ja00239a050; WEMMER DE, 1994, STRUCTURAL BIOL STAT, V2, P301; YOUNGQUIST RS, 1985, P NATL ACAD SCI USA, V82, P2565, DOI 10.1073/pnas.82.9.2565; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2	37	208	218	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					646	650		10.1126/science.7939719	http://dx.doi.org/10.1126/science.7939719			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939719				2022-12-28	WOS:A1994PN80700047
J	CHELSOM, J; HALSTENSEN, A; HAGA, T; HOIBY, EA				CHELSOM, J; HALSTENSEN, A; HAGA, T; HOIBY, EA			NECROTIZING FASCIITIS DUE TO GROUP-A STREPTOCOCCI IN WESTERN NORWAY - INCIDENCE AND CLINICAL-FEATURES	LANCET			English	Article							NECROTIZING FASCIITIS; INFECTIONS; DIAGNOSIS; EPIDEMIC; DISEASE	During November, 1992, to May, 1994, 13 patients were treated at Haukeland University Hospital, Norway, for necrotising fasciitis due to group A beta-haemolytic streptococci. 3 patients died, 1 before admission. Mucoid group A streptococci were isolated from affected tissue (12 patients) and/or blood (5). Strains from 11 patients were serotype M-1 (5 patients), M-3 (2), M-6 (2), M-28 (1), and M-untypable (T-1, opacity factor negative) (1). For the 12 patients admitted alive, the following preoperative events were recorded: 8 had clinical signs of shock with systolic blood pressure of 90 mm Hg or less, 8 had impaired renal function, and 7 had biochemical markers of disseminated intravascular coagulation. At least 6 patients fulfilled the criteria for streptococcal toxic shock syndrome. Preoperative C-reactive protein was substantially raised (>200 mg/L) in 10 patients. The 12 patients were given high doses of antibiotics and were operated on with aggressive debridement of necrotic skin and fascia, 7 of them within 24 h of admission. The increasing incidence of necrotising fasciitis in western Norway reflects the resurgence of invasive group A streptococcal infections documented in Scandinavia since 1987. The high case-fatality rate can be reduced by early diagnosis and aggressive surgery combined with adequate antibiotic therapy.	UNIV BERGEN,GADE INST,DEPT MED B,BERGEN,NORWAY; UNIV BERGEN,GADE INST,DEPT MICROBIOL,BERGEN,NORWAY; UNIV BERGEN,DEPT PLAST SURG,BERGEN,NORWAY; NATL INST PUBL HLTH,DEPT BACTERIOL,OSLO,NORWAY	University of Bergen; University of Bergen; University of Bergen								BARKER FG, 1987, J CLIN PATHOL, V40, P335, DOI 10.1136/jcp.40.3.335; BUCHER A, 1992, EUR J CLIN MICROBIOL, V11, P416, DOI 10.1007/BF01961856; CLEARY PP, 1992, LANCET, V339, P518, DOI 10.1016/0140-6736(92)90339-5; HASSELTVEDT V, 1994, COMMUNICABLE DISEASE, V22, P2; IGNACIO JU, 1988, J AM ACAD DERMATOL, V20, P774; KAISER RE, 1981, J TRAUMA, V21, P349, DOI 10.1097/00005373-198105000-00003; LEDINGHAM IM, 1975, BRIT J SURG, V62, P364; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; MELENEY FL, 1924, ARCH SURG-CHICAGO, V9, P217; PARKER MT, 1984, SYSTEMATIC BACTERIOL, P173; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; SEAL DV, 1988, BRIT J EXP PATHOL, V69, P813; STEGMAYR B, 1992, SCAND J INFECT DIS, V24, P589, DOI 10.3109/00365549209054644; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STEVENS DL, 1988, J INFECT DIS, V158, P23, DOI 10.1093/infdis/158.1.23; SUDARSKY LA, 1987, ANN SURG, V206, P661; Swartz MN, 1990, PRINCIPLES PRACTICES, V3rd, P796; UMAN SJ, 1975, ARCH INTERN MED, V135, P959, DOI 10.1001/archinte.135.7.959; WANG KC, 1992, J TRAUMA, V32, P179, DOI 10.1097/00005373-199202000-00011; WARD RG, 1991, BRIT J SURG, V78, P488, DOI 10.1002/bjs.1800780431; 1993, JAMA-J AM MED ASSOC, V269, P390; 1992, LANCET, V340, P639; [No title captured]; 1994, COMMUNICAB DIS REP, V4, P97	24	191	192	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1111	1115		10.1016/S0140-6736(94)90629-7	http://dx.doi.org/10.1016/S0140-6736(94)90629-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934492				2022-12-28	WOS:A1994PN06600008
J	ERTL, G; JUGDUTT, B				ERTL, G; JUGDUTT, B			ACE-INHIBITION AFTER MYOCARDIAL-INFARCTION - CAN MEGATRIALS PROVIDE ANSWERS	LANCET			English	Editorial Material							DYSFUNCTION; ENALAPRIL		UNIV ALBERTA,DIV CARDIOL,EDMONTON,AB,CANADA	University of Alberta	ERTL, G (corresponding author), UNIV WURZBURG,MED KLIN,D-97080 WURZBURG,GERMANY.							GAUDRON P, 1993, CIRCULATION, V87, P755, DOI 10.1161/01.CIR.87.3.755; JUGDUTT BI, 1993, CAN J CARDIOL, V9, P103; KONSTAM MA, 1993, CIRCULATION, V88, P2277, DOI 10.1161/01.CIR.88.5.2277; SUTTON MS, 1994, CIRCULATION, V89, P68, DOI 10.1161/01.CIR.89.1.68; VISCOLI CM, 1993, ANN INTERN MED, V118, P99, DOI 10.7326/0003-4819-118-2-199301150-00004; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N	6	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1068	1069		10.1016/S0140-6736(94)91717-5	http://dx.doi.org/10.1016/S0140-6736(94)91717-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934452				2022-12-28	WOS:A1994PL85200017
J	GOODKIN, DE				GOODKIN, DE			INTERFERON BETA-1B	LANCET			English	Article							REMITTING MULTIPLE-SCLEROSIS; REDUCES EXACERBATIONS; HUMAN-CELLS; TRIAL; MULTICENTER; ALPHA				GOODKIN, DE (corresponding author), UNIV CALIF SAN FRANCISCO,MT ZION MULTIPLE SCLEROSIS CTR,1600 DIVISADERO,SAN FRANCISCO,CA 94115, USA.							BLASCHKE TF, 1985, CLIN RES, V33, pA19; BORDEN EC, 1982, CANCER RES, V42, P4948; BORNSTEIN MB, 1987, NEW ENGL J MED, V317, P408, DOI 10.1056/NEJM198708133170703; COLVILLE PL, 1983, MULTIPLE SCLEROSIS P, P631; DEAN G, 1994, NEUROEPIDEMIOLOGY, V13, P1, DOI 10.1159/000110351; GIACOMINI P, 1984, J IMMUNOL, V133, P1649; GULICK EE, 1989, INT J NURS STUD, V26, P301, DOI 10.1016/0020-7489(89)90017-5; HERBERMAN RR, 1979, NATURE, V277, P221, DOI 10.1038/277221a0; HUANG K, 1971, INFECT IMMUN, V4, P581, DOI 10.1128/IAI.4.5.581-588.1971; JACOBS L, 1987, ARCH NEUROL-CHICAGO, V44, P589, DOI 10.1001/archneur.1987.00520180013008; JACOBS L, 1981, SCIENCE, V214, P1026, DOI 10.1126/science.6171035; JACOBS L, 1993, ANN NEUROL, V34, P310; KURTZKE JF, 1993, CLIN MICROBIOL REV, V6, P382, DOI 10.1128/CMR.6.4.382-427.1993; MARK D, 1984, P INT S INTERFERONS, P167; MAYBURY CP, 1984, J NEUROL NEUROSUR PS, V47, P372, DOI 10.1136/jnnp.47.4.372; MERIGAN TC, 1978, NEW ENGL J MED, V298, P981, DOI 10.1056/NEJM197805042981801; NEIGHBOUR PA, 1979, P NATL ACAD SCI USA, V76, P476, DOI 10.1073/pnas.76.1.476; NOKTA M, 1991, J INTERFERON RES, V11, P159, DOI 10.1089/jir.1991.11.159; NORONHA A, 1990, ANN NEUROL, V27, P207, DOI 10.1002/ana.410270219; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; RUDICK RA, 1992, TREATMENT MULTIPLE S; STEINMAN L, 1993, SCI AM, V269, P106, DOI 10.1038/scientificamerican0993-106; STIEHM ER, 1982, ANN INTERN MED, V96, P80, DOI 10.7326/0003-4819-96-1-80; The IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; THOMPSON AJ, 1991, ANN NEUROL, V29, P53, DOI 10.1002/ana.410290111; THOMPSON MR, 1985, J BIOL CHEM, V260, P563; YUDKIN PL, 1991, LANCET, V338, P1051, DOI 10.1016/0140-6736(91)91909-E; 1990, VITAL HLTH STATIS 10, V176	28	41	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1057	1060		10.1016/S0140-6736(94)91713-2	http://dx.doi.org/10.1016/S0140-6736(94)91713-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934448				2022-12-28	WOS:A1994PL85200013
J	FANTL, WJ; MUSLIN, AJ; KIKUCHI, A; MARTIN, JA; MACNICOL, AM; GROSS, RW; WILLIAMS, LT				FANTL, WJ; MUSLIN, AJ; KIKUCHI, A; MARTIN, JA; MACNICOL, AM; GROSS, RW; WILLIAMS, LT			ACTIVATION OF RAF-1 BY 14-3-3-PROTEINS	NATURE			English	Article							KINASE-KINASE; OOCYTE MATURATION; EXPRESSION; INDUCTION; PATHWAY; CLONING; GROWTH; CYCLIN; FAMILY; CELLS	THE protein Raf-1, a key mediator of mitogenesis and differentiation, associates with p21(ras) (refs 1-3). However, the regulation of the serine/threonine kinase activity of Raf-1 is still not understood(4-13). Using the yeast two-hybrid systems(8,14-16), we identified two structurally related proteins that interact with the aminoterminal region of Raf-1. These proteins, 14-3-3 zeta (PLA(2)) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins(17-23). Expression of 14-3-3 proteins in Xenopus oocytes enhanced Raf-1 activity and promoted Raf-1-dependent oocyte maturation. A dominant negative mutant of Raf-1 blocked the effects of 14-3-3 protein.	WASHINGTON UNIV, SCH MED, DIV BIOORGAN CHEM & MOLEC PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	FANTL, WJ (corresponding author), UNIV CALIF SAN FRANCISCO, DAIICHI RES CTR, INST CARDIOVASC RES, DEPT MED, SAN FRANCISCO, CA 94143 USA.							AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DU XP, 1994, J BIOL CHEM, V269, P18287; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NIELSEN PJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P425, DOI 10.1016/0167-4781(91)90136-A; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; RAPP UR, 1991, ONCOGENE, V6, P495; SMITH LD, 1989, DEVELOPMENT, V107, P685; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P9213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	30	326	331	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					612	614		10.1038/371612a0	http://dx.doi.org/10.1038/371612a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935795				2022-12-28	WOS:A1994PL55900054
J	DOLL, R; PETO, R; HALL, E; WHEATLEY, K; GRAY, R				DOLL, R; PETO, R; HALL, E; WHEATLEY, K; GRAY, R			MORTALITY IN RELATION TO CONSUMPTION OF ALCOHOL - 13 YEARS OBSERVATIONS ON MALE BRITISH DOCTORS	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; RISK	Objective-To assess the risk of death associated with various patterns of alcohol consumption. Design-Prospective study of mortality in relation to alcohol drinking habits in 1978, with causes of death sought over the next 13 years (to 1991). Subjects-12 321 British male doctors born between 1900 and 1930 (mean 1916) who replied to a postal questionnaire in 1978. Those written to in 1978 were the survivors of a long running prospective study of the effects of smoking that had begun in 1951 and was still continuing. Results-Men were divided on the basis of their response to the 1978 questionnaire into two groups according to whether or not they had ever had any type of vascular disease, diabetes, or ''life threatening disease'' and into seven groups according to the amount of alcohol they drank. By 1991 almost a third had died. All statistical analyses of mortality were standardised for age, calendar year, and smoking habit. There was a U shaped relation between all cause mortality and the average amount of alcohol reportedly drunk; those who reported drinking 8-14 units of alcohol a week (corresponding to an average of one to two units a day) had the lowest risks. The causes of death were grouped into three main categories: ''alcohol augmented'' causes (6% of all deaths: cirrhosis, liver cancer, upper aerodigestive (mouth, oesophagus, larynx, and pharynx) cancer, alcoholism, poisoning, or injury), ischaemic heart disease (33% of all deaths), and other causes. The few deaths from alcohol augmented causes showed, at least among regular drinkers, a progressive trend, with the risk increasing with dose. In contrast, the many deaths from ischaemic heart disease showed no significant trend among regular drinkers, but there were significantly lower rates in regular drinkers than in non-drinkers. The aggregate of all other causes showed a U shaped dose-response relation similar to that for all cause mortality, Similar differences persisted irrespective of a history of previous disease, age (under 75 or 75 and older), and period of follow up (first five and last eight years). Some, but apparently not much, of the excess mortality in non-drinkers could be attributed to the inclusion among them of a small proportion of former drinkers. Conclusion-The consumption of alcohol appeared to reduce the risk of ischaemic heart disease, largely irrespective of amount. Among regular drinkers mortality from all causes combined increased progressively with amount drunk above 21 units a week. Among British men in middle or older age the consumption of an average of one or two units of alcohol a day is associated with significantly lower all cause mortality than is the consumption of no alcohol, or the consumption of substantial amounts. Above about three units (two American units) of alcohol a day, progressively greater levels of consumption are associated with progressively higher all cause mortality.			DOLL, R (corresponding author), RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,IMPERIAL CANC RES FUND,CANC STUDIES UNIT,OXFORD OX2 6HE,ENGLAND.			Hall, Emma/0000-0001-5999-5020; Gray, Richard/0000-0003-4440-574X				Beaglehole R, 1992, Drug Alcohol Rev, V11, P275, DOI 10.1080/09595239200185811; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; FARCHI G, 1992, INT J EPIDEMIOL, V21, P74, DOI 10.1093/ije/21.1.74; FISHMAN AP, 1988, PULMONARY DISEASES D; GROENBAEK M, 1994, BRIT MED J, V308, P302; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; JARVIS J, 1994, ADDICTION, V89, P1371; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MARMOT MG, 1994, BRIT MED J, V308, P1263, DOI 10.1136/bmj.308.6939.1263; MEADE TW, 1987, LANCET, V2, P986; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PREEDY VR, 1994, BRIT MED BULL, V50, P152, DOI 10.1093/oxfordjournals.bmb.a072873; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RENAUD S, 1993, HLTH ISSUES RELATED, P81; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SHAPER AG, 1994, INT J EPIDEMIOL, V23, P4825; VANGIJN J, 1993, HLTH ISSUES RELATED, P43; 1991, J HUM HYPERTENS, V5, P227; 1991, ANCTION ALCOHOL MISU; 1992, CMN1523	25	515	522	0	26	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 8	1994	309	6959					911	918		10.1136/bmj.309.6959.911	http://dx.doi.org/10.1136/bmj.309.6959.911			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7950661	Green Published			2022-12-28	WOS:A1994PL78100017
J	WONG, TY; MIHM, MC				WONG, TY; MIHM, MC			PRIMARY SYPHILIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											WONG, TY (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.		Wong, Tien Yin/AAC-9724-2020	Wong, Tien Yin/0000-0002-8448-1264					0	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1492	1492						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969299				2022-12-28	WOS:A1994PU86600005
J	GRAHAMESMITH, DG				GRAHAMESMITH, DG			KOD BY RESEARCH-AND-DEVELOPMENT SPEAK - DECIPHERING CULYER	LANCET			English	Editorial Material											GRAHAMESMITH, DG (corresponding author), RADCLIFFE INFIRM,DEPT CLIN PHARMACOL,OXFORD OX2 6HE,ENGLAND.							CHURCHILL W, STRUGGLE SURVIVAL 19; PETERS K, 1994, BRIT MED J, V309, P751, DOI 10.1136/bmj.309.6957.751; 1994, SUPPORTING RES DEV N	3	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1452	1452		10.1016/S0140-6736(94)90285-2	http://dx.doi.org/10.1016/S0140-6736(94)90285-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968117				2022-12-28	WOS:A1994PT99500004
J	BAKER, DW; WRIGHT, RF				BAKER, DW; WRIGHT, RF			MANAGEMENT OF HEART-FAILURE .4. ANTICOAGULATION FOR PATIENTS WITH HEART-FAILURE DUE TO LEFT-VENTRICULAR SYSTOLIC DYSFUNCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							IDIOPATHIC DILATED CARDIOMYOPATHY; MYOCARDIAL-DISEASE; NATURAL-HISTORY; THROMBUS; THERAPY; RISK; ECHOCARDIOGRAPHY; THROMBOEMBOLISM; OUTPATIENTS; PREVENTION	Objective.-This article reviews the incidence of arterial thromboembolism in patients with heart failure who are not receiving anticoagulants. We also examine whether more severe ventricular dysfunction increases this incidence and the efficacy and risks of anticoagulation for patients in sinus rhythm. Data Sources.-English-language studies referenced in MEDLINE or EMBASE (January 1966 to September 1993) were reviewed. We used the search terms heart failure, congestive; congestive heart failure; heart failure; cardiac failure; and dilated cardiomyopathy in conjunction with the terms anticoagulation, cerebrovascular disorders, stroke, and thromboembolism. Study Selection.-All studies with separate data for patients with chronic heart failure not receiving anticoagulants were included. Articles addressing valvular heart disease or heart failure secondary to acute myocardial infarction or Chagas' disease were excluded. Studies of the occurrence of left ventricular mural thrombi were also reviewed. Data Extraction and Synthesis.-Inclusion and exclusion criteria, prevalence of atrial fibrillation, mean follow-up, and the occurrence of arterial thromboembolic events were extracted. If the incidence was not given, this was estimated using the proportion of patients with events divided by the mean follow-up. Conclusion.-The incidence of arterial thromboembolism ranged from 0.9 to 5.5 events per 100 patient-years, with the largest studies reporting incidence of 2.0% and 2.4%. Findings regarding the relationship between ventricular function and thromboembolic events are contradictory. No controlled trial has assessed the efficacy or risks of anticoagulation for patients with heart failure and sinus rhythm, and reported efficacy in case series ranged from 0% to 100%. Until adequate studies are performed, anticoagulation should be discouraged for patients with heart failure who are in sinus rhythm.	PACIFIC HEART INST, SANTA MONICA, CA 90404 USA; RAND CORP, HLTH SCI PROGRAM, SANTA MONICA, CA USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, DIV GEN INTERNAL MED, TORRANCE, CA 90509 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					PHS HHS [282-91-0064] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABELMANN WH, 1984, PROG CARDIOVASC DIS, V27, P73, DOI 10.1016/0033-0620(84)90020-3; ALBERS GW, 1991, ANN INTERN MED, V115, P727, DOI 10.7326/0003-4819-115-9-727; ANDERSON G M, 1948, South Med J, V41, P365, DOI 10.1097/00007611-194804000-00018; BLONDHEIM DS, 1991, AM HEART J, V122, P763, DOI 10.1016/0002-8703(91)90523-K; CIACCHERI M, 1989, BRIT HEART J, V62, P26; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1992, CIRCULATION, V86, P252; DAVIS FB, 1977, ARCH INTERN MED, V137, P197, DOI 10.1001/archinte.137.2.197; DUNKMAN WB, 1993, CIRCULATION, V87, P94; FALK RH, 1992, AM HEART J, V123, P136, DOI 10.1016/0002-8703(92)90757-M; FALK RH, 1990, AM J CARDIOL, V65, P914, DOI 10.1016/0002-9149(90)91436-A; FUSTER V, 1990, AM J CARDIOL, V65, pC38, DOI 10.1016/0002-9149(90)90114-G; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GOTTDIENER JS, 1983, AM J CARDIOL, V52, P1281, DOI 10.1016/0002-9149(83)90588-X; HALL D, 1992, J AM COLL CARDIOL, V20, P1549, DOI 10.1016/0735-1097(92)90449-W; HARVEY WP, 1950, NEW ENGL J MED, V242, P208, DOI 10.1056/NEJM195002092420603; HATLE L, 1976, ACTA MED SCAND, V199, P399; HUSTED S, 1976, ACTA MED SCAND, V200, P379; JOHNSON RA, 1989, PRACTICE CARDIOLOGY, P895; JONKER JJC, 1994, LANCET, V343, P499; KATZ SD, 1993, AM HEART J, V126, P141, DOI 10.1016/S0002-8703(07)80021-4; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KYRLE PA, 1985, THROMB HAEMOSTASIS, V54, P521; LANDEFELD CS, 1989, AM J MED, V87, P144; MASSUMI RA, 1965, CIRCULATION, V31, P19, DOI 10.1161/01.CIR.31.1.19; MAZE SS, 1989, J AM COLL CARDIOL, V13, P873, DOI 10.1016/0735-1097(89)90230-1; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; PITT B, 1986, AM J CARDIOL, V57, pB19, DOI 10.1016/0002-9149(86)90994-X; ROBERTS WC, 1987, AM J CARDIOL, V60, P1340, DOI 10.1016/0002-9149(87)90618-7; Segal J P, 1978, Curr Probl Cardiol, V3, P1, DOI 10.1016/0146-2806(78)90026-9; SHERMAN DG, 1989, CHEST, V95, pS140; SHERRY S, 1986, HEART, P1667; SMITH TW, 1988, HEART DISEASE, P485; STRATTON JR, 1988, CIRCULATION, V78, P1388, DOI 10.1161/01.CIR.78.6.1388; STRATTON JR, 1987, CIRCULATION, V75, P1004, DOI 10.1161/01.CIR.75.5.1004; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TSEVAT J, 1989, MED DECIS MAKING, V9, P162, DOI 10.1177/0272989X8900900303; WYNNE J, 1987, HARRISONS PRINCIPLES, P998; YOKOTA Y, 1989, JPN HEART J, V30, P1; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	41	86	91	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1614	1618		10.1001/jama.272.20.1614	http://dx.doi.org/10.1001/jama.272.20.1614			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966873				2022-12-28	WOS:A1994PR40500029
J	LONSTEIN, JE				LONSTEIN, JE			ADOLESCENT IDIOPATHIC SCOLIOSIS	LANCET			English	Review							INSTRUMENTATION				LONSTEIN, JE (corresponding author), MINNESOTA SPINE CTR, 606 24TH AVE S, MINNEAPOLIS, MN 55454 USA.							AKBARNIA BA, 1988, ORTHOP CLIN N AM, V19, P319; Bartie BA, 1993, ORTHOP T, V17, P176; BASSETT GS, 1986, J BONE JOINT SURG AM, V68A, P602, DOI 10.2106/00004623-198668040-00019; BUNNELL WP, 1986, SPINE, V11, P773, DOI 10.1097/00007632-198610000-00003; COTREL Y, 1984, REV CHIR ORTHOP, V70, P489; COWELL HR, 1969, J BONE JOINT SURG AM, VA 51, P1236; DRUMMOND DS, 1988, ORTHOP CLIN N AM, V19, P281; DUBOUSSET J, 1989, J PEDIATR ORTHOPED, V9, P541, DOI 10.1097/01241398-198909010-00008; DUVALBEAUPERE G, 1970, REV CHIR ORTHOP, V56, P56; DWYER AF, 1969, CLIN ORTHOP RELAT R, P192; FIDLER MW, 1976, J BONE JOINT SURG BR, V58, P200, DOI 10.1302/0301-620X.58B2.932082; Greulich WW., 1959, CALIF MED, V91, P53; HARRINGTON PR, 1962, J BONE JOINT SURG AM, V44, P591, DOI 10.2106/00004623-196244040-00001; LONSTEIN JE, 1984, J BONE JOINT SURG AM, V66A, P1061, DOI 10.2106/00004623-198466070-00013; LONSTEIN JE, 1994, J BONE JOINT SURG AM, V76A, P1207, DOI 10.2106/00004623-199408000-00011; LUQUE ER, 1982, CLIN ORTHOP RELAT R, V163, P192; MACEWEN GD, 1970, J BONE JOINT SURG AM, VA 52, P405; MCCOLLOUGH NC, 1986, SPINE, V11, P802, DOI 10.1097/00007632-198610000-00010; MIELKE CH, 1989, J BONE JOINT SURG AM, V71A, P1170, DOI 10.2106/00004623-198971080-00008; Moe J H, 1972, Orthop Clin North Am, V3, P17; NACHEMSON AL, 1993, SEP ANN M SCOL RES S; NASH CL, 1989, J BONE JOINT SURG AM, V71A, P627, DOI 10.2106/00004623-198971040-00019; ODONNELL CS, 1988, CLIN ORTHOP RELAT R, V229, P107; RISSER J C, 1958, Clin Orthop, V11, P111; STYBLO K, 1991, THESIS U LEIDEN; SULLIVAN JA, 1986, SPINE, V11, P903, DOI 10.1097/00007632-198611000-00010; TANNER JM, 1975, ENDOCRINE GENETIC DI, P14; VAUZELLE C, 1973, CLIN ORTHOP RELAT R, V93, P173; WILLNER S, 1975, ACTA ORTHOP SCAND, V46, P71, DOI 10.3109/17453677508989194; Winter R, 1992, ORTHOP T, V16, P135; WINTER RB, 1985, INT ORTHOP, V9, P239, DOI 10.1007/BF00266510; ZIELKE K, 1976, ARCH ORTHOP TRAUM SU, V85, P257, DOI 10.1007/BF00415189; ZUK T, 1962, J BONE JOINT SURG BR, V44, P102, DOI 10.1302/0301-620X.44B1.102; [No title captured]; 1992, LANCET, V338, P219	36	154	173	0	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 19	1994	344	8934					1407	1412						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968079				2022-12-28	WOS:A1994PR78600013
J	LOUDON, I				LOUDON, I			NECROTIZING FASCIITIS, HOSPITAL GANGRENE, AND PHAGEDENA	LANCET			English	Article																		BABINGTON G, 1826, LONDON MED PHYSICAL, P204; BIRD J, 1869, LANCET, V2, P23; Blackadder HH., 1818, OBSERVATIONS PHAGEDE; BLANE G, 1785, OBSERVATIONS DISEASE; COOPER S, 1838, DICT PRACTICAL SURGE; COPLAND James, 1844, DICT PRACTICAL MED; DEAN M, 1994, LANCET, V343, P1418, DOI 10.1016/S0140-6736(94)92533-X; EGAN JC, 1845, DUBLIN J MED SCI, V26, P423; FEDDEN WF, 1908, P ROY SOC MED, V2, P213; Fournier JA, 1883, SEMAINE MED, V3, P345; GILLESPIE L, 1785, LONDON MED J, V6, P373; HENNEN J, 1820, PRINCIPLES MILITARY; JONES J, 1872, SURGICAL MEMOIRS WAR; LOUDON I, 1992, DEATH CHILDBIRTH INT, P534; MACLEOD GHB, 1858, NOTES SURGERY WAR CR; Meleney FL, 1933, SURG GYNECOL OBSTET, V56, P847; Meleny FK, 1924, ARCH SURG-CHICAGO, V9, P317, DOI 10.1001/archsurg.1924.01120080083007; Nightingale F., 1863, NOTES ON HOSP, V3rd; PARK R, 1908, PRINCIPLES PRACTICE; PATINO JF, 1991, WORLD J SURG, V15, P235, DOI 10.1007/BF01659058; Pick T P, 1864, Br Med J, V1, P262; PINI P, 1994, LANCET, V343, P1376, DOI 10.1016/S0140-6736(94)92518-6; POUTEAU C, 1983, OEUVRES POSTHUMES, V3; SIMPSON JY, 1950, LONDON EDINBURGH NOV, P414; THOMSON J, 1813, LECTURES INFLAMMATIO; Trotter T., 1797, MED NAUTICA; WARD RG, 1991, BRIT J SURG, V78, P488, DOI 10.1002/bjs.1800780431; Welbank R, 1821, Med Chir Trans, V11, P361; 1994, JAMA-J AM MED ASSOC, V272, P16; 1911, ANN REPORTS REGISTRA; 1994, COMMON DIS REP, V4, P123	31	41	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1416	1419		10.1016/S0140-6736(94)90574-6	http://dx.doi.org/10.1016/S0140-6736(94)90574-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968080				2022-12-28	WOS:A1994PR78600015
J	PEDERSEN, TR; KJEKSHUS, J; BERG, K; HAGHFELT, T; FAERGEMAN, O; THORGEIRSSON, G; PYORALA, K; MIETTINEN, T; WILHELMSEN, L; OLSSON, AG; WEDEL, H; KRISTIANSON, K; THOMSEN, H; NORDERO, E; THOMSEN, B; LYNGBORG, K; ANDERSEN, GS; NIELSEN, F; TALLERUPHUUS, U; MCNAIR, A; EGSTRUP, K; SIMONSEN, EH; SIMONSEN, I; VEJBYCHRISTENSEN, H; SOMMER, L; EIDNER, PO; KLARHOLT, E; HENRIKSEN, A; MELLEMGAARD, K; LAUNBJERG, J; FREUERGAARD, P; NIELSEN, L; MADSEN, EB; IBSEN, H; ANDERSEN, U; ENEMARK, H; HAARBO, J; MARTINSEN, B; DAHLSTROM, CG; THYRRING, L; THOMASSEN, K; JENSEN, G; RASMUSSEN, SL; SKOV, N; HANSEN, KN; LARSEN, ML; HAASTRUP, B; HJAERE, I; THUROE, A; LETH, A; MUNCH, M; WORCK, R; NIELSEN, B; THORN, AG; PEDERSENBJERGAARD, O; FOURNAISE, B; SIGURD, B; ENK, B; NIELSEN, H; JACOBSEN, L; SVENDSEN, TL; HOEGHOLM, A; MUNTER, H; KAUFMANN, P; HAUNSO, S; GRANDE, P; ERIKSEN, C; NIELSEN, HH; JURLANDER, B; PINBORG, T; PINDBORG, J; TOST, H; CHRISTIANSEN, BD; OPPENHAGEN, M; EGEDE, F; HVIDT, S; KJAERBY, T; LEMMING, L; KLAUSEN, I; MIETTINEN, TA; VANHANEN, H; STRANDBERG, TE; HOLTTA, K; LUOMANMAKI, H; PEKURI, T; VUORINEN, A; PASTERNACK, A; OKSA, H; SIITONEN, L; RIMPI, R; KESANIEMI, YA; LILJA, M; KORHONEN, T; RANTALA, A; RANTALA, M; SAVOLAINEN, M; UKKOLA, O; LAINE, L; VIRKKALA, L; LEHTO, S; MIETTINEN, H; SALOKANNEL, A; RAISANEN, R; HOGNASON, J; KRISTJANSDOTTIR, H; THORVALDSDOTTIR, G; SIGURDSSON, G; SVERRISSON, JT; HANSTEEN, V; KJELSBERG, F; BERGET, K; PETTERSEN, R; BALTO, ER; HOLM, T; GUNDERSEN, T; ASLAKSEN, B; ANDERSEN, EH; TORSVIK, H; FABER, A; INDREBO, T; OSE, A; ROTERUD, T; HOLSTLARSEN, L; WAAGE, K; HOLSTLARSEN, E; HAEREM, JW; AUKRUST, P; TORP, R; RISBERG, K; MAUSETH, K; GERDTS, E; NYGARD, O; HALLARAKER, A; GRADEK, G; VANGEN, EM; SCHARTUMHANSEN, H; REFSUM, AM; LISTERUD, S; GUNDERSRUD, B; STENE, AM; KLYKKEN, B; AAKERVIK, O; LORAAS, A; FOSS, PO; HAGA, A; THORESEN, L; DRIVENES, A; LEM, P; GABRIELSEN, F; HESTAD, S; RODE, R; HAUG, BK; SKJELVAN, G; ELDORSEN, E; YTREARNE, K; RASMUSSEN, K; MYHRE, ESP; NERMOEN, I; CHRISTIANSEN, L; KARLSEN, AS; WALBERG, K; TJONNDAL, HA; KULSENG, B; ROKSETH, R; NERGARD, TV; ROE, MO; TENSTAD, O; LOFSNES, IL; BERGSRUD, U; MELBERG, TH; VONBRANDIS, C; BARVIK, S; WOIE, L; ABRAHAMSEN, AM; AARSLAND, T; SVANES, H; NOER, G; NORDLIE, KE; HANEDALEN, AE; JOHANSEN, T; LARSEN, CB; OSTHOLM, E; OVERSKEID, K; SANDVEI, P; JOHANSEN, A; SOGNEN, E; AARSKOG, D; DALE, A; HEGRESTAD, S; REIKVAM, A; HAWKES, L; HOFF, S; TORJUSSEN, T; NORVIK, R; JORGENSEN, C; HJERMANN, I; LEREN, P; NARVESTAD, A; FAUSA, D; GJESTVANG, FT; NORDLAND, B; BRUNMARK, P; BIOKLUND, H; BIOKLUND, B; FORSBERG, H; BERGSTROM, B; LAAKSONEN, I; VESTERMARK, MB; MASCHER, G; HAMMARSTROM, E; TROSELL, K; KARLSSON, L; HALLSTROM, L; STJERNA, A; SLETTE, MK; DIDERHOLM, E; PBERGLUND, K; LINDE, B; AHLMARK, G; SAETRE, H; AHLBERG, G; SUNDKVIST, K; GUSTAFSSON, PE; GUSTAFSSON, E; NORRBY, A; JAUP, B; SVENSSON, L; WIKLUND, O; LINDEN, T; BERGH, CH; JONSTEG, K; BONNIER, B; LUNDIN, Y; ROMANUS, K; ULVENSTAM, G; JOHANSSON, S; WALLIN, I; DUDAS, K; ANDREASSON, M; TORELUND, G; SKARFORS, E; RUTER, G; AKESSON, L; WAGNER, F; LJUNGDAHL, L; WAGNER, V; RASMANIS, G; EDHAG, O; VOURISALO, D; HJELMSELL, H; WESLEY, G; LUNDKVIST, L; ANGMAN, K; OLSSON, A; SVENSON, O; KUYLENSTIERNA, J; FRISENETTEFICH, K; BERGMAN, E; STROMBLAD, H; JENSEN, S; JONSSON, E; LEVIN, C; ODEBERG, H; BENGTSSON, PO; HOLMESSON, E; HEDSTRAND, H; BOJO, L; OBERG, S; LEKSELL, H; WERNER, P; PERSSON, S; SIMONSSON, M; WIRENSTAM, UB; MOBERG, B; EKSTRAND, AB; NICOL, P; MALMROS, B; SAAW, J; ARCINI, N; KOBOSKO, J; ANEVIK, IG; GYLAND, F; LUNDH, B; WENNERHOLM, M; OLSSON, C; KJELLBERG, J; FABIANSON, K; FRASER, T; BERGKVIST, I; BERGDAHL, B; FLUUR, C; WAJERSTAM, S; SVENSSON, KA; EKHOLM, L; TOREBO, E; RYBERG, A; FRISELL, JE; HEDMAN, A; WALLRUP, L; ANDERSEN, G; SANDSTROM, M; ALBERG, K; FAGHER, B; THULIN, T; SVENSTAM, I; BJURMAN, A; SKOGLUND, E; DAHL, G; KJELLSTROM, T; JUHLIN, P; SJOOBOQUIST, M; SJOGREN, A; LOOGNA, E; JANSSON, T; FRIDEN, J; NILSSON, O; ANDERSSON, PO; HENRIKSSON, C; ELLSTROM, J; BRODERSSON, H; LUNDQUIST, L; ASLUND, M; BOMAN, K; JANSSON, JH; NORRFORS, B; HOGLUND, C; LUNDBLAD, M; LILJEFORS, I; WENNERSTROM, L; PERZ, I; LEIJD, B; FALKENBERG, C; BERGSTEN, L; STROM, S; ENGSTROM, AC; EJDEBACK, J; MALMBERG, K; HOGSTROM, S; STAHL, L; MOLLER, BH; LYCKSELL, M; SODERSTROM, M; HANSSON, E; HALLEN, C; STAKEBARG, H; BORRETZEN, J; HEDEN, B; ANDERSSON, K; JOHNSON, O; BIRGANDER, LS; ELANDER, B; LIDELL, C; ANDERSSON, PE; MARKLUND, E; DAHLEN, M; RUCKER, F; LOFQVIST, M; WANNBERG, B; LIM, BH; LARSSON, O; ANDERSSON, G; HANSSON, A; UCHTO, M; GOWENIUS, M; UGGELDAHL, I; URSING, D; HAMMARLUND, P; NYMAN, P; TSUPPUKA, E; MALMBERG, L; GORANSSON, K; HASSELGREN, P; INSBERG, CM; PETTERSON, S; AHRLIN, A; LOVHEIM, O; ANDERSSON, LO; GRUNDSTROM, I				PEDERSEN, TR; KJEKSHUS, J; BERG, K; HAGHFELT, T; FAERGEMAN, O; THORGEIRSSON, G; PYORALA, K; MIETTINEN, T; WILHELMSEN, L; OLSSON, AG; WEDEL, H; KRISTIANSON, K; THOMSEN, H; NORDERO, E; THOMSEN, B; LYNGBORG, K; ANDERSEN, GS; NIELSEN, F; TALLERUPHUUS, U; MCNAIR, A; EGSTRUP, K; SIMONSEN, EH; SIMONSEN, I; VEJBYCHRISTENSEN, H; SOMMER, L; EIDNER, PO; KLARHOLT, E; HENRIKSEN, A; MELLEMGAARD, K; LAUNBJERG, J; FREUERGAARD, P; NIELSEN, L; MADSEN, EB; IBSEN, H; ANDERSEN, U; ENEMARK, H; HAARBO, J; MARTINSEN, B; DAHLSTROM, CG; THYRRING, L; THOMASSEN, K; JENSEN, G; RASMUSSEN, SL; SKOV, N; HANSEN, KN; LARSEN, ML; HAASTRUP, B; HJAERE, I; THUROE, A; LETH, A; MUNCH, M; WORCK, R; NIELSEN, B; THORN, AG; PEDERSENBJERGAARD, O; FOURNAISE, B; SIGURD, B; ENK, B; NIELSEN, H; JACOBSEN, L; SVENDSEN, TL; HOEGHOLM, A; MUNTER, H; KAUFMANN, P; HAUNSO, S; GRANDE, P; ERIKSEN, C; NIELSEN, HH; JURLANDER, B; PINBORG, T; PINDBORG, J; TOST, H; CHRISTIANSEN, BD; OPPENHAGEN, M; EGEDE, F; HVIDT, S; KJAERBY, T; LEMMING, L; KLAUSEN, I; MIETTINEN, TA; VANHANEN, H; STRANDBERG, TE; HOLTTA, K; LUOMANMAKI, H; PEKURI, T; VUORINEN, A; PASTERNACK, A; OKSA, H; SIITONEN, L; RIMPI, R; KESANIEMI, YA; LILJA, M; KORHONEN, T; RANTALA, A; RANTALA, M; SAVOLAINEN, M; UKKOLA, O; LAINE, L; VIRKKALA, L; LEHTO, S; MIETTINEN, H; SALOKANNEL, A; RAISANEN, R; HOGNASON, J; KRISTJANSDOTTIR, H; THORVALDSDOTTIR, G; SIGURDSSON, G; SVERRISSON, JT; HANSTEEN, V; KJELSBERG, F; BERGET, K; PETTERSEN, R; BALTO, ER; HOLM, T; GUNDERSEN, T; ASLAKSEN, B; ANDERSEN, EH; TORSVIK, H; FABER, A; INDREBO, T; OSE, A; ROTERUD, T; HOLSTLARSEN, L; WAAGE, K; HOLSTLARSEN, E; HAEREM, JW; AUKRUST, P; TORP, R; RISBERG, K; MAUSETH, K; GERDTS, E; NYGARD, O; HALLARAKER, A; GRADEK, G; VANGEN, EM; SCHARTUMHANSEN, H; REFSUM, AM; LISTERUD, S; GUNDERSRUD, B; STENE, AM; KLYKKEN, B; AAKERVIK, O; LORAAS, A; FOSS, PO; HAGA, A; THORESEN, L; DRIVENES, A; LEM, P; GABRIELSEN, F; HESTAD, S; RODE, R; HAUG, BK; SKJELVAN, G; ELDORSEN, E; YTREARNE, K; RASMUSSEN, K; MYHRE, ESP; NERMOEN, I; CHRISTIANSEN, L; KARLSEN, AS; WALBERG, K; TJONNDAL, HA; KULSENG, B; ROKSETH, R; NERGARD, TV; ROE, MO; TENSTAD, O; LOFSNES, IL; BERGSRUD, U; MELBERG, TH; VONBRANDIS, C; BARVIK, S; WOIE, L; ABRAHAMSEN, AM; AARSLAND, T; SVANES, H; NOER, G; NORDLIE, KE; HANEDALEN, AE; JOHANSEN, T; LARSEN, CB; OSTHOLM, E; OVERSKEID, K; SANDVEI, P; JOHANSEN, A; SOGNEN, E; AARSKOG, D; DALE, A; HEGRESTAD, S; REIKVAM, A; HAWKES, L; HOFF, S; TORJUSSEN, T; NORVIK, R; JORGENSEN, C; HJERMANN, I; LEREN, P; NARVESTAD, A; FAUSA, D; GJESTVANG, FT; NORDLAND, B; BRUNMARK, P; BIOKLUND, H; BIOKLUND, B; FORSBERG, H; BERGSTROM, B; LAAKSONEN, I; VESTERMARK, MB; MASCHER, G; HAMMARSTROM, E; TROSELL, K; KARLSSON, L; HALLSTROM, L; STJERNA, A; SLETTE, MK; DIDERHOLM, E; PBERGLUND, K; LINDE, B; AHLMARK, G; SAETRE, H; AHLBERG, G; SUNDKVIST, K; GUSTAFSSON, PE; GUSTAFSSON, E; NORRBY, A; JAUP, B; SVENSSON, L; WIKLUND, O; LINDEN, T; BERGH, CH; JONSTEG, K; BONNIER, B; LUNDIN, Y; ROMANUS, K; ULVENSTAM, G; JOHANSSON, S; WALLIN, I; DUDAS, K; ANDREASSON, M; TORELUND, G; SKARFORS, E; RUTER, G; AKESSON, L; WAGNER, F; LJUNGDAHL, L; WAGNER, V; RASMANIS, G; EDHAG, O; VOURISALO, D; HJELMSELL, H; WESLEY, G; LUNDKVIST, L; ANGMAN, K; OLSSON, A; SVENSON, O; KUYLENSTIERNA, J; FRISENETTEFICH, K; BERGMAN, E; STROMBLAD, H; JENSEN, S; JONSSON, E; LEVIN, C; ODEBERG, H; BENGTSSON, PO; HOLMESSON, E; HEDSTRAND, H; BOJO, L; OBERG, S; LEKSELL, H; WERNER, P; PERSSON, S; SIMONSSON, M; WIRENSTAM, UB; MOBERG, B; EKSTRAND, AB; NICOL, P; MALMROS, B; SAAW, J; ARCINI, N; KOBOSKO, J; ANEVIK, IG; GYLAND, F; LUNDH, B; WENNERHOLM, M; OLSSON, C; KJELLBERG, J; FABIANSON, K; FRASER, T; BERGKVIST, I; BERGDAHL, B; FLUUR, C; WAJERSTAM, S; SVENSSON, KA; EKHOLM, L; TOREBO, E; RYBERG, A; FRISELL, JE; HEDMAN, A; WALLRUP, L; ANDERSEN, G; SANDSTROM, M; ALBERG, K; FAGHER, B; THULIN, T; SVENSTAM, I; BJURMAN, A; SKOGLUND, E; DAHL, G; KJELLSTROM, T; JUHLIN, P; SJOOBOQUIST, M; SJOGREN, A; LOOGNA, E; JANSSON, T; FRIDEN, J; NILSSON, O; ANDERSSON, PO; HENRIKSSON, C; ELLSTROM, J; BRODERSSON, H; LUNDQUIST, L; ASLUND, M; BOMAN, K; JANSSON, JH; NORRFORS, B; HOGLUND, C; LUNDBLAD, M; LILJEFORS, I; WENNERSTROM, L; PERZ, I; LEIJD, B; FALKENBERG, C; BERGSTEN, L; STROM, S; ENGSTROM, AC; EJDEBACK, J; MALMBERG, K; HOGSTROM, S; STAHL, L; MOLLER, BH; LYCKSELL, M; SODERSTROM, M; HANSSON, E; HALLEN, C; STAKEBARG, H; BORRETZEN, J; HEDEN, B; ANDERSSON, K; JOHNSON, O; BIRGANDER, LS; ELANDER, B; LIDELL, C; ANDERSSON, PE; MARKLUND, E; DAHLEN, M; RUCKER, F; LOFQVIST, M; WANNBERG, B; LIM, BH; LARSSON, O; ANDERSSON, G; HANSSON, A; UCHTO, M; GOWENIUS, M; UGGELDAHL, I; URSING, D; HAMMARLUND, P; NYMAN, P; TSUPPUKA, E; MALMBERG, L; GORANSSON, K; HASSELGREN, P; INSBERG, CM; PETTERSON, S; AHRLIN, A; LOVHEIM, O; ANDERSSON, LO; GRUNDSTROM, I			RANDOMIZED TRIAL OF CHOLESTEROL-LOWERING IN 4444 PATIENTS WITH CORONARY-HEART-DISEASE - THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S)	LANCET			English	Article							MYOCARDIAL-INFARCTION; ARTERY DISEASE; REGRESSION; MORTALITY; PREVENTION; HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS; PATHOGENESIS; PROGRESSION; MECHANISMS	Drug therapy for hypercholesterolaemia has remained controversial mainly because of insufficient clinical trial evidence for improved survival. The present trial was designed to evaluate the effect of cholesterol lowering with simvastatin on mortality and morbidity in patients with coronary heart disease (CHD). 4444 patients with angina pectoris or previous myocardial infarction and serum cholesterol 5.5-8.0 mmol/L on a lipid-lowering diet were randomised to double-blind treatment with simvastatin or placebo. Over the 54 years median follow-up period, simvastatin produced mean changes in total cholesterol, low-density-lipoprotein cholesterol, and high-density-lipoprotein cholesterol of -25%, -35%, and +80%, respectively, with few adverse effects. 256 patients (12%) in the placebo group died, compared with 182 (8%) in the simvastatin group. The relative risk of death in the simvastatin group was 0.70 (95% CI 0.58-0.85, p=0.0003). The 6-year probabilities of survival in the placebo and simvastatin groups were 87.6% and 91.3%, respectively. There were 189 coronary deaths in the placebo group and 111 in the simvastatin group (relative risk 0.58, 95% CI 0.46-0.73), while noncardiovascular causes accounted for 49 and 46 deaths, respectively. 622 patients (28%) in the placebo group and 431 (19%) in the simvastatin group had one or more major coronary events. The relative risk was 0.66 (95% CI 0.59-0.75, p<0.00001), and the respective probabilities of escaping such events were 70.5% and 79.6%. This risk was also significantly reduced in subgroups consisting of women and patients of both sexes aged 60 or more. Other benefits of treatment included a 37% reduction (p<0.00001) in the risk of undergoing myocardial revascularisation procedures. This study shows that long-term treatment with simvastatin is safe and improves survival in CHD patients,	FREDERIKSBERG UNIV HOSP, COPENHAGEN, DENMARK; HADERSLEV SYGEHUS, HADERSLEV, DENMARK; HERNING SYGEHUS, COPENHAGEN, DENMARK; HILLEROD SYGEHUS, HILLEROD, DENMARK; HOLBAEK SYGEHUS, HOLBAEK, DENMARK; HVIDVORE HOSP, COPENHAGEN, DENMARK; ODENSE HOSP, ODENSE, DENMARK; KAS GLOSTRUP, COPENHAGEN, DENMARK; NYBORG SYGEHUS, NYBORG, DENMARK; NYKOBING FALSTER SYGEHUS, NYKOBING, DENMARK; NAESTVED SYGEHUS, NAESTVED, DENMARK; RIGSHOSP, DK-2100 COPENHAGEN, DENMARK; SVENDBORG SYGEHUS, SVENDBORG, DENMARK; VEJLE SYGEHUS, VEJLE, DENMARK; AARHUS AMSTSSYGEHUS, AARHUS, DENMARK; HELSINKI UNIV HOSP, HELSINKI, FINLAND; TAMPERE UNIV HOSP, TAMPERE, FINLAND; OULU UNIV HOSP, OULU, FINLAND; KUOPIO UNIV HOSP, KUOPIO, FINLAND; LANDSPITALINN UNIV HOSP, REYKJAVIK, ICELAND; REYKJAVIK CITY HOSP, REYKJAVIK, ICELAND; SJUKRAHUSID AKUREYRI, AKUREYRI, ICELAND; AUST AGDER SENTRALSJUKEHUS, ARENDAL, NORWAY; BAERUM SYKEHUS, SANDVIKA, NORWAY; GJOVIK FYLKESSJUKEHUSET, GJOVIK, NORWAY; FYKESSJUKEHUSET HAUGESUND, HAUGESUND, NORWAY; HAMAR SYKEHUS, HAMAR, NORWAY; HAUKELAND HOSP, BERGEN, NORWAY; HEDMARK SENTRALSYKEHUS, ELVERUM, NORWAY; INNHERRED SYKEHUS, LEVANGER, NORWAY; MOSS SYKEHUS, MOSS, NORWAY; NORDLAND SENTRALSYKEHUS, BODO, NORWAY; REG SYKEHUSET TROMSO, TROMSO, NORWAY; REG HOSP TRONDHEIM, TRONDHEIM, NORWAY; RINGERIKE SYKEHUS, HONEFOSS, NORWAY; CENT HOSP ROGALAND, STAVANGER, NORWAY; SANDEFJORD SYKEHUS, SANDEFJORD, NORWAY; OSTFOLD SENTRALSYKEHUS, AVD FREDRIKSTAAD, NORWAY; OSTFOLD SENTRALSYKEHUS, AVD SARSPBORG, NORWAY; SOGN & FJORDANE SENTRALSYKEHUS, FORDE, NORWAY; SPESIALISTSENTERET, KRISTIANSAND, NORWAY; ULLEVAL HOSP, OSLO, NORWAY; VEST AGDER SENTRALSYKEHUS, KRISTIANSAND, NORWAY; ARVIKA SJUKHUS, ARVIKA, SWEDEN; BODEN LULES SJUKHUS, BODEN, SWEDEN; BOLLNAS SJUKHUS, BOLLNAS, SWEDEN; ENKOPING LASARETT, ENKOPING, SWEDEN; MALARSJUKHUSET, ESKILSTUNA, SWEDEN; FALUN LASARETT, FALUN, SWEDEN; GAVLE SJUKHUS, GAVLE, SWEDEN; GLF LUNDBY SJUKHUS, GOTHENBURG, SWEDEN; SAHLGRENS HOSP, GOTHENBURG, SWEDEN; OSTRA HOSP, GOTHENBURG, SWEDEN; HALMSTADS LANSSJUKHUS, HALMSTAD, SWEDEN; HELSINGBORG LASARETT, HELSINGBORG, SWEDEN; HUDDINGE SJUKHUS, HUDDINGE, SWEDEN; HUDIKSVALLS SJUKHUS, HUDIKSVALLS, SWEDEN; LANSSJUKHUSET RYHOV, JONKOPING, SWEDEN; KARLSHAMN LANSLASARETT, KARLSHAMN, SWEDEN; KARLSKRONA CENT LASARETT, KARLSKRONA, SWEDEN; KARLSTAD CENT SJUKHUS, KARLSTAD, SWEDEN; KRISTIANSTADS CENT SJUKHUS, KRISTIANSTADS, SWEDEN; KRISTINEHAMN SJUKHUS, KRISTINEHAMN, SWEDEN; KOPING LASARETT, KOPING, SWEDEN; LANDSKRONA LASARETT, LANDSKRONA, SWEDEN; LIDKOPING BASSJUKHUS, LINKOPING, SWEDEN; LINDESBERG LASARETT, LINDESBERG, SWEDEN; LINKOPING UNIV SJUKHUS, LINKOPING, SWEDEN; LJUNGBY LASARETT, LJUNGBY, SWEDEN; LUDVIKA LASARETT, LUDVIKA, SWEDEN; UNIV SJUKHUSET LUND, LUND, SWEDEN; LYCKSELE LASARETT, LYCKSELE, SWEDEN; MALMO ALLAMNNA SJUKHUS, MALMO, SWEDEN; NOORKOPING LASARETT, NOORKOPING, SWEDEN; SANDVIKEN LASARETT, SANDVIKEN, SWEDEN; SKELLEFTEA LASARETT, SKELLEFTEA, SWEDEN; STOCKHOLM HEART CTR, STOCKHOLM, SWEDEN; SABBATSBERG SJUKHUS, STOCKHOLM, SWEDEN; ST GORAN SJUHHUS, STOCKHOLM, SWEDEN; SKOVDE KARNSJUKHUS, SKOVDE, SWEDEN; SUNDSVALLS SJUKHUS, SUNDSVALL, SWEDEN; SAFFLE SJUKHUS, SAFFLE, SWEDEN; TROLLHATAAN NAL, TROLLHATAAN, SWEDEN; UMEA UNIV SJUKHUS, UMEA, SWEDEN; UPPSALA AKAD SJUKHUS, UPPSALA, SWEDEN; VISBY LASARETT, VISBY, SWEDEN; VAXJO LASARETT, VAXJO, SWEDEN; ANGELHOLM SJUKHUS, ANGELHOLM, SWEDEN; OREBRO REG SJUKHUS, OREBRO, SWEDEN; ORNSKOLDSVIK SJUKHUS, ORNSKOLDSVIK, SWEDEN	Aarhus University; University of Copenhagen; Holbaek Hospital; University of Southern Denmark; Odense University Hospital; Naestved Hospital; Rigshospitalet; University of Copenhagen; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University Hospital; University of Oulu; Kuopio University Hospital; University of Eastern Finland; Landspitali National University Hospital; Landspitali National University Hospital; Norwegian University of Science & Technology (NTNU); University of Oslo; Falun Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital; Helsingborgs Hospital; Linkoping University; Lund University; Skane University Hospital	PEDERSEN, TR (corresponding author), AKER HOSP, DEPT MED, CARDIOL SECT, N-0514 OSLO, NORWAY.		Andersen, Ulrik B./AAA-5890-2021					[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; [Anonymous], 1990, WHO MONICA PROJECT M; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1977, ATHEROSCLEROSIS, V28, P81, DOI 10.1016/0021-9150(77)90201-5; COX DR, 1972, J R STAT SOC B, V34, P187; CROW RS, 1989, AM J CARDIOL, V64, P454, DOI 10.1016/0002-9149(89)90420-7; DAVIES MJ, 1991, BRIT HEART J, V65, P302; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; ILLINGWORTH DR, 1994, LANCET, V343, P1554, DOI 10.1016/S0140-6736(94)92945-9; KEECH A, 1994, EUR HEART J, V15, P255, DOI 10.1093/oxfordjournals.eurheartj.a060485; KJEKSHUS J, 1993, AM J CARDIOL, V71, P393; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; LEWIS B, 1987, EUR HEART J, V8, P77; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1994, LANCET, V344, P633; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P393, DOI 10.1136/bmj.304.6824.393; PYORALA K, 1994, EUR HEART J, V15, P1300; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; TODD PA, 1990, DRUGS, V40, P583, DOI 10.2165/00003495-199040040-00007; TUOMILEHTO J, 1992, EUR HEART J, V13, P577, DOI 10.1093/oxfordjournals.eurheartj.a060219; VOS J, 1993, PROG CARDIOVASC DIS, V35, P435, DOI 10.1016/0033-0620(93)90028-C; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067	36	9469	9840	4	185	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 19	1994	344	8934					1383	1389						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968073				2022-12-28	WOS:A1994PR78600007
J	KESSLER, DA; ROSE, JL; TEMPLE, RJ; SCHAPIRO, R; GRIFFIN, JP				KESSLER, DA; ROSE, JL; TEMPLE, RJ; SCHAPIRO, R; GRIFFIN, JP			THERAPEUTIC-CLASS WARS - DRUG PROMOTION IN A COMPETITIVE MARKETPLACE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									US FDA,DIV DRUG MKT ADVERTISING & COMMUN,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA)								ANDERS G, 1994, WALL STREET J   0628, pB1; CHREN MM, 1990, JAMA-J AM MED ASSOC, V263, P2178, DOI 10.1001/jama.1990.03440160039021; GOLDFINGER SE, 1987, NEW ENGL J MED, V316, P1408, DOI 10.1056/NEJM198705283162211; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; KESSLER DA, 1991, NEW ENGL J MED, V325, P201, DOI 10.1056/NEJM199107183250310; Kolata Gina, 1994, N Y Times Web, pA12; TANOUYE E, 1994, WALL ST J       0531, pA1; WAUD DR, 1992, NEW ENGL J MED, V327, P351, DOI 10.1056/NEJM199207303270511; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912; WOOSLEY RL, 1994, ISSUES SCI TECHNOL, V10, P59; 1993, US ETHICAL PHARM PLY; 1993, EARNING FAILING GRAD; 1993, STATISTICAL REPORT; 1994, MED ADVERTISING NEWS, P10	14	106	107	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1350	1353		10.1056/NEJM199411173312007	http://dx.doi.org/10.1056/NEJM199411173312007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935706	Bronze			2022-12-28	WOS:A1994PR21600007
J	ALEXANDER, S				ALEXANDER, S			PREDICTING PROGNOSIS AFTER MYOCARDIAL INFRACTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ALEXANDER, S (corresponding author), LAHEY CLIN MED CTR,BURLINGTON,MA 01803, USA.								0	1	1	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1543	1544						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966851				2022-12-28	WOS:A1994PQ90000038
J	HERMAN, J				HERMAN, J			EXPERIMENT AND OBSERVATION	LANCET			English	Editorial Material									BEN GURION UNIV NEGEV,UNIV CTR HLTH SCI,DEPT FAMILY MED,BEER SHEVA,ISRAEL	Ben Gurion University								[Anonymous], 1988, DORLANDS ILLUSTRATED; CRAGG DR, 1991, ANN INTERN MED, V115, P172; DANS PE, 1993, ANN INTERN MED, V119, P855, DOI 10.7326/0003-4819-119-8-199310150-00014; de Kruif P, 1926, MICROBE HUNTERS; de Kruif Paul, 1938, FIGHT LIFE; FEINSTEIN AR, 1975, NEW ENGL J MED, V292, P1400, DOI 10.1056/NEJM197506262922612; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P393, DOI 10.7326/0003-4819-99-3-393; Frank P., 1947, EINSTEIN HIS LIFE TI; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; KRAMER MS, 1992, J CLIN EPIDEMIOL, V45, P639, DOI 10.1016/0895-4356(92)90136-B; Mausner J, 1985, EPIDEMIOLOGY INTRO T; MODAN B, 1975, NEW ENGL J MED, V292, P1359, DOI 10.1056/NEJM197506262922601; Reichenbach Hans., 1961, EXPERIENCE PREDICTIO; SACKETT DL, 1994, ACP J CLUB S13, V120, P11; SARTWELL PE, 1974, ANN INTERN MED, V81, P381, DOI 10.7326/0003-4819-81-3-381; TONASCIA J, 1975, NEW ENGL J MED, V292, P1362, DOI 10.1056/NEJM197506262922602; VONKORFF M, 1994, ANN INTERN MED, V121, P187, DOI 10.7326/0003-4819-121-3-199408010-00005; 1990, AM J CARDIOL, V65, P401	18	7	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1209	1211		10.1016/S0140-6736(94)90516-9	http://dx.doi.org/10.1016/S0140-6736(94)90516-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934548				2022-12-28	WOS:A1994PN80300017
J	COLLINGHAM, D				COLLINGHAM, D			FUTURE OF THE EUROSCIENTIST	NATURE			English	Article								Labour mobility within the pharmaceutical and biotech sectors in Europe is becoming a crucial issue to both employers and employees.			COLLINGHAM, D (corresponding author), RUSTON POOLE INT,11-12 BUCKINGHAM GATE,LONDON SW1E 6LB,ENGLAND.							COLLINGHAM D, 1994, NATURE, V368, P778; 1994, BIOTECHNOLOGYS EC IM; 1994, GENETIC ENG NEWS, V14	3	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					724	724		10.1038/371724a0	http://dx.doi.org/10.1038/371724a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935821	Bronze			2022-12-28	WOS:A1994PM77300063
J	REUTHER, GW; FU, H; CRIPE, LD; COLLIER, RJ; PENDERGAST, AM				REUTHER, GW; FU, H; CRIPE, LD; COLLIER, RJ; PENDERGAST, AM			ASSOCIATION OF THE PROTEIN-KINASES C-BCR AND BCR-ABL WITH PROTEINS OF THE 14-3-3-FAMILY	SCIENCE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; DOMAIN; ONCOGENE; TRANSFORMATION; SEQUENCES; REGION; GENE; IDENTIFICATION; ACTIVATION	In this study, a protein that interacts with sequences encoded by the first exon of the protein kinase Bcr was cloned. The Bcr-associated protein 1 (Bap-1) is a member of the 14-3-3 family of proteins. Bap-1 interacts with full-length c-Bcr and with the chimeric Bcr-Abl tyrosine kinase of Philadelphia chromosome (Ph(1))-positive human leukemias. Bap-1 is a substrate for the Bcr serine-threonine kinase and is also phosphorylated on tyrosine by Bcr-Abl but not by c-Abl. Bap-1 may function in the regulation of c-Bcr and may contribute to the transforming activity of Bcr-Abl in vivo. 14-3-3 proteins are essential for cell proliferation and have a role in determining the timing of mitosis in yeast. Through direct binding to sequences present in Bcr and in other proteins implicated in signaling, the mammalian 14-3-3 proteins may link specific signaling protein components to mitogenic and cell-cycle control pathways.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, SHIPLEY INST MED, BOSTON, MA 02115 USA	Duke University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Reuther, Gary/AFR-2892-2022	Pendergast, Ann Marie/0000-0002-1250-6880; Collier, R John/0000-0002-2427-4239	NATIONAL CANCER INSTITUTE [R01CA061033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK001965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER; NCI NIH HHS [CA61033] Funding Source: Medline; NIDDK NIH HHS [DK01965] Funding Source: Medline; NIGMS NIH HHS [GM07184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NIELSEN PJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P425, DOI 10.1016/0167-4781(91)90136-A; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REUTHER GW, UNPUB; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; RON D, 1991, NEW BIOL, V3, P372; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x	39	218	223	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	1994	266	5182					129	133		10.1126/science.7939633	http://dx.doi.org/10.1126/science.7939633			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939633				2022-12-28	WOS:A1994PK58200041
J	KITCHENS, JM				KITCHENS, JM			DOES THIS PATIENT HAVE AN ALCOHOL PROBLEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAGE QUESTIONNAIRE; SCREENING-TEST; COLLABORATIVE PROJECT; LABORATORY TESTS; RISK-DRINKING; USE DISORDERS; CONSUMPTION; IDENTIFICATION; PREVALENCE; VALIDATION		UNIV TORONTO, DEPT INTERNAL MED, TORONTO, ON, CANADA	University of Toronto	KITCHENS, JM (corresponding author), ST MICHAELS HOSP, DIV GEN INTERNAL MED, 30 BOND ST, TORONTO M5B 1W8, ON, CANADA.							BERESFORD T, 1982, PSYCHOSOMATICS, V23, P713; BERNADT MW, 1982, LANCET, V1, P325; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; BUCHSBAUM DG, 1992, J GEN INTERN MED, V7, P517, DOI 10.1007/BF02599456; BUCHSBAUM DG, 1992, J AM GERIATR SOC, V40, P662, DOI 10.1111/j.1532-5415.1992.tb01956.x; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CHICK J, 1981, LANCET, V1, P1249; CLARK PMS, 1986, BR J ALCOHOL ALCOHOL, V16, P11; CLEARY PD, 1988, AM J MED, V85, P466; CURTIS JR, 1989, J AM GERIATR SOC, V37, P310, DOI 10.1111/j.1532-5415.1989.tb05496.x; DAWSON NV, 1992, J GEN INTERN MED, V7, P38, DOI 10.1007/BF02599100; ECKARDT MJ, 1981, JAMA-J AM MED ASSOC, V246, P648, DOI 10.1001/jama.246.6.648; ERNHART CB, 1988, ALCOHOL CLIN EXP RES, V12, P506, DOI 10.1111/j.1530-0277.1988.tb00233.x; ERNHART CB, 1987, AM J OBSTET GYNECOL, V156, P33, DOI 10.1016/0002-9378(87)90199-2; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; GIBBS LE, 1983, DRUG ALCOHOL DEPEN, V12, P279, DOI 10.1016/0376-8716(83)90071-6; KING M, 1986, PSYCHOL MED, V16, P213, DOI 10.1017/S0033291700002658; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; MARSH CM, 1989, 142ND ANN M AM PSYCH; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; MORROWTLUCAK M, 1989, ALCOHOL CLIN EXP RES, V13, P399, DOI 10.1111/j.1530-0277.1989.tb00343.x; PEQUIGNOT G, 1978, INT J EPIDEMIOL, V7, P113, DOI 10.1093/ije/7.2.113; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; RANKIN JG, 1992, PUBLIC HLTH PREVENTI, pCH43; ROSS HE, 1990, J STUD ALCOHOL, V51, P506, DOI 10.15288/jsa.1990.51.506; ROUNSAVILLE BJ, 1993, ADDICTION, V88, P337, DOI 10.1111/j.1360-0443.1993.tb00821.x; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAUNDERS JB, 1993, ADDICTION, V88, P349, DOI 10.1111/j.1360-0443.1993.tb00822.x; SCHUCKIT MA, 1985, JAMA-J AM MED ASSOC, V254, P2614, DOI 10.1001/jama.254.18.2614; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; SOKOL RJ, 1989, AM J OBSTET GYNECOL, V160, P863, DOI 10.1016/0002-9378(89)90302-5; Sox HC, 1988, MED DECISION MAKING; Spitzer RL, 1990, STRUCTURED CLIN INTE; WATERSON EJ, 1989, ALCOHOL ALCOHOLISM, V24, P21; WEST LJ, 1985, OXFORD TXB PUBLIC HL, V2, pCH9; 1992, INT STATISTICAL CLAS, pCH5; 1987, DIAGNOSTIC STATISTIC	44	115	116	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	1994	272	22					1782	1787		10.1001/jama.272.22.1782	http://dx.doi.org/10.1001/jama.272.22.1782			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV815	7966928				2022-12-28	WOS:A1994PV81500029
J	COLUCCIGUYON, E; PORTIER, MM; DUNIA, I; PAULIN, D; POURNIN, S; BABINET, C				COLUCCIGUYON, E; PORTIER, MM; DUNIA, I; PAULIN, D; POURNIN, S; BABINET, C			MICE LACKING VIMENTIN DEVELOP AND REPRODUCE WITHOUT AN OBVIOUS PHENOTYPE	CELL			English	Article							INTERMEDIATE FILAMENT PROTEIN; TRANSGENIC MICE; MOUSE EMBRYO; CELL-DIFFERENTIATION; MONOCLONAL-ANTIBODY; MESENCHYMAL CELLS; CULTURED-CELLS; GROWTH-FACTOR; EXPRESSION; CYTOKERATINS	To address the biological role of vimentin in the context of the living organism, we have introduced a null mutation of the vimentin gene into the germ line of mice. Surprisingly, animals homozygous for this mutation developed and reproduced without an obvious phenotype. Immunoblotting, immunofluorescence, and immunogold labeling analysis confirmed the absence of vimentin and of the corresponding filament network. Furthermore, no compensatory expression of another intermediate filament could be demonstrated. While these results leave open the question of the possible role of vimentin in unusual situations or pathological conditions, they show that a conspicuous developmental and cell-specific structure that is an integral part of the cytoskeleton can be eliminated without apparent effect on mouse reproduction and development.	BIOCHIM CELLULAIRE COLL FRANCE,F-75005 PARIS,FRANCE; UNIV PARIS 07,CNRS,INST JACQUES MONOD,F-75005 PARIS,FRANCE; INST PASTEUR,SERV CENT MICROSCOPIE ELECTR,F-75005 PARIS 15,FRANCE; UNIV PARIS 07,F-75005 PARIS 15,FRANCE	UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	COLUCCIGUYON, E (corresponding author), INST PASTEUR,UNITE GENET MAMMIFERES,CNRS,URA 361,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P901; BARIBAULT H, 1993, GENE DEV, V7, P1191, DOI 10.1101/gad.7.7a.1191; BENEDETTI EL, 1994, TREATISE CYTOSKELETO; BENZEEV A, 1984, J CELL BIOL, V99, P1424, DOI 10.1083/jcb.99.4.1424; BRADLEY A, 1987, TERATOCARCINOMAS EMB; Brookfield John, 1992, Current Biology, V2, P553, DOI 10.1016/0960-9822(92)90036-A; CAPETANAKI Y, 1990, ONCOGENE, V5, P645; CAPETANAKI Y, 1989, P NATL ACAD SCI USA, V86, P4882, DOI 10.1073/pnas.86.13.4882; CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHRISTIAN J L, 1990, New Biologist, V2, P700; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; COCHARD P, 1984, J NEUROSCI, V4, P2080; COHENTANNOUDJI M, 1992, MOL REPROD DEV, V33, P149, DOI 10.1002/mrd.1080330206; DELLAGI K, 1982, P NATL ACAD SCI-BIOL, V79, P446, DOI 10.1073/pnas.79.2.446; DELLAGI K, 1983, EMBO J, V2, P1509, DOI 10.1002/j.1460-2075.1983.tb01615.x; DELLAGI K, 1982, NATURE, V298, P284, DOI 10.1038/298284a0; DENT JA, 1989, DEVELOPMENT, V105, P61; DUNIA I, 1990, EUR J CELL BIOL, V53, P59; DUPOUEY P, 1985, DEV NEUROSCI-BASEL, V7, P81, DOI 10.1159/000112279; EDDE B, 1982, BIOCHIMIE, V64, P141, DOI 10.1016/S0300-9084(82)80416-1; FRANKE WW, 1979, EXP CELL RES, V123, P25, DOI 10.1016/0014-4827(79)90418-X; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HOULE J, 1983, DEV BRAIN RES, V9, P189, DOI 10.1016/0165-3806(83)90051-2; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLYMKOWSKY MW, 1981, NATURE, V291, P249, DOI 10.1038/291249a0; KLYMKOWSKY MW, 1992, P NATL ACAD SCI USA, V89, P8736, DOI 10.1073/pnas.89.18.8736; LANE EB, 1983, NATURE, V303, P701, DOI 10.1038/303701a0; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LIN JJC, 1981, CELL, V24, P185, DOI 10.1016/0092-8674(81)90514-6; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARKL J, 1989, EUR J CELL BIOL, V50, P1; MARKL J, 1991, J CELL SCI, V98, P261; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; NGAI J, 1987, MOL CELL BIOL, V7, P3955, DOI 10.1128/MCB.7.11.3955; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAULINLEVASSEUR M, 1988, EUR J CELL BIOL, V47, P121; PERREAU J, 1988, GENE, V62, P7, DOI 10.1016/0378-1119(88)90575-6; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; RAMAEKERS FCS, 1983, P NATL ACAD SCI-BIOL, V80, P2618, DOI 10.1073/pnas.80.9.2618; RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908; Robertson E. J., 1987, TERATOCARCINOMAS EMB; SARRIA AJ, 1992, J BIOL CHEM, V267, P19455; SCHULTHEISS T, 1991, J CELL BIOL, V114, P953, DOI 10.1083/jcb.114.5.953; SEJERSEN T, 1993, J CELL SCI, V106, P1291; SHEA TB, 1993, J NEUROSCI RES, V36, P66, DOI 10.1002/jnr.490360108; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; TORPEY N, 1992, NATURE, V357, P413, DOI 10.1038/357413a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WACKER IU, 1992, J CELL BIOL, V117, P813, DOI 10.1083/jcb.117.4.813; WEBER K, 1991, BIOCHEM SOC T, V19, P1021, DOI 10.1042/bst0191021; [No title captured]	62	479	488	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					679	694		10.1016/0092-8674(94)90553-3	http://dx.doi.org/10.1016/0092-8674(94)90553-3			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954832				2022-12-28	WOS:A1994PT48100015
J	GREY, AB; EVANS, MC; STAPLETON, JP; REID, IR				GREY, AB; EVANS, MC; STAPLETON, JP; REID, IR			BODY-WEIGHT AND BONE-MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH PRIMARY HYPERPARATHYROIDISM	ANNALS OF INTERNAL MEDICINE			English	Article						BODY WEIGHT; BONE DENSITY; HYPERPARATHYROIDISM; MENOPAUSE	CORTICAL BONE; PARATHYROIDECTOMY; ABSORPTIOMETRY	Objective: To assess bone mineral density and body composition in postmenopausal women with primary hyperparathyroidism. Design: Cross-sectional study with an age-matched control group. Setting: University teaching hospital. Patients: 41 postmenopausal women with mild primary hyperparathyroidism and 43 eucalcemic, age-matched controls. Measurements: Total body, lumbar spine, and proximal femoral (femoral neck, Ward's triangle, and trochanter) bone mineral density; body composition; and fat distribution were measured using dual-energy x-ray absorptiometry. Results: Women with primary hyperparathyroidism were heavier (75.5 kg compared with 66.3 kg; difference, 9.2 kg [95% Cl, 3.7 to 14.7 kg]; P = 0.002), had a higher fat mass (33.3 kg compared with 26.1 kg; difference, 7.2 kg [Cl, 3.0 to 11.4 kg]; P = 0.001), and had a more android pattern of fat distribution (android-to-gynoid fat ratio, 1.05 compared with 0.84; difference, 0.21 [Cl, 0.1 to 0.32]; P = 0.0004) than the controls. Unadjusted bone mineral density was similar in patients and controls at all sites: total body, 0.990 compared with 1.023 g/cm(2) (difference, 0.033; Cl, -0.004 to 0.070); posteroanterior lumbar spine, 1.032 compared with 1.018 g/cm(2) (difference, 0.014; Cl, -0.031 to 0.059); lateral lumbar spine, 0.569 compared with 0.528 g/cm(2) (difference, 0.041; Cl, -0.022 to 0.104); femoral neck, 0.799 compared with 0.825 g/cm(2) (difference, 0.026; Cl, -0.072 to 0.124); Ward's triangle, 0.653 compared with 0.677 g/cm(2) (difference, 0.024; Cl, -0.035 to 0.089); trochanter, 0.734 compared with 0.733 g/cm(2) (difference, 0.001; Cl, -0.024 to 0.026); and arms, 0.720 compared with 0.739 g/cm(2) (difference, 0.019; Cl, -0.015 to 0.053). After adjustment for body weight, bone mineral density in women with primary hyperparathyroidism was lower than that in controls for total body (P = 0.0004), femoral neck (P = 0.001), Ward's triangle (P = 0.01), trochanter (P = 0.02), and arms (P = 0.0006). Spinal bone mineral density did not differ between groups. Conclusions: Body weight, total body fat mass, and proportion of android fat are increased in postmenopausal women with primary hyperparathyroidism these unexplained factors may be relevant to the increased incidence of cardiovascular disease in this condition. Unadjusted bone mineral density values are similar in patients with primary hyperparathyroidism and in controls, suggesting that this condition is not associated with an increased risk for fracture.	UNIV AUCKLAND, DEPT MED, AUCKLAND 1, NEW ZEALAND	University of Auckland								HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; HESP R, 1987, BONE MINER, V2, P301; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; LEY CJ, 1992, AM J CLIN NUTR, V55, P950, DOI 10.1093/ajcn/55.5.950; MARTIN P, 1986, ARCH INTERN MED, V146, P689, DOI 10.1001/archinte.146.4.689; MAUTALEN C, 1986, ACTA ENDOCRINOL-COP, V111, P494, DOI 10.1530/acta.0.1110494; MAZESS RB, 1987, BONE MINER, V2, P211; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; MELTON LJ, 1991, J BONE MINER RES, V6, P1020; MITLAK B H, 1991, Journal of Bone and Mineral Research, V6, pS103; MOLE PA, 1992, BRIT J SURG, V79, P263, DOI 10.1002/bjs.1800790327; PARFITT A M, 1991, Journal of Bone and Mineral Research, V6, pS97; PARISIEN M, 1990, J CLIN ENDOCR METAB, V70, P930, DOI 10.1210/jcem-70-4-930; PFEILSCHIFTER J, 1992, ACTA ENDOCRINOL-COP, V127, P319, DOI 10.1530/acta.0.1270319; POTTS JT, 1991, ANN INTERN MED, V114, P593, DOI 10.7326/0003-4819-114-7-593; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; RICHARDSON ML, 1986, SKELETAL RADIOL, V15, P85, DOI 10.1007/BF00350200; SEEMAN E, 1982, J CLIN INVEST, V69, P1302, DOI 10.1172/JCI110570; SILVERBERG SJ, 1989, J BONE MINER RES, V4, P283, DOI 10.1002/jbmr.5650040302; STEVENSON JC, 1988, BRIT MED J, V296, P1016, DOI 10.1136/bmj.296.6628.1016-a; WARNER J, 1991, Journal of Bone and Mineral Research, V6, pS91; WISHART J, 1990, ARCH INTERN MED, V150, P1329, DOI 10.1001/archinte.150.6.1329	22	82	82	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					745	749		10.7326/0003-4819-121-10-199411150-00003	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944051				2022-12-28	WOS:A1994PQ92800003
J	ADAMI, HO; HSIEH, CC; LAMBE, M; TRICHOPOULOS, D; LEON, D; PERSSON, I; EKBOM, A; JANSON, PO				ADAMI, HO; HSIEH, CC; LAMBE, M; TRICHOPOULOS, D; LEON, D; PERSSON, I; EKBOM, A; JANSON, PO			PARITY, AGE AT FIRST CHILDBIRTH, AND RISK OF OVARIAN-CANCER	LANCET			English	Article							STATES CASE-CONTROL; EUROPEAN CASE-CONTROL; COLLABORATIVE ANALYSIS; POOLED ANALYSIS; WHITE WOMEN; PATHOGENESIS; DETERMINANTS	Increasing parity is associated with a reduction in the risk of ovarian cancer, but it is not clear whether this association applies to different histopathological types and to borderline tumours. Moreover, the temporal relations are poorly understood, and the possible role of age at first birth remains unequivocal. We have investigated these issues in a case-control study nested in a nationwide cohort of women born between 1925 and 1960 in Sweden. During follow-up until 1984, 3486 invasive ovarian cancers (2992 epithelial, 330 stromal, 149 germ-cell, 15 not classifiable) and 510 tumours of borderline malignant were diagnosed. 5 individually age-matched (total 19 980) were selected for each case woman. After simultaneous adjustment for parity and age at first birth, increasing parity was associated with a pronounced consistent decrease in relative risk of all invasive cancers (odds ratio for each additional birth 0.81 [95% Cl 0.77-0.85]), epithelial cancer (0.81 [0.77-0.86]), stromal cancer (0.84 [0.72-0.98]), and germ-cell cancer (0.71 [0.48-1.05]), but a less consistent decrease for borderline tumours (0.92 [0.81-1.04]). The risk of ovarian cancer decreased by about 10% for each 5-year increment in age at first childbirth (odds ratios 0.89 [0.84-0.94] epithelial cancer, 0.92 [0.77-1.10] stromal cancer, 0.92 [0.65-1.32] germ-cell cancer, 0.93 [0.80-1.09] borderline tumours). Because our findings cannot be readily explained by theories invoking incessant ovulation or high serum concentrations of gonadotropins, new aetiological hypotheses are needed. Pregnancy-dependent clearance from the ovaries of cells that have undergone malignant transformation could explain the reproductive risk factors for ovarian cancer.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; UNIV UPPSALA HOSP, DEPT SOCIAL MED, S-75185 UPPSALA, SWEDEN; LONDON SCH HYG & TROP MED, LONDON WC1, ENGLAND; SAHLGRENS UNIV HOSP, DEPT OBSTET & GYNECOL, GOTHENBURG, SWEDEN	Harvard University; Harvard T.H. Chan School of Public Health; Uppsala University; Uppsala University Hospital; University of London; London School of Hygiene & Tropical Medicine; Sahlgrenska University Hospital	ADAMI, HO (corresponding author), UNIV UPPSALA HOSP, DEPT CANC EPIDEMIOL, S-75185 UPPSALA, SWEDEN.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762; Lambe, Mats/0000-0002-4624-3767				CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; FATHALLA MF, 1971, LANCET, V2, P163; FRANCESCHI S, 1991, INT J CANCER, V49, P57, DOI 10.1002/ijc.2910490111; FRANCESCHI S, 1991, INT J CANCER, V49, P61, DOI 10.1002/ijc.2910490112; GRANAI CO, 1992, NEW ENGL J MED, V327, P197, DOI 10.1056/NEJM199207163270313; HAMILTON TC, 1992, CURR PROB CANCER, V16, P5, DOI 10.1016/0147-0272(92)90047-R; HANKINSON SE, 1993, JAMA-J AM MED ASSOC, V270, P2813, DOI 10.1001/jama.270.23.2813; HARRIS R, 1992, AM J EPIDEMIOL, V136, P1204, DOI 10.1093/oxfordjournals.aje.a116428; HORNROSS PL, 1992, EPIDEMIOLOGY, V3, P490, DOI 10.1097/00001648-199211000-00005; JOHANSSON L, 1983, 14 STAT SWED URV; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; MALIK S, 1991, BRIT J CANCER, V64, P617, DOI 10.1038/bjc.1991.372; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; MORELY JE, 1992, ENDOCRINOL METAB, P322; MUSEY VC, 1987, NEW ENGL J MED, V316, P229, DOI 10.1056/NEJM198701293160501; NEGRI E, 1991, INT J CANCER, V49, P50, DOI 10.1002/ijc.2910490110; Ryan K J, 1980, MATERNAL FETAL ENDOC, P3; Stadel B V, 1975, Am J Obstet Gynecol, V123, P772; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; Walker AM, 1991, OBSERVATION INFERENC; Whelan SL, 1990, IARC SCI PUBLICATION; WHITTEMORE AS, 1989, CANCER RES, V49, P4047; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1175, DOI 10.1093/oxfordjournals.aje.a116426; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1212, DOI 10.1093/oxfordjournals.aje.a116429; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WILLEMSEN W, 1993, LANCET, V341, P986, DOI 10.1016/0140-6736(93)91071-S; [No title captured]; 1990, SOS1989 NAT BOARD HL, P19; 1962, CENSUS POPULATION 19, V4	30	252	258	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	1994	344	8932					1250	1254		10.1016/S0140-6736(94)90749-8	http://dx.doi.org/10.1016/S0140-6736(94)90749-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967985				2022-12-28	WOS:A1994PP70100007
J	MCCORMICK, J				MCCORMICK, J			ESCHEWING THE PREDICTABLE	LANCET			English	Editorial Material											MCCORMICK, J (corresponding author), ST JAMES HOSP,TRINITY CTR,DEPT COMMUNITY HLTH & GEN PRACTICE,DUBLIN 8,IRELAND.							FEINSTEIN AR, 1994, ANN INTERN MED, V120, P799, DOI 10.7326/0003-4819-120-9-199405010-00012; MCCORMACK J, 1994, BRIT J GEN PRACT, V44, P50; ROBERTS I, 1994, NEW ZEAL MED J, V107, P331	3	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1243	1244		10.1016/S0140-6736(94)90746-3	http://dx.doi.org/10.1016/S0140-6736(94)90746-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967982				2022-12-28	WOS:A1994PP70100004
J	ASTROM, SU; BYSTROM, AS				ASTROM, SU; BYSTROM, AS			RIT1, A TRANSFER-RNA BACKBONE-MODIFYING ENZYME THAT MEDIATES INITIATOR AND ELONGATOR TRANSFER-RNA DISCRIMINATION	CELL			English	Article							TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SHUTTLE VECTORS; YEAST; DNA; SEQUENCES; GENE; TRANSFORMATION; TRANSLATION	Using a genetic screen in yeast aimed at identifying cellular factors involved in initiator and elongator methionine tRNA discrimination in the translational process, we have identified a mutation that abolish the requirement for elongator methionine tRNA. The gene affected, which we call the ribosylation of the initiator tRNA gene or RIT1, encodes a 2'-O-ribosyl phosphate transferase. This enzyme modifies exclusively the initiator tRNA in position 64 using 5-phosphoribosyl-1'-pyrophosphate as the modification donor. As the initiator tRNA participates both in the initiation and elongation of translation in a rit1 strain, we conclude that the 2'-O-ribosyl phosphate modification discriminates the initiator tRNAs from the elongator tRNAs during protein synthesis. The modification enzyme was shown to recognize the stem-loop IV region that is unique in eukaryotic cytoplasmic initiator tRNAs.			ASTROM, SU (corresponding author), UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN.			Astrom, Stefan/0000-0001-7721-6908; Bystrom, Anders/0000-0003-1281-3888				ASTROM SU, 1993, J MOL BIOL, V233, P43, DOI 10.1006/jmbi.1993.1483; BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BYSTROM AS, 1993, TRANSLATIONAL APPARA; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHAPMAN KB, 1992, P NATL ACAD SCI USA, V89, P3236, DOI 10.1073/pnas.89.8.3236; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; DESGRES J, 1989, NUCLEIC ACIDS RES, V17, P865, DOI 10.1093/nar/17.3.865; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDQVIST J, 1992, NUCLEIC ACIDS RES, V20, P6575, DOI 10.1093/nar/20.24.6575; FINNEGAN PM, 1991, CURR GENET, V20, P53, DOI 10.1007/BF00312765; FORSTER C, 1993, NUCLEIC ACIDS RES, V21, P5679; GEHRKE CW, 1982, J CHROMATOGR, V230, P297, DOI 10.1016/S0378-4347(00)80479-X; GEHRKE CW, 1990, CHROMATOGRAPHY MODIF, P3; GLASSER AL, 1991, NUCLEIC ACIDS RES, V19, P5199, DOI 10.1093/nar/19.19.5199; GORANSSON M, 1989, MOL MICROBIOL, V3, P1557, DOI 10.1111/j.1365-2958.1989.tb00141.x; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; HOUSMAN D, 1970, NATURE, V227, P913, DOI 10.1038/227913a0; JANIAK F, 1990, BIOCHEMISTRY-US, V29, P4268, DOI 10.1021/bi00470a002; Jensen KF, 1983, METABOLISM NUCLEOTID, P1; JOSHI RL, 1986, EMBO J, V5, P1143, DOI 10.1002/j.1460-2075.1986.tb04339.x; KIESEWETTER S, 1990, NUCLEIC ACIDS RES, V18, P4677, DOI 10.1093/nar/18.16.4677; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOZAK M, 1983, MICROBIOL REV, V47, P1; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; Miller J.H., 1972, EXPT MOL GENETICS; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Nishimura S., 1979, TRANSFER RNA STRUCTU, P551; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; RAJBHANDRAY UL, 1994, J BACTERIOL, V1766, P547; Rose MD., 1990, METHODS YEAST GENETI; SAFER B, 1975, J BIOL CHEM, V250, P9076; Sambrook J, 1989, MOL CLONING LABORATO; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHWARTZ M, 1975, J BACTERIOL, V121, P814, DOI 10.1128/JB.121.3.814-822.1975; SIKORSKI RS, 1989, GENETICS, V122, P19; Silberklang M, 1979, Methods Enzymol, V59, P58; SMITH AE, 1968, J MOL BIOL, V38, P241, DOI 10.1016/0022-2836(68)90409-9; SMITH AE, 1970, NATURE, V226, P607, DOI 10.1038/226607a0; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; SUNDARI RM, 1976, J BIOL CHEM, V251, P3338; VONPAWELRAMMINGEN U, 1992, MOL CELL BIOL, V12, P1432, DOI 10.1128/MCB.12.4.1432; YOSHIDA M, 1994, YEAST, V10, P371, DOI 10.1002/yea.320100309	51	58	60	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					535	546		10.1016/0092-8674(94)90262-3	http://dx.doi.org/10.1016/0092-8674(94)90262-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954819				2022-12-28	WOS:A1994PQ48800016
J	MENARD, R; SANSONETTI, P; PARSOT, C; VASSELON, T				MENARD, R; SANSONETTI, P; PARSOT, C; VASSELON, T			EXTRACELLULAR ASSOCIATION AND CYTOPLASMIC PARTITIONING OF THE IPAB AND IPAC INVASINS OF SHIGELLA-FLEXNERI	CELL			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; YERSINIA YOP PROTEINS; B-CELL EPITOPES; SHIGELLA-FLEXNERI; EPITHELIAL-CELLS; SALMONELLA-TYPHIMURIUM; SIGNAL-TRANSDUCTION; NUCLEOTIDE-SEQUENCE; PLASMID ANTIGENS; HELA-CELLS	Shigella species cause bacillary dysentery in humans by invading colonic epithelial cells. IpaB and IpaC, two major invasins of these pathogens, are secreted into the extracellular milieu. We show here that IpaB and IpaC form a complex in the extracellular medium and that each binds independently to a 17 kDa polypeptide, IpgC, in the bacterial cytoplasm. The IpgC polypeptide was found to be necessary for bacterial entry into epithelial cells, to stabilize the otherwise unstable IpaB protein, and to prevent the proteolytic degradation of IpaC that occurs through its association with unprotected IpaB. We propose that IpgC, which is not secreted and thus acts as a molecular chaperone, serves as a receptor that prevents premature oligomerization of IpaB and IpaC within the cytoplasm of Shigella cells.	INST PASTEUR, UNITE PATHOGENIE MICROBIENNE MOLEC, F-75724 PARIS 15, FRANCE; INST PASTEUR, INSERM, U389, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ADLER B, 1989, MOL MICROBIOL, V3, P627, DOI 10.1111/j.1365-2958.1989.tb00210.x; ALLAOUI A, 1992, J BACTERIOL, V174, P7661, DOI 10.1128/JB.174.23.7661-7669.1992; ALLAOUI A, 1992, MOL MICROBIOL, V6, P1605, DOI 10.1111/j.1365-2958.1992.tb00885.x; ALLAOUI A, 1993, MOL MICROBIOL, V7, P59, DOI 10.1111/j.1365-2958.1993.tb01097.x; ANDREWS GP, 1991, INFECT IMMUN, V59, P1997, DOI 10.1128/IAI.59.6.1997-2005.1991; BARZU S, 1993, INFECT IMMUN, V61, P3825, DOI 10.1128/IAI.61.9.3825-3831.1993; BAUDRY B, 1988, MICROB PATHOGENESIS, V4, P345, DOI 10.1016/0882-4010(88)90062-9; BERGMAN T, 1991, J BACTERIOL, V173, P1607, DOI 10.1128/jb.173.5.1607-1616.1991; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; DONNENBERG MS, 1992, INFECT IMMUN, V60, P3953, DOI 10.1128/IAI.60.10.3953-3961.1992; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GROISMAN EA, 1993, EMBO J, V12, P3779, DOI 10.1002/j.1460-2075.1993.tb06056.x; HAKANSSON S, 1993, INFECT IMMUN, V61, P71; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAURELLI AT, 1985, INFECT IMMUN, V49, P164, DOI 10.1128/IAI.49.1.164-171.1985; MENARD R, 1993, J BACTERIOL, V175, P5899; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; NEU HC, 1965, J BIOL CHEM, V240, P3685; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PHALIPON A, 1992, INFECT IMMUN, V60, P1919, DOI 10.1128/IAI.60.5.1919-1926.1992; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; SAKAI T, 1988, MOL MICROBIOL, V2, P589, DOI 10.1111/j.1365-2958.1988.tb00067.x; SANSONETTI PJ, 1982, INFECT IMMUN, V35, P852, DOI 10.1128/IAI.35.3.852-860.1982; SASAKAWA C, 1993, J BACTERIOL, V175, P2334, DOI 10.1128/JB.175.8.2334-2346.1993; SASAKAWA C, 1989, MOL MICROBIOL, V3, P1191, DOI 10.1111/j.1365-2958.1989.tb00269.x; SASAKAWA C, 1988, J BACTERIOL, V170, P2480, DOI 10.1128/jb.170.6.2480-2484.1988; SERENY B., 1957, ACTA MICROBIOL ACAD SCI HUNGARICAE, V4, P367; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; VENKATESAN MM, 1992, J BACTERIOL, V174, P1990, DOI 10.1128/jb.174.6.1990-2001.1992; WATTIAU P, 1993, MOL MICROBIOL, V8, P123, DOI 10.1111/j.1365-2958.1993.tb01209.x; YANG YX, 1993, INFECT IMMUN, V61, P3907, DOI 10.1128/IAI.61.9.3907-3913.1993	50	248	253	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					515	525		10.1016/0092-8674(94)90260-7	http://dx.doi.org/10.1016/0092-8674(94)90260-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954817				2022-12-28	WOS:A1994PQ48800014
J	SHIMKETS, RA; WARNOCK, DG; BOSITIS, CM; NELSONWILLIAMS, C; HANSSON, JH; SCHAMBELAN, M; GILL, JR; ULICK, S; MILORA, RV; FINDLING, JW; CANESSA, CM; ROSSIER, BC; LIFTON, RP				SHIMKETS, RA; WARNOCK, DG; BOSITIS, CM; NELSONWILLIAMS, C; HANSSON, JH; SCHAMBELAN, M; GILL, JR; ULICK, S; MILORA, RV; FINDLING, JW; CANESSA, CM; ROSSIER, BC; LIFTON, RP			LIDDLES SYNDROME - HERITABLE HUMAN HYPERTENSION CAUSED BY MUTATIONS IN THE BETA-SUBUNIT OF THE EPITHELIAL SODIUM-CHANNEL	CELL			English	Article							ALDOSTERONE SYNTHASE; GENE; DNA; LINKAGE; CELLS	Liddle's syndrome (pseudoaldosteronism) is an autosomal dominant form of human hypertension characterized by a constellation of findings suggesting constitutive activation of the amiloride-sensitive distal renal epithelial sodium channel. We demonstrate complete linkage of the gene encoding the beta subunit of the epithelial sodium channel to Liddle's syndrome in Liddle's original kindred. Analysis of this gene reveals a premature stop codon that truncates the cytoplasmic carboxyl terminus of the encoded protein in affected subjects. Analysis of subjects with Liddle's syndrome from four additional kindreds demonstrates either premature termination or frameshift mutations in this same carboxy-terminal domain in all four. These findings demonstrate that Liddle's syndrome is caused by mutations in the beta subunit of the epithelial sodium channel and have implications for the regulation of this epithelial ion channel as well as blood pressure homeostasis.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,DEPT MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT GENET,NEW HAVEN,CT 06510; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; VET AFFAIRS MED CTR,BIRMINGHAM,AL 35294; SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94110; NHLBI,HYPERTENS ENDOCRINE BRANCH,BETHESDA,MD 20892; VET AFFAIRS HOSP,BRONX,NY 10468; CAPITAL DIST RENAL PHYSICIANS,ALBANY,NY 12208; MED COLL WISCONSIN,ST LUKES MED CTR,MILWAUKEE,WI 53215; UNIV LAUSANNE,INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND	Howard Hughes Medical Institute; Yale University; Yale University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Medical College of Wisconsin; University of Lausanne								BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; BUBIEN JK, 1993, AM J PHYSIOL, V265, pC1175, DOI 10.1152/ajpcell.1993.265.4.C1175; BUBIEN JK, 1994, J BIOL CHEM, V269, P17780; CANESSA C, 1994, IN PRESS AM J PHYSL; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; EVANS GA, 1987, METHOD ENZYMOL, V152, P604; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; GARDNER JD, 1971, J CLIN INVEST, V50, P2253, DOI 10.1172/JCI106722; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KUHNLE U, 1990, J CLIN ENDOCR METAB, V70, P638, DOI 10.1210/jcem-70-3-638; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; LIFTON RP, 1993, J HYPERTENS, V11, P231, DOI 10.1097/00004872-199303000-00002; LIFTON RP, 1992, NAT GENET, V2, P66, DOI 10.1038/ng0992-66; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; RENARD S, 1994, J BIOL CHEM, V269, P12981; ROTIN D, 1994, IN PRESS EMBO J; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WARD R, 1990, HYPERTENSION PATHOPH, P81	29	1084	1101	1	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					407	414		10.1016/0092-8674(94)90250-X	http://dx.doi.org/10.1016/0092-8674(94)90250-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954808				2022-12-28	WOS:A1994PQ48800004
J	HENDERSON, WR				HENDERSON, WR			THE ROLE OF LEUKOTRIENES IN INFLAMMATION	ANNALS OF INTERNAL MEDICINE			English	Review							BRONCHOALVEOLAR LAVAGE FLUID; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; ACTIVE 5-LIPOXYGENASE INHIBITOR; RESPIRATORY-DISTRESS SYNDROME; RECEPTOR ANTAGONIST SC-41930; ARACHIDONIC-ACID METABOLISM; INTERFERON-GAMMA PRODUCTION; HUMAN ALVEOLAR MACROPHAGE; HUMAN INTRALOBAR AIRWAYS; SLOW-REACTING SUBSTANCE	Objective: To review the biochemistry and biological activities of leukotrienes, focusing on their role in the mediation of inflammatory diseases. Data Sources: MEDLINE (1966-1994), EMBASE (Excerpta Medica; 1974-1994), and other biomedical and drug directory databases (such as Pharmaprojects and IMSworld R&D Focus [1991-1994]) were searched to identify English-language articles (basic science, clinical trial research, and review articles) and abstracts of conference proceedings on leukotrienes and related terms. Study Selection: Basic science studies on leukotrienes and clinical research studies on the use of leukotriene inhibitors and antagonists in the treatment of inflammatory diseases such as asthma, psoriasis, rheumatoid arthritis, and ulcerative colitis. Data Extraction: Detailed summaries of data from basic science studies on the formation and actions of leukotrienes and from clinical studies of drugs that block the synthesis or receptor-mediated actions of leukotrienes. Data Synthesis: Leukotrienes are biologically active 5-lipoxygenase products of arachidonic acid metabolism that are involved in the mediation of various inflammatory disorders. Of these, leukotriene B-4 (a potent chemoattractant for leukocytes) and the sulfidopeptide leukotrienes C-4, D-4, and E(4) (which increase vascular permeability and constrict smooth muscle) exert their biological actions through specific ligand-receptor interactions. Selective leukotriene inhibitors and receptor antagonists are currently under evaluation in the treatment of Various inflammatory diseases. Conclusions: Further data on the in vitro and in vivo activities of the leukotriene inhibitors and antagonists should clarify the role of leukotrienes in the pathogenesis of such inflammatory diseases as asthma, rheumatoid arthritis, and inflammatory bowel disease. Leukotriene inhibitors and antagonists will probably become important agents in the group of anti-inflammatory drugs.			HENDERSON, WR (corresponding author), UNIV WASHINGTON, SCH MED, DEPT MED, SJ-10, SEATTLE, WA 98195 USA.				NHLBI NIH HHS [HL30542] Funding Source: Medline; NIAID NIH HHS [AI17758, AI34578] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034578, R01AI017758] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHARONY D, 1989, NEW TRENDS LIPID MED, P67; AHMADZADEH N, 1991, INFLAMMATION, V15, P497, DOI 10.1007/BF00923346; ALI A, 1993, FEBS LETT, V317, P195, DOI 10.1016/0014-5793(93)81275-5; ANDERSON G, 1988, BRIT J PHARMACOL, V94, P1115, DOI 10.1111/j.1476-5381.1988.tb11629.x; ANDERSON ME, 1982, P NATL ACAD SCI-BIOL, V79, P1088, DOI 10.1073/pnas.79.4.1088; ANTONELLI M, 1989, INTENS CARE MED, V15, P296, DOI 10.1007/BF00263864; ASHIDA Y, 1983, PROSTAGLANDINS, V26, P955, DOI 10.1016/0090-6980(83)90157-0; AUGSTEIN J, 1973, NATURE-NEW BIOL, V245, P215, DOI 10.1038/newbio245215a0; BACH MK, 1982, PROSTAGLANDINS, V23, P759; BADR KF, 1984, CIRC RES, V54, P492, DOI 10.1161/01.RES.54.5.492; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BASS DA, 1981, BIOCHEM BIOPH RES CO, V100, P1, DOI 10.1016/S0006-291X(81)80054-X; BAUD L, 1987, J IMMUNOL, V138, P1190; BAUD L, 1985, J CLIN INVEST, V76, P374, DOI 10.1172/JCI111972; BELCH JJF, 1989, SCAND J RHEUMATOL, V18, P213, DOI 10.3109/03009748909099931; BELL RL, 1993, AGENTS ACTIONS, V38, P178, DOI 10.1007/BF01976209; BELL RL, 1993, J LIPID MEDIATOR, V6, P259; BERNARD GR, 1991, AM REV RESPIR DIS, V144, P263, DOI 10.1164/ajrccm/144.2.263; BJORK J, 1982, INFLAMMATION, V6, P189, DOI 10.1007/BF00916243; BLACK AK, 1990, J INVEST DERMATOL, V95, P50, DOI 10.1111/1523-1747.ep12873300; BOKOCH GM, 1981, J BIOL CHEM, V256, P4156; BOMALASKI JS, 1987, PROSTAGLANDINS, V33, P855, DOI 10.1016/0090-6980(87)90114-6; BORGEAT P, 1979, J BIOL CHEM, V254, P2643; BRACH MA, 1992, EUR J IMMUNOL, V22, P2705, DOI 10.1002/eji.1830221034; BRAIN SD, 1982, LANCET, V2, P762; BRESNAHAN BA, 1992, J CLIN INVEST, V90, P2304, DOI 10.1172/JCI116118; BUCKNER CK, 1986, J PHARMACOL EXP THER, V237, P558; BUCKNER CK, 1988, ANN NY ACAD SCI, V524, P181, DOI 10.1111/j.1749-6632.1988.tb38540.x; CAMP R, 1984, J INVEST DERMATOL, V82, P202, DOI 10.1111/1523-1747.ep12259945; CAMP RDR, 1983, BRIT J PHARMACOL, V80, P497, DOI 10.1111/j.1476-5381.1983.tb10721.x; CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; CLAESSON HE, 1985, BIOCHEM BIOPH RES CO, V131, P579, DOI 10.1016/0006-291X(85)91276-8; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; COLES SJ, 1983, PROSTAGLANDINS, V25, P155, DOI 10.1016/0090-6980(83)90101-6; COLLAWN C, 1992, AM J GASTROENTEROL, V87, P342; COREY EJ, 1982, J AM CHEM SOC, V104, P1752, DOI 10.1021/ja00370a058; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; CROMWELL O, 1981, LANCET, V2, P164; DAHINDEN CA, 1985, P NATL ACAD SCI USA, V82, P6632, DOI 10.1073/pnas.82.19.6632; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DAVIDSON EM, 1983, ANN RHEUM DIS, V42, P677, DOI 10.1136/ard.42.6.677; DEGREEF H, 1990, J AM ACAD DERMATOL, V22, P751, DOI 10.1016/0190-9622(90)70103-O; DEJONG EMGJ, 1991, SKIN PHARMACOL, V4, P278; DIAS VC, 1992, GUT, V33, P622, DOI 10.1136/gut.33.5.622; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DOWD PM, 1985, ACTA DERM-VENEREOL, P18; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; ELMGREEN J, 1989, ANN RHEUM DIS, V48, P134, DOI 10.1136/ard.48.2.134; FAULER J, 1992, J INVEST DERMATOL, V99, P8, DOI 10.1111/1523-1747.ep12611380; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FELS AOS, 1982, P NATL ACAD SCI-BIOL, V79, P7866, DOI 10.1073/pnas.79.24.7866; FERRERI NR, 1986, J IMMUNOL, V136, P4188; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; FITZPATRICK F, 1984, J BIOL CHEM, V259, P1403; FOGH K, 1989, J INVEST DERMATOL, V92, P837, DOI 10.1111/1523-1747.ep12696858; FORDHUTCHINSON AW, 1993, SPRINGER SEMIN IMMUN, V15, P37; FRETLAND DJ, 1993, INFLAMMATION, V17, P353, DOI 10.1007/BF00918996; FRETLAND DJ, 1990, J PHARMACOL EXP THER, V255, P572; FRIEDMAN BS, 1993, AM REV RESPIR DIS, V147, P839, DOI 10.1164/ajrccm/147.4.839; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GOETZE AM, 1985, PROSTAGLANDINS, V29, P689, DOI 10.1016/0090-6980(85)90130-3; GOETZL EJ, 1979, J EXP MED, V150, P406, DOI 10.1084/jem.150.2.406; GOLDMAN DW, 1982, J IMMUNOL, V129, P1600; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; GOLDMAN G, 1992, SURGERY, V112, P578; GOLDYNE ME, 1984, J BIOL CHEM, V259, P8815; GONZALEZBURITICA H, 1989, ANN RHEUM DIS, V48, P267, DOI 10.1136/ard.48.4.267; GRIMES D, 1993, EUR J PHARMACOL, V236, P217, DOI 10.1016/0014-2999(93)90592-6; HACKSHAW KV, 1992, J RHEUMATOL, V19, P252; HAMBERG M, 1976, BIOCHIM BIOPHYS ACTA, V431, P651, DOI 10.1016/0005-2760(76)90232-0; HAND JM, 1989, INT ARCH ALLER A IMM, V89, P78, DOI 10.1159/000234927; HATZELMANN A, 1993, BIOCHEM PHARMACOL, V45, P101, DOI 10.1016/0006-2952(93)90382-7; HAWTHORNE AB, 1992, GUT, V33, P513, DOI 10.1136/gut.33.4.513; HAY DWP, 1987, J PHARMACOL EXP THER, V243, P474; HEDQVIST P, 1980, ACTA PHYSIOL SCAND, V110, P331, DOI 10.1111/j.1748-1716.1980.tb06676.x; HENDERSON WR, 1982, J IMMUNOL, V128, P2609; HENDERSON WR, 1991, AM REV RESPIR DIS, V143, pS86, DOI 10.1164/ajrccm/143.5_Pt_2.S86; HENDERSON WR, 1983, J BIOL CHEM, V258, P3522; HENDERSON WR, 1984, IMMUNOLOGY, V51, P679; HENDERSON WR, 1985, DRUGS AFFECTING LEUK, P339; HIGGS GA, 1979, BIOCHEM PHARMACOL, V28, P1959, DOI 10.1016/0006-2952(79)90651-8; HOGABOOM GK, 1986, MOL PHARMACOL, V30, P510; HOGABOOM GK, 1983, BIOCHEM BIOPH RES CO, V116, P1136, DOI 10.1016/S0006-291X(83)80261-7; HONN KV, 1982, FEBS LETT, V139, P65, DOI 10.1016/0014-5793(82)80488-2; HOOVER RL, 1984, P NATL ACAD SCI-BIOL, V81, P2191, DOI 10.1073/pnas.81.7.2191; HOWARTH PH, 1994, J ALLERGY CLIN IMMUN, V93, P297; HUI KP, 1991, AM REV RESPIR DIS, V143, P1015, DOI 10.1164/ajrccm/143.5_Pt_1.1015; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; JACKSON WT, 1993, J MED CHEM, V36, P1726, DOI 10.1021/jm00064a006; JAKOBSSON PJ, 1991, BIOCHEM BIOPH RES CO, V178, P302, DOI 10.1016/0006-291X(91)91814-S; JOHNSON HG, 1983, PROSTAGLANDINS, V25, P237, DOI 10.1016/0090-6980(83)90107-7; JOHNSON HM, 1986, J IMMUNOL, V137, P3053; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; JORG A, 1982, J EXP MED, V155, P390, DOI 10.1084/jem.155.2.390; JORIS I, 1987, AM J PATHOL, V126, P19; KATOH T, 1993, J CLIN INVEST, V91, P1507, DOI 10.1172/JCI116356; KISHIKAWA K, 1992, PROSTAGLANDINS, V44, P261, DOI 10.1016/0090-6980(92)90002-B; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; KONSTAN MW, 1993, AM REV RESPIR DIS, V148, P896, DOI 10.1164/ajrccm/148.4_Pt_1.896; KONSTAN MW, 1990, PEDIATR PULMONOL S5, V9, P273; KOSHIHARA Y, 1988, PROSTAG LEUKOTR ESS, V32, P113; KOSHISHARA Y, 1982, FEBS LETT, V143, P13, DOI 10.1016/0014-5793(82)80262-7; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LAURITSEN K, 1986, GASTROENTEROLOGY, V91, P837, DOI 10.1016/0016-5085(86)90684-0; LAURITSEN K, 1988, GASTROENTEROLOGY, V95, P11, DOI 10.1016/0016-5085(88)90284-3; LEBLANC Y, 1987, PROSTAGLANDINS, V33, P617, DOI 10.1016/0090-6980(87)90029-3; LEFKOWITH JB, 1992, J AM SOC NEPHROL, V2, P1560; LEHMAN PA, 1990, PROSTAGLANDINS, V39, P569, DOI 10.1016/0090-6980(90)90038-W; LEVINE JD, 1984, SCIENCE, V225, P743, DOI 10.1126/science.6087456; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P494; LIANOS EA, 1988, J CLIN INVEST, V82, P427, DOI 10.1172/JCI113615; LIN AH, 1984, PROSTAGLANDINS, V28, P837, DOI 10.1016/0090-6980(84)90038-8; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MARDER P, 1992, PROSTAG LEUKOTR ESS, V46, P265, DOI 10.1016/0952-3278(92)90033-F; MARGOLSKEE D, 1991, Journal of Allergy and Clinical Immunology, V87, P309, DOI 10.1016/0091-6749(91)91959-W; MARGOLSKEE D, 1992, 8TH INT C PROST REL, P163; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MARTIN TR, 1989, J CLIN INVEST, V84, P1609, DOI 10.1172/JCI114338; MARTIN TR, 1987, J CLIN INVEST, V80, P1114, DOI 10.1172/JCI113168; MARTIN TR, 1984, AM REV RESPIR DIS, V129, P106; MATHEWS WR, 1982, BIOCHEM PHARMACOL, V31, P2129, DOI 10.1016/0006-2952(82)90435-X; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MATTHAY MA, 1984, J CLIN IMMUNOL, V4, P479, DOI 10.1007/BF00916578; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MCGEE JE, 1986, P NATL ACAD SCI USA, V83, P1349, DOI 10.1073/pnas.83.5.1349; MCMILLAN RM, 1992, BRIT J PHARMACOL, V107, P1042, DOI 10.1111/j.1476-5381.1992.tb13404.x; MICHELASSI F, 1982, SCIENCE, V217, P841, DOI 10.1126/science.6808665; MILLER AM, 1986, EXP HEMATOL, V14, P760; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; MUSSER JH, 1992, J MED CHEM, V35, P2501, DOI 10.1021/jm00092a001; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NAGAI H, 1992, PROSTAG LEUKOTR ESS, V47, P51, DOI 10.1016/0952-3278(92)90185-L; NAKAI H, 1988, J MED CHEM, V31, P84, DOI 10.1021/jm00396a013; NG CF, 1991, J IMMUNOL, V147, P3096; NICHOLSON DW, 1992, EUR J BIOCHEM, V209, P725, DOI 10.1111/j.1432-1033.1992.tb17341.x; PALMBLAD JEW, 1992, CLIN EXP IMMUNOL, V90, P300; PALMER RMJ, 1980, PROSTAGLANDINS, V20, P411, DOI 10.1016/S0090-6980(80)80058-X; PEATFIELD AC, 1982, BRIT J PHARMACOL, V77, P391, DOI 10.1111/j.1476-5381.1982.tb09310.x; PECK MJ, 1981, PROSTAGLANDINS, V21, P315, DOI 10.1016/0090-6980(81)90149-0; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; PESKAR BM, 1986, AGENTS ACTIONS, V18, P381, DOI 10.1007/BF01965001; PHILLIPS GD, 1988, J PHARMACOL EXP THER, V246, P732; PICADO C, 1992, AM REV RESPIR DIS, V145, P65, DOI 10.1164/ajrccm/145.1.65; PONG SS, 1983, J BIOL CHEM, V258, P9616; PRASIT P, 1993, J LIPID MEDIATOR, V6, P239; RADMARK O, 1984, J BIOL CHEM, V259, P2339; RAHMAN MA, 1988, J CLIN INVEST, V81, P1945, DOI 10.1172/JCI113542; RANKIN JA, 1989, J CLIN INVEST, V83, P1691, DOI 10.1172/JCI114069; REID GK, 1990, J BIOL CHEM, V265, P19818; RICHARDS IM, 1989, AM REV RESPIR DIS, V140, P1712, DOI 10.1164/ajrccm/140.6.1712; ROLAPLESZCZYNSKI M, 1992, BLOOD, V80, P1004; ROLAPLESZCZYNSKI M, 1987, J IMMUNOL, V139, P513; ROLAPLESZCZYNSKI M, 1986, PROSTAG LEUKOTR ESS, V23, P207, DOI 10.1016/0262-1746(86)90187-3; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; ROVATI GE, 1992, BIOCHEM PHARMACOL, V44, P1411, DOI 10.1016/0006-2952(92)90543-R; RUZICKA T, 1986, J INVEST DERMATOL, V86, P105, DOI 10.1111/1523-1747.ep12284061; Salmon J A, 1991, Prog Drug Res, V37, P9; SAMPSON AP, 1990, BRIT J CLIN PHARMACO, V30, P861, DOI 10.1111/j.1365-2125.1990.tb05452.x; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SHAAFI RI, 1981, J CELL PHYSIOL, V108, P401, DOI 10.1002/jcp.1041080314; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIMIZU T, 1986, P NATL ACAD SCI USA, V83, P4175, DOI 10.1073/pnas.83.12.4175; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; SORENSEN LS, 1988, INT ARCH ALLER A IMM, V86, P267, DOI 10.1159/000234584; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SPENCER DA, 1992, PEDIATR PULM, V12, P90, DOI 10.1002/ppul.1950120206; SPERLING RI, 1992, ARTHRITIS RHEUM, V35, P376, DOI 10.1002/art.1780350403; STANKOVA J, 1992, BIOCHEM J, V282, P625; STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113, DOI 10.1164/ajrccm.150.1.8025736; STENKE L, 1987, EXP HEMATOL, V15, P203; SU MG, 1993, AM REV RESPIR DIS, V147, P448, DOI 10.1164/ajrccm/147.2.448; SUGASAWA T, 1992, AGENTS ACTIONS, V37, P232, DOI 10.1007/BF02028114; SUN FF, 1984, BIOCHIM BIOPHYS ACTA, V794, P56, DOI 10.1016/0005-2760(84)90297-2; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; TONNESEN MG, 1989, J INVEST DERMATOL, V93, pS53, DOI 10.1111/1523-1747.ep12581069; VANDERHOEK JY, 1980, J BIOL CHEM, V255, P64; VILLANIPRICE D, 1992, J PHARMACOL EXP THER, V260, P187; WALLACE JL, 1990, AM J PHYSIOL, V258, pG527, DOI 10.1152/ajpgi.1990.258.4.G527; WEGNER CD, 1993, J ALLERGY CLIN IMMUN, V91, P917, DOI 10.1016/0091-6749(93)90350-O; WEINBLATT ME, 1992, J RHEUMATOL, V19, P1537; WEIR MR, 1991, TRANSPLANTATION, V52, P1053, DOI 10.1097/00007890-199112000-00021; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; WENZEL SE, 1991, J ALLERGY CLIN IMMUN, V87, P540, DOI 10.1016/0091-6749(91)90013-E; WHITTLE BJR, 1985, AM J PHYSIOL, V248, pG580, DOI 10.1152/ajpgi.1985.248.5.G580; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; YARED A, 1991, J AM SOC NEPHROL, V2, P45; ZAKRZEWSKI JT, 1987, BRIT J CLIN PHARMACO, V23, P19, DOI 10.1111/j.1365-2125.1987.tb03004.x	206	524	547	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					684	697		10.7326/0003-4819-121-9-199411010-00010	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00010			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944079				2022-12-28	WOS:A1994PN45000010
J	SEYMOUR, JF; GAGEL, RF; HAGEMEISTER, FB; DIMOPOULOS, MA; CABANILLAS, F				SEYMOUR, JF; GAGEL, RF; HAGEMEISTER, FB; DIMOPOULOS, MA; CABANILLAS, F			CALCITRIOL PRODUCTION IN HYPERCALCEMIC AND NORMOCALCEMIC PATIENTS WITH NON-HODGKIN-LYMPHOMA	ANNALS OF INTERNAL MEDICINE			English	Article						CALCITRIOL; LYMPHOMA, NON-HODGKIN; HYPERCALCEMIA; PARATHYROID HORMONE; CALCIUM	HORMONE-RELATED PROTEIN; INTACT PARATHYROID-HORMONE; PRIMARY HYPERPARATHYROIDISM; CIRCULATING 1,25-DIHYDROXYVITAMIN-D; HUMORAL HYPERCALCEMIA; ALVEOLAR MACROPHAGES; MALIGNANCY; ASSAY; METABOLISM; DISEASE	Objective: To determine the following: a reference range for serum calcitriol during hypercalcemia in a control group of patients with myeloma in whom calcitriol production is known to be appropriately suppressed; the incidence of elevated serum calcitriol levels in hypercalcemic patients with non-Hodgkin lymphoma according to this derived reference range; and the incidence of abnormal calcium metabolism in normocalcemic patients with non-Hodgkin lymphoma. Design: Prospective clinical study. Setting: Referral cancer center. Patients: 2 groups of hypercalcemic patients: 16 control patients with myeloma and 22 patients with non-Hodgkin lymphoma divided into those with elevated or normal serum calcitriol levels; 1 group of 22 normocalcemic patients with non-Hodgkin lymphoma. Measurements: Serum chemistries and intact parathyroid hormone, calcitriol, parathyroid hormone-related protein, and urinary electrolyte levels. Results: On the basis of the mean serum calcitriol level of the control group plus 3 standard deviations, the reference range for serum calcitriol during hypercalcemia was defined as less than 42 pg/mL. Although serum calcium and parathyroid hormone levels in the study patients were similar to those in controls, 12 of the 22 hypercalcemic patients with non-Hodgkin lymphoma (55%) had serum calcitriol levels greater than 42 pg/mL (range, 51 to 170 pg/mL). No features distinguished the patients with elevated serum calcitriol levels from those with normal levels. Seventy-one percent of normocalcemic patients with non-Hodgkin lymphoma were hypercalciuric, and 18% had serum calcitriol levels greater than the normocalcemic reference range (20 to 76 pg/mL). Conclusions: Serum calcitriol levels are elevated in most hypercalcemic patients with non-Hodgkin lymphoma in the absence of elevated serum levels of parathyroid hormone, which implicates extrarenal calcitriol production in the pathogenesis of this syndrome. Abnormal calcium metabolism hypercalciuria, and dysregulated calcitriol production are also common in normocalcemic patients with non-Hodgkin lymphoma.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MED SPECIALTIES, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DIV MED, LYMPHOMA SECT, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	SEYMOUR, JF (corresponding author), ROYAL MELBOURNE HOSP, DEPT CLIN HAEMATOL & MED ONCOL, GRATTAN ST, PARKVILLE, VIC 3050, AUSTRALIA.		Seymour, John/K-7326-2019; Dimopoulos, Meletios Athanasios/AAD-4130-2019	Seymour, John/0000-0003-2188-6835; Cabanillas, Fernando/0000-0001-9234-7893; Dimopoulos, Meletios/0000-0001-8990-3254				ADAMS JS, 1983, J CLIN INVEST, V72, P1856, DOI 10.1172/JCI111147; ADAMS JS, 1989, BLOOD, V73, P235; BAECHLER R, 1985, SCHWEIZ MED WSCHR, V115, P332; BLIND E, 1993, HORM METAB RES, V25, P40, DOI 10.1055/s-2007-1002043; BLIND E, 1988, J CLIN ENDOCR METAB, V67, P353, DOI 10.1210/jcem-67-2-353; BRESLAU NA, 1984, ANN INTERN MED, V100, P1, DOI 10.7326/0003-4819-100-1-1; BROADUS AE, 1980, NEW ENGL J MED, V302, P421, DOI 10.1056/NEJM198002213020801; BROWN RC, 1987, J CLIN ENDOCR METAB, V65, P407, DOI 10.1210/jcem-65-3-407; BURT ME, 1980, ARCH SURG-CHICAGO, V115, P704, DOI 10.1001/archsurg.1980.01380060012004; DEVOGELAER JP, 1990, CLIN RHEUMATOL, V9, P404, DOI 10.1007/BF02114405; FRASER WD, 1991, BONE MINER, V12, P113, DOI 10.1016/0169-6009(91)90040-7; FUKUMOTO S, 1989, ENDOCRINOLOGY, V124, P2057, DOI 10.1210/endo-124-5-2057; GRILL V, 1991, J CLIN ENDOCR METAB, V73, P1309, DOI 10.1210/jcem-73-6-1309; GURNEY H, 1993, LANCET, V341, P1611, DOI 10.1016/0140-6736(93)90756-7; HORIUCHI N, 1987, SCIENCE, V238, P1566, DOI 10.1126/science.3685994; HULTER HN, 1985, J CLIN INVEST, V76, P695, DOI 10.1172/JCI112023; JENDIROBA D, 1994, P AN M AM SOC CLIN, V13, P379; KAO PC, 1992, MAYO CLIN PROC, V67, P637, DOI 10.1016/S0025-6196(12)60717-4; KAPLAN RA, 1977, J CLIN INVEST, V59, P756, DOI 10.1172/JCI108696; LAWSONMATTHEW P, 1989, BRIT J HAEMATOL, V73, P57, DOI 10.1111/j.1365-2141.1989.tb00220.x; Lemann Jacob Jr., 1993, P50; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; MASON RS, 1984, ANN INTERN MED, V100, P59, DOI 10.7326/0003-4819-100-1-59; MOSES AM, 1963, ANN INTERN MED, V59, P531, DOI 10.7326/0003-4819-59-4-531; MUDDE AH, 1987, CANCER-AM CANCER SOC, V59, P1543, DOI 10.1002/1097-0142(19870501)59:9<1543::AID-CNCR2820590902>3.0.CO;2-L; PANDIAN MR, 1992, CLIN CHEM, V38, P282; Portale Anthony A., 1993, P87; RALSTON SH, 1984, ACTA ENDOCRINOL-COP, V106, P556, DOI 10.1530/acta.0.1060556; RATCLIFFE WA, 1992, LANCET, V339, P164, DOI 10.1016/0140-6736(92)90220-W; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; REICHEL H, 1987, J CLIN ENDOCR METAB, V65, P1201, DOI 10.1210/jcem-65-6-1201; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; ROSENBERG SA, 1982, CANCER, V49, P2112; ROSENTHAL N, 1985, J CLIN ENDOCR METAB, V60, P29, DOI 10.1210/jcem-60-1-29; SCHEINMAN SJ, 1991, AM J MED SCI, V301, P178, DOI 10.1097/00000441-199103000-00005; SCHILLING T, 1993, J CLIN ENDOCR METAB, V76, P801, DOI 10.1210/jc.76.3.801; SENBA M, 1992, EUR J HAEMATOL, V48, P278; SENSEN HA, 1992, SCAND J CLIN LAB INV, V52, P457; SEYMOUR JF, 1993, BLOOD, V82, P1383; VASSILOPOULOUSE.R, 1991, P AN M AM SOC CLIN, V10, P131; WADA S, 1992, INTERNAL MED, V31, P968, DOI 10.2169/internalmedicine.31.968; WALKER AT, 1990, AM J PHYSIOL, V258, pE297, DOI 10.1152/ajpendo.1990.258.2.E297; WALTON RJ, 1975, LANCET, V2, P309, DOI 10.1016/S0140-6736(75)92736-1; WARRELL RP, 1993, CANCER PRINCIPLES PR, P2128	44	87	90	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					633	640		10.7326/0003-4819-121-9-199411010-00001	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944070				2022-12-28	WOS:A1994PN45000001
J	SACKS, FM; PASTERNAK, RC; GIBSON, CM; ROSNER, B; STONE, PH				SACKS, FM; PASTERNAK, RC; GIBSON, CM; ROSNER, B; STONE, PH			EFFECT ON CORONARY ATHEROSCLEROSIS OF DECREASE IN PLASMA-CHOLESTEROL CONCENTRATIONS IN NORMOCHOLESTEROLEMIC PATIENTS	LANCET			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; COLESTIPOL-NIACIN THERAPY; ARTERY DISEASE; HEART-DISEASE; QUANTITATIVE ANGIOGRAPHY; REGRESSION; MORTALITY; MEN; HYPERCHOLESTEROLEMIA; PATHOGENESIS	Lipid-lowering therapy ameliorates coronary atherosclerosis in patients with raised concentrations of low-density-lipoprotein (LDL) cholesterol. We have investigated whether a similar benefit can be obtained in normocholesterolaemic patients. We studied 79 normocholesterolaemic patients with coronary heart disease (70 male, 9 female), mean age 58 years, all non-smokers, with mean total cholesterol concentration 5.5 mmol/L. All patients received diet therapy and were randomly assigned placebo (39) or active treatment (40) with pravastatin, nicotinic acid, cholestyramine, and gemfibrozil stepwise as needed to reach the specified goal (total cholesterol less than or equal to 4.1 mmol/L, ratio of LDL/high-density-lipoprotein [HDL] cholesterol less than or equal to 2.0). Coronary angiograms at baseline and after 2.5 years of treatment were analysed by computer-assisted quantitative techniques. There was no significant difference in coronary atherosclerosis during follow-up between the active treatment and placebo groups; the mean minimum diameter narrowed significantly but to the same extent in both groups (change baseline to 2.5 years 0.14 [SD 0.42] and 0.15 [0.41] mm, respectively, both p<0.001). Similarly, the change in percentage stenosis did not differ between the groups (2.1 [10.6] vs 2.4 [10.3]%). By multiple regression analysis, the adjusted difference between the groups was a 0.04 mm (95% Cl -0.04 to 0.12 mm) increase in minimum diameter and a 0% (-1.7 to 1.7) change in percentage stenosis. The groups differed significantly in plasma lipids (% change in active minus % change in placebo group: -28% total cholesterol, -41% LDL-cholesterol, 13% HDL-cholesterol, -26% triglycerides, -31% apolipoprotein B, all p<0.001). Thus, intensive pharmacological treatment of normocholesterolaemic patients has significant effects on plasma lipid concentrations but no angiographically measurable benefit on the coronary arteries.	BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA USA; BETH ISRAEL HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Gibson, C. Michael/AAE-8212-2019		NCRR NIH HHS [MOI RR02635] Funding Source: Medline; NHLBI NIH HHS [R0I HL36392] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036392] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGMON J, 1992, CIRCULATION, V86, P839; Bachorik P S, 1986, Methods Enzymol, V129, P78; BLANKENHORN DH, 1992, CIRCULATION, V86, P1701, DOI 10.1161/01.CIR.86.6.1701; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GIBSON M, 1992, AM J CARDIOL, V69, P1286, DOI 10.1016/0002-9149(92)91222-P; GINSBURG GS, 1991, AM J CARDIOL, V68, P187, DOI 10.1016/0002-9149(91)90742-4; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; MILLER M, 1992, CIRCULATION, V86, P1165, DOI 10.1161/01.CIR.86.4.1165; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RICHARDSON PD, 1989, LANCET, V2, P941; ROSE G, 1977, LANCET, V1, P105; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; SACKS FM, 1991, AM J CARDIOL, V68, P1436, DOI 10.1016/0002-9149(91)90276-Q; SANDOR T, 1987, IEEE T MED IMAGING, V6, P258, DOI 10.1109/TMI.1987.4307835; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SPEARS JR, 1983, CIRCULATION, V68, P453, DOI 10.1161/01.CIR.68.2.453; STEWART BF, 1994, J AM COLL CARDIOL, V23, P899, DOI 10.1016/0735-1097(94)90635-1; STONE PH, 1993, AM J CARDIOL, V71, P766, DOI 10.1016/0002-9149(93)90821-S; Warnick G R, 1986, Methods Enzymol, V129, P101; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X	28	158	160	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 29	1994	344	8931					1182	1186		10.1016/S0140-6736(94)90506-1	http://dx.doi.org/10.1016/S0140-6736(94)90506-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934538				2022-12-28	WOS:A1994PN80300007
J	RUBENSTEIN, JLR; MARTINEZ, S; SHIMAMURA, K; PUELLES, L				RUBENSTEIN, JLR; MARTINEZ, S; SHIMAMURA, K; PUELLES, L			THE EMBRYONIC VERTEBRATE FOREBRAIN - THE PROSOMERIC MODEL	SCIENCE			English	Editorial Material							MOUSE FOREBRAIN; NEUROMERIC ORGANIZATION; HOMEOBOX GENES; EXPRESSION; BOUNDARIES; HINDBRAIN; INDUCTION; PATTERNS; SUGGEST; WNT-3		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA; UNIV MURCIA,FAC MED,DEPT MORPHOL SCI,E-30100 MURCIA,SPAIN	University of California System; University of California San Francisco; University of Murcia	RUBENSTEIN, JLR (corresponding author), UNIV CALIF SAN FRANCISCO,CTR PSYCHIAT & NEUROBIOL,NINA IRELAND LAB DEV NEUROBIOL,SAN FRANCISCO,CA 94143, USA.		Mratinez, Salvador/L-4896-2014	Mratinez, Salvador/0000-0002-9320-4103; PUELLES, LUIS/0000-0002-9541-7073; Martinez, Salvador/0000-0002-2910-8926	NIMH NIH HHS [MH01046-01, MH49428-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001046, R37MH049428, R01MH049428] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTABA ARI, 1994, TRENDS NEUROSCI, V17, P233, DOI 10.1016/0166-2236(94)90006-X; BIRGBAUER E, 1994, DEVELOPMENT, V120, P1347; BONCINELLI E, 1993, J NEUROBIOL, V24, P1356, DOI 10.1002/neu.480241008; BULFONE A, 1993, J NEUROSCI, V13, P3155; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; COHEN S, 1991, TRENDS GENET, V7, P267; COHENTANNOUDJI M, 1994, NATURE, V368, P460, DOI 10.1038/368460a0; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; Lawrence P., 1992, MAKING FLY GENETICS; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MARIN F, 1994, DEV BIOL, V163, P19, DOI 10.1006/dbio.1994.1120; MARTINEZ S, 1992, DEVELOPMENT, V116, P1069; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; OLEARY DDM, 1993, NEURON, V10, P991, DOI 10.1016/0896-6273(93)90049-W; PRICE M, 1993, J NEUROBIOL, V24, P1385, DOI 10.1002/neu.480241010; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; ROSS LS, 1992, J NEUROSCI, V12, P467; RUBENSTEIN JLR, 1994, CURR TOP DEV BIOL, V29, P1, DOI 10.1016/S0070-2153(08)60546-3; SALINAS PC, 1992, MECH DEVELOP, V39, P151, DOI 10.1016/0925-4773(92)90042-I; SHIMAMURA K, UNPUB; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; Vaage S., 1969, ERG ANAT ENTWICKLU, V41, P1; WILSON SW, 1993, TRENDS NEUROSCI, V16, P316, DOI 10.1016/0166-2236(93)90108-X; ZIMMER A, 1992, DEVELOPMENT, V116, P977	31	438	443	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 28	1994	266	5185					578	580		10.1126/science.7939711	http://dx.doi.org/10.1126/science.7939711			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN807	7939711				2022-12-28	WOS:A1994PN80700035
J	GIBBS, JB; OLIFF, A				GIBBS, JB; OLIFF, A			PHARMACEUTICAL RESEARCH IN MOLECULAR ONCOLOGY	CELL			English	Review							DNA-BINDING; DOMAIN; MAX; FOS; JUN; P53				GIBBS, JB (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,DEPT CANC RES,W POINT,PA 19486, USA.							AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BUCHDUNGER E, 1994, P NATL ACAD SCI USA, V91, P2334, DOI 10.1073/pnas.91.6.2334; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CREEKMORE S, 1992, P AN M AM SOC CLIN, V11, P345; CULVER KW, 1994, TRENDS GENET, V10, P174, DOI 10.1016/0168-9525(94)90095-7; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEVITA VT, 1993, CANCER PRINCIPLES PR; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Freidinger R M, 1993, Prog Drug Res, V40, P33; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; FRY DW, 1994, EXPERT OPIN INV DRUG, V3, P577; Gibbs J B, 1992, Semin Cancer Biol, V3, P383; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Gilman AG., 1990, J MED CHEM, V8th, DOI DOI 10.1021/acs.jmedchem.8b01308; GOULD RJ, 1994, DRUG DISCOVERY DESIG, V1, P537; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; Harris William, 1993, Drugs of the Future, V18, P727; HUBER HE, 1994, CURR MED CHEM, V1, P13; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MARX J, 1994, SCIENCE, V263, P319, DOI 10.1126/science.8278804; Mendelsohn J, 1992, J Natl Cancer Inst Monogr, P125; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POWIS G, 1991, TRENDS PHARMACOL SCI, V12, P188, DOI 10.1016/0165-6147(91)90545-4; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; TARTOUR E, 1992, BIOMED PHARMACOTHER, V46, P473, DOI 10.1016/0753-3322(92)90005-R; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VITETTA ES, 1993, TRENDS PHARMACOL SCI, V14, P148, DOI 10.1016/0165-6147(93)90199-T; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; 1994, NEW ENGL J MED, V330, P820	40	121	148	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					193	198		10.1016/0092-8674(94)90189-9	http://dx.doi.org/10.1016/0092-8674(94)90189-9			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954788				2022-12-28	WOS:A1994PN63000004
J	VANDENBERG, AV; BRENNER, E				VANDENBERG, AV; BRENNER, E			WHY 2 EYES ARE BETTER THAN ONE FOR JUDGMENTS OF HEADING	NATURE			English	Article							OPTICAL-FLOW; PERCEPTION; MOVEMENTS; MOTION; IMAGE	ARE two eyes needed for judging direction of self-motion? Traditional analyses stress that the pattern of optic flow in one eye is sufficient(1-5). The main difficulty is how to deal with the eye or head rotation. Extraretinal signals help(6-8), but humans can also discount the effect of rotation purely on the basis of monocular flow(6,7,9-12) provided the scene contains depth(6,9,10). Depth differences give rise to changing binocular disparities when the observer moves. These disparities are ignored in monocular theories of judgements of heading. Using computer generated displays, we investigated whether stereoscopic presentation improves heading judgements for conditions that pose problems to the monocular observer. We found that adding disparities to simulated ego-motion through a cloud of dots made heading judgements up to four times more tolerant to motion noise. The same improvement was found when the disparities specify the initial distances throughout the motion sequence. We conclude that binocular disparities improve judgements of heading by imposing a depth order on the elements of the scene, not because they provide additional information on the elements' motion in depth.			VANDENBERG, AV (corresponding author), ERASMUS UNIV ROTTERDAM,FAC MED,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		van den Berg, Albert/G-3108-2012	van den Berg, Albert Victor/0000-0002-1543-5408				Gibson JJ, 1950, PERCEPTION VISUAL WO; Heeger DJ, 1990, NEURAL COMPUT, V2, P129, DOI 10.1162/neco.1990.2.2.129; KOENDERINK JJ, 1987, BIOL CYBERN, V56, P247, DOI 10.1007/BF00365219; LONGUETHIGGINS HC, 1980, PROC R SOC SER B-BIO, V208, P385, DOI 10.1098/rspb.1980.0057; RIEGER JH, 1985, BIOL CYBERN, V52, P377, DOI 10.1007/BF00449594; RIEGER JH, 1985, J OPT SOC AM A, V2, P354, DOI 10.1364/JOSAA.2.000354; ROYDEN CS, 1992, NATURE, V360, P583, DOI 10.1038/360583a0; VANDENBERG AV, 1992, VISION RES, V32, P1285, DOI 10.1016/0042-6989(92)90223-6; VANDENBERG AV, 1993, NATURE, V365, P497, DOI 10.1038/365497a0; VANDENBERG AV, 1994, VISION RES, V34, P2153, DOI 10.1016/0042-6989(94)90324-7; WARREN WH, 1990, J OPT SOC AM A, V7, P160, DOI 10.1364/JOSAA.7.000160; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0	12	87	87	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 20	1994	371	6499					700	702		10.1038/371700a0	http://dx.doi.org/10.1038/371700a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935814	Green Submitted			2022-12-28	WOS:A1994PM77300055
J	SULLENGER, BA; CECH, TR				SULLENGER, BA; CECH, TR			RIBOZYME-MEDIATED REPAIR OF DEFECTIVE MESSENGER-RNA BY TARGETED TRANSSPLICING	NATURE			English	Article							RNA ENZYME; TETRAHYMENA RIBOZYME; ESCHERICHIA-COLI; SEQUENCE; CLEAVAGE; EXPRESSION; BINDING; INVIVO; MODEL; VIRUS	RIBOZYMES can be targeted to cleave specific RNAs(1-8), which has led to much interest in their potential as gene inhibitors(3,9,10). Such trans-cleaving ribozymes join a growing list of agents that stop the flow of genetic information(11,12). Here we describe a different application of ribozymes for which they may be uniquely suited. By targeted trans-splicing, a ribozyme can replace a defective portion of RNA with a functional sequence. The self-splicing intron from Tetrahymena thermophila(13) was previously shown to mediate trans-splicing of oligonucleotides in vitro(14,15). As a model system for messenger RNA repair, this group I intron was re-engineered to regenerate the proper coding capacity of short, truncated lacZ transcripts. Trans-splicing was efficient in vitro and proceeded in Escherichia coli to generate translatable lacZ messages. Targeted trans-splicing represents a general means of altering the sequence of specified transcripts and may provide a new approach to the treatment of many genetic diseases.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CECH TR, 1992, J BIOL CHEM, V267, P17479; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; FORD E, 1994, P NATL ACAD SCI USA, V91, P3117, DOI 10.1073/pnas.91.8.3117; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; GILBOA E, 1994, TRENDS GENET, V10, P139, DOI 10.1016/0168-9525(94)90216-X; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; INOUE T, 1985, CELL, V43, P431, DOI 10.1016/0092-8674(85)90173-4; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; Miller J. H, 1972, EXPT MOL GENETICS; MORGAN RA, 1993, ANNU REV BIOCHEM, V62, P191; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PRICE JV, 1985, SCIENCE, V228, P719, DOI 10.1126/science.2986286; ROSSI J J, 1992, Current Opinion in Biotechnology, V3, P3, DOI 10.1016/0958-1669(92)90117-2; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1990, CURRENT PROTOCOLS MO; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; WARING RB, 1985, CELL, V40, P371, DOI 10.1016/0092-8674(85)90151-5; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU M, 1994, GENE THER, V1, P13; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	30	196	225	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					619	622		10.1038/371619a0	http://dx.doi.org/10.1038/371619a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935797				2022-12-28	WOS:A1994PL55900056
J	ELLIS, CJ; WALLIS, WE; CARUANA, M				ELLIS, CJ; WALLIS, WE; CARUANA, M			PERIPHERAL NEUROPATHY WITH BEZAFIBRATE	BRITISH MEDICAL JOURNAL			English	Letter											ELLIS, CJ (corresponding author), MIDDLEMORE HOSP,AUCKLAND 1006,NEW ZEALAND.							DOLLERY C, 1991, THERAPEUTIC DRUGS, V1, pB77; GABRIEL R, 1976, LANCET, V2, P906; MONK JP, 1987, DRUGS, V33, P539, DOI 10.2165/00003495-198733060-00002; 1993, AUSTR ADVERSES DRUG, V12, P6	4	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 8	1994	309	6959					929	929		10.1136/bmj.309.6959.929b	http://dx.doi.org/10.1136/bmj.309.6959.929b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7950666	Green Published			2022-12-28	WOS:A1994PL78100024
J	BLAND, JM; ALTMAN, DG				BLAND, JM; ALTMAN, DG			SOME EXAMPLES OF REGRESSION TOWARDS THE MEAN .7.	BRITISH MEDICAL JOURNAL			English	Note							WEIGHT; HEIGHT		IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	BLAND, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							BARRETT JFR, 1990, LANCET, V336, P549, DOI 10.1016/0140-6736(90)92097-2; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; DAVIS CE, 1976, AM J EPIDEMIOL, V104, P493, DOI 10.1093/oxfordjournals.aje.a112321; ESMAIL A, 1990, LANCET, V336, P819, DOI 10.1016/0140-6736(90)93291-V; HAYES RJ, 1988, STAT MED, V7, P915, DOI 10.1002/sim.4780070903; KUSKOWSKAWOLK A, 1989, INT J OBESITY, V13, P441; Rousseeuw P. J., 1991, CHANCE, V4, P41; SCHLICHTING P, 1981, INT J OBESITY, V5, P67	9	282	288	2	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					780	780		10.1136/bmj.309.6957.780	http://dx.doi.org/10.1136/bmj.309.6957.780			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7950567	Green Published, Bronze			2022-12-28	WOS:A1994PJ28200025
J	BRIDGES, AJ				BRIDGES, AJ			SILICONE IMPLANT CONTROVERSY CONTINUES	LANCET			English	Editorial Material							BREAST IMPLANTS; WOMEN				BRIDGES, AJ (corresponding author), UNIV WISCONSIN HOSP,MADISON,WI, USA.							ANGELL M, 1994, NEW ENGL J MED, V330, P1748, DOI 10.1056/NEJM199406163302409; BORENSTEIN D, 1993, ARTHRITIS RHEUM, V36, pS117; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; BRIDGES AJ, 1993, ARCH INTERN MED, V153, P2638, DOI 10.1001/archinte.153.23.2638; BRIDGES AJ, 1993, ARTHRITIS RHEUM, V36, pS191; BRIDGES AJ, IN PRESS J BIOMAT SC; CUELLAR ML, 1993, ARTHRITIS RHEUM, V36, pS219; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; KOSSOVSKY N, 1993, J APPL BIOMATER, V4, P281, DOI 10.1002/jab.770040402; OJOAMAIZE EA, IN PRESS CLIN DIAG L; SOLOMON G, 1994, SEMIN ARTHRITIS RHEU, V24, P29, DOI 10.1016/0049-0172(94)90107-4; SPIERA H, 1993, J RHEUMATOL, V20, P958; TEUBER SS, 1993, J AUTOIMMUN, V6, P367, DOI 10.1006/jaut.1993.1031	14	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1451	1452		10.1016/S0140-6736(94)90284-4	http://dx.doi.org/10.1016/S0140-6736(94)90284-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968116				2022-12-28	WOS:A1994PT99500003
J	THOMAS, JM; REILLY, D				THOMAS, JM; REILLY, D			APPENDICITIS RUPTURES THE SERVICE	LANCET			English	Editorial Material											THOMAS, JM (corresponding author), WATFORD DIST GEN HOSP,WATFORD,HERTS,ENGLAND.							BRAVEMAN P, 1994, NEW ENGL J MED, V331, P444, DOI 10.1056/NEJM199408183310706; KLEIN R, 1994, BRIT MED J, V308, P215, DOI 10.1136/bmj.308.6923.215; RELMAN AS, 1994, NEW ENGL J MED, V331, P471, DOI 10.1056/NEJM199408183310711; WHITEHEAD M, 1994, BRIT MED J, V308, P1284, DOI 10.1136/bmj.308.6939.1284	4	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1381	1382						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968071				2022-12-28	WOS:A1994PR78600005
J	ZEIHER, AM; IHLING, C; PISTORIUS, K; SCHACHINGER, V; SCHAEFER, HE				ZEIHER, AM; IHLING, C; PISTORIUS, K; SCHACHINGER, V; SCHAEFER, HE			INCREASED TISSUE ENDOTHELIN IMMUNOREACTIVITY IN ATHEROSCLEROTIC LESIONS ASSOCIATED WITH ACUTE CORONARY SYNDROMES	LANCET			English	Note							ARTERY DISEASE; PATHOGENESIS; MECHANISMS; VASOSPASM	Acute coronary syndromes are accompanied by exaggerated vasoconstriction. Since thrombin induces production of the potent vasoconstrictor endothelin-1, we used immunohistochemistry on coronary atherosclerotic specimens from 30 consecutive patients. Endothelin-1-like immunoreactivity was present in 5 of 9 (55%) lesions from patients with stable angina, in 6 of 7 (86%) from crescendo angina, and in all 14 from angina at rest. Endothelin-1 immunoreactivity was most common in areas with a positive Prussian-blue reaction indicative of previous intraplaque haemorrhage. Tissue endothelin-1-like immunoreactivity might contribute to the exaggerated coronary vasoconstriction.	UNIV FREIBURG,DEPT PATHOL,D-79106 FREIBURG,GERMANY	University of Freiburg	ZEIHER, AM (corresponding author), UNIV FREIBURG,DEPT INTERNAL MED 3,DIV CARDIOL,D-79106 FREIBURG,GERMANY.							EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; HOLLANDER M, 1973, NONPARAMETRIC STATIS; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; WINKLES JA, 1993, BIOCHEM BIOPH RES CO, V191, P1081, DOI 10.1006/bbrc.1993.1327; YANG ZH, 1990, CIRCULATION, V82, P188, DOI 10.1161/01.CIR.82.1.188; YANIGASAWA M, 1988, NATURE, V332, P411; ZEIHER AM, 1991, CIRCULATION, V83, P1519, DOI 10.1161/01.CIR.83.5.1519; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391	11	90	93	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1405	1406		10.1016/S0140-6736(94)90571-1	http://dx.doi.org/10.1016/S0140-6736(94)90571-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968078				2022-12-28	WOS:A1994PR78600012
J	KING, RW; JACKSON, PK; KIRSCHNER, MW				KING, RW; JACKSON, PK; KIRSCHNER, MW			MITOSIS IN TRANSITION	CELL			English	Review							MATURATION-PROMOTING FACTOR; CYCLIN-DEPENDENT KINASES; EMBRYONIC-CELL CYCLE; WEE1 PROTEIN-KINASE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; NEGATIVE REGULATION; ASPERGILLUS-NIDULANS; AMPHIBIAN EGGS				KING, RW (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.			King, Randall/0000-0001-7882-8180; Jackson, Peter/0000-0002-1742-2539				AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; EARNSHAW WC, 1994, MITOSIS BIOESSAYS, V16, P639; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FEILOTTER H, 1991, GENETICS, V127, P309; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FRIEDMAN H, 1994, P NATL ACAD SCI USA, V91, P2031, DOI 10.1073/pnas.91.6.2031; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAGAN I, 1988, J CELL SCI, V91, P587; HARPER JW, 1993, CELL, V75, P805; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KARSENTI E, 1987, DEV BIOL, V119, P442, DOI 10.1016/0012-1606(87)90048-0; KINOSHITA N, 1993, GENE DEV, V7, P1059, DOI 10.1101/gad.7.6.1059; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LABIB K, 1993, CURR BIOL, V3, P164, DOI 10.1016/0960-9822(93)90261-L; LEE TH, 1994, MOL BIOL CELL, V5, P323, DOI 10.1091/mbc.5.3.323; LORCA T, 1992, J CELL SCI, V102, P55; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; LORCA T, 1992, FEBS LETT, V306, P90, DOI 10.1016/0014-5793(92)80844-7; LU KP, 1993, J CELL BIOL, V121, P621, DOI 10.1083/jcb.121.3.621; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; LUNDGREN K, 1991, CELL, V64, P111; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Maller James L., 1994, Seminars in Developmental Biology, V5, P183, DOI 10.1006/sedb.1994.1024; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; VANDERVELDEN HMW, 1994, MOL BIOL CELL, V5, P713, DOI 10.1091/mbc.5.7.713; VANDRE DD, 1989, J CELL SCI, V94, P245; WALKER DH, 1992, MOL BIOL CELL, V3, P687, DOI 10.1091/mbc.3.6.687; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	97	721	741	1	33	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					563	571		10.1016/0092-8674(94)90542-8	http://dx.doi.org/10.1016/0092-8674(94)90542-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954823				2022-12-28	WOS:A1994PT48100004
J	NURSE, P				NURSE, P			ORDERING S-PHASE AND M-PHASE IN THE CELL-CYCLE	CELL			English	Review							FISSION YEAST; TYROSINE PHOSPHORYLATION; DNA-REPLICATION; MITOSIS; KINASE; CHECKPOINT; COMPLETION; P34CDC28; ROLES; G2				NURSE, P (corresponding author), IMPERIAL CANC RES FUND,CELL CYCLE LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HAYLES J, 1994, CELL, V78, P713; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WEINERT TA, 1993, GENETICS, V134, P63	26	528	537	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					547	550		10.1016/0092-8674(94)90539-8	http://dx.doi.org/10.1016/0092-8674(94)90539-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954820				2022-12-28	WOS:A1994PT48100001
J	OGATA, K; MORIKAWA, S; NAKAMURA, H; SEKIKAWA, A; INOUE, T; KANAI, H; SARAI, A; ISHII, S; NISHIMURA, Y				OGATA, K; MORIKAWA, S; NAKAMURA, H; SEKIKAWA, A; INOUE, T; KANAI, H; SARAI, A; ISHII, S; NISHIMURA, Y			SOLUTION STRUCTURE OF A SPECIFIC DNA COMPLEX OF THE MYB DNA-BINDING DOMAIN WITH COOPERATIVE RECOGNITION HELICES	CELL			English	Article							C-MYB; CRYSTAL-STRUCTURE; V-MYB; PROTOONCOGENE PRODUCT; NMR-SPECTROSCOPY; ONCOGENE PRODUCT; CDNA CLONES; MIM-1 GENE; ONCOPROTEIN; PROTEINS	The DNA-binding region of Myb consists of three imperfect tandem repeats (R1, R2, and R3). We have determined the solution structure of a specific DNA complex of the minimum DNA-binding domain (R2R3) by heteronuclear multidimensional NMR. Both R2 and R3 contain three helices, and the third helix in each is found to be a recognition helix. R2 and R3 are closely packed in the major groove, so that the two recognition helices contact each other directly to bind to the specific base sequence, AACNG cooperatively; this is a significant arrangement of recognition helices. The three key base pairs in this sequence are specifically recognized by Asn-183 (R3), Lys-182 (R3), and Lys-128 (R2). In contrast, R1 has no specific interactions with DNA from our NMR study of the DNA complex of the full DNA-binding domain (R1R2R3).	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN	RIKEN	OGATA, K (corresponding author), YOKOHAMA CITY UNIV,GRAD SCH INTEGRATED SCI,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN.		Ishii, Shunsuke/A-5271-2016; Nakamura, Haruki/O-4028-2014	Ishii, Shunsuke/0000-0002-6530-2478; Nishimura, Yoshifumi/0000-0002-5148-3458				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V47, P1504, DOI 10.1016/0006-291X(72)90243-4; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRANKIEL T, 1990, J MAGN RESON, V90, P420; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRONENBORN AM, 1989, BIOCHEMISTRY-US, V28, P5978, DOI 10.1021/bi00440a039; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KAY LE, 1989, J MAGN RESON, V84, P7284; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MESSERLE BA, 1989, J MAGN RESON, V85, P608, DOI 10.1016/0022-2364(89)90252-7; MORIKAMI K, 1992, COMPUT CHEM, V16, P243, DOI 10.1016/0097-8485(92)80010-W; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NAKAI T, 1993, J BIOMOL NMR, V3, P19; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SARAI A, 1993, BIOCHEMISTRY-US, V32, P7759, DOI 10.1021/bi00081a022; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WIDER G, 1990, J AM CHEM SOC, V112, P9015, DOI 10.1021/ja00180a076; WUTHERICH K, 1986, NMR PROTEINS NUCLEIC	55	437	465	3	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					639	648		10.1016/0092-8674(94)90549-5	http://dx.doi.org/10.1016/0092-8674(94)90549-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954830				2022-12-28	WOS:A1994PT48100011
J	WOODARD, CT; BAEHRECKE, EH; THUMMEL, CS				WOODARD, CT; BAEHRECKE, EH; THUMMEL, CS			A MOLECULAR MECHANISM FOR THE STAGE SPECIFICITY OF THE DROSOPHILA PREPUPAL GENETIC RESPONSE TO ECDYSONE	CELL			English	Article							HORMONE-RECEPTOR SUPERFAMILY; POLYTENE CHROMOSOMES; INDUCIBLE GENE; PUPAL CUTICLE; EARLY PUFF; ECDYSTEROID TITERS; BINDING PROTEIN; IMAGINAL DISKS; FUSHI-TARAZU; ENCODES 2	Two successive pulses of ecdysone signal the ends of larval and prepupal development in Drosophila, inducing early and late puffs in the salivary gland polytene chromosomes. Early puff induction in prepupae is dependent on a preceding period of protein synthesis and low ecdysone concentration. We demonstrate here that the competence acquired during this interval can be provided by beta FTZ-F1, a nuclear hormone receptor superfamily member derived from the 75CD mid-prepupal puff. We show that beta FTZ-F1 represses its own transcription and is repressed by ecdysone, explaining its brief expression in mid-prepupae. We further show that ectopic beta FTZ-F1 expression leads to enhanced levels of ecdysone-induced BR-C, E74, and E75 early gene transcription and premature induction of the stage-specific 93F early puff and E93 transcription. These findings indicate that beta FTZ-F1 plays a central role in the prepupal genetic response to ecdysone and provide a molecular mechanism for stage-specific responses to steroid hormones.			WOODARD, CT (corresponding author), UNIV UTAH,ECCLES INST HUMAN GENET,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		Woodard, Craig/L-7293-2019					ANDRES AJ, 1994, METHOD CELL BIOL, V44, P565, DOI 10.1016/S0091-679X(08)60932-2; ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; APPLE RT, 1991, DEV BIOL, V146, P569, DOI 10.1016/0012-1606(91)90257-4; ASHBURNER M, 1967, CHROMOSOMA, V21, P398, DOI 10.1007/BF00336950; ASHBURNER M, 1974, DEV BIOL, V39, P141, DOI 10.1016/S0012-1606(74)80016-3; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER HJ, 1959, CHROMOSOMA, V10, P654, DOI 10.1007/BF00396591; Bodenstein D, 1965, BIOL DROSOPHILA, P275; BOYD M, 1977, J INSECT PHYSIOL, V23, P517, DOI 10.1016/0022-1910(77)90263-3; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHAO AT, 1986, EMBO J, V5, P143, DOI 10.1002/j.1460-2075.1986.tb04188.x; CLEVER U, 1960, EXP CELL RES, V20, P623, DOI 10.1016/0014-4827(60)90141-5; CROWLEY TE, 1984, CELL, V39, P149, DOI 10.1016/0092-8674(84)90200-9; DIBELLO PR, 1991, GENETICS, V129, P385; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FECHTEL K, 1988, GENETICS, V120, P465; FECHTEL K, 1989, DEVELOPMENT, V106, P649; FRISTROM JW, 1982, DEV BIOL, V91, P337, DOI 10.1016/0012-1606(82)90040-9; FRISTROM JW, 1986, ARCH INSECT BIOCH S, V1, P119; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HANDLER AM, 1982, DEV BIOL, V93, P73, DOI 10.1016/0012-1606(82)90240-8; HUET F, 1993, DEVELOPMENT, V118, P613; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KARIM FD, 1991, GENE DEV, V5, P1067, DOI 10.1101/gad.5.6.1067; KARIM FD, 1993, DEVELOPMENT, V118, P977; KOELLE MR, 1992, THESIS STANFORD U ST; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; MARONI G, 1983, DROS INFORM SERV, V59, P142; MARTIN P, 1978, GENETICS BIOL DROS A, V2, P219; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; RICHARDS G, 1981, BIOL REV, V56, P501, DOI 10.1111/j.1469-185X.1981.tb00358.x; RICHARDS G, 1976, DEV BIOL, V54, P264, DOI 10.1016/0012-1606(76)90304-3; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; RICHARDS G, 1976, DEV BIOL, V54, P256, DOI 10.1016/0012-1606(76)90303-1; Riddiford L., 1993, DEV DROSOPHILA MELAN, V2, P899; ROBB JA, 1969, J CELL BIOL, V41, P876, DOI 10.1083/jcb.41.3.876; Robertson CW, 1936, J MORPHOL, V59, P351, DOI 10.1002/jmor.1050590207; ROBERTSON HM, 1988, GENETICS, V118, P461; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1988, THESIS STANFORD U ST; SLITER TJ, 1992, GENETICS, V130, P555; STONE BL, 1993, CELL, V75, P307, DOI 10.1016/0092-8674(93)80072-M; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; Thummel CS, 1992, DROS INF SERV, V71, P150; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0	50	178	186	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					607	615		10.1016/0092-8674(94)90546-0	http://dx.doi.org/10.1016/0092-8674(94)90546-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7954827				2022-12-28	WOS:A1994PT48100008
J	KLEIJNEN, J; DECRAEN, AJM; VANEVERDINGEN, J; KROL, L				KLEIJNEN, J; DECRAEN, AJM; VANEVERDINGEN, J; KROL, L			PLACEBO-EFFECT IN DOUBLE-BLIND CLINICAL-TRIALS - A REVIEW OF INTERACTIONS WITH MEDICATIONS	LANCET			English	Article									UNIV AMSTERDAM,ACAD MED CTR,DEPT MED PSYCHOL,1100 DE AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	KLEIJNEN, J (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,POB 22700,MEIBERGDREEF 9,1100 DE AMSTERDAM,NETHERLANDS.							Affleck, 1966, NEBR STATE MED J, P331; BERGMANN JF, 1994, CLIN TRIAL META-ANAL, V29, P41; GRACELY RH, 1985, LANCET, V1, P43; HULL JG, 1986, PSYCHOL BULL, V99, P347, DOI 10.1037/0033-2909.99.3.347; KIENE H, 1993, KRITIK KLINISCHEN DO; LEVINE JD, 1984, NATURE, V312, P755, DOI 10.1038/312755a0; LINDAHL O, 1982, METAMEDICINE, V3, P255; LYERLY SB, 1964, J ABNORM SOC PSYCH, V68, P321, DOI 10.1037/h0044351; MATHEWS A, 1983, PSYCHOL MED, V13, P83, DOI 10.1017/S0033291700050091; PECK C, 1991, THEOR MED, V12, P247, DOI 10.1007/BF00489609; ROHSENOW DJ, 1981, ADDICT BEHAV, V6, P107, DOI 10.1016/0306-4603(81)90003-4; ROSS S, 1962, PSYCHOL REP, V10, P382; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V104, P587, DOI 10.1093/oxfordjournals.aje.a112335; SKOVLUND E, 1991, LANCET, V337, P1041, DOI 10.1016/0140-6736(91)92701-3; UHLENHUTH EH, 1966, PSYCHOPHARMACOLOGIA, V9, P392, DOI 10.1007/BF00406450; UHLENHUTH EH, 1959, AM J PSYCHIAT, V115, P905, DOI 10.1176/ajp.115.10.905; VANDERMOLEN GM, 1988, PSYCHOSOM MED, V50, P439, DOI 10.1097/00006842-198807000-00011; WIED G L, 1953, Arztl Wochensch, V8, P623	18	133	134	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1347	1349		10.1016/S0140-6736(94)90699-8	http://dx.doi.org/10.1016/S0140-6736(94)90699-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PQ926	7968033				2022-12-28	WOS:A1994PQ92600015
J	POL, S; NALPAS, B; LEGENDRE, C; KREIS, H				POL, S; NALPAS, B; LEGENDRE, C; KREIS, H			EFFECTS OF INTERLEUKIN-2 ON HEPATITIS-B VACCINATION IN UREMIC PATIENTS	LANCET			English	Letter							NONRESPONSE				POL, S (corresponding author), HOP NECKER ENFANTS MALAD,SERV TRANSPLANTAT RENALE,UNITE HEPATOL,F-75747 PARIS,FRANCE.		Nalpas, Bertrand/M-4981-2018	Nalpas, Bertrand/0000-0002-8215-2942				ALPER CA, 1989, NEW ENGL J MED, V321, P708, DOI 10.1056/NEJM198909143211103; NALPAS B, 1993, ALCOHOL CLIN EXP RES, V17, P295, DOI 10.1111/j.1530-0277.1993.tb00766.x; POL S, 1990, J HEPATOL, V11, P385, DOI 10.1016/0168-8278(90)90226-H	3	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1369	1369						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7968056				2022-12-28	WOS:A1994PQ92600051
J	SANCHEZ, JL; VASQUEZ, B; BEGUE, RE; MEZA, R; CASTELLARES, G; CABEZAS, C; WATTS, DM; SVENNERHOLM, AM; SADOFF, JC; TAYLOR, DN				SANCHEZ, JL; VASQUEZ, B; BEGUE, RE; MEZA, R; CASTELLARES, G; CABEZAS, C; WATTS, DM; SVENNERHOLM, AM; SADOFF, JC; TAYLOR, DN			PROTECTIVE EFFICACY OF ORAL WHOLE-CELL RECOMBINANT-B-SUBUNIT CHOLERA VACCINE IN PERUVIAN MILITARY RECRUITS	LANCET			English	Article							ABO BLOOD-GROUPS; SWEDISH VOLUNTEERS; CELL VACCINE; FIELD TRIAL; IMMUNOGENICITY; BANGLADESH; SAFETY	The cholera epidemic in South America has reinforced the need for safe and effective oral vaccines. In a randomised, double-blind, placebo-controlled efficacy trial among 1563 Peruvian military recruits we have investigated the protective efficacy of an oral inactivated whole-cell/recombinant-B-subunit (WC/rBS) cholera vaccine. Participants were given two oral doses of cholera vaccine or Escherichia coli K12 placebo, with an interval of 7-14 days. 1426 (91%) subjects received the two prescribed doses and were followed up for a mean of 18 weeks (median 21 weeks). After vaccination, Vibrio cholerae O1 El Tor Ogawa was isolated from 17 subjects with diarrhoea. 16 of the cholera cases occurred 2 weeks or longer after the second dose of vaccine (14 placebo recipients, 2 vaccinees). We also detected 14 symptomless infections (11 [7 placebo recipients, 4 vaccinees]) 2 weeks or longer after the second dose. The vaccine had significant protective efficacy against cholera (86% [95% Cl 37-97], p<0.01) but not against symptomless infection (42% [-96 to 85]). All cholera cases were in people of blood group O, who made up 76% of the study population (p<0.01). Two doses of WC/rBS vaccine, given 1 to 2 weeks apart, provide rapid, short-term protection against symptomatic cholera in adult South Americans, who are predominantly of blood group O. Long-term efficacy studies in Peruvian adults and children are under way.	WALTER REED ARMY INST RES,DIV PREVENT MED,WASHINGTON,DC; USN,MED RES INST DETACHMENT,LIMA,PERU; UNIV GOTHENBURG,DEPT MED MICROBIOL & IMMUNOL,GOTHENBURG,SWEDEN; WALTER REED ARMY INST RES,DIV COMMUNICABLE DIS & IMMUNOL,WASHINGTON,DC	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of Gothenburg; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)				CABEZAS, CESAR/0000-0001-5120-0713				[Anonymous], MANUAL CLIN MICROBIO; BARUA D, 1977, ANN HUM BIOL, V4, P489, DOI 10.1080/03014467700002481; BEGUE RE, IN PRESS VACCINE; BEGUE RE, IN PRESS AM J TROP M; Bennish Michael L., 1994, P229; CHAUDHURI A, 1977, LANCET, V2, P404; CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1987, J INFECT DIS, V155, P79, DOI 10.1093/infdis/155.1.79; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1989, J INFECT DIS, V159, P770, DOI 10.1093/infdis/159.4.770; CLEMENS JD, 1988, J INFECT DIS, V158, P60, DOI 10.1093/infdis/158.1.60; GARRATY G, 1992, MANUAL CLIN LABORATO, P308; GLSS RI, 1992, CHOLERA, P129; GOTUZZO E, 1994, INFECT DIS CLIN N AM, V8, P183; HOLMGREN J, 1989, VACCINE, V7, P94, DOI 10.1016/0264-410X(89)90042-X; JERTBORN M, 1993, VACCINE, V11, P1007, DOI 10.1016/0264-410X(93)90125-H; JERTBORN M, 1992, VACCINE, V10, P130, DOI 10.1016/0264-410X(92)90030-N; LEVINE MM, 1979, ANN HUM BIOL, V6, P359; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; SANCHEZ JL, 1993, J INFECT DIS, V167, P1446, DOI 10.1093/infdis/167.6.1446; WILLEMS J, 1981, J INFECT DIS, V144, P4486; 1994, EPIDEMIOL B, V15, P13; 1991, EPIDEMIOL B, V12, P5	23	134	141	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1273	1276		10.1016/S0140-6736(94)90755-2	http://dx.doi.org/10.1016/S0140-6736(94)90755-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967990				2022-12-28	WOS:A1994PP70100013
J	CONNOR, EM; SPERLING, RS; GELBER, R; KISELEV, P; SCOTT, G; OSULLIVAN, MJ; VANDYKE, R; BEY, M; SHEARER, W; JACOBSON, RL; JIMENEZ, E; ONEILL, E; BAZIN, B; DELFRAISSY, JF; CULNANE, M; COOMBS, R; ELKINS, M; MOYE, J; STRATTON, P; BALSLEY, J				CONNOR, EM; SPERLING, RS; GELBER, R; KISELEV, P; SCOTT, G; OSULLIVAN, MJ; VANDYKE, R; BEY, M; SHEARER, W; JACOBSON, RL; JIMENEZ, E; ONEILL, E; BAZIN, B; DELFRAISSY, JF; CULNANE, M; COOMBS, R; ELKINS, M; MOYE, J; STRATTON, P; BALSLEY, J			REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-TRIALS GROUP; RETROVIRAL DISEASE; HIV-1 INFECTION; PREGNANCY; VIREMIA; EMBRYOS; THERAPY; 3'-AZIDO-3'-DEOXYTHYMIDINE; PHARMACOKINETICS; PREIMPLANTATION	Background and Methods. Maternal-infant transmission is the primary means by which young children become infected with human immunodeficiency virus type 1 (HIV). We conducted a randomized, double-blind, placebo-controlled trial of the efficacy and safety of zidovudine in reducing the risk of maternal-infant HIV transmission. HIV-infected pregnant women (14 to 34 weeks' gestation) with CD4+ T-lymphocyte counts above 200 cells per cubic millimeter who had not received antiretroviral therapy during the current pregnancy were enrolled. The zidovudine regimen included antepartum zidovudine (100 mg orally five times daily), intrapartum zidovudine (2 mg per kilogram of body weight given intravenously over a one-hour period, then 1 mg per kilogram per hour until delivery), and zidovudine for the newborn (2 mg per kilogram orally every six hours for six weeks). Infants with at least one positive HIV culture of peripheral-blood mononuclear cells were classified as HIV-infected. Results. From April 1991 through December 20, 1993, the cutoff date for the first interim analysis of efficacy, 477 pregnant women were enrolled; during the study period, 409 gave birth to 415 live-born infants. HIV-infection status was known for 363 births (180 in the zidovudine group and 183 in the placebo group). Thirteen infants in the zidovudine group and 40 in the placebo group were HIV-infected. The proportions infected at 18 months, as estimated by the Kaplan-Meier method, were 8.3 percent (95 percent confidence interval, 3.9 to 12.8 percent) in the zidovudine group and 25.5 percent (95 percent confidence interval, 18.4 to 32.5 percent) in the placebo group. This corresponds to a 67.5 percent (95 percent confidence interval, 40.7 to 82.1 percent) relative reduction in the risk of HIV transmission (Z = 4.03, P = 0.00006). Minimal short-term toxic effects were observed. The level of hemoglobin at birth in the infants in the zidovudine group was significantly lower than that in the infants in the placebo group. By 12 weeks of age, hemoglobin values in the two groups were similar. Conclusions. In pregnant women with mildly symptomatic HIV disease and no prior treatment with antiretroviral drugs during the pregnancy, a regimen consisting of zidovudine given ante partum and intra partum to the mother and to the newborn for six weeks reduced the risk of maternal-infant HIV transmission by approximately two thirds.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PEDIAT,NEWARK,NJ 07103; CUNY MT SINAI SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,NEW YORK,NY 10029; HARVARD UNIV,SCH PUBL HLTH,AIDS CLIN TRIALS GRP,CTR STAT & DATA ANAL,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA; UNIV MIAMI,SCH MED,DEPT PEDIAT,MIAMI,FL; UNIV MIAMI,SCH MED,DEPT OBSTET & GYNECOL,MIAMI,FL 33101; TULANE UNIV,SCH MED,DEPT PEDIAT,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,SCH MED,DEPT OBSTET & GYNECOL,NEW ORLEANS,LA; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DEPT OBSTET & GYNECOL,HOUSTON,TX; SAN JUAN CITY HOSP,DEPT PEDIAT,SAN JUAN,PR; SAN JUAN CITY HOSP,DEPT OBSTET & GYNECOL,SAN JUAN,PR; AGENCE NATL RECH SIDA,PARIS,FRANCE; UNIV WASHINGTON,SCH MED,SEATTLE,WA; BURROUGHS WELLCOME CO,RES TRIANGLE PK,NC 27709; NICHHD,BETHESDA,MD; NIAID,DIV AIDS,PEDIAT MED BRANCH,BETHESDA,MD 20892	Rutgers State University New Brunswick; Rutgers State University Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; University of Miami; University of Miami; Tulane University; Louisiana State University System; Baylor College of Medicine; University of Texas System; University of Washington; University of Washington Seattle; Burroughs Wellcome Fund; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Shearer, William/0000-0002-2483-2130; Culnane, Mary/0000-0003-2070-4454; moye, john/0000-0001-9976-8586				BLANCHE S, 1994, NEW ENGL J MED, V330, P308, DOI 10.1056/NEJM199402033300502; BOUCHER FD, 1993, J PEDIATR-US, V122, P137, DOI 10.1016/S0022-3476(05)83507-3; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; CALVELLI T, 1993, CYTOMETRY, V14, P702, DOI 10.1002/cyto.990140703; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; Cox DR., 1970, ANAL BINARY DATA; DEROSSI A, 1993, AIDS, V7, P1528, DOI 10.1097/00002030-199311000-00020; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; Greenwood M., 1926, REPORTS PUBLIC HLTH, V33, P1; HA JC, 1994, J ACQ IMMUN DEF SYND, V7, P154; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIM K, 1990, BIOMETRICS, V46, P81, DOI 10.2307/2531632; KRIVINE A, 1992, LANCET, V339, P1187, DOI 10.1016/0140-6736(92)91131-Q; Mofenson L., 1994, PEDIATRIC AIDS CHALL, P179; Mofenson LM, 1994, SEMIN PEDIAT INFECT, V5, P252; NEWELL ML, 1993, AIDS, V7, pS91, DOI 10.1097/00002030-199301001-00012; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OSULLIVAN MJ, 1993, AM J OBSTET GYNECOL, V168, P1510, DOI 10.1016/S0002-9378(11)90791-1; Oxtoby MJ, 1994, PEDIATRIC AIDS CHALL, P3; PONS JC, 1991, EUR J OBSTET GYN R B, V40, P229, DOI 10.1016/0028-2243(91)90122-2; ROUZIOUX C, 1992, AIDS, V6, P373, DOI 10.1097/00002030-199204000-00003; ROUZIOUX C, 1993, J CELL BIOCH E S, V17, P100; RUPRECHT RM, 1986, NATURE, V323, P467, DOI 10.1038/323467a0; SHARPE AH, 1987, SCIENCE, V236, P1671, DOI 10.1126/science.3037694; SHARPE AH, 1988, P NATL ACAD SCI USA, V85, P9792, DOI 10.1073/pnas.85.24.9792; SHARPE AH, 1989, P NATL ACAD SCI USA, V86, P2045; SHIH CC, 1991, J INFECT DIS, V163, P625, DOI 10.1093/infdis/163.3.625; SIEH E, 1992, AIDS RES HUM RETROV, V8, P639, DOI 10.1089/aid.1992.8.639; SPERLING RS, 1992, AM J PERINAT, V9, P247, DOI 10.1055/s-2007-994781; SPERLING RS, 1992, NEW ENGL J MED, V326, P857, DOI 10.1056/NEJM199203263261303; TOLTZIS P, 1993, ANTIMICROB AGENTS CH, V37, P1610, DOI 10.1128/AAC.37.8.1610; VANROMPAY KKA, 1992, ANTIMICROB AGENTS CH, V36, P2381, DOI 10.1128/AAC.36.11.2381; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WATTS DH, 1991, J INFECT DIS, V163, P226, DOI 10.1093/infdis/163.2.226; 1992, J ACQ IMMUN DEF SYND, V5, P1169; 1993, COMPREHENSIVE INFORM; 1994, HIV AIDS SURVEILLANC	39	2787	2897	2	134	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1173	1180		10.1056/NEJM199411033311801	http://dx.doi.org/10.1056/NEJM199411033311801			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935654				2022-12-28	WOS:A1994PN80600001
J	DONADIO, JV; BERGSTRALH, EJ; OFFORD, KP; SPENCER, DC; HOLLEY, KE				DONADIO, JV; BERGSTRALH, EJ; OFFORD, KP; SPENCER, DC; HOLLEY, KE			A CONTROLLED TRIAL OF FISH-OIL IN IGA NEPHROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNSATURATED FATTY-ACIDS; EICOSAPENTAENOIC ACID; DISEASE; GLOMERULONEPHRITIS; SUPPLEMENTATION; INDEXES	Background. The n-3 fatty acids in fish oil affect eicosanoid and cytokine production and therefore have the potential to alter renal hemodynamics and inflammation. The effects of fish oil could prevent immunologic renal injury in patients with IgA nephropathy. Methods. In a multicenter, placebo-controlled, randomized trial we tested the efficacy of fish oil in patients with IgA nephropathy who had persistent proteinuria. The daily dose of fish oil was 12 g; the placebo was a similar dose of olive oil. Serum creatinine concentrations, elevated in 68 percent of the patients at base line, and creatinine clearance were measured for two years. The primary end point was an increase of 50 percent or more in the serum creatinine concentration at the end of the study. Results. Fifty-five patients were assigned to receive fish oil, and 51 to receive placebo. According to Kaplan-Meier estimation, 3 patients (6 percent) in the fish-oil group and 14 (33 percent) in the placebo group had increases of 50 percent or more in their serum creatinine concentrations during treatment (P = 0.002). The annual median changes in the serum creatinine concentrations were 0.03 mg per deciliter (2.7 mu mol per liter) in the fish-oil group and 0.14 mg per deciliter (12.4 mu mol per liter) in the placebo group. Proteinuria was slightly reduced and hypertension was controlled to a comparable degree in both groups. The cumulative percentage of patients who died or had end-stage renal disease was 40 percent in the placebo group after four years and 10 percent in the fish-oil group (P = 0.006). No patient discontinued fish-oil treatment because of adverse effects. Conclusions. In patients with IgA nephropathy, treatment with fish oil for two years retards the rate at which renal function is lost,	MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,ROCHESTER,MN 55905	Mayo Clinic	DONADIO, JV (corresponding author), MAYO CLIN & MAYO FDN,DEPT MED,DIV NEPHROL,200 1ST ST SW,ROCHESTER,MN 55905, USA.							BENNETT WM, 1989, CLIN NEPHROL, V31, P128; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARTWRIGHT IJ, 1985, ATHEROSCLEROSIS, V55, P267, DOI 10.1016/0021-9150(85)90106-6; CHENG IKP, 1990, NEPHROL DIAL TRANSPL, V5, P241, DOI 10.1093/ndt/5.4.241; CLARK WF, 1993, KIDNEY INT, V44, P75, DOI 10.1038/ki.1993.215; COX DR, 1972, J R STAT SOC B, V34, P187; DAMICO G, 1987, Q J MED, V64, P709; DECATERINA R, 1993, KIDNEY INT, V44, P843, DOI 10.1038/ki.1993.320; DONADIO JV, 1991, MAYO CLIN PROC, V66, P1018, DOI 10.1016/S0025-6196(12)61725-X; DONADIO JV, 1994, CLIN NEPHROL, V41, P65; Droz D, 1984, Contrib Nephrol, V40, P202; EMANCIPATOR SN, 1989, LAB INVEST, V60, P168; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; FISCHER S, 1983, BIOCHEM BIOPH RES CO, V116, P1091, DOI 10.1016/S0006-291X(83)80254-X; HABIB R, 1994, RENAL PATHOLOGY CLIN, P472; HALL AV, 1992, J AM SOC NEPHROL, V3, P1321; HAMAZAKI T, 1984, LANCET, V1, P1017; HOLUB BJ, 1987, METHOD ENZYMOL, V141, P234; HOOD SA, 1981, CLIN NEPHROL, V16, P55; JULIAN BA, 1988, AM J MED, V84, P129, DOI 10.1016/0002-9343(88)90019-8; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELI SO, 1994, STROKE, V25, P328, DOI 10.1161/01.STR.25.2.328; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KUSUMOTO Y, 1987, CLIN NEPHROL, V28, P118; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PETTERSSON EE, 1994, CLIN NEPHROL, V41, P183; SCHMEKEL B, 1981, ACTA MED SCAND, V210, P363; SPERLING RI, 1987, J IMMUNOL, V139, P4186; VANDERHEIDE JJH, 1993, NEW ENGL J MED, V329, P769, DOI 10.1056/NEJM199309093291105	29	325	330	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1194	1199		10.1056/NEJM199411033311804	http://dx.doi.org/10.1056/NEJM199411033311804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935657				2022-12-28	WOS:A1994PN80600004
J	POLANECZKY, M; SLAP, G; FORKE, C; RAPPAPORT, A; SONDHEIMER, S				POLANECZKY, M; SLAP, G; FORKE, C; RAPPAPORT, A; SONDHEIMER, S			THE USE OF LEVONORGESTREL IMPLANTS (NORPLANT) FOR CONTRACEPTION IN ADOLESCENT MOTHERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; PREGNANCY; RISK	Background. Although levonorgestrel implants (Norplant) would appear to be a good contraceptive option for adolescent mothers, there is little information about the use of Norplant in this population. Methods. We studied 100 postpartum adolescents who chose a contraceptive method at an urban teaching hospital between September 1991 and July 1992. Structured interviews were conducted and medical records were reviewed soon after delivery and at a mean (+/-SD) of 15.5+/-2.9 months post partum. Results. Forty-eight of the adolescent mothers chose Norplant, 50 chose oral contraceptives, and 2 (not further studied) chose barrier methods of contraception. The factors significantly associated with the choice of Norplant were older age (16.7 years among those who chose Norplant, vs. 16.2 years among those who chose oral contraceptives), multiparity (24 subjects vs. 6 subjects), and previous use of oral contraceptives (34 subjects vs. 21 subjects). During follow-up, there were no differences between the Norplant group and the oral-contraceptive group in the frequency of clinic visits (an average of 2.3 visits per subject in each group), failure to return after the postpartum visit (9 subjects vs. 11 subjects), or the incidence of sexually transmitted diseases (42 percent vs. 36 percent). At follow-up, 95 percent of the subjects in the Norplant group and 33 percent of those in the oral-contraceptive group were still using the method they had chosen (P<0.001). During the first postpartum year 1 subject in the Norplant group and 19 in the oral-contraceptive group became pregnant (P<0.001). Norplant users did not differ from all other adolescents studied with regard to sexual activity or condom use. Conclusions. The selection of Norplant by adolescent mothers as a method of contraception is associated with higher rates of continued use and lower rates of new pregnancy than the selection of oral contraceptives and does not affect the use of health care services, sexual activity, condom use, or the rate of sexually transmitted diseases.	UNIV PENN,SCH MED,DEPT MED,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104; QUEENS UNIV,KINGSTON,ON,CANADA	University of Pennsylvania; University of Pennsylvania; Queens University - Canada	POLANECZKY, M (corresponding author), NEW YORK HOSP,CORNELL MED CTR,DEPT OBSTET & GYNECOL,DIV WOMENS HLTH,BOX 392,525 E 68TH ST,NEW YORK,NY 10021, USA.							BALASSONE ML, 1989, J ADOLESCENT HEALTH, V10, P527, DOI 10.1016/0197-0070(89)90016-8; COOPERSMITH S, 1986, ANTECEDENTS SELF EST; DEWITT K, 1992, NY TIMES        1215, pA7; EMANS SJ, 1987, JAMA-J AM MED ASSOC, V257, P3377, DOI 10.1001/jama.257.24.3377; FORD K, 1983, FAM PLANN PERSPECT, V15, P268, DOI 10.2307/2135292; FREEMAN EW, 1982, AM J PUBLIC HEALTH, V72, P815, DOI 10.2105/AJPH.72.8.815; FREEMAN EW, 1993, EARLY CHILDBEARING P, P172; FURSTENBERG FF, 1972, FAM PLANN PERSPECT, V4, P54, DOI 10.2307/2133939; FURSTENBERG FF, 1987, FAM PLANN PERSPECT, V19, P142, DOI 10.2307/2135159; HARLAP S, 1991, PREVENTING PREGNANCY, P31; HENSHAW SK, 1993, FAM PLANN PERSPECT, V25, P122, DOI 10.2307/2136160; HOFFERTH SL, 1987, FAM PLANN PERSPECT, V19, P46, DOI 10.2307/2135048; IPSEN J, 1970, BANCROFTS INTRO BIOS, P153; JONES EF, 1989, FAM PLANN PERSPECT, V21, P103, DOI 10.2307/2135659; JONES EF, 1985, FAM PLANN PERSPECT, V17, P53, DOI 10.2307/2135261; JONES EF, 1992, FAM PLANN PERSPECT, V24, P19; KANTROWITZ B, 1993, NEWSWEEK        1224, P37; LEE E T, 1972, Computer Programs in Biomedicine, V2, P315, DOI 10.1016/0010-468X(72)90019-0; MOTT FL, 1986, FAM PLANN PERSPECT, V18, P5, DOI 10.2307/2135193; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI DOI 10.1515/9781400876136; SHOUPE D, 1991, OBSTET GYNECOL, V77, P256, DOI 10.1097/00006250-199102000-00018; SHOUPE D, 1989, AM J OBSTET GYNECOL, V160, P1268; SIVIN I, 1988, STUD FAMILY PLANN, V19, P81, DOI 10.2307/1966493; SLAP GB, 1991, J ADOLESCENT HEALTH, V12, P434, DOI 10.1016/1054-139X(91)90020-X; SOKAL RR, 1987, INTRO BIOSTATISTICS, P112; WOODS ER, 1992, AM J OBSTET GYNECOL, V166, P901, DOI 10.1016/0002-9378(92)91359-I; Zar J. H, 1984, BIOSTAT ANAL, P176; Zar JH, 1984, BIOSTAT ANAL, P150; ZELNIK M, 1980, FAM PLANN PERSPECT, V12, P69, DOI 10.2307/2134748	29	128	128	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1201	1206		10.1056/NEJM199411033311806	http://dx.doi.org/10.1056/NEJM199411033311806			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN806	7935659				2022-12-28	WOS:A1994PN80600006
J	BURMAN, JF; CHUNG, HI; LANE, DA; PHILIPPOU, H; ADAMI, A; LINCOLN, JCR				BURMAN, JF; CHUNG, HI; LANE, DA; PHILIPPOU, H; ADAMI, A; LINCOLN, JCR			ROLE OF FACTOR-XII IN THROMBIN GENERATION AND FIBRINOLYSIS DURING CARDIOPULMONARY BYPASS	LANCET			English	Note							DEFICIENCY; SURGERY	During cardiopulmonary bypass, thrombin is generated, which is thought to be initiated by activation of factor XII on the surface of the bypass equipment. We present a patient with severe factor XII deficiency who underwent cardiac surgery. As much thrombin was formed during cardiopulmonary bypass (measured by the prothrombin activation fragment F-1+2 and thrombin-antithrombin complexes) as in normal patients, showing that factor XII was not necessary for thrombin generation. Factor X, but not factor IX, was activated (as measured by their activation peptides), and this activation correlated with F-1+2 and thrombin-antithrombin complexes, suggesting that the tissue-factor/factor-VIIa pathway is the trigger for thrombin formation.	CHARING CROSS & WESTMINSTER MED SCH,DEPT HAEMATOL,LONDON W6,ENGLAND	Imperial College London	BURMAN, JF (corresponding author), ROYAL BROMPTON HOSP,DEPT HAEMATOL,LONDON SW3 6NP,ENGLAND.			Philippou, Helen/0000-0002-9199-4201	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOISCLAIR MD, 1993, BLOOD, V82, P3350; CANDIO J, 1981, PENN MED, V84, P40; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAVIES GC, 1980, CIRCULATION, V61, P808, DOI 10.1161/01.CIR.61.4.808; Fuhrer G, 1986, Adv Exp Med Biol, V198 Pt B, P385; KAPELMAYER J, 1993, THROMB HAEMOSTASIS, V69, P974; KELSEY PR, 1985, CLIN LAB HAEMATOL, V7, P379, DOI 10.1111/j.1365-2257.1985.tb00053.x; Moorman R M, 1993, J Cardiothorac Vasc Anesth, V7, P452, DOI 10.1016/1053-0770(93)90169-L; RATNOFF OD, 1955, J CLIN INVEST, V34, P602, DOI 10.1172/JCI103109; SALMENPERA M, 1991, ANESTHESIOLOGY, V75, P539, DOI 10.1097/00000542-199109000-00027	10	82	82	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1192	1193		10.1016/S0140-6736(94)90509-6	http://dx.doi.org/10.1016/S0140-6736(94)90509-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934541				2022-12-28	WOS:A1994PN80300010
J	JOHNSON, A				JOHNSON, A			LARYNGEAL-CANCER - VARIATIONS IN TREATMENT	LANCET			English	Editorial Material							RADIATION-THERAPY; GLOTTIC CANCER; CARCINOMA; TOBACCO; ALCOHOL; RISK; HEAD				JOHNSON, A (corresponding author), QUEEN ELIZABETH HOSP,DEPT OTOLARYNGOL,BIRMINGHAM,W MIDLANDS,ENGLAND.							[Anonymous], 1991, NEW ENGL J MED, V324, P1685; ECKEL HE, 1992, ANN OTO RHINOL LARYN, V101, P113, DOI 10.1177/000348949210100202; KIM RY, 1992, RADIOLOGY, V182, P273, DOI 10.1148/radiology.182.1.1727295; MAIER H, 1992, CLIN INVESTIGATOR, V70, P320; MCDONALD S, 1989, INT J RADIAT ONCOL, V17, P457, DOI 10.1016/0360-3016(89)90095-3; MUSCAT JE, 1992, CANCER, V69, P2244, DOI 10.1002/1097-0142(19920501)69:9&lt;2244::AID-CNCR2820690906&gt;3.0.CO;2-O; OSULLIVAN B, 1994, RADIOTHER ONCOL, V31, P23, DOI 10.1016/0167-8140(94)90410-3; OTT S, 1992, LARYNGO RHINO OTOL, V71, P236, DOI 10.1055/s-2007-997287; ROBIN PE, 1987, S BROWNS OTOLARYNGOL, V5, P194; ROBSON NLK, 1990, J LARYNGOL OTOL, V104, P699, DOI 10.1017/S0022215100113660; SMALL W, 1992, RADIOLOGY, V183, P789, DOI 10.1148/radiology.183.3.1584935; TERHAARD CHJ, 1992, CLIN OTOLARYNGOL, V17, P393, DOI 10.1111/j.1365-2273.1992.tb01681.x	12	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1173	1174		10.1016/S0140-6736(94)90503-7	http://dx.doi.org/10.1016/S0140-6736(94)90503-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934535				2022-12-28	WOS:A1994PN80300004
J	HOGG, RS; STRATHDEE, SA; CRAIB, KJP; OSHAUGHNESSY, MV; MONTANER, JSG; SCHECHTER, MT				HOGG, RS; STRATHDEE, SA; CRAIB, KJP; OSHAUGHNESSY, MV; MONTANER, JSG; SCHECHTER, MT			LOWER SOCIOECONOMIC-STATUS AND SHORTER SURVIVAL FOLLOWING HIV-INFECTION	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; HOMOSEXUAL MEN; MORTALITY; AIDS; PROGRESSION; HEALTH	We studied the association between socioeconomic status and survival in a prospective study of 364 HIV-infected homosexual men who were recruited during 1982-84. The participants were divided by annual income; those earning above Canadian $10 000 (high-income; n=274) and those below $10 000 (low-income; n=90) at recruitment. The latter threshold closely approximated to the poverty level for this population. Low income men were significantly younger than high income men but the groups were similar with respect to baseline CD4 counts, subsequent use of anti-retrovirals and prophylaxis against Pneumocystis carinii pneumonia (PCP), and number of visits attended during follow-up. Subjects were followed for a median of 9.5 years (range 1.8-13.1). By Dec 31, 1993, there were 135 deaths yielding a cumulative mortality rate of mean 45% (SD 4.0) at 11.5 years. Men aged 30 or more at infection had poorer survival than those under 30 (mortality risk ratio 1.56; 95% CI 1.09-2.24; p=0.015), and longer survival was significantly associated with a higher CD4 count at the earliest seropositive visit. The age-adjusted mortality risk ratio for low income men compared with high income men was significantly increased at 1.63 (95% CI 1.11-2.40; p=0.013). The significant risk of death for low income men persisted despite adjustment for age at infection, CD4 count, use of zidovudine, dideoxyinosine, and dideoxycytidine, use of PCP prophylaxis, and year of infection. We cannot attribute our findings to income loss as a result of more rapid HIV progression because the same effect was present in people who provided income data before seroconversion. Similarly, our findings are not due to differential access to care because the study was done within the context of a universal health care system, and the two income groups received treatments equally. This finding is consistent with the association socioeconomic status with increased mortality observed within large populations and in other diseases.	UNIV BRITISH COLUMBIA,BRITISH COLUMBIA CTR EXCELLENCE IN HIV AIDS,VANCOUVER V6Z 1Y6,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6Z 1Y6,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6Z 1Y6,BC,CANADA; ST PAULS HOSP,VANCOUVER V6Z 1Y6,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia; St. Paul's Hospital; University of Saskatchewan			Strathdee, Steffanie A/B-9042-2009; Montaner, Julio/K-7621-2012; Hogg, Robert S/B-2783-2012	Hogg, Robert S/0000-0003-3463-5488; Schechter, Martin/0000-0001-6063-2155				BLAXTER M, 1983, SOC SCI MED, V17, P1139, DOI 10.1016/0277-9536(83)90006-0; CALDWELL JC, 1986, POPUL DEV REV, V12, P171, DOI 10.2307/1973108; CAPITANIO JP, 1991, AIDS, V5, P1103, DOI 10.1097/00002030-199109000-00007; CELLA DF, 1991, J CLIN ONCOL, V9, P1500, DOI 10.1200/JCO.1991.9.8.1500; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; HOGG RS, 1994, CAN MED ASSOC J, V150, P711; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; HUANG CM, 1988, CLIN CHEM, V34, P1957; KASS NE, 1994, J ACQ IMMUN DEF SYND, V7, P86; KESSLER RC, 1988, SOC SCI MED, V27, P569, DOI 10.1016/0277-9536(88)90004-4; KOOT M, 1993, ANN INTERN MED, V321, P1626; MARNEROS A, 1990, ACTA PSYCHIAT SCAND, V82, P352, DOI 10.1111/j.1600-0447.1990.tb01400.x; MOSESON M, 1989, J ACQ IMMUN DEF SYND, V2, P235; MOSS AR, 1988, BRIT MED J, V297, P1067, DOI 10.1136/bmj.297.6656.1067; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; SCHECHTER MT, 1994, J CLIN EPIDEMIOL, V47, P59, DOI 10.1016/0895-4356(94)90034-5; SCHECHTER MT, 1986, CAN MED ASSOC J, V118, P681; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; SYME SL, 1976, AM J EPIDEMIOL, V104, P1; TANG AM, 1993, AM J EPIDEMIOL, V138, P937, DOI 10.1093/oxfordjournals.aje.a116814; VEUGELERS PJ, IN PRESS AM J EPIDEM; Wilkins R, 1989, Health Rep, V1, P137; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; WISE PH, 1985, NEW ENGL J MED, V313, P360, DOI 10.1056/NEJM198508083130605; 1982, INCOME DISTRIBUTIONS; 1987, MMWR-MORBID MORTAL W, V36, P24; 1993, JAMA-J AM MED ASSOC, V270, P305	30	89	91	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1120	1124		10.1016/S0140-6736(94)90631-9	http://dx.doi.org/10.1016/S0140-6736(94)90631-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN066	7934494				2022-12-28	WOS:A1994PN06600010
J	MARCH, L; IRWIG, L; SCHWARZ, J; SIMPSON, J; CHOCK, C; BROOKS, P				MARCH, L; IRWIG, L; SCHWARZ, J; SIMPSON, J; CHOCK, C; BROOKS, P			N OF 1 TRIALS COMPARING A NONSTEROIDAL ANTIINFLAMMATORY DRUG WITH PARACETAMOL IN OSTEOARTHRITIS	BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CLINICAL USEFULNESS; GENERAL-PRACTICE; OSTEO-ARTHRITIS; SINGLE SUBJECTS; KNEE; ACETAMINOPHEN; ULCERS; 2-YEAR; NSAID	Objective-To evaluate the efficacy of paracetamol and a non-steroidal anti-inflammatory drug for symptom reliefin osteoarthritis. Design-Double blind, randomised, controlled trials in individual patients (n of 1 trials). Three treatment cycles with two weeks' each of paracetamol (1 g twice daily) and diclofenac (50 mg twice daily) prepared in identical gelatin capsules. Setting-General practices in metropolitan Sydney, Australia. Subjects-25 patients (median age 64 years) with pain of osteoarthritis (median duration of disease eight years) considered by their general practitioners to require regular treatment. 20 were already taking non-steroidal anti-inflammatory drugs. Main outcome measures-Diary of pain and stiffness, function, and side effects. Results-15 patients completed the study, five withdrew early but had made a therapeutic decision, and five dropped out very early. Results from 20 patients were analysed. Several patterns of response evolved. Eight of the 20 patients found no clear difference, symptoms being adequately controlled by paracetamol; five indicated a clear preference for the non-steroidal anti-inflammatory drug; two showed control of symptoms after their initial two weeks of the non-steroidal antiinflammatory drug which continued throughout subsequent treatment changes; in five the nonsteroidal anti-inflammatory drug may have been better but neither agent gave satisfactory control. After three months nine of the 20 patients had adequate symptom control with paracetamol alone. Conclusions-n Of 1 studies-that is, randomised trials in individual patients-are clinically useful in deciding treatment in heterogeneous conditions which require long term symptomatic relief. In osteoarthritis many patients currently receiving or being considered for non-steroidal anti-inflammatory drugs may achieve adequate control with paracetamol.	UNIV SYDNEY,NSAHS PUBL HLTH UNIT,SYDNEY,NSW 2006,AUSTRALIA; UNIV SYDNEY,DEPT PUBL HLTH,SYDNEY,NSW 2006,AUSTRALIA; ST VINCENTS HOSP,DARLINGHURST,NSW 2010,AUSTRALIA	University of Sydney; University of Sydney; St Vincents Hospital Sydney	MARCH, L (corresponding author), ROYAL N SHORE HOSP,FLORANCE & COPE PROFESSORIAL DEPT RHEUMATOL,ST LEONARDS,NSW 2065,AUSTRALIA.							ALLISON MC, 1992, NEW ENGL J MED, V327, P749, DOI 10.1056/NEJM199209103271101; Bellamy N, 1988, J ORTHOP RHEUMATOL, V1, P95; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BROOKS PM, 1982, J RHEUMATOL, V9, P3; DEBONO GG, 1986, BRIT J CLIN PRACT, V40, P421; DIEPPE P, 1993, BRIT J RHEUMATOL, V32, P595; DIEPPE PA, 1993, LANCET, V341, P353, DOI 10.1016/0140-6736(93)90147-9; DOYLE DV, 1981, ANN RHEUM DIS, V40, P75, DOI 10.1136/ard.40.1.75; ELLIOTT SL, 1993, AUSTR PRESCRIBER, V16, P93; ERIKSSON LS, 1992, J INTERN MED, V231, P567, DOI 10.1111/j.1365-2796.1992.tb00976.x; FELSON DT, 1990, RHEUM DIS CLIN N AM, V16, P499; FRIES JF, 1991, ARTHRITIS RHEUM, V34, P1353; GABRIEL SE, 1990, J RHEUMATOL, V17, P1; GIBSON T, 1989, BR J RHEUMATOL, V27, P87; GOLDSTEIN DJ, 1991, NEW ENGL J MED, V325, P1808; GUYATT G, 1988, CAN MED ASSOC J, V139, P497; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; HENRY DA, 1987, BRIT MED J, V300, P278; HOITSMA AJ, 1991, DRUG SAFETY, V6, P131, DOI 10.2165/00002018-199106020-00004; INSEL PA, 1990, GOODMAN GILMANS PHAR; JAESCHKE R, 1991, J RHEUMATOL, V18, P447; JOHANNESSEN T, 1991, BMJ-BRIT MED J, V303, P173, DOI 10.1136/bmj.303.6795.173; JONES AC, 1992, BRIT J RHEUMATOL, V31, P45; LAWRENCE RC, 1989, J RHEUMATOL, V16, P427; LEWIS JA, 1991, BRIT MED J, V303, P175, DOI 10.1136/bmj.303.6795.175; PARR G, 1989, BRIT J CLIN PHARMACO, V27, P235, DOI 10.1111/j.1365-2125.1989.tb05356.x; RASHAD S, 1989, LANCET, V2, P519; SOMERVILLE K, 1986, LANCET, V1, P462; SPIEGELHALTER DJ, 1988, SCAND J GASTROENTE S, V147, P40; STAMP J, 1989, BRIT J CLIN PRACT, V43, P24; SWIFT GL, 1992, BRIT J CLIN PRACT, V46, P92; WILLIAMS HJ, 1993, ARTHRITIS RHEUM-US, V36, P1196, DOI 10.1002/art.1780360904	33	102	107	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1041	1045		10.1136/bmj.309.6961.1041	http://dx.doi.org/10.1136/bmj.309.6961.1041			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN733	7950736	Green Published			2022-12-28	WOS:A1994PN73300018
J	MIDDLETON, FA; STRICK, PL				MIDDLETON, FA; STRICK, PL			ANATOMICAL EVIDENCE FOR CEREBELLAR AND BASAL GANGLIA INVOLVEMENT IN HIGHER COGNITIVE FUNCTION	SCIENCE			English	Article							RHESUS-MONKEY; GLOBUS PALLIDUS; HORSERADISH-PEROXIDASE; FRONTAL-LOBE; PREFRONTAL CORTEX; MACACA-MULATTA; MOTOR CORTEX; PROJECTIONS; ORGANIZATION; CONNECTIONS	The possibility that neurons in the basal ganglia and cerebellum innervate areas of cerebral cortex that are involved in cognitive function has been a contriversial subject. Here, retrograde transneuronal transport of herpes simplex virus type 1 (HSV1) was used to identify subcortical neurons that project via the thalamus to area 46 of the primate prefrontal cortex. This cortical area is known to be involved in spatial working memory. Many neurons in restricted regions of the dentate nucleus of the cerebral and in the internal segment of the globus pallidus were labeled by transneuronal transport of visus from area 46. The location of these neurons was different from those labeled after HSV1 transport from motor areas of the cerebral cortex. These observations define an anatomical substrate for the involvement of basal ganglia and cerrebellar output in higher cognitive function.	VET ADM MED CTR, RES SERV, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PHYSIOL, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, PROGRAM NEUROSCI, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT NEUROSURG, SYRACUSE, NY 13210 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center				Middleton, Frank/0000-0002-3107-7188	NINDS NIH HHS [NS24328] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024328] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKSHOOMOFF NA, 1992, BEHAV NEUROSCI, V106, P731, DOI 10.1037/0735-7044.106.5.731; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ANDERSON ME, 1985, J NEUROPHYSIOL, V54, P433, DOI 10.1152/jn.1985.54.2.433; BARBAS H, 1991, J COMP NEUROL, V313, P65, DOI 10.1002/cne.903130106; BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306; BLOEDEL JR, 1993, TRENDS NEUROSCI, V16, P451, DOI 10.1016/0166-2236(93)90075-W; BRODAL P, 1979, NEUROSCIENCE, V4, P193, DOI 10.1016/0306-4522(79)90082-4; BUTTERS N, 1978, ARCH NEUROL-CHICAGO, V35, P585, DOI 10.1001/archneur.1978.00500330033006; CANAVAN AGM, 1994, BEHAV NEUROSCI, V108, P475, DOI 10.1037/0735-7044.108.3.475; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DELONG MR, 1971, J NEUROPHYSIOL, V34, P414, DOI 10.1152/jn.1971.34.3.414; DEVITO JL, 1982, EXP BRAIN RES, V46, P107; EVARTS EV, 1969, ANNU REV PHYSIOL, V31, P451, DOI 10.1146/annurev.ph.31.030169.002315; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; Fuster J.M., 1985, CEREB CORTEX, V4, P151; Fuster J.M., 1989, PREFRONTAL CORTEX; GLICKSTEIN M, 1985, J COMP NEUROL, V235, P343, DOI 10.1002/cne.902350306; GLICKSTEIN M, 1993, TRENDS NEUROSCI, V16, P450, DOI 10.1016/0166-2236(93)90074-V; GOLDMAN PS, 1977, J COMP NEUROL, V171, P369, DOI 10.1002/cne.901710305; GOLDMANRAKIC PS, 1990, PROG BRAIN RES, V85, P325; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; GRAFMAN J, 1992, NEUROLOGY, V42, P1493, DOI 10.1212/WNL.42.8.1493; HOLSAPPLE JW, 1991, J NEUROSCI, V11, P2644; Hoover J. E., 1993, Society for Neuroscience Abstracts, V19, P1590; HOOVER JE, 1993, SCIENCE, V259, P819, DOI 10.1126/science.7679223; ITO M, 1993, TRENDS NEUROSCI, V16, P448, DOI 10.1016/0166-2236(93)90073-U; KEMP JM, 1971, PHILOS T R SOC B, V262, P441, DOI 10.1098/rstb.1971.0106; KIEVIT J, 1977, EXP BRAIN RES, V29, P299; Kievit J., 1972, CORTICOTHALAMIC PROJ, P91; KIM R, 1976, J COMP NEUROL, V169, P263, DOI 10.1002/cne.901690302; KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851; KUO JS, 1973, J COMP NEUROL, V151, P201, DOI 10.1002/cne.901510302; KUSAMA T, 1971, P JPN ACAD, V47, P505, DOI 10.2183/pjab1945.47.505; LEICHNETZ GR, 1984, J COMP NEUROL, V228, P388, DOI 10.1002/cne.902280307; LEINER HC, 1991, BEHAV BRAIN RES, V44, P113, DOI 10.1016/S0166-4328(05)80016-6; LEINER HC, 1993, TRENDS NEUROSCI, V16, P444, DOI 10.1016/0166-2236(93)90072-T; LYNCH JC, IN PRESS EXP BRAIN R; MINK JW, 1991, J NEUROPHYSIOL, V65, P273, DOI 10.1152/jn.1991.65.2.273; NAUTA WALLE J. H., 1966, BRAIN RES, V1, P3, DOI 10.1016/0006-8993(66)90103-X; olszewski j, 1952, THALAMUS MACACA MULA; ORIOLI PJ, 1989, J COMP NEUROL, V288, P612, DOI 10.1002/cne.902880408; PARENT A, 1982, BRAIN RES, V245, P201, DOI 10.1016/0006-8993(82)90802-2; PERCHERON G, 1977, J HIRNFORSCH, V18, P375; PETERSEN SE, 1993, ANNU REV NEUROSCI, V16, P509, DOI 10.1146/annurev.ne.16.030193.002453; SASAKI K, 1979, EXP BRAIN RES, V37, P193, DOI 10.1007/BF01474266; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; SELEMON LD, 1985, J NEUROSCI, V5, P776; SELEMON LD, 1988, J NEUROSCI, V8, P4049; STANTON GB, 1980, J COMP NEUROL, V190, P699, DOI 10.1002/cne.901900406; STRICK PL, 1993, INT CONGR SER, V1024, P171; STRICK PL, 1993, EXPT NEUROANATOMY PR, P81; STRUB RL, 1989, ARCH NEUROL-CHICAGO, V46, P1024, DOI 10.1001/archneur.1989.00520450096027; TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P57, DOI 10.1152/jn.1993.69.1.57; Walker AE, 1940, J COMP NEUROL, V73, P59, DOI 10.1002/cne.900730106; WETTS R, 1985, J NEUROPHYSIOL, V54, P231, DOI 10.1152/jn.1985.54.2.231; WIESENDANGER R, 1985, EXP BRAIN RES, V59, P105; YAMAMOTO T, 1992, BRAIN RES, V579, P315, DOI 10.1016/0006-8993(92)90067-J; YETERIAN EH, 1978, BRAIN RES, V139, P43, DOI 10.1016/0006-8993(78)90059-8; ZEMANICK MC, 1991, P NATL ACAD SCI USA, V88, P8048, DOI 10.1073/pnas.88.18.8048	60	944	966	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	1994	266	5184					458	461		10.1126/science.7939688	http://dx.doi.org/10.1126/science.7939688			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939688				2022-12-28	WOS:A1994PN27200041
J	VANLUENEN, HGAM; COLLOMS, SD; PLASTERK, RHA				VANLUENEN, HGAM; COLLOMS, SD; PLASTERK, RHA			THE MECHANISM OF TRANSPOSITION OF TC3 IN C-ELEGANS	CELL			English	Article							TRANSPOSABLE ELEMENT TC1; CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; INTEGRASE PROTEIN; FAMILY; EXCISION; INSERTION; GENE; DNA; SEQUENCES	The Tc3 transposon of C. elegans belongs to a family of inverted repeat DNA transposons, found in many different phyla. We studied the mechanism of Tc3 transposition by expression of Tc3 transposase from a heat-shock promoter in transgenic nematodes. Transposition is accompanied by the appearance of linear extrachromosomal Tc3 DNA. Analysis of the ends of this presumed transposition intermediate shows that the transposon is excised incompletely: the 5' ends of the transposon lack two nucleotides. The 3' ends coincide with the last nucleotide of the integrated element and carry 3' hydroxyls. The nucleotides that are not coexcised with the transposon remain at the donor site and result in a characteristic footprint. A model is derived for the mechanism of Tc3 jumping that probably applies to the entire family of Tc1/mariner transposable elements.			VANLUENEN, HGAM (corresponding author), NETHERLANDS CANC INST, DIV MOLEC BIOL, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS.			van Luenen, Henri/0000-0002-5584-7968; Colloms, Sean/0000-0003-2369-8168				ABAD P, 1991, J MOL EVOL, V33, P251, DOI 10.1007/BF02100676; ATKINSON PW, 1993, P NATL ACAD SCI USA, V90, P9693, DOI 10.1073/pnas.90.20.9693; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; BREZINSKY L, 1990, NUCLEIC ACIDS RES, V18, P2053, DOI 10.1093/nar/18.8.2053; BRYAN G, 1990, GENETICS, V125, P103; CAIZZI R, 1993, GENETICS, V133, P335; CARR B, 1994, MOL CELL BIOL, V14, P3426, DOI 10.1128/MCB.14.5.3426; COLLINS J, 1989, GENETICS, V121, P47; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; DABOUSSI MJ, 1992, MOL GEN GENET, V232, P12, DOI 10.1007/BF00299131; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; EIDE D, 1988, MOL CELL BIOL, V8, P737, DOI 10.1128/MCB.8.2.737; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FRANZ G, 1991, NUCLEIC ACIDS RES, V19, P6646, DOI 10.1093/nar/19.23.6646; GARCIAFERNANDEZ J, 1993, NATURE, V364, P109, DOI 10.1038/364109a0; HARRIS LJ, 1988, NUCLEIC ACIDS RES, V16, P5991, DOI 10.1093/nar/16.13.5991; HARRIS LJ, 1990, J MOL EVOL, V30, P359, DOI 10.1007/BF02101890; HEIERHORST J, 1992, P NATL ACAD SCI USA, V89, P6798, DOI 10.1073/pnas.89.15.6798; HEINKOFF S, 1992, NEW BIOL, V4, P382; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KIFF JE, 1988, NATURE, V331, P631, DOI 10.1038/331631a0; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MOORE SP, 1994, P NATL ACAD SCI USA, V91, P1843, DOI 10.1073/pnas.91.5.1843; OBROCHTA DA, 1991, MOL GEN GENET, V225, P387, DOI 10.1007/BF00261678; PLASTERK RHA, 1992, EMBO J, V11, P287, DOI 10.1002/j.1460-2075.1992.tb05051.x; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; RADICE AR, 1994, IN PRESS MOL GEN GEN; ROBERTSON HM, 1992, NUCLEIC ACIDS RES, V20, P6409, DOI 10.1093/nar/20.23.6409; ROSE AM, 1984, NATURE, V311, P485, DOI 10.1038/311485a0; RUAN KS, 1987, NUCLEIC ACIDS RES, V15, P6875, DOI 10.1093/nar/15.17.6875; RUAN KS, 1984, P NATL ACAD SCI-BIOL, V81, P4018, DOI 10.1073/pnas.81.13.4018; Sambrook J, 1989, MOL CLONING LABORATO; SHIN CG, 1994, J VIROL, V68, P1633, DOI 10.1128/JVI.68.3.1633-1642.1994; SKALKA AM, 1993, GENE, V135, P175, DOI 10.1016/0378-1119(93)90063-9; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; SULSTON J, 1987, NEMATODE CAENORHABDI, P587; TAUSTA SL, 1989, CELL, V59, P1019, DOI 10.1016/0092-8674(89)90758-7; TENZEN T, 1990, J BACTERIOL, V172, P3830, DOI 10.1128/jb.172.7.3830-3836.1990; TUDOR M, 1992, MOL GEN GENET, V232, P126, DOI 10.1007/BF00299145; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANLUENEN HGAM, 1994, NUCLEIC ACIDS RES, V22, P262, DOI 10.1093/nar/22.3.262; VANLUENEN HGAM, 1993, EMBO J, V12, P2513, DOI 10.1002/j.1460-2075.1993.tb05906.x; VARMUS H, 1989, MOBILE DNA, P53; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S; VOS JC, 1993, GENE DEV, V7, P1244, DOI 10.1101/gad.7.7a.1244; [No title captured]	58	164	169	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	1994	79	2					293	301		10.1016/0092-8674(94)90198-8	http://dx.doi.org/10.1016/0092-8674(94)90198-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954797				2022-12-28	WOS:A1994PN63000013
J	SHVARTZMAN, P				SHVARTZMAN, P			CONTROVERSIES IN MANAGEMENT - ARE ANTIBIOTICS APPROPRIATE FOR SORE THROATS - CAREFUL PRESCRIBING IS BENEFICIAL	BRITISH MEDICAL JOURNAL			English	Article							STREPTOCOCCAL PHARYNGITIS; RHEUMATIC-FEVER; DIAGNOSIS				SHVARTZMAN, P (corresponding author), BEN GURION UNIV NEGEV,CTR HLTH SCI,DEPT FAMILY MED,POB 653,IL-84105 BEER SHEVA,ISRAEL.		SHVARTZMAN, PESACH/F-2134-2012					CENTOR RM, 1986, ANN INTERN MED, V105, P892, DOI 10.7326/0003-4819-105-6-892; DENEEF P, 1987, J FAM PRACTICE, V25, P347; GERBER MA, 1988, AM J DIS CHILD, V142, P562, DOI 10.1001/archpedi.1988.02150050100043; HAGEN MD, 1992, J FAM PRACTICE, V34, P141; HERMAN J, 1993, J CLIN EPIDEMIOL, V46, P489, DOI 10.1016/0895-4356(93)90026-W; Hoffmann S, 1986, Scand J Prim Health Care, V4, P143, DOI 10.3109/02813438609014821; PICHICHERO ME, 1990, AM FAM PHYSICIAN, V42, P1567; STILLERMAN M, 1961, AM J DIS CHILD, V101, P476, DOI 10.1001/archpedi.1961.04020050066011; TALBOT RG, 1984, NEW ZEAL MED J, V97, P630; TOUWOTTEN FWMM, 1992, FAM PRACT, V9, P255, DOI 10.1093/fampra/9.3.255; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; [No title captured]	12	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					1011	1012		10.1136/bmj.309.6960.1011	http://dx.doi.org/10.1136/bmj.309.6960.1011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950696	Green Published			2022-12-28	WOS:A1994PM41700033
J	KALE, R				KALE, R			HEALTH INFORMATION FOR THE DEVELOPING-WORLD	BRITISH MEDICAL JOURNAL			English	Article								Doctors and other health professionals in developing countries are missing out on relevant information about health. A lot of the information they need is available in the developed countries, and those who have it are happy to share it with them. But transporting information, like food or medicines, from one part of the world to another is not an easy task nor is it the complete answer to the information drought. It is one thing to ferry books and journals from Europe to Africa and another to make relevant information available to the right person at the right time at an affordable cost.											0	46	46	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 8	1994	309	6959					939	942		10.1136/bmj.309.6959.939	http://dx.doi.org/10.1136/bmj.309.6959.939			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7950670	Green Published			2022-12-28	WOS:A1994PL78100028
J	SCHNEIDER, KR; SMITH, RL; OSHEA, EK				SCHNEIDER, KR; SMITH, RL; OSHEA, EK			PHOSPHATE-REGULATED INACTIVATION OF THE KINASE PHO80-PHO85 BY THE CDK INHIBITOR PHO81	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SACCHAROMYCES-CEREVISIAE; G1 CYCLIN; GENE; PROTEIN; YEAST; SYSTEM; FAR1; IDENTIFICATION; COMPLEXES	A complex consisting of the cyclin-dependent kinase (CDK) PHO85 and the cyclin PHO80 phosphorylates and is thought to inactivate the transcription factor PHO4 when yeast cells are grown in medium containing high concentrations of phosphate. The CDK inhibitor PHO81 inhibits the kinase activity of the PHO80-PHO85 complex when Saccharomyces cerevisiae cells are grown in medium depleted of phosphate. A region of PHO81 with similarity to the mammalian CDK inhibitor p16(INK4) is sufficient for inhibition in vitro. These studies demonstrate that CDK inhibitors are used to regulate kinases involved in processes other than cell cycle control and suggest that the ankyrin repeat motif may be commonly used for interaction with cyclin-CDK complexes.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco				Schneider, Ken Robert/0000-0002-6638-6810				BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CREASY CL, 1993, NUCLEIC ACIDS RES, V21, P1975, DOI 10.1093/nar/21.8.1975; GILLIQUET V, 1987, NUCLEIC ACIDS RES, V15, P5893, DOI 10.1093/nar/15.14.5893; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HARPER JW, 1993, CELL, V75, P805; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LEMIRE JM, 1985, MOL CELL BIOL, V5, P2131, DOI 10.1128/MCB.5.8.2131; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; OCONNELL KF, 1992, GENETICS, V132, P63; OGAWA N, 1993, MOL GEN GENET, V238, P444, DOI 10.1007/BF00292004; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHNEIDER K, UNPUB; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Toh-e A, 1986, Yeast, V2, P129, DOI 10.1002/yea.320020209; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940	35	203	215	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 7	1994	266	5182					122	126		10.1126/science.7939631	http://dx.doi.org/10.1126/science.7939631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7939631				2022-12-28	WOS:A1994PK58200039
J	LAZARO, C; RAVELLA, A; GAONA, A; VOLPINI, V; ESTIVILL, X				LAZARO, C; RAVELLA, A; GAONA, A; VOLPINI, V; ESTIVILL, X			NEUROFIBROMATOSIS TYPE-1 DUE TO GERM-LINE MOSAICISM IN A CLINICALLY NORMAL FATHER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VONRECKLINGHAUSEN NEUROFIBROMATOSIS; GONADAL MOSAICISM; MUTATION-RATE; NF1 GENE; DELETION; SEQUENCE; POLYMORPHISM; REPEAT; FAMILY; IV	Background. The mutation rate of the neurofibromatosis type 1 (NF1) gene is one of the highest in the human genome, with about 50 percent of cases being due to new mutations. We describe a family in which neurofibromatosis type 1 occurred in two siblings with clinically normal parents, and we demonstrate germ-line mosaicism in the father. Methods. We studied lymphocyte DNA from each member of the family and the father's spermatozoa for several polymorphic intragenic markers of the NF1 gene. Southern blots of DNA digested with several enzymes were hybridized with complementary DNA and individual NF1 exon probes to search for alterations in the gene. Results. The affected siblings, with a clinically severe form of neurofibromatosis type 1, showed no inheritance of paternal alleles for a marker in intron 38 of the NF1 gene, whereas they received alleles from both parents for other NF1 markers. Analysis with probes from this region of the NF1 gene showed a 12-kb deletion of the NF1 gene, involving exons 32 to 39, in the affected offspring. Ten percent of the father's spermatozoa carried the same NF1 deletion, but the abnormality was not detected in DNA from his lymphocytes. Conclusions. The presence of the NF1 mutation in 10 percent of the clinically normal father's spermatozoa supports the hypothesis that most germ-line mutations occur in precursors of gametes. In cases of spontaneous mutation, analyzing the specific NF1 mutation in the father's sperm might help in the detection of mosaicism and thus facilitate genetic counseling about further pregnancies.	LHOSP LLOBREGAT, HOSP DURAN & REYNALS, INST RECERCA ONCOL, DEPT MOLEC GENET, E-08907 BARCELONA, SPAIN; HOSP CREU ROJA DE BARCELONA, BARCELONA, SPAIN; HOSP CLIN BARCELONA, GENET SERV, E-08036 BARCELONA, SPAIN	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Barcelona; Hospital Clinic de Barcelona			Estivill, Xavier/A-3125-2013; GARCIA, CONXI LAZARO/Q-2410-2016	Estivill, Xavier/0000-0002-0723-2256; GARCIA, CONXI LAZARO/0000-0002-7198-5906				ALLANSON JE, 1986, CLIN GENET, V29, P429; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BAKKER E, 1987, NATURE, V329, P554, DOI 10.1038/329554a0; BRADLEY TB, 1980, JOHNS HOPKINS MED J, V146, P236; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAREY JC, 1986, ANN NY ACAD SCI, V486, P45, DOI 10.1111/j.1749-6632.1986.tb48061.x; CAWTHON, 1990, CELL, V62, P609; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; FRYNS JP, 1983, CLIN GENET, V24, P156; FUENTES JJ, 1993, INT J LEGAL MED, V105, P271, DOI 10.1007/BF01370384; GITSCHIER J, 1989, LANCET, V1, P273; HALL JG, 1988, AM J HUM GENET, V43, P355; HALL JG, 1987, AM J MED GENET, V28, P143, DOI 10.1002/ajmg.1320280121; HUSON SM, 1989, J MED GENET, V26, P704, DOI 10.1136/jmg.26.11.704; JADAYEL D, 1990, NATURE, V343, P558, DOI 10.1038/343558a0; LAZARO C, 1993, HUM GENET, V92, P429, DOI 10.1007/BF01247353; LAZARO C, 1993, HUM MOL GENET, V2, P725, DOI 10.1093/hmg/2.6.725; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; MADDALENA A, 1988, NEW ENGL J MED, V319, P999, DOI 10.1056/NEJM198810133191507; MILEWICZ DM, 1993, AM J HUM GENET, V53, P62; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MURRAY EW, 1992, AM J HUM GENET, V50, P199; RICCARDI VM, 1988, AM J HUM GENET, V42, P284; RICCARDI VM, 1986, NEUROIBROMATOSIS PHE; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SERGEYEV AS, 1975, HUMANGENETIK, V28, P129, DOI 10.1007/BF00735745; SOLERA J, 1992, AM J HUM GENET, V50, P434; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALLACE MR, 1990, SCIENCE, V250, P1749; XU GF, 1991, NUCLEIC ACIDS RES, V19, P3764, DOI 10.1093/nar/19.13.3764; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	34	115	121	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1403	1407		10.1056/NEJM199411243312102	http://dx.doi.org/10.1056/NEJM199411243312102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7969279				2022-12-28	WOS:A1994PU53300002
J	MILLARD, PS; GENSHEIMER, KF; ADDISS, DG; SOSIN, DM; BECKETT, GA; HOUCKJANKOSKI, A; HUDSON, A				MILLARD, PS; GENSHEIMER, KF; ADDISS, DG; SOSIN, DM; BECKETT, GA; HOUCKJANKOSKI, A; HUDSON, A			AN OUTBREAK OF CRYPTOSPORIDIOSIS FROM FRESH-PRESSED APPLE CIDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; TRANSMISSION; COMMUNITY; SYMPTOMS; GEORGIA; GIARDIA; DISEASE; OOCYSTS	Background.-Recent waterborne outbreaks have established Cryptosporidium as an emerging enteric pathogen, but foodborne transmission has rarely been reported. In October 1993, an outbreak of cryptosporidiosis occurred among students and staff attending a 1-day school agricultural fair in central Maine. Design.-Environmental/laboratory investigation and cohort study. Participants.-Attendees of the fair and their household members. Main Outcome Measures.-Clinical or laboratory-confirmed cryptosporidiosis. Clinical cryptosporidiosis was defined as 3 days of either diarrhea (three loose stools in a 24-hour period) or vomiting. Results.-Surveys were completed for 611 (81%) of the estimated 759 fair attendees. Among attendees who completed the survey, there were 160 (26%) primary cases. Cryptosporidium oocysts were detected in the stools of 50 (89%) of 56 primary and secondary case patients tested. The median incubation period was 6 days (range, 10 hours to 13 days); the median duration of illness was 6 days (range, 1 to 16 days). Eighty-four percent of primary case patients had diarrhea and 82% had vomiting. Persons drinking apple cider that was hand pressed in the afternoon were at increased risk for cryptosporidiosis (154 [54%] of 284 exposed vs six [2%] of 292 unexposed; relative risk, 26; 95% confidence interval, 12 to 59). Cryptosporidium oocysts were detected in the apple cider, on the cider press, and in the stool specimen of a calf on the farm that supplied the apples. The secondary household transmission rate was 15% (53/353). Conclusions.-This is the first large cryptosporidiosis outbreak in which foodborne transmission has been documented. It underscores the need for agricultural producers to take measures to avoid contamination of foodstuffs with infectious agents common to the farm environment.	MAINE BUR HLTH, DIV DIS CONTROL, AUGUSTA, ME 04333 USA; CTR DIS CONTROL & PREVENT, EPIDEMIOL PROGRAM OFF, DIV FIELD EPIDEMIOL, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, EPIDEMIOL PROGRAM OFF, EPIDEM INTELLIGENCE SERV, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV PARASIT DIS, ATLANTA, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA				Hudson, Arlene/0000-0003-3980-4383				ADDISS DG, 1991, PEDIATR INFECT DIS J, V10, P907, DOI 10.1097/00006454-199112000-00005; ALPERT G, 1986, PEDIATRICS, V77, P152; ANDERSON BC, 1985, AM J PUBLIC HEALTH, V75, P1433, DOI 10.2105/AJPH.75.12.1433; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; CAMPBELL I, 1982, VET REC, V111, P414, DOI 10.1136/vr.111.18.414; CASEMORE DP, 1990, EPIDEMIOL INFECT, V104, P1, DOI 10.1017/S0950268800054480; CASEMORE DP, 1990, LANCET, V336, P1427, DOI 10.1016/0140-6736(90)93115-6; CASEMORE DP, 1993, LANCET, V342, P312, DOI 10.1016/0140-6736(93)91863-H; COMBEE CL, 1986, PEDIATR INFECT DIS J, V5, P528, DOI 10.1097/00006454-198609000-00008; CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325, DOI 10.1128/CMR.4.3.325-358.1991; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; EGGER M, 1990, ARCH DIS CHILD, V65, P445, DOI 10.1136/adc.65.4.445; FREIDANK H, 1987, EUR J CLIN MICROBIOL, V6, P56, DOI 10.1007/BF02097194; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; JOKIPII L, 1986, NEW ENGL J MED, V315, P1643, DOI 10.1056/NEJM198612253152604; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; LELAND D, 1993, J AM WATER WORKS ASS, V85, P34; LENGERICH EJ, 1993, J INFECT DIS, V167, P1252, DOI 10.1093/infdis/167.5.1252; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MILLER RA, 1990, J INFECT DIS, V161, P312, DOI 10.1093/infdis/161.2.312; MIRON D, 1991, PEDIATR INFECT DIS J, V10, P438, DOI 10.1097/00006454-199106000-00004; NEWMAN RD, 1994, ANN INTERN MED, V120, P500, DOI 10.7326/0003-4819-120-6-199403150-00009; PALMER SR, 1990, BRIT MED J, V300, P774, DOI 10.1136/bmj.300.6727.774; Romanova T. V., 1992, Meditsinskaya Parazitologiya i Parazitarnye Bolezni, V0, P50; SHIELD J, 1990, J INFECTION, V21, P297, DOI 10.1016/0163-4453(90)94053-3; SMITH JL, 1993, J FOOD PROTECT, V56, P451, DOI 10.4315/0362-028X-56.5.451; STEHRGREEN JK, 1987, AM J TROP MED HYG, V36, P338, DOI 10.4269/ajtmh.1987.36.338; TANGERMANN RH, 1991, AM J EPIDEMIOL, V133, P471, DOI 10.1093/oxfordjournals.aje.a115914; UNGAR BLP, 1990, CRYPTOSPORIDIOSIS MA; 1975, MMWR-MORBID MORTAL W, V24, P87; 1993, MANUAL MASSACHUSETTS; 1992, EMERGING INFECTIONS; 1994, MMWR-MORBID MORTAL W, V42, P1; 1990, SAS RELEASE 6 03	35	224	240	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	1994	272	20					1592	1596		10.1001/jama.272.20.1592	http://dx.doi.org/10.1001/jama.272.20.1592			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR405	7966869				2022-12-28	WOS:A1994PR40500025
J	NIGHTINGALE, SL				NIGHTINGALE, SL			DEATHS ASSOCIATED WITH ALLERGENIC EXTRACTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1994, FDA MED B, P24	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1488	1488						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966836				2022-12-28	WOS:A1994PQ90000022
J	LAPORTE, JR; FIGUERAS, A				LAPORTE, JR; FIGUERAS, A			PLACEBO-EFFECTS IN PSYCHIATRY	LANCET			English	Article							ALZHEIMERS-DISEASE; GENERAL-PRACTICE; TERM TREATMENT; DEPRESSION; TRIAL; DRUGS; DISORDER; ANXIETY				LAPORTE, JR (corresponding author), UNIV AUTONOMA BARCELONA,CSU VALL HEBRON,INST CATALA FARMACOL,DEPT PHARMACOL & PSYCHIAT,E-08035 BARCELONA,SPAIN.		Figueras, Albert/H-7743-2012; Laporte, Joan-Ramon/A-1302-2011; Figueras, Albert/I-7421-2013	Figueras, Albert/0000-0002-2740-2013; Figueras, Albert/0000-0002-2740-2013				BALLENGER JC, 1988, ARCH GEN PSYCHIAT, V45, P413; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; CAPELLA D, 1988, BRIT MED J, V297, P722, DOI 10.1136/bmj.297.6650.722; EISENBERG L, 1992, NEW ENGL J MED, V326, P1080, DOI 10.1056/NEJM199204163261610; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; HORVATH P, 1988, PSYCHOL BULL, V104, P214, DOI 10.1037/0033-2909.104.2.214; JOHNSTONE EC, 1978, LANCET, V1, P848; JOLLEY AG, 1989, BRIT MED J, V298, P985, DOI 10.1136/bmj.298.6679.985; KELLER MB, 1982, JAMA-J AM MED ASSOC, V248, P1848, DOI 10.1001/jama.248.15.1848; KOENIG W, 1987, EUR J CLIN PHARMACOL, V32, P43, DOI 10.1007/BF00609956; LAPORTE JR, 1987, LANCET, V1, P1324; LAPORTE JR, 1990, EUR J CLIN PHARMACOL, V38, P387, DOI 10.1007/BF00315580; LAPORTE JR, 1986, LANCET, V2, P853; LOWINGER P, 1969, ARCH GEN PSYCHIAT, V20, P84; MANT A, 1988, BRIT MED J, V296, P251, DOI 10.1136/bmj.296.6617.251; MICHELS R, 1993, NEW ENGL J MED, V329, P552, DOI 10.1056/NEJM199308193290808; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; POPE HG, 1991, ARCH GEN PSYCHIAT, V48, P62; RATNER J, 1972, J AM GERIATR SOC, V20, P556, DOI 10.1111/j.1532-5415.1972.tb00758.x; SHEEHAN DV, 1980, ARCH GEN PSYCHIAT, V37, P51; SPAGNOLI A, 1983, DRUGS, V26, P44, DOI 10.2165/00003495-198326010-00003; SUMMERS WK, 1986, NEW ENGL J MED, V315, P1241, DOI 10.1056/NEJM198611133152001; TARIOT PN, 1987, ARCH GEN PSYCHIAT, V44, P427; THOMPSON C, 1989, Human Psychopharmacology, V4, P91, DOI 10.1002/hup.470040204; THOREN P, 1980, ARCH GEN PSYCHIAT, V37, P1281; WOODS JH, 1987, PHARMACOL REV, V39, P251; ZITRIN CM, 1983, ARCH GEN PSYCHIAT, V40, P125; 1993, DRUG UTILIZATIION BI	29	51	51	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1206	1209		10.1016/S0140-6736(94)90515-0	http://dx.doi.org/10.1016/S0140-6736(94)90515-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN803	7934547				2022-12-28	WOS:A1994PN80300016
J	WHITE, NJ				WHITE, NJ			TOUGH TEST FOR MALARIA VACCINE	LANCET			English	Editorial Material											WHITE, NJ (corresponding author), WELLCOME MAHIDOL UNIV,OXFORD TROP MED RES PROGRAMME,BANGKOK,THAILAND.		White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012	White, Nick/0000-0002-1897-1978; 				ALONSO PL, 1994, VACCINE, V12, P181, DOI 10.1016/0264-410X(94)90058-2; AMADOR R, 1992, J INFECT DIS, V166, P139, DOI 10.1093/infdis/166.1.139; CIUCA M, 1955, CONTRIBUTION EXPT ET, P60; CLYDE DF, 1975, AM J TROP MED HYG, V24, P397, DOI 10.4269/ajtmh.1975.24.397; NOYA GO, 1994, J INFECT DIS, V170, P396; PATARROYO ME, 1987, NATURE, V328, P629, DOI 10.1038/328629a0; SEMPERTEGUI F, 1994, VACCINE, V12, P337, DOI 10.1016/0264-410X(94)90098-1; VALERO MV, 1993, LANCET, V341, P706	8	5	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1172	1173		10.1016/S0140-6736(94)90502-9	http://dx.doi.org/10.1016/S0140-6736(94)90502-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934534				2022-12-28	WOS:A1994PN80300003
J	RICE, P; SIMMONS, K; CARR, R; BANATVALA, J				RICE, P; SIMMONS, K; CARR, R; BANATVALA, J			LESSON OF THE WEEK - NEAR-FATAL CHICKENPOX DURING PREDNISOLONE TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							VARICELLA-ZOSTER VIRUS; INDIRECT IMMUNOFLUORESCENCE		UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT VIROL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT HAEMATOL,LONDON SE1 7EH,ENGLAND	University of London; King's College London; University of London; King's College London								ASANO Y, 1977, PEDIATRICS, V59, P3; ASANO Y, 1993, PEDIATRICS, V92, P219; CLORE GC, 1981, LANCET, V2, P480; DONOWITZ LG, 1987, AM J INFECT CONTROL, V15, P212, DOI 10.1016/0196-6553(87)90098-8; DOWELL SF, 1993, PEDIATRICS, V92, P223; ELLIS ME, 1987, BRIT MED J, V294, P1002, DOI 10.1136/bmj.294.6578.1002; GERSHON A, 1972, J PEDIATR-US, V81, P1034, DOI 10.1016/S0022-3476(72)80566-3; GRAYSON ML, 1988, J INFECTION, V16, P312, DOI 10.1016/S0163-4453(88)97892-9; KEENE JK, 1978, JAMA-J AM MED ASSOC, V239, P45, DOI 10.1001/jama.239.1.45; MILLER E, 1993, LANCET, V341, P308, DOI 10.1016/0140-6736(93)92663-E; SILK HJ, 1988, J ALLERGY CLIN IMMUN, V81, P47, DOI 10.1016/0091-6749(88)90219-9; STEINBERG SP, 1991, J CLIN MICROBIOL, V29, P1527, DOI 10.1128/JCM.29.7.1527-1529.1991; TAKAHASH.M, 1974, LANCET, V2, P1288, DOI 10.1016/S0140-6736(74)90144-5; WILLIAMS V, 1974, J INFECT DIS, V130, P669, DOI 10.1093/infdis/130.6.669; WREGHITT TG, 1984, J MED VIROL, V13, P361, DOI 10.1002/jmv.1890130407; 1994, CURRENT PROBLEMS PHA, V20; 1992, IMMUNISATION INFECTI	17	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1994	309	6961					1069	1070		10.1136/bmj.309.6961.1069	http://dx.doi.org/10.1136/bmj.309.6961.1069			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN733	7950743	Green Published			2022-12-28	WOS:A1994PN73300028
J	LLOYD, AM; SCHENA, M; WALBOT, V; DAVIS, RW				LLOYD, AM; SCHENA, M; WALBOT, V; DAVIS, RW			EPIDERMAL-CELL FATE DETERMINATION IN ARABIDOPSIS - PATTERNS DEFINED BY A STEROID-INDUCIBLE REGULATOR	SCIENCE			English	Article							MAMMALIAN GLUCOCORTICOID RECEPTOR; GENE; EXPRESSION; TRANSFORMATION; DROSOPHILA; SYSTEM; TRANSCRIPTION; SUPERFAMILY; HOMOLOGY; PROTEINS	The Arabidopsis mutant ttg lacks both trichomes (epidermal hairs) and anthocyanin pigments. Trichomes and anthocyanins are restored by the constitutive expression of the maize transcriptional regulator (R). The expression of an R-glucocorticoid receptor chimeric protein results in a steroid hormone-dependent, conditional allele of R that functions in whole Arabidopsis plants. The response of the chimeric protein to pulses of hormone was used to define the pattern ana timing of trichome formation on the developing leaf epidermis. Each adaxial epidermal leaf cell appears to have an equal probability of differentiating into a trichome; there is a temporal zone of decision for trichome cell fate that proceeds as a wave from the tip to the base of developing leaves.	STANFORD UNIV,DEPT SCI BIOL,STANFORD,CA 94305	Stanford University	LLOYD, AM (corresponding author), STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305, USA.			Walbot, Virginia/0000-0002-1596-7279	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32422] Funding Source: Medline; PHS HHS [R37-H600198] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; DRUMMHERREL H, 1981, PHOTOCHEM PHOTOBIOL, V33, P391, DOI 10.1111/j.1751-1097.1981.tb05435.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GALWAY ME, IN PRESS DEV BIOL; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; HELD LI, 1991, BIOESSAYS, V13, P633, DOI 10.1002/bies.950131203; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HULSKAMP M, 1994, CELL, V76, P555, DOI 10.1016/0092-8674(94)90118-X; Koornneef M., 1981, ARABID INF SERV, V18, P45; Koornneef M., 1990, ARABIDOPSIS INFO SER, V27, P1; KORN RW, 1981, DEV BIOL, V88, P115, DOI 10.1016/0012-1606(81)90223-2; LARKIN JC, 1993, PLANT CELL, V5, P1739, DOI 10.1105/tpc.5.12.1739; LLOYD AL, UNPUB; LLOYD AM, 1992, SCIENCE, V258, P1173; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; LUDWIG SR, 1990, SCIENCE, V247, P449, DOI 10.1126/science.247.4941.449; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; POWER RF, 1992, TRENDS PHARMACOL SCI, V13, P318, DOI 10.1016/0165-6147(92)90099-R; QUATTROCCHIO F, 1993, PLANT CELL, V5, P1497, DOI 10.1105/tpc.5.11.1497; ROTH BA, 1991, PLANT CELL, V3, P317, DOI 10.1105/tpc.3.3.317; SAMUELS HH, 1970, J MOL BIOL, V52, P57, DOI 10.1016/0022-2836(70)90177-4; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SCHENA M, 1991, P NATL ACAD SCI USA, V88, P10421, DOI 10.1073/pnas.88.23.10421; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WILLIAMS MH, 1988, PROTOPLASMA, V147, P77, DOI 10.1007/BF01403879; YOSHINAGA SK, 1991, MOL ENDOCRINOL, V5, P844, DOI 10.1210/mend-5-6-844	33	203	215	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 21	1994	266	5184					436	439		10.1126/science.7939683	http://dx.doi.org/10.1126/science.7939683			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939683				2022-12-28	WOS:A1994PN27200035
J	OLTVAI, ZN; KORSMEYER, SJ				OLTVAI, ZN; KORSMEYER, SJ			CHECKPOINTS OF DUELING DIMERS FOIL DEATH WISHES	CELL			English	Review							CELL-DEATH; B-CELLS; APOPTOSIS; BCL-2; GENE; SURVIVAL; ENCODES; EVENTS; ENZYME; MYC		WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,DIV MOLEC ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,DIV MOLEC ONCOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	OLTVAI, ZN (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60610, USA.							BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SEIVAKUMARAN M, 1994, ONCOGENE, V9, P1791; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG YS, 1993, ONCOGENE, V8, P3427; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	31	745	780	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					189	192		10.1016/0092-8674(94)90188-0	http://dx.doi.org/10.1016/0092-8674(94)90188-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7954787				2022-12-28	WOS:A1994PN63000003
J	MCCARTNEY, A				MCCARTNEY, A			THE TIP OF THE ICEBERG	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					1025	1025		10.1136/bmj.309.6960.1025	http://dx.doi.org/10.1136/bmj.309.6960.1025			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950711	Green Published			2022-12-28	WOS:A1994PM41700081
J	MARSHALL, MN; GRAY, DJP; PEARSON, V; PHILLIPS, DR; OWEN, M				MARSHALL, MN; GRAY, DJP; PEARSON, V; PHILLIPS, DR; OWEN, M			PROMOTION OF FAMILY-PLANNING-SERVICES IN PRACTICE LEAFLETS	BRITISH MEDICAL JOURNAL			English	Article									DEPT PUBL HLTH MED,EXETER EX1 1PQ,DEVON,ENGLAND; UNIV EXETER,INST POPULAT STUDIES,EXETER EX4 6DT,DEVON,ENGLAND	University of Exeter	MARSHALL, MN (corresponding author), UNIV EXETER,POSTGRAD MED SCH,INST GEN PRACTICE,EXETER EX2 5DW,DEVON,ENGLAND.			PEREIRA GRAY, DENIS/0000-0001-7917-3841				BHOPAL RS, 1990, FAM PRACT, V7, P132, DOI 10.1093/fampra/7.2.132; BROOMHAM DR, 1993, BRIT MED J, V306, P556; MORRELL DC, 1980, BRIT MED J, V280, P769, DOI 10.1136/bmj.280.6216.769; 1989, TERMS SERVICE DOCTOR; 1991, HLTH NATION	5	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 8	1994	309	6959					927	928		10.1136/bmj.309.6959.927	http://dx.doi.org/10.1136/bmj.309.6959.927			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PL781	7950663	Green Published			2022-12-28	WOS:A1994PL78100020
J	REESE, JC; APONE, L; WALKER, SS; GRIFFIN, LA; GREEN, MR				REESE, JC; APONE, L; WALKER, SS; GRIFFIN, LA; GREEN, MR			YEAST TAF(II)S IN A MULTISUBUNIT COMPLEX REQUIRED FOR ACTIVATED TRANSCRIPTION	NATURE			English	Article							TATA-BINDING PROTEIN; POLYMERASE-II TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; DNA; SUBUNIT; INVITRO; GENE; TBP	IN higher eukaryotes the RNA polymerase II transcription factor TFIID is composed of a TATA-box-binding protein (TBP) and a set of tightly bound polypeptides, designated TBP-associated fao tors (TAF(II)s). One or more TAF(II)s are coactivators that are required for activated but not basal transcription(1-3). The eukaryotic transcription machinery is highly conserved and it is therefore puzzling that TAF(II)s have aot been identified in yeast. Here we use TBP as a protein-affinity ligand to isolate from yeast a multi-subunit complex that is required specifically for activated transcription by RNA polymerase II. Microsequence analysis and cloning of two subunits of this complex reveal that they are the homologues of known mammalian and Drosophila TAF(II)s. The genes encoding these two yeast TAF(II)s are essential, suggesting that activated transcription is required for viability of Saccharomyces cerevisiae.			REESE, JC (corresponding author), UNIV MASSACHUSETTS, MED CTR, HOWARD HUGHES MED INST, PROGRAM MOLEC MED, 373 PLANTAT ST, WORCESTER, MA 01605 USA.			reese, joseph/0000-0003-3578-4266				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; POON D, 1993, J BIOL CHEM, V268, P15325; PUGH BF, 1992, J BIOL CHEM, V267, P679; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	22	155	158	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 6	1994	371	6497					523	527		10.1038/371523a0	http://dx.doi.org/10.1038/371523a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935765				2022-12-28	WOS:A1994PK58900058
J	LANDS, RH				LANDS, RH			CHOREA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1636	1636		10.1001/jama.272.21.1636	http://dx.doi.org/10.1001/jama.272.21.1636			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7966874				2022-12-28	WOS:A1994PU75900001
J	PELTOLA, H; HEINONEN, OP; VALLE, M; PAUNIO, M; VIRTANEN, M; KARANKO, V; CANTELL, K				PELTOLA, H; HEINONEN, OP; VALLE, M; PAUNIO, M; VIRTANEN, M; KARANKO, V; CANTELL, K			THE ELIMINATION OF INDIGENOUS MEASLES, MUMPS, AND RUBELLA FROM FINLAND BY A 12-YEAR, 2-DOSE VACCINATION PROGRAM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; CHILDREN; VIRUS; IMMUNIZATION; ANTIBODY; VACCINES; PERSISTENCE; INCREASE; IMMUNITY; TRIAL	Background. In the 1970s measles, mumps, and rubella were rampant in Finland, and rates of immunization were inadequate. in 1982 a comprehensive national vaccination program began in which two doses of a combined live-virus vaccine were used. Methods. Public health nurses at 1036 child health centers administered the vaccine to children at 14 to 18 months of age and again at 6 years, and also to selected groups of older children and young adults. Vaccination was voluntary and free of charge. In follow-up studies, we focused on rates of vaccination, reasons for noncompliance, adverse reactions, immunogenicity, persistence of antibody, and incidence of the three diseases. Since 1987, paired serum samples have been collected from all patients with suspected cases of measles, mumps, or rubella. Results. Over a period of 12 years, 1.5 million of the 5 million people in Finland were vaccinated. Coverage now exceeds 95 percent. The vaccine was efficient and safe, even in those with a history of severe allergy. No deaths or persistent sequelae were attributable to vaccination. The most frequent complication requiring hospitalization was acute thrombocytopenic purpura, which occurred at a rate of 3.3 per 100,000 vaccinated persons. The 99 percent decrease in the incidence of the three diseases was accompanied by an increasing rate of false positive clinical diagnoses. In 655 vaccinated patients with clinically diagnosed disease, serologic studies confirmed the presence of measles in only 0.8 percent, mumps in 2.0 percent, and rubella in 1.2 percent. The few localized outbreaks were confined to patients in the partially vaccinated age groups. There are now fewer than 30 sporadic cases of each of the three diseases per year,and those are probably imported. Conclusions. Over a 12-year period, an immunization program using two doses of combined live-virus vaccine has eliminated indigenous measles, mumps, and rubella from Finland. Serologic studies show that most reported sporadic cases are now due to other causes, but a continued high rate of vaccination coverage is essential to prevent outbreaks resulting from exposure to imported disease.	UNIV HELSINKI,CHILDRENS HOSP,NATL PUBL HLTH INST,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,DEPT PUBL HLTH,HELSINKI,FINLAND	Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki	PELTOLA, H (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,DIV INFECT DIS,STENBACKINKATU 11,SF-00290 HELSINKI,FINLAND.							AABY P, 1986, J PEDIATR-US, V109, P40, DOI 10.1016/S0022-3476(86)80569-8; ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X; BAYER WL, 1965, NEW ENGL J MED, V273, P1362, DOI 10.1056/NEJM196512162732504; BRUNELL PA, 1983, JAMA-J AM MED ASSOC, V250, P1409, DOI 10.1001/jama.250.11.1409; CARTER H, 1992, BRIT MED J, V304, P637, DOI 10.1136/bmj.304.6827.637; CHANTLER JK, 1985, NEW ENGL J MED, V313, P1117, DOI 10.1056/NEJM198510313131803; CHRISTENSON B, 1983, BRIT MED J, V287, P389, DOI 10.1136/bmj.287.6389.389; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; EDMONSON MB, 1990, JAMA-J AM MED ASSOC, V263, P2467, DOI 10.1001/jama.263.18.2467; FORREST JM, 1974, AUST NZ J MED, V4, P352, DOI 10.1111/j.1445-5994.1974.tb03203.x; GALLOWAY Y, 1991, COMMUN DIS NZ, V12, P107; GERSHON AA, 1979, DIAGNOSTIC PROCEDURE, P685; GRAHAM DY, 1974, JAMA-J AM MED ASSOC, V227, P1162, DOI 10.1001/jama.227.10.1162; HEINONEN OP, 1977, BIRTH DEFECTS DRUGS, P7; HETHCOTE HW, 1983, AM J EPIDEMIOL, V117, P2, DOI 10.1093/oxfordjournals.aje.a113511; HOWSON CP, 1992, PEDIATRICS, V89, P318; HUDSON JB, 1956, J PEDIATR-US, V48, P48, DOI 10.1016/S0022-3476(56)80116-9; HYOTY H, 1993, DIABETOLOGIA, V36, P1303, DOI 10.1007/BF00400810; JUNTUNENBACKMAN K, 1987, AM J DIS CHILD, V141, P1103, DOI 10.1001/archpedi.1987.04460100081032; KATZ SL, 1991, REP PEDIAT INFECT DI, V1, P1; KIEFABER RW, 1981, NEW ENGL J MED, V305, P225; KOSKINIEMI M, 1989, LANCET, V1, P31; LAU YL, 1992, J INFECT DIS, V165, P1111, DOI 10.1093/infdis/165.6.1111; LERMAN SJ, 1981, PEDIATRICS, V68, P18; LOKIETZ H, 1965, J LANCET, V85, P226; MARKOWITZ LE, 1992, J INFECT DIS, V166, P205, DOI 10.1093/infdis/166.1.205; NIEMINEN U, 1993, ACTA PAEDIATR, V82, P267, DOI 10.1111/j.1651-2227.1993.tb12657.x; Ohga Shouichi, 1992, Acta Paediatrica Japonica, V34, P447; PAUNIO M, 1991, AM J EPIDEMIOL, V133, P1152, DOI 10.1093/oxfordjournals.aje.a115827; PELTOLA H, 1993, LANCET, V341, P994, DOI 10.1016/0140-6736(93)91077-Y; PELTOLA H, 1986, LANCET, V1, P137; PELTOLA H, 1986, LANCET, V1, P939; PENTTINEN K, 1968, AM J EPIDEMIOL, V88, P234, DOI 10.1093/oxfordjournals.aje.a120882; UEDA K, 1986, AM J EPIDEMIOL, V124, P807, DOI 10.1093/oxfordjournals.aje.a114457; UKKONEN P, 1988, SCAND J INFECT DIS, V20, P255, DOI 10.3109/00365548809032448; VAANANEN P, 1979, J MED VIROL, V3, P245, DOI 10.1002/jmv.1890030402; VAHERI A, 1982, LANCET, V2, P685; VALMARI P, 1987, PEDIATR INFECT DIS J, V6, P59, DOI 10.1097/00006454-198701000-00015; VESIKARI T, 1984, AM J DIS CHILD, V138, P843, DOI 10.1001/archpedi.1984.02140470043013; VUORI M, 1962, Acta Otolaryngol, V55, P231, DOI 10.3109/00016486209127357; WEIBEL RE, 1980, P SOC EXP BIOL MED, V165, P260, DOI 10.3181/00379727-165-40967; WEIBEL RE, 1980, P SOC EXP BIOL MED, V165, P323, DOI 10.3181/00379727-165-40979; WILKINS J, 1979, J PEDIATR-US, V94, P865, DOI 10.1016/S0022-3476(79)80203-6; 1994, MMWR-MORBID MORTAL W, V43, P57; 1993, MMWR-MORBID MORTAL W, V42, P378	46	243	246	1	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1397	1402		10.1056/NEJM199411243312101	http://dx.doi.org/10.1056/NEJM199411243312101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7969278	Bronze			2022-12-28	WOS:A1994PU53300001
J	CHONG, LD; TRAYNORKAPLAN, A; BOKOCH, GM; SCHWARTZ, MA				CHONG, LD; TRAYNORKAPLAN, A; BOKOCH, GM; SCHWARTZ, MA			THE SMALL GTP-BINDING PROTEIN-RHO REGULATES A PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE IN MAMMALIAN-CELLS	CELL			English	Article							NEUTROPHIL NADPH OXIDASE; ENDOTHELIAL-CELLS; GROWTH-FACTORS; ACTIVATION; CALCIUM; 4,5-BISPHOSPHATE; RAS; PURIFICATION; STIMULATION; REQUIREMENT	Integrin-mediated adhesion is known to stimulate production of phosphatidylinositol 4,5-bisphosphate (4,5-PIP2) and increase 4,5-PIP2 hydrolysis in response to platelet-derived growth factor (PDGF). We now show that treatment of cells with lovastatin, which inhibits modification of small GTP-binding proteins, reduced PIP2 levels and decreased calcium mobilization in response to PDGF and thrombin. In cell lysates, GTP gamma S stimulated PIP 5-kinase activity, and this effect was blocked by botulinum C3 exoenzyme, suggesting that Rho was responsible. GTP-bound recombinant Rho stimulated PIP B-kinase activity, whereas GDP-Rho was much less potent and GTP-bound Rac was ineffective. Microinjected botulinum C3 exoenzyme caused diminished calcium mobilization in response to PDGF or thrombin. Conversely, microinjection of activated Rho reversed the decrease in calcium mobilization normally seen in nonadherent cells. These data demonstrate that Rho regulates 4,5-PIP2 synthesis and, indirectly, 4,5-PIP2 hydrolysis. They also raise the possibility that PIP2 synthesis could mediate the effects of Rho on the actin cytoskeleton.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA 92103 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego				schwartz, martin/0000-0002-2071-1243	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48728] Funding Source: Medline; NIGMS NIH HHS [R01 GM47214, R01 GM4428] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; AULLO P, 1993, EMBO J, V12, P921, DOI 10.1002/j.1460-2075.1993.tb05733.x; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BIFULCO M, 1993, J CELL PHYSIOL, V155, P340, DOI 10.1002/jcp.1041550215; BOKOCH GM, 1992, J CLIN INVEST, V89, P402, DOI 10.1172/JCI115599; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; KACHINTORN U, 1993, AM J PHYSIOL, V264, pC671, DOI 10.1152/ajpcell.1993.264.3.C671; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LING LE, 1989, J BIOL CHEM, V264, P5080; MCNAMEE HM, 1992, J CELL BIOL, V121, P673; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SCHWARTZ MA, 1992, P NATL ACAD SCI USA, V89, P6138, DOI 10.1073/pnas.89.13.6138; SELF AJ, 1993, ONCOGENE, V8, P655; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; TUCKER RW, 1990, CELL CALCIUM, V11, P201, DOI 10.1016/0143-4160(90)90071-2; URUMOW T, 1986, FEBS LETT, V207, P253, DOI 10.1016/0014-5793(86)81499-5; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; ZHANG J, 1993, J BIOL CHEM, V268, P22251	36	603	611	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					507	513		10.1016/0092-8674(94)90259-3	http://dx.doi.org/10.1016/0092-8674(94)90259-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954816				2022-12-28	WOS:A1994PQ48800013
J	CHUANG, PT; ALBERTSON, DG; MEYER, BJ				CHUANG, PT; ALBERTSON, DG; MEYER, BJ			DPY-27 - A CHROMOSOME CONDENSATION PROTEIN HOMOLOG THAT REGULATES C. ELEGANS DOSAGE COMPENSATION THROUGH ASSOCIATION WITH THE X-CHROMOSOME	CELL			English	Article							SILENT MATING LOCI; CAENORHABDITIS-ELEGANS; SEX DETERMINATION; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; GENE-EXPRESSION; BINDING DOMAIN; PHYSICAL MAP; ATP-BINDING; HISTONE-H4	dpy-27 is an essential dosage compensation gene that acts to reduce expression of both hermaphrodite X chromosomes. The DPY-27 protein becomes specifically localized to the X chromosomes of wild-type XX embryos, but remains diffusely distributed throughout the nuclei of male (XO) embryos. In xol-1 mutant XO embryos that activate the XX mode of dosage compensation and die from inappropriately low X chromosome transcript levels, DPY-27 becomes localized to X. Therefore, sex specificity of the dosage compensation process is regulated at the step of DPY-27 X chromosome localization. DPY-27 exhibits striking similarity to proteins required for assembly and structural maintenance of Xenopus chromosomes in vitro and for segregation of yeast chromosomes in vivo. These findings suggest a link between global regulation of gene expression and higher order chromosome structure. We propose that DPY-27 implements dosage compensation by condensing the chromatin structure of X in a manner that causes general reduction of X chromosome expression.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	University of California System; University of California Berkeley; MRC Laboratory Molecular Biology				Meyer, Barbara/0000-0002-6530-4588	NIGMS NIH HHS [R01 GM030702, GM30702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030702, R37GM030702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTSON DG, 1993, GENETICS, V134, P211; Albertson DG, 1993, CHROMOSOME RES, V1, P15, DOI 10.1007/BF00710603; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DELONG L, 1993, GENETICS, V133, P875; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; EDGAR LG, 1994, DEVELOPMENT, V120, P443; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GORMAN M, 1993, CELL, V72, P39, DOI 10.1016/0092-8674(93)90048-U; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HODGKIN J, 1983, MOL GEN GENET, V192, P452, DOI 10.1007/BF00392190; HOLBROOK SR, 1993, BIOTECHNIQUES, V14, P984; Hsu David R., 1993, Seminars in Developmental Biology, V4, P93, DOI 10.1006/sedb.1993.1012; HSU DR, 1994, GENETICS, V137, P999; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; KURODA MI, 1993, SEM DEV BIOL, V4, P107; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MIGEON BR, 1994, TRENDS GENET, V10, P230, DOI 10.1016/0168-9525(94)90169-4; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NUSBAUM C, 1989, GENETICS, V122, P579; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PALMER MJ, 1993, GENETICS, V134, P545; PALMER MJ, 1994, GENE DEV, V8, P698, DOI 10.1101/gad.8.6.698; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PINKEL D, 1986, COLD SPRING HARB SYM, V51, P151, DOI 10.1101/SQB.1986.051.01.018; PLENEFISCH JD, 1989, GENETICS, V121, P57; RAO R, 1988, J BIOL CHEM, V263, P15957; RHIND NR, 1995, IN PRESS CELL, V80; RINE J, 1987, GENETICS, V116, P9; RUVKUN G, 1989, GENETICS, V121, P501; SAKA Y, 1994, IN PRESS EMBO J; SAMEJIMA I, 1993, J CELL SCI, V105, P135; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; VILLENEUVE AM, 1987, CELL, V48, P25, DOI 10.1016/0092-8674(87)90352-7	45	215	225	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					459	474		10.1016/0092-8674(94)90255-0	http://dx.doi.org/10.1016/0092-8674(94)90255-0			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954812				2022-12-28	WOS:A1994PQ48800009
J	PAPE, JW; VERDIER, RI; BONCY, M; BONCY, J; JOHNSON, WD				PAPE, JW; VERDIER, RI; BONCY, M; BONCY, J; JOHNSON, WD			CYCLOSPORA INFECTION IN ADULTS INFECTED WITH HIV - CLINICAL MANIFESTATIONS, TREATMENT, AND PROPHYLAXIS	ANNALS OF INTERNAL MEDICINE			English	Article						ACQUIRED IMMUNODEFICIENCY SYNDROME; DIARRHEA; CYCLOSPORA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; HAITI	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; ISOSPORA-BELLI INFECTION; ORGANISM; DIARRHEA; TRAVELERS; NEPAL	Objective: To determine the prevalence and clinical manifestations of Cyclospora in Haitians infected with human immunodeficiency virus (HIV) who have diarrhea and to evaluate therapy and prophylaxis. Design: Cohort study. From 1990 to 1993, stool samples were collected from adults seropositive for HIV who had had diarrhea for at least 3 weeks. Setting: A clinic in Haiti. Interventions: Stool samples were examined for enteric protozoa after acid-fast staining. Patients with Cyclospora infection were treated with trimethoprim-sulfamethoxazole (160 mg and 800 mg, respectively) given orally four times a day for 10 days. After completion of therapy, patients were evaluated weekly and re-treated if clinical and parasitologic recurrences occurred, followed by trimethoprim-sulfamethoxazole prophylaxis three times a week. Results: 804 of 2400 patients (33%) seropositive for HIV had a history of chronic or intermittent diarrhea; 502 of these 804 patients (62%) currently had diarrhea, and 450 patients each provided two stool specimens for examination. Enteric protozoa identified included Cryptosporidium (30%), Isospora belli (12%), Cyclospora species (11%), Giardia lamblia (3%), and Entamoeba histolytica (1%). Forty-three patients with diarrhea and Cyclospora infection were studied; their symptoms were indistinguishable from those seen in patients with isosporiasis or cryptosporidiosis. In all patients, diarrhea ceased and results from stool examinations were negative within 2.5 days after beginning oral tri methoprim-sulfamethoxazole therapy. Recurrent symptomatic cyclosporiasis developed in 12 of 28 patients (43%) followed for 1 month or more, but it also responded promptly to trimethoprim-sulfamethoxazole therapy. These 12 patients received trimethoprim-sulfamethoxazole three times a week as secondary prophylaxis, with only a single recurrence after 7 months. Conclusion: Cyclospora infection is common in Haitian patients with HIV infection, responds to trimethoprim-sulfamethoxazole therapy, and has a high recurrence rate that can be largely prevented with long-term trimethoprim-sulfamethoxazole prophylaxis.	CORNELL UNIV, COLL MED, DIV INTERNAL MED, NEW YORK, NY 10021 USA; HAITIAN STUDY GRP KAPOSIS SARCOMA & OPPORTUNIST I, PORT AU PRINCE, HAITI	Cornell University					FOGARTY INTERNATIONAL CENTER [D43TW000018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033877, R37AI022624] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW 00018] Funding Source: Medline; NIAID NIH HHS [R21 AI 33877, R37 AI 22624] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; LEVINE ND, 1973, COCCIDIA, P1; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; PAPE JW, 1989, NEW ENGL J MED, V320, P1044, DOI 10.1056/NEJM198904203201604; PAPE JW, 1987, AM J TROP MED HYG, V36, P333, DOI 10.4269/ajtmh.1987.36.333; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533; SOAVE R, 1988, J INFECT DIS, V157, P225, DOI 10.1093/infdis/157.2.225; VERDIER RI, 1993, 8 INT C AIDS 3 STD W; WURTZ RM, 1993, CLIN INFECT DIS, V16, P136, DOI 10.1093/clinids/16.1.136; 1991, MMWR-MORBID MORTAL W, V40, P325	16	176	188	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1994	121	9					654	657		10.7326/0003-4819-121-9-199411010-00004	http://dx.doi.org/10.7326/0003-4819-121-9-199411010-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN450	7944073				2022-12-28	WOS:A1994PN45000004
J	GOMEZ, F; RUIZ, P; SCHREIBER, AD				GOMEZ, F; RUIZ, P; SCHREIBER, AD			IMPAIRED FUNCTION OF MACROPHAGE FC-GAMMA RECEPTORS AND BACTERIAL-INFECTION IN ALCOHOLIC CIRRHOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONONUCLEAR PHAGOCYTE SYSTEM; PRIMARY BILIARY-CIRRHOSIS; RETICULOENDOTHELIAL SYSTEM; LIVER-DISEASE; IMMUNOGLOBULIN-G; MEDIATED CLEARANCE; RENAL-FAILURE; IGG; PERITONITIS; COMPLEMENT	Background. Bacterial infection is a frequent and often fatal complication in patients with cirrhosis. Macrophages play an important part in the host defense against infection because their Fc gamma receptors recognize antibody-coated bacteria. Methods. We prospectively studied macrophage Fcr receptor function in vivo and in vitro in 49 patients with alcoholic cirrhosis, 10 alcoholics without cirrhosis, and 20 normal volunteers. Results. The clearance of IgG-sensitized autologous red cells was decreased in 37 of the 49 patients with cirrhosis but in none of the subjects without cirrhosis. In the 49 patients clearance was inhibited by a mean (+/-SE) of 47+/-3 percent at 1 hour and 53+/-3 percent at 11/2 hours, as compared with the clearance in the normal controls (P<0.001). The impairment of macrophage Fc gamma-receptor-dependent clearance correlated with the degree of liver insufficiency but not with age, sex, nutritional status, HLA haplotype, or the presence of circulating immune complexes. The clearance of unsensitized and heat-altered autologous erythrocytes was normal. In vitro recognition of IgG-sensitized red cells by monocytes from the patients was not significantly decreased. During a two-year follow-up period, 11 patients had severe bacterial infections, and in 4 they were fatal. The mean clearance of IgG-sensitized red cells in these 11 patients (half-time, 126.2+/-22 hours) was significantly impaired, as compared with that in the 38 patients without severe infection (half-time, 32.2+/-18 hours, P<0.001). Conclusions. The function of macrophage Fc gamma receptors is impaired in patients with alcoholic cirrhosis, and this impairment probably contributes to the high incidence of bacterial infections among such patients.	UNIV PENN,SCH MED,PHILADELPHIA,PA 19104; HOSP UNIV CADIZ,DEPT MED,PUERTO REAL,SPAIN	University of Pennsylvania; Universidad de Cadiz					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022193, R21AI022193] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/HL-22193] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMDAL T, 1986, INFECTION, V14, P68, DOI 10.1007/BF01644445; ALMDAL TP, 1987, SCAND J GASTROENTERO, V22, P295, DOI 10.3109/00365528709078594; BENDER BS, 1985, J INFECT DIS, V152, P409, DOI 10.1093/infdis/152.2.409; BISTRIAN BR, 1976, JAMA-J AM MED ASSOC, V235, P1567, DOI 10.1001/jama.235.15.1567; Blackburn G L, 1977, JPEN J Parenter Enteral Nutr, V1, P11, DOI 10.1177/014860717700100111; BLUMENKRANTZ MJ, 1980, AM J CLIN NUTR, V33, P1567, DOI 10.1093/ajcn/33.7.1567; BOYKO WJ, 1982, AM J CLIN PATHOL, V77, P745; CINES DB, 1979, NEW ENGL J MED, V300, P106, DOI 10.1056/NEJM197901183000302; DRASAR BS, 1986, INFECT GASTROINTESTI, P1; EKDAHL KN, 1991, GASTROENTEROLOGY, V101, P1076, DOI 10.1016/0016-5085(91)90736-5; FRANK MM, 1983, ANN INTERN MED, V98, P206, DOI 10.7326/0003-4819-98-2-218; FRANK MM, 1979, NEW ENGL J MED, V300, P518, DOI 10.1056/NEJM197903083001002; FRIEDMAN D, 1985, J CLIN INVEST, V75, P162, DOI 10.1172/JCI111669; GAITHER TA, 1974, J IMMUNOL, V113, P574; GOMEZ F, 1982, J RETICULOENDOTH SOC, V31, P241; GOMEZ F, 1989, BLOOD, V74, P1058; GRAUDAL N, 1986, LIVER, V6, P297; HARVEY KB, 1980, AM J CLIN NUTR, V33, P1586, DOI 10.1093/ajcn/33.7.1586; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HSU CCS, 1971, CLIN EXP IMMUNOL, V8, P749; HUET PM, 1982, J CLIN INVEST, V70, P1234, DOI 10.1172/JCI110722; JAFFE CJ, 1978, J CLIN INVEST, V62, P1069, DOI 10.1172/JCI109212; Jelliffe DB, 1966, WHO MONOGRAPH SERIES, V53; KIMBERLY RP, 1983, AM J MED, V74, P481, DOI 10.1016/0002-9343(83)90986-5; KLINMAN DM, 1988, IMMUNOLOGICAL DISEAS, V2, P1335; MAS EJ, 1983, MED CLIN-BARCELONA, V81, P584; MORGAN MY, 1985, LIVER BILIARY DISEAS, P119; OKEEFE SJ, 1980, LANCET, V2, P615; ORREGO H, 1979, GASTROENTEROLOGY, V76, P105; PARRIS TM, 1982, ANN INTERN MED, V97, P526, DOI 10.7326/0003-4819-97-4-526; RAJKOVIC IA, 1985, CLIN SCI, V68, P247, DOI 10.1042/cs0680247; RAJKOVIC IA, 1986, HEPATOLOGY, V6, P252, DOI 10.1002/hep.1840060217; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RIMOLA A, 1984, HEPATOLOGY, V4, P53, DOI 10.1002/hep.1840040109; RIMOLA A, 1991, OXFORD TXB CLIN HEPA, V2, P1272; ROSSMAN MD, 1993, EXP HEMATOL, V21, P177; RUIZ P, 1990, NEW ENGL J MED, V322, P717, DOI 10.1056/NEJM199003153221102; RUNYON BA, 1988, HEPATOLOGY, V8, P632, DOI 10.1002/hep.1840080332; RUNYON BA, 1988, HEPATOLOGY, V8, P1184; SCHREIBER AD, 1975, J CLIN INVEST, V56, P1189, DOI 10.1172/JCI108196; SCHREIBER AD, 1987, NEW ENGL J MED, V316, P503, DOI 10.1056/NEJM198702263160903; SCHREIBER AD, 1972, J CLIN INVEST, V51, P575, DOI 10.1172/JCI106846; TITO L, 1988, HEPATOLOGY, V8, P27, DOI 10.1002/hep.1840080107; UNKELESS JC, 1989, J CLIN INVEST, V83, P355, DOI 10.1172/JCI113891; WALLAERT B, 1991, AM REV RESPIR DIS, V144, P278, DOI 10.1164/ajrccm/144.2.278; ZETTERMAN RK, 1981, GASTROENTEROLOGY, V81, P616; ZUBLER RH, 1976, IN VITRO METHODS CEL, P565; 1993, MMWR-MORBID MORTAL W, V41, P969	48	145	153	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1122	1128		10.1056/NEJM199410273311704	http://dx.doi.org/10.1056/NEJM199410273311704			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7935636	Bronze			2022-12-28	WOS:A1994PN06500004
J	CULLY, DF; VASSILATIS, DK; LIU, KK; PARESS, PS; VANDERPLOEG, LHT; SCHAEFFER, JM; ARENA, JP				CULLY, DF; VASSILATIS, DK; LIU, KK; PARESS, PS; VANDERPLOEG, LHT; SCHAEFFER, JM; ARENA, JP			CLONING OF AN AVERMECTIN-SENSITIVE GLUTAMATE-GATED CHLORIDE CHANNEL FROM CAENORHABDITIS-ELEGANS	NATURE			English	Article							AMINO-ACID RECEPTORS; XENOPUS-OOCYTES; INSECT MUSCLE; BINDING-SITE; MEMBRANE; RNA; IVERMECTIN; MODULATION; EXPRESSION; FIBERS	THE avermectins are a family of macrocyclic lactones used in the control of nematode and arthropod parasites(1). Ivermectin (22,23-dihydroavermectin B-1a) is widely used as an anthelmintic in veterinary medicine and is used to treat onchocerciasis or river blindness in humans(1,2). Abamectin (avermectin B-1a) is a miticide and insecticide used in crop protection(1). Avermectins interact with vertebrate and invertebrate GABA receptors(3-7) and invertebrate glutamate-gated chloride channels(8-11). The soil nematode Caenorhabditis elegans has served as a useful model to study the mechanism of action of avermectins(11-15). A C. elegans messenger RNA expressed in Xenopus oocytes encodes an avermectin-sensitive glutamate-gated chloride channel(11,14). To elucidate the structure and properties of this channel, we used Xenopus oocytes for expression cloning of two functional complementary DNAs encoding an avermectin-sensitive glutamate-gated chloride channel. We find that the electrophysiological and structural properties of these proteins indicate that they are new members of the ligand-gated ion channel superfamily.	MERCK & CO INC, RES LABS, DEPT GENET & MOLEC BIOL, RAHWAY, NJ 07065 USA	Merck & Company	CULLY, DF (corresponding author), MERCK & CO INC, RES LABS, DEPT CELLULAR BIOCHEM & PHYSIOL, RAHWAY, NJ 07065 USA.							ARENA JP, 1992, MOL BRAIN RES, V15, P339, DOI 10.1016/0169-328X(92)90127-W; ARENA JP, 1991, MOL PHARMACOL, V40, P368; ARENA JP, IN PRESS J PARASITOL; AZIZ MA, 1982, LANCET, V2, P171; Campbell WW, 1989, IVERMECTIN ABAMECTIN; CULLCANDY SG, 1976, J PHYSIOL-LONDON, V255, P449, DOI 10.1113/jphysiol.1976.sp011289; CULLY DF, 1991, MOL PHARMACOL, V40, P326; DINGLEDINE R, 1990, FASEB J, V4, P2636, DOI 10.1096/fasebj.4.9.2161372; DUCE IR, 1985, BRIT J PHARMACOL, V85, P395, DOI 10.1111/j.1476-5381.1985.tb08874.x; FRASER SP, 1990, MOL BRAIN RES, V8, P331, DOI 10.1016/0169-328X(90)90047-H; FRITZ LC, 1979, P NATL ACAD SCI USA, V76, P2062, DOI 10.1073/pnas.76.4.2062; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KASS IS, 1980, P NATL ACAD SCI-BIOL, V77, P6211, DOI 10.1073/pnas.77.10.6211; LEA T J, 1973, Comparative and General Pharmacology, V4, P351, DOI 10.1016/0010-4035(73)90046-3; LEA T J, 1973, Comparative and General Pharmacology, V4, P333, DOI 10.1016/0010-4035(73)90045-1; LINGLE C, 1981, BRAIN RES, V212, P481, DOI 10.1016/0006-8993(81)90482-0; Maniatis T., 1982, MOL CLONING; MELLIN TN, 1983, NEUROPHARMACOLOGY, V22, P89, DOI 10.1016/0028-3908(83)90265-4; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PONG SS, 1982, J NEUROCHEM, V38, P375, DOI 10.1111/j.1471-4159.1982.tb08639.x; ROHERER SP, 1992, P NATL ACAD SCI USA, V89, P4168, DOI 10.1073/pnas.89.9.4168; SCHAEFFER JM, 1989, BIOCHEM PHARMACOL, V38, P2329, DOI 10.1016/0006-2952(89)90473-5; SCOTT RH, 1985, PESTIC SCI, V16, P599, DOI 10.1002/ps.2780160605; SIGEL E, 1987, MOL PHARMACOL, V32, P749; WAFFORD KA, 1989, J EXP BIOL, V144, P449; ZUFALL F, 1989, J EXP BIOL, V142, P191	28	560	590	8	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 20	1994	371	6499					707	711		10.1038/371707a0	http://dx.doi.org/10.1038/371707a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM773	7935817				2022-12-28	WOS:A1994PM77300058
J	POWELLTUCK, J				POWELLTUCK, J			MANAGEMENT OF GUT FAILURE - A PHYSICIANS VIEW	LANCET			English	Review							TOTAL PARENTERAL-NUTRITION; INTESTINAL-PSEUDO-OBSTRUCTION; BOWEL LIVER-TRANSPLANTATION; UNITED-KINGDOM; CHILDREN; INFANTS; LENGTH				POWELLTUCK, J (corresponding author), ROYAL LONDON HOSP,DEPT DIGEST DISORDERS,LONDON E1 1BB,ENGLAND.							BIANCHI A, 1984, J ROY SOC MED, V77, P35; BURNES JU, 1992, JPEN-PARENTER ENTER, V16, P327, DOI 10.1177/0148607192016004327; BUSUTTIL RW, 1993, WESTERN J MED, V158, P184; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; CALNE RY, 1993, LANCET, V342, P58, DOI 10.1016/0140-6736(93)91927-E; CLARK CI, 1992, ARCH DIS CHILD, V67, P976, DOI 10.1136/adc.67.7.976; CLARK CLI, 1992, TRANSPLANT P, V24, P1060; COHEN Z, 1986, TRANSPLANTATION, V42, P613, DOI 10.1097/00007890-198612000-00008; COLOMB V, 1992, TRANSPLANT P, V24, P1054; COSNES J, 1994, EUR J GASTROEN HEPAT, V6, P197, DOI 10.1097/00042737-199403000-00002; DELTZ E, 1990, TRANSPLANT P, V22, P2501; GEORGESON K, 1994, J PEDIATR SURG, V29, P316, DOI 10.1016/0022-3468(94)90339-5; GOULET O, 1990, TRANSPLANT P, V22, P2499; GOUTTEBEL MC, 1986, DIGEST DIS SCI, V31, P718, DOI 10.1007/BF01296449; GRANT D, 1990, LANCET, V335, P181, DOI 10.1016/0140-6736(90)90275-A; HOWARD L, 1991, JPEN-PARENTER ENTER, V15, P384, DOI 10.1177/0148607191015004384; HUSKISSON LJ, 1993, J PEDIATR SURG, V28, P720, DOI 10.1016/0022-3468(93)90041-I; KILPE VE, 1993, TRANSPLANTATION, V56, P554, DOI 10.1097/00007890-199309000-00012; LILLEHEI RC, 1967, SURGERY, V62, P721; MALONE M, 1994, CURR OPIN GASTROEN, V10, P227; MUGHAL M, 1986, LANCET, V2, P383; MUGHAL MM, 1988, GUT, V29, P1613, DOI 10.1136/gut.29.11.1613; NIGHTINGALE JMD, 1992, GUT, V33, P1493, DOI 10.1136/gut.33.11.1493; PITT HA, 1985, ARCH SURG-CHICAGO, V120, P614; QUIGLEY EMM, 1993, GASTROENTEROLOGY, V104, P286, DOI 10.1016/0016-5085(93)90864-9; REIQUAM CW, 1965, AM J DIS CHILD, V109, P447, DOI 10.1001/archpedi.1965.02090020449013; SHANBHOGUE LKR, 1994, BRIT J SURG, V81, P486, DOI 10.1002/bjs.1800810404; SIEBERT JR, 1980, AM J DIS CHILD, V134, P593, DOI 10.1001/archpedi.1980.02130180051015; SMITH CE, 1993, JPEN-PARENTER ENTER, V17, P501, DOI 10.1177/0148607193017006501; STARZL TE, 1993, GASTROENTEROLOGY, V104, P673, DOI 10.1016/0016-5085(93)91001-X; TODO S, 1994, TRANSPLANTATION, V57, P840, DOI 10.1097/00007890-199403270-00012; TODO S, 1992, TRANSPLANTATION, V53, P369, DOI 10.1097/00007890-199202010-00020; TOULOUKIAN RJ, 1983, J PEDIATR SURG, V18, P720, DOI 10.1016/S0022-3468(83)80011-6; WALLEMACQ PE, 1993, CLIN CHEM, V39, P2219; 1992, TRANSPLANT P, V24, P1053; 1990, TRANSPLANT P, V22, P2423	36	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1061	1064		10.1016/S0140-6736(94)91714-0	http://dx.doi.org/10.1016/S0140-6736(94)91714-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934449				2022-12-28	WOS:A1994PL85200014
J	SCHOENENBERGER, RA; HEIM, SM				SCHOENENBERGER, RA; HEIM, SM			INDICATION FOR COMPUTED-TOMOGRAPHY OF THE BRAIN IN PATIENTS WITH FIRST UNCOMPLICATED GENERALIZED SEIZURE	BRITISH MEDICAL JOURNAL			English	Article							1ST SEIZURE; EMERGENCY; EPILEPSY; ALCOHOL	Objectives-To assess the yield of emergency computed tomography of the brain in patients with a first generalised epileptic seizure and to evaluate a four item screening questionnaire on alcohol misuse (CAGE questionnaire) as a triage tool to avoid unnecessary scans in cases of seizures related to withdrawal from alcohol. Design-Prospective, observational. Setting-Medical casualty unit in a university hospital. Patients-119 adult patients presenting to casualty within one hour of a generalised seizure. Measurements-A clinical examination focusing on focal neurological symptoms, the CAGE questionnaire, and computed tomography of the brain with contrast enhancement. Results-Computed tomography showed a focal, structural lesion of the brain in 40 patients (34% (95% confidence interval 25% to 42%)). In 20 patients (17% (10% to 24%)) an important therapeutic intervention resulted. The presence of a focal neurological deficit had a sensitivity of 50% and a specificity of 89% in predicting focal lesions on computed tomography. Answering ''yes'' to fewer than two CAGE questions had a sensitivity of 90% and specificity of 44% in identifying patients with focal computed tomography lesions. Focal lesions were not detected on computed tomography in any of the 35 patients (0% (0% to 10%)) who showed no focal neurological symptoms and answered ''yes'' to two or more CAGE questions. Conclusions-The diagnostic yield of computed tomography of the brain in adults after a first generalised seizure is high. Combined with the clinical examination, the CAGE questionnaire can reliably identify patients with uncomplicated seizures related to withdrawal from alcohol, in whom computed tomography may not be absolutely necessary.	UNIV BASEL HOSP,DEPT MED,CH-4031 BASEL,SWITZERLAND; UNIV BASEL,DEPT NEUROL,BASEL,SWITZERLAND	University of Basel; University of Basel								BERESFORD TP, 1991, LANCET, V337, P1175; EARNEST M P, 1987, Neurology, V37, P142; EARNEST MP, 1976, EPILEPSIA, V17, P387, DOI 10.1111/j.1528-1157.1976.tb04450.x; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FEUSSNER JR, 1981, ANN INTERN MED, V94, P519, DOI 10.7326/0003-4819-94-4-519; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HILLBOM ME, 1980, EPILEPSIA, V21, P459, DOI 10.1111/j.1528-1157.1980.tb04296.x; HOPKINS A, 1988, LANCET, V1, P721; MCKEE PJW, 1990, BRIT MED J, V300, P978, DOI 10.1136/bmj.300.6730.978; Morris J C, 1987, Emerg Med Clin North Am, V5, P827; RAMIREZLASSEPAS M, 1984, ANN NEUROL, V15, P536, DOI 10.1002/ana.410150605; ROSENTHAL RH, 1980, ANN EMERG MED, V9, P242, DOI 10.1016/S0196-0644(80)80379-9; RUSSO LS, 1983, ARCH NEUROL-CHICAGO, V40, P744, DOI 10.1001/archneur.1983.04050110062010; SAUNDERS S, 1975, EPILEPSIA, V16, P731; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SEMPERE AP, 1992, ACTA NEUROL SCAND, V86, P134, DOI 10.1111/j.1600-0404.1992.tb05054.x; TEASDALE G, 1974, LANCET, V2, P81; VANDONSELAAR CA, 1989, NEUROLOGY, V49, P267; YOUNG AC, 1982, LANCET, V2, P1446; 1990, SAS USERS GUIDE STAT; 1993, ANN EMERG MED, V22, P875	23	46	48	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					986	989		10.1136/bmj.309.6960.986	http://dx.doi.org/10.1136/bmj.309.6960.986			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950718	Green Published			2022-12-28	WOS:A1994PM41700020
J	DECETY, J; PERANI, D; JEANNEROD, M; BETTINARDI, V; TADARY, B; WOODS, R; MAZZIOTTA, JC; FAZIO, F				DECETY, J; PERANI, D; JEANNEROD, M; BETTINARDI, V; TADARY, B; WOODS, R; MAZZIOTTA, JC; FAZIO, F			MAPPING MOTOR REPRESENTATIONS WITH POSITRON EMISSION TOMOGRAPHY	NATURE			English	Article							ANTERIOR CINGULATE CORTEX; PET IMAGES; VOLUNTARY; MOVEMENTS	BRAIN activity was mapped in normal subjects during passive observation of the movements of an 'alien' hand and while imagining grasping objects with their own hand. None of the tasks required actual movement. Shifting from one mental task to the other greatly changed the pattern of brain activation. During observation of hand movements, activation was mainly found in visual cortical areas, but also in subcortical areas involved in motor behaviour, such as the basal ganglia and the cerebellum. During motor imagery, cortical and subcortical areas related to motor preparation and programming were strongly activated. These data support the notion that motor learning during observation of movements and mental practice involves rehearsal of neural pathways related to cognitive stages of motor control(1-3).	UNIV MILAN,SCI INST H SAN RAFFAELE,INB,CNR,I-20132 MILAN,ITALY; UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,DIV BRAIN MAPPING,LOS ANGELES,CA 90024	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	DECETY, J (corresponding author), INSERM,U94,16 AVE DOYEN LEPINE,F-69500 BRON,FRANCE.		Perani, Daniela/AAN-3221-2020					DECETY J, 1991, BEHAV BRAIN RES, V42, P1, DOI 10.1016/S0166-4328(05)80033-6; FOX PT, 1987, NEUR ABSTR, P1433; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; JEANNEROD M, 1994, BEHAV BRAIN SCI, V17, P187, DOI 10.1017/S0140525X00034026; MUSHIAKE H, 1991, J NEUROPHYSIOL, V66, P705, DOI 10.1152/jn.1991.66.3.705; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PAUS T, 1993, J NEUROPHYSIOL, V70, P453, DOI 10.1152/jn.1993.70.2.453; PERRETT DI, 1989, J EXP BIOL, V146, P87; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P137, DOI 10.1152/jn.1980.43.1.137; SPINKS TJ, 1988, IEEE T NUCL SCI, V35, P721, DOI 10.1109/23.12819; Talairach J., 1988, COPLANAR STEREOTAXIC; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; YUE G, 1992, J NEUROPHYSIOL, V67, P1114, DOI 10.1152/jn.1992.67.5.1114	17	766	772	2	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					600	602		10.1038/371600a0	http://dx.doi.org/10.1038/371600a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935791				2022-12-28	WOS:A1994PL55900050
J	NISWANDER, L; JEFFREY, S; MARTIN, GR; TICKLE, C				NISWANDER, L; JEFFREY, S; MARTIN, GR; TICKLE, C			A POSITIVE FEEDBACK LOOP COORDINATES GROWTH AND PATTERNING IN THE VERTEBRATE LIMB	NATURE			English	Article							APICAL ECTODERMAL RIDGE; CHICK WING DEVELOPMENT; SKELETAL-MUSCLE; RETINOIC ACID; HOX-4 GENES; FGF FAMILY; BUD CELLS; EXPRESSION; MOUSE; OUTGROWTH	LIMB development depends on signals from the apical ectodermal ridge and underlying mesenchyme(1,2). Fibroblast growth factor (FGF) can replace the ridge(3,4) and, because Fgf4 RNA is localized to the mouse posterior ridge(5), we proposed that FGF4 is the endogenous ridge signal(3). Ridge signals control limb outgrowth and maintain the zone of polarizing activity (ZPA) at the limb posterior margin(6), which is important in limb patterning: a ZPA graft to limb anterior mesenchyme causes cell respecification and mirror-image duplications(1,2). Sonic hedgehog (SHH7,8) has polarizing activity, and Shh RNA co-localizes with ZPA activity, suggesting SHH is the endogenous polarizing signal(7). We have investigated the molecular regulation of Fgf4 and Shh expression. We report here that Fgf4 expression in the ridge can be regulated by Shh-expressing cells. Moreover, Shh expression in mesenchyme can be activated by FGF4 in combination with retinoic acid. Once induced, Shh expression can be maintained by FGF4 alone, thus establishing a positive feedback loop between ZPA and ridge.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; UNIV COLL & MIDDLESEX SCH MED,DEPT ANAT & DEV BIOL,LONDON W1P 6DB,ENGLAND	University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; University of London; University College London	NISWANDER, L (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.		Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594				ANDERSON R, 1993, DEVELOPMENT, V117, P1421; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; EICHELE G, 1985, J CELL BIOL, V101, P1913, DOI 10.1083/jcb.101.5.1913; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HAN JK, 1993, DEV BIOL, V158, P549, DOI 10.1006/dbio.1993.1212; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KOYAMA E, 1993, DEV GROWTH DIFFER, V35, P189; LEE J, 1985, J EMBRYOL EXP MORPH, V90, P139; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; VOGEL A, 1993, DEVELOPMENT, V119, P199	23	612	631	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					609	612		10.1038/371609a0	http://dx.doi.org/10.1038/371609a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7935794				2022-12-28	WOS:A1994PL55900053
J	SILAGY, C				SILAGY, C			RECENT ADVANCES - GENERAL-PRACTICE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SYSTEM; CARE; DISEASE		FLINDERS UNIV S AUSTRALIA, DEPT GEN PRACTICE, ADELAIDE, SA 5001, AUSTRALIA	Flinders University South Australia								[Anonymous], 1988, LANCET, V2, P349; BAILEY JJ, 1994, BRIT MED J, V308, P1083, DOI 10.1136/bmj.308.6936.1083; BRAMBLE MG, 1993, GUT, V34, P422, DOI 10.1136/gut.34.3.422; BURKE P, 1993, BRIT MED J, V306, P1304; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; CHOP WM, 1994, AM FAM PHYSICIAN, V49, P749; COULTER A, 1994, BRIT MED J, V308, P308; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; GIBBINS RL, 1993, BMJ-BRIT MED J, V306, P1652, DOI 10.1136/bmj.306.6893.1652; GLASER WA, 1993, JAMA-J AM MED ASSOC, V270, P980, DOI 10.1001/jama.270.8.980; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; HANDYSIDES S, 1994, BRIT MED J, V308, P513, DOI 10.1136/bmj.308.6927.513; Hanna J N, 1993, Aust Fam Physician, V22, P1015; HARRIS MF, 1993, MED J AUSTRALIA, V158, P304, DOI 10.5694/j.1326-5377.1993.tb121782.x; HAYES GM, 1993, P ANN S COMPUT MED C, V17, P103; Howie J G, 1993, Health Bull (Edinb), V51, P94; HUBBLE JP, 1993, MOVEMENT DISORD, V8, P380, DOI 10.1002/mds.870080326; IRVINE D, 1993, BRIT J GEN PRACT, V43, P121; JOUSIMAA J, 1993, MED INFORM, V18, P103, DOI 10.3109/14639239309034473; JULIAN DG, 1989, BMJ-BRIT MED J, V299, P555; KIDD MR, IN PRESS J PRIMARY C; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882, DOI 10.1001/jama.1988.03720190050031; LAM W, 1987, LANCET, V2, P27; Liaw S T, 1994, Aust Fam Physician, V23, P209; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; MOHER M, 1994, BMJ-BRIT MED J, V308, P761, DOI 10.1136/bmj.308.6931.761; MOHER M, 1994, BMJ-BRIT MED J, V308, P760, DOI 10.1136/bmj.308.6931.760; MONTALTO M, 1993, MED J AUSTRALIA, V159, P263, DOI 10.5694/j.1326-5377.1993.tb137831.x; MORRIS NV, 1994, MED J AUSTRALIA, V160, P68, DOI 10.5694/j.1326-5377.1994.tb126516.x; NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32; Norton S A, 1993, Hawaii Med J, V52, P340; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; RUSSELL MAH, 1993, BRIT MED J, V306, P1308, DOI 10.1136/bmj.306.6888.1308; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; SANTOSHAM M, 1993, VACCINE, V11, pS52, DOI 10.1016/0264-410X(93)90161-P; SILAGY C, 1993, FAM PRACT, V10, P364, DOI 10.1093/fampra/10.4.364; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; SMITH LFP, 1994, BMJ-BRIT MED J, V308, P1679, DOI 10.1136/bmj.308.6945.1679; STAREY N, 1993, BRIT MED J, V306, P586; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; TRUMBLE SC, 1992, P MEDINFO 92 AMSTERD, P84; WOOD DA, 1994, BRIT MED J, V308, P313, DOI 10.1136/bmj.308.6924.313	42	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	1994	309	6959					943	945		10.1136/bmj.309.6959.943	http://dx.doi.org/10.1136/bmj.309.6959.943			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7950671	Green Published			2022-12-28	WOS:A1994PL78100029
J	MIRZA, DF; GUNSON, BK; DASILVA, RF; MAYER, AD; BUCKELS, JAC; MCMASTER, P				MIRZA, DF; GUNSON, BK; DASILVA, RF; MAYER, AD; BUCKELS, JAC; MCMASTER, P			POLICIES IN EUROPE ON MARGINAL QUALITY DONOR LIVERS	LANCET			English	Article							TRANSPLANTATION; CRITERIA; DONATION; GRAFTS; TESTS; AGE	Shortage of donor livers has led several liver transplant centres to widen their definition of liver donor suitability. We have assessed the function of liver grafts from ''marginal'' donors and attitudes to use of such organs. Over an 18-month period, livers used in 30 of 213 consecutive liver transplantations in Birmingham, UK, came from marginal donors (history of alcoholism, abnormal liver function test results, drug overdose that included paracetamol, advanced cardiovascular disease, sepsis, lengthy hypotension [systolic blood pressure <80 mm Hg for >1 h], high-dose inotropic drug use). 16 of these donors had been refused by other UK liver transplant centres, 11 on medical grounds. The controls were grafts retrieved from ''good'' donors (n=183) during the same period. All 30 grafts showed satisfactory early function but had greater day 1 (p=0.004) and peak serum aspartate aminotransferase (p=0.0008) values than control grafts. Graft and patient survival at 1 year in the two groups was similar (72% vs 73% and 80% vs 82%, respectively). To assess attitudes to marginal donor livers, a questionnaire outlining the details of these 30 donors was sent to the 80 centres in the European Liver Transplant Group, and 60 replied. Median immediate refusal rate of the marginal donors was 7/30 (range 0-18) and median outright acceptance rate was only 11/30 (1-26). Larger centres were less selective, with a significantly lower refusal rate (p=0.03). These results indicate that, because of existing liver donor criteria within Europe, usable donor livers are being unnecessarily refused on medical grounds.	QUEEN ELIZABETH HOSP,LIVER & HEPATOBILIARY UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham			da Silva, Renato Ferreira/A-3016-2019	da Silva, Renato Ferreira/0000-0002-9548-1892; Gunson, Bridget/0000-0001-6149-9915				ADAM R, 1991, TRANSPLANT P, V23, P1538; ADAM R, 1993, TRANSPLANT P, V25, P1536; ALEXANDER JW, 1991, TRANSPLANTATION, V51, P135, DOI 10.1097/00007890-199101000-00021; BUCKEL E, 1993, TRANSPLANT P, V25, P1558; BURDELSKI M, 1987, TRANSPLANT P, V19, P3838; DALESSANDRO AM, 1991, TRANSPLANTATION, V51, P157, DOI 10.1097/00007890-199101000-00024; DEBOER J, 1993, TRANSPLANT COUCIL EU, V5, P37; GORE SM, 1992, BRIT MED J, V305, P406, DOI 10.1136/bmj.305.6850.406; GORE SM, 1992, BRIT MED J, V305, P349; GREIG PD, 1990, TRANSPLANT P, V22, P2072; KAKIZOE S, 1990, TRANSPLANT P, V22, P416; KARAYALCIN K, 1994, TRANSPLANTATION, V57, P1323, DOI 10.1097/00007890-199405150-00006; LAMESCH P, 1990, TRANSPLANT P, V22, P1539; MAKOWKA L, 1987, TRANSPLANT P, V19, P2378; MOR E, 1992, TRANSPLANTATION, V53, P383, DOI 10.1097/00007890-199202010-00022; OELLERICH M, 1989, LANCET, V1, P640; PERSIJN GG, 1992, EUROTRANSPLANT NEWSL, V96, P12; PLOEG RJ, 1993, TRANSPLANTATION, V55, P807, DOI 10.1097/00007890-199304000-00024; POST J, 1993, TRANSPLANT P, V25, P1570; PRUIM J, 1993, TRANSPLANT INT, V6, P226, DOI 10.1111/j.1432-2277.1993.tb00653.x; REDING R, 1993, TRANSPLANTATION, V56, P323, DOI 10.1097/00007890-199308000-00012; TODO S, 1989, TRANSPLANTATION, V47, P903, DOI 10.1097/00007890-198905000-00034; WALL WJ, 1990, TRANSPLANTATION, V49, P377, DOI 10.1097/00007890-199002000-00030; 1944, USERS B, V10, P2; 1993, 1993 US SC REG TRANS, pH2; 1993, 1992 93 UK TRANSPL S, P25	26	91	93	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1480	1483		10.1016/S0140-6736(94)90294-1	http://dx.doi.org/10.1016/S0140-6736(94)90294-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7968124				2022-12-28	WOS:A1994PT99500013
J	URSIN, G; PETERS, RK; HENDERSON, BE; DABLAING, G; MONROE, KR; PIKE, MC				URSIN, G; PETERS, RK; HENDERSON, BE; DABLAING, G; MONROE, KR; PIKE, MC			ORAL-CONTRACEPTIVE USE AND ADENOCARCINOMA OF CERVIX	LANCET			English	Article							UTERINE CERVIX; YOUNG-WOMEN; CANCER; RISK; ESTROGEN	The incidence of adenocarcinoma of the cervix in the USA more than doubled between the early 1970s and the mid 1980s among women under 35 years of age. It was suggested that this increase was due to the introduction of oral contraceptives in the early 1960s. Adenocarcinoma of the cervix diagnosed in women born after 1935 was identified between 1977 and 1991, from the Los Angeles County Cancer Surveillance Program, Data from personal interviews of 195 cases and 386 controls (matched on age, race, and neighbourhood) were analysed. Information on medical, sexual, contraceptive, reproductive history, previous cervical smears, sexually transmitted diseases was collected. Compared with never use, eve, use of oral contraceptives was associated with twice as great a risk of adenocarcinoma of the cervix (adjusted odds ratio 2.1, 95% CI 1.1-3.8). The highest risk was observed for oral contraceptive use for more than 12 years (4.4, 1.8-10.8). No additional increased risk was found for early age at start of oral contraceptive use, use before age 20 or before first pregnancy, time since first use, time since last use, or particular formulations, once total duration of use had been accounted for.	UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033; SALK INST BIOL STUDIES,LA JOLLA,CA 92037	University of Southern California; Salk Institute	URSIN, G (corresponding author), UNIV SO CALIF,SCH MED,DEPT PREVENT MED,1420 SAN PABLO ST,LOS ANGELES,CA 90033, USA.		Ursin, Giske/U-6637-2017	Ursin, Giske/0000-0002-0835-9507	NATIONAL CANCER INSTITUTE [R01CA044401] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44401-05, P01 CA1754] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1962, NOVAKS GYNECOLOGIC O; Breslow N, 1980, STATISTICAL METHODS, V32; BRINTON LA, 1986, INT J CANCER, V38, P339, DOI 10.1002/ijc.2910380307; BRINTON LA, 1990, INT J EPIDEMIOL, V19, P4, DOI 10.1093/ije/19.1.4; CANDY AA, 1968, JAMA-J AM MED ASSOC, V203, P85; CANO A, 1990, FERTIL STERIL, V54, P1058; CHILVERS C, 1987, BRIT MED J, V295, P1446, DOI 10.1136/bmj.295.6611.1446; DALLENBACHHELLWEG G, 1984, PATHOL RES PRACT, V179, P38, DOI 10.1016/S0344-0338(84)80059-X; EIDE TJ, 1987, J NATL CANCER I, V79, P199; FORD LC, 1983, GYNECOL ONCOL, V15, P27, DOI 10.1016/0090-8258(83)90113-0; GALL SA, 1969, J AMER MED ASSOC, V207, P2243, DOI 10.1001/jama.207.12.2243; GOLDACRE MJ, 1978, BRIT MED J, V1, P748, DOI 10.1136/bmj.1.6115.748; HARRISON HR, 1985, AM J OBSTET GYNECOL, V153, P244, DOI 10.1016/S0002-9378(85)80105-8; HENDERSON BE, 1982, CANCER RES, V42, P3232; HONORE LH, 1989, GYNECOL OBSTET INVES, V32, P98; HOROWITZ IR, 1988, GYNECOL ONCOL, V31, P25, DOI 10.1016/0090-8258(88)90265-X; JONES MW, 1989, OBSTET GYNECOL, V73, P984; KJAER SK, 1993, EPIDEMIOL REV, V15, P486, DOI 10.1093/oxfordjournals.epirev.a036131; KYRIAKOS M, 1968, CANCER, V22, P99, DOI 10.1002/1097-0142(196807)22:1<99::AID-CNCR2820220113>3.0.CO;2-4; LOUV WC, 1989, AM J OBSTET GYNECOL, V160, P396, DOI 10.1016/0002-9378(89)90456-0; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; PARAZZINI F, 1988, BRIT J CANCER, V57, P201, DOI 10.1038/bjc.1988.43; PERSSON E, 1987, EUR J OBSTET GYN R B, V26, P85, DOI 10.1016/0028-2243(87)90011-6; PETERS RK, 1986, JNCI-J NATL CANCER I, V76, P423; SCHWARTZ SM, 1986, AM J EPIDEMIOL, V124, P1045, DOI 10.1093/oxfordjournals.aje.a114474; SCOTT JR, 1990, DANFORTHS OBSTETRICS; SILCOCKS PBS, 1987, BRIT J CANCER, V55, P321, DOI 10.1038/bjc.1987.63; TAYLOR HB, 1967, J AMER MED ASSOC, V202, P637, DOI 10.1001/jama.202.7.637; URSIN G, 1994, ADV CONTRA DELI SYST, V10, P370	29	88	93	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1390	1394		10.1016/S0140-6736(94)90567-3	http://dx.doi.org/10.1016/S0140-6736(94)90567-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7968074				2022-12-28	WOS:A1994PR78600008
J	ALPER, PR				ALPER, PR			PRIMARY-CARE IN TRANSITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; MEDICAL SPECIALTIES; INTERNAL-MEDICINE; UNITED-STATES; OUTCOMES; SYSTEMS; REFORM; COSTS	It is generally agreed that too few physicians have chosen careers in primary care. The advent of managed care as a popular method of health care provision is now affecting primary care physicians in ways that may further discourage enthusiasm for the practice of primary care and have an unintended negative effect on the primary care physician supply. In addition, the early implementation of the resource-based relative value scale by Medicare and some insurance carriers has been less beneficial to primary care physicians than expected and may even have been harmful to general internists. Efforts to improve the position of primary care physicians in relation to payers and among peers are hindered by the fact that, as a group, primary care physicians are less affluent, less influential, and greatly outnumbered by their more specialized colleagues. Consequently, some of the support currently directed toward primary care may be more apparent than real. My proposals, which aim both to protect and to enhance primary care practice, are the creation of separate primary care fee schedules and separate primary care budgets within health plans, changes in consumer protection rules that intrude on primary care practice, and the development of statewide primary care associations for mutual support and greater bargaining power. Some aspects of contracting and gatekeeping require further study.	UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								ABRAMS FR, 1993, NEW ENGL J MED, V328, P975, DOI 10.1056/NEJM199304013281320; ALPER PR, 1987, NEW ENGL J MED, V316, P337, DOI 10.1056/NEJM198702053160611; ALPER PR, 1984, NEW ENGL J MED, V311, P1249, DOI 10.1056/NEJM198411083111910; ALPER PR, 1992, CALIFORNIA INTERNIST, V47, P11; ALPER PR, 1992, CALIFORNIA INTERNIST, V47, P3; APPEL AJ, 1992, INTERN MED CARDI NOV, P3; AYMOND R, 1994, DOCTOR TALK, P1; BERENSON R, 1992, JAMA-J AM MED ASSOC, V267, P686; FITZGERALD FT, 1993, NEW ENGL J MED, V328, P654, DOI 10.1056/NEJM199303043280912; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P1449, DOI 10.1001/jama.270.12.1449; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRUMBACH K, 1993, NEW ENGL J MED, V328, P940, DOI 10.1056/NEJM199304013281308; HSIAO WC, 1993, NEW ENGL J MED, V328, P928, DOI 10.1056/NEJM199304013281306; IGLEHART JK, 1991, NEW ENGL J MED, V325, P1820, DOI 10.1056/NEJM199112193252523; KASSIRER JP, 1993, NEW ENGL J MED, V328, P648, DOI 10.1056/NEJM199303043280910; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LEVEY S, 1985, NEW ENGL J MED, V312, P644, DOI 10.1056/NEJM198503073121009; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; PETERSDORF RG, 1993, NEW ENGL J MED, V328, P651, DOI 10.1056/NEJM199303043280911; PULLEY M, 1993, NO CALIFORNIA CRUCIB, P1; RELMAN AS, 1993, NEW ENGL J MED, V329, P1574, DOI 10.1056/NEJM199311183292113; ROSENBLATT RA, 1991, WESTERN J MED, V154, P43; SCHROEDER SA, 1992, ANN INTERN MED, V116, P583, DOI 10.7326/0003-4819-116-7-583; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; WEXLER D, 1993, JAMA-J AM MED ASSOC, V269, P1944, DOI 10.1001/jama.269.15.1944; WHITCOMB ME, 1992, NEW ENGL J MED, V326, P1469, DOI 10.1056/NEJM199205283262205; 1993, REBUILDING PRIMARY C; 1991, PHYSICIANS CONTRACTI; 1994, PHYSICIAN MARKETPLAC	30	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1523	1527		10.1001/jama.272.19.1523	http://dx.doi.org/10.1001/jama.272.19.1523			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966845				2022-12-28	WOS:A1994PQ90000032
J	MARCANTONIO, ER; JUAREZ, G; GOLDMAN, L; MANGIONE, CM; LUDWIG, LE; LIND, L; KATZ, N; COOK, EF; ORAV, EJ; LEE, TH				MARCANTONIO, ER; JUAREZ, G; GOLDMAN, L; MANGIONE, CM; LUDWIG, LE; LIND, L; KATZ, N; COOK, EF; ORAV, EJ; LEE, TH			THE RELATIONSHIP OF POSTOPERATIVE DELIRIUM WITH PSYCHOACTIVE MEDICATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURGICAL PATIENTS; ELDERLY PATIENT; ACTIVITY SCALE; RISK-FACTORS; ASSOCIATION; MEPERIDINE; PROGNOSIS; SURGERY	Objective.-To examine the role of medications with known psychoactive properties in the development of postoperative delirium. Design.-Nested case-control study within a prospective cohort study. Setting.-General surgery, orthopedic surgery, and gynecology services at Brigham and Women's Hospital, Boston, Mass. Patients.-Cases (n=91) were patients enrolled in a prospective cohort study who developed delirium during postoperative days 2 through 5. One or two controls (n=154) were matched to each case by the calculated preoperative risk for delirium using a predictive model developed and validated in the prospective cohort study. Main Outcome Measures.-Medication exposures were ascertained from the medical record by a reviewer blinded to the study hypothesis. Exposures to narcotics, benzodiazepines, and anticholinergics were recorded for the 24-hour period before delirium developed in the 91 cases and for the same 24-hour postoperative period for the 154 matched controls. Results.-Delirium was significantly associated with postoperative exposure to meperidine (odds ratio [OR], 2.7; 95% confidence interval [Cl], 1.3 to 5.5) and to benzodiazepines (OR, 3.0; 95% Cl, 1.3 to 6.8). Meperidine had similar associations with delirium whether administered via epidural or patient-controlled routes, although only the epidural route reached significance (OR, 2.4; 95% Cl, 1.3 to 4.4; OR, 2.1; 95% Cl, 0.4 to 10.7, respectively). For benzodiazepines, long-acting agents had a trend toward stronger association with delirium than did short-acting agents (OR, 5.4; 95% Cl, 1.0 to 29.2; vs 2.6; 1.1 to 6.5), and high-dose exposures had a trend toward slightly stronger association than low-dose exposures (OR, 3.3; 95% Cl, 1.0 to 11.0; vs 2.6; 0.8 to 9.1). Neither narcotics (OR, 1.4; 95% Cl, 0.5 to 4.3) nor anticholinergic drugs (OR, 1.5; 95% Cl, 0.6 to 3.4) were significantly associated with delirium as a class, although statistical power was limited because of the high use of narcotics and the low use of anticholinergics in the study population. Conclusions.-Clinicians caring for patients at risk for delirium should carefully evaluate the need for meperidine and benzodiazepines in the postoperative period and consider alternative therapies whenever possible.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CLIN EPIDEMIOL SECT,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GEN MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GERONTOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CLIN INITIAT DEV PROGRAM,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; CEDARS SINAI MED CTR,DEPT ANESTHESIA,LOS ANGELES,CA 90048	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Cedars Sinai Medical Center			Marcantonio, Edward R/U-3929-2017	Marcantonio, Edward R/0000-0002-2911-4250	AHRQ HHS [1RO1-HS06573] Funding Source: Medline; BHP HRSA HHS [5T32PE110011-04] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		BRIZER DA, 1982, AM J PSYCHIAT, V139, P1343; EISENDRATH SJ, 1987, AM J PSYCHIAT, V144, P1062; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1992, J AM GERIATR SOC, V40, P829, DOI 10.1111/j.1532-5415.1992.tb01859.x; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; FRANCIS J, 1990, J GEN INTERN MED, V5, P65, DOI 10.1007/BF02602312; FRANCIS J, 1992, J AM GERIATR SOC, V40, P848, DOI 10.1111/j.1532-5415.1992.tb01861.x; FRANCIS J, 1994, PRINCIPLES GERIATRIC; GILMAN AG, 1980, GOODMAN GILMANS PHAR; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GOLINGER RC, 1987, AM J PSYCHIAT, V144, P1218; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P325; Hegyvary ST, 1979, USERS MANUAL RUSH ME; HODSMAN NBA, 1987, ANAESTHESIA, V42, P1005, DOI 10.1111/j.1365-2044.1987.tb05377.x; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; LEE TH, 1988, AM HEART J, V115, P203, DOI 10.1016/0002-8703(88)90545-5; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MIETTINEN OS, 1976, AM J EPIDEMIOL, V104, P609, DOI 10.1093/oxfordjournals.aje.a112339; MILLAR HR, 1981, BRIT J PSYCHIAT, V138, P17, DOI 10.1192/bjp.138.1.17; MORSE RM, 1969, AM J PSYCHIAT, V126, P388, DOI 10.1176/ajp.126.3.388; MURRAY AM, 1993, J GERONTOL, V48, pM181, DOI 10.1093/geronj/48.5.M181; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; SEYMOUR DG, 1983, GERONTOLOGY, V29, P262, DOI 10.1159/000213125; STAMBAUGH JE, 1976, J CLIN PHARMACOL, V16, P245, DOI 10.1002/j.1552-4604.1976.tb02401.x; THOMAS RI, 1988, ARCH GEN PSYCHIAT, V45, P937; TUNE LE, 1981, LANCET, V2, P651; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x	33	361	375	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1518	1522		10.1001/jama.272.19.1518	http://dx.doi.org/10.1001/jama.272.19.1518			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PQ900	7966844				2022-12-28	WOS:A1994PQ90000031
J	NIGHTINGALE, SL				NIGHTINGALE, SL			LEFT-VENTRICULAR ASSIST DEVICE APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1488	1488						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966836				2022-12-28	WOS:A1994PQ90000023
J	BEHRINGER, RR; FINEGOLD, MJ; CATE, RL				BEHRINGER, RR; FINEGOLD, MJ; CATE, RL			MULLERIAN-INHIBITING SUBSTANCE FUNCTION DURING MAMMALIAN SEXUAL DEVELOPMENT	CELL			English	Article							DUCT SYNDROME; BIOLOGICAL-ACTIVITY; EXPRESSION CLONING; HORMONE GENE; RAT OVARY; MOUSE; MICE; RECEPTOR; FETAL; CELLS	To investigate the role of Mullerian-inhibiting substance (MIS) in mammalian sexual development, we generated MIS-deficient mice. Although MIS-deficient males had testes that were fully descended and produced functional sperm, they also developed female reproductive organs, which interfered with sperm transfer into females, rendering most of these males infertile. Their testes had Leydig cell hyperplasia and, in one instance, neoplasia. The actions of the two primary hormones of male sexual differentation were genetically eliminated using the testicular feminization (Tfm) mutation in combination with the MIS mutant allele. XY Tfm/MIS double mutants developed as females, with a uterus, coiled oviducts, and no male reproductive organs except undescended dysfunctional testes. These results suggest that eliminating the presumptive female reproductive tract in male fetuses facilitates fertility and that in testes MIS is a negative regulator of Leydig cell proliferation. Eliminating the presumptive male reproductive tract is necessary for proper oviductal morphogenesis during female mouse development.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; BIOGEN INC, CAMBRIDGE, MA 02142 USA	Baylor College of Medicine; Biogen	BEHRINGER, RR (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA.				NICHD NIH HHS [HD30284] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD030284] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAARENDS WM, 1994, DEVELOPMENT, V120, P189; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BEZARD J, 1987, J REPROD FERTIL, V80, P509, DOI 10.1530/jrf.0.0800509; BISHOP CE, 1987, NUCLEIC ACIDS RES, V15, P2959, DOI 10.1093/nar/15.7.2959; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUDZIK GP, 1985, DEV MECHANISMS NORMA, P207; CARREEUSEBE D, 1992, HUM GENET, V90, P389; Cate R. L., 1993, Genes in mammalian reproduction., P185; Cate R.L, 1990, PEPTIDE GROWTH FACTO, P179; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CATLIN EA, 1988, AM J OBSTET GYNECOL, V159, P1299, DOI 10.1016/0002-9378(88)90467-X; CHAREST NJ, 1991, MOL ENDOCRINOL, V5, P573, DOI 10.1210/mend-5-4-573; DICLEMENTE N, 1994, ENDOCRINE, V2, P553; DICLEMENTE N, 1992, DEVELOPMENT, V114, P721; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; DONAHOE PK, 1977, J PEDIATR SURG, V12, P323, DOI 10.1016/0022-3468(77)90008-2; GREEN MC, 1990, GENETIC VARIANTS STR; GUERRIER D, 1989, J CLIN ENDOCR METAB, V68, P46, DOI 10.1210/jcem-68-1-46; HAQQ C, 1992, GENOMICS, V12, P665, DOI 10.1016/0888-7543(92)90291-Y; HE WW, 1991, NUCLEIC ACIDS RES, V19, P2373, DOI 10.1093/nar/19.9.2373; HUTSON JM, 1986, ENDOCR REV, V7, P270, DOI 10.1210/edrv-7-3-270; IMBEAUD S, 1994, HUM MOL GENET, V3, P125, DOI 10.1093/hmg/3.1.125; JOSSO N, 1986, PHYSIOL REV, V66, P1038, DOI 10.1152/physrev.1986.66.4.1038; JOSSO N, 1993, RECENT PROG HORM RES, V48, P1; Jost, 1947, ARCH ANAT MICR MORPH, V36, P271; JOST A, 1972, J REPROD FERTIL, V29, P349, DOI 10.1530/jrf.0.0290349; JOST A, 1953, RECENT PROG HORM RES, V8, P379; KIM JH, 1992, J CLIN ENDOCR METAB, V75, P911, DOI 10.1210/jc.75.3.911; KNEBELMANN B, 1991, P NATL ACAD SCI USA, V88, P3767, DOI 10.1073/pnas.88.9.3767; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEYERSWALLEN VN, 1989, BIOL REPROD, V41, P881, DOI 10.1095/biolreprod41.5.881; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PEPINSKY RB, 1988, J BIOL CHEM, V263, P18961; PICARD JY, 1984, MOL CELL ENDOCRINOL, V34, P23, DOI 10.1016/0303-7207(84)90155-2; PICARD JY, 1986, P NATL ACAD SCI USA, V83, P5464, DOI 10.1073/pnas.83.15.5464; PICON R, 1969, ARCH ANAT MICROSC MO, V58, P1; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKAHASHI M, 1986, BIOL REPROD, V35, P447, DOI 10.1095/biolreprod35.2.447; TRAN D, 1981, BIOL REPROD, V24, P923, DOI 10.1095/biolreprod24.4.923; UENO S, 1989, ENDOCRINOLOGY, V125, P1060, DOI 10.1210/endo-125-2-1060; UENO S, 1989, ENDOCRINOLOGY, V124, P1000, DOI 10.1210/endo-124-2-1000; VIGIER B, 1987, DEVELOPMENT, V100, P43; WILSON CA, 1993, MOL ENDOCRINOL, V7, P247, DOI 10.1210/me.7.2.247	51	512	532	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	1994	79	3					415	425		10.1016/0092-8674(94)90251-8	http://dx.doi.org/10.1016/0092-8674(94)90251-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7954809				2022-12-28	WOS:A1994PQ48800005
J	TERADA, K; KATAMINE, S; EGUCHI, K; MORIUCHI, R; KITA, M; SHIMADA, H; YAMASHITA, I; IWATA, K; TSUJI, Y; NAGATAKI, S; MIYAMOTO, T				TERADA, K; KATAMINE, S; EGUCHI, K; MORIUCHI, R; KITA, M; SHIMADA, H; YAMASHITA, I; IWATA, K; TSUJI, Y; NAGATAKI, S; MIYAMOTO, T			PREVALENCE OF SERUM AND SALIVARY ANTIBODIES TO HTLV-1 IN SJOGRENS-SYNDROME	LANCET			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; CLINICAL ENTITY; TRANSMISSION; MYELOPATHY; PROLIFERATION; IMPROVEMENT; ANTIGEN; PROTEIN; GENE	There is accumulating evidence that human T-lymphotropic virus-1 (HTLV-1) infection contributes to the development of various inflammatory disorders. To elucidate the relation between the infection and Sjogren's syndrome, seroepidemiological and virological studies were conducted on patients with this syndrome in Nagasaki Prefecture, Japan, an area heavily endemic for HTLV-1. The HTLV-1 seroprevalence rate among the patients with Sjogren's syndrome (17/74, 23%) was significantly higher than that among blood donors (916/27 284, 3%), whereas the difference between patients with systemic lupus erythematosus and blood donors was insignificant. Moreover, among Sjogren's syndrome patients the seroprevalence was high irrespective of age, unlike that among blood donors, which rose with age. Titres of serum antibodies in the HTLV-1 seropositive patients with Sjojgren's syndrome were similar to those among patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and significantly higher than those among healthy carriers. IgM class antibodies were commonly detected in the serum of patients with Sjogren's syndrome. However, unlike that in HAM/TSP patients, the viral load in peripheral-blood mononuclear cells was not necessarily high in the seropositive Sjogren syndrome group. Salivary IgA antibodies to HTLV-1 were common among seropositive patients with Sjojgren's syndrome (5/7), which might be due to increased viral activity in the salivary glands. These antibodies were barely detectable in HAM/TSP patients (prevalence 1/10) or in healthy carriers (0/11). The findings strongly suggest that HTLV-1 is involved in the pathogenesis of the disease in a subset of patients with Sjogren's syndrome in endemic areas.	NAGASAKI UNIV,SCH MED,DEPT BACTERIOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 1,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PREVENT MED & HLTH PROMOT,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PAEDIAT,NAGASAKI 852,JAPAN	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University				nagataki, shigenobu/0000-0002-9974-3554				BIEBERICH CJ, 1993, VIROLOGY, V196, P309, DOI 10.1006/viro.1993.1481; EGUCHI K, 1992, ANN RHEUM DIS, V51, P769, DOI 10.1136/ard.51.6.769; FUJINO R, 1991, JPN J CANCER RES, V82, P367, DOI 10.1111/j.1349-7006.1991.tb01856.x; FURUKAWA Y, 1992, BLOOD, V80, P1012; GESSAIN A, 1985, LANCET, V2, P407; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HINO S, 1985, JPN J CANCER RES, V76, P474; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KATAMINE S, 1994, LANCET, V343, P1326, DOI 10.1016/S0140-6736(94)92469-4; KAWASE K, 1992, JPN J CANCER RES, V83, P968, DOI 10.1111/j.1349-7006.1992.tb02009.x; KUGA T, 1988, JPN J CANCER RES, V79, P1168, DOI 10.1111/j.1349-7006.1988.tb01541.x; MARIETTE X, 1993, ARTHRITIS RHEUM-US, V36, P1423, DOI 10.1002/art.1780361015; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MIYAKOSHI H, 1992, J CLIN MICROBIOL, V30, P2555, DOI 10.1128/JCM.30.10.2555-2559.1992; MOCHIZUKI M, 1992, JPN J CANCER RES, V83, P236, DOI 10.1111/j.1349-7006.1992.tb00092.x; MOUTSOPOULOS HM, 1994, HARRISONS PRINCIPLES, P1662; NISHIOKA K, 1989, LANCET, V1, P441; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; SAKAI M, 1993, J CLIN INVEST, V92, P1957, DOI 10.1172/JCI116789; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; TAJIMA K, 1982, GANN, V73, P893; TALAL N, 1987, SJOGRENS SYNDROME CL; VERNANT JC, 1988, LANCET, V1, P177; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; YOSHIDA M, 1989, ANN NEUROL, V26, P331, DOI 10.1002/ana.410260304; 1990, WKLY EPIDEMIOL REC, V65, P281	28	185	189	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1116	1119		10.1016/S0140-6736(94)90630-0	http://dx.doi.org/10.1016/S0140-6736(94)90630-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934493				2022-12-28	WOS:A1994PN06600009
J	FAN, C; MOEWS, PC; WALSH, CT; KNOX, JR				FAN, C; MOEWS, PC; WALSH, CT; KNOX, JR			VANCOMYCIN RESISTANCE - STRUCTURE OF D-ALANINE-D-ALANINE LIGASE AT 2.3-ANGSTROM RESOLUTION	SCIENCE			English	Article							ALANYL-D-ALANINE; GLYCOPEPTIDE RESISTANCE; GLUTATHIONE SYNTHETASE; ESCHERICHIA-COLI; ENZYMES; ATP; BIOSYNTHESIS; PROTEINS; GENE; VANA	The molecular structure of the D-alanine:D-alanine ligase of the ddlB gene of Escherichia coli, co-crystallized with an S,R-methylphosphinate and adenosine triphosphate, was determined by x-ray diffraction to a resolution of 2.3 angstroms. A catalytic mechanism for the ligation of two D-alanine substrates is proposed in which a helix dipole and a hydrogen-bonded triad of tyrosine, serine, and glutamic acid assist binding and deprotonation steps. From sequence comparison, it is proposed that a different triad exists in a recently discovered D-alanine:D-lactate ligase (VanA) present in vancomycin-resistant enterococci. A molecular mechanism for the altered specificity of VanA is suggested.	UNIV CONNECTICUT, DEPT MOLEC & CELL BIOL, STORRS, CT 06269 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	University of Connecticut; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034330] Funding Source: NIH RePORTER; NIAID NIH HHS [1RO1-AI-34330] Funding Source: Medline; NIGMS NIH HHS [GM-49338] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1992, CHEM B LACTAMS; ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DUTKAMALEN S, 1990, MOL GEN GENET, V224, P364, DOI 10.1007/BF00262430; DUTKAMALEN S, 1992, GENE, V112, P53, DOI 10.1016/0378-1119(92)90302-6; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HAMMES WP, 1981, PHARMACOL THERAPEUT, V14, P265; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JACK JS, 1988, J MOL GRAPHICS, V6, P224; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; MCDERMOTT AE, 1990, BIOCHEMISTRY-US, V29, P5767, DOI 10.1021/bi00476a018; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NEUHAUS FC, 1962, J BIOL CHEM, V237, P778; NEUHAUS FC, 1964, BIOCHEMISTRY-US, V3, P471, DOI 10.1021/bi00892a001; NEUHAUS FC, 1962, J BIOL CHEM, V237, P3128; PARSONS WH, 1988, J MED CHEM, V31, P1772, DOI 10.1021/jm00117a017; REYNOLDS PE, 1994, BIOCHEM J, V301, P5, DOI 10.1042/bj3010005; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SPRATT BG, 1994, SCIENCE, V264, P388, DOI 10.1126/science.8153626; STROMINGER JL, 1960, J AM CHEM SOC, V82, P998, DOI 10.1021/ja01489a058; TANAKA T, 1993, BIOCHEMISTRY-US, V32, P12398, DOI 10.1021/bi00097a018; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; Waley SG, 1992, CHEM BLACTAMS, P198; WALSH C, UNPUB; WALSH CT, 1989, J BIOL CHEM, V264, P2393; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; WRIGHT GD, 1993, PROTEIN SCI, V2, P1765, DOI 10.1002/pro.5560021020; WRIGHT GD, 1992, ACCOUNTS CHEM RES, V25, P468, DOI 10.1021/ar00022a006; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106; ZAWADZKE LE, 1991, BIOCHEMISTRY-US, V30, P1673, DOI 10.1021/bi00220a033	34	245	249	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	1994	266	5184					439	443		10.1126/science.7939684	http://dx.doi.org/10.1126/science.7939684			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939684				2022-12-28	WOS:A1994PN27200036
J	MCPHERSON, K; STEEL, CM; DIXON, JM				MCPHERSON, K; STEEL, CM; DIXON, JM			ABC OF BREAST DISEASES - BREAST-CANCER - EPIDEMIOLOGY, RISK-FACTORS, AND GENETICS	BRITISH MEDICAL JOURNAL			English	Article									UNIV ST ANDREWS,ST ANDREWS,FIFE,SCOTLAND; EDINBURGH ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of St Andrews; Royal Infirmary of Edinburgh; University of Edinburgh	MCPHERSON, K (corresponding author), LONDON SCH HYG & TROP MED,LONDON WC1,ENGLAND.								0	87	88	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					1003	1006		10.1136/bmj.309.6960.1003	http://dx.doi.org/10.1136/bmj.309.6960.1003			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7950693	Green Published			2022-12-28	WOS:A1994PM41700030
J	HAY, RJ; CASTANON, RE; HERNANDEZ, HA; LOPEZ, GC; FUENTES, LFL; SOLIS, SP; ANDERSSON, N				HAY, RJ; CASTANON, RE; HERNANDEZ, HA; LOPEZ, GC; FUENTES, LFL; SOLIS, SP; ANDERSSON, N			WASTAGE OF FAMILY INCOME ON SKIN-DISEASE IN MEXICO	BRITISH MEDICAL JOURNAL			English	Article									UNIV AUTONOMA GUERRERO,CTR INVEST ENFERMEDADES TROP,ACAPULCO,GUERRERO,MEXICO		HAY, RJ (corresponding author), GUYS HOSP,ST JOHNS INST DERMATOL,LONDON SE1 9RT,ENGLAND.		Andersson, Neil/G-2248-2011					ANDERSSON N, 1992, HLTH POLICY PLANNING, V7, P1; BECHELLI LM, 1981, DERMATOLOGICA, V163, P78, DOI 10.1159/000250144; CASTELLS S, 1992, J INTELL DISABIL RES, V36, P29; Hay R, 1991, LANCET, V337, P906; TAPLIN D, 1991, LANCET, V337, P1016, DOI 10.1016/0140-6736(91)92669-S	5	57	58	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					848	848		10.1136/bmj.309.6958.848	http://dx.doi.org/10.1136/bmj.309.6958.848			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7950615	Green Published			2022-12-28	WOS:A1994PK50100024
J	MORGAN, HG				MORGAN, HG			PREVENTION IS POSSIBLE IF DOCTORS ARE TAUGHT HOW	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; SUICIDE				MORGAN, HG (corresponding author), UNIV BRISTOL,DEPT MENTAL HLTH,BRISTOL BS2 8DZ,ENGLAND.							BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; FAWCETT J, 1992, J CLIN PSYCHIAT, V53, P9; Morgan HG, 1979, DEATH WISHES UNDERST; MORGAN HG, 1990, PERSONS RISK SUICIDE; MURPHY GE, 1984, AM J PSYCHOTHER, V38, P341, DOI 10.1176/appi.psychotherapy.1984.38.3.341; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; VASSILAS CA, 1993, BRIT MED J, V307, P300, DOI 10.1136/bmj.307.6899.300; WRIGHT AF, 1993, DEPRESSION RECOGNITI	8	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					861	862		10.1136/bmj.309.6958.861	http://dx.doi.org/10.1136/bmj.309.6958.861			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7950619	Green Published			2022-12-28	WOS:A1994PK50100030
J	RECORD, MC; SPENCER, JA; JONES, RH; JONES, KP				RECORD, MC; SPENCER, JA; JONES, RH; JONES, KP			GENERAL-PRACTITIONERS VIEWS ABOUT THE STATUTORY ANNUAL PRACTICE REPORT	BRITISH MEDICAL JOURNAL			English	Article							STANDARDIZATION; CONTRACT	Objective-To ascertain the views of primary care professionals about the current purpose, uses, potential, and workload implications of the statutory general practice annual report. Design-Postal questionnaire survey. Setting-General practices in the Northern region. Subjects-All practices in the region that were singlehanded, fundholding, non-fundholding and with more than five partners, and a one in three random sample of all non-fundholding practices (n = 318). Results-263 practices responded (83%). The report took a median of 12 hours to produce (95% confidence interval 11 to 15 hours; interquartile range 7-35). The main perceived purpose of the report was to monitor practice activity (165 respondents; 63% (95% confidence interval 57% to 69%)), but 44 respondents (17%; 13% to 22%) produced it only because it was contractually required. Practices included statutory and non-statutory data in these reports and would have liked comparative practice activity information (155 respondents; 59%) and ''good ideas'' (165 respondents; 63%) fed back to them. Respondents would have liked the annual report used to improve practice development planning (122 respondents; 46% (40% to 52%)), to facilitate audit (115 respondents; 44% (38% to 50%)), and to influence resource allocation (104 respondents; 40% (34% to 46%)). One hundred and eighteen practices (45%; 39% to 51%) would produce an annual report even if not contractually required. Data collected were perceived to be already available elsewhere. Conclusions-Primary care professionals have concerns about the current annual report. They would prefer to collect relevant, standardised data which could lead to better audit, planning, and resource allocation.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK								CHAMBERS R, 1993, BRIT J GEN PRACT, V43, P410; GARDNER MJ, 1989, CONFIDENCE INTERVAL; HANNAY D, 1992, BRIT MED J, V304, P615, DOI 10.1136/bmj.304.6827.615; HARRINGTON B, 1993, HLTH LIFESTYLE NEWCA; HOWARTH FP, 1989, J ROY COLL GEN PRACT, V39, P463; KEEBLE BR, 1989, J ROY COLL GEN PRACT, V39, P467; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; NORUSIS MJ, 1989, SPSS GUIDE DATA ANAL; SZCZEPURA A, 1994, BRIT J GEN PRACT, V44, P19; WILKINSON J, 1993, J PUBLIC HEALTH MED, V15, P342, DOI 10.1093/oxfordjournals.pubmed.a042887; WILSON A, 1989, J ROY COLL GEN PRACT, V39, P250; WILTON J, 1990, BRIT MED J, V300, P851, DOI 10.1136/bmj.300.6728.851; 1989, GENERAL PRACTICE NAT; 1989, WORKING PATIENTS	14	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					849	852		10.1136/bmj.309.6958.849	http://dx.doi.org/10.1136/bmj.309.6958.849			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7950616	Green Published			2022-12-28	WOS:A1994PK50100025
J	MANFREDINI, R; GALLERANI, M; CARACCIOLO, S; TOMELLI, A; CALO, G; FERSINI, C				MANFREDINI, R; GALLERANI, M; CARACCIOLO, S; TOMELLI, A; CALO, G; FERSINI, C			CIRCADIAN VARIATION IN ATTEMPTED-SUICIDE BY DELIBERATE SELF-POISONING	BRITISH MEDICAL JOURNAL			English	Article									ST ANNA HOSP,DEPT ACCID & EMERGENCY,FERRARA,ITALY; UNIV FERRARA,SCH MED,DEPT PSYCHOL,I-44100 FERRARA,ITALY; UNIV FERRARA,INST PHARMACOL,I-44100 FERRARA,ITALY; WHO,PARASUICIDE MULTICTR STUDY,MENTAL HLTH SERV,FERRARA,ITALY	University of Ferrara; Arcispedale Sant'Anna; University of Ferrara; University of Ferrara; World Health Organization	MANFREDINI, R (corresponding author), UNIV FERRARA,SCH MED,INST INTERNAL MED,I-44100 FERRARA,ITALY.		Manfredini, Roberto/N-3859-2019; Manfredini, Roberto/AAJ-5442-2020; Manfredini, Roberto/A-3471-2008	Manfredini, Roberto/0000-0002-8364-2601; Manfredini, Roberto/0000-0002-8364-2601; Caracciolo, Stefano/0000-0002-3605-1905				MALDONADO G, 1991, SUICIDE LIFE-THREAT, V21, P174; MOTOHASHI Y, 1990, SUICIDE LIFE-THREAT, V20, P352; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; ROY A, 1988, ACTA PSYCHIAT SCAND, V78, P529, DOI 10.1111/j.1600-0447.1988.tb06380.x	5	22	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					774	775		10.1136/bmj.309.6957.774	http://dx.doi.org/10.1136/bmj.309.6957.774			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PJ282	7950563	Green Published			2022-12-28	WOS:A1994PJ28200020
J	NAIMAN, JL				NAIMAN, JL			DIGITALIS PURPUREA (FOXGLOVE)	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											NAIMAN, JL (corresponding author), STANFORD UNIV,SCH MED,STANFORD,CA 94303, USA.								0	1	1	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	1994	331	23					1563	1563						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PV292	7969327				2022-12-28	WOS:A1994PV29200006
J	AMARENCO, P; COHEN, A; TZOURIO, C; BERTRAND, B; HOMMEL, M; BESSON, G; CHAUVEL, C; TOUBOUL, PJ; BOUSSER, MG				AMARENCO, P; COHEN, A; TZOURIO, C; BERTRAND, B; HOMMEL, M; BESSON, G; CHAUVEL, C; TOUBOUL, PJ; BOUSSER, MG			ATHEROSCLEROTIC DISEASE OF THE AORTIC-ARCH AND THE RISK OF ISCHEMIC STROKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CHOLESTEROL EMBOLIZATION; CARDIOPULMONARY BYPASS; SYSTEMIC EMBOLIZATION; CEREBRAL INFARCTION; EMBOLISM; PLAQUE; COMPLICATION; ATHEROMAS; THROMBUS	Background. Atherosclerotic disease of the aortic arch has been suspected to be a potential source of cerebral emboli. We conducted a study to quantify the risk of ischemic stroke associated with atherosclerotic disease of the aortic arch. Methods. Using transesophageal echocardiography, we performed a prospective case-control study of the frequency and thickness of atherosclerotic plaques in the ascending aorta and proximal arch in 250 consecutive patients admitted to the hospital with ischemic stroke and 250 consecutive controls, all over the age of 60 years. Results. Atherosclerotic plaques greater than or equal to 4 mm in thickness were found in 14.4 percent of the patients but in only 2 percent of the controls. After adjustment for atherosclerotic risk factors, the odds ratio for ischemic stroke among patients with such plaques was 9.1 (95 percent confidence interval, 3.3 to 25.2; P<0.001). Among the 78 patients who had brain infarcts with no obvious cause, 28.2 percent had plaques greater than or equal to 4 mm in thickness, as compared with 8.1 percent of the 172 patients who had infarcts whose possible or likely causes were known (odds ratio, 4.7; 95 percent confidence interval, 2.2 to 10.1; P<0.001). Plaques of greater than or equal to 4 mm in the aortic arch were not associated with the presence of atrial fibrillation or stenosis of the extracranial internal carotid artery. In contrast, plaques that were 1 to 3.9 mm thick were frequently associated with carotid stenosis of greater than or equal to 70 percent. Conclusions. These results indicate a strong, independent association between atherosclerotic disease of the aortic arch and the risk of ischemic stroke. The association was particularly strong with thick plaques. Atherosclerotic disease of the aortic arch should be regarded as a risk factor for ischemic stroke and as a possible source of cerebral emboli.	UNIV PARIS 06,HOP ST ANTOINE,SERV CARDIOL,PARIS,FRANCE; INSERM,U360,VILLEJUIF,FRANCE; CHU GRENOBLE,NEUROL CLIN,GRENOBLE,FRANCE; CHU GRENOBLE,CARDIOL CLIN,GRENOBLE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	AMARENCO, P (corresponding author), UNIV PARIS 06,HOP ST ANTOINE,SERV NEUROL,184 RUE FAUBOURG ST ANTOINE,F-75571 PARIS 12,FRANCE.		Tzourio, christophe/L-6344-2019; Tzourio, Christophe I/B-7459-2008; Tzourio, christophe/B-4015-2009	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984; Touboul, Pierre-Jean/0000-0002-8872-9917				AMARENCO P, 1992, STROKE, V23, P1005, DOI 10.1161/01.STR.23.7.1005; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; BEAL MF, 1981, NEUROLOGY, V31, P860, DOI 10.1212/WNL.31.7.860; BRUNS FJ, 1978, AM J MED SCI, V275, P105, DOI 10.1097/00000441-197801000-00013; CAPLAN LR, 1993, NEUROLOGY, V43, P1281, DOI 10.1212/WNL.43.7.1281; CHESEBRO JH, 1990, NEW ENGL J MED, V323, P1556; COGAN DG, 1964, ARCH OPHTHALMOL-CHIC, V71, P308; Culliford Alfred T., 1993, Journal of the American College of Cardiology, V21, p342A; DAVID NJ, 1963, NEUROLOGY, V13, P708, DOI 10.1212/WNL.13.8.708; FAZIO GP, 1993, J AM COLL CARDIOL, V21, P144, DOI 10.1016/0735-1097(93)90729-K; FEDER W, 1961, ANN INTERN MED, V55, P911, DOI 10.7326/0003-4819-55-6-911; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; GORE I, 1960, AM J CLIN PATHOL, V33, P416; HAUSMANN D, 1992, NEW ENGL J MED, V327, P500; HOLLENHORST RW, 1966, AM J OPHTHALMOL, V61, P1159, DOI 10.1016/0002-9394(66)90238-8; HOROWITZ DR, 1992, NEUROLOGY, V42, P1602, DOI 10.1212/WNL.42.8.1602; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; KATZ ES, 1992, J AM COLL CARDIOL, V20, P70, DOI 10.1016/0735-1097(92)90139-E; MCKIBBIN DW, 1976, J THORAC CARDIOV SUR, V71, P741; MOHR-KAHALY S, 1992, European Heart Journal, V13, P17; MOLDVEEN.M, 1967, CIRCULATION, V35, P946, DOI 10.1161/01.CIR.35.5.946; NIHOYANNOPOULOS P, 1993, AM J CARDIOL, V71, P1208, DOI 10.1016/0002-9149(93)90647-U; OSTER P, 1979, JAMA-J AM MED ASSOC, V242, P2070, DOI 10.1001/jama.242.19.2070; PFAFFENBACH DD, 1973, AM J OPHTHALMOL, V75, P66, DOI 10.1016/0002-9394(73)90653-3; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; PRICE DL, 1970, NEUROLOGY, V20, P1209, DOI 10.1212/WNL.20.12.1209; RAMIREZ G, 1978, ARCH INTERN MED, V138, P1430, DOI 10.1001/archinte.138.9.1430; RUSSELL RWR, 1983, VASCULAR DISEASE CTR, P394; SOLOWAY HB, 1964, ARCH NEUROL-CHICAGO, V11, P657, DOI 10.1001/archneur.1964.00460240089012; STURGILL BC, 1963, ARCH PATHOL, V76, P189; TOUBOUL PJ, 1992, J HYPERTENS, V10, pS37, DOI 10.1097/00004872-199207005-00006; TOYODA K, 1992, STROKE, V23, P1056, DOI 10.1161/01.STR.23.8.1056; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423; TUNICK PA, 1992, AM HEART J, V124, P239; WINTER WJ, 1957, ARCH PATHOL, V64, P137; 1972, NEW ENGL J MED, V286, P1146; 1967, NEW ENGL J MED, V276, P1368; 1990, SAS USERS GUIDE, V1	39	722	742	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1474	1479		10.1056/NEJM199412013312202	http://dx.doi.org/10.1056/NEJM199412013312202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969297	Bronze			2022-12-28	WOS:A1994PU86600002
J	GORDON, SM; EATON, ME; GEORGE, R; LARSEN, S; LUKEHART, SA; KUYPERS, J; MARRA, CM; THOMPSON, S				GORDON, SM; EATON, ME; GEORGE, R; LARSEN, S; LUKEHART, SA; KUYPERS, J; MARRA, CM; THOMPSON, S			THE RESPONSE OF SYMPTOMATIC NEUROSYPHILIS TO HIGH-DOSE INTRAVENOUS PENICILLIN-G IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TREPONEMA-PALLIDUM; SECONDARY SYPHILIS; HIV INFECTION; THERAPY; AIDS; CEFTRIAXONE	Background. Infection with the human immunodeficiency virus (HIV) may affect both the natural course syphilis and the response to treatment. We examined the response to treatment with high-dose penicillin G in HIV-infected patients with symptomatic neurosyphilis. Methods. Neurosyphilis was defined by reactivity in serum treponemal tests for syphilis, neurologic manifestations consistent with neurosyphilis, and a positive Venereal Disease Research Laboratory (VDRL) test on cerebrospinal fluid. We identified 11 HIV-infected patients with symptomatic neurosyphilis; 5 had been treated previously for early syphilis with penicillin G benzathine. Patients were treated with 18 million to 24 million units of penicillin G per day administered intravenously for 10 days. Cerebrospinal fluid was examined approximately 6 and 24 weeks after treatment, when the polymerase chain reaction and rabbit inoculation were used to detect Treponema pallidum. Results. In four of the seven patients studied 24 weeks after treatment, the serum titers on rapid plasma reagin (RPR) testing decreased by at least two doubling dilutions, and four patients had reductions in the cerebrospinal fluid titers on VDRL testing or reverted to nonreactive results. In two patients there was no normalization or improvement in serum titers on RPR testing or cerebrospinal fluid titers on VDRL testing, cell counts, or protein concentrations. One patient relapsed with meningovascular syphilis six months after therapy. T. pallidum was detected by the polymerase chain reaction in cerebrospinal fluid from 3 of 10 patients before treatment, but in none of the 10 post-treatment specimens. Conclusions. In patients with early syphilis who are also infected with HIV, therapy with penicillin G benzathine may fail, and neurosyphilis may develop. The regimen of high-dose penicillin recommended for neurosyphilis is not consistently effective in patients infected with HIV.	EMORY UNIV, GRADY MEM HOSP, SCH MED, DEPT MED, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, CTR INFECT DIS, SEXUALLY TRANSMITTED DIS LAB, ATLANTA, GA USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA USA	Emory University; Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001529] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 01529] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAYNE LL, 1986, ARCH NEUROL-CHICAGO, V43, P137, DOI 10.1001/archneur.1986.00520020031012; BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; BROWN ST, 1985, JAMA-J AM MED ASSOC, V253, P1296, DOI 10.1001/jama.253.9.1296; BURSTAIN JM, 1991, J CLIN MICROBIOL, V29, P62, DOI 10.1128/JCM.29.1.62-69.1991; Centers for Disease Control and Prevention Use of Race and Ethnicity in Public Health Surveillance, 1993, MMWR-MORBID MORTAL W, V42, P1; CLARK R, 1988, SOUTHERN MED J, V81, P1204, DOI 10.1097/00007611-198809000-00040; DATTNER B, 1951, AM J MED, V10, P463, DOI 10.1016/0002-9343(51)90292-6; DATTNER B, 1944, MANAGEMENT NEUROSYPH, P69; DOWELL ME, 1992, AM J MED, V93, P481, DOI 10.1016/0002-9343(92)90574-U; HAHN RD, 1956, ARCH DERMATOL, V74, P367, DOI 10.1001/archderm.1956.01550100035007; HARRIS RL, 1985, HOSP PRACT, V20, P167; JAFFE HW, 1982, REV INFECT DIS, V4, pS842; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; KASE CS, 1988, ARCH NEUROL-CHICAGO, V45, P832, DOI 10.1001/archneur.1988.00520320018007; KATZ DA, 1989, ARCH NEUROL-CHICAGO, V46, P895, DOI 10.1001/archneur.1989.00520440085024; LANSKA MJ, 1988, NEUROLOGY, V38, P1297, DOI 10.1212/WNL.38.8.1297; LARSEN SA, 1990, MANUAL TESTS SYPHILI, P78; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MARRA CM, 1992, J INFECT DIS, V165, P396, DOI 10.1093/infdis/165.2.396; Merritt HH., 1946, NEUROSYPHILIS; MUSHER DM, 1991, J INFECT DIS, V163, P1201, DOI 10.1093/infdis/163.6.1201; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; ROMANOWSKI B, 1991, ANN INTERN MED, V114, P1005, DOI 10.7326/0003-4819-114-12-1005; RONALD AR, 1992, CLIN INFECT DIS, V15, pS140, DOI 10.1093/clind/15.Supplement_1.S140; SALLOUM E, 1992, INFECT DIS CLIN PRAC, V1, P43; SMITH ME, 1989, LARYNGOSCOPE, V99, P365, DOI 10.1288/00005537-198904000-00001; TIEN RD, 1992, AM J ROENTGENOL, V158, P1325, DOI 10.2214/ajr.158.6.1590135; TRAMONT EC, 1976, JAMA-J AM MED ASSOC, V236, P2206, DOI 10.1001/jama.236.19.2206; TRAMONT EC, 1987, NEW ENGL J MED, V316, P1600, DOI 10.1056/NEJM198706183162510; TURNER TB, 1969, BRIT J VENER DIS, V45, P183; ZENKER PN, 1990, REV INFECT DIS, V12, pS590; IN PRESS RABBIT INFE; 1967, PHS PUBLICATION, V1660	33	113	121	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1469	1473		10.1056/NEJM199412013312201	http://dx.doi.org/10.1056/NEJM199412013312201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7969296				2022-12-28	WOS:A1994PU86600001
J	REX, JH; BENNETT, JE; SUGAR, AM; PAPPAS, PG; VANDERHORST, CM; EDWARDS, JE; WASHBURN, RG; SCHELD, WM; KARCHMER, AW; DINE, AP; LEVENSTEIN, MJ; WEBB, CD				REX, JH; BENNETT, JE; SUGAR, AM; PAPPAS, PG; VANDERHORST, CM; EDWARDS, JE; WASHBURN, RG; SCHELD, WM; KARCHMER, AW; DINE, AP; LEVENSTEIN, MJ; WEBB, CD			A RANDOMIZED TRIAL COMPARING FLUCONAZOLE WITH AMPHOTERICIN-B FOR THE TREATMENT OF CANDIDEMIA IN PATIENTS WITHOUT NEUTROPENIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FUNGEMIA; MORTALITY; FREQUENCY	Background. Amphotericin B has long been the standard treatment for candidemia, but its use is complicated by its toxicity. More recently, fluconazole, a water-soluble triazole with activity against candida species and little toxicity, has become available. We conducted a multicenter randomized trial that compared amphotericin B with fluconazole as treatment for candidemia. Methods. To be eligible, patients had to have a positive blood culture for candida species, a neutrophil count greater than or equal to 500 per cubic millimeter, and no major immunodeficiency. Patients were randomly assigned to receive either amphotericin B (0.5 to 0.6 mg per kilogram of body weight per day) or fluconazole (400 mg per day), each continued for at least 14 days after the last positive blood culture. Outcomes were assessed by a group of investigators blinded to treatment assignment. Results. Of the 237 patients enrolled, 206 met all entry criteria. The most common diagnoses were renal failure, nonhematologic cancer, and gastrointestinal disease. There was no statistically significant difference in outcome: of the 103 patients treated with amphotericin B, 81 (79 percent) were judged to have been treated successfully, as were 72 of the 103 patients treated with fluconazole (70 percent; P = 0.22; 95 percent confidence interval for the difference, -5 to 23 percent). The bloodstream infection failed to clear in 12 patients in the amphotericin group and 15 in the fluconazole group; the species most commonly associated with failure was Candida albicans. There were 41 deaths in the amphotericin group and 34 deaths in the fluconazole group (P = 0.20). Intravascular catheters appeared to be the most frequent source of candidemia. There was less toxicity with fluconazole than with amphotericin B. Conclusions. In patients without neutropenia and without major immunodeficiency, fluconazole and amphotericin B are not significantly different in their effectiveness in treating candidemia.-	NIAID, CLIN INVEST LAB, BETHESDA, MD 20892 USA; BOSTON UNIV HOSP, MED CTR, BOSTON, MA 02118 USA; UNIV ALABAMA, BIRMINGHAM, AL USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; UCLA, HARBOR MED CTR, TORRANCE, CA USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC USA; UNIV VIRGINIA, CHARLOTTESVILLE, VA USA; NEW ENGLAND DEACONESS HOSP, BOSTON, MA 02215 USA; ROERIG PFIZER, NEW YORK, NY USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Boston University; University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Virginia; Pfizer	REX, JH (corresponding author), UNIV TEXAS, SCH MED, 6431 FANNIN 1728 JFB, HOUSTON, TX 77030 USA.			Rex, John/0000-0003-3265-5872	NIAID NIH HHS [N01-AI-15082] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		EDWARDS JE, 1992, CLIN INFECT DIS, V15, P422, DOI 10.1093/clind/15.3.422; EDWARDS JE, 1974, MEDICINE, V53, P47, DOI 10.1097/00005792-197401000-00002; ELLIS CA, 1967, ANN INTERN MED, V67, P511, DOI 10.7326/0003-4819-67-3-511; FRASER VJ, 1992, CLIN INFECT DIS, V15, P414, DOI 10.1093/clind/15.3.414; HARVEY RL, 1987, ARCH INTERN MED, V147, P2117, DOI 10.1001/archinte.147.12.2117; HORN R, 1985, REV INFECT DIS, V7, P646; KLEIN JJ, 1979, AM J MED, V67, P51, DOI 10.1016/0002-9343(79)90073-1; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOMSHIAN SV, 1989, REV INFECT DIS, V11, P379; LAINE L, 1992, ANN INTERN MED, V117, P655, DOI 10.7326/0003-4819-117-8-655; MARSH PK, 1983, ANN SURG, V198, P42, DOI 10.1097/00000658-198307000-00008; RICHARDSON K, 1990, REV INFECT DIS, V12, pS267; WEY SB, 1988, ARCH INTERN MED, V148, P2642, DOI 10.1001/archinte.148.12.2642	13	797	820	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1325	1330		10.1056/NEJM199411173312001	http://dx.doi.org/10.1056/NEJM199411173312001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935701				2022-12-28	WOS:A1994PR21600001
J	BLENDON, RJ; KOHUT, A; BENSON, JM; DONELAN, K; BOWMAN, C				BLENDON, RJ; KOHUT, A; BENSON, JM; DONELAN, K; BOWMAN, C			HEALTH SYSTEM REFORM - PHYSICIANS VIEWS ON THE CRITICAL CHOICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									TIMES MIRROR CTR PEOPLE & PRESS,WASHINGTON,DC		BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Donelan, Karen/R-6162-2019					BLENDON RJ, 1994, JAMA-J AM MED ASSOC, V271, P1539, DOI 10.1001/jama.271.19.1539; 1993, TIMES MIRROR    0315; 1994, TIMES MIRROR    0623; 1993, USA TODAY       1001	4	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	1994	272	19					1546	1550		10.1001/jama.272.19.1546	http://dx.doi.org/10.1001/jama.272.19.1546			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ900	7966852				2022-12-28	WOS:A1994PQ90000040
J	SCHOFIELD, JR; ROBINSON, WA; MURPHY, JR; ROVIRA, DK				SCHOFIELD, JR; ROBINSON, WA; MURPHY, JR; ROVIRA, DK			LOW-DOSES OF INTERFERON-ALPHA ARE AS EFFECTIVE AS HIGHER DOSES IN INDUCING REMISSIONS AND PROLONGING SURVIVAL IN CHRONIC MYELOID-LEUKEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						LEUKEMIA, MYELOID, CHRONIC; INTERFERON-ALPHA; REMISSION INDUCTION; DOSE-RESPONSE RELATIONSHIP, DRUG; COST-BENEFIT ANALYSIS	CHRONIC MYELOGENOUS LEUKEMIA; HAIRY-CELL LEUKEMIA; PHILADELPHIA-CHROMOSOME; MARROW TRANSPLANTATION; CYTOGENETIC IMPROVEMENT; INTENSIVE TREATMENT; ANTIBODIES; GENE	Objective: To determine the toxicity and efficacy of low-dose interferon-alpha therapy in inducing remissions and prolonging survival in patients with chronic myeloid leukemia. Design: Phase II evaluation and comparison with historical control patients and other series in which the investigators used higher interferon-alpha doses. Setting: Tertiary care leukemia research clinic. Patients: 41 patients with newly diagnosed or previously treated chronic-phase, Philadelphia chromosome-positive chronic myeloid leukemia received interferon-alpha at a dose of 2 x 10(6) U/m(2) body surface area daily for 28 days and then three times weekly. Measurements: Complete blood counts and physical examinations were done monthly to determine hematologic remission and toxicity. To determine karyotypic response, bone marrow cytogenetic analyses were done at 6 monthly intervals in patients who achieved a complete hematologic remission. In addition, Kaplan-Meier survival curves and median survival values were generated from diagnosis and the start of therapy with interferon-alpha. Results: 70% of patients treated with low-dose interferon-alpha within 1 year of diagnosis achieved a complete hematologic remission, and 22% of these patients had a major or complete karyotypic response. Investigators who used higher interferon-alpha doses in similar patient populations have reported complete hematologic remission rates of 59% to 70% and major and complete cytogenetic response rates of 16% to 29%. The Kaplan-Meier estimated 5-year survival rate of minimally pretreated patients in our study is 73% (95% Cl, 51% to 95%), which compares favorably with survivals reported by investigators who used higher doses. The estimated yearly cost of the interferon-alpha used in our study is $5953 compared with a median of $24 375 for the higher doses used by other investigators. Less toxicity was also observed. Conclusion: Low-dose interferon-alpha is as effective as higher-dose interferon-alpha in inducing remissions and prolonging survival in patients with chronic myeloid leukemia but is considerably less expensive and toxic.	UNIV COLORADO, HLTH SCI CTR, DIV MED ONCOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DIV PREVENT MED & BIOMETR, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Robinson, William/0000-0003-1875-9691				ALIMENA G, 1988, BLOOD, V72, P642; BEDI A, 1993, BLOOD, V81, P2898; BUTTURINI A, 1990, LANCET, V335, P1255, DOI 10.1016/0140-6736(90)91313-Y; CHAMPLIN RE, 1988, SEMIN HEMATOL, V25, P74; CUNNINGHAM I, 1979, BLOOD, V53, P375; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; FREUND M, 1989, BRIT J HAEMATOL, V72, P350, DOI 10.1111/j.1365-2141.1989.tb07715.x; GOTO T, 1982, BLOOD, V59, P793; HENNES U, 1987, J BIOL STAND, V15, P231, DOI 10.1016/0092-1157(87)90026-6; Jameson P, 1981, Methods Enzymol, V78, P357; KANTARJIAN HM, 1993, BLOOD, V82, P691; KLOKE O, 1993, BRIT J HAEMATOL, V83, P399, DOI 10.1111/j.1365-2141.1993.tb04663.x; KOLITZ JE, 1992, SEMIN ONCOL, V19, P27; LEE ET, 1980, STATISTICAL METHODS; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OZER H, 1993, BLOOD, V82, P2975; QUESADA JR, 1986, CANCER, V57, P1678, DOI 10.1002/1097-0142(19860415)57:8+<1678::AID-CNCR2820571308>3.0.CO;2-6; SMALLEY RV, 1991, BLOOD, V78, P3133; SOKAL JE, 1988, SEMIN HEMATOL, V25, P49; TALPAZ M, 1991, ANN INTERN MED, V114, P532, DOI 10.7326/0003-4819-114-7-532; TALPAZ M, 1987, BLOOD, V69, P1280; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; THOMAS ED, 1989, BLOOD, V73, P861; THOMAS MR, 1984, AM J HEMATOL, V16, P105, DOI 10.1002/ajh.2830160202; TURA S, 1994, NEW ENGL J MED, V330, P820; SAS USERS GUIDE STAT, P507	26	59	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1994	121	10					736	744		10.7326/0003-4819-121-10-199411150-00002	http://dx.doi.org/10.7326/0003-4819-121-10-199411150-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ928	7944050				2022-12-28	WOS:A1994PQ92800002
J	JOYCE, CRB				JOYCE, CRB			PLACEBO AND COMPLEMENTARY MEDICINE	LANCET			English	Article							QUALITY-OF-LIFE; CLINICAL-TRIALS				JOYCE, CRB (corresponding author), ROYAL COLL SURGEONS IRELAND,ST STEPHENS GN,DUBLIN 2,IRELAND.							Aldridge D., 1992, ADVANCES, V8, P58; CHRISTOPHER E, 1991, J R SOC MED, V84, P178; COMFORT A, 1984, J ROY SOC MED, V77, P631, DOI 10.1177/014107688407700802; DESAINTONGE DMC, 1994, LANCET, V344, P995, DOI 10.1016/S0140-6736(94)91647-0; GOTZSCHE PC, 1994, LANCET, V344, P925; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; HORNUNG J, 1994, FORSCH KOMPLEMENTMED, V1, P44; HORNUNG J, 1994, FORSCHENDE KOMPLEMEN, V1, P76; JONAS WB, 1993, J NIH RES, V5, P64; JOYCE CRB, 1994, J CARDIOVASC PHARM, V23, pS26; JOYCE CRB, 1989, NONSPECIFIC ASPECTS; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LEWIT K, 1994, J ROY SOC MED, V87, P36; MacMahon B, 1970, EPIDEMIOLOGY PRINCIP; OBOYLE CA, 1992, LANCET, V339, P1088, DOI 10.1016/0140-6736(92)90673-Q; SARTORIUS N, 1987, INTEGRATIVE PSYCHIAT, V5, P151; SARTORIUS N, 1986, PLACEBO THEORY RES M; SCHUNDERTATZBER S, 1994, FORSCH KOMPLEMENT, V1, P107; SHAPIRO AK, 1978, PRINCIPLES PSYCHOPHA; Suls J., 1993, INT REV HLTH PSYCHOL, P3; THUNEDBORG K, 1993, INT J METHOD PSYCH, V3, P45; VINCENT CA, 1986, PAIN, V24, P1, DOI 10.1016/0304-3959(86)90022-9; WATT J, 1988, TALKING HLTH CONVENT; 1986, LANCET, V2, P287	24	22	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1279	1281		10.1016/S0140-6736(94)90757-9	http://dx.doi.org/10.1016/S0140-6736(94)90757-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7967992				2022-12-28	WOS:A1994PP70100015
J	FELTON, CV; CROOK, D; DAVIES, MJ; OLIVER, MF				FELTON, CV; CROOK, D; DAVIES, MJ; OLIVER, MF			DIETARY POLYUNSATURATED FATTY-ACIDS AND COMPOSITION OF HUMAN AORTIC PLAQUES	LANCET			English	Note							CORONARY HEART-DISEASE	How long-term dietary intake of essential fatty acids affects the fatty-acid content of aortic plaques is not clear. We compared the fatty-acid composition of aortic plaques with that of post-mortem serum and adipose tissue, in which essential fatty-acid content reflects dietary intake. Positive associations were found between serum and plaque omega 6 (r=0.75) and omega 3 (r=0.93) polyunsaturated fatty acids, and monounsaturates (r=0.70), and also between adipose tissue and plaque omega 6 polyunsaturated fatty acids (r=0.89). No associations were found with saturated fatty acids. These findings imply a direct influence of dietary polyunsaturated fatty acids on aortic plaque formation and suggest that current trends favouring increased intake of polyunsaturated fatty acids should be reconsidered.	ST GEORGE HOSP,SCH MED,BRITISH HEART FDN,CARDIOVASC PATHOL UNIT,LONDON,ENGLAND; NATL HEART & LUNG INST,LONDON,ENGLAND	St Georges University London; University of London; University College London; UCL Medical School; Imperial College London	FELTON, CV (corresponding author), WYNN INST METAB RES,21 WELLINGTON RD,LONDON NW8 9SQ,ENGLAND.		Davies, Michael/GWV-2527-2022	Crook, David/0000-0002-9587-3730				ELVEVOLL EO, 1990, ATHEROSCLEROSIS, V81, P71, DOI 10.1016/0021-9150(90)90060-V; Felton CV, 1993, J VASC MED BIOL, V4, P228; HEFFERNAN AGA, 1963, CLIN SCI, V25, P423; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; RAPP JH, 1991, ARTERIOSCLER THROMB, V11, P903, DOI 10.1161/01.ATV.11.4.903; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; WOOD DA, 1992, CORONARY HEART DISEA, P179	9	29	34	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1195	1196		10.1016/S0140-6736(94)90511-8	http://dx.doi.org/10.1016/S0140-6736(94)90511-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934543				2022-12-28	WOS:A1994PN80300012
J	JOHNSON, AG				JOHNSON, AG			SURGERY AS A PLACEBO	LANCET			English	Article							TRIAL				JOHNSON, AG (corresponding author), UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SURG UNIT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							ADAMS R, 1958, NEW ENGL J MED, V258, P113, DOI 10.1056/NEJM195801162580302; AITCHISON M, 1989, BRIT J UROL, V64, P478, DOI 10.1111/j.1464-410X.1989.tb05280.x; Balint M., 1957, DOCTOR; BARKER AT, 1984, LANCET, V1, P994; BARKER AT, 1985, PHYSIOTHERAPY, V12, P500; BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; GOLIGHER JC, 1979, ANN SURG, V189, P18, DOI 10.1097/00000658-197901000-00004; GOTZSCHE PC, 1994, LANCET, V344, P925; MAJEED AW, 1994, APR ASS SURG GB IR A; MCMAHON AJ, 1994, LANCET, V343, P135, DOI 10.1016/S0140-6736(94)90932-6; NICHOLL JP, 1992, LANCET, V340, P801, DOI 10.1016/0140-6736(92)92682-6; TATE JJT, 1993, LANCET, V342, P633, DOI 10.1016/0140-6736(93)91757-D; WOLF S, 1959, PHARMACOL REV, V11, P689	14	120	121	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1140	1142		10.1016/S0140-6736(94)90637-8	http://dx.doi.org/10.1016/S0140-6736(94)90637-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934500				2022-12-28	WOS:A1994PN06600016
J	GRIGORIADIS, AE; WANG, ZQ; CECCHINI, MG; HOFSTETTER, W; FELIX, R; FLEISCH, HA; WAGNER, EF				GRIGORIADIS, AE; WANG, ZQ; CECCHINI, MG; HOFSTETTER, W; FELIX, R; FLEISCH, HA; WAGNER, EF			C-FOS - A KEY REGULATOR OF OSTEOCLAST-MACROPHAGE LINEAGE DETERMINATION AND BONE REMODELING	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; CELL-POPULATION; DIFFERENTIATION; EXPRESSION; RESORPTION; MARROW; MOUSE; PROLIFERATION	Mice lacking the proto-oncogene c-fos develop the bone disease osteopetrosis. Fos mutant mice were found to have a block in the differentiation of bone-resorbing osteoclasts that was intrinsic to hematopoietic cells. Bone marrow transplantation rescued the osteopetrosis, and ectopic c-fos expression overcame this differentiation block. The lack of Fos also caused a lineage shift between osteoclasts and macrophages that resulted in increased numbers of bone marrow macrophages. These results identify Fos as a key regulator of osteoclast-macrophage lineage determination in vivo and provide insights into the molecular mechanisms underlying metabolic bone diseases.	RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA; UNIV BERN, DEPT PATHOPHYSIOL, CH-3010 BERN, SWITZERLAND	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Bern				Hofstetter, Wilhelm/0000-0003-0126-8423; Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aubin Jane E., 1993, P1; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; CECCHINI MG, UNPUB; CHAMBERS TJ, 1989, BONE MINERAL RES, V6, P1; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; FELIX R, 1990, J BONE MINER RES, V5, P781; FELIX R, UNPUB; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, UNPUB; Grigoriadis Agamemnon E., 1993, P497; HATTERSLEY G, 1991, BIOCHEM BIOPH RES CO, V177, P526, DOI 10.1016/0006-291X(91)92015-C; HO MK, 1982, J IMMUNOL, V128, P1221; HOFSTETTER W, 1992, P NATL ACAD SCI USA, V89, P9637, DOI 10.1073/pnas.89.20.9637; HOFSTETTER W, UNPUB; HOYLAND J, 1994, J BONE MINER RES, V9, P1191; HUME DA, 1984, J CELL SCI, V66, P189; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KERBY JA, 1992, J BONE MINER RES, V7, P353; KRATOCHWIL K, 1989, CELL, V57, P807, DOI 10.1016/0092-8674(89)90795-2; LEE MY, 1992, BLOOD, V80, P1710; LEENEN PJM, 1990, EUR J IMMUNOL, V20, P27, DOI 10.1002/eji.1830200105; LLIANG J, UNPUB; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; MARKS SC, 1989, AM J MED GENET, V34, P43, DOI 10.1002/ajmg.1320340110; MARKS SC, 1984, CLIN ORTHOP RELAT R, P239; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; MULLER R, 1994, FOS JUN FAMILIES TRA, P189; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NIIDA S, 1994, J BONE MINER RES, V9, P873; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; RUTHER U, 1989, ONCOGENE, V4, P861; SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SANDBERG M, 1988, DEV BIOL, V130, P324, DOI 10.1016/0012-1606(88)90438-1; SCHEVEN BAA, 1986, ANAT RECORD, V214, P418, DOI 10.1002/ar.1092140413; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; SHERR CJ, 1990, BLOOD, V75, P1; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WANG ZQ, 1993, J BONE MINER RES, V8, P839; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WUCHERPFENNIG AL, 1994, J BONE MINER RES, V9, P549	56	1027	1057	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	1994	266	5184					443	448		10.1126/science.7939685	http://dx.doi.org/10.1126/science.7939685			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7939685				2022-12-28	WOS:A1994PN27200037
J	GOURLAY, SG; FORBES, A; MARRINER, T; PETHICA, D; MCNEIL, JJ				GOURLAY, SG; FORBES, A; MARRINER, T; PETHICA, D; MCNEIL, JJ			PROSPECTIVE-STUDY OF FACTORS PREDICTING OUTCOME OF TRANSDERMAL NICOTINE TREATMENT IN SMOKING CESSATION	BRITISH MEDICAL JOURNAL			English	Article							QUITTING SMOKING; UNITED-STATES; CONTROLLED TRIAL; RELAPSE; HEAVINESS; CIGARETTE; REASONS; PATCHES; SMOKERS	Objective-To assess the factors associated with cessation of smoking with transdermal nicotine and brief behavioural counselling. Design-Interviews, treatment, and follow up for 26 weeks. Subjects-1481 subjects recruited by mass media publicity who smoked greater than or equal to 15 cigarettes a day and were motivated to stop smoking. Interventions-Twelve weeks' treatment with transdermal nicotine and brief behavioural counselling at monthly visits. Main outcome measure-Sustained smoking cessation for the 28 days before the visit at week 26 verified by expired carbon monoxide concentrations. The logistic regression analysis included all subjects. Results-Most subjects were dependent on nicotine, and the mean (SD) number of cigarettes smoked a day was 32 (12). Overall, 316/1481 subjects (21.3%) stopped smoking. Factors associated with stopping were being male (adjusted odds ratio 2.0; 95% confidence interval 1.5 to 2.7), age greater than or equal to 40 years (1.5; 1.1 to 2.0), living with a spouse or partner (1.5; 1.1 to 2.1), motivation (''want to quit'' 1.7; 1.2 to 2.3), and concern about weight gain (1.7; 1.3 to 2.2). Negative associations were smoking marijuana (0.4; 0.2 to 0.8) and the presence of other smokers in the household (0.8; 0.6 to 0.9). Almost all subjects who smoked three or more cigarettes in the first four weeks of treatment resumed smoking in the long term (525/547, 96%). Conclusions-Age, sex, marital status (living with a spouse or partner), motivation, concern about weight gain, recent marijuana smoking, and other smokers in the household were baseline factors associated with differences in outcome of smoking cessation attempts. Smoking three or more cigarettes in the first few weeks after stopping strongly predicted long term relapse.	CIBA GEIGY NEW ZEALAND,AUCKLAND,NEW ZEALAND		GOURLAY, SG (corresponding author), ALFRED HOSP,MONASH MED SCH,DEPT SOCIAL & PREVENT MED,PRAHRAN,VIC 3181,AUSTRALIA.		McNeil, John/L-6440-2019	McNeil, John/0000-0002-1049-5129; Forbes, Andrew/0000-0003-4269-914X				ABRAMS DB, 1992, PREV MED, V21, P679, DOI 10.1016/0091-7435(92)90075-S; Beck A. T., 1960, ARCH GEN PSYCHIAT, V4, P53, DOI DOI 10.1001/ARCHPSYC.1961.01710120031004; Beck A.T., 1987, BECK DEPRESSION INVE; BLONDAL T, 1989, ARCH INTERN MED, V149, P1818, DOI 10.1001/archinte.149.8.1818; COAMBS RB, 1992, AM J EPIDEMIOL, V135, P240, DOI 10.1093/oxfordjournals.aje.a116277; Collins R L, 1990, J Subst Abuse, V2, P389; DUNCAN CL, 1992, J GEN INTERN MED, V7, P398, DOI 10.1007/BF02599155; FAGERSTROM KO, 1982, J BEHAV MED, V5, P343, DOI 10.1007/BF00846161; FIORE MC, 1990, JAMA-J AM MED ASSOC, V263, P2760, DOI 10.1001/jama.263.20.2760; FREUND KM, 1992, AM J EPIDEMIOL, V135, P957, DOI 10.1093/oxfordjournals.aje.a116407; GARVEY AJ, 1992, ADDICT BEHAV, V17, P367, DOI 10.1016/0306-4603(92)90042-T; GOURLAY S, 1994, MED J AUSTRALIA, V160, P152, DOI 10.5694/j.1326-5377.1994.tb126568.x; GOURLAY SG, 1990, MED J AUSTRALIA, V153, P699, DOI 10.5694/j.1326-5377.1990.tb126327.x; HATZIANDREU EJ, 1990, J NATL CANCER I, V82, P1402, DOI 10.1093/jnci/82.17.1402; HEATHERTON TF, 1989, BRIT J ADDICT, V84, P791; KABAT GC, 1987, AM J PUBLIC HEALTH, V77, P1301, DOI 10.2105/AJPH.77.10.1301; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; KILLEN JD, 1992, J CONSULT CLIN PSYCH, V60, P797, DOI 10.1037/0022-006X.60.5.797; NORREGAARD J, 1993, PREV MED, V22, P261, DOI 10.1006/pmed.1993.1021; OLSEN J, 1993, SCAND J SOC MED, V3, P197; ORLEANS CT, 1994, JAMA-J AM MED ASSOC, V271, P601, DOI 10.1001/jama.271.8.601; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P61, DOI 10.1001/jama.261.1.61; RUSSELL MAH, 1993, BRIT MED J, V306, P1308, DOI 10.1136/bmj.306.6888.1308; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; SALIVE ME, 1992, AM J PUBLIC HEALTH, V82, P1268, DOI 10.2105/AJPH.82.9.1268; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; VANREEK J, 1988, BRIT J ADDICT, V83, P588; 1993, BRIT MED J, V306, P1304; 1991, GOOD CLIN RES PRACTI; 1991, EGRET EPIDEMIOLOGICA; 1988, SAS USERS GUIDE STAT	32	155	155	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					842	846		10.1136/bmj.309.6958.842	http://dx.doi.org/10.1136/bmj.309.6958.842			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK501	7950614	Green Published			2022-12-28	WOS:A1994PK50100021
J	VOHRA, RK; MCCOLLUM, CN				VOHRA, RK; MCCOLLUM, CN			FORTNIGHTLY REVIEW - PRESSURE SORES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SPINAL-CORD INJURY; FASCIAE-LATAE FLAP; HOSPITALIZED-PATIENTS; MUSCLE STIMULATION; MYOCUTANEOUS FLAP; ELDERLY SUBJECTS; BRADEN SCALE; RISK-FACTORS; MANAGEMENT; PREVENTION		UNIV S MANCHESTER HOSP, DEPT SURG, MANCHESTER M20 8LR, LANCS, ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital				edwards, Paige/0000-0001-5897-0497				ALLMAN RM, 1986, ANN INTERN MED, V105, P337, DOI 10.7326/0003-4819-105-3-337; [Anonymous], 1989, Decubitus, V2, P24; BAR CA, 1991, PROSTHET ORTHOT INT, V15, P232; BARBENEL JC, 1990, J BIOMED ENG, V12, P519, DOI 10.1016/0141-5425(90)90062-R; BARBENEL JC, 1977, LANCET, V2, P548; BARBENEL JC, 1991, PROSTHET ORTHOT INT, V15, P225; BERGSTROM N, 1987, NURS CLIN N AM, V22, P417; BERGSTROM N, 1992, J AM GERIATR SOC, V40, P747, DOI 10.1111/j.1532-5415.1992.tb01845.x; BERGSTROM N, 1987, NURS RES, V36, P205, DOI 10.1097/00006199-198707000-00002; BERLOWITZ DR, 1989, J AM GERIATR SOC, V37, P1043, DOI 10.1111/j.1532-5415.1989.tb06918.x; BLISS MR, 1988, UPDATE, V36, P2258; Braden B J, 1989, Decubitus, V2, P44; CHAPMAN EJ, 1986, CLIN NURSING PRACTIC; Clark M, 1989, Decubitus, V2, P34; CLARK M, 1989, J BIOMED ENG, V11, P197, DOI 10.1016/0141-5425(89)90140-4; COLEN SR, 1990, PLASTIC SURGERY, V6; Davies K, 1991, J TISSUE VIABILITY, V1, P18; DEALEY C, 1991, J ADV NURS, V16, P663, DOI 10.1111/j.1365-2648.1991.tb01724.x; DISA JJ, 1992, PLAST RECONSTR SURG, V89, P272, DOI 10.1097/00006534-199202000-00012; Exton-Smith A., 1962, INVESTIGATION GERIAT; FERGUSON ACB, 1992, PARAPLEGIA, V30, P474, DOI 10.1038/sc.1992.101; FINESTONE HM, 1991, J REHABIL RES DEV, V28, P27, DOI 10.1682/JRRD.1991.10.0027; GOLDSTONE LA, 1980, INT J NURS STUD, V17, P17, DOI 10.1016/0020-7489(80)90004-8; GOLDSTONE LA, 1982, J ADV NURS, V7, P419, DOI 10.1111/j.1365-2648.1982.tb00258.x; HAGISAWA S, 1988, ARCH PHYS MED REHAB, V69, P668; HAWTHORN P, 1987, NURS TIMES, V83, P45; HIBBS P, 1982, NURS MIRROR, V155, P1311; KEMP MG, 1990, RES NURS HEALTH, V13, P293, DOI 10.1002/nur.4770130505; KNIGHT AL, 1988, J FAM PRACTICE, V27, P95; KOSIAK M, 1961, Arch Phys Med Rehabil, V42, P19; KROLL SS, 1989, PLAST RECONSTR SURG, V84, P296, DOI 10.1097/00006534-198908000-00018; KUHN W, 1992, PARAPLEGIA, V30, P396, DOI 10.1038/sc.1992.89; LESAVOY MA, 1990, PLAST RECONSTR SURG, V85, P390, DOI 10.1097/00006534-199003000-00009; LEVINE JM, 1989, GERIATRICS, V44, P75; LEVINE SP, 1990, ARCH PHYS MED REHAB, V71, P210; LEVINE SP, 1990, ARCH PHYS MED REHAB, V71, P682; Low A W, 1990, Oncol Nurs Forum, V17, P179; LUSCHER NJ, 1991, ANN PLAS SURG, V26, P306; MAWSON AR, 1988, AM J PHYS MED REHAB, V67, P123, DOI 10.1097/00002060-198806000-00007; McGregor J C, 1991, J R Coll Surg Edinb, V36, P399; MEIJER JH, 1989, MED BIOL ENG COMPUT, V27, P502, DOI 10.1007/BF02441469; MICHOCKI RJ, 1976, J AM GERIATR SOC, V24, P323, DOI 10.1111/j.1532-5415.1976.tb06804.x; MOODY BL, 1988, ARCH INTERN MED, V148, P2241, DOI 10.1001/archinte.148.10.2241; PALETTA CE, 1989, PLAST RECONSTR SURG, V83, P852, DOI 10.1097/00006534-198905000-00012; PENA MM, 1992, PLAST RECONSTR SURG, V89, P90, DOI 10.1097/00006534-199289010-00018; PETERSEN NC, 1976, BEDSORE BIOMECHANICS, P219; RAWAT SS, 1991, PLAST RECONSTR SURG, V88, P154, DOI 10.1097/00006534-199107000-00028; REICHEL SM, 1958, JAMA-J AM MED ASSOC, V166, P762, DOI 10.1001/jama.1958.62990070004010a; RELANDER M, 1988, SCAND J PLAST RECONS, V22, P89, DOI 10.3109/02844318809097940; REULER JB, 1981, ANN INTERN MED, V94, P661, DOI 10.7326/0003-4819-94-5-661; ROBERTSON JC, 1987, CARE SCI PRACTICE, V5, P2; ROJVIROJ S, 1989, Journal of the Medical Association of Thailand, V72, P629; ROWLING JT, 1961, P ROY SOC MED, V54, P409, DOI 10.1177/003591576105400515; RYAN DW, 1989, CLIN PHYS PHYSIOL M, V10, P331, DOI 10.1088/0143-0815/10/4/004; SCALES JT, 1982, LANCET, V2, P1150; SCHUBERT V, 1991, AGE AGEING, V20, P255, DOI 10.1093/ageing/20.4.255; SCHUBERT V, 1989, CLIN PHYSIOL, V9, P535, DOI 10.1111/j.1475-097X.1989.tb01007.x; SIDERANKO S, 1992, RES NURS HEALTH, V15, P245, DOI 10.1002/nur.4770150403; SOLIS I, 1988, ARCH PHYS MED REHAB, V69, P524; STAAS WE, 1991, WESTERN J MED, V154, P539; TURBA RM, 1992, ARCH PHYS MED REHAB, V73, P498; VIDAL J, 1991, PARAPLEGIA, V29, P261, DOI 10.1038/sc.1991.37; Waltman N L, 1991, Oncol Nurs Forum, V18, P867; WHITE GW, 1989, J APPL BEHAV ANAL, V22, P287, DOI 10.1901/jaba.1989.22-287; Wild D, 1991, Nurs Stand, V5, P25; YOUNG JB, 1992, DRUG AGING, V2, P42, DOI 10.2165/00002512-199202010-00006; 1992, AHCPR920047 AG HLTH	67	38	39	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	1994	309	6958					853	857		10.1136/bmj.309.6958.853	http://dx.doi.org/10.1136/bmj.309.6958.853			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7950617	Green Published			2022-12-28	WOS:A1994PK50100027
J	HOWIE, JGR; HEANEY, DJ; MAXWELL, M				HOWIE, JGR; HEANEY, DJ; MAXWELL, M			EVALUATING CARE OF PATIENTS REPORTING PAIN IN FUNDHOLDING PRACTICES	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; NHS; PATTERNS; COSTS	Objective-To compare quality of care between 1990 and 1992 in patients with self diagnosed joint pain. Design-Questionnaire and record based study. Subjects-Patients identified at consecutive consultations during two weeks in 1990, 1991, and 1992. Setting-Six practice groups in pilot fundholding scheme in Scotland. Main outcome measures-length of consultation; numbers referred or investigated or prescribed drugs; responses to questions about enablement and satisfaction. Results-About 15% of patients consulted with joint pain each year. 25% (316) of them had social problems in 1990 and 37% (370) in 1992; about a fifth wanted to discuss their social problems. Social problems were associated with a raised general health questionnaire score. The mean length of consultation for patients with pain was 7.6 min in 1990 and 7.7 min in 1992. Patients wishing to discuss social problems received longer consultations (8.5 min 1990; 10.4 min 1992); but other patients with social problems received shorter consultations (7.4 min; 7.2 min). The level of prescribing was stable but the proportion of patients having investigations or attending hospital fell significantly from 1990 to 1992 (31% to 24%; 31% to 13% respectively). Fewer patients responded ''much better'' to six questions about enablement in 1992 than in 1990. Enablement was better after longer than shorter consultations for patients with social problems. Conclusions-Quality of care for patients with pain has been broadly maintained in terms of consultation times. The effects of lower rates of investigation and referral need to be investigated further.			HOWIE, JGR (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,SCOTLAND.			Maxwell, Margaret/0000-0003-3318-9500				BAIN J, 1993, BRIT MED J, V306, P1185, DOI 10.1136/bmj.306.6886.1185; BAIN J, 1992, BRIT MED J, V304, P971, DOI 10.1136/bmj.304.6832.971; BAIN J, 1991, BRIT MED J, V302, P771, DOI 10.1136/bmj.302.6779.771; BAZANGER I, 1989, SOC SCI MED, V29, P425; BOWIE C, 1994, BRIT J GEN PRACT, V44, P38; CORNEY R, 1994, BRIT J GEN PRACT, V44, P34; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; COULTER A, 1992, BRIT MED J, V304, P397, DOI 10.1136/bmj.304.6824.397; COULTER A, 1993, BRIT MED J, V307, P1186; CROOK J, 1984, PAIN, V18, P299, DOI 10.1016/0304-3959(84)90824-8; CRUMP BJ, 1991, BRIT MED J, V302, P1582, DOI 10.1136/bmj.302.6792.1582; DAY P, 1991, BRIT MED J, V303, P168, DOI 10.1136/bmj.303.6795.168; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; HOPTON JL, 1991, FAM PRACT, V8, P253, DOI 10.1093/fampra/8.3.253; Howie J G, 1993, Health Bull (Edinb), V51, P94; Howie J G, 1992, Health Bull (Edinb), V50, P316; HOWIE JGR, 1991, BRIT J GEN PRACT, V41, P48; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; NEWTON J, 1993, BRIT MED J, V306, P375, DOI 10.1136/bmj.306.6874.375; PURVES IN, 1993, BRIT MED J, V306, P496, DOI 10.1136/bmj.306.6876.496; 1986, MORBIDITY STATISTICS	21	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					705	710		10.1136/bmj.309.6956.705	http://dx.doi.org/10.1136/bmj.309.6956.705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7950524	Green Published			2022-12-28	WOS:A1994PH40700018
